<SEC-DOCUMENT>0001193125-21-085043.txt : 20210318
<SEC-HEADER>0001193125-21-085043.hdr.sgml : 20210318
<ACCEPTANCE-DATETIME>20210318081623
ACCESSION NUMBER:		0001193125-21-085043
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210318
DATE AS OF CHANGE:		20210318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Generation Bio Co.
		CENTRAL INDEX KEY:			0001733294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				814301281
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39319
		FILM NUMBER:		21753153

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		857-529-5908

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d108483d10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML><HEAD>
<TITLE>10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-K</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: <FONT STYLE="white-space:nowrap">001-39319</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>GENERATION BIO CO. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-4301284</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>301 Binney Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02142</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">655-7500</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title&nbsp;of&nbsp;each&nbsp;class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name&nbsp;of&nbsp;each&nbsp;exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on&nbsp;which&nbsp;registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Common&nbsp;Stock,&nbsp;$0.0001&nbsp;Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>GBIO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Nasdaq Global&nbsp;Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>None </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check
mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the
registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#146;s assessment of the effectiveness of
its internal control over financial reporting under Section&nbsp;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">The aggregate market value of
Common Stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;of</FONT> the registrant computed by reference to the price of the registrant&#146;s Common Stock as of June&nbsp;30, 2020, the last business day of the registrant&#146;s
most recently completed second fiscal quarter, was approximately $646.2&nbsp;million (based on the last reported sale price on the Nasdaq Global Select Market as of such date). For this computation, the registrant has excluded the market value of
all shares of Common Stock reported as beneficially owned by its executive officer and directors; such exclusion shall not be deemed to constitute an admission that any such person is an affiliate of the registrant. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">As of February&nbsp;28, 2021, there were 56,427,399 shares of the registrant&#146;s Common Stock, $0.0001 par value per share, outstanding. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Portions of the registrant&#146;s Proxy Statement for its 2021 Annual Meeting of Stockholders, which the registrant intends to file with the
Securities and Exchange Commission not later than 120 days after the registrant&#146;s fiscal year ended December&nbsp;31, 2020, are incorporated by reference into Part III of this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT>
</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Generation Bio Co. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><U><A HREF="#tx108483_1">PART I </A></U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_2">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1B.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_4">Unresolved Staff Comments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_5">Properties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_6">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_7">Mine Safety Disclosures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><U><A HREF="#tx108483_8">PART II </A></U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_9">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer
 Purchases of Equity Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_10">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_12">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_13">Financial Statements and Supplementary Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_14">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_15">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9B.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_16">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><U><A HREF="#tx108483_17">PART III </A></U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_18">Directors, Executive Officers and Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_19">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_20">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
 Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_21">Certain Relationships and Related Transactions, and Director
Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_22">Principal Accounting Fees and Services</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><U><A HREF="#tx108483_23">PART&nbsp;IV </A></U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_24">Exhibits, Financial Statement Schedules</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_25">Form <FONT STYLE="white-space:nowrap">10-K</FONT> Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_26">Signatures</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> or this Annual Report, of Generation Bio Co. contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are
forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would,&#148; or the negative of these words or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this Annual
Report include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our research and development programs and preclinical studies and
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the
period over which we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and, if approved, subsequently commercialize any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to submit applications for, obtain and maintain regulatory approvals for any
product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential addressable patient populations for our programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and our response to the pandemic;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify additional products, product candidates or technologies with significant commercial
potential that are consistent with our commercial objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and expectations regarding developments and projections relating to our competitors and
any competing therapies that are or become available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and expectations regarding developments and projections relating to our competitors and our
industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations or obtain additional funding; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our
Business Startup Act of 2012. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking
statements, and stockholders should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have
included important factors in the cautionary statements included in this Annual Report, particularly in the &#147;Risk Factors Summary&#148; and &#147;Risk Factors&#148; sections, that we believe could cause actual results or events to differ
materially from the forward-looking statements that we make. Moreover, we operate in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a competitive and rapidly changing environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and
uncertainties. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders should read this Annual Report and the documents that we file with the Securities and Exchange Commission with the understanding that our actual
future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report are made as of the date of this Annual Report, and we do not assume any obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except where the context otherwise
requires or where otherwise indicated, the terms &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company,&#148; and &#147;our business&#148; in this Annual Report refer to Generation Bio Co. and its consolidated
subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RISK FACTOR SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are providing the following summary of the risk factors contained in this Annual Report to enhance the readability and accessibility of our risk factor
disclosures. We encourage stockholders to carefully review the full risk factors contained in this Annual Report in their entirety for additional information regarding the material factors that make an investment in our securities speculative or
risky. These risks and uncertainties include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are very early in our development efforts. We have not identified any product candidates for <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical development. As a result, it will be many years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical
studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to
delay, reduce or eliminate our product development programs or commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our limited operating history may make it difficult for our stockholders to evaluate the success of our business
to date and to assess our future viability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is based on novel technologies that
are unproven, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter substantial delays in commencement, enrollment or completion of our clinical trials or we may
fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, any of which could prevent us from commercializing any product candidates we may develop on a timely basis, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If any product candidates we may develop cause undesirable side effects or have other unexpected adverse
properties, such side effects or properties could delay or prevent regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The outcome of preclinical studies may not be predictive of later preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or if we will
obtain regulatory approval to commercialize a product candidate we may develop, or the approval may be for a more narrow indication than we expect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacture of genetic medicine products is complex and difficult and is subject to a number of scientific
and technical risks, some of which are common to the manufacture of drugs and biologics and others of which are unique to the manufacture of gene therapies. We could experience manufacturing problems that result in delays in our development or
commercialization programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product
manufacturing, research, preclinical and clinical testing, and these third parties may not perform satisfactorily; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to comply with our obligations under our existing license agreements, or under any future intellectual
property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent protection for our products and technology, or if the scope of the
patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop and
technology may be adversely affected; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its effects on our business and
operations are uncertain. We and our contract development and manufacturing organizations and contract research organizations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
experienced a temporary reduction in the capacity to undertake research scale production and to execute some preclinical studies, and we may face disruptions in the future that affect our ability
to initiate and complete preclinical studies and to procure items that are essential for our research and development activities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_1"></A>PART I </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_2"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BUSINESS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an innovative genetic medicines company
creating a new class of gene therapy utilizing our proprietary <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases. Our <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform incorporates our high-capacity DNA construct called closed-ended DNA, or ceDNA; our cell-targeted lipid nanoparticle delivery system, or ctLNP; and our established, scalable
capsid-free manufacturing process. Using our approach, we are developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of diseases. We are also
engineering our gene therapies to be redosable, which may enable individualized patient titration to reach the desired level of therapeutic expression and to maintain efficacy throughout a patient&#146;s life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a broad and expansive portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. We are focused on
diseases with significant unmet need for which our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform may substantially improve clinical efficacy relative to current gene therapy approaches. We are initially prioritizing rare
monogenic diseases of the liver and retina, which are diseases that result from mutations in a single gene, that have well-established biomarkers and clear clinical and regulatory pathways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to expand our portfolio to include rare and prevalent diseases of the skeletal muscle, the central nervous system, or CNS, and oncology by developing
discrete ctLNPs, each engineered to reach a different tissue. In parallel, we are developing the constructs and manufacturing capacity to rapidly advance new disease programs in a tissue or area once human proof of concept is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform may allow patients to produce antibody therapies from their own cells
for years at a time from a single dose, and plan to advance antibody gene therapy programs across multiple therapeutic areas. The combination of the expected multi-year durability of a single dose of ceDNA, tissue-specific delivery and manufacturing
capacity may provide dosing for millions of patients living with prevalent diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we are currently a preclinical stage company and are early in
our development efforts, we believe that our new class of gene therapy has the potential to reach previously untreatable or under-treated patients and address new indications, including those with large patient populations, thereby unlocking the
full potential of genetic medicine. Specifically, we believe that our platform has the potential to provide durable and redosable therapies that will enable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded patient access, including the ability to treat children; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivery of large genetic payload, including large and multiple genes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">native gene regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">targeted delivery to a range of tissues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">large-scale cost-effective production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">treatment for millions of patients across the globe; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a sustainable payer model. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is comprised of three essential components: our high-capacity ceDNA construct,
which can accommodate large or multiple genes as well as native regulatory elements; our ctLNP delivery system, which enables highly specific delivery of ceDNA to a range of tissues; and our established, scalable capsid-free manufacturing process,
which uses a cost-effective biologics infrastructure that has the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential to reach patients with rare diseases and to expand access to patients with prevalent diseases, requiring millions of doses, on a sustainable basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ceDNA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our high-capacity ceDNA is an engineered,
double-stranded, linear, covalently closed-ended DNA construct that includes the gene of interest and associated regulatory sequences. We have produced ceDNA constructs of 12 kilobases, or kb, which have almost three times the 4.7 kb capacity of
adeno-associated virus, or AAV, gene therapy approaches. The structure and relative size of ceDNA as compared to AAV is shown in the figure below. We believe ceDNA can deliver a significant majority of the human coding sequences known to be relevant
for the treatment of diseases that result from mutations in a single gene or in multiple genes. ceDNA may address many diseases, including prevalent diseases and diseases requiring more than one type of genetic correction that are beyond the scope
of current gene therapy. This capacity can also accommodate native or engineered regulatory elements, potentially enabling a powerful new dimension of gene therapy that responds to the body&#146;s own signals. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ceDNA structure and capacity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g10s25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ctLNP </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ctLNP
delivery system builds upon clinically validated lipid nanoparticles, or LNPs, and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. We have taken a significant step
beyond current LNP technology by adding a biological targeting molecule, called a ligand, on the surface of our LNPs to direct their biodistribution to specific tissues. Different targeting ligands may enable our ctLNPs to actively target specific
cell receptors in the liver, retina, skeletal muscle, CNS and tumors. In addition, our ctLNP delivery system may confer the advantages of predictable behavior across species, minimal <FONT STYLE="white-space:nowrap">off-target</FONT> effects and a
foundational platform approach that unlocks the ability to target the widest possible spectrum of diseases with our therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Manufacturing process
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our established, scalable manufacturing employs a proprietary, capsid-free process and utilizes standard biologics infrastructure, unlike traditional
viral gene therapy manufacturing. Viral gene therapy relies on a protein capsid for therapeutic delivery of a viral vector, and as a result, the manufacturing process for viral gene therapies requires the production of protein capsids, which limit
process scalability and consistency. Our capsid-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
free manufacturing process is an efficient and reproducible process that includes rigorous, industrial-scale purification that consistently yields greater than 99% pure ceDNA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established a current Good Manufacturing Practices, or cGMP, -ready process at the <FONT STYLE="white-space:nowrap">200-liter</FONT> scale, which we
have successfully transferred to external contract development and manufacturing organizations, or CDMOs, for production of clinical supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability
to conduct this manufacturing process at the <FONT STYLE="white-space:nowrap">200-liter</FONT> scale with high product quality suggests that further scaling to thousands of liters per batch is feasible using standard biological production equipment
and engineering methods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the combination of the expected multi-year durability of a single dose of ceDNA, tissue-specific delivery and
manufacturing capacity may provide dosing for millions of patients living with prevalent diseases. We also believe these features will allow the cost of production for our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform to
compare favorably to the cost of production of current biologic products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a broad and expansive portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. We are focused on
diseases with significant unmet need for which our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform may substantially improve clinical efficacy relative to current gene therapy approaches. We are initially prioritizing rare
monogenic diseases of the liver and retina that have well-established biomarkers and clear clinical and regulatory pathways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to expand our
portfolio to include rare and prevalent diseases of the skeletal muscle, the CNS and oncology by developing discrete ctLNPs, each engineered to reach a different tissue. In parallel, we are developing the constructs and manufacturing capacity to
rapidly advance new disease programs in a tissue or area once human proof of concept is established. As shown in the figure below, our most advanced liver disease programs are in hemophilia A and phenylketonuria, or PKU, which are in the preclinical
stage of development, and our most advanced retina disease programs are in Leber&#146;s Congenital Amaurosis, or LCA10, and Stargardt disease, which are in the lead optimization stage of development. In the lead optimization stage, we are seeking to
identify ceDNA constructs that provide disease relevant expression in an animal model, and in the preclinical stage of development, we are conducting additional <I>in vivo </I>studies to identify development candidates and are assessing these
candidates in investigational new drug, or IND, -enabling studies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g52r77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, we held an Initial Targeted Engagement for Regulatory Advice on CBER Products, or INTERACT, meeting with
the FDA&#146;s Office of Tissues and Advanced Therapies, or OTAT, to introduce our platform and align on the manufacturing and analytical control strategy to support clinical development in PKU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We expect to select the development candidate for each of our hemophilia A and PKU programs and to initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for these programs in
2021, followed by IND applications for these programs in 2022. We anticipate submitting IND applications for additional programs in 2023 and beyond. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
programs in the liver and retina as well as in our expansion opportunities are wholly owned by us. For the majority of our programs, we have designed and produced ceDNAs that have shown expression <I>in vitro</I> and/or disease correction <I>in
vivo</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our strategy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to become
an industry leader in the field of genetic medicines, advancing our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform to discover, develop, manufacture and globally commercialize a new class of gene therapy that is durable,
redosable and specifically delivered to a range of tissues for the treatment of diseases caused by single, large or multiple gene defects. We aim to provide sustainable, life-long treatment for millions of patients living with rare and prevalent
diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development efforts have resulted in numerous innovations and breakthroughs across every aspect of our platform. We own or
exclusively license patent applications in 41 patent application families covering our programs and technology, including our ceDNA platform, ctLNP delivery system and our manufacturing processes, and have taken other steps to protect our
proprietary position with respect to these innovations and breakthroughs. Our wholly owned intellectual property, combined with the background technology we have licensed from the National Institutes of Health, or NIH, and the University of
Massachusetts Medical School, or UMass, and Voyager Therapeutics, Inc., or Voyager, based on our <FONT STYLE="white-space:nowrap">co-founder&#146;s</FONT> prior work, supports the leading position of our
<FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform and provides a strong foundation for its continued advancement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our culture
and team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established a highly collaborative, patient-first culture that fuels our innovation. Our team learns, develops and thrives as a
community guided by four core values: together we are thoughtful, inclusive, courageous and <FONT STYLE="white-space:nowrap">all-in</FONT> for our mission to create solutions for patients and their families. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team has extensive collective expertise in human genetics, rare disease drug development and commercialization and the manufacture and delivery
of nucleic acid therapeutics. Geoff McDonough, M.D., our President and Chief Executive Officer, brings over 20 years of leadership experience with innovative life science companies across strategy, corporate and business development, program
management and global drug development and launches. Douglas Kerr, M.D., Ph.D., M.B.A., our Chief Medical Officer, is a pioneer in the development of rare neuroscience programs with more than 15 years of industry experience. Matthew Norkunas, M.D.,
M.B.A., our Chief Financial Officer, brings his combined financial and medical expertise and depth of experience in both biotechnology company and investor settings. Matthew Stanton, Ph.D., our Chief Scientific Officer, is an expert in nucleic acid
therapeutic development and delivery platforms with over 20 years of experience across pharmaceutical and biotechnology companies. Tracy Zimmermann, Ph.D., our Chief Development Officer, has 20 years of industry experience advancing novel nucleic
acid based therapeutics into development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the aggregate, our management team has been involved in the filing of over 25 INDs and contributed to the
development of 20 approved products, including Biogen&#146;s SPINRAZA (nusinersen); Sanofi Genzyme&#146;s FABRAZYME (agalsidase beta), ALDURAZYME (laronidase) and MYOZYME (alglucosidase alfa); Sobi and Biogen&#146;s ELOCTATE and ALPROLIX; Vertex
Pharmaceuticals Inc.&#146;s KALYDECO (ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and SYMDEKO (tezacaftor/ivacaftor); Alnylam&#146;s ONPATTRO (patisiran) and GIVLAARI (givosiran); and Moderna, Inc.&#146;s mRNA-1944, an investigational therapy for the
chikungunya virus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our organization is comprised of more than 100 talented individuals with significant experience across discovery, preclinical
research, manufacturing and clinical development. We have also established scientific and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical advisory boards comprised of leading experts in the fields of human genetics, rare disease drug discovery and development and global regulatory engagement, who share our mission of
providing sustainable, life-long treatment for millions of patients living with rare and prevalent diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The genetic medicines industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The human genome is made up of
approximately 25,000 genes, which act as a set of instructions to influence and determine every aspect of how the body functions. A genetic disease is caused by a change, or a mutation, in an individual&#146;s DNA sequence. Genetic diseases can be
caused by a mutation in a single gene, known as a monogenic disorder, or by mutations in multiple genes, known as a multifactorial inheritance disorder. Current estimates suggest that there are more than 10,000 monogenic diseases. Many of these are
rare, affecting hundreds or thousands of patients worldwide, such as hemophilia A or PKU. There are an even greater number of prevalent diseases whose genetics are multifactorial, affecting millions of people on a global scale, such as many types of
metabolic disease and cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genetic medicines are designed to correct disease-causing dysfunction at the genetic level and utilize recombinant nucleic
acids to regulate, repair, replace, add or delete a genetic sequence to achieve the desired therapeutic effect. Viral gene therapy, gene editing and messenger RNA, or mRNA, are genetic medicine modalities that specifically aim to replace the
function of disease-causing genes by either inserting a gene, modifying the DNA, or inserting mRNA into a patient&#146;s cell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Early gene therapy
clinical trials in the 1990&#146;s used adenovirus to deliver genetic material. However, developers have moved away from using adenoviruses because they can trigger a strong immune reaction and their effect is short lived. Another form of viral gene
therapy uses retroviral vectors, including lentiviral vectors, to incorporate DNA directly into a cell&#146;s chromosome upon infection, typically through <I>ex vivo </I>delivery. In <I>ex vivo</I> delivery, genetic modification of isolated patient
or donor cells are conducted outside of the patient and then <FONT STYLE="white-space:nowrap">re-introduced</FONT> to the patient. As an integrating virus, these vectors pose additional safety risks, and create the potential for disrupting genes or
activating cancer-causing genes. In addition, <I>ex vivo</I> delivery poses a significant operational challenge and higher cost relative to <I>in vivo</I> therapies. As a result, AAV has become a preferred viral vector for gene therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant progress has been made in the field of genetic medicine over the last decade with products approved in viral gene therapy, and several gene
editing and mRNA programs in clinical development. While we expect that there will be further advancements in these modalities, each possesses distinct clinical and commercial limitations due to known safety, efficacy, therapeutic delivery and
manufacturing scale challenges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and emerging genetic medicines and their limitations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Viral gene therapy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Viral gene therapy, in which viral
vectors are employed to deliver therapeutic genes to defective cells or tissues, has made significant progress in the past decade. The most advanced system for systemic administration is AAV gene therapy, which has demonstrated durable transduction
of cells in several organ systems, with long-lasting expression in <FONT STYLE="white-space:nowrap">non-dividing</FONT> cells. Several AAV gene therapy products have been approved, including LUXTURNA (voretigene
<FONT STYLE="white-space:nowrap">neparvovec-rzyl)</FONT> for the treatment of the rare inherited blindness disorder biallelic RPE65 mutation-associated retinal dystrophy and ZOLGENSMA (onasemnogene abeparvovec-xioi) for spinal muscular atrophy, or
SMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, current AAV gene therapy has demonstrated limitations, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Single dose administration only</I>:<I> </I>Following a single dose of AAV, antibodies are induced against the
AAV capsid, the protein shell of the virus used for delivery. Because of these antibodies, AAV can only be dosed once, and it is typically dosed at the upper end of its therapeutic index to maximize potential efficacy across all treated patients.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Variable expression</I>: Administration of a single fixed dose to all patients prevents repeat dosing to
adjust the expression level in each patient, called titration, and leads to variable levels of expression, with many patients expressing the therapeutic protein above or below target levels. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Inefficient clinical development</I>: Because patients cannot be redosed, those who do not achieve a
therapeutic effect in early clinical trials cannot benefit from AAV therapy or contribute to further clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Inability to extend expression</I>: The antibodies formed following a single dose of AAV prevent <FONT
STYLE="white-space:nowrap">re-treatment</FONT> to increase or extend efficacy for patients with inadequate initial response or declining levels of expression. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Exclusion of pediatric patients</I>: The inability to redose precludes treatment of pediatric patients, whose
organ growth and dividing cells would dilute expression over time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">Pre-existing</FONT> immunity</I>:<I> </I>Up to half of patients have
antibodies against AAV due to naturally acquired infections. These antibodies prevent them from receiving AAV gene therapy due to <FONT STYLE="white-space:nowrap">pre-existing</FONT> AAV immunity to the capsid. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Payload capacity</I>:<I> </I>AAV constructs are limited to 4.7 kb in length, restricting both the size of
genes and complexity of regulatory sequences that can be delivered. This restricts the diseases that can be addressed to those requiring single genes that can fit within this limited capacity and prevents the use of native regulatory sequences that
may respond to the body&#146;s own signals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">Off-target,</FONT> multi-tissue delivery</I>: Due to the inherent features of
AAV, <FONT STYLE="white-space:nowrap">off-target</FONT> delivery to unintended tissues and cell-types can lead to adverse events. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Quality control</I>: A lack of process and analytic control over the composition of AAV vectors leads to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">batch-to-batch</FONT></FONT> variation in potency and potentially contributes to inconsistency in patients&#146; responses. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Manufacturing scale</I>: The production systems for AAV gene therapies are limited in scale to 2,000 liters
per batch or less. In general, the high doses required by AAV gene therapies and the low productivity of these systems combine to limit treatment to rare disease populations at a higher cost relative to other treatment modalities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Payer coverage</I>:<I> </I>The<I> </I>relatively<I> </I>high cost of AAV gene therapies, combined with
uncertain clinical durability and the inability to redose to extend expression, make it challenging for payers to predict clinical outcomes and, as a result, payers may be less inclined to pay for AAV gene therapies within the current reimbursement
paradigm. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gene editing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gene
editing is the process of deleting, modifying or replacing defective DNA directly in the native genomic location. Zinc finger nuclease, TALEN and CRISPR-based gene editing are the most advanced approaches to gene editing and are currently in early
clinical trials. CRISPR uses a combination of a nuclease to make a double-stranded break in the DNA and a guide RNA to direct the nuclease to the correct location for editing. Given insertion of full-length genes into the chromosome has remained
relatively inefficient for gene editing, particularly <I>in vivo</I>, these approaches have primarily focused on <I>ex vivo</I> therapeutic applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, viral vectors are used widely to deliver gene editing nucleases <I>in vivo</I>, thereby conveying many of the same clinical and commercial
challenges as viral gene therapy. Additional limitations for gene editing include the potential for unwanted DNA modifications related to double-stranded DNA breaks, the inability to control the level and duration of protein expression and low
efficiency of precise gene correction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Messenger RNA therapies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Messenger RNA therapies are designed to increase mRNA levels by exogenous delivery of modified mRNA. However, the use of modified mRNA is limited by a lack of
durable expression due to the half-life, or stability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
profile, of an mRNA transcript in the cell, which is approximately 10 hours. Due to the lack of durable expression for mRNA and the resulting requirement of frequent dosing, clinical development
of mRNA therapies has focused primarily on novel vaccines. The safety of this frequent repeat dosing has yet to be proven clinically. In addition, the standard LNP approaches used for mRNA do not enable precise targeting of tissues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of limitations of current approaches </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
advancements in gene therapy have demonstrated the potential of these modalities to replace full genes and the aggregate market capitalization of publicly traded gene therapy companies in the United States exceeds $50&nbsp;billion. However, as
illustrated in the figure below, the current approaches also have important limitations. While the development of our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is still in the early stage and we have not yet identified
a product candidate, and thus contrasts with other approaches may not be a direct comparison, we have designed our platform to overcome the limitations of these gene therapy approaches. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Comparison of genetic medicine approaches </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g20k14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advantages of our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform, comprised of our ceDNA construct, our ctLNP delivery system and our established,
scalable capsid-free manufacturing process, is designed to overcome the limitations of current gene therapy approaches and we believe will disrupt the field of genetic medicine. We believe that our platform may provide the following advantages: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Durable expression</I>: Our ceDNA is highly stable and establishes extra-chromosomal episomes in the nucleus
of cells to drive durable expression of the gene of interest. This durability has the potential to enable years-long expression for patients with each dose, minimizing the treatment burden for patients. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Redosable administration</I>:<I> </I>Our ctLNP system has been designed to avoid stimulating an antibody
response in patients, thereby enabling redosing. The ability to redose provides several advantages: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Individualized patient titration to reach desired expression level</I>: We expect our gene therapies will
enable individualized patient titration, allowing each patient to be redosed until they reach the expression level required to address their specific needs. Patients and physicians may achieve individual therapeutic goals in a predictable manner.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Greater opportunity to demonstrate efficacy in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials</I>: Because we may be able to redose, we expect that a greater proportion of patients participating in our early clinical trials may achieve the
desired level of gene expression. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Extending expression</I>: If expression of the gene of interest begins to wane for an individual patient, we
expect that redosing could restore effective expression levels, prolonging the benefits of our therapies throughout the patient&#146;s life. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Reach pediatric patients</I>:<I> </I>Rapidly waning expression due to organ growth and dividing cells in
children limits the utility of a single administration of gene therapy. We expect that the properties of our therapies may allow us to initiate treatment in childhood and allow the patient to prolong the benefits thereafter. Early intervention near
the onset of disease may enable a greater therapeutic benefit throughout the patient&#146;s life. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Address untreated or under-treated patients</I>: Our therapies may be used to treat patients with <FONT
STYLE="white-space:nowrap">pre-existing</FONT> immunity to the AAV viral capsid, and therefore, not able to receive AAV gene therapy treatments, as well as patients whose efficacy outcomes on current gene therapy were insufficient in level or
duration of expression. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Delivery of large genetic payloads</I>: The large payload capacity of ceDNA enables our constructs to carry
large genes, multiple genes or combinations of genes with regulatory elements. This capacity arises from the lack of capsid packaging constraints that limit DNA incorporation in AAV gene therapy to less than 4.7 kb. Our established, scalable
manufacturing process routinely prepares constructs of up to 12 kb without loss in yield or quality. We have not identified an upper limit of construct length. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>More potent constructs</I>:<I> </I>Our ceDNA constructs have the potential to improve upon existing gene
therapy modalities by utilizing novel expression elements that exceed the capacity of AAV gene therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Larger genes</I>: Our ceDNA constructs may enable treatment of monogenic diseases requiring larger genes that
are not possible to deliver with current gene therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Multiple genes</I>: Our ceDNA constructs have the potential to include novel multi-gene constructs to produce
complex biologics such as monoclonal antibodies, or to address conditions that need more than one type of genetic correction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Native gene regulation</I>:<I> </I>The large capacity of our constructs provides us the ability to incorporate
native regulatory elements that are naturally associated with the gene we are replacing. We believe this will allow for activity of the replaced gene to increase or decrease in response to the body&#146;s own signals. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Targeted, multi-tissue delivery</I>:<I> </I>Our ctLNP delivery system has been engineered to use biological
ligands to reach receptors in a specific tissue. We believe that highly specific targeting to the key cell type for therapeutic benefit with limited delivery to <FONT STYLE="white-space:nowrap">off-target</FONT> cells will improve the safety profile
of our products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected scale to reach millions of patients</I>: The combination of the expected multi-year durability of a
single dose of ceDNA, tissue-specific delivery and manufacturing capacity may provide dosing for millions of patients living with prevalent diseases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Sustainable payer model</I>: Our cost-effective manufacturing process combined with the potential to redose
patients to extend expression may allow payers to better predict clinical outcomes and, as a result, to cover our therapies within the current reimbursement paradigm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our new class of gene therapy has the potential to reach previously untreatable or under-treated patients and address new indications,
including those with large patient populations, thereby unlocking the full potential of genetic medicine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to become an industry leader in the field of genetic medicine, advancing our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy
platform to discover, develop, manufacture and globally commercialize a new class of gene therapy that is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
durable, redosable and specifically delivered to a range of tissues for the treatment of diseases caused by single, large or multiple gene defects. We aim to provide sustainable, life-long
treatment for millions of patients living with rare and prevalent diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key components of our strategy include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Establish ceDNA as a new class of gene therapy, initially demonstrating its potential across rare monogenic
diseases of the liver and retina.</I></B> We are prioritizing rare monogenic diseases of the liver and retina with significant unmet need for which our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform may substantially improve
clinical efficacy relative to current gene therapy approaches, beginning with hemophilia A, PKU, LCA10 and Stargardt disease. We believe our initial focus on these rare indications, which have well-established biomarkers and clear clinical and
regulatory pathways, may enable us to achieve rapid human proof of concept, regulatory approval and eventually, commercialization. We expect to submit our first IND applications beginning in 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leverage our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform to advance additional
programs for diseases of the liver and retina and to expand quickly into additional tissues.</I></B> We are advancing additional programs for the liver and retina by making minimal changes to our ceDNA construct and by using the same ctLNP delivery
system for each tissue. We believe this process can reduce the risk and accelerate the speed of development for subsequent indications in these tissues. We also plan to apply this approach as we develop biological ligands for our ctLNP delivery
system to reach skeletal muscle, the CNS and tumors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Utilize our eight-week research cycle to rapidly design, produce and screen ceDNA constructs to enable new
disease programs within a tissue or therapeutic area.</I></B> We have established a highly efficient eight-week research cycle to rapidly design, produce and screen ceDNA constructs to enable new disease programs within a therapeutic area once human
proof of concept is established in that area. We intend to invest in technologies to further accelerate our research cycle and create additional efficiency and scope for this process. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expand manufacturing scale to access previously unattainable markets for gene
therapy.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We have established a capsid-free manufacturing process for ceDNA that is scalable, cost-effective and yields a high-quality product using standard biological production equipment and engineering methods. We
intend to further develop our internal manufacturing capabilities and to continue to expand our high-quality network of suppliers to increase capacity. We believe that our ability to conduct our manufacturing process at the <FONT
STYLE="white-space:nowrap">200-liter</FONT> scale with high product quality suggests that further scaling to thousands of liters per batch is feasible using standard biological production equipment and engineering methods. We believe the combination
of the expected multi-year durability of a single dose of ceDNA, tissue-specific delivery and manufacturing capacity may provide dosing for millions of patients living with prevalent diseases. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expand patient access to our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies through a
high-value network of alliances and collaborations.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We are developing a broad and expandable portfolio of gene therapies that have the distinct opportunity to address rare monogenic diseases, as well as prevalent
diseases. To help us realize the full breadth of opportunities and to expedite patient access to our gene therapies, we have established and plan to continue to explore a limited set of innovative collaborations and strategic alliances with
biopharmaceutical companies whose capabilities and resources are additive or complementary to our own. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Build a sustainable leadership position in <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy
as a fully integrated innovative biotechnology company.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We have established a leading position in <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy for gene transfer by investing in our ceDNA, ctLNP and
manufacturing technologies and capabilities, and by rigorously protecting our innovations through an expanding intellectual property portfolio. We intend to evaluate and invest in new technologies that may further
<FONT STYLE="white-space:nowrap">de-risk</FONT> and accelerate the development of our new class of gene therapy, and to build out our capabilities to commercialize our gene therapies on our own. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is comprised of three essential components: our high-capacity ceDNA construct,
which can accommodate large or multiple genes as well as native regulatory elements; our ctLNP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivery system, which enables highly specific delivery of ceDNA to a range of tissues; and our established, scalable capsid-free manufacturing process, which uses a cost-effective biologics
infrastructure that has the potential to reach patients with rare diseases and to expand access to patients with prevalent diseases, requiring millions of doses on a sustainable basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The three components of our platform are designed to enable critical features that address key limitations of existing genetic medicines. The ceDNA construct
is designed to enable durable expression with a single dose. As shown in the figures below, in immunocompetent mice, a single intravenous dose of ceDNA formulated in an LNP provided months-long expression in the liver using both the reporter protein
luciferase (denoted in the left figure below as Luc ceDNA/LNP) and human Factor IX, or FIX, the protein that is missing or defective in hemophilia B (denoted in the right figure below as FIX ceDNA/LNP). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">ceDNA-LNP:</FONT> durable expression in immunocompetent mice after single IV administration </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g11a64.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the figure below, ceDNA delivered in an LNP could be redosed in mice with normal immune systems
because the first dose did not induce neutralizing antibodies. As the figure demonstrates, in immunocompetent mice, redosing ceDNA formulated in an LNP achieved increased expression using both reporter protein luciferase (denoted in the left figure
below as Luc ceDNA/LNP) and human FIX (denoted in the right figure below as FIX ceDNA/LNP). In both studies, we intravenously administered ceDNA formulated in an LNP and then repeated the administration five weeks later. After the first
administration of Luc ceDNA/LNP, mice demonstrated stable expression of luciferase protein and then higher, stable expression after repeat administration. After the first administration of FIX ceDNA/LNP, mice demonstrated <FONT
STYLE="white-space:nowrap">5-10%</FONT> activity levels of FIX protein in the blood and then <FONT STYLE="white-space:nowrap">10-20%</FONT> activity after repeat administration. These results support our belief that our platform may enable us to
titrate every patient to the desired level of protein expression. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">ceDNA-LNP:</FONT> redosing achieves
increased expression in immunocompetent mice </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g61b88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the figure below, our upstream manufacturing process is comparable to biologics manufacturing and includes
accumulation of ceDNA in Sf9 cells, which are then lysed to harvest ceDNA. The downstream process includes high-capacity purification of ceDNA drug substance, followed by ctLNP formulation. We have successfully completed ceDNA drug substance and
purification runs of one liter, 50 liters and 200 liters, with a consistent processing time in the manufacturing plant of three weeks per run. With the process and controls we have developed, we achieve greater than 99% purity ceDNA following the
downstream purification process, and have consistently demonstrated this up to the <FONT STYLE="white-space:nowrap">200-liter</FONT> scale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview of our capsid-free manufacturing process </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g47s43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Closed-ended DNA (ceDNA) construct </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ceDNA was discovered by our scientific <FONT STYLE="white-space:nowrap">co-founder</FONT> Robert Kotin, who during his two decades as a senior investigator at
the NIH also invented the Sf9 AAV production system and discovered the insertion site for AAV on chromosome 19. We have continued to build upon Dr.&nbsp;Kotin&#146;s work by assembling an expert team of leaders in molecular biology in order to
deepen our understanding of ceDNA biology. In addition, we are expanding on Dr.&nbsp;Kotin&#146;s early work to create a broad palette of structural and sequence motifs for ceDNA constructs to explore novel mechanisms and to address multiple
diseases. We are also deepening our expertise in computational biology, virology and cell biology to exploit the potential of large genomic datasets to elucidate the mechanisms underlying large subsets of prevalent and complex diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ceDNA is an engineered, double-stranded, linear, covalently closed-ended DNA construct, with no free ends or viral capsid. As shown in the figure below, ceDNA
includes the target gene or genes of interest, along with key components of the expression cassette, which is the full genetic sequence necessary to derive transcription including spacers, promoters and untranslated regions flanked by two inverted
terminal repeat, or ITR, sequences. By gene of interest, we specifically mean the transcribed region of the target gene. ITRs, which are also present in AAV technology, are thought to be critical for durable expression in the nucleus of cells. To
date, we have designed, produced and purified ceDNA constructs of up to 12 kb and have not identified an upper limit of construct length. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ceDNA structure </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g32r93.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nuclear entry </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In an AAV system, it is thought that the capsid mediates nuclear entry. For our capsid-free <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy, we
believe our ceDNA accesses the nucleus due to a previously unrecognized function of the ITR structure. In an <I>in vitro</I> study, we injected plasmid lacking ITR sequences, plasmid containing ITR sequences and ceDNA into the cytoplasm of
individual cells. As shown in the figure below, the plasmid lacking ITR sequences was not able to access the nucleus, and the plasmid containing ITR sequences resulted in low but measurable expression. By contrast, ceDNA displayed positive green
fluorescent protein, or GFP, expression, indicating that the ceDNA had effectively translocated to the nucleus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ceDNA&#146;s ITR
structure drives translocation to the nucleus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g35b35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Episomal expression </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ceDNA-derived expression has been observed in <I>in vivo </I>and <I>in vitro </I>studies to be episomal, meaning that it can deliver genetic material outside
of the chromosome without being directly incorporated into or altering the cell&#146;s genome. This characteristic of ceDNA is a potentially important safety feature of our redosable gene therapy platform. In cell culture studies, as depicted in the
figure below, the expression in dividing cells transfected with ceDNA encoding GFP decayed rapidly as the cells divided, consistent with lack of genomic integration as each successive cell division effectively diluted the amount of ceDNA in new
generations of cells. In contrast, in cells transfected with ceDNA encoding GFP which are post-mitotic and therefore not dividing, we observed sustained and durable GFP expression over the course of two weeks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ceDNA-derived GFP expression observed to be episomal </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g13s54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ceDNA capacity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
large payload capacity of ceDNA enables our constructs to carry large genes, multiple genes, or combinations of genes with regulatory elements. This capacity arises from the lack of capsid packaging constraints that limit DNA incorporation in AAV
gene therapy to less than 4.7 kb. Our established, scalable manufacturing process routinely prepares constructs of up to 12 kb in length without loss in yield or quality. We have not identified an upper limit of construct length. We believe ceDNA
can deliver a significant majority of the human coding sequences known to be relevant for the treatment of diseases that result from mutations in a single gene or in multiple genes. The practical applications of increased capacity include the
ability: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to improve expression of existing targets of viral gene therapy and mRNA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to incorporate genes too large to be packaged in viral vectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to include multiple genes, or to produce more than one transcript, which opens the possibility of creating
several therapeutic molecules per ceDNA to address conditions that need more than one type of genetic correction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add native regulatory elements that are naturally associated with the gene we are replacing, which may allow
for activity of the replaced gene to increase or decrease in response to the body&#146;s own signals. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have observed the impact of the increased payload capacity of our constructs on improved expression
efficiency in <I>in vitro </I>and<I> in vivo</I> studies. We undertook studies of Factor VIII, a protein involved in the coagulation cascade. Defects in Factor VIII are known to give rise to hemophilia A. Factor VIII is a large protein having a
minimal gene of interest domain accounting for 4.4 kb (in the <FONT STYLE="white-space:nowrap">B-domain</FONT> deleted format) which is almost the entire AAV capsid capacity. For this reason, AAV Factor VIII constructs currently in clinical
development contain the minimal, <FONT STYLE="white-space:nowrap">B-domain</FONT> deleted coding region along with a small core promoter of 0.3 kb and limited transcriptional enhancer regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have designed ceDNA constructs that have larger promoter elements and more substantial transcriptional enhancer regions than can be accommodated within the
payload capacity of AAV. We have observed in a mouse model that a ceDNA construct, labeled as GB ceDNA in the figure below, showed <FONT STYLE="white-space:nowrap">six-fold</FONT> improved expression of Factor VIII relative to ceDNA constructs with
the expression cassette of each of three AAV Factor VIII product candidates currently in clinical development. The identification of constructs with improved potency may enable us to lower the dose required to achieve therapeutic efficacy. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Increased ceDNA payload capacity enables the design of more potent constructs </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g25k44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to improving the activity of typical AAV target genes like Factor VIII, the capacity of ceDNA allows us to
address monogenic diseases caused by large genes whose coding region is outside of the packaging capacity of AAV. One such example is LCA10, the most common genetic cause of childhood vision loss. LCA10 is caused by mutations in the CEP290 gene,
which has a gene of interest region of 7.4 kb. Since this exceeds the payload capacity of AAV, there are no current transfer-based gene therapy programs in clinical trials for LCA10. By replacing the entire gene, gene therapy can potentially restore
vision to patients with all forms of LCA10, irrespective of which mutation is present. We have created a ceDNA construct encoding the CEP290 gene that has demonstrated expression of full-length protein after transfection in cells, as shown in the
immunoblot below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expression of full length CEP290 </B><B><I>in vitro</I></B><B> </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g108483g27s60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In <I>in vivo </I>studies, we have encoded and expressed two different proteins independently within the same ceDNA
construct. To do this, we created a ceDNA that independently expressed heavy and light chain fragments of the antibody immunoglobulin, or IgG, with unique promoters for each, a requirement for producing distinct and separate proteins off one
construct. Each promoter, a unique sequence that defines where DNA transcription starts, governs the independent production of its own transcript. This construct was able to produce fully formed and secreted IgG <I>in vivo, </I>as shown in the
figure below. This ability to include novel multi-gene constructs to produce complex biologics, such as monoclonal antibodies, also opens the potential to address conditions that need more than one type of genetic correction, such as one that could
knock down a gene and another that replaces a missing or defective gene. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ceDNA dual promoter construct produced fully formed and
secreted IgG </B><B><I>in vivo</I></B><B> </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g14a64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also shown in <I>in vitro </I>studies that our constructs can establish context-dependent expression by inclusion
of regulatory sequences. The inclusion of regulatory sequences may enable expression of the therapeutic protein to adjust in response to changes in the patient&#146;s body, an example of which might be an anti-inflammatory antibody that is only
expressed when the patient is in an inflammatory state. For these studies, we created a construct that contained multiple simian virus 40, or SV40, -derived nuclear factor kappa-light-chain-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enhancer of activated B cells, or NF<FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>b, and <FONT STYLE="white-space:nowrap">DNA-targeting</FONT> sequences, or DTS, that are known to be responsive
to tumor necrosis factor alpha, or TNF&#945;. As shown in the figure below, expression in HepG2 cells, as measured in reflected light units, or RLUs, was significantly increased in the presence of TNF&#945; relative to control. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulatory elements increased expression with TNF</B>&#945;<B></B><B> stimulus </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g15e64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe this finding supports the potential to develop context-dependent expression cassettes and to take advantage of
the sequence capacity necessary to accomplish this. Another example of such an application would be the inclusion of the native promoter in a construct expressing ABCB4 for progressive familial intrahepatic cholestasis type III where the native
promoter is approximately 3.0 kb in size, which restricts its application in viral gene therapy. We have prepared this ceDNA and demonstrated that it expresses protein in cell culture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development of ceDNA has dramatically increased our understanding of the construct&#146;s properties, capabilities and <I>in vivo</I>
functioning. We have filed numerous patent applications on our innovations in ceDNA structure, applications of the technology and specific classes of therapeutic ceDNA. We intend to continue investing in both ceDNA development and its intellectual
property protection. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cell-targeted LNP (ctLNP) delivery system </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lipid nanoparticle&nbsp;technology has been developed over the past two decades for the effective delivery of nucleic acids to the liver, culminating in the
first approved small interfering RNA, or siRNA, therapy for the treatment of transthyretin amyloidosis. Second-generation LNP technologies incorporate novel lipid components that improve potency, increase tolerability and are biodegradable. A
second-generation LNP was recently clinically validated in a Phase 1 study of a passive immunization approach to Chikungunya virus. We have hired a team of chemists and formulation scientists along with cellular biologists and pharmacologists to
advance our LNP technology and expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building on the attributes of both the first- and second-generation LNP technology, we have designed our ctLNP
delivery platform so that its biodistribution can be selectively controlled through the addition of a targeting molecule, or ligand. In addition, our ctLNP may confer the advantages of predictable behavior across species, minimal <FONT
STYLE="white-space:nowrap">off-target</FONT> effects, and a foundational platform approach that unlocks the ability to delivery to other tissues, including retina, skeletal muscle, the CNS and tumors. The graphic below illustrates the evolution from
first generation LNPs to ctLNP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novel ctLNP enables biologically-driven cell and tissue targeting </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g64y37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key feature of our ctLNP technology is the use of biological targeting ligands. This is a strategy that is shared with
antibody-drug conjugates and with oligonucleotide conjugates, both of which have demonstrated clinical success. The application of targeting ligand technology has historically been unavailable to nanoparticles. This is primarily due to the <FONT
STYLE="white-space:nowrap">non-specific</FONT> and efficient uptake of nanoparticles by cells of the reticuloendothelial system, or RES, a system of cells that removes immune complexes and foreign particulates from circulation in healthy persons,
and historically overwhelms the effectiveness of the targeting ligand. We have applied our chemistry and formulation capabilities to identify LNPs that avoid <FONT STYLE="white-space:nowrap">RES-mediated</FONT> clearance, which has enabled the use
of biological targeting ligands. We have achieved proof of concept for tissue-specific delivery with ctLNP <I>in vivo</I> for liver and retina and <I>in vitro</I> for skeletal muscle. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liver </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have employed
<FONT STYLE="white-space:nowrap">N-acetyl</FONT> galactosamine, or GalNAc, as the ligand of choice for targeting the majority of liver cells, called hepatocytes, specifically in the liver through the asialoglycoprotein receptor, or ASGPr, a well
validated, selective ligand-receptor pair for delivery to hepatocytes that is conserved across species including mouse, rat, <FONT STYLE="white-space:nowrap">non-human</FONT> primates and humans. Prior third-party research has shown that the
pharmacology of the ASGPr receptor in <FONT STYLE="white-space:nowrap">non-human</FONT> primates is strongly correlated with the pharmacology of the ASGPr receptor in humans. GalNAc targeted oligonucleotides have also demonstrated broad distribution
to all hepatocytes. When we dosed GalNAc targeted ctLNPs in mice, we observed a profound selectivity for ceDNA delivery to the liver. As shown in the left figure below, ceDNA was distributed selectively to the liver, with more than 97% of the total
ceDNA copies in that tissue. By contrast, less than 3% of the copies per tissue was present in blood, lung, spleen and kidney combined. This stands in contrast to first generation LNPs, as shown in the middle and right figures below. At six hours
post administration, first generation LNPs distribute equal ceDNA copies in spleen relative to liver. In contrast, distribution of ceDNA with ctLNP is highly selective for liver at this time point. This selectivity enhancement of ctLNP relative to
first-generation LNP minimized <FONT STYLE="white-space:nowrap">off-target</FONT> effects and enabled well-tolerated dosing up to 5.0 mg/kg in mice. When we examined the liver tissue by <I>in situ</I> hybridization, we observed up to 100% of
hepatocytes transduced with ceDNA at early time points, highlighting the breadth of distribution of ctLNP. Additionally, we have demonstrated the successful dosing of a ctLNP in preliminary <FONT STYLE="white-space:nowrap">non-human</FONT> primate
experiments at doses up to 0.5 mg/kg. The 0.5 mg/kg ctLNP dose level was tolerated and not associated with signs of hepatotoxicity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>ctLNP Longitudinal PK in mice</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Biodistribution by tissue at 6hr for 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Gen LNP</B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g108483g31h01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have demonstrated in mice both high-level and dose-dependent expression from ceDNA incorporating our ctLNP system using
a reporter ceDNA that expresses firefly luciferase after a single intravenous administration on day one. The expression was also determined to be dose proportional as we increased the ctLNP from 0.5 mg/kg to 2.0 mg/kg, as shown in the left figure
below. The protein expression was specific to the liver region as determined by <FONT STYLE="white-space:nowrap">in-life</FONT> imaging, as shown in the right figure below. We continue to apply chemistry and formulation optimization efforts to
improve the activity of ctLNP, with our latest ctLNPs providing three to five times improvements in expression over our first iteration. We plan to continue to make further improvements in this technology. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>High-level and dose-dependent luciferase expression from ceDNA-ctLNP </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g32u77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In two further <I>in vivo</I> studies, we demonstrated translation of expression from mice to <FONT
STYLE="white-space:nowrap">non-human</FONT> primates and confirmed delivery of ceDNA to the liver via ctLNPs in <FONT STYLE="white-space:nowrap">non-human</FONT> primates. In the studies, we delivered the same weight-adjusted dose of a ceDNA
construct in each species systemically via a liver-directed ctLNP and observed an approximately 2:1 species translation from mice to <FONT STYLE="white-space:nowrap">non-human</FONT> primates. In the first study, we observed a mean human factor VIII
expression level of approximately 1% of normal levels in mice at day 7 following a single 1.0 mg/kg dose of the ceDNA construct and a mean human factor VIII expression level of approximately 1% of normal levels in
<FONT STYLE="white-space:nowrap">non-human</FONT> primates at day 5 using identical material and weight-adjusted dosing (1.0 mg/kg) as shown in the left figure below. In the second study, employing a slightly different ctLNP, we observed a mean
human factor VIII expression level of approximately 3% of normal levels in mice at day 5 following a single 2.0 mg/kg dose of the ceDNA construct and a mean human factor VIII expression level of approximately 1% of normal levels in <FONT
STYLE="white-space:nowrap">non-human</FONT> primates at day 5 using identical material and weight-adjusted dosing (2.0 mg/kg) as shown in the right figure below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All doses in mice and <FONT STYLE="white-space:nowrap">non-human</FONT> primates were well-tolerated up to the highest dose of 2.0 mg/kg. There were no
adverse clinical observations, changes in clinical pathology, or histopathology findings including in the liver and spleen in <FONT STYLE="white-space:nowrap">non-human</FONT> primates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Species translation with research construct (systemic IV administration via ctLNP, day 5
or 7) </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g63z71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Retina </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to
assessing the specificity and activity of ctLNP established for systemic administration to the liver, we have also assessed ctLNP in local administration to the retina in the eye. Second-generation LNPs containing ceDNA, when dosed subretinally
<I>in vivo </I>in rats, led to significant inflammation and retinal degeneration and failed to express protein. This degeneration is evident by measuring the thickness of the outer nuclear layer, or ONL, by optical coherence tomography imaging,
shown in the yellow labels in the figures below. By contrast, administration of ctLNP subretinally <I>in vivo</I> in rats led to high levels of expression and lack of retinal degeneration at day 21. We believe this improved retinal tolerability
profile is due to ctLNP avoiding <FONT STYLE="white-space:nowrap">off-target</FONT> delivery to local immune cells. We have additionally demonstrated efficient transduction of retinal photoreceptor and retinal pigment epithelial, or RPE, cells with
ctLNP, which we believe enables disease relevant expression for our lead retinal programs, LCA10 and Stargardt disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subretinal injection of ceDNA-ctLNP led to high levels of expression and lack of retinal
degeneration </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g35w02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Skeletal muscle </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have identified a number of potential ligands for skeletal muscle and have been able to conjugate peptide-based ligands to ctLNP that have enhanced uptake into a differentiated skeletal muscle cell line, or myocyte, <I>in</I> <I>vitro</I>. These
peptide-based ligands target known receptors, such as the transferrin receptor that is present on the surface of skeletal muscle. ctLNPs that include these peptide-based ligands on the surface of the particle show high levels of uptake in muscle
cells in culture. We have observed this in <I>in vitro</I> studies in which we included a red dye in the ctLNP enabling quantification of uptake into these cells, as shown in the figure below. We are pursuing muscle-targeted ctLNPs for <I>in
vivo</I>, systemic administration to target skeletal muscle and replace missing or defective genes, such as dystrophin in Duchenne Muscular Dystrophy. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ctLNP targeting skeletal muscle using peptide ligand </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g02c06.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Enhanced uptake in c2c12 myocytes </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g26l36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LNPs are one of the most advanced <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery solutions for nucleic acid
therapeutics. We have built on the attributes of the second generation of clinical LNPs, which include improved tolerability through utilization of biodegradable lipids. Specifically, we have engineered our ctLNP to allow for active targeting of
specific cell types <I>in vivo</I>. Targeted delivery of DNA <I>in vivo</I> without incurring innate immune reactions has long been a challenge in the field. The profile of our ctLNP has led to further improvements in tolerability, increased
delivery efficiency and application to tissues beyond liver and immune cells. Our ctLNP delivery system has shown proof of concept <I>in vivo</I> in liver and retina with <I>in vitro</I> proof of concept for skeletal muscle. We plan to continue to
seek to optimize ctLNP for use in liver, retina and skeletal muscle and to expand its application across a range of tissues, including the CNS and tumors. We have filed numerous patent applications to solidify our leadership in this area, including
ones covering fundamental LNP technology as well as methods to avoid or reduce immune response. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Established, scalable manufacturing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our founding, we have invested in internalizing core development capabilities to build our manufacturing processes and analytical testing as a point of
strength. We have recruited a seasoned team of development and manufacturing experts who have enabled more than 20 INDs and negotiated multiple product launches, including for both a cell and a gene therapy product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have built
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> development laboratories to create novel upstream and downstream processes as well as analytical methodologies
that have shifted the product profile from early research efforts of approximately 10% pure ceDNA to one that is consistently greater than 99% pure ceDNA. Our current internal development efforts are focused on industrialization of the process to
enable unit operations that are scalable using standard biological production equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our established, scalable manufacturing employs a proprietary,
capsid-free process and utilizes standard biologics infrastructure, unlike traditional viral gene therapy manufacturing. Viral gene therapy relies on a protein capsid for therapeutic delivery of a viral vector, and as a result, the manufacturing
process for viral gene therapies requires the production of protein capsids, which limit process scalability and consistency. Our capsid-free manufacturing process is an efficient and reproducible process that includes rigorous, industrial-scale
purification that consistently yields greater than 99% pure ceDNA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have completed ceDNA drug substance and purification runs of one liter, 50 liters
and 200 liters, with a consistent processing time in the manufacturing plant of three weeks per run, and greater than 99% purity ceDNA following the downstream purification process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We now routinely produce material at <FONT STYLE="white-space:nowrap">50-liter</FONT> scale internally to support research studies, and our CDMOs have
produced material at <FONT STYLE="white-space:nowrap">200-liter</FONT> scale, using our cGMP-ready process, to supply <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies and early clinical trials. Additional development efforts
have been initiated to further scale the process to thousands of liters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scalability and productivity of the manufacturing process is a significant
driver of the cost-effectiveness of any therapeutic. We believe being able to produce ceDNA at a scale of thousands of liters per batch should </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enable a significant reduction in our overall cost of goods, and our goal over time is to be competitive with traditional biologics in scale and cost. We believe that our ability to conduct our
manufacturing process at the <FONT STYLE="white-space:nowrap">200-liter</FONT> scale with high product quality suggests that further scaling to thousands of liters is feasible using standard biological production equipment and engineering methods.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Significant cost and scale advantage, eventually comparable to biologics </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g90s31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ongoing work in manufacturing technology has led to numerous innovations in production processes and analytics, some of
which may have broader applications in related fields. We continue to seek to protect the full reach of these discoveries through both patent application filings and as trade secrets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform represents a powerful product engine fueled by ceDNA, which in preclinical studies has provided durable episomal expression with large capacity, and our highly selective and modular
ctLNP delivery system. We have designed the combination of these platform components with a goal of enabling a broad and expandable product portfolio that can be deployed against a range of tissues, including liver, retina, skeletal muscle, the CNS
and tumors. These characteristics are supported by our established, scalable capsid-free manufacturing process, which supports the potential to extend the reach of gene therapy beyond rare diseases to prevalent diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our integrated research and development approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
development strategy is differentiated and informed by our extensive experience in rare disease drug development, regulatory engagement and commercialization. We are focused on diseases with significant unmet need for which our <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform may substantially improve clinical efficacy relative to current gene therapy approaches. We are initially prioritizing rare monogenic diseases of the liver and retina that have
well-established biomarkers and clear clinical and regulatory pathways. We plan to incorporate redosing in our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trials, which may allow us to
reach the desired therapeutic expression level in every patient, providing early and robust human proof concept. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In parallel, we are developing the
constructs and manufacturing capacity for programs to address additional rare and prevalent diseases. We have established a highly efficient eight-week research cycle to rapidly design, produce and screen ceDNA constructs to enable new disease
programs within a tissue once human proof of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concept is established. By leveraging a common ctLNP for each tissue, we believe we can reduce the risk and accelerate the speed of development for subsequent indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research cycle, illustrated in the figure below, utilizes <I>in vitro</I> activity screens of novel plasmid DNA designs, followed by <I>in vivo</I>
activity screens of select ceDNA constructs. We have iteratively employed this cycle to rapidly identify ceDNA constructs that achieve disease correction in animal models and have observed that learnings from our more mature programs accelerate our
ability to identify effective ceDNA constructs for subsequent indications. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our eight-week research cycle rapidly identifies ceDNA
constructs for new programs </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g54x17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to apply this integrated research and development strategy across liver, retina, skeletal muscle, oncology and the
CNS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our portfolio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a broad and
expansive portfolio including programs for rare and prevalent diseases of the liver and retina. We are focused on diseases with significant unmet need for which our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform may
substantially improve clinical efficacy relative to current gene therapy approaches. We are initially prioritizing rare monogenic diseases of the liver and retina that have well-established biomarkers and clear clinical and regulatory pathways. We
plan to expand our portfolio to include rare and prevalent diseases of the skeletal muscle, the CNS and oncology by developing discrete ctLNPs, each engineered to reach a different tissue. As shown in the figure below, our most advanced liver
disease programs are in hemophilia A and PKU, which are in the preclinical stage of development, and our most advanced retina disease programs are in LCA10 and Stargardt disease, which are in the lead optimization stage of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we believe that our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform may allow patients to produce antibody therapies from
their own cells for years at a time from a single dose and plan to advance programs to deliver antibody genes, directing the body&#146;s own cells to express and secrete therapeutic antibodies. We believe the combination of the expected multi-year
durability of a single dose of ceDNA, tissue-specific delivery and manufacturing capacity may provide dosing for millions of patients living with prevalent diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g52r77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within the therapeutic area of the liver, we have established programs for inborn errors of metabolism in PKU and Wilson
disease. We are also advancing programs for systemic disorders in which the liver can be utilized to secrete therapeutic proteins in hemophilia A, Gaucher disease and antibody gene therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to utilize our eight-week research cycle to rapidly design, produce and screen ceDNA constructs for other diseases within a tissue, so that we may
rapidly expand clinical development efforts to include additional rare and prevalent diseases once human proof of concept is established in that tissue. For instance, if human proof of concept is established in PKU, we plan to rapidly expand our
development efforts to include additional inborn errors of metabolism such as progressive familial intrahepatic cholestasis 2, or PFIC2, glycogen storage disease type 1a, or GSD1a, and ornithine transcarbamylase deficiency, or OTC. Similarly, if
human proof of concept in hemophilia A is established, we plan to expand our programs in other diseases requiring secretion of therapeutic proteins such as Gaucher disease, Pompe disease, hereditary angioedema, or HAE, alpha1-antitrypsin deficiency,
or A1AT, antibodies against <FONT STYLE="white-space:nowrap">Cov-2</FONT> and human immunodeficiency virus, or HIV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to apply this strategic
approach of rapid expansion following initial human proof of concept in a therapeutic area across our portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liver diseases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the majority of our liver programs, we have designed and manufactured disease-modifying ceDNAs that have shown expression <I>in vitro</I> and/or disease
correction <I>in vivo</I>. We have employed GalNAc as the targeting ligand in our ctLNP delivery system to selectively drive biodistribution to the liver. GalNAc binds to the ASGPr on hepatocytes, and the biology of this selective ligand-receptor
pair for delivery to hepatocytes has been well validated in human clinical trials. For each liver program, we plan to formulate ceDNA within a ctLNP-GalNAc expressing the relevant gene of interest for intravenous delivery. GalNAc targeting has been
demonstrated to efficiently deliver ceDNA to up to 100% of hepatocytes and we believe that broad biodistribution of ctLNP-GalNAc to hepatocytes will be a key strength of our pipeline programs since current gene therapy approaches deliver payload to
30% or fewer of hepatocytes with a single dose. Additionally, our potential to redose patients until they are in the therapeutic range of expression may enable early and robust human proof of concept in Phase 1/2 clinical trials and is a key
differentiator from current gene therapy approaches. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hemophilia A </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hemophilia A is a rare <FONT
STYLE="white-space:nowrap">X-linked</FONT> hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation Factor VIII. There are approximately 16,000 hemophilia A
patients in the United States and 320,000 patients worldwide. Because of the deficiency of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coagulation Factor VIII, hemophilia A patients bleed in joints, muscles, soft tissues and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending
on the severity of the disease. The clinical presentation of hemophilia A can be mild, moderate or severe, depending on the residual level of circulating Factor VIII. The diagnosis of hemophilia A is often made at a young age, earlier than 36
months, based on persistent bleeding or internal hemorrhage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most patients with hemophilia A in the United States and the European Union are currently treated with clotting factors according to practice guidelines, which
are relatively consistent around the world. Children are generally treated prophylactically, while adults may be treated either prophylactically or on demand, depending on the residual level of Factor VIII activity in the blood. Compliance with
clotting factors is 50% to 80%, and up to 30% of patients with severe disease develop inhibitors to Factor VIII replacement. Approximately 75% of hemophilia A patients worldwide still receive inadequate treatment or have no access to treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HEMLIBRA (emicizumab) is a bispecific Factor <FONT STYLE="white-space:nowrap">IXa-</FONT> and Factor <FONT STYLE="white-space:nowrap">X-directed</FONT>
antibody indicated for routine adult and pediatric patients ages newborn and older with hemophilia A. However, this product has safety concerns as several cases of thrombotic microangiopathy/thrombosis have occurred, in some cases in the context of <FONT
STYLE="white-space:nowrap">co-administration</FONT> of activated prothrombin complex concentrate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are several AAV gene therapies currently in
late-stage clinical trials, including Valrox (valoctocogene roxaparvovec), for which a biologics license application, or BLA, is under review by the FDA. Early data from these trials have shown variation in the amount of Factor VIII expressed from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">patient-to-patient</FONT></FONT> with a substantial proportion of patients either becoming supratherapeutic or remaining subtherapeutic after Valrox administration. Many hemophilia A
patients have <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity to AAV and, therefore, are not candidates for this therapy. Mean Factor VIII levels decline over two to three years after treatment with Valrox, which means that it is
possible that patients will become subtherapeutic over three to five years and cannot be redosed with AAV gene therapy. In addition, AAV gene therapy will not be available to children with hemophilia A since their livers are still growing and only
one dose is possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no current or investigational therapies that have been shown to durably induce therapeutic Factor VIII levels in all
patients of all ages, nor therapies that can be redosed when Factor VIII expression wanes through the life of the patient. Given the variable response to gene therapy in patients with hemophilia A, titration at onset of therapy is critical to ensure
that all patients get within a therapeutic range. Since there are potential consequences to expressing too much Factor VIII, such as excess blood clotting, the ability to titrate the therapy will enable an optimal dosing regimen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our gene therapy approach aims to do the
following in hemophilia A: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve therapeutic Factor VIII levels in patients of all ages, resulting in normalization of bleeding risk;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">treat infants and children to prevent bleeds early in disease and prevent irreversible tissue and organ
dysfunction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve the desired level of gene expression in a greater proportion of patients participating in our early
clinical trials through our ability to redose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that all patients achieve curative levels of Factor VIII of greater than 25% of normal activity levels
with the ability to titrate expression to higher target levels for some patients as needed based on lifestyle and circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver ceDNA-FVIII to a large percentage of hepatocytes resulting in a relatively low burden of expression for
each hepatocyte, which may lead to more durable expression compared to other gene therapy modalities; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase the safety index by achieving therapeutic Factor VIII levels at lower doses because of more potent
ceDNA-FVIII constructs and greater hepatic biodistribution. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach has the potential to titrate expression in each patient to
reach target Factor VIII levels, avoiding supratherapeutic levels and minimizing the thrombotic, or clotting, risk to the patient. In addition, we can potentially treat patients for life by episodically following Factor VIII levels and redosing as
needed, should expression wane over time. Redosing may also enable broader access for all patients with severe disease, and for children with mild to moderate disease severity who are currently managed through
<FONT STYLE="white-space:nowrap">on-demand</FONT> treatment, as shown in the right figure below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have created multiple distinct ceDNA-FVIII constructs
with different expression cassette elements, including promoter, intron, untranslated regions, or UTRs, and codon optimization sequences.<I> In vitro</I> screening of ceDNA-FVIII constructs revealed that several constructs express Factor VIII, as
defined by functional activity measures, as shown in the figure below. All of our ceDNA constructs, labeled as GB ceDNA in the figure below, expressed greater activity of FVIII compared to a ceDNA construct with the expression cassette of an <FONT
STYLE="white-space:nowrap">AAV-FVIII</FONT> product candidate that is currently in clinical trials, AAV #1, with some expressing up to <FONT STYLE="white-space:nowrap">six-fold</FONT> more Factor&nbsp;VIII activity. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Several ceDNA-FVIII demonstrated greater activity compared to <FONT STYLE="white-space:nowrap">AAV-FVIII</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g66z31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The enhanced potency of our ceDNA-FVIII constructs has also been confirmed <I>in vivo</I>. In an <I>in vivo</I> study, we
measured serum levels of human Factor VIII after hydrodynamic injection of various ceDNA constructs into the tail vein of mice and assessed protein levels by <FONT STYLE="white-space:nowrap">enzyme-linked</FONT> immunosorbent assay for human Factor
VIII. As shown in the figure below, two ceDNA constructs listed as GB ceDNA #1 and GB ceDNA #2 demonstrated 1.0 and 6.0 IU/ml Factor VIII activity, or 100% and 600% of normal levels, respectively. In contrast, at the same dose, ceDNA constructs with
the expression cassette of each of three <FONT STYLE="white-space:nowrap">AAV-FVIII</FONT> product candidates currently in clinical development, demonstrated approximately 0.5 IU/ml Factor VIII activity, or 50% of normal levels in animals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>In vivo</I></B><B> activity of ceDNA-FVIII constructs </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g66t01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The direct relevance of having more potent ceDNA constructs is that the input dose required to have a therapeutic effect
may be lower, thereby increasing the safety profile and lowering the metabolic requirements on individual hepatocytes to produce and secrete Factor VIII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a separate <I>in vivo</I> study, we achieved targeted levels of human factor VIII expression in hemophilia A mice at day 10 following a single dose of a
ceDNA construct delivered systemically via a liver-directed ctLNP. In this study, which was conducted in three cohorts, we observed a dose-response relationship with a mean human factor VIII expression level of 23% of normal levels following a dose
of 2.0 mg/kg, a mean human factor VIII expression level of 16% of normal levels following a dose of 1.0 mg/kg and a mean human factor VIII expression level of 9% of normal levels following a dose of 0.5 mg/kg as shown in the figure below. The doses
were well-tolerated by the hemophilia A mice at all dose levels. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expression of FVIII in mice dosed with hemophilia A development
construct </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(systemic IV administration via ctLNP at Day 10) </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g75p65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approximately 2:1 expression ratio from mice to <FONT STYLE="white-space:nowrap">non-human</FONT> primates that we
historically observed is similar to expression ratios from mice to <FONT STYLE="white-space:nowrap">non-human</FONT> primates observed across other modalities delivered via LNPs, including RNA interference and mRNA, and we believe establishes a
basis for us to select a development candidate in our hemophilia A program. The expression levels in mice using a ceDNA construct, coupled with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the approximately 2:1 expression ratio from mice to <FONT STYLE="white-space:nowrap">non-human</FONT> primates and the expected 1:1 translation from
<FONT STYLE="white-space:nowrap">non-human</FONT> primates to humans that has been established for LNPs, support the selection of a final hemophilia A clinical development candidate. The expression levels we observed may correspond to or exceed the
human factor VIII expression level of 5% of normal levels that has been clinically demonstrated to prevent serious bleeds in patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate achieving proof of concept for biodistribution and durable expression in <FONT STYLE="white-space:nowrap">non-human</FONT> primates
using our ctLNP with a reporter protein such as Factor IX in 2021. We plan to begin <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in 2021, and to submit an IND application for this program in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phenylketonuria </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PKU is a rare autosomal recessive genetic disorder caused by deficiency of the hepatic enzyme phenylalanine hydroxylase, or PAH, that metabolizes the essential
amino acid phenylalanine, or Phe, to tyrosine, or Tyr, an essential amino acid for CNS development and function. PAH deficiency leads to elevated levels of Phe in the blood and toxic Phe accumulation in the brain resulting in neurocognitive
manifestations including failure to attain early developmental milestones and progressive impairment of cerebral function. Patients with uncontrolled severe PKU will develop profound neuropsychiatric disorders and irreversible intellectual
disability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are approximately 15,000 patients with PKU in the United States and 41,000 patients in the European Union. PKU is usually diagnosed at
birth through newborn screening, which provides the opportunity to introduce therapies that reduce Phe levels. However, as shown in the left figure below, without strict dietary control, current therapies do not normalize Phe levels. Attaining
consistent levels of Phe in childhood is correlated with higher IQ levels and executive functioning in adults, and short-term spikes in Phe result in long-term impairment of neurocognitive function, as shown in the middle figure below. Even without
optimal correction of Phe levels in childhood, control in adolescent and adult PKU patients has been shown to result in higher levels of executive function and attention and lower levels of depression and anxiety. As shown in the right figure below,
adolescents are unable to maintain such a strict diet, with 50% of patients age <FONT STYLE="white-space:nowrap">10-14</FONT> above the recommended Phe levels and almost 80% of patients outside the normal Phe range in the late teen years. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Early consistent Phe normalization key to neurocognitive outcome </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g21o57.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The standard of care for PKU is strict, life-long dietary modification to control blood Phe levels to the recommended target range of 120 to 360 micromoles per
liter. This requires PKU patients and caregivers to carefully monitor diet and severely restrict protein intake and other <FONT STYLE="white-space:nowrap">Phe-rich</FONT> foods. Medical foods including formula and foods modified to be low in protein
are also required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initiation of a <FONT STYLE="white-space:nowrap">Phe-restricted</FONT> diet is recommended as early as possible in infancy to avoid
irreversible neurocognitive decline due to elevated Phe levels. While this allows some patients to approach target Phe levels, it is challenging to maintain as a life-long treatment. Even with full compliance of dietary therapy during childhood,
many patients have episodic or chronic high Phe levels and suffer irreversible neurocognitive impairment as a result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PALYNZIQ (pegvaliase) and KUVAN
(sapropterin dihydrochloride), a biologic and a small molecule, respectively, are approved in the United States for patients with PKU and both have been shown to have modest benefits in a subset of patients. PALYNZIQ is approved only for adult PKU
patients. KUVAN does not normalize Phe in most patients and has shown to be ineffective in patients with severe PKU. Despite treatment advances, including availability of a larger selection of medical and low protein foods and the approval of the
two treatments, many patients still do not achieve the recommended daily Phe levels and are at risk of developing neurocognitive manifestations, including intellectual disability and neuropsychiatric disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Several AAV gene therapy approaches are currently being tested in clinical trials in patients with PKU. However, following a single dose of AAV, antibodies
are induced against the AAV capsid and thus, AAV gene therapy can only be administered once. The antibodies formed following a single dose of AAV prevent <FONT STYLE="white-space:nowrap">re-treatment</FONT> to increase or extend efficacy for
patients with inadequate initial response or declining levels of expression. Further, it precludes treatment of pediatric patients, whose organ growth and dividing cells would dilute expression over time, and therefore would require redosing. As a
result, these therapies do not have the opportunity to correct PKU at or near the onset of disease, allowing for normal neurocognitive development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given
the limitations of currently approved therapies and the AAV gene therapy approaches under development, there is a substantial unmet need for more effective therapies for PKU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
<FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy approach aims to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve stable correction of Phe levels in PKU patients of all ages upon initial dose or through individualized
patient dose titration, allowing them to normalize their diet, eliminate the burden of ongoing treatment and stabilizing and/or preserving neurocognitive function; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve the desired level of gene expression for each patient through our ability to redose;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">treat patients effectively for life by episodically monitoring serum Phe levels and redosing as needed, should
expression wane over time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reverse attention, memory or executive function deficits in adults and adolescents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preserve normal neurocognitive development in infants and children. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To establish benchmarks for full correction in PKU, we conducted a study utilizing the established mouse model of PKU, known as PAH<SUP
STYLE="font-size:85%; vertical-align:top">enu2</SUP>, a mouse model in which the PAH gene is mutated, leading to dramatically elevated Phe, to assess how many copies of ceDNA, ceDNA-derived PAH RNA and ceDNA-derived PAH protein are required for full
correction in this model. In this study, we administered a <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> construct by hydrodynamic injection into PAH<SUP STYLE="font-size:85%; vertical-align:top">enu2</SUP> mice. As shown in the figure below, we
found that animals that had full correction of Phe, which is greater than 360 micromolar, or &micro;M, had the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> DNA copies in the liver of at least ~0.5 copies per diploid
genome, or dg; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> derived RNA transcripts at least 1 x 10<SUP
STYLE="font-size:85%; vertical-align:top">6</SUP> copies/&micro;g; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> derived protein of at least 10% of normal levels.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Threshold levels for <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> correction in PKU mice </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g108483g98n32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the left figure below, several <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> constructs express PAH protein
at varying levels by Western Blot in cell culture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the right figure below, our most potent <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT>
construct, when administered hydrodynamically, has normalized Phe levels in PAH<SUP STYLE="font-size:85%; vertical-align:top">enu2</SUP> mice. The PAH<SUP STYLE="font-size:85%; vertical-align:top">enu2 </SUP>mice serum samples at baseline exhibited
very high Phe levels of greater than 1500&micro;M, and dropped below target Phe levels (shown by the dashed red line) at three and seven days after IV administration of <FONT STYLE="white-space:nowrap">ceDNA-PAH.</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expression of <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> </B><B><I>in vitro</I></B><B> and correction of Phe after hydrodynamic
injection of <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> </B><B><I>in vivo</I></B><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Expression of <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> by immunoblot</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phenylalanine normalization after hydrodynamic injection of <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> in PKU mice</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g73r83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect
to achieve murine preclinical proof of concept in early 2021, defined as Phe normalization in PAH<SUP STYLE="font-size:85%; vertical-align:top">enu2 </SUP>in mice after administration of <FONT STYLE="white-space:nowrap">ceDNA-PAH</FONT> formulated
in ctLNP. We plan to begin <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in 2021 and to submit an IND application for this program in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Wilson disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson disease is a rare autosomal recessive disease due to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT>
mutation in the ATB7B copper transporter. There are approximately 11,000 patients with Wilson disease in the United States and 17,000 patients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the European Union. Mutations in the ATP7B copper transporter prevent incorporation of copper into ceruloplasmin and diminishes biliary secretion of copper excess, resulting in toxic
accumulation of copper in the liver and brain. Clinically, liver damage begins by six years of life and then progresses with inflammation, fibrosis and joint pain. Many patients also develop CNS manifestations of copper overload, including
psychosis, tremors, dysarthria, or slurred speech and muscle stiffness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no approved gene therapies for Wilson disease. Current treatment approaches include chelators promoting excretion of copper from the body and zinc
salts that reduce copper absorption. These therapies have demonstrated limited effectiveness and safety issues, resulting in poor compliance in patients. The only curative option for acute liver failure related to Wilson disease today is a liver
transplant, which cannot be offered to most patients due to lack of availability of matched donors. The average age of Wilson disease patients undergoing liver transplantation is 15 years old for those who have an available donor, indicating the
need for intervention in childhood to prevent progression to this point. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no current gene therapy clinical trials for Wilson disease. The ATP7B
gene is 4.4 kb, which means the size of the gene plus the remainder of the expression cassette cannot fit within an AAV. One preclinical AAV gene therapy program, known as <FONT STYLE="white-space:nowrap">VTX-801,</FONT> is in development for Wilson
disease utilizing a truncated ATP7B gene that may not have the full functionality of ATP7B. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our gene therapy approach aims to do the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enable full correction of copper metabolism by broadly transducing hepatocytes and utilizing full-length ATP7B
gene and an optimized expression cassette; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve full hepatic correction early in the disease, <FONT STYLE="white-space:nowrap">re-directing</FONT> copper
to be incorporated into ceruloplasmin and normalizing bile excretion, thereby avoiding hepatic and CNS tissue accumulation and irreversible liver fibrosis and neurocognitive decline; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate treatment in children, early in the disease, to prevent the accumulation of liver damage and
irreversible neurocognitive decline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain correction of hepatocytes by redosing to compensate for the effect of injury-driven cell division in the
liver; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve the appropriate therapeutic level of ATP7B needed for correction using serum biomarkers via
individualized patient titration at the onset of therapy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain copper and ceruloplasmin levels in the normal range throughout life with maintenance therapy, as needed.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated Wilson disease plasmid constructs and demonstrated the expression and appropriate
<FONT STYLE="white-space:nowrap">sub-cellular</FONT> location of the expressed protein <I>in vitro</I>. We have induced cells to produce the full length ATP7B protein at 157 kilodaltons using Western Blot, as shown in the figure below. We have also
demonstrated, by immunohistochemistry, appropriate localization of ATP7B in the golgi apparatus around the nucleus within cells, consistent with where native ATP7B localizes. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATP7B plasmid constructs result in full length ATP7B protein production </B><B><I>in vitro</I></B><B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g108483g13d64.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to begin preclinical development in 2021 for this program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gaucher disease, Type 1 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gaucher disease is a rare inherited autosomal recessive disorder caused by the insufficient expression of lysosomal enzyme glucocerebrosidase, or GCase.
Gaucher disease is the most common inherited lysosomal storage disease. There are approximately 6,000 patients with Gaucher disease in the United States and 9,000 patients in the European Union. Ninety percent of Gaucher patients are classified as
Type 1, the most common form, which has no CNS involvement in the disease. Patients with Type 1 disease are typically diagnosed between 10 to 15 years of age. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with Gaucher disease do not produce adequate levels of GCase, which causes glucosylceramide, a toxic lipid, to accumulate in macrophage lineage cells
in visceral organs. This results in splenomegaly, hepatomegaly and cytopenia. Disease progression commonly involves loss of bone mass, either osteopenia or osteoporosis and can lead to painful bone crises and avascular necrosis, or death of bone
tissue. We are specifically developing a gene therapy approach to address Type 1 Gaucher disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current standard of care for Gaucher disease includes enzyme replacement therapy, or ERT, for patients of all ages or substrate reduction therapy, or SRT,
for adults with Type 1. ERT is recommended as a potentially suitable treatment for all symptomatic Type 1 patients, though the required IV infusions every two weeks can lead to difficult treatment burden. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SRT treats Gaucher disease by inhibiting cellular production of glucosylceramide, rather than increasing the degradation of glucosylceramides through ERT.
ZAVESCA (miglustat) and CERDELGA (eliglustat) effectively treat hepatosplenomegaly in a similar time course to ERT, though improvement in hematological aspects of the disease takes longer to materialize. SRT does not correct the fundamental lack of
GCase and biochemical and tissue abnormalities persist. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our gene therapy approach aims to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide continuous therapeutic levels of GCase in serum and tissues that can break down glucosylceramide, which
may enhance tissue correction over episodic ERT; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administer ceDNA-GCase early in disease before the onset of inflammation, fibrosis and irreversible tissue
injury; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve the appropriate GCase levels for potential disease modification using biomarkers such as
glucosylsphingosine, or <FONT STYLE="white-space:nowrap">Lyso-Gb1,</FONT> via individualized patient titration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">treat patients for life by maintaining <FONT STYLE="white-space:nowrap">Lyso-Gb1</FONT> levels in the normal
range through redosing as needed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce immune reactions to GCase, which occur in 2% to 15% of Gaucher patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have created multiple distinct GCase plasmid constructs and have tested them for activity <I>in vivo</I>. These constructs differ in various expression
cassette elements, including promoter, intron, UTR and codon optimization expression elements. We administered these plasmid GCase constructs hydrodynamically into mice and measured GCase enzymatic activity in the serum. As shown in the figure
below, many of our GCase plasmid constructs have exhibited functional GCase activity in serum, indicating that hepatocytes are not only able to produce the GCase, but can also secrete it for uptake by other tissues that are affected in Gaucher. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Detection of GCase in plasma after hydrodynamic injection of plasmid constructs
</B><B><I>in vivo</I></B><B> </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g28p75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to
begin preclinical development in 2021 for this program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Antibody gene therapy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to advance product candidates to deliver
antibody genes to direct the liver to express and secrete antibodies. Monoclonal antibodies, or mAbs, have demonstrated therapeutic benefit in many areas, including infectious diseases, rheumatology, hematology and oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that utilizing the patient&#146;s own cells to produce and secrete therapeutic mAbs, fragments or derivatives is a potentially transformative
approach that can result in greater efficacy, produced at a larger scale and with lower cost of goods compared to the passive administration of some mAbs. This approach is called antibody gene therapy, or AGT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost of goods,
the burden of frequent administration and the manufacturing scale limitations of mAb therapy preclude their widespread utilization in many diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our gene therapy approach aims to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enable a patient&#146;s own body to sustainably produce and secrete a therapeutic mAb from the liver by
introducing <FONT STYLE="white-space:nowrap">ceDNA-AGT;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enable continuous production of protein, resulting in a stable, effective levels of serum mAb, thereby avoiding
toxicity due to <FONT STYLE="white-space:nowrap">off-target</FONT> effects of pulsatile delivery and/or loss of efficacy often associated with rapid reduction in concentrations when delivered passively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rapidly induce a therapeutic effect due to liver production of the therapeutic mAb within days of administration;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially eliminate compliance risk due to sustained expression after a single dose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">encode multiple mAbs on a single ceDNA construct for broad therapeutic application; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve the appropriate mAb levels in the blood via individualized patient titration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">induce rapid onset, durable immunity via expression of mAbs to prevent infection for large populations.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have demonstrated hepatic expression of antibodies with
<FONT STYLE="white-space:nowrap">ceDNA-AGT.</FONT> As shown in the figure below, hydrodynamic injection of <FONT STYLE="white-space:nowrap">ceDNA-AGT</FONT> resulted in serum mAb levels of greater than 40.0 &micro;g/ml. Since many therapeutic mAbs
are effective at serum concentrations of 1.0 to 5.0 &micro;g/ml, we believe the level of mAb expression observed with our <FONT STYLE="white-space:nowrap">ceDNA-AGT</FONT> is likely to be therapeutically relevant in humans. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hydrodynamic injection of <FONT STYLE="white-space:nowrap">ceDNA-AGT</FONT> results in serum levels up to 40.0&micro;g/ml </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g79f61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also demonstrated stacking of mAb expression after repeat dosing via hydrodynamic injection, as shown in the figure
below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>mAb expression increases after repeat dosing via hydrodynamic injection </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g33r43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
advancing our initial AGT program for the treatment of an infectious disease and we are evaluating ceDNA constructs that express neutralizing mAbs targeting a surface protein for a variety of infectious agents, including hepatitis B virus, or HBV,
HIV and respiratory syncytial virus, or RSV, and plan to demonstrate expression in the liver in preclinical studies in 2021. Separately, we have established a research collaboration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with Vir Biotechnology, Inc. to explore the potential for our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform to extend the duration and reach of Vir&#146;s mAb therapies
against the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> coronavirus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retinal diseases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 200&nbsp;million individuals suffer from inherited retinal diseases, in which a gene mutation leads to degeneration of the retina. Many of these
diseases are caused by genes too large to be enclosed within AAV, including LCA10 and Stargardt disease. Current AAV gene therapy approaches are not able to encode and deliver large genetic payloads and cannot provide the full gene required to treat
LCA10 and Stargardt disease. We believe using ceDNA to deliver large gene payloads efficiently and specifically to relevant cell types in the retina, with the opportunity to optimize ctLNP for minimally invasive routes of delivery, represents an
important therapeutic approach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lebers Congenital Amaurosis Type 10 (LCA10) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LCA10 is the most common genetic cause of
childhood vision loss. There are approximately 2,200 patients with LCA10 in the United States and 3,400 patients in the European Union. It is a severe, autosomal recessive retinal dystrophy due to a mutation in the CEP290 protein that is expressed
in and required for proper functioning of retinal photoreceptors. LCA10 causes blindness or severe vision loss, often from birth or within the first year of life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no approved
therapies for LCA10. Several therapeutic programs are in clinical development for LCA10, including a splicing oligonucleotide given episodically by intravitreal injection and a gene editing approach. Both approaches address only a subset of LCA10
patients, specifically those with a CEP290 mutation amenable to splicing alteration, which makes up approximately 60% of the population. CEP290 is a large gene of 7.4 kb, which exceeds the 4.7 kb payload capacity of AAV. No single approach has been
able to address the many mutations that cause LCA10. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our gene therapy approach aims to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver directly to the retina; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">treat patients irrespective of their CEP290 mutation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">utilize ctLNP to specifically deliver CEP290 to photoreceptors and not to retinal glial and immune cells, thereby
potentially increasing the safety, tolerability and durability of transgene expression; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enable single-dose therapy delivered subretinally, which may increase efficacy and compliance when compared, for
example, to episodic intravitreal delivery; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">treat infants and children to halt further decline of and restore vision. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have created multiple plasmid and ceDNA constructs encoding the CEP290 gene and have demonstrated expression of full-length protein after transfection in
cells in culture, as shown in the figure below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plasmid and CEP290 express full-length protein in HEK293 cells </B><B><I>in
vitro</I></B><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g54m92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to
begin preclinical development in 2021 for this program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stargardt disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stargardt disease is the most common inherited
macular dystrophy. There are approximately 37,000 patients with Stargardt disease in the United States and 66,000 patients in the European Union. Stargardt disease is an autosomal recessive disease due to mutation in the ABCA4 gene that is expressed
in both the RPE and retinal photoreceptors. Loss of ABCA4 function disrupts normal processing of retinaldehyde, or Vitamin A, in both photoreceptors and RPE cells leading to accumulation of toxic <FONT STYLE="white-space:nowrap">bis-retinoid</FONT>
byproducts and photoreceptor death. Patients usually present in childhood with loss of visual acuity and exhibit progressive loss of RPE and photoreceptor cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are currently
no proven treatments for Stargardt disease. The ABCA4 gene is approximately 6.7 kb, too large to be delivered by AAV. There are currently no ongoing gene therapy trials for Stargardt disease. The goal of therapy in Stargardt disease is to preserve
vision by correcting ABCA4 expression in enough photoreceptors and RPE cells to halt the progressive loss of these cells that would otherwise occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our gene therapy approach aims to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver to photoreceptors and RPE cells to halt progressive loss in cells and preserve vision;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protect photoreceptors and RPE cells through expression of normal ABCA4, resulting in clearance of <FONT
STYLE="white-space:nowrap">bis-retinoid</FONT> byproducts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drive the appropriate level of ABCA4 expression in photoreceptors and RPE cells utilizing a native ABCA4 promoter
and native regulation of expression; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain normal macular vision and visual acuity when given to earlier-diagnosed patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver the entire ABCA4 gene in a single gene therapy vector, thereby increasing efficacy relative to dual AAV
approaches. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated plasmid constructs that express full length ABCA4. Further, as shown in the figure below, when we
fractionate cellular lysates into cytosolic and membrane compartments, we see that plasmid ABCA4 expresses appropriately in the membrane bound subcellular compartment. This is important because ABCA4 is expressed in the cellular membrane of
photoreceptors. Its cellular function requires that it be expressed and also appropriately trafficked to the correct intracellular compartment. The red circle in the figure below highlights the ABCA4 protein localized within cellular membrane. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expression and appropriate subcellular localization of plasmid ABCA4 in vitro </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g48d06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to
begin preclinical development in 2021 for this program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (Wet AMD)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Age-related</FONT> macular degeneration, or AMD, is the leading cause of irreversible vision loss occurring in approximately
10&nbsp;million people in the United States. Wet AMD is the most severe form, characterized by neovascularization of the retina, leading to significant loss in visual acuity and rapid progression to blindness. There are approximately
1.2&nbsp;million patients with wet AMD in the United States and over 2.5&nbsp;million patients in the European Union. Wet AMD is most common in individuals over the age of 50, with increasing incidence every decade thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current approaches and limitations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Passive
administration of anti-vascular endothelial growth factor, or anti-VEGF, mAbs are an established therapy for patients with wet AMD. Anti-VEGF therapy, such as EYLEA (aflibercept), is effective in slowing the loss of visual acuity in patients with
wet AMD. However, the frequency of intravitreal administration is a barrier to adherence and to widespread adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AAV gene therapy to establish
intra-ocular expression of anti-VEGF molecules is in early clinical development, either by subretinal or intravitreal delivery. It is unclear today if these therapies will generate sufficient expression of anti-VEGF in the retina. If successful, the
scale limitations of AAV may present additional challenges to providing therapy for a substantial proportion of wet AMD patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our approach
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our gene therapy approach aims to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver intravitreally to enable retinal cells to express and secrete an anti-VEGF molecule;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide a durable and sustained level of expression of anti-VEGF, which may enhance regression of
neovascularization and improve visual acuity and may enable administration only a few times over the life of a patient; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">define when repeat therapy would be indicated to optimally preserve the retina. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to establish a baseline for the biodistribution of ctLNP in the eye, we administered mRNA-luciferase intravitreally at two doses of 0.2&micro;g and
0.6&micro;g using our ctLNP delivery system. As shown in the figure below, this resulted in luciferase expression in the retina. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expression after intravitreal administration of mRNA-luciferase using ctLNP </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g108483g79z77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated several anti-VEGF mAb ceDNA constructs and have shown that these constructs result in high levels of
anti-VEGF mAb levels in the blood after hydrodynamic intravenous delivery. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Next steps </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We aim to combine these constructs with ctLNP to achieve intravitreal delivery of relevant antibody levels in the retina. We plan to begin preclinical
development in 2021 for this program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expansion opportunities in other tissues </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to expand our portfolio by pursuing additional programs in rare and prevalent diseases of the skeletal muscle, oncology and the CNS by developing
discrete ctLNPs, each engineered to reach a specific tissue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Skeletal muscle </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are a variety of genetic muscle disorders, including muscular dystrophies, that may be treated by efficient and systemic gene therapy to skeletal muscle.
We are currently developing a ctLNP utilizing a targeting ligand to deliver ceDNA specifically to skeletal muscle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe this approach would have
several benefits for rare monogenic diseases of the skeletal muscle, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">early treatment, near the onset of disease, before inflammation and fibrosis progressively replace muscle fibers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivery of full-length of defective skeletal muscle genes, which are often very large as is the case, for
example, for dystrophin, the gene responsible for Duchenne Muscular Dystrophy, or DMD, and genes that form the sarcoglycan complex, which are responsible for various forms of limb-girdle muscular dystrophy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efficient delivery of the gene of interest to enough muscle fibers to change the course of disease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficient expression within transduced muscle fibers to allow for normal constitution of the skeletal muscle
fibers during growth and development; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">keeping up with patients&#146; needs over time through redosing. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe there are many diseases in the skeletal muscle with unmet need such as DMD, myotonic dystrophy, limb girdle dystrophies and fascioscapulohumeral
dystrophies, which we may pursue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CNS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to explore the use of ceDNA to correct disorders of the CNS. The work we are doing with local delivery in the retina to photoreceptors may inform
expansion into the CNS, beginning for example with focal epilepsies, in which expression of a novel gene within a specific region of neurons may stop the abnormal seizures. One </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such example is Dravet syndrome, an epilepsy disorder that begins in infancy or early childhood usually caused by a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> mutation in the SCN1A gene. Another example is MPSII, or Hunter syndrome, which is caused by a deficiency in iduronate sulfatase resulting in both
somatic (liver, bone and visceral organs) and CNS accumulation of toxic glycosaminoglycans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oncology </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to develop the use of ceDNA to treat a variety of cancer indications. We believe that we can use distinct targeting ligands to deliver ceDNA
specifically and efficiently to tumors and can utilize ceDNA to express high levels of relevant proteins within the tumor. For example, we believe after systemic delivery and efficient uptake by tumors, the expression of checkpoint inhibitors and
particular cytokines encoded by the ceDNA may have both direct anti-tumor activity and may stimulate the immune system to respond to and attack tumor cells. Many of the genes that we can express within tumors have limited efficacy and substantial
safety and tolerability issues when given systemically. The key attribute of this approach is the ability to drive efficient and selective uptake of ceDNA within tumors and then local, high concentrations of relevant anti-tumor agents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have personnel with extensive
technical, manufacturing, analytical and quality experience to oversee all internal and contracted manufacturing and testing activities. Relying on these personnel, we have built development laboratories to produce ceDNA (drug substance) and lipid
nanoparticle-encapsulated ceDNA (drug product) for use in our research activities. We have produced ceDNA drug substance at up to 200 liters at our CDMOs. We routinely manufacture drug product through our ctLNP manufacturing process to support our
research studies. We plan to use our CDMOs to support our <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and to fully supply our clinical trials and commercial activities. As we scale manufacturing, we intend to continue to expand and
strengthen our network of CDMOs, and we will also consider investing in internal cGMP manufacturing capabilities and infrastructure in the future if there is a technical need or a strategic or financial benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. These regulations govern record keeping,
manufacturing processes and controls, personnel, quality control and quality assurance. Our systems and contractors are required to comply with these regulations and are assessed through regular monitoring and formal audits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug substance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the ceDNA drug
substance requirements for our programs can be met by a variety of domestic and international contractors with standard biological manufacturing equipment. We have established a cGMP-ready process at the
<FONT STYLE="white-space:nowrap">200-liter</FONT> scale, which we have transferred to our drug substance CDMOs to supply ceDNA drug substance for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, clinical trials and early commercial
activities. To ensure supply chain continuity, we have also established service agreements with additional suppliers to afford redundancy and flexibility in scaling. We have access rights to a biologics facility at one of our CDMOs that we believe
could fully support multiple clinical programs if and when we advance our programs into clinical trials, as well as the early phases of commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested in technical expertise and internal capabilities to optimize and develop the ceDNA drug substance process and to provide technical management
and quality oversight for our process transfers to CDMOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future ceDNA drug substance processes may require additional manufacturing capabilities, which
may be addressed by either expanding our capabilities with existing contractors or establishing manufacturing supply relationships with new contract manufacturers. These changes in processes may also require new supply chain agreements with CDMOs
that specialize in raw material manufacturing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug product </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our drug product is ceDNA formulated with ctLNP. We believe that our drug product requirements can be met by a variety of domestic and international CDMOs. We
have selected a subset of experienced organizations familiar with the specific operations that our current drug product processes require. We have established a service agreement with one of these CDMOs and have also engaged with suppliers for key
components of our ctLNP delivery system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested in technical expertise and internal capabilities to optimize and develop the drug product
process and to provide technical management and quality oversight for our process transfers to CDMOs. We have transitioned our drug product process from research-scale using microfluidics to standard clinical-scale equipment supporting cGMP
operations for other established <FONT STYLE="white-space:nowrap">LNP-based</FONT> modalities. These scaled systems have generated representative and well-characterized drug product that we have used in our preclinical studies. Additionally, as with
our drug substance processes, progress on analytics has allowed us to leverage insights into our delivery system to upgrade and characterize purity and homogeneity. We plan to continue to implement process changes to improve purity and yield. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strive to protect our
proprietary technology, inventions, improvements, platforms, product candidates and components thereof, their methods of use and processes for their manufacture that we believe are important to our business, including by obtaining, maintaining,
defending and enforcing patent and other intellectual property rights for the foregoing in the United States and in certain foreign jurisdictions. We also rely on trade secrets and confidentiality agreements to protect our confidential information
and <FONT STYLE="white-space:nowrap">know-how</FONT> and other aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, enforce and defend patent and other intellectual property rights for our commercially important
technology, inventions and improvements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preserve the confidentiality of our trade secrets and other confidential information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain licenses to use and exploit intellectual property owned or controlled by third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operate without infringing, misappropriating or otherwise violating any valid and enforceable patents and other
intellectual property rights of third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against challenges and assertions by third parties challenging the validity or enforceability of our
intellectual property rights, or our rights in our intellectual property, or asserting that the operation of our business infringes, misappropriates or otherwise violates their intellectual property rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent portfolio </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we
own approximately 40 patent application families related to our business, including 11&nbsp;pending Patent Cooperation Treaty, or PCT, patent applications and eight PCT applications that have entered the national stage in the United States and
certain foreign jurisdictions, including Europe and Japan (one of which is jointly owned with UMass), and we exclusively license one patent application family, which has entered the national stage in the United States and certain foreign
jurisdictions, including Europe and Japan. We also <FONT STYLE="white-space:nowrap">non-exclusively</FONT> license one patent application family, which includes issued patents in each of the United States, Australia and Israel and national stage
patent applications in several other jurisdictions, including Europe and Japan. In addition, we own approximately 22 U.S. provisional patent applications within the priority year. We do not currently own or exclusively license any issued patents
covering any of our programs or technology, including the ceDNA platform, ctLNP delivery system and manufacturing processes. Our owned and licensed patent applications cover various aspects of our programs and technology, including our ceDNA
construct, ctLNP delivery system and manufacturing process as further described below. Any U.S. or foreign patents issued from national stage filings of our owned or exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> PCT patent
applications and any U.S. patents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued from <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications we may file in connection with our provisional patent applications would be scheduled to expire on various dates
from 2037 through 2041, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity and other governmental fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ceDNA construct </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we own
approximately 28 patent application families, including four pending PCT patent applications and six PCT applications that have entered the national stage in a number of jurisdictions outside the United States (one of which is jointly owned with
UMass), and we exclusively license from UMass and Voyager one patent application family, which has entered the national stage in the United States and other jurisdictions, including Europe and Japan. These patent applications cover various aspects
of our ceDNA construct, including ceDNA construct variants, certain disease-targeted ceDNA compositions and methods of use. We have also <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed one patent application family from the NIH and
the Institut de Myologie, Universite Pierre et Marie Curie, Centre National de la Recherche Scientifique and Inserm Transfert SA, which we refer to as the French Institutions, which includes issued patents in each of the United States, Australia and
Israel and national stage patent applications in other jurisdictions, including Europe and Japan, which cover our ceDNA construct, certain disease-targeted ceDNA compositions and methods of use. In addition, we own approximately 19&nbsp;U.S.
provisional patent applications within the priority year, which cover ceDNA construct variants, general applications of the ceDNA construct technology and certain properties of the construct, specific disease-targeted ceDNA compositions and methods
of use. Any U.S. or foreign patents issued from the pending U.S. or foreign <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications or from <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications we may file in
connection with the pending provisional patent applications would be scheduled to expire on various dates from 2038 through 2041, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate
maintenance, renewal, annuity and other governmental fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ctLNP delivery system </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we own approximately 10 patent application families, including six pending PCT patent applications and one PCT application that
has entered the national stage in the United States and a number of jurisdictions outside the United States, and approximately three U.S. provisional patent applications within the priority year with respect to our ctLNP delivery system, including
certain lipid and lipid nanoparticle compositions and combinations with ceDNA and/or targeting agents and methods of use. Any U.S. or foreign patents issued from the pending U.S. or foreign <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent applications or from any <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications we may file in connection with these provisional patent applications would be scheduled to expire on various dates from 2038 through 2041, without
taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity and other governmental fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Manufacturing processes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we
own approximately two patent application families, including one pending PCT patent application and one PCT application that has entered the national stage in the United States and a number of jurisdictions outside the United States, with respect to
our ceDNA manufacturing processes. Any U.S. or foreign patents issued from the pending U.S. or foreign <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications or from any <FONT STYLE="white-space:nowrap">non-provisional</FONT>
applications we may file in connection with these provisional patent applications would be scheduled to expire on various dates from 2039 through 2040, without taking into account any possible patent term adjustments or extensions and assuming
payment of all appropriate maintenance, renewal, annuity and other governmental fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent prosecution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A PCT patent application is not eligible to become an issued patent until, among other things, we file one or more national stage patent applications within 30
months, 31 months or 32 months of the PCT application&#146;s priority date, depending on the jurisdiction, in the countries in which we seek patent protection. If we do not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent application and any potential patent protection on the inventions disclosed in
such PCT patent application. Moreover, a provisional patent application is not eligible to become an issued patent. A provisional patent application may serve as a priority filing for
<FONT STYLE="white-space:nowrap">a&nbsp;non-provisional&nbsp;patent</FONT> application we file within 12 months of such provisional patent application. If we do not timely <FONT STYLE="white-space:nowrap">file&nbsp;non-provisional&nbsp;patent</FONT>
applications, we may lose our priority date with respect to our existing provisional patent applications and any potential patent protection on the inventions disclosed in our provisional patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we intend to timely file additional provisional patent applications and national stage and <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent applications relating to our PCT patent applications, we cannot predict whether any of our patent applications will result in the issuance of patents. If we do not successfully obtain patent protection, or if the scope of the patent
protection we or our licensors obtain with respect to&nbsp;our product candidates or technology, including our ceDNA constructs, ctLNP delivery system or manufacturing processes is not sufficiently broad, we will be unable to prevent others from
using our technology or from developing or commercializing technology and products similar or identical to ours or other similar competing products and technologies. Our ability to stop third parties from making, using, selling, offering to sell,
importing or otherwise commercializing any of our technology, inventions and improvements, either directly or indirectly, will depend in part on our success in obtaining, maintaining, defending and enforcing patent claims that cover our technology,
inventions and improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. The
protection afforded by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-to-jurisdiction,</FONT></FONT> and depends upon many factors, including the type of patent, the scope of its coverage, the availability of patent term adjustments and
regulatory-related patent term extensions, the availability of legal remedies in a particular jurisdiction and the validity and enforceability of the patent. No consistent policy regarding the scope of patent claims allowable in the field of genetic
therapy has emerged in the United States. Moreover, patent laws and related enforcement in various jurisdictions outside of the United States are uncertain and may not protect our rights to the same extent as the laws of the United States. Changes
in the patent laws and rules, whether by legislation, judicial decisions or regulatory interpretation, in the United States and other jurisdictions may diminish our ability to protect our inventions and obtain, maintain, defend and enforce our
patent rights, and could therefore affect the value of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The area of patent and other intellectual property rights in biotechnology is
evolving and has many risks and uncertainties, and third parties may have blocking patents and other intellectual property that could be used to prevent us from commercializing our platforms and product candidates and practicing our proprietary
technology. Our patent rights may be challenged, narrowed, circumvented, invalidated or ruled unenforceable, which could limit our ability to stop third parties from marketing and commercializing related platforms or product candidates or limit the
term of patents that cover our platforms and product candidates. In addition, the rights granted under any issued patents may not provide us with protection or competitive advantages against third parties with similar technology, and third parties
may independently develop similar technologies. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any of our product candidates can be commercialized,
any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any competitive advantage provided by the patent. For this and other risks related to our proprietary technology, inventions,
improvements, platforms and product candidates and intellectual property rights related to the foregoing, please see the section entitled &#147;Risk factors&#151;Risks related to our intellectual property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent term extensions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of individual
patents depends upon the laws of the jurisdictions in which they are obtained. In most jurisdictions in which we file, the patent term is 20&nbsp;years from the earliest date of filing of the first
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application to which the patent claims priority. However, the term of U.S. patents may be extended or adjusted for delays incurred due to compliance with FDA requirements or by delays
encountered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
during prosecution that are caused by the United States Patent and Trademark Office, or the USPTO. For example, in the United States, a patent claiming a new biologic product, its method of use
or its method of manufacture may be eligible for a limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, for up to five years beyond the normal expiration date of the patent.
Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#146;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and
the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the
approvals. For more information on patent term extensions, see &#147;Business&#151;Government regulation&#151;Patent term restoration and extension&#148;. In the future, if and when any product candidates we may develop receive FDA approval, we
expect to apply for patent term extensions on issued patents covering those product candidates. Moreover, we intend to seek patent term adjustments and extensions for any of our issued patents in any jurisdiction where such adjustments and
extensions are available. However, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such adjustments and extensions should be granted, and even if granted, the length of
such adjustments and extensions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade secrets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> unpatented technology and other proprietary
information to strengthen our competitive position. We take steps to protect and preserve our trade secrets and other confidential and proprietary information and prevent the unauthorized disclosure of the foregoing, including by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and invention assignment agreements with parties who have access to our trade secrets or other confidential and proprietary information, such as employees, consultants, outside scientific
collaborators, contract research and manufacturing organizations, sponsored researchers and other advisors, at the commencement of their employment, consulting or other relationships with us. In addition, we take other appropriate precautions, such
as maintaining physical security of our premises and physical and electronic security of our information technology systems, to guard against any misappropriation or unauthorized disclosure of our trade secrets and other confidential and proprietary
information by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite these efforts, third parties may independently develop substantially equivalent proprietary information and
techniques or otherwise gain access to our trade secrets or other confidential or proprietary information. In addition, we cannot provide any assurances that all of the foregoing <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and invention
assignment agreements have been duly executed, and any of the counterparties to such agreements may breach them and disclose our trade secrets and other confidential and proprietary information. Although we have confidence in the measures we take to
protect and preserve our trade secrets and other confidential and proprietary information, they may be inadequate, our agreements or security measures may be breached, and we may not have adequate remedies for such breaches. Moreover, to the extent
that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to our rights in any <FONT STYLE="white-space:nowrap">know-how</FONT> or inventions
arising out of such work. For more information, please see the section entitled &#147;Risk factors&#151;Risks related to our intellectual property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a party to a number of
license agreements under which we license patents, patent applications and other intellectual property from third parties. These licenses impose various diligence and financial payment obligations on us. We expect to continue to enter into these
types of license agreements in the future. We consider the following license agreements to be material to our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License agreement with the
National Institutes of Health </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2017, we entered into a license agreement with the NIH, which was amended in July 2019 to include the French
Institutions as licensors. Pursuant to the amended agreement, or the NIH Agreement, NIH and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
French Institutions granted us a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under a patent application family related to our ceDNA construct. This patent application
family includes national stage patent applications in jurisdictions outside the United States, including Europe and Japan, and issued patents in each of the United States, Australia and Israel. The issued patents and any future patents issued from
the pending patent applications would be scheduled to expire on various dates from March 2032 through October 2032, without taking into account any possible extensions and assuming payment of all appropriate maintenance, renewal, annuity and other
governmental fees. The <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license confers the right to make and have made, research and have researched, use and have used, sell and have sold, offer to sell and import products and to practice
processes, in each case, covered by the licensed patents and patent applications, for the treatment, prevention or palliation of any human disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the NIH Agreement, we are obligated to use reasonable commercial efforts to ensure that the licensed products and processes are utilized and made
available to the public on reasonable terms, including pursuing commercially reasonable broad international patient accessibility for licensed gene therapy products for the treatment of rare diseases, in accordance with an agreed upon commercial
development plan for gene therapy-based human therapeutics and certain performance milestone events. Unless terminated earlier, the NIH Agreement remains in effect until the last to expire of the licensed patent rights on a&nbsp;licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis.</FONT></FONT> NIH and the French Institutions
may terminate the NIH Agreement if we fail to perform our material obligations, including but not limited to our failure to meet the applicable performance milestones despite using commercially reasonable efforts, and have not remediated such
deficiency within a specified time period. NIH and the French Institutions can terminate the NIH Agreement in the event we become insolvent, file a petition in bankruptcy, have such a petition filed against us, or determine to file a petition in
bankruptcy. In addition, NIH and the French Institutions may terminate the NIH Agreement in the event of a material breach by us and failure to cure such breach within a certain period of time. We can voluntarily terminate the NIH Agreement with
prior notice to NIH and the French Institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the NIH Agreement, we agreed to make milestone payments upon the achievement of certain
milestones up to a maximum aggregate total of $350,000 for each licensed product, as well as a low single-digit royalty on net sales of licensed products. These royalty obligations last on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of the last licensed patent rights covering such
licensed product in such country. In addition, if we sublicense rights under the NIH Agreement, we are required to pay a high single-digit percent of the sublicense revenue to NIH. Additionally, under the NIH Agreement, we may be required to
reimburse the French Institutions for a portion of certain past and ongoing patent related expenses, including expenses associated with the preparation, filing, prosecution and maintenance of all patents and patent applications. As of
December&nbsp;31, 2020, there have been no invoiced expenses related to these reimbursable costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with the University of
Massachusetts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, we entered into a license agreement with UMass pursuant to which UMass granted us an exclusive, worldwide license under a
patent application family related to our ceDNA construct, which has pending national stage patent applications in the United States and certain foreign jurisdictions. In June 2020 Voyager became a joint owner with UMass of the licensed patent
application family, and we entered into an amendment to the UMass Agreement under which UMass, on behalf of Voyager, expanded the license granted to us to include an exclusive license to Voyager&#146;s rights in the licensed patent application
family, subject to Voyager&#146;s retained <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights to practice and exploit the licensed patent application family solely for its AAV gene therapy products. Any U.S. or foreign patents issued from
the pending licensed U.S. or foreign patent applications would be scheduled to expire in March 2037, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity
and other governmental fees. The exclusive license confers the right to research, develop, manufacture, have manufactured, use, offer for sale, sell and import products and practice and have practiced processes, in each case, covered by the patent
application family. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, our license agreement with UMass, as amended, which we refer to as the UMass Agreement, will continue
until the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of the licensed patents. UMass may terminate the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
UMass Agreement if we fail to perform our material obligations, including but not limited to our failure to meet the applicable performance milestones despite using commercially reasonable
efforts, and have not remediated such deficiency within a specified time period or negotiated a revised performance timeline. UMass can terminate the UMass Agreement if we fail to make any payments within a specified period after receiving written
notice of such failure, or in the event of a material breach by us and failure to cure such breach within a certain period of time, provided that, if we fail to make payments due under the UMass Agreement more than a certain number of times, UMass
may terminate the agreement immediately without any cure period. We can voluntarily terminate the UMass Agreement with prior notice to UMass. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
UMass Agreement, we agreed to use diligent efforts to develop the licensed products and introduce them into the commercial market and make them reasonably available to the public thereafter. Specifically, we agreed to achieve regulatory approval for
and commercially launch at least one licensed product in the U.S. by certain specified dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the UMass Agreement, we have issued to UMass
125,677 shares of our common stock. In addition, we may be obligated to make milestone payments up to $1,143,750 per licensed product that are contingent upon the achievement of certain regulatory and commercialization milestones, as well as low
single-digit royalties on net sales of licensed products on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. If we sublicense our rights under the UMass Agreement, we are required to pay a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digit percentage of the license revenue to UMass, which will vary depending on when the sublicense agreement to a third party was executed. Royalty
obligations under the UMass Agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. As of December&nbsp;31, 2020, we have recorded no royalty or milestone liabilities
under the UMass Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
biotechnology and biopharmaceutical industries generally, and the genetic medicine field specifically, are characterized by rapid evolution of technologies, sharp competition and strong defense of intellectual property. Any product candidates that
we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our technology, development experience and scientific knowledge in the field of
gene therapy, nucleic acid delivery and manufacturing provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
institutions and governmental agencies and public and private research institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are numerous companies that are selling or developing genetic
medicines, including in indications for which we may develop our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies. These companies include viral gene therapy companies such as BioMarin Pharmaceuticals, Inc., Homology Medicines, Inc.,
Adverum Biotechnologies, Inc., Ultragenyx Pharmaceutical Inc. and Hoffmann La Roche Ltd; gene editing companies such as CRISPR Therapeutics AG, Intellia Therapeutics, Inc., and Editas Medicine, Inc.; and mRNA companies such as Moderna, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, either independently or with strategic partners, have substantially greater financial, technical and human resources than we do.
Accordingly, our competitors may be more successful than we are in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval for treatments and achieving widespread market acceptance.
Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified
scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be
significant competitors, particularly through collaborative arrangements with large and established companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be
substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than products we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
develop. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in
advance of the entry of our products. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of other drugs. The key competitive factors affecting the successful of all
any products we may develop are likely to be their efficacy, safety, convenience, price and availability of reimbursement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government regulation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European
Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing,
post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with
subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Licensure and regulation of biologics in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, any product candidates we may develop would be regulated as biological products, or biologics, under the Public Health Service Act, or
PHSA, and the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations and guidance. The failure to comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing,
clinical testing, the approval process, or post-approval process, may subject an applicant to delays in the conduct of the study, regulatory review and approval and/or administrative or judicial sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the
FDA&#146;s Good Laboratory Practices, or GLP regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor
intends to use in human clinical trials along with required analytical and stability testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND application for human clinical testing, which must become effective before human
clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB, representing each clinical site before each
clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of
the product candidate for each proposed indication, in accordance with current Good Clinical Practices, or GCP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of a BLA for a biologic product requesting marketing for one or more
proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of the product by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including
those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength,
quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure
compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user Prescription Drug User Fee Act, or PDUFA, securing FDA approval of the BLA and licensure of the
new biologic product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy, or REMS, and any post-approval studies or other post-marketing commitments required by the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical studies and investigational new drug application </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing any biologic product candidate in humans, including a gene therapy product candidate, the product candidate must undergo preclinical testing.
Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. The conduct of the preclinical tests and formulation of the
compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical
trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the
product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical
trials can begin or recommence. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to
commence on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial <FONT STYLE="white-space:nowrap">30-day</FONT> period, or at any time during the IND review process, it may
choose to impose a partial or complete clinical hold. Clinical holds are imposed by the FDA whenever there is concern for patient safety, may be a result of new data, findings, or developments in clinical, preclinical and/or chemistry, manufacturing
and controls or where there is <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all
outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing our planned clinical trial or future clinical trials in a
timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the NIH also
are potentially subject to review by a committee within the NIH&#146;s Office of Science Policy called the Novel and Exceptional Technology and Research Advisory, or the NExTRAC. As of 2019, the charter of this review group has evolved to focus
public review on clinical trials that cannot be evaluated by standard oversight bodies and pose unusual risks. With certain gene therapy protocols, FDA review of or clearance to allow the IND to proceed could be delayed if the NExTRAC decides that
full public review of the protocol is warranted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expanded access to an investigational drug for treatment use </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expanded access, sometimes called &#147;compassionate use,&#148; is the use of investigational products outside of clinical trials to treat patients with
serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational
products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis for: individual patients (single-patient IND applications for treatment in emergency settings and <FONT STYLE="white-space:nowrap">non-emergency</FONT> settings); <FONT
STYLE="white-space:nowrap">intermediate-size</FONT> patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the
sponsor and treating physicians or investigators will determine </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative
therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded
use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development
of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century
Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Sponsors are required to make such policies publicly available upon the earlier of
initiation of a Phase 2 or Phase 3 trial; or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy, or RMAT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to
access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and
without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Human clinical trials in support of a BLA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical
trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements.
Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol
for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a
clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a
foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval.
Specifically, the FDA requires that such trials be conducted in accordance with GCP, including review and approval by an independent ethics committee and informed consent from participants. The GCP requirements encompass both ethical and data
integrity standards for clinical trials. The FDA&#146;s regulations are intended to help ensure the protection of human subjects enrolled in <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trials, as well as the quality and
integrity of the resulting data. They further help ensure that <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign trials are conducted in a manner comparable to that required for clinical trials in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be
conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA
regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the
participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety
monitoring board, or DSMB. This group may recommend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB has
access. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required
after approval. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;1</I> clinical trials are initially conducted in a limited population to test the
product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;2</I> clinical trials are generally conducted in a limited patient population to
identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase&nbsp;2 clinical trials may be conducted by the
sponsor to obtain information prior to beginning larger and more costly Phase&nbsp;3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;3</I> clinical trials proceed if the Phase&nbsp;2 clinical trials demonstrate that a
dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase&nbsp;3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical
efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase&nbsp;3 trial may be designed to deliver the data that
regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase&nbsp;3 studies are referred to as &#147;pivotal.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#146;s
safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase&nbsp;4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication
and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use
the data from these clinical trials to meet all or part of any Phase&nbsp;4 clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting Phase&nbsp;4 clinical trials could
result in withdrawal of approval for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act of 2003, a BLA or supplement thereto must contain data that are
adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any
deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#146;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA
or the applicant may request an amendment to the plan at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For products intended to treat a serious or life-threatening disease or condition, the
FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss
pediatric study plans with sponsors and the FDA must meet with sponsors by no later than the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 1 meeting for serious or life-threatening diseases and by no
later than 90 days after the FDA&#146;s receipt of the study plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may, on its own initiative or at the request of the applicant, grant deferrals
for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests
for extension of deferrals are contained in the Food and Drug Administration Safety and Innovation Act. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about applicable clinical trials must be submitted within specific timeframes to the NIH for
public dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special regulations and guidance governing gene therapy products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the procedures and standards applied to gene therapy products will be applied to any product candidates we may develop. The FDA has defined a
gene therapy product as one that seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. The products may be used to modify cells <I>in vivo</I> or transferred to cells <I>ex
vivo</I> prior to administration to the recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy
products. Within CBER, the review of gene therapy and related products is consolidated in the OTAT and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. The NIH, including the NExTRAC
also advises the FDA on gene therapy issues and other issues related to emerging biotechnologies. The FDA and the NIH have published guidance documents with respect to the development and submission of gene therapy protocols. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January 2020 relating to chemistry,
manufacturing and controls information for gene therapy INDs, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> after the administration of gene therapy products, gene therapies for rare diseases and gene therapies for retinal disorders,
as well as draft guidance in January 2021 for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, compliance with them is likely
necessary to gain approval for any gene therapy product candidate. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical
assessment of gene therapies; the chemistry, manufacturing and control information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe
for potential delayed adverse effects in participants who have received investigational gene therapies with the duration of <FONT STYLE="white-space:nowrap">follow-up</FONT> based on the potential for risk of such effects. For AAV vectors
specifically, the FDA typically recommends that sponsors continue to monitor participants for potential gene therapy-related adverse events for up to a <FONT STYLE="white-space:nowrap">5-year</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until 2019, most gene therapy clinical trials in the United States required <FONT STYLE="white-space:nowrap">pre-review</FONT> by the predecessor of NExTRAC
before being approved by the IRBs and any local biosafety boards or being allowed to proceed by the FDA. In 2019, the NIH substantially eliminated the <FONT STYLE="white-space:nowrap">pre-review</FONT> process and going forward, the review of gene
therapy clinical trial protocols would be largely handled by local IRBs and institutional biosafety committees, or IBCs, in addition to the FDA. Furthermore, in 2019, the NIH removed from public access the Genetic Modification Clinical Research
Information System database, which previously contained substantial amounts of safety and other participant information regarding human gene therapy trials performed up to that time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity
Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and
administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies
the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#146;s internal review committee must then review the
information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of
the product for use in adults, or full or partial waivers from the pediatric </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in the FDA Safety and Innovation Act. The FDA
maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. In 2017, with passage of the FDA Reauthorization Act of 2017, or FDARA, Congress further modified these provisions.
Previously, drugs that had been&nbsp;granted&nbsp;orphan drug designation were exempt from the requirements of the PREA. Under the amended section 505B, beginning on&nbsp;August 18, 2020, the submission of a pediatric assessment, waiver or deferral
will be required for certain molecularly targeted cancer indications with the submission of an application or supplement to an application. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compliance
with cGMP requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA
will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA
emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers and others
involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the
FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to
periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#147;risk-based schedule&#148; that may result in certain establishments being inspected more frequently.
Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Review and approval of a BLA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of product
candidate development, preclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive
manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to an application user fee, which for federal
fiscal year 2021 is $2,875,842 for an application requiring clinical data. The sponsor of a licensed BLA is also subject to an annual program fee, which for fiscal year 2021 is $336,432. Certain exceptions and waivers are available for some of these
fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has
60&nbsp;days after submission of the application to conduct an initial review to determine whether it is sufficient to accept for filing based on the agency&#146;s threshold determination that it is sufficiently complete to permit substantive
review. Once the submission has been accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten months in
which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review
process may often be significantly extended by FDA requests for additional information or clarification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the PHSA, the FDA may approve a BLA if it
determines that the product is safe, pure and potent, and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. On the basis of the FDA&#146;s evaluation of the
application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of preclinical and clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter or a
complete response </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the application is not approved, the FDA will
issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that
receive a CRL may submit to the FDA information that represents a complete response to the issues identified by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may also refer the
application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult
questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the
application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA approves a new product, it may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or
precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase&nbsp;4 clinical trials, to further assess the product&#146;s efficacy and/or safety after approval. The agency may also require
testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product
outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for
prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance
programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expedited Review Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA is authorized to
expedite the review of BLAs in several ways. Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the
IND application. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation
applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a
Fast Track application before the application is complete, a process known as rolling review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidate submitted to the FDA for marketing,
including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Breakthrough therapy designation. </I>To qualify for the breakthrough therapy program, product candidates must
be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over
existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a
proactive, collaborative and cross-disciplinary review and rolling review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Priority review.</I> A product candidate is eligible for priority review if it treats a serious condition and,
if approved, it would be a significant improvement in the safety or effectiveness of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
treatment, diagnosis or prevention compared to marketed products. The FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard
review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Accelerated approval. </I>Drug or biologic products studied for their safety and effectiveness in treating
serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well
controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a
drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Regenerative medicine advanced therapy.</I> With passage of the 21st Century Cures Act, or the Cures Act, in
December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is an RMAT that is intended to treat, modify, reverse or cure a
serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of an RMAT designation include early
interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of these expedited programs change the standards for approval but they may help expedite the development or approval process of product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-approval regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval for
marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part
of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional
labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies
for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend
time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the
manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot, to the FDA. The FDA may in
addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements,
may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other
potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recall, seizure or detention, or refusal to permit the import or export of products; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Although healthcare
providers may prescribe products for uses not described in the drug&#146;s labeling, known as <FONT STYLE="white-space:nowrap">off-label</FONT> uses, in their professional judgment, drug manufacturers are prohibited from soliciting, encouraging or
promoting unapproved uses of a product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted
<FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling,
advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving
the Internet and social media. Promotional claims about a drug&#146;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as
reflected in the product&#146;s prescribing information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a company is found to have promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses,
it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities.
This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The
federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is
changed or curtailed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orphan drug designation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In
the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no
reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#146;s marketing approval
if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the
Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication
for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition
if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking
orphan drug designation must file&nbsp;a complete request for designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product with orphan designation receives the first FDA approval for the
disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that
the FDA may not approve another sponsor&#146;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. In particular, the concept of what constitutes the &#147;same drug&#148; for
purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA has issued recent draft guidance suggesting that it would not consider two gene therapy products to be different drugs solely based on minor
differences in the transgenes or vectors within a given vector class. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be
entitled to exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the
indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. Orphan drug
exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is shown to
be clinically superior to the approved product on the basis of greater efficacy or safety, or provide a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the
FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by President Trump on December&nbsp;27, 2020, the requirement for a product to show clinical superiority applies to drugs and
biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric
exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity in the United States
and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the <FONT STYLE="white-space:nowrap">non-patent</FONT> and orphan exclusivity. This <FONT
STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the
pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#146;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the
statutory time limits, whatever statutory or regulatory periods of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity that cover the product are extended by six months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Biosimilars and exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2010 Patient Protection
and Affordable Care Act, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars
and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> &#147;reference product.&#148; As of January&nbsp;1, 2021, the FDA has approved 29
biosimilar products for use in the United States. No interchangeable biosimilars, however, have been approved. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Additional guidances are
expected to be finalized by the FDA in the near term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that
is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a previously approved biological product or &#147;reference product.&#148; In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of
safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and
(for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the
reference biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of
approval of the reference product. The FDA may not approve a biosimilar product until 12&nbsp;years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity,
another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety,
purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in
fact, be readily substituted by pharmacies, which are governed by state pharmacy law. Since the passage of the BPCIA, many states have passed laws or amendments to laws, including laws governing pharmacy practices, which are state-regulated, to
regulate the use of biosimilars. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal and state data privacy and security laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the federal Health Insurance Portability and Accountability Act of 1966, or HIPAA, the U.S. Department of Health and Human Services, or HHS, has issued
regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization
of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 or HITECH, and
their regulations, including the omnibus final rule published on January&nbsp;25, 2013, also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of
covered entities. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to our business. In addition to possible federal civil and criminal
penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#146;s fees and costs associated with pursuing federal civil actions.
Accordingly, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#146;s privacy and security rules. New laws and regulations governing privacy
and security may be adopted in the future as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, California recently enacted legislation that has been dubbed the first
&#147;GDPR-like&#148; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security
obligations on entities handling personal data of consumers or households. The CCPA went into effect on January&nbsp;1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to <FONT
STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information, and allow for a new cause of action for data breaches. Additionally, effective starting on January&nbsp;1, 2023, the California Privacy Rights Act, or CPRA, will
significantly modify the CCPA, including by expanding consumers&#146; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and
the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and
protected health information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available
under such laws, it is possible that some of our current or future business activities, including certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data
security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility
that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any
other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future
earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be
subject to similar foreign laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patent term restoration and extension </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term
extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration
period for a patent covering a product is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of the IND application and the submission date of the BLA, plus the time between the submission date of the BLA
and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&nbsp;years from the product&#146;s approval date in the United States. Only one patent applicable to an approved
product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be
extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>FDA approval of companion diagnostics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014,
the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and <I>in vitro</I> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding
therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#146;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately
evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and <I>in vitro</I> companion diagnostic device on issues related to
<FONT STYLE="white-space:nowrap">co-development</FONT> of the products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2014 guidance also explains that a companion diagnostic device used to make
treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical
treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#146;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will
be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the
study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND application alone, or both an <FONT
STYLE="white-space:nowrap">IND-</FONT> and <FONT STYLE="white-space:nowrap">IDE-application.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the FDCA, <I>in vitro</I> diagnostics,
including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage,
advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA previously has required <I>in vitro</I> companion diagnostics intended to select the patients who will respond to the product candidate to obtain <FONT
STYLE="white-space:nowrap">pre-market</FONT> approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA,
can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its
components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal year 2021, the standard fee is $365,657 and the small business fee is $91,414. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation and procedures governing approval of medicinal products in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries
and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant
will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of
medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the
product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be
marketed and sold in the European Union. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical trial approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in
the European Union has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to
be conducted, or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the applicant may only start a clinical trial at a specific site after the competent ethics committee has issued a
favorable opinion. The clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the
member states and further detailed in applicable guidance documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No
536/2014, but it has not yet become effective. It will overhaul the current system of approvals for clinical trials in the European Union. Specifically, the new legislation, which will be directly applicable in all member states, aims at simplifying
and streamlining the approval of clinical trials in the European Union. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure via a single-entry point and strictly defined deadlines for the assessment of
clinical trial applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable
provisions until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the
duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable, the Clinical Trials Regulation will at that time begin to apply to the
clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2020, the website of the European Commission reported that the implementation of the new
Clinical Trials Regulation was dependent on the development of a fully functional clinical trials portal and database, which would be confirmed by an independent audit, and that the new legislation would come into effect six months after the
European Commission publishes a notice of this confirmation. In late 2020, the EMA indicated that it plans to focus on the findings of a system audit; improving the usability, quality and stability of the clinical trial information system; and
knowledge transfer to prepare users and their organizations for the new clinical trial system. The EMA has indicated that the system will go live in December 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at the EudraCT website:
https://eudract.ema.europa.eu. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PRIME designation in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies
currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized
procedure. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME
designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment
once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased
understanding of the product at the EMA&#146;s Committee level. A <FONT STYLE="white-space:nowrap">kick-off</FONT> meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall
development and regulatory strategies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must submit an MAA, either under a centralized
procedure administered by the EMA or one of the procedures administered by competent authorities in European Union member states (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted
only to an applicant established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in an <FONT
STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the measures
included in the PIP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for
all European Union member states. Pursuant to Regulation (EC) No.&nbsp;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan
medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the
treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. Manufacturers must demonstrate the quality, safety and efficacy of
their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specifically, the grant of marketing authorization in the European Union for products containing viable human tissues or cells such as gene therapy medicinal
products is governed by Regulation&nbsp;1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Council, commonly known as the Community code on medicinal products. Regulation&nbsp;1394/2007/EC lays down specific rules concerning the authorization, supervision and pharmacovigilance of
gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to EMA which provides
an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by EMA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting an initial assessment of a product. Under the centralized
procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the
CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts
such a request, the time limit of 210&nbsp;days will be reduced to 150&nbsp;days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an
accelerated assessment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Specialized procedures for gene therapies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grant of marketing authorization in the European Union for gene therapy products is governed by Regulation 1394/2007/EC on advanced therapy medicinal
products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC includes specific rules concerning the authorization,
supervision and pharmacovigilance of gene therapy medicinal products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA.
The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to obtaining a marketing authorization in the European Union, applicants must demonstrate compliance with all measures included in an <FONT
STYLE="white-space:nowrap">EMA-approved</FONT> PIP covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The
respective requirements for all marketing authorization procedures are provided in Regulation (EC) No 1901/2006, the <FONT STYLE="white-space:nowrap">so-called</FONT> Paediatric Regulation. This requirement also applies when a company wants to add a
new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Paediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine
for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only
affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Regulatory data protection in the European Union </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC)
No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic (abbreviated) application for a period of eight
years. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator&#146;s data may be referenced, but no generic medicinal
product can be marketed until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of eleven years if, during the first eight years of those ten
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a
significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the
product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patent term extensions in the European Union and other jurisdictions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules and requirements for obtaining a
SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. In
certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained, which is described in detail below. Although SPCs are available throughout the European Union, sponsors must apply on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Periods of authorization and renewals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A marketing
authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the
marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at
least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to
pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the
authorizing member state within three years after authorization ceases to be valid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Regulatory requirements after marketing authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing,
promotion and sale of the medicinal product. These include compliance with the European Union&#146;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be
imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#146;s license is mandatory, must also be conducted in strict compliance with the EMA&#146;s GMP requirements and comparable requirements of other
regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products,
including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orphan drug designation and exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulation (EC)
No 141/2000 and Regulation (EC) No.&nbsp;847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of
(1)&nbsp;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2)&nbsp;a life-threatening, seriously debilitating or serious and chronic
condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must
demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized
European Union marketing authorization. Marketing authorization for an orphan drug leads to a <FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity. During this market exclusivity period, neither the EMA nor the European
Commission or the member states can accept an application or grant a marketing authorization for a &#147;similar medicinal product.&#148; A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance
or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the
end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an applicant obtains a
marketing authorization in all European Union member states, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information,
even when negative, the medicine is then eligible for an additional <FONT STYLE="white-space:nowrap">six-month</FONT> period of qualifying patent protection through extension of the term of the SPC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Brexit and the regulatory framework in the United Kingdom </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted
negotiations, the United Kingdom left the European Union on January&nbsp;31, 2020. Under the withdrawal agreement, there was a transitional period until December&nbsp;31, 2020 (extendable by up to two years). On December&nbsp;24, 2020, the United
Kingdom and the European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Since the regulatory framework for pharmaceutical
products in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and
regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom, as the United Kingdom legislation now has the potential to diverge from European Union
legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the United Kingdom in the long-term. The Medicines and Healthcare Regulatory Agency has recently published detailed guidance for
industry and organizations to follow from January&nbsp;1, 2021 now the transition period is over, which will be updated as the United Kingdom&#146;s regulatory position on medicinal products evolves over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, while the Data Protection Act of 2018 in the United Kingdom that &#147;implements&#148; and complements the European Union General Data
Protection Regulation, or GDPR, has achieved Royal Assent on May&nbsp;23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area, or EEA, to the United Kingdom will remain lawful
under GDPR. The Trade and Cooperation Agreement provides for a transitional period during which the United Kingdom will be treated like an European Union member state in relation to processing and transfers of personal data for four months from
January 1, 2021. This may be extended by two further months. After such period, the United Kingdom will be a &#147;third country&#148; under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data
to the United Kingdom. The United Kingdom government has already determined that it considers all European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the
European Union/EEA remain unaffected. We may, however, incur liabilities, expenses, costs and other operational losses under GDPR and applicable European </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Union member states and the United Kingdom privacy laws in connection with any measures we take to comply with them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General Data Protection Regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collection, use,
disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the GDPR, which became effective on May&nbsp;25, 2018. The GDPR is wide-ranging in scope and imposes
numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to
individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The
GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential
fines of up to &#128;20&nbsp;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial
remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business
practices to ensure full compliance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage, pricing and reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or
other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payers to reimburse all or
part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any
product candidates we may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payers, including government health programs in the United States such as Medicare and Medicaid, commercial
health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payer will provide coverage for a product may be separate from the
process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the prices charged, examining the medical necessity, and reviewing the
cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved
products for a particular indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need
to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product
candidates may not be considered medically necessary or cost effective. A decision by a third-party payer not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a
material adverse effect on our sales, results of operations and financial condition. Additionally, a payer&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one
payer&#146;s determination to provide coverage for a product does not assure that other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer.
Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, any companion diagnostic tests require coverage and
reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will
apply to any companion diagnostics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs also has become a priority of federal, state and foreign governments and
the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of
generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any
approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing
approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we obtain approval in the future to market in the
United States any product candidates we may develop, we may be required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare
programs such as Medicaid. Participation in such programs may require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices accurately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription
pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial
that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after
a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments)
in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the
prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the
market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the
amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union.
The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may
further complicate pricing negotiations and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between
<FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Healthcare Law and Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval.
Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other healthcare laws and regulations that may
constrain business and/or financial arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restrictions under applicable federal and state healthcare laws and regulations, include the federal
Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either
the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; the federal civil and criminal
false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for
payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government; the Foreign Corrupt Practices Act,
or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make, improper payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose of obtaining or retaining business or
otherwise seeking favorable treatment; and the federal transparency requirements known as the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the
Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as
well as ownership and investment interests held by physicians and their immediate family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, some state laws require pharmaceutical
companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments
to physicians and other healthcare providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and
security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Healthcare reform </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A primary trend in the U.S. healthcare
industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and
other medical products, government control and other changes to the healthcare system in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2010, the United States Congress
enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA, which, among other things, includes changes to the coverage and payment for drug products
under government healthcare programs. Other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A
Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic
reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 under the Coronavirus
Aid, Relief, and Economic Security Act, or the CARES Act. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain
regulatory approval or the frequency with which any such product candidate is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since enactment of the PPACA, there have been, and
continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the Tax Act, which was signed by President Trump on
December&nbsp;22, 2017, Congress repealed the &#147;individual mandate.&#148; The repeal of this provision, which requires most Americans to carry a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
minimal level of health insurance, became effective in 2019. Further, on December&nbsp;14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate
portion of the PPACA is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. On December&nbsp;18, 2019, the Court of
Appeals for the Fifth Circuit court affirmed the lower court&#146;s ruling that the individual mandate portion of the PPACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and
additional analysis of the provisions of the PPACA. Thereafter, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November&nbsp;10, 2020. On February&nbsp;10, 2021, the Biden Administration withdrew the
Department of Justice&#146;s support for this lawsuit. A ruling by the Court is expected sometime this year. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Trump Administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities
and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or
manufacturers of pharmaceuticals or medical devices. On January&nbsp;28, 2021, however, President Biden rescinded those orders and issued a new executive order that directs federal agencies to reconsider rules and other policies that limit
Americans&#146; access to healthcare, and consider actions that will protect and strengthen that access. Under this order, federal agencies are directed to <FONT STYLE="white-space:nowrap">re-examine:</FONT> policies that undermine protections for
people with <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions, including complications related to <FONT STYLE="white-space:nowrap">COVID-19;</FONT> demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or
undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and under the PPACA; and policies that
reduce affordability of coverage or financial assistance, including for dependents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The costs of prescription pharmaceuticals have also been the subject
of considerable discussion in the United States. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug
pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. To those ends, President Trump issued five
executive orders intended to lower the costs of prescription drug products, but it is unclear whether, and to what extent, these orders will remain in force under the Biden Administration. Further, on September&nbsp;24, 2020, the Trump
Administration finalized a rulemaking allowing states or certain other <FONT STYLE="white-space:nowrap">non-federal</FONT> government entities to submit importation program proposals to the FDA for review and approval. Applicants are required to
demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers. The FDA has issued draft guidance that would allow manufacturers to import their own <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> drugs that are authorized for sale in other countries (multi-market approved products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the state
level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our
products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay
for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had more than 100 full-time employees, including a total of 38 employees with M.D. or Ph.D. degrees. Of these full-time
employees, approximately 75 employees are engaged in research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and newly hired employees. We
design our compensation and benefit programs to help meet the needs of our employees, focusing on programs that promote well-being across all aspects of their lives, including healthcare, retirement planning and paid time off. We pay our employees
competitively by performing a formal compensation benchmark analysis of our employees&#146; salary, bonus potential, and equity awards twice per year and by linking annual bonuses to overall company performance. In addition to our compensation
benchmarking analysis, we perform a gender pay gap analysis designed to ensure that women are paid equally to their male counterparts. Employees are paid based on our compensation philosophy, which includes paying employees competitively and at a
rate consistent with an employee&#146;s position, knowledge and skills. Our equity incentive plans are designed to attract, retain and motivate our employees, consultants and directors through the granting of stock-based compensation awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also strive to make our company an inclusive, safe and healthy workplace, with opportunities for each of our employees to grow and develop in their
careers. Additionally, we promote opportunities for all employees to join our Acting for Justice and Women&#146;s Forums, which support and promote certain mutual objectives of both us and our employees, including inclusion and
diversity.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the state of Delaware on October&nbsp;21, 2016 under the name Torus Therapeutics, Inc. On November&nbsp;17, 2017 we
changed our name to Generation Bio Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 301 Binney Street, Cambridge, MA 02142 and our telephone number is
(617) <FONT STYLE="white-space:nowrap">655-7500.&nbsp;Our</FONT> website address is http://www.generationbio.com. The information contained on, or accessible through, our website does not constitute part of this Annual Report. We have included our
website address in this Annual Report solely as an inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Internet address is <I>www.generationbio.com</I>. Our Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> Quarterly Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to
Sections&nbsp;13(a) and 15(d) of the Exchange Act are available through the &#147;Investors&#148; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the
Securities and Exchange Commission, or SEC. Information on our website is not part of this Annual Report or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be
accessed through the SEC&#146;s Interactive Data Electronic Applications system at <I>http://www.sec.gov</I>. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of
the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_3"></A>ITEM&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RISK FACTORS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Careful consideration should be given to
the following risk factors, in addition to the other information set forth in this Annual Report and in other documents that we file with the Securities and Exchange Commission, or SEC, in evaluating the Company and our business. Investing in our
common stock involves a high degree of risk. If any of the following risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below
are not intended to be exhaustive and are not the only risks facing the Company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impact our business, prospects, financial condition and
results of operations. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our financial position and need for additional capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since our inception, have no products approved for sale and we expect to incur losses over the next several years.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred significant operating losses. Our net losses were $80.5&nbsp;million and $61.3&nbsp;million for the years ended
December&nbsp;31, 2020 and 2019, respectively. As of December&nbsp;31, 2020, we had an accumulated deficit of $189.0&nbsp;million. To date, we have funded our operations with the proceeds from instruments convertible into convertible preferred stock
(which converted into convertible preferred stock in 2017), the sale of convertible preferred stock (which converted into common stock in 2020) and, most recently, from the sale of common stock in both our initial public offering, or IPO, and our <FONT
STYLE="white-space:nowrap">follow-on</FONT> public offering in January 2021. We have devoted substantially all of our financial resources and efforts to research and development. We are still in the early stages of development of our product
candidates, and we have not commenced or completed clinical development. We expect to continue to incur significant expenses and operating losses over the next several years. Our operating expenses and net losses may fluctuate significantly from
quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our current research programs and conduct additional research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance any product candidates we identify into preclinical and clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the capabilities of our proprietary <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy
platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, expand, maintain, defend and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, regulatory and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which
we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial
quantities of any product candidates we may develop for which we may obtain regulatory approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, legal, compliance, financial and management information systems and personnel to support our
research, product development, future commercialization efforts and operations as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory
approval of and are successful in commercializing one or more of any product candidates we may develop, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may
encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability
to generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never generated revenue from product sales and may never achieve or maintain profitability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not initiated clinical development of any product candidate and expect that it will be many years, if ever, before we have a product
candidate ready for commercialization. To become and remain profitable, we must succeed in developing, obtaining the necessary regulatory approvals for and eventually commercializing a product or products that generate significant revenue. The
ability to achieve this success will require us to be effective in a range of challenging activities, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying product candidates and completing preclinical and clinical development of any product candidates we
may identify; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approval for any product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing, marketing and selling any products for which we may obtain regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving market acceptance of any product candidates we may develop for which we obtain regulatory approval as a
viable treatment option; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfying any post-marketing requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. We are
currently only in the preclinical stage of our research programs. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or
when, or if, we will be able to achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a
quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or even continue our
operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need
substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we identify, continue the research and development
of, initiate preclinical testing and clinical trials of and potentially seek marketing approval for any product candidates we may develop. In addition, if we obtain marketing approval for any product candidates we may develop, we expect to incur
significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to
obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed, on attractive terms or at all, we may be forced to delay, reduce or eliminate our research and development programs or
future commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our existing cash, cash equivalents and marketable securities, including the net proceeds from the <FONT
STYLE="white-space:nowrap">follow-on</FONT> public offering that we completed in January 2021, will enable us to fund our operating expenses and capital expenditure requirements into 2024. However, we have based this estimate on assumptions that may
prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to seek additional funding sooner than
planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identification of additional research programs and additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, costs and results of preclinical and clinical development for any product candidates we may
develop; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any product candidates we may develop for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and scope of the continued development of our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene
therapy platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of satisfying any post-marketing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of product candidates we may develop for which we receive
marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting applications for patents, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operational, financial and management information systems and associated personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the associated costs in connection with any acquisition of <FONT STYLE="white-space:nowrap">in-licensed</FONT>
products, intellectual property and technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that
takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates and those are approved, we
may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all, and such revenues may not be sufficient to sustain our
operations. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize any product candidates. We cannot be certain that additional funding will be
available on acceptable terms, or at all. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or
discontinue the development or commercialization of our product candidates or other research and development initiatives. We could be required to seek collaborators for product candidates we may develop at an earlier stage than otherwise would be
desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we otherwise would seek to pursue development or
commercialization ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one
or more of our research or development programs or the commercialization of any product candidate we may develop, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect
our business, financial condition and results of operations. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a
combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital through the sale of equity or convertible debt securities, our stockholders&#146; ownership interests will be diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other
arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would
otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our limited operating history may make it difficult to evaluate the success of our business to
date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced operations in 2016, and our operations to date have been limited to organizing and staffing
our company, business planning, raising capital, conducting research activities and filing and prosecuting patent applications. All of our research programs are still in the research or preclinical stage of development, and their risk of failure is
high. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and
distribution activities necessary for successful product commercialization. Consequently, any predictions our stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a
history of successfully developing and commercializing genetic medicine products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our limited operating history, particularly in light of the rapidly
evolving genetic medicine field, may make it difficult to evaluate our technology and industry and predict our future performance. Our limited history as an operating company makes any assessment of our future success or viability subject to
significant uncertainty. We will encounter risks and difficulties frequently experienced by early stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown
factors. We will need to transition at some point from a company with a research focus to a company capable of conducting development activities and then to a company supporting commercial activities. We may not be successful in such transitions.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards may be subject to limitations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether
or when we will generate taxable income necessary to utilize our net operating losses, or NOLs, or research and development tax credit carryforwards. As of December&nbsp;31, 2020, we had federal NOLs of $177.3&nbsp;million and state NOLs of
$174.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, and corresponding
provisions of state law, a corporation that undergoes an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to
limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset future taxable income. We have not conducted a study to assess whether any such
ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future as a result of changes in our stock ownership (which may be outside our control). As a result, if,
and to the extent that, we earn net taxable income, our ability to use our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or
otherwise become unavailable to offset future income tax liabilities. As described below in &#147;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#148; the Tax Act, as
amended by the CARES Act includes changes to U.S. federal tax rates and the rules governing NOL carryforwards that may significantly impact our ability to utilize our NOLs to offset taxable income in the future. In addition, state NOLs generated in
one state cannot be used to offset income generated in another state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to discovery and development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are
very early in our development efforts. We have not identified any product candidates for Investigational New Drug, or IND, -enabling studies or clinical development and as a result it will be years before we commercialize a product candidate, if
ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be
materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are very early in our development efforts and have invested our research efforts to date in developing our platform. We have
a portfolio of programs, including those listed in &#147;Business&#151;Our portfolio,&#148; that are in early stages of preclinical development and have not identified any product candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
studies or clinical development. We may never identify any product candidates or advance to clinical-stage development. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the
successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing clinical trials in the United States is subject to acceptance by the U.S. Food and Drug Administration, or FDA, of an IND application and
finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA requests prior to commencing
clinical trials, the start of our first clinical trials may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their
requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter
approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercialization of any product candidates we may develop will require preclinical and clinical development; regulatory and marketing approval in multiple
jurisdictions, including by the FDA and the European Medicines Agency, or EMA; obtaining manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. The success of product candidates we may
identify and develop will depend on many factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies
and minimally efficacious dose studies in animals, where applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or
future clinical trials for any product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment and completion of clinical trials, including under the FDA&#146;s current Good Clinical
Practices, or GCPs, current Good Laboratory Practices, or cGLPs, and any additional regulatory requirements from foreign regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive results from our future clinical programs that support a finding of safety and effectiveness and an
acceptable risk-benefit profile in the intended populations of any product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply
and, where applicable, commercial manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual
property protection or regulatory exclusivity for any product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercial launch of any product candidates we may develop, if approved, whether alone or in collaboration with
others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of the benefits and use of any product candidates we may develop, including method of administration,
if and when approved, by patients, the medical community and third-party payers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective competition with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may
develop following approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment and maintenance of healthcare coverage and adequate reimbursement by payers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully
commercialize any product candidates we may develop, which would materially harm our business. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product
candidates, or experience significant delays in doing so, our business will be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in
commencement, enrollment or completion of our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine
to develop on a timely basis, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk of failure for any product candidates we determine to develop is high. It is impossible to
predict when or if any product candidate would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical
development and then conduct extensive clinical trials to demonstrate the safety and efficacy of product candidates in humans. We have not yet begun or completed a clinical trial of any product candidate. Clinical trials may fail to demonstrate that
our product candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional
statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our IND applications
and other regulatory filings. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and
studies will ultimately support the further development of any product candidates. As a result, we cannot be sure that we will be able to submit IND applications for our preclinical programs on the timelines we expect, if at all, and we cannot be
sure that submission of IND applications will result in the FDA allowing clinical trials to begin. Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing.
The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, timely completion of preclinical activities is dependent upon the availability of preclinical sites, researchers, investigators and research
materials, which may be adversely affected by global health matters, such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as pandemics. We and our contract development and manufacturing organizations and contract research organizations experienced a temporary reduction in the capacity to undertake research scale
production and to execute some preclinical studies, and we may face disruptions in the future that affect our ability to initiate and complete preclinical studies and to procure items that are essential for our research and development activities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee
that any clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws
in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying and
qualifying patients to participate in clinical trials of any product candidates we may develop is critical to our success. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired
characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of novel genetic medicine-based approaches; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">size of the patient population, in particular for rare diseases, and process for identifying patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design of the trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility and exclusion criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the product candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of competing therapies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease or disorder under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to obtain and maintain patient consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that enrolled patients will drop out before completion of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">travel restrictions as a result of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to monitor patients adequately during and after treatment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials, we may need to delay, limit or terminate ongoing or planned
clinical trials, any of which would harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other events that may prevent successful
or timely completion of clinical development include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with regulatory authorities on trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CLROs, and
clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in opening clinical trial sites or obtaining required institutional review board, or IRB, or independent
ethics committee approval, or the equivalent review groups for sites outside the United States, at each clinical trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an
inspection of our clinical trial operations or trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us, any CLROs we engage or any other third parties to adhere to clinical trial requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s GCPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by physicians to adhere to delivery protocols leading to variable results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the testing, validation, manufacturing and delivery of any product candidates we may develop to the
clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites or patients dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, our response thereto and responses by
other businesses and governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its
potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events associated with a product candidate in development by another company, which
are viewed to outweigh its potential benefits, and which may negatively impact the perception of our product due to a similarity in technology or approach; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the legal or regulatory regimes domestically or internationally related to patient rights and privacy;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the clinical trial. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical studies and clinical trials could result in additional costs to us or impair our ability to generate
revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to any product candidates we may develop, we may need to conduct additional studies or trials to
bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize any product candidates we may develop or allow our competitors to bring
products to market before we do, which could impair our ability to successfully commercialize any product candidates we may develop and may harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if the results of future clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with any product
candidates we may develop, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining marketing approval for product candidates, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to changes in the way the product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its
distribution in the form of a modified risk evaluation and mitigation strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to the addition of labeling statements, such as warnings or contraindications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be sued; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genetic medicine is an emerging area of drug development that poses many scientific and other risks. We have only limited prior experience in genetic
medicine research and manufacturing and no prior experience in genetic medicine clinical development. Our lack of experience for our genetic medicine programs may limit our ability to be successful or may delay our development efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genetic medicine is an emerging field of drug development with only a small number of genetic medicines having received FDA or EMA approval to date. Our
genetic medicine research programs are still at an early </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stage, and there remain several areas of drug development risk, which pose particular uncertainty for our programs given the relatively limited development history of, and our limited prior
experience with, genetic medicines. Translational science, manufacturing materials and processes, safety concerns, regulatory pathway and clinical trial design and execution all pose particular risk to our drug development activities. Furthermore,
the medical community&#146;s understanding of the genetic causes of many diseases continues to evolve and further research may change the medical community&#146;s views on what therapies and approaches are most effective for addressing certain
diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an organization, we have not previously conducted any <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical trials,
including any later stage or pivotal clinical trials. In pursuing our new technologies, we have begun to establish our own genetic medicine technical capabilities, but we will need to continue to expand those capabilities by either hiring internally
or seeking assistance from outside service providers. Genetic medicine is an area of significant investment by biotechnology and pharmaceutical companies and there may be a scarcity of talent available to us in these areas. If we are not able to
expand our genetic medicine capabilities, we may not be able to develop in the way we intend or desire any promising product candidates that emerge from our program or our other collaborative genetic medicine sponsored research programs, which would
limit our prospects for future growth. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we may develop. Failure to commence or complete, or delays
in, our clinical trials, could prevent us from or delay us in commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need to build our internal and external
capabilities in designing and executing a genetic medicine clinical trial. There are many known and unknown risks involved in translating preclinical development of gene therapies to clinical development, including selecting appropriate endpoints
and dosage levels for dosing humans based on preclinical data. Furthermore, our genetic medicine programs are initially targeting rare diseases with relatively small populations, which limits the pool of potential subjects for our genetic medicine
clinical trials. If we are unable to initiate and conduct our genetic medicine clinical trials in a manner that satisfies our expectations or regulatory requirements, the value of our genetic medicine programs may be diminished. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is based on novel technologies that are unproven, which makes it difficult
to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have concentrated our research and
development efforts on our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform, and our future success depends on the successful development of our platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the technologies that comprise our platform are new and largely unproven. These technologies have not been clinically tested and the scientific
evidence to support the feasibility of developing product candidates based on those technologies is both preliminary and limited. Successful development of product candidates by us will require solving a number of issues, including the expansion of
our cell-targeted lipid nanoparticle delivery system, or ctLNP, delivery system to tissues beyond the liver and retina and obtaining expression levels sufficient to address or ameliorate each target disease or indication. There can be no assurance
we will be successful in solving any or all of these issues. We have concentrated our research efforts to date on developing the components of our platform, and our future success is highly dependent on the successful development of our closed-ended
DNA, or ceDNA, constructs, our ctLNP delivery system and therapeutic applications of these technologies. We may decide to alter or abandon our initial programs as new data become available and we gain experience in developing our therapeutics. We
cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in any indication we pursue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any development problems we experience in the future related to our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene
therapy platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring
that process to commercial partners, which may prevent us from initiating or conducting clinical trials or commercializing our products on a timely or profitable basis, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the clinical trial requirements of the FDA, the EMA and other regulatory agencies and the
criteria these regulators use to determine the safety and efficacy of a product candidate may vary according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product
candidates can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates, and even more so for product candidates intended to treat diseases for which there are approved
therapies that may allow a normal life span as compared with those intended to treat serious and life-threatening diseases for which there are no other treatment options available. There are approved therapies for our lead indications, hemophilia A
and PKU, in some jurisdictions in the world. As a result, the regulatory burden to initiate clinical trials or to obtain regulatory approval of any product candidate we may develop for those indications may be more extensive in those jurisdictions
than for product candidates intended to treat diseases that are life threatening and for which no therapies are approved. Only a small number of <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies have successfully reached the clinical
trial phase of development, limiting insight into the regulatory review process for this field of genetic medicine. Requirements by regulatory authorities for any product candidate we may develop may change in response to the availability of other
therapies for the indication our product candidates are designed to treat or to issues observed in clinical trials of genetic medicines of other companies, even if using technology that differs from ours. We intend to pursue genetic medicine
programs in both rare and prevalent diseases, some of which may have available approved therapies. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals in either the United States or
the European Union for any product candidates we may develop or how long it will take to commercialize any product candidate that receives marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any product candidates we may develop cause undesirable side effects or have other unexpected adverse properties, such side effects or properties
could delay or prevent regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not evaluated any product candidates in human clinical trials. Moreover, there have been only a limited number of clinical trials involving the use of <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapies and none involving ceDNA constructs or other technology similar to our technology. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. In
the genetic medicine field, there have been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia and death. There can be no assurance that our technologies will not cause undesirable side
effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use a ctLNP delivery system to deliver our ceDNA constructs. Lipid nanoparticles have been shown to induce necrosis in the liver at certain
doses and induce infusion related reactions, as well as to initiate systemic inflammatory responses. While our ctLNPs are a new generation of LNP, there can be no assurance that our ctLNPs will not have undesired effects. Our ctLNPs could
contribute, in whole or in part, to immune reactions, infusion reactions, complement reactions or antibody reactions. In addition, certain aspects of our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies may induce immune reactions
from the lipid as well as adverse reactions within liver pathways or degradation of the LNP into its component molecules or metabolites, any of which could lead to significant adverse events in one or more of our future clinical trials. Many of
these types of side effects have been seen for LNPs. Once delivered to target cells, <FONT STYLE="white-space:nowrap">DNA-based</FONT> payloads, such as those carried by our ceDNA constructs, may interact with host proteins or chromosomal DNA in the
cell endosome, cytosol or nucleus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adeno-associated virus, or AAV, genomes have been shown in some cases to initiate intracellular immune activation,
which can lead to transcriptional changes, and local tissue interferon responses, which may lead to immune infiltrates and tissue damage. AAV genetic material may also integrate into the host chromosome, which could contribute to modified cell
function transformation. There may be uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in future clinical trials and would result in significant delays in our
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may
need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prevalent, less severe or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations and
prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If in the future we are unable to demonstrate that such side effects were caused by factors others than our product candidates, the FDA, the EMA or other
regulatory authorities could order us to cease further development of, or deny approval of, any product candidates for any or all targeted indications. Even if we are able to demonstrate that any future serious adverse events are not
product-related, and regulatory authorities do not order us to cease further development of our product candidates, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect,
or are required, to delay, suspend or terminate any clinical trial of any product candidate, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be
delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory approval of and/or demand for our potential products will depend in part on public acceptance of the use of genetic medicine for the prevention or
treatment of human diseases. Safety issues that might arise in trials for gene therapies other than our own could adversely impact public attitudes towards our platform and product candidates notwithstanding that the gene therapies we are developing
are <FONT STYLE="white-space:nowrap">non-viral.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are a number of clinical trials of gene therapies ongoing. There is a potential risk of
delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry genetic material. Possible adverse side effects that may occur with
treatment with gene therapy products include an immunologic reaction early after administration that could substantially limit the effectiveness of the treatment or represent safety risks for patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may develop and could significantly harm our
business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The outcome of preclinical studies and earlier-stage clinical trials may not be
predictive of future results or the success of later preclinical studies and clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are in the early stage of research in the
development of our platform and have not identified any product candidates or conducted any <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or any clinical trials. As a result, our belief in the capabilities of our platform is based on
early research and preclinical studies. However, the results of preclinical studies may not be predictive of the results of preclinical studies or clinical trials, and the results of any early-stage clinical trials may not be predictive of the
results of later clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our future clinical trials may not
ultimately be successful or support further clinical development of any product candidates we may develop. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to identify, discover or develop potential product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates based on our <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform. All of our product development programs are still in the research or preclinical stage of development. Our research programs may fail to identify potential product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates, our potential product candidates may be
shown to have harmful side effects in preclinical <I>in vitro</I> experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the
product candidates impractical to manufacture, unmarketable or unlikely to receive marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, although we believe our platform will
position us to rapidly expand our portfolio of programs beyond our current programs, we have not yet successfully developed any product candidate and our ability to expand our portfolio may never materialize. The process by which we identify and
disclose product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to assemble sufficient resources to acquire or discover product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates we develop may nevertheless be covered by third parties&#146; patents or other
intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other
characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may not be effective in treating their targeted diseases or disorders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market for a potential product candidate may change so that the continued development of that product
candidate is no longer reasonable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable
cost, or at all; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the regulatory pathway for a potential product candidate is too complex and difficult to navigate successfully or
economically. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to identify and discover suitable product candidates for clinical development, this would adversely
impact our business strategy and our financial position and share price and could potentially cause us to cease operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The genetic medicine
field is relatively new and evolving rapidly. We are focusing our research and development efforts on our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform, but other gene therapy technologies may be discovered that provide
significant advantages over our platform, which could materially harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have focused our efforts on the advancement of our
<FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform, which is designed to overcome the limitations of current viral gene therapy approaches. However, while these modalities have demonstrated their limitations, there are many
companies that are developing new genetic medicines, including viral gene therapies, gene editing, base editing of either DNA or RNA and messenger RNA, or mRNA, -based therapeutics. There can be no certainty that these companies will not develop
genetic medicines that address some of these limitations and will be considered to have advantages over our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform. For example, in December 2019, Dyno Therapeutics announced a new
technique for AAV delivery that allows the researchers to engineer the virus shell to deliver the gene package to the exact cell type in the body they intend to treat. This new method may reduce concerns about
<FONT STYLE="white-space:nowrap">off-target</FONT> AAV delivery and make it a more attractive delivery system. Additionally, Selecta Biosciences and AskBio are developing a transient immunosuppressive approach with AAV and a new formulation of
rapamycin that is designed to shield AAV from an immune response, potentially enabling redosing to improve efficacy, initiate treatment in children or extend the time of effective therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular program, product candidate or indication
and fail to capitalize on programs, product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and expect to focus on product candidates that we identify for
specific indications among many potential options. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential, or we may choose to focus
our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending
on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular
product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate. Any such event could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit
commercialization of any product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will face an inherent risk of clinical trial and product liability exposure related
to the testing of any product candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no product candidates in clinical trials or that have
been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product,
healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of
merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidates we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need to increase our insurance coverage if we commence clinical trials or if we commence commercialization of any product candidates. Insurance
coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of
claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks relating to manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of
genetic medicine products is complex and difficult and is subject to a number of scientific and technical risks, some of which are common to the manufacture of drugs and biologics and others of which are unique to the manufacture of gene therapies.
We could experience manufacturing problems that result in delays in our development or commercialization programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genetic medicine drug products
are complex and difficult to manufacture. We have an established cGMP-ready process at the <FONT STYLE="white-space:nowrap">200-liter</FONT> scale which we have successfully transferred to external contract development and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing organizations, or CDMOs, to supply our gene therapies for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies and early clinical trials. We believe that we will
be able to enter into arrangements with existing and/or additional CDMOs to provide commercial supply. We may also seek to eventually establish our own manufacturing facility for long-term commercial supply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of factors common to the manufacturing of biologics and drugs could also cause production issues or interruptions for our gene therapies, including
raw material or starting material variability in terms of quality, cell line viability, productivity or stability issues, shortages of any kind, shipping, distribution, storage and supply chain failures, growth media contamination, equipment
malfunctions, operator errors, facility contamination, labor problems, natural disasters, disruption in utility services, terrorist activities, or acts of god that are beyond our or our contract manufacturer&#146;s control. It is often the case that
early stage process development is conducted with materials that are not manufactured using cGMP starting materials, techniques or processes and which are not subject to the same level of analysis that would be required for clinical grade material.
We may encounter difficulties in translating the manufacturing processes used to produce research grade materials to cGMP compliant processes, and any changes in the manufacturing process may affect the safety and efficacy profile of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm
our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing process, such as Sf9 cells, are derived
from biologic sources. Such raw materials may be difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of any
product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is novel, and the combination of novel
constructs with untested scaling may cause us to experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of any product candidates we may
develop or otherwise harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is novel and the manufacture
of products on the basis of our platform is untested at a large scale. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures,
product recalls, product liability claims, insufficient inventory or potentially delay progression of our preclinical or clinical development of any product candidates we may develop. If we successfully develop product candidates, we may encounter
problems achieving adequate quantities and quality that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. The ability to scale our manufacturing and maintain
the manufacturing process at the same levels of quality and efficacy that we are currently manufacturing is yet to be tested. If we or our CDMOs are unable to scale our manufacturing at the same levels of quality and efficiency, we may not be able
to supply the required number of doses for clinical trials or commercial supply, and our business could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing the ctLNP
component of a potential product candidate may be complex and difficult, and we could experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization, limit the supply of
any product candidates we may develop or otherwise harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many product candidates we may develop will require the manufacture of the
ctLNP component, which may require processing steps that are more complex than those required for current products that utilize LNPs. In order to manufacture ctLNPs that are specialized for a given platform program, we may need to add biologic
ligands to existing LNPs. This process is challenging and may pose a risk to our ability to manufacture on a scale sufficient to meet clinical and commercial needs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Testing of and changes to methods of product candidate manufacturing or formulation may result in
additional costs or delay. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As product candidates proceed through preclinical studies to clinical trials towards potential approval and
commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are tested and then altered along the way in an effort to optimize processes and results. Such changes carry the risk
that they will not achieve these intended objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An important part of the manufacturing of our potential product candidates is analytical testing.
Analytical testing of gene therapies involves tests that are more numerous, more complex in scope and take a longer time to develop and to conduct as compared to traditional dugs. We and our CDMOs may need to expend considerable time and resources
to develop assays and other analytical tests for our product candidates, including assays to assess the potency of our product candidates. Some assays may need to be outsourced to specialized testing laboratories. Even when assays are developed,
they may need to be further tested, qualified and validated, which may take substantial time and resources. Because of the lagging nature of analytical testing, we may proceed with additional manufacturing and other development activities without
having first fully characterized our manufactured materials. If the results of the testing fail to meet our expectations, we may need to delay or repeat certain manufacturing and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may make changes to our manufacturing methods as part of our product development activities. Any such changes could cause any product candidates we may
develop to perform differently and affect the results of clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay
completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and
generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA, the EMA, and other regulatory authorities may require us to submit samples of any lot of and approved product
together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA, or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight
deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause
us to delay product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently depend on a small number of third-party suppliers for our drug substance and drug product, and we expect to continue to depend on
third-party suppliers for materials used in the manufacture of any product candidates we may develop, and the loss of these third-party suppliers or their inability to supply us with adequate materials, particularly those raw materials that are in
short supply, could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely on a small number of third-party suppliers for our drug substance and drug product and
expect to continue to rely on third-party suppliers for certain materials and components required for the production of any product candidates we may develop. Our dependence on these third-party suppliers and the challenges we may face in obtaining
and maintaining adequate supplies of materials involve several risks, including limited control over pricing, availability and quality and delivery schedules. There is substantial demand and limited supply for certain of the raw materials used to
manufacture genetic medicine products and these raw materials are usually sole-sourced, as there are a limited number of qualified suppliers. This limited supply, combined with any problems that may arise during the manufacturing process
development, may create long lead times to manufacture or procure starting materials. The progress of our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform is highly dependent on these suppliers providing us or our contract
manufacturer with the necessary starting materials that meet our requirements in a timely manner. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors that are larger than we are. We
cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any supply interruption in limited or sole-sourced raw materials could materially harm our ability to
manufacture any product candidates we may develop until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any
performance failure on the part of our suppliers could delay the development and potential commercialization of any product candidates we may develop, including limiting supplies necessary for clinical trials and regulatory approvals, which would
have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our dependence on third parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and
clinical testing, and these third parties may not perform satisfactorily. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to independently conduct all aspects of our product
manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including CDMOs for the manufacturing of any product candidates we test in
preclinical or clinical development, as well as contract research organizations, or CROs for the conduct of our animal testing and research.<B> </B>Any of these third parties may terminate their engagements with us at any time. If we need to enter
into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility
to ensure compliance with all required regulations and study protocols. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and clinical trials are conducted in accordance with the study plan and protocols. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although
we intend to design the clinical trials for any product candidates we may develop, CLROs will conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be
outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than
would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have staffing difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to comply with contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience regulatory compliance issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undergo changes in priorities or become financially distressed; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form relationships with other entities, some of which may be our competitors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may
subject us to unexpected cost increases that are beyond our control. If the CLROs and other third parties do not perform preclinical studies and future clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with
regulatory requirements, the development, regulatory approval and commercialization of any product candidates we may develop may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development
programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CLROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any
preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic has impacted, and may continue to impact, our third-party CDMOs, CROs and CLROs, including through the effects of facility closures, reductions in operating hours, staggered shifts and other social
distancing efforts, labor shortages, decreased productivity and unavailability of materials or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
components. While we maintain an inventory of materials necessary to conduct our research and any preclinical studies, a prolonged outbreak could lead to shortages in these materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory
requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support future IND submissions and approval of any product candidates we
may develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing
facilities on which we rely may not continue to meet regulatory requirements and have limited capacity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All entities involved in the preparation
of therapeutics for clinical trials or commercial sale, including any contract manufacturers of any product candidates we may develop, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or
used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure
the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants or to inadvertent changes in the properties or stability of our
product candidates that may not be detectable in final product testing. We or our contract manufacturer must supply all necessary documentation in support of a biologics license application, or BLA, on a timely basis and must adhere to the
FDA&#146;s cGLP and cGMP regulations enforced through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a <FONT
STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the applicable regulations as a condition of regulatory approval of any product candidates we may develop or any of our other potential products. In addition, the
regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations
applicable to the activities being conducted. If these facilities do not pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> plant inspection, FDA approval of the products will not be granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party
contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant
regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or
permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or
revocation of a <FONT STYLE="white-space:nowrap">pre-existing</FONT> approval. As a result, our business, financial condition and results of operations may be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms or at
all if they are affiliated with our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities,
particularly if they are under contract with our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly
or damaging to us; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our
business or operations, including the bankruptcy of the manufacturer or supplier. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical trial
delays or failure to obtain regulatory approval or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of
production. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in supply. An alternative
manufacturer would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may also require additional studies or trials if a new manufacturer is relied upon for commercial production. Switching
manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors could
cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our
suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may from time to time be dependent on single-source suppliers for some of the components and materials used in, and the processes required to
develop, our development candidates and investigational medicines. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time depend on single-source suppliers for some of the
components and materials used in, and manufacturing processes required to develop, our development candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity
or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and
finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling
to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish
replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we have to switch to a replacement supplier, the manufacture and delivery of our development candidates or investigational
medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our investigational medicines, if required, may not be
accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain
adequate inventory of the single source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices
in a timely manner, could impair our ability to meet the demand for our investigational medicines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any contract manufacturers and
suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety laws, regulations
and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the
ground, air and water; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce
hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of
hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at third-party facilities.
We also could incur significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with applicable environmental laws and
regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these
materials or wastes. Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate
coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from
biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory
approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations and permitting requirements. These current or future laws, regulations and permitting requirements may impair our
research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions or business disruption, which could have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any third-party contract manufacturers and suppliers we engage will
also be subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to rely on third parties to conduct, supervise
and monitor <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and clinical studies, and if these third parties perform in an unsatisfactory manner, it may harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to rely on CROs and CLROs and research and clinical trial sites to ensure our <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and
clinical trials are conducted properly and on time. While we will have agreements governing their activities, we will have limited influence over their actual performance. We will control only certain aspects of our CROs and CLROs&#146; activities.
Nevertheless, we will be responsible for ensuring that each of these studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs and CLROs does not relieve us of our
regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our CROs and CLROs will be required to comply with the FDA&#146;s GCPs for conducting, recording and reporting the
results of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and clinical trials to assure that the data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are
protected. The FDA enforces these GCPs through periodic inspections of study sponsors, principal investigators and clinical trial sites. If we or our CROs or CLROs fail to comply with applicable GCPs, the preclinical and clinical data generated in
our studies may be deemed unreliable and the FDA may require us to perform additional studies before approving any marketing applications. Upon inspection, the FDA may determine that our studies did not comply with GCPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our CLROs and CROs are not our employees, and we are therefore unable to directly monitor whether or not they devote sufficient time and resources to our
clinical and nonclinical programs. These CLROs and CROs may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our
competitive position. If our CROs or CLROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to
our protocols or regulatory requirements, or for any other reasons, our studies may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidates we may develop. As
a result, our financial results and commercial prospects would be harmed, our costs could increase, and our ability to generate revenues could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may enter into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may
develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
may seek third-party collaborators for the research, development and commercialization of certain of the product candidates we may develop. If we enter into any such arrangements with any third parties, we will likely have limited control over the
amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our
collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations involving our research programs or any product candidates we may develop pose numerous risks to us, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of any product candidates we may develop or may
elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#146;s strategic focus or available funding or external factors such as an acquisition that diverts resources or
creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay programs, preclinical studies or clinical trials, provide insufficient funding for
programs, preclinical studies or clinical trials, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with any product candidates we may develop if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may be acquired by a third party having competitive products or different priorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing and distribution rights to one or more medicines may not commit sufficient resources
to the marketing and distribution of such medicine or medicines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary
rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research,
development, or commercialization of our medicines or any product candidates we may develop or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may lose certain valuable rights under certain circumstances, including if we undergo a change of control;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable product candidates we may develop; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaboration agreements may not lead to development or commercialization of product candidates in the most
efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be
delayed, diminished or terminated. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our collaborations do not result in the successful development and commercialization of product
candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements,
our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable
replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development,
regulatory approval and commercialization described in this Annual Report apply to the activities of our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These relationships, or those
like them, may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and
business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things,
upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#146;s evaluation of several factors. If we license rights to any product candidates we or
our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability
to implement our strategies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may
act in a manner adverse to us and could limit our ability to implement our strategies. Some of our academic collaborators are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our
collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing
products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop
competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, fail to devote sufficient resources to the development and
commercialization of products, or merge with or be acquired by a third party who may do any of these things. Any of these developments could harm our product development efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development and research programs and the potential commercialization of any product candidates we may develop will require
substantial additional cash to fund expenses. For some of the product candidates we may develop, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will
depend, among other things, upon our assessment of the collaborator&#146;s resources and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of
clinical trials, the likelihood of approval by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such
product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge,
and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive
than the one with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of
recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be
able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development
program or one or more of our other development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities, or increase our own expenditures on the development of the product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to commercialization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face
substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug products is highly competitive. We face competition with respect to any product candidates that we may
develop from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the
development of products for the treatment of many of the disorders for which we are conducting research programs. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach,
and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish
collaborative arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are numerous companies that are selling or developing
genetic medicines, including in indications for which we may develop our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies. These companies include viral gene therapy companies such as BioMarin Pharmaceuticals, Inc., Homology
Medicines, Inc., Adverum Biotechnologies, Inc., Ultragenyx Pharmaceutical Inc. and Hoffmann La Roche Ltd; gene editing companies such as Crispr Therapeutics AG, Intellia Therapeutics, Inc. and Editas Medicine, Inc.; and mRNA companies such as
Moderna, Inc. See &#145;&#145;Business&#151;Competition&#146;&#146; for additional information regarding competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be
reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our product candidates or that would render any
product candidates that we may develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which
could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may
not be successful in marketing any product candidates we may develop against competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the companies against which we are competing or against
which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved
products than we do. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any product candidate that we may develop receives marketing approval, it may fail to achieve the degree of
market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any product
candidate we may develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payers and others in the medical community. Sales of medical products depend in part on the
willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost-effective. In addition, the inclusion or exclusion of products
from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#146;
organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost-effective as compared with competing treatments. Efforts to educate the medical
community and third-party payers on the benefits of any product candidates we may develop may require significant resources and may not be successful. If any product candidates we may develop do not achieve an adequate level of acceptance, we may
not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of such product candidates as demonstrated in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages and limitations compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products, if approved, together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and
reimbursement for our future product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial target platforms in our pipeline are indications with small patient populations. For product candidates that are designed to treat smaller patient
populations to be commercially viable, the reimbursement for such product candidates must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any
approved product candidate that accounts for the smaller potential market size. If we are unable to establish or sustain coverage and adequate reimbursement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for any future product candidates from third-party payers, the adoption of those product candidates and sales revenue will be adversely affected, which, in turn, could adversely affect the
ability to market or sell those product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that coverage and reimbursement by third-party payers will be essential for
most patients to be able to afford these treatments. Accordingly, sales of our future product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by
health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payers. Even if coverage is provided, the
approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions
about reimbursement by government authorities for new products are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, since CMS decides whether and to what extent a new product will be covered and reimbursed under
Medicare. Private payers tend to follow CMS to a substantial degree. However, one payer&#146;s determination to provide coverage for a product does not assure that other payers will also provide coverage for the drug product. Further, a payer&#146;s
decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement agencies in the European Union may be more conservative than CMS. For example, a number of cancer drugs have been
approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States,
international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue
to put pressure on the pricing and usage of therapeutics such as any product candidates we may develop. In many countries, particularly the countries of the European Union, the prices of medical products are subject to varying price control
mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. As a result, we might obtain marketing approval
for a product in a particular country, but then be subject to price regulations that delay or might even prevent our commercial launch of the product, possibly for lengthy periods of time. To obtain reimbursement or pricing approval in some
countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United
States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for
product candidates. Accordingly, in markets outside the United States, the reimbursement for any product candidates we may develop may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues
and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payers, in the United States and internationally, to cap or reduce healthcare
costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for any product candidates we may develop. We expect to experience
pricing pressures in connection with the sale of any product candidates we may develop due to the trend toward managed healthcare, the increasing influence of certain third-party payers, such as health maintenance organizations, and additional
legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry
of new products into the healthcare market. Recently there have been instances in which third-party payers have refused to reimburse treatments for patients for whom the treatment is indicated in the
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> product label. Even if we are successful in obtaining FDA approvals to commercialize our product candidates, we cannot guarantee that we will be able to secure reimbursement for all patients for
whom treatment with our product candidates is indicated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to CMS and private payers, professional organizations such as the American Medical Association,
or the AMA, can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payers contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization
of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates. Even if favorable coverage and
reimbursement status is attained for one or more product candidates for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third
parties, we may not be successful in commercializing any product candidates we may develop if and when they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have a sales
or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales,
marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, we may build
a sales and marketing infrastructure to market some of the product candidates we may develop if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting
and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for
any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our products on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or
reimbursement, customer service, medical affairs and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to educate adequate numbers of physicians on the benefits of any future
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and
other acceptance by payers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the
patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties
to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into
arrangements with third parties to sell, market and distribute any product candidates we may develop or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail
to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be
successful in commercializing any product candidates we may develop. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidates for which we intend to seek approval as biologic products may face competition
sooner than anticipated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Amendment, or the PPACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed
by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of
exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled
clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.
While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our biological products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a risk that any product candidates we may develop that are approved as a biological product under a BLA would not qualify for the <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products
for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation.
Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for nonbiological products is not yet clear, and will depend on a
number of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunities for any product candidates we may develop are
smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer. Because the target patient populations for many of the initial product candidates we may develop are small, we must be able to
successfully identify patients and achieve a significant market share to maintain profitability and growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focusing our initial research
and product development on treatments for rare genetically defined diseases; as a result, the relevant patient population may be small. Our projections of both the number of people who have these diseases, as well as the subset of people with these
diseases who have the potential to benefit from treatment with product candidates we may develop, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases.
The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with our product candidates we may develop, or may become increasingly difficult to identify or
gain access to, all of which would adversely affect our business, financial condition, results of operations and prospects. Additionally, because of the potential that any product candidates we may develop could cure a target disease, we may not
receive recurring revenues from patients and may deplete the patient population prevalence through curative therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our intellectual
property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Although we own and license a number of pending patent applications which have not yet issued as patents, we do not currently own or
exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> any issued patents relating to any product candidates we may develop or technology, including with respect to our ceDNA constructs, ctLNP delivery system and </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>manufacturing process. If we or our licensors are unable to obtain, maintain and defend patent and other intellectual property protection for our product
candidates and technology, or if the scope of the patent or </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to
successfully develop and commercialize any product candidates we may develop or our technology may be adversely affected due to such competition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our and our licensors&#146; ability to obtain and maintain patent and other intellectual property protection in the United
States and other jurisdictions with respect to any product candidates we may develop and our technology, including&nbsp;our ceDNA constructs, ctLNP delivery system, manufacturing processes and&nbsp;their respective components, formulations,
combination therapies, methods of treatment, processes and development that are important to our business, as well as successfully defending these patents and other intellectual property against third-party challenges. We and our licensors have
sought, and will seek, to protect our proprietary position by filing patent applications in the United States and abroad related to certain technologies and our platform that are important to our business. However, our patent portfolio is at an
early stage and we currently do not own or exclusively license any issued patents in any jurisdiction. Moreover, there can be no assurance as to whether or when our patent applications will issue as granted patents. Our ability to stop third parties
from making, using, selling, marketing, offering to sell, importing and commercializing any product candidates we may develop and our technology is dependent upon the extent to which we have rights under valid and enforceable patents and other
intellectual property that cover our platform and technology. If we are unable to secure, maintain, defend and enforce patents and other intellectual property with respect to&nbsp;any product candidates we may develop and technology, it would have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own certain patent applications, and exclusively <FONT
STYLE="white-space:nowrap">in-license</FONT> from University of Massachusetts as represented by and solely on behalf of its Medical School, or UMass, and Voyager Therapeutics, Inc. certain other patent applications, which cover our ceDNA platform
structure, use and/or function, our ctLNP platform and its use, and ceDNA manufacturing processes, as applicable. Our pending Patent Cooperation Treaty, or PCT, patent applications are not eligible to become issued patents until, among other things,
we file a national stage patent application within 30 to 32 months, depending on the jurisdiction, from such application&#146;s priority date in the jurisdictions in which we are seeking patent protection. Similarly, our pending provisional patent
applications are not eligible to become issued patents until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of such provisional patent application&#146;s filing date. If we
do not timely file such national stage patent applications or <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we may lose our priority date with respect to such PCT or provisional patent applications, respectively, and
any patent protection on the inventions disclosed in such PCT or provisional patent applications, respectively. While we and our licensors intend to timely file national stage and <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
applications relating to our PCT and provisional patent applications, respectively, we cannot predict whether any such patent applications will result in the issuance of patents. If we or our licensors do not successfully obtain issued patents, or,
if the scope of any patent protection we or our licensors obtain is not sufficiently broad, we will be unable to prevent others from using any product candidates we may develop or our technology or from developing or commercializing technology and
products similar or identical to ours or other competing products and technologies.&nbsp;Any failure to obtain or maintain patent protection with respect to&nbsp;our ceDNA constructs, ctLNP delivery system, manufacturing processes or our other
product candidates and technology would have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
patent prosecution process is expensive, time-consuming and complex, and we and our licensors may not be able to file, prosecute, maintain, defend, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely
manner. We and our licensors may not be able to obtain, maintain or defend patents and patent applications due to the subject matter claimed in such patents and patent applications being in the public domain. For example, in some cases, the work of
certain academic researchers in the genetic medicine field has entered or will enter the public domain, which may compromise our and our licensors&#146; ability to obtain patent protection for certain inventions related to or building upon such
prior work. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our
research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose
such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we would not be able to prevent any third party from using any of our technology that is in the public domain to compete with
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and
factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of patent rights are highly uncertain. Our pending and future owned and licensed patent
applications may not result in patents being issued which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and product or otherwise provide any competitive advantage. In fact,
patent applications may not issue as patents at all, and even if such patent applications do issue as patents, they may not issue in a form, or with a scope of claims, that will provide us with any meaningful protection, prevent others from
competing with us or otherwise provide us with any competitive advantage. In addition, the scope of claims of an issued patent can be reinterpreted after issuance, and changes in either the patent laws or interpretation of the patent laws in the
United States and other jurisdictions may diminish the value of our patent rights or narrow the scope of our patent protection. Furthermore, our competitors or other third parties may be able to circumvent our patents by developing similar or
alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties have developed technologies that
may be related or competitive to our own technologies and product candidates and may have filed or may file patent applications, or may have obtained issued patents, claiming inventions that may overlap or conflict with those claimed in our owned or
licensed patent applications or issued patents. We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates and technology. Publications of discoveries in the scientific
literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing or, in some cases, not at all. Therefore, we cannot know for certain
whether the inventors of our owned or licensed patents and patent applications were the first to make the inventions claimed in any owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of
such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patent applications may not issue as patents and even if issued,
may be challenged and invalidated or ruled unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or
enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and other jurisdictions. For example, we may be subject to a third-party submission of prior art to the United States Patent
and Trademark Office, or USPTO, challenging the validity of one or more claims of our owned or licensed patents. Such submissions may also be made prior to a patent&#146;s issuance, precluding the granting of a patent based on one of our owned or
licensed pending patent applications. We may become involved in opposition, derivation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter partes</I> review, post-grant review or interference proceedings and similar proceedings in
foreign jurisdictions (for example, opposition proceedings) challenging our owned or licensed patent rights. In addition, a third party may claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. An adverse
result in any litigation or patent office proceeding could put one or more of our owned or licensed patents at risk of being invalidated, ruled unenforceable or interpreted narrowly and could allow third parties to commercialize products identical
or similar to any product candidates we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our
licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or
other features of patentability. Such challenges and proceedings may result in loss of patent rights, exclusivity, freedom to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operate or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and
products, or limit the duration of the patent protection of our technology and any product candidates we may develop. Such challenges and proceedings may also result in substantial cost and require significant time from our scientists and
management, even if the eventual outcome is favorable to us. Moreover, there could be public announcements of the results of hearings, motions or other interim proceedings or developments related to such challenges and proceedings and if securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore,
patents have a limited lifespan. In the United States, the expiration of a patent is generally 20 years from the earliest date of filing of the first <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application to which the patent
claims priority. Patent term adjustments and extensions may be available; however, the overall term of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent and other intellectual property rights may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to our technology and any product candidates we may develop. Any of the foregoing could have a material adverse effect on our competitive position, business,
financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize any product candidates are subject, in part, to
the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future intellectual property license agreements or otherwise experience disruptions to our business relationships
with our current or any future licensors, we could lose intellectual property rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are reliant upon
licenses from third parties for certain patent and other intellectual property rights that are important or necessary to the development of our technology and product candidates. For example, we rely on a license from the National Institutes of
Health, or NIH, and the Association Institut de Myologie, Universite Pierre et Marie Curie, Centre National de la Recherche Scientifique and Inserm Transfert SA, which we refer to as the French Institutions, pursuant to which we have been granted a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-bearing license to certain patent rights related to our ceDNA construct, to make and have made, research and have researched, use and have used, sell and have sold, offer to sell
and to import products for the treatment, prevention or palliation of any human disease, disorder or condition. In addition, we rely on a license from UMass pursuant to which we have been granted an exclusive, worldwide, royalty-bearing license to
certain patent rights related to our ceDNA construct to research, develop, manufacture, have manufactured, use, offer for sale, sell and import products in the treatment, prevention or palliation of any human disease, disorder or condition. Our
existing license agreements, including our license agreements with NIH and UMass, impose, and we expect that future license agreements will impose, specified diligence, milestone payment, royalty, commercialization, development and other obligations
on us and require us to meet development timelines, or to exercise diligent or commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. For more information on the terms of the license
agreements with NIH and UMass, see &#147;Business&#151;Intellectual property&#151;License agreements.&#148; We may enter into additional license agreements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the licensors of our license agreements have the right to terminate the agreement if we materially breach the agreement and fail to cure such
breach within a specified period or in the event we undergo certain bankruptcy events. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements and might therefore
terminate the license agreements. If our license agreements are terminated, we may lose our rights to develop and commercialize any product candidates we may develop and technology, lose patent protection any product candidates we may develop and
our technology, experience significant delays in the development and commercialization of our product candidates and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology and incur liability for damages. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying intellectual property fails to provide the intended
exclusivity, our competitors or other third parties could have the freedom to seek regulatory approval of, and to market, products and technologies identical or competitive to ours and we may be required to cease our development and
commercialization of certain of our product candidates and technology. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner
that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to
compete with any product candidates we may develop and our technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our or our licensors&#146; ability to obtain, maintain and defend intellectual property and to enforce
intellectual property rights against third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology, product candidates and processes infringe, misappropriate or otherwise
violate the intellectual property of the licensor that is not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other intellectual property rights under our license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence, development, regulatory, commercialization, financial or other obligations under the license
agreement and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our current or future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our license agreements are, and future license agreements are likely to be, complex, and certain provisions in such agreements may be susceptible
to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be
our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed or any other dispute described above related to our license agreements prevent or impair our
ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technology. Any of the foregoing could have a material adverse effect
on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our license agreement with NIH is, and other license agreements we may enter
into in the future may be, <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> Accordingly, third parties may also obtain <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses from such licensors, including NIH, with respect to the
intellectual property licensed to us under such license agreements, including our NIH license agreement. Accordingly, our NIH license agreement does not, and other license agreements may not, provide us with exclusive rights to use such licensed
patent and other intellectual property rights, or may not provide us with exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or
commercialize our technology and any product candidates we may develop in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, some of our
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent and other intellectual property rights are, and may in the future be, subject to third party interests such as <FONT STYLE="white-space:nowrap">co-ownership.</FONT> If we choose not to or
are unable to obtain an exclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
license to such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest, in such patent and other intellectual property rights, such third-party <FONT
STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We or our licensors may need the cooperation of
any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our licensed patent and other intellectual property rights in order to enforce them against third parties, and such cooperation may not be provided to us or our licensors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we do not have complete control over the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent
applications that we license from third parties. For example, pursuant to each of our intellectual property licenses with NIH and UMass, our licensors retain control of preparation, filing, prosecution and maintenance, and, in certain circumstances,
enforcement and defense of their patents and patent applications. It is possible that our licensors&#146; filing, prosecution and maintenance of the licensed patents and patent applications, enforcement of patents against infringers or defense of
such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, and accordingly, we cannot be certain that these patents and patent applications will be prepared, filed,
prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to file, prosecute, maintain, enforce and defend such patents and patent applications, or lose rights to those
patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our technology and any product candidates we may develop that are the subject of such licensed rights could be
adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing products. Any of these events could have a material adverse effect on our competitive position, business, financial
conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights may be
subject to a reservation of rights by one or more third parties. For example, inventions contained within some of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights may be made using U.S. government funding. When new technologies
are developed with government funding, in order to secure ownership of patent rights related to the technologies, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions
claimed in such patent rights to the U.S. government and timely electing title to such inventions. We rely on our licensors to ensure compliance with applicable obligations arising from such funding, including such timely disclosure and election of
title. The failure of our licensors to meet their obligations may lead to a loss of rights or the unenforceability of relevant patents or patent applications. In addition, the U.S. government has certain rights in such
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. If
the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government&#146;s rights may also permit it to disclose the funded inventions and technology, which may
include our confidential information, to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The
U.S. government may exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because we or our licensors failed to achieve practical application of the U.S. government-funded technology, because
action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such <FONT STYLE="white-space:nowrap">in-licensed</FONT> U.S. government-funded
inventions may be subject to certain requirements to manufacture any product candidates we may develop embodying such inventions in the United States. Any of the foregoing could harm our business, financial condition, results of operations and
prospects significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, maintaining, enforcing and defending patents and other intellectual property rights on our technology and any product candidates we may
develop in all jurisdictions throughout the world would be prohibitively expensive, and accordingly, our intellectual property rights in some jurisdictions outside the United States could be less extensive than those in the United States. In some
cases, we or our licensors may not be able to obtain patent or other intellectual property protection for certain technology and product candidates outside the United States. In addition, the laws of some foreign jurisdictions do not protect
intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors may not be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain issued patents or other intellectual property rights covering any product candidates we may develop and our technology in all jurisdictions outside the United States and, as a result, may
not be able to prevent third parties from practicing our and our licensors&#146; inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Third parties may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent or other intellectual property protection to develop their own products and, further, may export otherwise
infringing, misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement is not as strong as that in the United States. These products may compete with any product candidates
we may develop and our technology and our or our licensors&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain jurisdictions, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could
make it difficult for us to stop the infringement, misappropriation or other violation of our patent and other intellectual property rights or marketing of competing products in violation of our intellectual property rights generally. For example,
an April 2019 report from the Office of the United States Trade Representative identified a number of countries, including China, Russia, Argentina, Chile and India, where challenges to the procurement and enforcement of patent rights have been
reported. Proceedings to enforce our or our licensors&#146; patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put
our patent and other intellectual property rights at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not
prevail in any lawsuits that we or our licensors initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many jurisdictions have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. In these jurisdictions, the patent owner may
have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be
impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our
patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other
government fees on patents and/or patent applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patent rights. We rely on our outside counsel
and other professionals or our licensing partners to pay these fees due to the USPTO and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government
patent agencies also require compliance with several procedural, documentary and other similar provisions during the patent application process. We rely on our outside counsel and other professionals to help us comply and we are also dependent on
our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Moreover, complications due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in inadvertent
lapses due to, for example, unexpected closures of the USPTO or foreign patent offices, delays in delivery of notifications relating to deadlines, or failure to timely and/or properly obtain signatures on necessary documents. In many cases, an
inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment, loss of
priority or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our competitive position, business, financial conditions, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining necessary rights to product candidates we may develop through acquisitions and <FONT
STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have rights to certain intellectual property through licenses from third parties.
Because our programs may require the use of additional intellectual property rights held by third parties, the growth of our business likely will depend, in part, on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use
these intellectual property rights. In addition, with respect to any patent or other intellectual property rights that we <FONT STYLE="white-space:nowrap">co-own</FONT> with third parties, we may require exclusive licenses to such <FONT
STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patent or other intellectual property rights. However, we may be unable to secure such licenses or otherwise acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any
intellectual property rights related to compositions, methods of use, processes or other components from third parties that we identify as necessary for any product candidates we may develop and our technology on commercially reasonable terms, or at
all. Even if we are able to <FONT STYLE="white-space:nowrap">in-license</FONT> any such necessary intellectual property, it could be on <FONT STYLE="white-space:nowrap">non-exclusive</FONT> terms, thereby giving our competitors and other third
parties access to the same intellectual property licensed to us, and the applicable licensors could require us to make substantial licensing and royalty payments. The licensing or acquisition of third-party intellectual property rights is a
competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage
over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to
license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We sometimes
collaborate with <FONT STYLE="white-space:nowrap">non-profit</FONT> and academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an
option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are
acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to third parties, potentially blocking our ability to pursue our research program and develop and commercialize our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we
have licensed, we may be required to expend significant time and resources to redesign any product candidates we may develop or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a
technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could have a material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering any product candidates we may develop could be found invalid or unenforceable if challenged in court or before
administrative bodies in the United States or abroad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our owned and licensed patent rights may be subject to priority, validity, inventorship and
enforceability disputes. If we or our licensors are unsuccessful in any of these proceedings, such patent rights may be narrowed, invalidated or held unenforceable, we may be required to obtain licenses from third parties, which may not be available
on commercially reasonable terms or at all, or we may be required to cease the development, manufacture and commercialization of one or more of our product candidates. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If one of our licensing partners, one of our <FONT STYLE="white-space:nowrap">co-owners,</FONT>
we or our licensor&#146;s other licensees initiate legal proceedings against a third party to enforce a patent covering any of any product candidates we may develop or our technology, the defendant could counterclaim that the patent covering the
product candidate or technology is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an
alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of utility, lack of written description or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion
could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> interference proceedings, derivation proceedings, post grant review,
<I>inter partes</I> review and equivalent proceedings such as opposition, invalidation and revocation proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way
that they no longer cover any product candidates we may develop or our technology or prevent third parties from competing with any product candidates we may develop or our technology. The outcome following legal assertions of invalidity and
unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a
third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or technology. Such a loss of patent protection could
have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the
confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we
rely on trade secret protection and confidentiality agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and
any other elements of our product candidate discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. However, trade secrets can be
difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with
our employees, consultants, scientific advisors, contractors and other parties who have access to such technology and processes. However, we may not be able to prevent the unauthorized disclosure or use of our technical <FONT
STYLE="white-space:nowrap">know-how</FONT> or other trade secrets by the parties to these agreements. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary
technologies will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breach or violate the terms of any of these agreements, we may not have adequate remedies for any such
breach or violation. As a result, we could lose our trade secrets and third parties could use our trade secrets to compete with any product candidates we may develop and our technology. Additionally, we cannot guarantee that we have entered into
such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also seek to preserve
the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems; however, such systems and security measures may be breached,
and we may not have adequate remedies for any breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our trade secrets may otherwise become known or be independently discovered by
competitors or other third parties. Competitors or third parties could purchase any product candidates we may develop or our technology and attempt to replicate some or all of the competitive advantages we derive from our development efforts,
willfully infringe our intellectual property rights, design around our intellectual property rights or develop their own competitive technologies that fall outside the scope of our intellectual property rights. If any of our trade secrets were to be
lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. If our
trade secrets are not adequately protected so as to protect our market against competitors&#146; products, our business, financial condition, results of operations and prospects could be materially and adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or
otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial
success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual
property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may become party to, or be threatened with,
adversarial proceedings or litigation in which third parties may assert infringement, misappropriation or other violation claims against us, alleging that any product candidates we may develop, manufacturing methods, formulations or administration
methods are covered by their patents. Given the vast number of patents and other intellectual property in our field of technology, we cannot be certain or guarantee that we do not infringe, misappropriate or otherwise violate patents or other
intellectual property. Other companies and institutions have filed, and continue to file, patent applications that may be related to our technology and, more broadly, to gene therapy and related manufacturing methods. Some of these patent
applications have already been allowed or issued and others may issue in the future. Since this area is competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and
additional patents granted in the future, as well as additional research and development programs expected in the future. If a patent holder believes the manufacture, use, sale or importation of any product candidates we may develop or our
technology infringes its patent, the patent holder may sue us even if we have licensed other patent rights for our technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is also possible that
we have failed to identify relevant third-party patents or applications. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications
now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of any product candidates we may develop or our technology and we may not be aware of such patents. Furthermore, applications
filed before November&nbsp;29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until a patent issues. Moreover, it is difficult for industry participants, including us, to
identify all third-party patent rights that may be relevant to any product candidates we may develop and our technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty
in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may
issue with claims of relevance to our technology. In addition, we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published
can, subject to certain limitations, be later amended in a manner that could cover our technologies, any product candidates we may develop or the use of any product candidates we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.
There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these
third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize any product candidates we may develop or any other of our product candidates or technologies covered by the asserted third-party
patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the
invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#146;s valid and enforceable intellectual property
rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing any product candidates we may develop and our technology. However, we may not be able to obtain any required license on
commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and
commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent or other
intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing any product candidates we may develop or force us to cease some of our business operations, which could harm our business. Claims that we
have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation or other proceedings could cause us to spend substantial resources and distract our personnel from their normal
responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may challenge the validity and enforceability of our patent rights or those of our licensing partners, infringe,
misappropriate or otherwise violate our or our licensors&#146; patent and other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violation. Litigation and other proceedings in
connection with any of the foregoing claims can be unpredictable, expensive and time consuming. Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and
could distract our scientific, technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources
available for development activities or any future sales, marketing or distribution activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not have sufficient financial or other resources
to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and
more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace and could have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our
employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we
may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. Litigation may be necessary to
defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or be required to obtain licenses to such intellectual property rights, which may not be
available on commercially reasonable terms or at all. An inability to incorporate such intellectual property rights would harm our business and may prevent us from successfully commercializing any product candidates we may develop or at all. In
addition, we may lose personnel as a result of such claims and any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could
hamper or prevent our ability to commercialize any product candidates we may develop and our technology, which would have a material adverse effect on our business, results of operations, financial condition and prospects. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to our scientific and management personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain
agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have <FONT STYLE="white-space:nowrap">pre-existing</FONT> or competing obligations
to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property that we own may have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we or our licensors may in the future be
subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or licensed patent rights. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom
to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could
limit the duration of the patent protection covering our technology and any product candidates we may develop. Such challenges may also result in our inability to develop, manufacture or commercialize our technology and product candidates without
infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or licensed patent rights are threatened, it could dissuade companies from collaborating with us to license, develop or commercialize
current or future technology and product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law in the United States or worldwide could diminish the value of patents in general, thereby impairing our ability to protect any
product candidates we may develop and our technology. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of patent laws in the United States and
worldwide, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of any owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and the maintenance, enforcement or defense of any current <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents and issued patents we may own or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art,
provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a
patent at USPTO-administered post-grant proceedings, including post-grant review, <I>inter partes</I> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the
first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to
the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents and issued patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future, all of which could have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the
development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners
in certain situations. As one example, in the case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable simply because they have been isolated from surrounding
material. Moreover, in 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional
elements or steps that integrate the natural principle into the claimed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to patent-ineligible
subject matter. Accordingly, in view of the guidance memo, there can be no assurance that claims in our patent rights covering any product candidates we may develop or our technology will be held by the USPTO or equivalent foreign patent offices or
by courts in the United States or in foreign jurisdictions to cover patentable subject matter. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions
by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our
patent rights in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business
may be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop and our
technology, one or more of our U.S. patents that we license or may own in the future may be eligible for limited patent term extension under Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as
compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval, only one patent may be extended and
only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A
patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing
phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of
patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the
cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue
could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our patent and other intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent rights, trade secrets or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we or our licensors may have inventorship disputes arise
from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or technology. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our
licensors&#146; ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use intellectual property that is important to any product candidates we may develop or our technology. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed trademark applications with the USPTO for the mark &#147;Generation Bio&#148;
and the Generation Bio logo. Our current and future trademark applications in the United States and other foreign jurisdictions may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be allowed or may be subsequently opposed. Once filed and registered, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing
on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming,
particularly for a company of our size. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, third parties
may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners
of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we
may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be
ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make gene therapy products that are similar to any product candidates we may develop but
that are not covered by the intellectual property, including the claims of the patents, that we own or license currently or in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to make the
inventions covered by the issued patent or pending patent application that we own or license currently or in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing, misappropriating or otherwise violating our owned or licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our or our licensors&#146; current or future pending patent applications will not lead to
issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties might conduct research and development activities in jurisdictions where we do not have patent or
other intellectual property rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents or other intellectual property rights of others may have an adverse effect on our business; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file&nbsp;a patent for certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file&nbsp;a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility
that a competitor or other third party will discover our trade secrets or that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we
currently rely on certain third parties to manufacture all or part of our drug product and to perform quality testing, and because we collaborate with various organizations and academic institutions for the advancement of our product engine and
pipeline, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements and, if applicable,
material transfer agreements, collaborative research agreements, consulting agreements and other similar agreements with our collaborators, advisors, employees, consultants and contractors prior to beginning research or disclosing any proprietary
information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to
share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors or other third parties, are inadvertently incorporated into the technology of others or are disclosed or used in
violation of these agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade
secrets by third parties. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s or other third party&#146;s discovery of our proprietary technology and
confidential information or other unauthorized use or disclosure would impair our competitive position and may harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to regulatory approval and other legal compliance matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory requirements governing genetic medicine products, and in particular any novel gene therapy products we may develop, have changed frequently
and may continue to change in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory requirements governing gene and cell therapy products, and in particular any novel gene
therapy products we may develop, have changed frequently and may continue to change in the future. We are aware of a limited number of gene therapy products that have received marketing authorization from the FDA and EMA. Even with respect to more
established products in the gene therapy field, the regulatory landscape is still developing. For example, the FDA has established the Office of Tissues and Advanced Therapies (formerly the Office of Cellular, Tissue and Gene Therapies) within its
Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials
conducted at institutions that receive funding for recombinant DNA research from the NIH also are potentially subject to review by the Office of Biotechnology Activities&#146; Recombinant DNA Advisory Committee, or the RAC; however, the NIH
announced that the RAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The same applies in the European Union. The EMA&#146;s Committee for Advanced Therapies, or CAT, is responsible for assessing the quality, safety and efficacy
of advanced-therapy medicinal products. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the Committee for Medicinal Products for Human Use,
or CHMP, before CHMP adopts its final opinion. In the European Union, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant European Union guidelines. The EMA may issue new guidelines
concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. As a result, the procedures and standards applied to gene therapy products and cell therapy products may
be applied to any product candidates we may develop, but that remains uncertain at this point. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These regulatory review committees and advisory groups and
the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and
commercialization of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates we may develop or lead to significant post-approval limitations or restrictions. As we advance any product candidates we may develop, we will be required to consult with these
regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of these product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the
regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the FDA decides whether individual genetic medicine protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of
a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RAC has provided a favorable review or an exemption from <FONT
STYLE="white-space:nowrap">in-depth,</FONT> public review. If we were to engage an <FONT STYLE="white-space:nowrap">NIH-funded</FONT> institution to conduct a clinical trial, that institution&#146;s IBC as well as its IRB would need to review the
proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of genetic medicine products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of
any product candidates we may develop. Similarly, the EMA may issue new guidelines concerning the development and marketing authorization for genetic medicine products and require that we comply with these new guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we are initially seeking to identify and develop product candidates to treat diseases using novel technologies, there is heightened risk that the FDA, the
EMA or other regulatory authority may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. Even if the endpoints are deemed clinically meaningful, we may not achieve these endpoints to a degree of
statistical significance, particularly because many of the diseases we are targeting with our platform have small patient populations, making development of large and rigorous clinical trials more difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adverse developments in post-marketing experience or in clinical trials conducted by others of gene therapy products or cell therapy products may cause the
FDA, the EMA, and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of products utilizing <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy
technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a
product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as the product candidates we may develop can be
more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and
marketing of products utilizing <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result
in expenses, delays or other impediments to our research programs or the commercialization of resulting products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, ethical, social and legal
concerns about genetic medicine, genetic testing and genetic research could result in additional regulations or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed their
intentions to further regulate biotechnology. More restrictive regulations or claims that any product candidates we may develop are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be
established that could delay or prevent regulatory approval of any product candidates we may develop under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or
interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we advance any product candidates we may develop
through clinical development, we will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen
the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of any product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates we may develop or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to
bring a potential product to market could decrease our ability to generate sufficient product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary
preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we may develop. If we are not able to
obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we may develop, and our ability to generate revenue will be materially
impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates we may develop and the activities associated with their development and commercialization, including their
design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and
by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate we may develop will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any
product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CLROs to assist us in this process.
Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the
biologic product candidate&#146;s safety, purity and potency. Any product candidates we may develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities, or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of obtaining marketing approvals, both
in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of
the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may
cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is
insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product
candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved medicine not commercially viable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, disruptions at the FDA and other agencies may prolong the time necessary for new drugs to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop
critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. The Trump
Administration also took several executive actions that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, if we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects
for those product candidates may be harmed, and our ability to generate revenues will be materially impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic
research may adversely impact public perception of our future product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our potential therapeutic products involve introducing genetic
material into patients&#146; cells. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy and gene regulation for the prevention or treatment of human diseases. Public
attitudes may be influenced by claims that gene therapy and gene regulation are unsafe, unethical or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely
impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition
to, existing treatments with which they are already familiar and for which greater clinical data may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More restrictive government
regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. For example,
in 2003, trials using early versions of murine gamma-retroviral vectors, which integrate with, and thereby alter, the host cell&#146;s DNA, have led to several well-publicized adverse events, including reported cases of leukemia. Although our
delivery system is <FONT STYLE="white-space:nowrap">non-viral,</FONT> any product candidates we may develop may be associated with such viral delivery systems as a gene therapy platform. Adverse events in our clinical trials, even if not ultimately
attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling
requirements for those product candidates that are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene therapy and we cannot assure that it will not occur in any of our planned or future
clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic
material. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our business and operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such
jurisdictions, which, in turn, would materially impair our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market and sell any product candidates we may
develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can
involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with
obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain
approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority
outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines
in any jurisdiction, which would materially impair our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we could face heightened risks with respect to seeking
marketing approval in the United Kingdom as a result of the recent withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the
European Union, the United Kingdom withdrew from the European Union, effective December&nbsp;31, 2020. On December&nbsp;24, 2020, the United Kingdom and European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain
procedures for approval and recognition of medical products in each jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality,
safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could materially impact the
future regulatory regime that applies to products and the approval of product candidates in the United Kingdom. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from
commercializing any product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts
to seek regulatory approval in the United Kingdom and/or European Union for any product candidates, which could significantly and materially harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A Fast Track, Breakthrough Therapy or Priority Review designation by the FDA may not lead to a faster development or regulatory review or approval
process, and does not assure FDA approval of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product candidate is intended for the treatment of a serious or
life-threatening condition and the product candidate demonstrates the potential to address unmet medical need for this condition, the sponsor may apply to the FDA for fast track designation. For fast track products, sponsors may have greater
interactions with the FDA and the FDA may initiate review of sections of a fast track product&#146;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical
data submitted by the sponsor, that a fast track product may be effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, an applicant may seek designation of its product as a
breakthrough therapy, which is a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough
therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA
may designate the product candidate for priority review. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product
reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority review designation means that the goal for the FDA to review an
application is six months, rather than the standard review period of ten months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek these and other designations for our product candidates. The
FDA has broad discretion with respect to whether or not to grant these designations to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it.
Moreover, a fast track or breakthrough therapy designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. As a result, while we may
seek and receive these designations for our product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw these designations if it believes that
the designation is no longer supported by data from our clinical development program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain orphan drug exclusivity for any
product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A
similar regulatory scheme governs approval of orphan products by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such
designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable
period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the
product is sufficiently profitable so that market exclusivity is no longer justified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order for the FDA to grant orphan drug exclusivity to one of our
products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease
for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for
the same condition. In particular, the concept of what constitutes the &#147;same drug&#148; for purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA has issued recent draft guidance suggesting that it
would not consider two genetic medicine products to be different drugs solely based on minor differences in the transgenes or vectors. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same
condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that
the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2017, the Congress passed the FDARA. FDARA, among other things, codified the FDA&#146;s <FONT STYLE="white-space:nowrap">pre-existing</FONT> regulatory
interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under Omnibus
legislation signed by President Trump on December&nbsp;27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been
approved or licensed by the FDA. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to
its orphan drug regulations and policies, our business could be adversely impacted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary preclinical studies and
clinical trials, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate we may develop or the approval may be for a more narrow indication than we expect. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if any product candidates
we may develop demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA
Advisory Committee or other regulatory authority recommends <FONT STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future
legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Regulatory agencies also may approve a product candidate for fewer or more limited
indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of any
product candidates we may develop. For example, our development of any product candidates for pediatric use is an important part of our current business strategy, and if we are unable to obtain regulatory approval for the desired age ranges, our
business may suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we
may develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to
generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical
data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing
information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to
physicians and recordkeeping. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The FDA typically advises that patients treated with
genetic medicine undergo <FONT STYLE="white-space:nowrap">follow-up</FONT> observations for potential adverse events for a <FONT STYLE="white-space:nowrap">15-year</FONT> period. The holder of an approved BLA must also submit new or supplemental
applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated
uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we may develop, we, and such
collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we and such collaborators
are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#146;, ability to market any future
products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial
condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable regulatory requirements following approval of any product candidates we may develop, a
regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue a warning letter asserting that we are in violation of the law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek an injunction or impose civil or criminal penalties or monetary fines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve a pending BLA or supplements to a BLA submitted by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to allow us to enter into supply contracts, including government contracts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative
publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we may develop and generate revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidate we may develop for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may
be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the
approved indications and in accordance with the provisions of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved labeling. The FDA and other regulatory agencies impose stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use, and
if we do not market our medicines for their approved indications, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing by the FDA and other federal and state enforcement agencies, including the
Department of Justice. Violation of the Federal Food, Product, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of
violations of federal and state healthcare fraud and abuse laws and state consumer protection laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown
problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on such medicines, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a medicine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the distribution or use of a medicine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of warning or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the medicines from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of medicines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension of any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our medicines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative
publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if any product candidates we may develop receive marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation
Strategy, or REMS, to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to healthcare practitioners.
Furthermore, if we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product candidate is administered or conduct additional clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with healthcare providers, physicians and third-party payers will be subject to applicable anti-kickback, fraud and abuse, and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any product candidates that we develop
for which we obtain marketing approval. Our future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we market, sell and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment
may be made under federal and state healthcare programs such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam
actions, against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other government payers that are false or fraudulent or making a false
statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant <FONT STYLE="white-space:nowrap">per-claim</FONT> penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as further amended by the Health Information Technology for Economic and Clinical Health Act, which
imposes certain requirements, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the
rule, such as health plans, healthcare clearinghouses and healthcare providers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering
up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency requirements under the federal Physician Payment Sunshine Act, which requires
manufacturers of drugs, devices, biologics and medical supplies to report to HHS, information related to payments and other transfers of value to physicians and teaching hospitals and ownership and investment interests held by physicians and other
healthcare providers and their immediate family members and applicable group purchasing organizations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales
or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payers, including private insurers, and certain state laws that require pharmaceutical
companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to
payments to physicians and other healthcare providers or marketing expenditures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the
narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws
described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government healthcare programs, such as Medicare and
Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial
costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If
our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government
funded healthcare programs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be
not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Liabilities they incur pursuant to these laws could result in significant
costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and
commercialize our product candidates and affect the prices we, or they, may obtain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there
have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of any product candidates we may develop, restrict or regulate
post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures
that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2010, the United States Congress enacted PPACA. In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In
August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for
the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2%
per fiscal year, which went into effect in April 2013 and will remain in effect through 2029 unless additional Congressional action is taken. The CARES Act suspended the 2% Medicare sequester from May&nbsp;1, 2020 through December&nbsp;31, 2020, and
extended the sequester by one year, through 2030. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory
approval or the frequency with which any such product candidate is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since enactment of the PPACA, there have been, and continue to be,
numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Act, Congress repealed the &#147;individual mandate.&#148; The repeal of this provision, which requires most
Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December&nbsp;14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an
essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. On December&nbsp;18, 2019, the Court of Appeals for the Fifth Circuit
court affirmed the lower court&#146;s ruling that the individual mandate portion of the PPACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the
provisions of the PPACA. Thereafter, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November&nbsp;10, 2020. On February&nbsp;10, 2021, the Biden Administration withdrew the federal government&#146;s support
for overturning the PPACA. A ruling by the Court is expected sometime this year. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Trump Administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities
and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or
manufacturers of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmaceuticals or medical devices. On January&nbsp;28, 2021, however, President Biden issued a new executive rrder which directs federal agencies to reconsider rules and other policies that
limit Americans&#146; access to healthcare, and consider actions that will protect and strengthen that access. Under this order, federal agencies are directed to <FONT STYLE="white-space:nowrap">re-examine:</FONT> policies that undermine protections
for people with <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions, including complications related to <FONT STYLE="white-space:nowrap">COVID-19;</FONT> demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or
undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and under the PPACA; and policies that
reduce affordability of coverage or financial assistance, including for dependents. This executive order also directs the U.S. Department of Health and Human Services to create a special enrollment period for the Health Insurance Marketplace in
response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that these healthcare reforms, as well as other healthcare reform
measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for
any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our
products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect
on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions
and could impact the prices we obtain for our products, if and when licensed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prices of prescription pharmaceuticals have also been the
subject of considerable discussion in the United States. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to
drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for products. To those ends, President Trump issued several
executive orders intended to lower the costs of prescription drug products. Certain of these orders are reflected in recently promulgated regulations, including an interim final rule implementing President Trump&#146;s most favored nation model, but
such final rule is currently subject to a nationwide preliminary injunction. It remains to be seen whether these orders and resulting regulations will remain in force during the Biden Administration. Further, on September&nbsp;24, 2020, the Trump
Administration finalized a rulemaking allowing states or certain other <FONT STYLE="white-space:nowrap">non-federal</FONT> government entities to submit importation program proposals to the FDA for review and approval. Applicants are required to
demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers. The FDA has issued draft guidance that would allow manufacturers to import their own <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> drugs that are authorized for sale in other countries (multi-market approved products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the state
level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our
products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay
for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, similar political, economic and regulatory developments may affect our ability to
profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price
ceilings on specific products and therapies. In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with
governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the
cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly
materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities,
including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to
the risk of fraud or other misconduct by our employees, consultants and partners, and, if we commence clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the
regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States
and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other
business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause
serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant
fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laws and regulations governing any international operations we may have in the future may preclude us from developing,
manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and
maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any
foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose
securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries,
and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the
books and records provisions of the FCPA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA and other anti-corruption laws potentially applicable to our business is expensive
and difficult, particularly in countries in which corruption is a recognized problem. In addition, compliance with the FCPA and other anti-corruption laws presents particular challenges in the pharmaceutical industry, because, in many countries,
hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to
government officials and have led to FCPA enforcement actions. Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and
these laws may preclude us from developing, manufacturing or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs. For example, the provision of benefits or
advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also
governed by the national anti-bribery laws of European Union member states and the UK Bribery Act 2010. Violation of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain European Union member states
must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the
individual European Union member states. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union member states. Failure to comply with these requirements could result in
reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business
practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the
right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship
as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may
suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to
stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such
requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying
information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in
jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us,
including fines, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is
likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure,
transfer or other processing of personal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data regarding individuals in the European Union, including personal health data, is subject to the European Union General Data Protection Regulation (EU) 2016/679, or the GDPR, which took effect
across all member states of the EEA in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining
consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of
data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring
changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the
United States and, as a result, increases the scrutiny that such rules should apply to transfers of personal data from clinical trial sites located in the EEA to the United States. The GDPR also permits data protection authorities to require
destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20&nbsp;million Euros, whichever is greater, and confers a private
right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that
European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR&#146;s requirements are rigorous and time
intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in
the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to
change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement
actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that
may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission
and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or
the CCPA, which became effective on January&nbsp;1, 2020, requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, allow consumers to opt out of
certain data sharing with third parties and provide a new cause of action for data breaches. Additionally, effective starting on January&nbsp;1, 2023, the California Privacy Rights Act, or the CPRA, will significantly modify the CCPA, including by
expanding consumers&#146; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. Many other states are considering
similar legislation, and a broad range of legislative measures also have been introduced at the federal level. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are numerous U.S. federal and state
laws and regulations related to the privacy and security of personal information, including certain laws that regulate the use and disclosure of personal health information. In particular, regulations promulgated pursuant to HIPAA establish privacy
and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy
of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. These provisions may be applicable to our business in the future. Determining whether protected
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to properly protect the privacy and security of protected health information, we could be found to have violated these privacy and security
laws and/or breached certain contracts with our business partners. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement
activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either
injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement
activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that new and existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with
the evolving data protection rules may be unsuccessful. If so, this could result in government-imposed fines or penalties or orders requiring that we change our practices, which could adversely affect our business. We must devote significant
resources to understanding and complying with this changing landscape. Failure to comply with federal, state and international laws regarding privacy and security of personal information could expose us to fines and penalties under such laws. Any
such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action,
litigation and significant costs for remediation, any of which could adversely affect our business. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to
have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business, financial condition, results of
operations or prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to employee matters and managing growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as
the other principal members of our management, scientific and clinical teams. Although we have entered into employment offer letters with our executive officers, each of them may terminate their employment with us at any time. We do not maintain
&#147;key person&#148; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization
objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of
individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire,
train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success as a public company also depends on
implementing and maintaining internal controls and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a
result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in
the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs and, if any product candidate we may develop receives marketing approval, sales, marketing and distribution. To
manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The
expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a growing biotechnology company, we are actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of
diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes
in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified
personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The
physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development
and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete
effectively and commercialize our product candidates, if approved, will depend in part on our ability to effectively manage the future development and expansion of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or drugs, form strategic alliances or create joint ventures with third parties that we believe will complement or augment
our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company
culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new drugs resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We
cannot assure our stockholders that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions, include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management time and focus from operating our business to addressing acquisition integration
challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordination of research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees from the acquired company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning
resulting from the acquisition; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural challenges associated with integrating employees from the acquired company into our organization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition
may have lacked sufficiently effective controls, procedures and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liability for activities of the acquired company before the acquisition, including intellectual property
infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated write-offs or charges; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation or other claims in connection with the acquired company, including claims from terminated employees,
customers, former stockholders or other third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our failure to address these risks or other problems encountered in connection
with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that
future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal information technology systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer
security breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical
information, potentially exposing us to liability or otherwise adversely affecting our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are increasingly dependent upon information
technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information
and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, given the size and complexity of our internal information technology systems and those of our current and any
future third-party vendors, collaborators and other contractors and consultants, and the increasing amounts of confidential information that they maintain, such information technology systems are vulnerable to damage or interruption from computer
viruses, computer hackers, malicious code, employee theft or misuse, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, sophisticated nation-state and nation-state-supported actors,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign
governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and we
may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including
outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While
we seek to protect our information technology systems from system failure, accident and security breach, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our
business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and
potential notification of the breach to counterparties and data subjects could be material. In addition, our remediation efforts may not be successful. Moreover, if the information technology systems of our third-party vendors, collaborators and
other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from
occurring. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain
or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our third-party vendors&#146;, collaborators&#146; or
other contractors&#146; or consultants&#146; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability including litigation exposure, penalties and fines, we could become the subject of
regulatory action or investigation based primarily on the laws and regulations discussed above in the privacy discussion, our competitive position and reputation could be harmed and the further development and commercialization of our product
candidates could be delayed. Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation, compel us to
comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal
information, which could result in significant legal and financial exposure and reputational damages. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operations or those of the third parties upon whom we depend might be affected by the occurrence of a natural disaster, pandemic or other
catastrophic event. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend on our employees, consultants, CDMOs, CLROs, as well as regulatory agencies and other parties, for the continued
operation of our business. While we maintain disaster recovery plans, they might not adequately protect us. Despite any precautions we take for natural disasters or other catastrophic events, these events, including terrorist attack, pandemics,
hurricanes, fire, floods and ice and snowstorms, could result in significant disruptions to our research and development, preclinical studies, clinical trials, and, ultimately, commercialization of our products. Long-term disruptions in the
infrastructure caused by events, such as natural disasters, the outbreak of war, the escalation of hostilities and acts of terrorism or other &#145;&#145;acts of God,&#146;&#146; particularly involving cities in which we have offices, manufacturing
or clinical trial sites, could adversely affect our businesses. Although we carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, our coverage might not respond or be
adequate to compensate us for all losses that may occur. Any natural disaster or catastrophic event affecting us, our CDMOs, our CLROs, regulatory agencies or other parties with which we are engaged could have a significant negative impact on our
operations and financial performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to ownership of our common stock and our status as a public company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not know whether a market will continue to develop or be sustained for our common stock, and, as a result, it may be difficult for our stockholders
to sell their shares of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although our common stock is listed on the Nasdaq Global Select Market, an active trading market for our
shares may not continue to develop or be sustained. As a result, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for purchasers of our common stock.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price has been, and is likely to continue to be, volatile and could be subject to wide fluctuations in response to various factors, some
of which are beyond our control. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.
As a result of this volatility, our stockholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be able to sell their common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of or developments in preclinical studies and clinical trials of any product candidates we may develop or
those of our competitors or potential collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing of the results of our preclinical studies and clinical trials or those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our success in commercializing any product candidates we may develop, if and when approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or
proprietary rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
products, product candidates, technologies or data referencing rights, the costs of commercializing any such products and the costs of development of any such product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of common stock by us, our executive officers, directors or principal stockholders or others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry, political and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, following periods of volatility in the market price of a company&#146;s securities, securities class-action litigation has often been instituted
against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial
damages or fines, damage to our reputation or adverse changes to our business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#146;s attention and resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our
business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our
common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or
unfavorable research about our business, or provide more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the
market for our stock, which in turn could cause our stock price and trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which began in late 2019 and was
declared a global pandemic by the World Health Organization in March 2020, may affect our ability to initiate and complete preclinical studies, delay the initiation of our planned clinical trial or future clinical trials, disrupt regulatory
activities, or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, each of which could result in adverse
effects on our business, on raising capital and on our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which began in
December 2019 and was declared a global pandemic by the World Health Organization in March 2020, has caused and continues to cause many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions,
heightened border scrutiny and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have
been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future
progression of the outbreak and its effects on our business and operations continue to be uncertain. We and our CDMOs and CROs experienced a temporary reduction in the capacity to undertake research-scale production and to execute some preclinical
studies, and may face disruptions in the future that affect our ability to initiate and complete preclinical studies, and disruptions in procuring items that are essential for our research and development activities, such as raw materials used in
the manufacture of any product candidates we may develop, laboratory supplies used in our preclinical studies, or animals that are used for preclinical testing for which there are shortages because of ongoing efforts to address the outbreak. We and
our CROs and CDMOs may also face disruptions related to our future <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and clinical trials arising from delays in preclinical studies, manufacturing disruptions, and the ability to obtain
necessary IRB, IBC or other necessary site approvals, as well as other delays at clinical trial sites. The response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may redirect resources with respect to regulatory and intellectual
property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit <FONT
STYLE="white-space:nowrap">in-person</FONT> interactions. The pandemic has caused significant disruptions in the financial markets, and may continue to cause such disruptions, which may impact the volatility of our stock price and trading in our
stock. Moreover, the pandemic has significantly impacted economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the 2008
global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the 2008 global financial crisis, could result in a variety of risks to our business, including,
weakened demand for any product candidates we may develop and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption.
If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a
material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers
and other partners may not survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. Any of the foregoing could harm our business and we cannot anticipate all of the ways
in which the current economic climate and financial market conditions could adversely impact our business. Furthermore, our stock price may decline due in part to the volatility of the stock market and any general economic downturn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors and their affiliates, if they choose to act together, will continue
to have the ability to significantly influence all matters submitted to stockholders for approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2021, our executive
officers and directors and their affiliates, in the aggregate, beneficially owned shares representing approximately 26% of our common stock. As a result, if these stockholders were to choose to act together, they would be able to significantly
influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of directors and approval of any merger,
consolidation or sale of all or substantially all of our assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This concentration of ownership may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, defer or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entrench our management and board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or prevent a merger, consolidation, takeover or other business combination involving us that other
stockholders may desire. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of cash, cash equivalents and marketable securities and may not use
them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management has broad discretion in the application of cash, cash equivalents and marketable securities and could spend them
in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could cause the price of our common stock to decline
and delay the development of our product candidates. Pending their use, we may invest these funds in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole
source of gain for our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our
future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares is eligible to be sold into the market in the near future, which could cause the market price of
our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the
public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock and make it more difficult for our stockholders to sell their common stock at a time
and price that they deem appropriate. As of February&nbsp;28, 2021, we had 56,427,399 shares of common stock outstanding. In connection with our <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering, we and each our directors and
executive officers and certain of our stockholders entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. As of February&nbsp;28, 2021, 14,230,587 shares of common stock are restricted as a result of these <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements, which, subject to certain specified exceptions, will become eligible to be sold after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period on April&nbsp;7, 2021. The
representatives of the underwriters may release some or all of the shares of common stock subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time in their sole discretion and without notice, which would allow for earlier
sales of shares in the public market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain of our executive officers, directors and affiliated stockholders have entered or may enter
into Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans providing for sales of shares of our common stock from time to time. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters
established by the executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT>
plan may be amended or terminated in some circumstances. Our executive officers, directors and affiliated stockholders also may buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in
possession of material, nonpublic information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, as of February&nbsp;28, 2021, holders of an aggregate of 22,972,666 shares of our common stock had
rights, along with holders of an additional 450,076 shares of our common stock issuable upon exercise of outstanding options, subject to specified conditions, to require us to file registration statements covering their shares or to include their
shares in registration statements that we may file for ourselves or other stockholders. We have also filed a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> to register all of the shares of common stock that we were
able to issue under our equity compensation plans as of December&nbsp;31, 2020, and we intend to file a registration statement on Form&nbsp;S-8 to register the additional 2,348,500 shares of our common stock that became issuable under our equity
compensation plans on January&nbsp;1, 2021. Shares registered under these registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> can be freely sold in the public market upon issuance, subject to volume limitations applicable to
affiliates, vesting arrangements and exercise of options, and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into in connection with our <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and a &#147;smaller reporting company&#148; and the reduced disclosure requirements applicable to
emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; or EGC, as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until December&nbsp;31, 2025, although if the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeds $700.0&nbsp;million as of any June&nbsp;30 before that time or if we have annual gross revenues of $1.07&nbsp;billion or more in any fiscal year, we would cease to be an EGC as of December&nbsp;31 of the applicable year. We also would cease
to be an EGC if we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure
requirements that are applicable to other public companies that are not EGCs. These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements in this Annual Report, in addition to
any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even after we no longer qualify as an emerging growth company, we
may continue to qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements. In addition, if we are a smaller reporting company with less than $100&nbsp;million in annual revenue, we would not be required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, or Section&nbsp;404. In reliance on these exemptions, we have taken advantage of reduced reporting obligations in this Annual Report. In particular, in this Annual Report, we have provided only two years of audited
financial statements and have not included all of the executive compensation related information that would be required if we were not an EGC or a smaller reporting company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS
Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
private companies. We have elected to take advantage of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition
period or&nbsp;no longer qualify as an EGC. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred and will continue to incur increased costs as a result of operating as a newly public company, and our management has devoted and will
continue to be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company we incur,
and particularly after we are no longer an EGC or a smaller reporting company, we will further incur, significant legal, accounting and other expenses that we did not previously incur as a private company. The Sarbanes-Oxley Act of 2002, the
Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and
maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules
and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements and will make some activities
more time-consuming and costly compared to when we were a private company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict or estimate the amount of additional costs we may incur or
the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our
filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC for the year ended December&nbsp;31, 2021. However, while we remain an EGC or a smaller reporting company with less than $100&nbsp;million in annual
revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we
are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional
financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate,
validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to
conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses in our internal control over financial reporting, it
could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail
to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public
reporting, which would harm our business and the trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective internal control over financial reporting is
necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in
connection with Section&nbsp;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require
prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could
harm our business and have a negative effect on the trading price of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to disclose changes made in our internal controls and
procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an EGC under the JOBS Act or a smaller reporting company, our independent registered public
accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&nbsp;404. We could be an EGC for up to five years. An independent assessment of the effectiveness of our
internal control over financial reporting could detect problems that our management&#146;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and
require us to incur the expense of remediation, which could have a negative effect on the trading price of our stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and
procedures may not prevent or detect all errors or acts of fraud. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to certain reporting requirements of the Exchange Act. Our
disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally,
controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or
insufficient disclosures due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws or in their implementation or interpretation may
adversely affect our business and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent changes in tax law may adversely affect our business or financial condition. On
December&nbsp;22, 2017, the U.S. government enacted the Tax Act, which significantly reformed the Code. The Tax Act, among other things, contained significant changes to corporate taxation, including a reduction of the corporate tax rate from a top
marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for NOLs arising in taxable years
beginning after December&nbsp;31, 2017 to 80% of current year taxable income and elimination of NOL carrybacks for losses arising in taxable years ending after December&nbsp;31, 2017 (though any such NOLs may be carried forward indefinitely), the
imposition of a <FONT STYLE="white-space:nowrap">one-time</FONT> taxation of offshore earnings at reduced rates regardless of whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions),
the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of Congress&#146; response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Families First Coronavirus Response Act, or FFCR Act,
was enacted on March&nbsp;18, 2020, and the CARES Act was enacted on March&nbsp;27, 2020 and COVID relief provisions were included in the Consolidated Appropriations Act, 2021 or CAA, which was enacted on December&nbsp;27, 2020. All contain numerous
tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January&nbsp;1, 2021) suspends application of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">80%-of-income</FONT></FONT> limitation on the use of NOLs, which was enacted as part of the Tax Act. It also provides that NOLs arising in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any taxable year beginning after December&nbsp;31, 2017, and before January&nbsp;1, 2021 are generally eligible to be carried back up to five years. The CARES Act also temporarily (for taxable
years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30% to 50% of adjusted taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory guidance under the Tax Act, the FFCR Act, the CARES Act and the CAA is and continues to be forthcoming, and such guidance could ultimately increase
or lessen impact of these laws on our business and financial condition. Congress may enact additional legislation in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and as a result of the changes in the U.S.
presidential administration and control of the U.S. Senate, additional tax legislation may also be enacted; any such additional legislation could have an impact on our company. In addition, it is uncertain if and to what extent various states will
conform to the Tax Act, the FFCR Act, the CARES Act or the CAA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware law could make an
acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions in our restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change
in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to
pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate
or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by
our stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to
cast to amend or repeal specified provisions of our restated certificate of incorporation or amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or
combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our restated certificate of incorporation designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of
actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the
State of Delaware (or, if the Court of Chancery of the State of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of proceedings: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or
stockholders to our company or our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers
jurisdiction on the Court of Chancery of the State of Delaware; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or
amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the
Securities Act, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction. Furthermore, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum,
the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for
disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find the choice of forum provisions contained in our restated
certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition and
operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operations or those of the third parties upon whom we depend might be affected by the occurrence of a natural disaster,
pandemic or other catastrophic event. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend on our employees, consultants, CDMOs, CLROs, as well as regulatory agencies and other parties, for
the continued operation of our business. While we maintain disaster recovery plans, they might not adequately protect us. Despite any precautions we take for natural disasters or other catastrophic events, these events, including terrorist attack,
pandemics, hurricanes, fire, floods and ice and snowstorms, could result in significant disruptions to our research and development, preclinical studies, clinical trials, and, ultimately, commercialization of our products. Long-term disruptions in
the infrastructure caused by events, such as natural disasters, the outbreak of war, the escalation of hostilities and acts of terrorism or other &#145;&#145;acts of God,&#146;&#146; particularly involving cities in which we have offices,
manufacturing or clinical trial sites, could adversely affect our businesses. Although we carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, our coverage might not respond
or be adequate to compensate us for all losses that may occur. Any natural disaster or catastrophic event affecting us, our CDMOs, our CLROs, regulatory agencies or other parties with which we are engaged could have a significant negative impact on
our operations and financial performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_4"></A>ITEM&nbsp;1B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>UNRESOLVED STAFF COMMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_5"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROPERTIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our headquarters are located at 301 Binney Street, Cambridge, Massachusetts, where we occupy approximately 71,562 square feet of research and development,
laboratory and office space. This lease expires in 2029. We believe that our office and laboratory space is sufficient to meet our needs for the foreseeable future and that suitable additional space will be available as and when needed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_6"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL PROCEEDINGS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or
claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_7"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MINE SAFETY DISCLOSURES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_8"></A>PART II </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_9"></A>ITEM&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Information Regarding the Trading of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock trades under the symbol &#147;GBIO&#148; on the Nasdaq Global Select Market and has been publicly traded since June&nbsp;16, 2020. Prior to
this time, there was no public market for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2021, there were approximately 54 holders of record of shares of our common stock. This number does not include stockholders for whom
shares are held in &#147;nominee&#148; or &#147;street&#148; name. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock since our inception. We currently intend to retain all available funds and any future
earnings to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of
directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds from the Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
June&nbsp;2020, we closed our initial public offering, or IPO, of our common stock, pursuant to which we issued and sold 12,105,263 shares of our common stock, including 1,578,947 shares sold by us pursuant to the full exercise of the
underwriters&#146; option to purchase additional shares, at a price to the public of $19.00 per share for aggregate gross proceeds of $230.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;S-1&nbsp;(File&nbsp;No.&nbsp;333-238608),&nbsp;which</FONT></FONT> was declared effective by the SEC on June&nbsp;11, 2020. J.P. Morgan Securities LLC, Jefferies LLC and
Cowen and Company, LLC acted as joint book-running managers and Wedbush PacGrow acted as lead manager of our IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We received aggregate net proceeds of
approximately $210.7&nbsp;million after deducting underwriting discounts and commissions and other offering expenses payable by us. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or
officers of ours or their associates or to persons owning 10&nbsp;percent or more of our common stock or to any of our affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2020, we have used approximately $40.2&nbsp;million of net offering proceeds. There has been no material change in our planned use of the net proceeds from the offering as described in our final prospectus filed pursuant to Rule
424(b)(4) under the Securities Act with the SEC on June&nbsp;12, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Sales of Unregistered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding shares of our common stock and preferred stock issued and stock options granted by us during the year ended
December&nbsp;31, 2020 that were not registered under the Securities Act. Also included is the consideration, if any, received by us for such shares, warrants and options and information relating to the section of the Securities Act, or rule of the
SEC, under which exemption from registration was claimed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Issuances of Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;9, 2020, we issued and sold 19,936,296 shares of our Series C preferred stock to 54 investors at a price per share of $5.5914 in cash, for an
aggregate purchase price of $111.5&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing issuance of securities. The securities described in this
section (a)&nbsp;were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and, in certain cases, Regulation D thereunder, relative
to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All purchasers received written disclosures that the securities had not been registered under the Securities Act and that
any resale must be made pursuant to a registration statement or an available exemption from such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of our IPO in June 2020,
all outstanding shares of our convertible preferred stock automatically converted into 27,094,085 shares of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Stock Option Grants
and Exercises </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between January&nbsp;1, 2020 and June&nbsp;11, 2020, we granted options to our employees, advisors and consultants to purchase an
aggregate of 2,340,596 shares of common stock, with exercise prices ranging from $5.16 to $19.00 per share, pursuant to our 2017 Stock Incentive Plan. During the year ended December&nbsp;31, 2020, we issued 788,791 shares of our common stock upon
the exercise of stock options outstanding under our 2017 Stock Incentive Plan for aggregate consideration of $3.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No underwriters were
involved in the foregoing issuance of securities. The stock options and shares of common stock issued upon the exercise of the options were issued pursuant to written compensatory plans or arrangements with our employees, in reliance on the
exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(2) of the Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration
was required. All recipients either received adequate information about our company or had access, through employment and other relationships, to such information. On June&nbsp;12, 2020, we filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all of the shares of our common stock subject to outstanding options. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_10"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SELECTED FINANCIAL DATA </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company, as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2&nbsp;under</FONT> the Exchange Act, for this reporting
period and are not required to provide the information required under this item. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_11"></A>ITEM&nbsp;7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our
consolidated financial statements and related notes appearing at the end of this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our
plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this Annual Report, our actual
results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an innovative genetic medicines company
creating a new class of gene therapy utilizing our proprietary <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases. Our <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform incorporates our high-capacity DNA construct called closed-ended DNA, or ceDNA; our cell-targeted lipid nanoparticle delivery system, or ctLNP; and our established, scalable
capsid-free manufacturing process. Using our approach, we are developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of diseases. We are also
engineering our gene therapies to be redosable, which may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enable individualized patient titration to reach the desired level of therapeutic expression and to maintain efficacy throughout a patient&#146;s life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception in October 2016, we have focused substantially all of our resources on building our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene
therapy platform, establishing and protecting our intellectual property portfolio, conducting research and development activities, developing our manufacturing process, organizing and staffing our company, business planning, raising capital and
providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales. To date, we have funded our operations with proceeds from instruments convertible
into convertible preferred stock (which converted into convertible preferred stock in 2017) and the sales of convertible preferred stock (which converted into common stock in 2020) and, most recently, with proceeds from the sale of common stock in
our public offerings. In June 2020, we completed our initial public offering, or IPO, pursuant to which we issued and sold 12,105,263 shares of our common stock, including 1,578,947 shares sold by us pursuant to the full exercise of the
underwriters&#146; option to purchase additional shares. We received net proceeds of $210.7&nbsp;million, after deducting underwriting discounts and commissions and other offering expenses. In January 2021, we issued and sold 9,200,000 shares of our
common stock, including 1,200,000 shares sold by us pursuant to the full exercise of the underwriters&#146; option to purchase additional shares, in a <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering, resulting in net proceeds of
$211.3&nbsp;million after deducting underwriting discounts and commissions and other offering expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant
operating losses. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more product candidates we may develop. For the
years ended December&nbsp;31, 2020 and 2019, we reported net losses of $80.5&nbsp;million and $61.3&nbsp;million, respectively. As of December&nbsp;31, 2020, we had an accumulated deficit of $189.0&nbsp;million. We expect to continue to incur
significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our current research programs and conduct additional research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance any product candidates we identify into preclinical and clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the capabilities of our proprietary <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy
platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, expand, maintain, defend and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, regulatory and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which
we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial
quantities of any product candidates for which we may obtain regulatory approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, legal, compliance, financial and management information systems and personnel to support our
research, product development, future commercialization efforts and operations as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not generate revenue from
product sales unless and until we successfully complete clinical development and obtain regulatory approval for any product candidates we may develop. If we obtain regulatory approval for any product candidates we may develop, we expect to incur
significant expenses related to developing our commercial capability to support product sales, marketing and distribution. Further, we expect to continue to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can
generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We may be unable to raise
additional funds or enter into such other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements when needed or on terms acceptable to us, we would be required to
delay, limit, reduce or terminate our product development or future commercialization of one or more of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous
risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to
generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or
terminate our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our existing cash, cash equivalents and marketable securities, including the net proceeds from the offering we
completed in January 2021, will enable us to fund our operating expenses and capital expenditures into 2024. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong. We
could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when
needed would have a negative impact on our financial condition and our ability to pursue our business strategy. See &#147;&#151;Liquidity and capital resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, <FONT STYLE="white-space:nowrap">COVID-19</FONT> was declared a global pandemic by the World Health Organization and to date, the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. We, our contract development and manufacturing
organizations, or CDMOs, and our contract research organizations, or CROs, experienced temporary reductions in the capacity to undertake research-scale production and to execute some preclinical studies. While these operations have since normalized,
we, together with our CDMOs and CROs, are closely monitoring the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on these operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also plan to continue to closely monitor the ongoing impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our employees and our other
business operations. In an effort to provide a safe work environment for our employees, we have, among other things, limited employees in our office and lab facilities to those where <FONT STYLE="white-space:nowrap">on-site</FONT> presence is needed
for their job activities, increased the cadence of sanitization of our office and lab facilities, implemented various social distancing measures in our offices and labs including replacing all <FONT STYLE="white-space:nowrap">in-person</FONT>
meetings with virtual interactions, and are providing personal protective equipment for our employees present in our office and lab facilities. We are continuing to monitor the impact and effects of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and our response to it, and we expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and
other business partners in light of the pandemic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development
expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the
development of our programs, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel-related costs, including salaries, benefits and stock-based compensation expense, for employees engaged
in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred in connection with our research programs, including under agreements with third parties, such
as consultants and contractors and CROs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of developing and scaling our manufacturing process and manufacturing drug substance and drug product
for use in our research and preclinical studies, including under agreements with third parties, such as consultants and contractors and CDMOs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies and research materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation and amortization and other expenses, which include direct and allocated expenses for
rent and maintenance of facilities and insurance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments made under third-party licensing agreements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research
and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our external research and development expenses consist of costs that include fees and other costs paid to consultants, contractors, CDMOs and CROs in
connection with our preclinical and manufacturing activities. We do not allocate our research and development costs to specific programs because costs are deployed across multiple programs and our platform and, as such, are not separately
classified. We expect that our research and development expenses will increase substantially as we advance our programs into clinical development and expand our discovery, research and preclinical activities in the near term and in the future. At
this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any product candidates we may develop. The successful development of any of
our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of preclinical studies, including investigational new drug, or IND, -enabling studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raising additional funds necessary to complete preclinical and clinical development of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of filing and acceptance of IND applications or comparable foreign applications that allow
commencement of future clinical trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successful initiation, enrollment and completion of clinical trials, including under current good clinical
practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve positive results from our future clinical programs that support a finding of safety and
effectiveness and an acceptable risk-benefit profile in the intended patient populations of any product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of specialty raw materials for use in production of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish arrangements with third-party manufacturers for clinical supply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish new licensing or collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt and related terms of regulatory approvals from the FDA, and other applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish, obtain, maintain, enforce and defend patent, trademark, trade secret protection and
other intellectual property rights or regulatory exclusivity for any product candidates we may develop and our technology; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain a continued acceptable safety, tolerability and efficacy profile of our product
candidates following approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to any product candidates we may develop
could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidates we may develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for employees engaged in executive, legal, finance and accounting and other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, investor and public relations and accounting and audit services as well
as direct and allocated facility-related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future as we increase our
headcount to support our continued research activities and development of our programs and platform. We also anticipate that we will continue to incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs
and investor and public relations expenses associated with operating as a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest income and other income (expense), net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest
income consists of interest earned on our invested cash balances. Other income (expense) consists of miscellaneous income and expense unrelated to our core operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have not
recorded any income tax benefits for the net losses we have incurred or for the research and development tax credits earned in each year, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net
operating loss carryforwards and tax credit carryforwards will not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had federal net operating loss
carryforwards of $177.3&nbsp;million, which may be available to offset future taxable income, of which $8.2&nbsp;million of the total net operating loss carryforwards begin to expire in 2036, while the remaining $169.1&nbsp;million do not expire but
may be limited in their usage to an annual deduction equal to 80% of annual taxable income. In addition, as of December&nbsp;31, 2020, we had state net operating loss carryforwards of $174.7&nbsp;million, which may be available to offset future
taxable income and expire at various dates beginning in 2036. As of December&nbsp;31, 2020, we also had federal and state research and development tax credit carryforwards of $6.3&nbsp;million and $3.9&nbsp;million, respectively, which may be
available to reduce future tax liabilities and expire at various dates beginning in 2036 and 2032, respectively. Due to our history of cumulative net losses since inception and uncertainties surrounding our ability to generate future taxable income,
we have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2020 and 2019 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were $58.5&nbsp;million for the year ended December&nbsp;31, 2020 compared to
$50.1&nbsp;million for the year ended December&nbsp;31, 2019. The increases in personnel-related costs and stock-based compensation costs of $4.6&nbsp;million and $1.5&nbsp;million, respectively, were primarily due to increased headcount in our
research and development function. The increase in preclinical and manufacturing costs of $1.8&nbsp;million was primarily due to increased preclinical spend as we prepare to advance our two lead programs into
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. The increase in consulting and professional services of $0.4&nbsp;million was primarily due to consulting services to develop and scale our manufacturing process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $22.6&nbsp;million for the year ended December&nbsp;31, 2020, compared to
$12.2&nbsp;million for the year ended December&nbsp;31, 2019. The increases in personnel-related costs and stock-based compensation costs of $4.6&nbsp;million and $2.7&nbsp;million, respectively, were primarily a result of an increase in headcount
in our general and administrative function. Professional and consultant fees increased by $2.5&nbsp;million primarily due to professional fees relating to accounting, audit and legal services as well as costs associated with ongoing business
activities and operating as a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net for the year ended December&nbsp;31, 2020 was $0.6&nbsp;million compared to $1.0&nbsp;million for the year
ended December&nbsp;31, 2019 and consisted primarily of interest income earned on invested cash balances. The decrease in interest income from 2019 was primarily due to lower interest rates during 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we
have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we support our continued research activities and development of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs and platform. We have not yet commercialized any product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. To date,
we have funded our operations with proceeds from instruments convertible into convertible preferred stock (which converted into convertible preferred stock in 2017), the sale of convertible preferred stock and, most recently, with proceeds from the
sale of common stock in our public offerings. As of December&nbsp;31, 2020, we had cash, cash equivalents and marketable securities of $262.3&nbsp;million. In June&nbsp;2020, we completed our IPO, pursuant to which we issued and sold 12,105,263
shares of our common stock, including 1,578,947 shares sold by us pursuant to the full exercise of the underwriters&#146; option to purchase additional shares. We received net proceeds of $210.7&nbsp;million, after deducting underwriting discounts
and commissions and other expenses. In January 2021, we issued and sold 9,200,000 shares of our common stock, including 1,200,000 shares sold by us pursuant to the full exercise of the underwriters&#146; option to purchase additional shares, in a <FONT
STYLE="white-space:nowrap">follow-on</FONT> public offering, resulting in net proceeds of $211.3&nbsp;million after deducting underwriting discounts and commissions and other offering expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our
sources and uses of cash for each of the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(70,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(205,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2020, operating activities used $70.1&nbsp;million of cash, primarily resulting from our net loss of $80.5&nbsp;million
and changes in our operating assets and liabilities of $1.7&nbsp;million, both partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $12.1&nbsp;million. Net cash used by changes in our operating assets and liabilities for
the year ended December&nbsp;31, 2020 consisted primarily of a $2.8&nbsp;million increase in prepaid expenses and other current assets and a $1.1&nbsp;million decrease in deferred rent, partially offset by an increase of $2.0&nbsp;million in
accounts payable and accrued expenses and other current liabilities and a decrease of $0.4&nbsp;million in tenant receivable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2019, operating activities used $40.3&nbsp;million of cash, primarily resulting from our net loss of $61.3&nbsp;million, partially offset by net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $5.7&nbsp;million and net
cash provided by changes in our operating assets and liabilities of $15.2&nbsp;million. Net cash provided by changes in our operating assets and liabilities for the year ended December&nbsp;31, 2019 consisted primarily of a $13.0&nbsp;million
increase in deferred rent and a $3.2&nbsp;million increase in accounts payable and accrued expenses and other current liabilities, partially offset by a $1.9&nbsp;million increase in prepaid expenses and other current assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in accounts payable, accrued expenses and other current liabilities and prepaid expenses and other current assets in all periods were generally due to
growth in our business, the advancement of our research programs and the timing of vendor invoicing and payments. Changes in deferred rent were primarily related to a tenant improvement allowance from our landlord. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2020, net cash used in investing activities was $205.2&nbsp;million, due to the purchases of marketable securities and property and equipment during the period, partially offset by sales and maturities of marketable securities.
Property and equipment purchases of $5.5&nbsp;million were primarily related to leasehold improvements and lab equipment for our facility in Cambridge, Massachusetts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, net cash provided by investing activities was
$48.0&nbsp;million, due primarily to net sales and maturities of marketable securities, partially offset by the acquisition of property and equipment during the year. Property and equipment purchases during the year ended December&nbsp;31, 2019
primarily related to leasehold improvements and lab equipment for our new facility in Cambridge, Massachusetts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2020, net cash provided by financing activities was $323.1&nbsp;million, consisting primarily of proceeds from our IPO
of common stock of $213.9&nbsp;million, net of discounts and commissions, and proceeds from the sale of our Series C preferred stock of $108.9&nbsp;million, partially offset by the payment of $3.2&nbsp;million of public offering costs. We also
received proceeds of $3.6&nbsp;million from the exercise of common stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, net cash provided by
financing activities was $0.1&nbsp;million, consisting primarily of proceeds from the exercise of common stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities
and initiate clinical trials for our product candidates in development. The timing and amount of our operating expenditures will depend largely on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identification of additional research programs and product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, costs and results of preclinical and clinical development for any product candidates we may
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any product candidates we may develop for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and scope of the continued development of our <FONT STYLE="white-space:nowrap">non-viral</FONT> gene
therapy platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of satisfying any post-marketing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of product candidates we may develop for which we receive
marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting applications for patents, obtaining, maintaining,
defending and enforcing our intellectual property rights and defending against any intellectual property-related claims, including claims of infringement, misappropriation or other violation of third-party intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operational, financial and management information systems and associated personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the associated costs in connection with any acquisition of <FONT STYLE="white-space:nowrap">in-licensed</FONT>
products, intellectual property and technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our existing cash, cash equivalents and marketable securities, including the net proceeds from the offering we completed in January 2021, will
enable us to fund our operating expenses and capital expenditures into 2024. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong. We could use our available capital
resources sooner than we currently expect, in which case we would be required to obtain additional financing, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative
impact on our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial condition and our ability to pursue our business strategy. We do not have any committed external source of funds. Accordingly, we will be required to obtain further funding through
public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into
which we enter would result in fixed payment obligations and may involve agreements that include grants of security interests on our assets and restrictive covenants that limit our ability to take specific actions, such as incurring additional debt,
making capital expenditures, granting liens over our assets, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. Any debt financing or additional equity that we raise may contain terms that could
adversely affect the holdings or the rights of our common stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to raise sufficient capital as and when needed, we may be
required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate we may develop, or be unable to expand our operations or otherwise capitalize on our
business opportunities. If we raise additional funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to future revenue streams or product candidates or grant licenses on terms that may
not be favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#148; for additional risks associated with our substantial capital requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical accounting policies and significant judgments and estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation
of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our
consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere
in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued research and development expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part
of the process of preparing our consolidated financial statements, we are required to estimate certain accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for
the service when we have not yet been invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at
that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vendors in connection with discovery and preclinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CROs in connection with preclinical studies and testing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CDMOs in connection with the process development and scale up activities and the production of materials.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We base the expense recorded related to contract research and manufacturing on our estimates of the services received and efforts
expended pursuant to quotes and contracts with multiple CROs and CDMOs that conduct </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services and supply materials. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In accruing service fees,
we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual
accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary
and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. While the majority of our service
providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met; some require advance payments. There may be instances in which payments made to our
vendors will exceed the level of services provided and result in a prepayment of the expense. We record these as prepaid expenses on our consolidated balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We measure all
stock-based awards granted to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and directors based on their fair value on the date of the grant using the Black-Scholes option-pricing model for options or the difference between the
purchase price, if any, and the fair value of our common stock for restricted stock awards and units. Compensation expense for awards with service-based vesting is generally recognized over the vesting period of the award using the straight-line
method to record the expense. We use the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable.
We&nbsp;account for forfeitures of share-based awards as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model uses as inputs the fair value of our common
stock and assumptions we make for the expected volatility of our common stock, the expected term of stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options and our expected dividend
yield. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We determine the fair market value of our common stock using the closing price of our common stock as reported on the Nasdaq Global Select Market.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as
defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in
Note&nbsp;2 to our consolidated financial statements included in this Annual Report. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_12"></A>ITEM&nbsp;7A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company, as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2&nbsp;under</FONT> the Exchange Act, for this reporting
period and are not required to provide the information required under this item. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_13"></A>ITEM&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERATION BIO CO. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Index to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page(s)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_27">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_28">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_29">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_30">Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Equity (Deficit)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_31">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx108483_32">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_27"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Generation Bio Co. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Generation Bio Co. (the Company) as of December&nbsp;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#146; equity
(deficit) and cash flows for each of the two years in the period ended December&nbsp;31, 2020, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2020,
in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;18, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_28"></A>Generation Bio Co. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Equity (Deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (Series A, B and C), $0.0001 par value; no shares and 26,425,664
shares authorized at December&nbsp;31, 2020 and 2019, respectively; no shares and 26,425,664 shares issued and outstanding at December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 5,000,000 and no shares authorized at December&nbsp;31, 2020
and 2019, respectively; no shares issued or outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 150,000,000 and 46,750,000 shares authorized at December&nbsp;31,
2020 and 2019, respectively; 46,970,012 and 6,976,077 shares issued at December&nbsp;31, 2020 and 2019, respectively; 46,291,877 and 5,270,889 shares outstanding at December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">456,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(188,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated<B> </B>financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_29"></A>Generation Bio Co. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,256,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,731,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gains on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated<B> </B>financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_30"></A>Generation Bio Co. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Other</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Comprehensive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Income (Loss)</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stockholders&#146;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Equity</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Deficit)</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,425,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 115,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,054,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock for license</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,055,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrealized gains on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,425,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,270,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series C convertible preferred stock, net of issuance costs of $2,640</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,936,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of convertible preferred stock into common stock upon initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,361,960</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(224,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,094,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock upon initial public offering, net of issuance costs of $3,185</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,105,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">792,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,022,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of restricted common stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrealized gains on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,291,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">456,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(188,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated<B> </B>financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_31"></A>Generation Bio Co. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization (accretion) of premium (discount) on marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,863</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(70,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(243,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,789</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(205,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock, net of issuance costs incurred and paid in
current period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from initial public offering of common stock, net of underwriting discounts and
commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of deferred offering cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash investing and financing information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible preferred stock to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated<B> financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_32"></A>Generation Bio Co. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business and Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company was incorporated on October&nbsp;21, 2016 as Torus Therapeutics, Inc. and subsequently changed its name to Generation Bio Co. (the &#147;Company&#148;). The Company is an innovative genetic medicines company creating a new class of gene
therapy utilizing its proprietary <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases. The Company&#146;s <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy platform incorporates its high-capacity DNA construct called closed-ended DNA (&#147;ceDNA&#148;), its cell-targeted lipid nanoparticle delivery system (&#147;ctLNP&#148;) and its established,
scalable capsid-free manufacturing process. Using its approach, the Company is developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of
diseases. The Company is also engineering its gene therapies to be redosable, which may enable individualized patient titration to reach the desired therapeutic expression and to maintain efficacy throughout a patient&#146;s life. The Company is
headquartered in Cambridge, Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology
industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and
commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and
clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the
Company&#146;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
June&nbsp;2020, the Company completed its initial public offering (&#147;IPO&#148;) pursuant to which it issued and sold 12,105,263 shares of its common stock, including 1,578,947 shares pursuant to the full exercise of the underwriters&#146; option
to purchase additional shares, at a public offering price of $19.00 per share, resulting in net proceeds of $210.7&nbsp;million, after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, all of
the Company&#146;s outstanding convertible preferred stock automatically converted into shares of common stock. In January 2021, the Company issued and sold 9,200,000 shares of our common stock, including 1,200,000 shares pursuant to the full
exercise of the underwriters&#146; option to purchase additional shares, in a <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering, resulting in net proceeds of $211.3&nbsp;million after deducting underwriting discounts and commissions
and other offering expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations with proceeds from the sales of instruments convertible into convertible preferred stock (which
converted into convertible preferred stock in 2017), the sale of convertible preferred stock, and most recently, with proceeds from the sale of common stock in underwritten public offerings. The Company has incurred recurring losses, including net
losses of $80.5&nbsp;million for the year ended December&nbsp;31, 2020. As of December&nbsp;31, 2020, the Company had an accumulated deficit of $189.0&nbsp;million. The Company expects to continue to generate operating losses in the foreseeable
future. As of March&nbsp;18, 2021, the issuance date of these consolidated financial statements, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure
requirements for at least 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will need to obtain additional funding through public or private equity offerings, debt financings,
collaborations, strategic alliances and/or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing
arrangements. The terms of any financing may adversely affect the holdings or the rights of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company&#146;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to
obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management
will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements reflect the operations of the Company and the Company&#146;s wholly owned subsidiary, Generation Bio
Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles
(&#147;GAAP&#148;) in the United States of America. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Update
(&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based
compensation expense. The Company bases its estimates on historical experience, known trends and other&nbsp;market-specific&nbsp;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management
evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of credit risk and of significant suppliers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and marketable
securities. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in money market
funds that invest in U.S. treasury securities. The Company&#146;s marketable securities as of December&nbsp;31, 2020 consisted of U.S government treasury securities, commercial paper and corporate debt securities. The Company has adopted an
investment policy that limits the amounts the Company may invest in the securities of single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to significant
credit risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company
relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant
interruption in the supply process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts included in restricted
cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#146;s leased facilities. These amounts are classified as restricted cash (current and noncurrent) on the Company&#146;s consolidated
balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketable securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s marketable securities, which consisted of debt securities as of December&nbsp;31, 2020, are classified <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">as&nbsp;available-for-sale&nbsp;and</FONT></FONT> are reported at fair value. Unrealized gains and losses <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on&nbsp;available-for-sale&nbsp;debt</FONT></FONT>
securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#146; equity (deficit). Realized gains and losses and declines in value determined to be other than temporary are based on the specific
identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for
other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its
original cost, the Company&#146;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in
the value of the investment that the Company considers to be &#147;other than temporary,&#148; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were
necessary during the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an
asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair
value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and financial liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value
hierarchy, of which the first two are considered observable and the last is considered unobservable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets
for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to
determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see
Note 3). The carrying values of the Company&#146;s accounts payable and accrued expenses approximate their fair values due to the&nbsp;short-term&nbsp;nature of these liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred rent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment escalations, rent holidays
and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are
recorded as deferred rent and amortized over the respective lease terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the
straight-line method over the estimated useful life of each asset as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Estimated Useful Life</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Estimated Useful Life</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter of remaining life of lease or useful life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for capital assets not yet placed into service are capitalized as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">construction-in-progress</FONT></FONT> and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the
accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets
consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of
a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company did not record any
impairment losses on long-lived assets during the years ended December&nbsp;31, 2020 or 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classification and accretion of convertible preferred
stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred stock outstanding prior to the IPO was classified outside of stockholders&#146; equity (deficit) on
the consolidated balance sheets because the holders of such shares had redemption rights in the event of a deemed liquidation that, in certain situations, was not solely within the control of the Company and would have required the redemption of the
then-outstanding convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has determined that its chief executive officer is the chief operating decision maker (&#147;CODM&#148;). The CODM reviews financial information
presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or
components below the consolidated unit level. As such, the Company has concluded that it operates as one segment. All long-lived assets are located in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs,
laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upfront payments and milestone payments made for the licensing of technology with no alternative future use are expensed as research and development expenses
in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are
delivered or the services are performed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and manufacturing contract costs and accruals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and costs for research
and development and manufacturing activities are expensed in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred. The Company records
accruals for costs incurred but not billed. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received
and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual estimates
have not been materially different from the actual costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures stock options with service-based vesting or performance-based vesting granted to employees,
<FONT STYLE="white-space:nowrap">non-employees</FONT> and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards and units using the difference between
the purchase price per share of the award or unit, if any, and the fair value of the Company&#146;s common stock at the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation
expense for awards with service-based vesting is generally recognized over the vesting period of the award using the straight-line method to record the expense. The Company uses the graded-vesting method to record the expense of awards with both
service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&nbsp;accounts for forfeitures of share-based awards as they occur. The Company classifies stock-based
compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#146;s payroll costs are classified or in which the award recipient&#146;s service payments are classified. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes
net loss as well as other changes in stockholders&#146; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&nbsp;31, 2020 and 2019, the Company&#146;s only element of
other comprehensive loss was unrealized gains (losses) on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income
taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the
Company&#146;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the
differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to
the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying
<FONT STYLE="white-space:nowrap">a&nbsp;two-step&nbsp;process</FONT> to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination
by the taxing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorities. If the tax position is <FONT STYLE="white-space:nowrap">deemed&nbsp;more-likely-than-not&nbsp;to</FONT> be sustained, the tax position is then assessed to determine the amount of
benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes
includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&nbsp;The Company&#146;s policy is to recognize interest and/or penalties related to
income tax matters in income tax expense. The Company had accrued no amounts for interest and penalties on its consolidated balance sheets at December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net loss per share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to closing of the IPO,
the Company followed the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net income (loss) per share as the Company had issued shares that met the definition of participating securities. The
<FONT STYLE="white-space:nowrap">two-class</FONT> method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the
earnings as if all income (loss) for the period had been distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share attributable to common stockholders is computed
by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by adjusting net income
(loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net
income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the
holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss
attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if
their effect is anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per
common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted
average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per
common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reported a net loss attributable to common stockholders for each of the years ended December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently adopted accounting pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT> Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement. The new standard added, modified or removed disclosure requirements under Topic
820 for clarity and consistency. ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2019. The Company adopted ASU <FONT
STYLE="white-space:nowrap">2018-03</FONT> on January&nbsp;1, 2020 and the adoption did not have a material impact on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently issued accounting pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective
date. The Company qualifies as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#147;opt out&#148; of the extended transition related to complying with new or revised
accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or
revised standard and can do so until such time that the Company either (i)&nbsp;irrevocably elects to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualifies as an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842). The new standard requires that all lessees
recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. In July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT>
which provides entities with an additional transition method to adopt Topic 842. Under the new transition method, an entity initially applies the new lease requirements at the adoption date, not the earliest period presented, and recognizes a
cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. For public entities, the guidance was effective for annual reporting periods beginning after December&nbsp;15, 2018 and for interim periods within
those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&nbsp;15, 2019. In November 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-10,</FONT> which deferred the
effective date for nonpublic entities to annual reporting periods beginning after December&nbsp;15, 2020, and interim periods within fiscal years beginning after December&nbsp;15, 2021. In June 2020, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2020-05,</FONT> which grants a <FONT STYLE="white-space:nowrap">one-year</FONT> effective-date delay for nonpublic entities to annual reporting periods beginning after December&nbsp;15, 2021 and to interim periods within
fiscal years beginning after December&nbsp;15, 2022. Early adoption is allowed. The Company plans to adopt ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> and related amendments, on January&nbsp;1, 2021 using the modified retrospective approach
transition method as of the date of adoption. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any
expired or existing leases, or initial direct costs for any existing leases. Upon adoption of the new standard, the Company expects to recognize a lease liability and related right <FONT STYLE="white-space:nowrap">of-use</FONT> asset on the
consolidated balance sheet of approximately $49.7&nbsp;million and $33.4&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments &#150; Credit Losses (Topic 326). The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale.</FONT></FONT> The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses.
The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting
periods beginning after December&nbsp;15, 2019 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&nbsp;15, 2020. Early adoption was permitted
for all entities. In November 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-10,</FONT> which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&nbsp;15, 2022, including interim
periods within those fiscal years. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12</FONT><I>, </I>Income Taxes &#150; Simplifying the Accounting for
Income Taxes (Topic 740). The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles as well as clarifying and amending existing guidance to improve consistent application. For
public entities, the guidance is effective for annual reporting periods beginning after December&nbsp;15, 2020 and for interim periods within those fiscal years. For nonpublic entities, the guidance is effective for annual reporting periods
beginning after December&nbsp;15, 2021 and to interim periods within fiscal years beginning after December&nbsp;15, 2022. Early adoption is permitted for all entities. Depending on the amendment, adoption may be applied on the retrospective,
modified retrospective or prospective basis. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Marketable securities and fair value measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of December&nbsp;31, 2020, marketable securities by security type consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated</B><br><B>Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Totals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not have marketable securities as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present the Company&#146;s assets that are measured at fair value on a recurring basis and their level within the fair value hierarchy,
which is described further within Note&nbsp;2,<I> </I>Summary of Significant Accounting Policies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;December&nbsp;31,&nbsp;2020&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Totals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;December&nbsp;31,&nbsp;2019&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Totals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Money market funds were valued by the Company based on quoted market prices, which represent a Level&nbsp;1 measurement within
the fair value hierarchy. Marketable securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level&nbsp;2 measurement within the fair value hierarchy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&nbsp;31, 2020 and 2019 was $3.4&nbsp;million and
$1.9&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Convertible preferred stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, the Company had issued Series A convertible preferred stock (the &#147;Series A&#148;), Series B convertible preferred stock (the
&#147;Series B&#148;) and Series C convertible preferred stock (the &#147;Series C&#148;). Collectively the Series A, Series B and Series C are referred to as the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;9, 2020, the Company issued and sold 19,936,296 shares of Series C at a price of $5.5914 per share for gross proceeds of $111.5&nbsp;million.
The Company incurred issuance costs in connection with this transaction of $2.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon issuance of each class of Preferred Stock, the Company
assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed
on the issuance date of each class of Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the IPO in June 2020, the Company&#146;s Preferred Stock automatically
converted into 27,094,085 shares of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company&#146;s restated certificate of incorporation authorizes the Company to issue 150,000,000 shares of common stock, par
value $0.0001 per share, and 5,000,000&nbsp;shares of preferred stock, par value $0.0001 per share, all of which preferred stock is undesignated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the
Company&#146;s stockholders. Holders of common stock are not entitled to receive dividends, unless declared by the board of directors. <B></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.
Stock-based compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2017 Stock Incentive Plan (the &#147;2017 Plan&#148;) provided for the Company to grant incentive or
nonstatutory stock options, restricted stock, restricted stock units and other equity awards to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and directors of the Company. In January 2020, the number of shares of common stock
authorized for issuance under the 2017 Plan was increased from 8,407,405&nbsp;shares to 10,275,717&nbsp;shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020 the Company&#146;s board of
directors adopted, and in June 2020 the Company&#146;s stockholders approved, the 2020 Stock Incentive Plan (the &#147;2020 Plan&#148; and, together with the 2017 Plan the &#147;Plans&#148;), which became effective on June&nbsp;11, 2020. The 2020
Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. Upon effectiveness of the 2020 Plan, the number of shares of
common stock reserved for issuance under the 2020 Plan was the sum of (1) 2,547,698 shares; plus (2)&nbsp;the number of shares (up to a maximum of 7,173,014 shares) as was equal to the sum of (x)&nbsp;the number of shares of common stock reserved
for issuance under the 2017 Plan that remained available for grant under the 2017 Plan on June&nbsp;11, 2020 and (y)&nbsp;the number of shares of common stock subject to outstanding awards granted under the 2017 Plan that expire, terminate or are
otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3)&nbsp;an annual increase, to be added on the first day of each fiscal year, beginning with
the fiscal year ending December&nbsp;31, 2021 and continuing until, and including, the fiscal year ending December&nbsp;31, 2030, equal to the lesser of (i) 4% of the number of shares of common stock outstanding on such date, and (ii)&nbsp;an amount
determined by the board of directors. Upon the effectiveness of the 2020 Plan, the Company ceased granting additional awards under the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Plans are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions on any award under the Plans are determined at the
discretion of the board of directors, or its committee if so delegated. Stock options granted under the Plans with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options
granted is not less than the fair value of common stock as of the date of grant. Prior to the Company&#146;s IPO, fair value of common stock was determined by the board of directors. Subsequent to the IPO, fair value of common stock is based on
quoted market prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, 2,500,761 shares remained available for future issuance under the 2020 Plan. Shares subject to
outstanding awards granted under the Plans that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be available for
future awards under the 2020 Plan. The number of authorized shares reserved for issuance under the 2020 Plan was increased by 1,878,800 shares effective as of January&nbsp;1, 2021 in accordance with the provisions of the 2020 Plan described above.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee stock purchase plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020 the
Company&#146;s board of directors adopted, and in June 2020 the Company&#146;s stockholders approved, the 2020 Employee Stock Purchase Plan (the &#147;2020 ESPP&#148;), which became effective June&nbsp;11, 2020. The 2020 ESPP will be administered by
the Company&#146;s board of directors or by a committee appointed by the board of directors. The 2020 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 481,231 shares of common stock. The number
of shares of common stock reserved for issuance under the 2020 ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January&nbsp;1, 2021 and continuing for each fiscal year until, and
including the fiscal year commencing on, January&nbsp;1, 2030, in an amount equal to the lowest of (1) 1,302,157 shares of common stock, (2) 1% of the number of shares of common stock outstanding on such date, and (3)&nbsp;an amount determined by
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors. As of December&nbsp;31, 2020, no offering periods had commenced under the 2020 ESPP and 481,231 shares were available for issuance. The number of authorized shares reserved
for issuance under the 2020 ESPP was increased by 469,700 shares effective as of January&nbsp;1, 2021 in accordance with the provisions of the 2020 ESPP described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock option valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of stock
option grants is estimated using the Black-Scholes option-pricing model. The Company completed its IPO in 2020 and, accordingly, lacks company-specific historical and implied volatility information. Therefore, it estimated its expected stock
volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with
service-based vesting conditions, the expected term of the Company&#146;s stock options was determined utilizing the &#147;simplified&#148; method for awards that qualified as &#147;plain-vanilla&#148; options. The risk-free interest rate was
determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was based on the fact that the Company has never
paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents, on a weighted average basis,
the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77.30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s stock option activity since December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Contractual</B><br><B>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,373,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,090,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(792,845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(429,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,241,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,585,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,108,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options
and the fair value of the Company&#146;s common stock for those stock options that had strike prices lower than the fair value of the Company&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average grant-date fair value of awards granted during the years ended December&nbsp;31, 2020 and 2019 was $10.41 per share and $4.46 per share,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total intrinsic value of stock options exercised during the years ended December&nbsp;31, 2020 and 2019 was $20.0&nbsp;million and
$0.1&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted common stock units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2020, the Company issued 26,242 restricted stock units with a fair value of $0.5&nbsp;million. The Company did not
issue restricted stock units in the year ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted common stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s restricted common stock activity since December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant&nbsp;Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,705,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,022,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">678,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total fair value of restricted common stock vested during the years ended December&nbsp;31, 2020 and 2019 was
approximately $15.8&nbsp;million and $7.0&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records compensation cost for all share-based payment arrangements, including employee, <FONT STYLE="white-space:nowrap">non-employee</FONT> and
director stock options and restricted common stock. The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, total unrecognized compensation cost related to unvested stock-based awards was
$27.1&nbsp;million, which is expected to be recognized over a weighted average period of 3.2&nbsp;years. Additionally, as of December&nbsp;31, 2020, the Company has unrecognized compensation cost related to unvested stock-based awards with
performance-based vesting conditions for which performance has not been deemed probable of $2.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Income taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred or for the research and
development tax credits generated in each year, due to the uncertainty of realizing a benefit from those items. All of the Company&#146;s operating losses since inception have been generated in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#146;s effective income tax
rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net deferred tax assets as of December&nbsp;31, 2020 and 2019 consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had federal net operating loss carryforwards of $177.3&nbsp;million, which may be
available to offset future taxable income, of which $8.2&nbsp;million of the total net operating loss carryforwards expire at various dates beginning in 2036, while the remaining $169.1&nbsp;million do not expire but may be limited in their usage to
an annual deduction equal to 80% of annual taxable income. As of December&nbsp;31, 2020, the Company had state net operating loss carryforwards of $174.7&nbsp;million, which may be available to offset future taxable income and expire at various
dates beginning in 2036. In addition, as of December&nbsp;31, 2020, the Company also had federal and state research and development tax credit carryforwards of $6.3&nbsp;million and $3.9&nbsp;million, respectively, which may be available to reduce
future tax liabilities and expire at various dates beginning in 2036 and 2032, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilization of the U.S. federal and state net operating loss
carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&nbsp;382 and Section&nbsp;383 of the Internal Revenue Code of 1986 as amended (the &#147;Code&#148;), and
corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable
income and tax liabilities. In general, an ownership change, as defined by Section&nbsp;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year
period. The Company has not conducted a study to assess whether a change of control has occurred or whether there </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by
Section&nbsp;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation, which is determined by first multiplying the value of the
Company&#146;s stock at the time of the ownership change by the applicable <FONT STYLE="white-space:nowrap">long-term&nbsp;tax-exempt&nbsp;rate,</FONT> and then could be subject to additional adjustments. Any limitation may result in expiration of
a&nbsp;portion of the net operating loss carryforwards or research and development tax credit carryforwards before their utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as
an uncertain tax position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets,
which consist primarily of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&#146;s history of cumulative net losses incurred since inception, estimated future taxable
income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of federal and state net deferred tax assets. Accordingly, a full valuation allowance has been
established against the net deferred tax assets as of December&nbsp;31, 2020 and 2019. The Company reevaluates the positive and negative evidence at each reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in the valuation allowance for deferred tax assets during the year ended December&nbsp;31, 2020 and 2019 related primarily to the increases in net
operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance for 2020 and 2019 were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more
likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting
<FONT STYLE="white-space:nowrap">the&nbsp;more-likely-than-not&nbsp;threshold,</FONT> the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate
settlement with the relevant taxing authority. No reserve for uncertain tax positions or related interest and penalties has been recorded at December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is
subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2017 to the present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was signed into law making several changes to the Code. The
changes include, but are not limited to, increasing the limitation on the amount of deductible interest expense, allowing companies to carryback certain net operating losses, and increasing the amount of net operating loss carryforwards that
corporations can use to offset taxable income. The tax law changes in the CARES Act did not have a material impact on the Company&#146;s income tax provision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. License agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NIH </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an agreement with the U.S. Department of Health and Human Services, as represented by The National Heart, Lung, and Blood Institute, an
Institute of the National Institutes of Health (&#147;NIH&#148;), entered into in 2017, pursuant to which NIH granted the Company a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, with the right to grant sublicenses, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under certain NIH intellectual property related to the Company&#146;s ceDNA construct. In July 2019, the agreement was amended to include Association Institut de Myologie, Universite Pierre et
Marie Curie, Centre National de la Recherche Scientifique, and Inserm Transfert SA, collectively referred to as the French Institutions, as a licensor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to make future milestone payments of up to $0.4&nbsp;million per licensed product upon the achievement of specified milestones as
well as royalties on a&nbsp;licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis</FONT></FONT> of a low single&nbsp;digit percentage of annual net sales of licensed products. The Company is obligated to pay a high single-digit royalty
percentage of all sublicensing income. The royalties on net sales may be reduced by up to 25% in certain circumstances as defined in the agreement. The Company&#146;s royalty obligation expires on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">licensed&nbsp;product-by-licensed&nbsp;product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis</FONT></FONT> upon the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed intellectual property rights in such country. Additionally, the Company is required to reimburse the French Institutions for a portion of certain past
and ongoing patent related expenses related to the licensed technology. The agreement requires the Company to use reasonable commercial efforts to meet certain performance milestones and execute a commercial development plan within specified
timeframes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the agreement remains in effect until the last to expire of the licensed patent rights on a&nbsp;licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis.</FONT></FONT> NIH and the French Institutions
may terminate the agreement if the Company fails to perform its material obligations, including but not limited to its failure to meet the applicable performance milestones despite using commercially reasonable efforts, and has not remediated such
deficiency within a specified time period. NIH and the French Institutions can terminate the agreement in the event the Company becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, or determines to file a petition
in bankruptcy. In addition, NIH and the French Institutions may terminate the agreement in the event of a material breach by the Company and failure to cure such breach within a certain period of time. The Company is currently in compliance with the
terms of the agreement. The Company can voluntarily terminate the agreement with prior notice to NIH and the French Institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During each of the
years ended December&nbsp;31, 2020 and 2019, the Company recorded research and development expense of less than $0.1&nbsp;million under this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UMass </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an agreement with the
University of Massachusetts as represented by and solely on behalf of its Medical School (&#147;UMass&#148;), entered into in 2017, pursuant to which UMass granted the Company an exclusive license, with the right to grant sublicenses, under the
UMass intellectual property related to the Company&#146;s ceDNA construct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to make future milestone payments of up to
$0.8&nbsp;million per licensed product upon the achievement of specified milestones as well as royalties on a&nbsp;licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis</FONT></FONT> of a low single&nbsp;digit percentage of annual net sales of licensed products, subject to annual minimum royalties as defined in the agreement.
Additionally, the Company has agreed to pay a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digit royalty percentage of all sublicensing income, which will vary depending on when the sublicense
agreement to a third party was executed. The milestone payments are <FONT STYLE="white-space:nowrap">non-refundable</FONT> and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">non-creditable</FONT> against any other payments due to UMass under the agreement. The Company&#146;s royalty obligation expires on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">licensed&nbsp;product-by-licensed&nbsp;product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis</FONT></FONT> upon the
expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed intellectual property rights in such country. The agreement requires the Company to use diligent efforts to meet certain
performance milestones within specified timeframes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the arrangement, the Company agreed to issue 125,677 shares of its common stock to UMass.
The Company recorded $0.1&nbsp;million as research and development expense and <FONT STYLE="white-space:nowrap">additional-paid-in</FONT> capital at the time of the agreement in 2017, representing the fair value of the common stock at that time. The
shares were issued in August 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the agreement will continue until the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of the licensed patents. UMass may terminate the agreement if the Company fails to perform its material obligations, including but not limited to its failure to meet the applicable
performance milestones despite using commercially reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efforts, and has not remediated such deficiency within a specified time period or negotiated a revised performance timeline. UMass can terminate the agreement if the Company fails to make any
payments within a specified period after receiving written notice of such failure, or in the event of a material breach by the Company and failure to cure such breach within a certain period of time. The Company is currently in compliance with the
terms of the agreement. The Company can voluntarily terminate the agreement with prior notice to UMass. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During each of the years ended December&nbsp;31,
2020 and 2019, the Company recorded research and development expense of less than $0.1&nbsp;million under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other license agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has other license agreements under which it may become subject to future additional fees and milestone payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Commitments and contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases its
office and laboratory space under a noncancelable operating lease that was entered into in August 2018, as amended in July 2019, and expires in 2029. The Company has an option to extend for one additional term of five years at the greater of the
then-current base rent, or the then-current fair market value. The lease agreement includes provisions for a free-rent period and annual rent increases, which are accrued or deferred as appropriate such that rent expense for the lease is recognized
on a&nbsp;straight-line&nbsp;basis over the lease term (see Note&nbsp;2). The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The lease provides for a tenant improvement
allowance, at the cost of the lessor, not to exceed $14.7&nbsp;million. Costs incurred by the Company for tenant improvements but not yet reimbursed by the landlord are presented on the accompanying consolidated balance sheets as tenant receivable.
The Company posted a customary letter of credit in the amount of approximately $2.1&nbsp;million as a security deposit.&nbsp;The letter of credit is subject to increase if the Company were to sublease any portion of the leased premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously, the Company leased its office and laboratory space under noncancelable operating leases that expired during 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rent expense for the years ended December&nbsp;31, 2020 and 2019 was $7.5&nbsp;million and $7.9&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments as of December&nbsp;31, 2020 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has a defined-contribution plan under Section&nbsp;401(k) of the Code (the &#147;401(k) Plan&#148;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of
their annual compensation on <FONT STYLE="white-space:nowrap">a&nbsp;pre-tax&nbsp;basis.</FONT> In September 2020, the Company adopted a match program, beginning on January&nbsp;1, 2021, for employee contributions to the 401(k) Plan up to a maximum
of four percent of the employee&#146;s salary, subject to the maximums established under the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations,
business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has
entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or
service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result
of such indemnifications and is not currently aware of any indemnification claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal
proceedings during the years ended December&nbsp;31, 2020 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Net loss per share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net loss per share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has generated a net
loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. The Company excluded the following
potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,961,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">678,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,705,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,241,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,373,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,939,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,040,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Selected Quarterly Financial Data (Unaudited) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following information has been derived from unaudited consolidated financial statements that, in the opinion of management, include all recurring
adjustments necessary for a fair statement of such information: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dec. 31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sept. 30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dec. 31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sept. 30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><B>(in thousands, except per share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 24,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 20,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 17,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 15,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 14,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_14"></A>ITEM&nbsp;9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_15"></A>ITEM&nbsp;9A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONTROLS AND PROCEDURES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our
disclosure controls and procedures as of December&nbsp;31, 2020. The term &#147;disclosure controls and procedures,&#148; as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT>
under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the SEC&#146;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a
company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#146;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions
regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in
evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&nbsp;31, 2020, our President and Chief Executive Officer and our Chief Financial Officer
concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Annual
Report on Internal Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This annual report does not include a report of management&#146;s assessment regarding internal
control over financial reporting or an attestation report of the Company&#146;s independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No
change in our internal control over financial reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange Act) occurred during the three months ended
December&nbsp;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_16"></A>ITEM&nbsp;9B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_17"></A>PART III </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_18"></A>ITEM&nbsp;10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this Item&nbsp;10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual
Meeting of Stockholders and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_19"></A>ITEM&nbsp;11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXECUTIVE COMPENSATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this Item&nbsp;11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual
Meeting of Stockholders and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_20"></A>ITEM&nbsp;12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this Item&nbsp;12 will be included in our definitive proxy statement to be filed with the SEC with
respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_21"></A>ITEM&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this Item&nbsp;13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual
Meeting of Stockholders and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_22"></A>ITEM&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PRINCIPAL ACCOUNTING FEES AND SERVICES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this Item&nbsp;14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual
Meeting of Stockholders and is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_23"></A>PART IV </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_24"></A>ITEM&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXHIBITS, FINANCIAL STATEMENT SCHEDULES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1. Financial Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a list of the financial
statements included herein, see Index to the Consolidated Financial Statements on page 152 of this Annual Report, incorporated into this Item by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2. Financial Statement Schedules </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial statement
schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>3. Exhibits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits required by Item&nbsp;601 of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and Item&nbsp;15(b) of this Annual Report are listed in the Exhibit Index immediately preceding the signature page of this Annual Report.&nbsp;The exhibits listed in the Exhibit Index are
incorporated by reference herein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx108483_25"></A>ITEM&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORM <FONT STYLE="white-space:nowrap">10-K</FONT> SUMMARY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520170386/d937923dex31.htm">Restated Certificate of Incorporation of the registrant, effective as of June 16, 2020 (incorporated by reference to Exhibit 3.1 to the registrant&#146;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> File No. <FONT STYLE="white-space:nowrap">001-39319,</FONT> filed June 16, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520170386/d937923dex32.htm">Bylaws of the registrant, effective as of June 16, 2020 (incorporated by reference to Exhibit 3.2 to the registrant&#146;s Current Report on Form
 <FONT STYLE="white-space:nowrap">8-K,</FONT> File No. <FONT STYLE="white-space:nowrap">001-39319,</FONT> filed June 16, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520162714/d924849dex41.htm">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed June 8, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex42.htm">Second Amended and Restated Investors&#146; Rights Agreement dated as of January 9, 2020 by and among the registrant and the other parties thereto
 (incorporated by reference to Exhibit 4.2 to the registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d108483dex43.htm">Description of Capital Stock </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex101.htm">2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex102.htm">Form of Stock Option Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex103.htm">Form of Restricted Stock Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex104.htm">2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex105.htm">Form of Stock Option Agreement under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex106.htm">Form of Restricted Stock Agreement under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex107.htm">Form of Restricted Stock Unit Agreement under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the registrant&#146;s Registration
 Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex108.htm">2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to the registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520215659/d875797dex101.htm">Lease, dated August 2, 2018, by and between the registrant and <FONT STYLE="white-space:nowrap">BMR-Rogers</FONT> Street LLC, as amended (incorporated
 by reference to Exhibit 10.1 to the registrant&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> File No. <FONT STYLE="white-space:nowrap">001-39319,</FONT> filed August 11, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex1010.htm">Form of Indemnification Agreement between the registrant and each of its executive officers and directors (incorporated by reference to Exhibit
 10.10 to the registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex1011.htm">Exclusive License Agreement, dated June 28, 2017, by and between the registrant and the University of Massachusetts, as amended (incorporated
 by reference to Exhibit 10.11 to the registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex1012.htm">Public Health Service Patent License Agreement Nonexclusive Sublicensable, dated February 2, 2017, by and between the registrant and the U.S.
 Department of Health and Human Services, as represented by the National Heart, Lung, and Blood Institute, as amended on June 20, 2019 (incorporated by reference to Exhibit 10.12 to the registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex1013.htm">Offer letter, dated October 12, 2017, by and between the registrant and Geoff McDonough (incorporated by reference to Exhibit 10.13 to the registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex1014.htm">Offer letter, dated June 25, 2017, by and between the registrant and Douglas Kerr (incorporated by reference to Exhibit 10.14 to the registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520215659/d875797dex102.htm">Offer letter, dated June 19, 2020, by and between the registrant and Matthew Norkunas, as amended July 6, 2020 (incorporated by reference to
 Exhibit 10.2 to the registrant&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> File No. <FONT STYLE="white-space:nowrap">001-39319,</FONT> filed August 11, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312520150059/d924849dex1019.htm">Form of Severance Plan Benefit Agreement by and between the registrant and certain of its executive officers (incorporated by reference to Exhibit
 10.19 to the registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> File No. <FONT STYLE="white-space:nowrap">333-238608,</FONT> filed May 22, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733294/000119312521000941/d78071dex1020.htm">Offer letter, dated August&nbsp;
26, 2018, by and between the registrant and Tracy Zimmermann, as modified by Promotion letter, dated November&nbsp;10, 2020 (incorporated by reference to Exhibit 10.20 to the registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-251872,</FONT> filed January&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d108483dex211.htm">Subsidiaries of the registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d108483dex231.htm">Consent of Ernst&nbsp;&amp; Young LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d108483dex311.htm">Certification of Principal Executive Officer pursuant to Rule <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> of the Securities Exchange Act, as adopted pursuant to Section&nbsp;
302 of the Sarbanes-Oxley Act of 2002 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d108483dex312.htm">Certification of Principal Financial Officer pursuant to Rule <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> of the Securities Exchange Act, as adopted pursuant to Section&nbsp;
302 of the Sarbanes-Oxley Act of 2002 </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d108483dex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d108483dex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Furnished herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx108483_26"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>GENERATION BIO CO.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;18, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Matthew Norkunas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Norkunas, M.D., MBA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial
and Accounting Officer)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Geoff McDonough</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Geoff McDonough, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Norkunas</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Matthew Norkunas, M.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal&nbsp;Financial&nbsp;and&nbsp;Accounting&nbsp;Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gustav Christensen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Gustav Christensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron H.W. Cooper</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ron H.W. Cooper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey Jonas</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jeffrey Jonas, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald Nicholson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Donald Nicholson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anthony Quinn</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Anthony Quinn, M.B. Ch.B., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason Rhodes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jason Rhodes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Charles Rowland</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Charles Rowland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Catherine Stehman-Breen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Catherine Stehman-Breen, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;18, 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>d108483dex43.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF REGISTRANT&#146;S SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTERED PURSUANT TO SECTION 12 OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of the capital stock and provisions of Generation Bio Co.&#146;s (the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and/or
&#147;our&#148;) restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our restated certificate of incorporation and amended and restated bylaws, each of which is filed as an exhibit to
our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission. For additional information, please read our restated certificate of incorporation and amended and restated bylaws
and the applicable provisions of the Delaware General Corporation Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 150,000,000 shares of our common stock, par value $0.0001 per share, and 5,000,000 shares of our preferred stock, par
value $0.0001 per share, all of which preferred stock is undesignated. Our common stock is registered under Section&nbsp;12(b) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to
one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled
to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock that we may designate and
issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately all assets
available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or
conversion rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. Our common stock is listed on the Nasdaq Global Select
Market under the symbol &#147;GBIO.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of our restated certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more series
without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation
preferences, of each series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and
preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could
have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. There are no shares of preferred stock currently outstanding, and we
have no present plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware anti-takeover law and certain charter and bylaw provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of
the Delaware General Corporation Law. Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for three years
following the date that the person became an interested stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved by our board of directors and stockholders in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it
became an interested stockholder. A &#147;business combination&#148; includes, among other things, a merger or consolidation involving us and the &#147;interested stockholder&#148; and the sale of more than 10% of our assets. In general, an
&#147;interested stockholder&#148; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered board; removal of directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
restated certificate of incorporation and our amended and restated bylaws divide our board of directors into three classes with staggered three-year terms. In addition, our restated certificate of incorporation and our amended and restated bylaws
provide that directors may be removed only for cause and only by the affirmative vote of the holders of at least 75% of our shares of capital stock present in person or by proxy and entitled to vote. Under our restated certificate of incorporation
and our amended and restated bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our restated certificate of incorporation provides that the authorized number of directors may be changed only by the resolution of our board of
directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to
acquire, or discourage a third party from seeking to acquire, control of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Super-majority voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to
amend a corporation&#146;s certificate of incorporation or bylaws, unless a corporation&#146;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our amended and restated bylaws may be amended or repealed by a
majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of
at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our restated certificate of incorporation
described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder action; special meeting of stockholders; advance notice requirements for stockholder proposals and director
nominations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our amended and restated bylaws provide that any action required or permitted to be
taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our restated certificate of incorporation
and our amended and restated bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called by our board of directors. In addition, our amended and restated bylaws establish an advance notice
procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual meeting may only consider proposals or
nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has
delivered timely written notice in proper form to our secretary of the stockholder&#146;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions
that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our common stock because even if the third party acquired a majority of our
outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive forum provision </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated
certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings: (1)&nbsp;any derivative action or
proceeding brought on behalf of our company, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3)&nbsp;any action asserting a
claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware, or
(4)&nbsp;any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or our amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs
doctrine. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction. Furthermore, our
restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and
exclusive forum for the resolution of any claims arising under the Securities Act. Although our restated certificate of incorporation contains the choice of forum provisions described above, it is possible that a court could rule that such
provisions are inapplicable for a particular claim or action or that such provisions are unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d108483dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Subsidiaries of the Registrant </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Entity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Jurisdiction of Incorporation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generation Bio Securities Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Massachusetts</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d108483dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent&nbsp;of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We&nbsp;consent&nbsp;to the incorporation by reference in the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8</FONT> <FONT
STYLE="white-space:nowrap">No.&nbsp;333-239116)</FONT> pertaining to the 2017 Stock Incentive Plan, 2020 Stock Incentive Plan and 2020 Employee Stock Purchase Plan of Generation Bio Co. of our report dated March&nbsp;18, 2021, with respect to the
consolidated financial statements of Generation Bio Co. included in this Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;18, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d108483dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Geoff McDonough, hereby certify that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;of</FONT> Generation Bio Co.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)&nbsp;and&nbsp;15d-15(e))&nbsp;for</FONT></FONT> the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during
the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;18, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Geoff McDonough</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Geoff McDonough, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d108483dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Matthew Norkunas, hereby certify that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;of</FONT> Generation Bio Co.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)&nbsp;and&nbsp;15d-15(e))&nbsp;for</FONT></FONT> the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during
the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;18, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Norkunas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew Norkunas, M.D., M.B.A.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d108483dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Geoff McDonough, certify pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of
2002, that, to my knowledge, the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;of</FONT> Generation Bio Co. for the fiscal year ended December&nbsp;31, 2020 fully complies with the requirements of Section&nbsp;13(a) or 15(d)
of the Securities Exchange Act of 1934 and the information contained in such <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;fairly</FONT> presents, in all material respects, the financial condition and results of operations of Generation Bio
Co. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Geoff McDonough</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Geoff McDonough, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">March&nbsp;18, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>d108483dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Matthew Norkunas, certify pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of
2002, that, to my knowledge, the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;of</FONT> Generation Bio Co. for the fiscal year ended December&nbsp;31, 2020 fully complies with the requirements of Section&nbsp;13(a) or 15(d)
of the Securities Exchange Act of 1934 and the information contained in such <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;fairly</FONT> presents, in all material respects, the financial condition and results of operations of Generation Bio
Co. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Norkunas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew Norkunas, M.D., M.B.A.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Financial and Accounting Officer)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">March&nbsp;18, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>gbio-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 17-March-2021 [09:33:23] {AM}-->
<xbrli:xbrl xmlns:gbio="http://gbio.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31">
<link:schemaRef xlink:type="simple" xlink:href="gbio-20201231.xsd" />
<xbrli:context id="P01_01_2020To12_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P12_31_2019To12_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-12-31</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_30_2019To09_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-09-30</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_30_2019To06_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-06-30</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_31_2019To03_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-03-31</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P12_31_2020To12_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-12-31</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_30_2020To09_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-09-30</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_30_2020To06_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-06-30</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_31_2020To03_31_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-03-31</xbrli:startDate>
<xbrli:endDate>2020-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn02_28_2021">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-02-28</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndTwentyStockIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_UnvestedStockAwardsForWhichPerformanceIsNotProbableMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gbio:UnvestedStockAwardsForWhichPerformanceIsNotProbableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gbio:LaboratoryEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gbio:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FederalIncomeTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">gbio:FederalIncomeTaxAuthorityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMemberusgaapIncomeTaxAuthorityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">gbio:FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_NihMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gbio:NihMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gbio:UmassMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandAndSeventeenStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gbio:LaboratoryEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gbio:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gbio:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gbio:SeriesABAndCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndTwentyStockIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_ServiceBasedOptionsMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gbio:ServiceBasedOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_NihMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gbio:NihMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gbio:UmassMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_NihMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gbio:NihMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gbio:LaboratoryEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gbio:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2020To12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_ServiceBasedOptionsMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gbio:ServiceBasedOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_NihMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gbio:NihMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gbio:UmassMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_09_2020To01_09_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gbio:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-09</xbrli:startDate>
<xbrli:endDate>2020-01-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn01_09_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gbio:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-01-09</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-16</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-16</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn01_31_2020_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandAndSeventeenStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-01-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_11_2020To06_11_2020_AnnualIncrease2021To2030MemberGBIODateAxis_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="gbio:DateAxis">gbio:AnnualIncrease2021To2030Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-06-11</xbrli:startDate>
<xbrli:endDate>2020-06-11</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_11_2020To06_11_2020_AnnualIncrease2021To2030MemberGBIODateAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="gbio:DateAxis">gbio:AnnualIncrease2021To2030Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndTwentyStockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-06-11</xbrli:startDate>
<xbrli:endDate>2020-06-11</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_11_2020_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-11</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_11_2020_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndTwentyStockIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-11</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_11_2020_AdditionalFrom2017PlanMemberGBIODateAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndTwentyStockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="gbio:DateAxis">gbio:AdditionalFrom2017PlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-11</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_16_2020To06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-06-16</xbrli:startDate>
<xbrli:endDate>2020-06-16</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_16_2020To06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-06-16</xbrli:startDate>
<xbrli:endDate>2020-06-16</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_31_2021To01_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-31</xbrli:startDate>
<xbrli:endDate>2021-01-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_31_2021To01_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-31</xbrli:startDate>
<xbrli:endDate>2021-01-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn01_01_2021_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:TwoThousandAndTwentyStockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-01-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn01_01_2021_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gbio:EmployeeStockPurchasePlanTwoThousandAndTwentyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-01-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gbio:SeriesABAndCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gbio:SeriesABAndCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001733294</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_19138391" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">62889000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_19138392" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">15076000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:MarketableSecuritiesCurrent id="Factid_19138393" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">199438000</us-gaap:MarketableSecuritiesCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_19138395" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">5408000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_19138396" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">2577000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:RestrictedCashCurrent id="Factid_19138397" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">55000</us-gaap:RestrictedCashCurrent>
<us-gaap:AssetsCurrent id="Factid_19138398" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">267735000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_19138399" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">18156000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_19138400" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">23781000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_19138401" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">21845000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:RestrictedCashNoncurrent id="Factid_19138402" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">2051000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:RestrictedCashNoncurrent id="Factid_19138403" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">2052000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:DeferredCosts id="Factid_19138404" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">87000</us-gaap:DeferredCosts>
<us-gaap:OtherAssetsNoncurrent id="Factid_19138405" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">252000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets id="Factid_19138406" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">294155000</us-gaap:Assets>
<us-gaap:Assets id="Factid_19138407" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">42140000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent id="Factid_19138408" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">267000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent id="Factid_19138409" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">2251000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesAndOtherLiabilities id="Factid_19138410" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">10953000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
<us-gaap:AccruedLiabilitiesAndOtherLiabilities id="Factid_19138411" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">6907000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
<us-gaap:LiabilitiesCurrent id="Factid_19138412" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">11220000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_19138413" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">9158000</us-gaap:LiabilitiesCurrent>
<us-gaap:DeferredRentCreditNoncurrent id="Factid_19138414" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">14922000</us-gaap:DeferredRentCreditNoncurrent>
<us-gaap:DeferredRentCreditNoncurrent id="Factid_19138415" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">15981000</us-gaap:DeferredRentCreditNoncurrent>
<us-gaap:Liabilities id="Factid_19138416" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">26142000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_19138417" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">25139000</us-gaap:Liabilities>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Factid_19138418" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">115593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:CommonStockValue id="Factid_19138421" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">5000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue id="Factid_19138422" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">1000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital id="Factid_19138423" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">456974000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital id="Factid_19138424" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">9859000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Factid_19138425" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">9000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_19138426" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">-188975000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_19138427" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">-108452000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity id="Factid_19138428" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">268013000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138429" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">-98592000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_19138430" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">294155000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_19138431" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">42140000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_19138432" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">58532000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_19138433" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">50134000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_19138434" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">22582000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_19138435" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">12168000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses id="Factid_19138436" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">81114000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_19138437" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">62302000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss id="Factid_19138438" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-81114000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_19138439" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-62302000</us-gaap:OperatingIncomeLoss>
<us-gaap:NonoperatingIncomeExpense id="Factid_19138440" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">591000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_19138441" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">985000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_19138442" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-80523000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Factid_19138443" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-61317000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19138444" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">-2.95</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19138445" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2">-12.96</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_19138446" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0">27256494</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_19138447" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0">4731519</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:NetIncomeLoss id="Factid_19138448" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-80523000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19138449" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-61317000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="Factid_19138450" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="Factid_19138451" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_19138452" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-80514000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_19138453" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-61308000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:SharesOutstanding id="Factid_19138454" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">4054475</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_19138455" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138456" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">5552000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138457" contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-9000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138458" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-47135000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138459" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">-41591000</us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="Factid_19138460" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">125677</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Factid_19138461" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">34740</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_19138462" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_19138463" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures id="Factid_19138464" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">1055997</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_19138465" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">4207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_19138466" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">4207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="Factid_19138467" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="Factid_19138468" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:ProfitLoss id="Factid_19138469" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-61317000</us-gaap:ProfitLoss>
<us-gaap:SharesOutstanding id="Factid_19138471" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">5270889</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_19138472" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138473" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">9859000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138475" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-108452000</us-gaap:StockholdersEquity>
<us-gaap:TemporaryEquitySharesOutstanding id="Factid_19138477" contextRef="PAsOn12_31_2018_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">26425664</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Factid_19138478" contextRef="PAsOn12_31_2018_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">115593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:TemporaryEquitySharesOutstanding id="Factid_19138479" contextRef="PAsOn12_31_2019_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">26425664</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Factid_19138480" contextRef="PAsOn12_31_2019_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">115593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<gbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="Factid_19138481" contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF">19936296</gbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="Factid_19138482" contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3">108832000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
<us-gaap:ConversionOfStockSharesConverted1 id="Factid_19138483" contextRef="P01_01_2020To12_31_2020_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">46361960</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockAmountConverted1 id="Factid_19138484" contextRef="P01_01_2020To12_31_2020_SeriesABAndCPreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">224425000</us-gaap:ConversionOfStockAmountConverted1>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Factid_19138485" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">27094085</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_19138486" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_19138487" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">224422000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_19138488" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">224425000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_19138489" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">12105263</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_19138490" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_19138491" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">210714000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_19138492" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">210715000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Factid_19138493" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">792845</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_19138494" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">3567000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_19138495" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">3567000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures id="Factid_19138496" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">1022234</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<gbio:VestingOfRestrictedCommonStockUnits id="Factid_19138497" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">6561</gbio:VestingOfRestrictedCommonStockUnits>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_19138498" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">8412000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_19138499" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">8412000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="Factid_19138500" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="Factid_19138501" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:ProfitLoss id="Factid_19138502" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-80523000</us-gaap:ProfitLoss>
<us-gaap:SharesOutstanding id="Factid_19138504" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">46291877</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_19138505" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">5000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138506" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">456974000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138507" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">9000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_19138508" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-188975000</us-gaap:StockholdersEquity>
<us-gaap:ProfitLoss id="Factid_19138510" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-80523000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss id="Factid_19138511" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-61317000</us-gaap:ProfitLoss>
<us-gaap:ShareBasedCompensation id="Factid_19138512" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">8412000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_19138513" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">4207000</us-gaap:ShareBasedCompensation>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_19138514" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">3432000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_19138515" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">1864000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium id="Factid_19138516" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-249000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
<us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium id="Factid_19138517" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">317000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
<gbio:IncreaseDecreaseInTenantImprovementsAllowanceReceivable id="Factid_19138518" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-448000</gbio:IncreaseDecreaseInTenantImprovementsAllowanceReceivable>
<gbio:IncreaseDecreaseInTenantImprovementsAllowanceReceivable id="Factid_19138519" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-840000</gbio:IncreaseDecreaseInTenantImprovementsAllowanceReceivable>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_19138520" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">2831000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_19138521" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">1863000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="Factid_19138522" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">252000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable id="Factid_19138523" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-1444000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable id="Factid_19138524" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">761000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="Factid_19138525" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">3426000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="Factid_19138526" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">2470000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInDeferredCharges id="Factid_19138527" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">1059000</us-gaap:IncreaseDecreaseInDeferredCharges>
<us-gaap:IncreaseDecreaseInDeferredCharges id="Factid_19138528" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-13019000</us-gaap:IncreaseDecreaseInDeferredCharges>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_19138529" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-70142000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_19138530" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-40346000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_19138531" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">5518000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_19138532" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">19986000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquireMarketableSecurities id="Factid_19138533" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">243178000</us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:PaymentsToAcquireMarketableSecurities id="Factid_19138534" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">20789000</us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="Factid_19138535" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">88680000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_19138536" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-205196000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_19138537" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">47985000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="Factid_19138538" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">108854000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Factid_19138539" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">213900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromStockOptionsExercised id="Factid_19138540" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">3567000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised id="Factid_19138541" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">100000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:PaymentsOfStockIssuanceCosts id="Factid_19138542" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">3185000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_19138543" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">323095000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_19138544" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">78000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_19138545" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">47757000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_19138546" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">7717000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Factid_19138547" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">17183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Factid_19138548" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">9466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="Factid_19138549" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">64940000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:StockIssued1 id="Factid_19138551" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">224425000</us-gaap:StockIssued1>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid id="Factid_19138552" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">494000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid id="Factid_19138553" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">644000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_19138554" contextRef="P06_16_2020To06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">12105263</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_19138555" contextRef="P06_16_2020To06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">1578947</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharesIssuedPricePerShare id="Factid_19138556" contextRef="PAsOn06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF">19.00</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="Factid_19138557" contextRef="P06_16_2020To06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5">210700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="Factid_19138560" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">129446000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="Factid_19138561" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="Factid_19138562" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities id="Factid_19138563" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">129451000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="Factid_19138564" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">52441000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities id="Factid_19138566" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">52441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="Factid_19138567" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">17542000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="Factid_19138568" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities id="Factid_19138570" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">17546000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="Factid_19138571" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">199429000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="Factid_19138572" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="Factid_19138573" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities id="Factid_19138574" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">199438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:EmployeeRelatedLiabilitiesCurrent id="Factid_19138590" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">6150000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent id="Factid_19138591" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">3255000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<gbio:AccruedExternalResearchAndDevelopmentExpensesCurrent id="Factid_19138592" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">1772000</gbio:AccruedExternalResearchAndDevelopmentExpensesCurrent>
<gbio:AccruedExternalResearchAndDevelopmentExpensesCurrent id="Factid_19138593" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">1344000</gbio:AccruedExternalResearchAndDevelopmentExpensesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_19138594" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">940000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_19138595" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">619000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:DeferredRentCreditCurrent id="Factid_19138596" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">1389000</us-gaap:DeferredRentCreditCurrent>
<us-gaap:DeferredRentCreditCurrent id="Factid_19138597" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">1370000</us-gaap:DeferredRentCreditCurrent>
<us-gaap:OtherLiabilitiesCurrent id="Factid_19138598" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">702000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent id="Factid_19138599" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">319000</us-gaap:OtherLiabilitiesCurrent>
<gbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="Factid_19138602" contextRef="P01_09_2020To01_09_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF">19936296</gbio:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharesIssuedPricePerShare id="Factid_19138603" contextRef="PAsOn01_09_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF">5.5914</us-gaap:SharesIssuedPricePerShare>
<gbio:GrossProceedsFromIssuanceOfConvertiblePreferredStock id="Factid_19138604" contextRef="P01_09_2020To01_09_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5">111500000</gbio:GrossProceedsFromIssuanceOfConvertiblePreferredStock>
<gbio:StockIssuanceCosts id="Factid_19138605" contextRef="P01_09_2020To01_09_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5">2600000</gbio:StockIssuanceCosts>
<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="Factid_19138606" contextRef="PAsOn06_16_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">27094085</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:CommonStockSharesAuthorized id="Factid_19138607" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_19138608" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_19138611" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandAndSeventeenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">8407405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_19138612" contextRef="PAsOn01_31_2020_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandAndSeventeenStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">10275717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Factid_19138613" contextRef="PAsOn06_11_2020_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">2547698</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Factid_19138614" contextRef="PAsOn06_11_2020_AdditionalFrom2017PlanMemberGBIODateAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">7173014</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<gbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage id="Factid_19138615" contextRef="P06_11_2020To06_11_2020_AnnualIncrease2021To2030MemberGBIODateAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF">0.04</gbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Factid_19138616" contextRef="PAsOn12_31_2020_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0">2500761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_19138617" contextRef="PAsOn06_11_2020_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0">481231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="Factid_19138618" contextRef="P06_11_2020To06_11_2020_AnnualIncrease2021To2030MemberGBIODateAxis_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="0">1302157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
<gbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage id="Factid_19138619" contextRef="P06_11_2020To06_11_2020_AnnualIncrease2021To2030MemberGBIODateAxis_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.01</gbio:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Factid_19138620" contextRef="PAsOn12_31_2020_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0">481231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_19138621" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">4301000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_19138622" contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">2753000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_19138623" contextRef="P01_01_2020To12_31_2020_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">4111000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_19138624" contextRef="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">1454000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_19138625" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">8412000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_19138626" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">4207000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Factid_19138627" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5">27100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Factid_19138628" contextRef="P01_01_2020To12_31_2020">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Factid_19138629" contextRef="PAsOn12_31_2020_UnvestedStockAwardsForWhichPerformanceIsNotProbableMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5">2200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19138630" contextRef="P01_01_2019To12_31_2019_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">14961027</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19138631" contextRef="P01_01_2020To12_31_2020_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">678135</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19138632" contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">1705188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19138633" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">5241770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19138634" contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">3373884</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19138635" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0">5939586</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19138636" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0">20040099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<gbio:LesseeOperatingLeaseYearOfExpiry id="Factid_19138637" contextRef="P01_01_2020To12_31_2020">2029</gbio:LesseeOperatingLeaseYearOfExpiry>
<gbio:TenantImprovementAllowanceMaximum id="Factid_19138638" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5">14700000</gbio:TenantImprovementAllowanceMaximum>
<gbio:LetterOfCreditForSecurityDeposit id="Factid_19138639" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5">2100000</gbio:LetterOfCreditForSecurityDeposit>
<us-gaap:LeaseAndRentalExpense id="Factid_19138640" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5">7500000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense id="Factid_19138641" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5">7900000</us-gaap:LeaseAndRentalExpense>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Factid_19138642" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">7053000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Factid_19138643" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">7251000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Factid_19138644" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">7441000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="Factid_19138645" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">7679000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="Factid_19138646" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">7881000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="Factid_19138647" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">27570000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="Factid_19138648" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">64875000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<dei:AmendmentFlag id="Factid_19139088" contextRef="P01_01_2020To12_31_2020">false</dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus id="Factid_19139089" contextRef="P01_01_2020To12_31_2020">2020</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_19139097" contextRef="P01_01_2020To12_31_2020">FY</dei:DocumentFiscalPeriodFocus>
<dei:EntityInteractiveDataCurrent id="Factid_19139119" contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityInteractiveDataCurrent>
<dei:EntityCentralIndexKey id="Factid_19139120" contextRef="P01_01_2020To12_31_2020">0001733294</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate id="Factid_19139135" contextRef="P01_01_2020To12_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentAnnualReport id="Factid_19139136" contextRef="P01_01_2020To12_31_2020">true</dei:DocumentAnnualReport>
<dei:DocumentTransitionReport id="Factid_19139145" contextRef="P01_01_2020To12_31_2020">false</dei:DocumentTransitionReport>
<dei:DocumentType id="Factid_19139160" contextRef="P01_01_2020To12_31_2020">10-K</dei:DocumentType>
<dei:DocumentPeriodEndDate id="Factid_19139161" contextRef="P01_01_2020To12_31_2020">2020-12-31</dei:DocumentPeriodEndDate>
<dei:EntityRegistrantName id="Factid_19139236" contextRef="P01_01_2020To12_31_2020">GENERATION BIO CO.</dei:EntityRegistrantName>
<dei:TradingSymbol id="Factid_19139244" contextRef="P01_01_2020To12_31_2020">GBIO</dei:TradingSymbol>
<dei:EntityFileNumber id="Factid_19139246" contextRef="P01_01_2020To12_31_2020">001-39319</dei:EntityFileNumber>
<dei:EntityIncorporationStateCountryCode id="Factid_19139258" contextRef="P01_01_2020To12_31_2020">DE</dei:EntityIncorporationStateCountryCode>
<dei:EntityCurrentReportingStatus id="Factid_19139259" contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityShellCompany id="Factid_19139262" contextRef="P01_01_2020To12_31_2020">false</dei:EntityShellCompany>
<dei:EntitySmallBusiness id="Factid_19139335" contextRef="P01_01_2020To12_31_2020">true</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany id="Factid_19139336" contextRef="P01_01_2020To12_31_2020">true</dei:EntityEmergingGrowthCompany>
<dei:EntityAddressStateOrProvince id="Factid_19139343" contextRef="P01_01_2020To12_31_2020">MA</dei:EntityAddressStateOrProvince>
<dei:SecurityExchangeName id="Factid_19139360" contextRef="P01_01_2020To12_31_2020">NASDAQ</dei:SecurityExchangeName>
<dei:EntityExTransitionPeriod id="Factid_19139380" contextRef="P01_01_2020To12_31_2020">false</dei:EntityExTransitionPeriod>
<dei:IcfrAuditorAttestationFlag id="Factid_19139474" contextRef="P01_01_2020To12_31_2020">false</dei:IcfrAuditorAttestationFlag>
<us-gaap:DeferredCosts id="Factid_19139561" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">336000</us-gaap:DeferredCosts>
<us-gaap:CommitmentsAndContingencies id="Factid_19140005" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_19140006" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:TemporaryEquityParOrStatedValuePerShare id="Factid_19142470" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare id="Factid_19142471" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquitySharesAuthorized id="Factid_19142479" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">0</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized id="Factid_19142481" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">26425664</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesIssued id="Factid_19142483" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesOutstanding id="Factid_19142509" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesIssued id="Factid_19142510" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">26425664</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesOutstanding id="Factid_19142519" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">26425664</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_19142520" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_19142521" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized id="Factid_19142522" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized id="Factid_19142523" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">0</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued id="Factid_19143619" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding id="Factid_19143620" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued id="Factid_19143622" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding id="Factid_19143627" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_19143632" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_19143635" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">46750000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Factid_19143641" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">46970012</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Factid_19143643" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">46291877</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding id="Factid_19143644" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">5270889</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued id="Factid_19143645" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">6976077</us-gaap:CommonStockSharesIssued>
<gbio:StockIssuanceCosts id="Factid_19143709" contextRef="P01_01_2020To12_31_2020_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3">2640000</gbio:StockIssuanceCosts>
<gbio:StockIssuanceCosts id="Factid_19143720" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3">3185000</gbio:StockIssuanceCosts>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Factid_19143738" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">10000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Factid_19143740" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">80000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="Factid_19143741" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">43500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
<us-gaap:PaymentsOfFinancingCosts id="Factid_19143750" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">41000</us-gaap:PaymentsOfFinancingCosts>
<us-gaap:PaymentsOfFinancingCosts id="Factid_19143751" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">22000</us-gaap:PaymentsOfFinancingCosts>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="Factid_19143777" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Nature of the Business and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company was incorporated on October&amp;#160;21, 2016 as Torus Therapeutics, Inc. and subsequently changed its name to Generation Bio Co. (the &amp;#8220;Company&amp;#8221;). The Company is an innovative genetic medicines company creating a new class of gene therapy utilizing its proprietary &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-viral&lt;/div&gt; gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases. The Company&amp;#8217;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-viral&lt;/div&gt; gene therapy platform incorporates its high-capacity DNA construct called closed-ended DNA (&amp;#8220;ceDNA&amp;#8221;), its cell-targeted lipid nanoparticle delivery system (&amp;#8220;ctLNP&amp;#8221;) and its established, scalable capsid-free manufacturing process. Using its approach, the Company is developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of diseases. The Company is also engineering its gene therapies to be redosable, which may enable individualized patient titration to reach the desired therapeutic expression and to maintain efficacy throughout a patient&amp;#8217;s life. The Company is headquartered in Cambridge, Massachusetts. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&amp;#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;In June 2020, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) pursuant to which it issued and sold&lt;/div&gt;&amp;#160;12,105,263&lt;div style="display:inline;"&gt;&amp;#160;shares of its common stock, including&amp;#160;&lt;/div&gt; 1,578,947&lt;div style="display:inline;"&gt;&amp;#160;shares&amp;#160;&lt;/div&gt; pursuant to the full exercise of the underwriters&amp;#8217; option to purchase additional shares, at a public offering price of $19.00&lt;div style="display:inline;"&gt;&amp;#160;per share, resulting&amp;#160;&lt;/div&gt;in net proceeds of $210.7&amp;#160;million, after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, all of the Company&amp;#8217;s outstanding convertible preferred stock automatically converted into shares of common stock. In January 2021, the Company issued and sold 9,200,000 shares of our common stock, including 1,200,000 shares pursuant to the full exercise of the underwriters&amp;#8217; option to purchase additional shares, in a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;follow-on&lt;/div&gt; public offering, resulting in net proceeds of $211.3&amp;#160;million after deducting underwriting discounts and commissions and other offering expenses. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations with proceeds from the sales of instruments convertible into convertible preferred stock (which converted into convertible preferred stock in 2017), the sale of convertible preferred stock, and most recently, with proceeds from the sale of common stock in underwritten public offerings. The Company has incurred recurring losses, including net losses of $80.5&amp;#160;million for the year ended December&amp;#160;31, 2020. As of December&amp;#160;31, 2020, the Company had an accumulated deficit of $189.0&amp;#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&amp;#160;18, 2021, the issuance date of these consolidated financial statements, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&amp;#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements reflect the operations of the Company and the Company&amp;#8217;s wholly owned subsidiary, Generation Bio Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) in the United States of America. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;). &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_19143862" contextRef="P01_31_2021To01_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_19143863" contextRef="P01_31_2021To01_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0">1200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="Factid_19143872" contextRef="P01_31_2021To01_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5">211300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<dei:EntityIncorporationDateOfIncorporation id="Factid_19143874" contextRef="P01_01_2020To12_31_2020">2016-10-21</dei:EntityIncorporationDateOfIncorporation>
<us-gaap:SignificantAccountingPoliciesTextBlock id="Factid_19143885" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other&amp;#160;market-specific&amp;#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentrations of credit risk and of significant suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&amp;#8217;s marketable securities as of December&amp;#160;31, 2020 consisted of U.S government treasury securities, commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to significant credit risk. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Restricted cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&amp;#8217;s leased facilities. These amounts are classified as restricted cash (current and noncurrent) on the Company&amp;#8217;s consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Marketable securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s marketable securities, which consisted of debt securities as of December&amp;#160;31, 2020, are classified &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as&amp;#160;available-for-sale&amp;#160;and&lt;/div&gt;&lt;/div&gt; are reported at fair value. Unrealized gains and losses &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on&amp;#160;available-for-sale&amp;#160;debt&lt;/div&gt;&lt;/div&gt; securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&amp;#8217; equity (deficit). Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&amp;#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &amp;#8220;other than temporary,&amp;#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and financial liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2&amp;#8212;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 0px; margin-bottom: 0px;"&gt;&amp;#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company&amp;#8217;s accounts payable and accrued expenses approximate their fair values due to the&amp;#160;short-term&amp;#160;nature of these liabilities. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Deferred rent &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:51%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:47%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid rgb(0, 0, 0); line-height: 10pt; font-size: 10pt;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: 10pt;;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;5 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Computer equipment and software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;5 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;Shorter of remaining life of lease or useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;construction-in-progress&lt;/div&gt;&lt;/div&gt; and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. &lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Impairment of long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company did not record any impairment losses on long-lived assets during the years ended December&amp;#160;31, 2020 or 2019. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Classification and accretion of convertible preferred stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s convertible preferred stock outstanding prior to the IPO was classified outside of stockholders&amp;#8217; equity (deficit) on the consolidated balance sheets because the holders of such shares had redemption rights in the event of a deemed liquidation that, in certain situations, was not solely within the control of the Company and would have required the redemption of the then-outstanding convertible preferred stock. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Segment information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has determined that its chief executive officer is the chief operating decision maker (&amp;#8220;CODM&amp;#8221;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Company has concluded that it operates as one segment. All long-lived assets are located in the United States. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and development costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upfront payments and milestone payments made for the licensing of technology with no alternative future use are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. &lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and manufacturing contract costs and accruals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and costs for research and development and manufacturing activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred. The Company records accruals for costs incurred but not billed. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical accrual estimates have not been materially different from the actual costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Patent costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. &lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company measures stock options with service-based vesting or performance-based vesting granted to employees, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards and units using the difference between the purchase price per share of the award or unit, if any, and the fair value of the Company&amp;#8217;s common stock at the date of grant. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation expense for awards with service-based vesting is generally recognized over the vesting period of the award using the straight-line method to record the expense. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&amp;#160;accounts for forfeitures of share-based awards as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&amp;#8217;s payroll costs are classified or in which the award recipient&amp;#8217;s service payments are classified. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Comprehensive loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&amp;#160;31, 2020 and 2019, the Company&amp;#8217;s only element of other comprehensive loss was unrealized gains (losses) on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities. &lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&amp;#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&amp;#160;two-step&amp;#160;process&lt;/div&gt; to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;deemed&amp;#160;more-likely-than-not&amp;#160;to&lt;/div&gt; be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&amp;#160;The Company&amp;#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had accrued no amounts for interest and penalties on its consolidated balance sheets at December&amp;#160;31, 2020 and 2019. &lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Net loss per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Prior to closing of the IPO, the Company followed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method when computing net income (loss) per share as the Company had issued shares that met the definition of participating securities. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reported a net loss attributable to common stockholders for each of the years ended December&amp;#160;31, 2020 and 2019. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13,&lt;/div&gt; Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement. The new standard added, modified or removed disclosure requirements under Topic 820 for clarity and consistency. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2019. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-03&lt;/div&gt; on January&amp;#160;1, 2020 and the adoption did not have a material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recently issued accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &amp;#8220;opt out&amp;#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&amp;#160;irrevocably elects to &amp;#8220;opt out&amp;#8221; of such extended transition period or (ii)&amp;#160;no longer qualifies as an emerging growth company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. In July 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11,&lt;/div&gt; which provides entities with an additional transition method to adopt Topic 842. Under the new transition method, an entity initially applies the new lease requirements at the adoption date, not the earliest period presented, and recognizes a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. For public entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2018 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2019. In November 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10,&lt;/div&gt; which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&amp;#160;15, 2020, and interim periods within fiscal years beginning after December&amp;#160;15, 2021. In June 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-05,&lt;/div&gt; which grants a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; effective-date delay for nonpublic entities to annual reporting periods beginning after December&amp;#160;15, 2021 and to interim periods within fiscal years beginning after December&amp;#160;15, 2022. Early adoption is allowed. The Company plans to adopt ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; and related amendments, on January&amp;#160;1, 2021 using the modified retrospective approach transition method as of the date of adoption. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. Upon adoption of the new standard, the Company expects to recognize a lease liability and related right &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of-use&lt;/div&gt; asset on the consolidated balance sheet of approximately $49.7&amp;#160;million and $33.4&amp;#160;million, respectively. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; Financial Instruments &amp;#8211; Credit Losses (Topic 326). The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale.&lt;/div&gt;&lt;/div&gt; The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2020. Early adoption was permitted for all entities. In November 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10,&lt;/div&gt; which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&amp;#160;15, 2022, including interim periods within those fiscal years. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2019-12&lt;/div&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;, &lt;/div&gt;Income Taxes &amp;#8211; Simplifying the Accounting for Income Taxes (Topic 740). The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles as well as clarifying and amending existing guidance to improve consistent application. For public entities, the guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2020 and for interim periods within those fiscal years. For nonpublic entities, the guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2021 and to interim periods within fiscal years beginning after December&amp;#160;15, 2022. Early adoption is permitted for all entities. Depending on the amendment, adoption may be applied on the retrospective, modified retrospective or prospective basis. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:UseOfEstimates id="Factid_19143886" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other&amp;#160;market-specific&amp;#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>
<us-gaap:FairValueDisclosuresTextBlock id="Factid_19143942" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Marketable securities and fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&amp;#160;31, 2020, marketable securities by security type consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:56%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gains&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;129,446&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;129,451&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,542&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,546&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Totals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;199,429&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;13&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(4&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;199,438&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company did not have marketable securities as of December&amp;#160;31, 2019. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present the Company&amp;#8217;s assets that are measured at fair value on a recurring basis and their level within the fair value hierarchy, which is described further within Note&amp;#160;2,&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt; &lt;/div&gt;Summary of Significant Accounting Policies: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:59%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&amp;#160;December&amp;#160;31,&amp;#160;2020&amp;#160;Using:&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;63,827&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;63,827&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;129,451&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;129,451&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;17,546&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;17,546&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Totals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;63,827&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;199,438&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;263,265&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:16;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16" style="font-family: &amp;quot;times new roman&amp;quot;;;height:16;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&amp;#160;December&amp;#160;31,&amp;#160;2019&amp;#160;Using:&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Totals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds were valued by the Company based on quoted market prices, which represent a Level&amp;#160;1 measurement within the fair value hierarchy. Marketable securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level&amp;#160;2 measurement within the fair value hierarchy. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:MarketableSecuritiesTextBlock id="Factid_19144854" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&amp;#160;31, 2020, marketable securities by security type consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:56%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gains&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;129,446&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;129,451&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,542&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,546&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Totals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;199,429&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;13&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(4&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;199,438&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="Factid_19144856" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present the Company&amp;#8217;s assets that are measured at fair value on a recurring basis and their level within the fair value hierarchy, which is described further within Note&amp;#160;2,&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt; &lt;/div&gt;Summary of Significant Accounting Policies: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:59%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&amp;#160;December&amp;#160;31,&amp;#160;2020&amp;#160;Using:&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;63,827&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;63,827&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;129,451&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;129,451&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;52,441&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;17,546&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;17,546&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Totals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;63,827&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;199,438&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;263,265&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:16;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16" style="font-family: &amp;quot;times new roman&amp;quot;;;height:16;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&amp;#160;December&amp;#160;31,&amp;#160;2019&amp;#160;Using:&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Totals&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,076&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Factid_19144924" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">63827000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Factid_19144927" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">63827000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities id="Factid_19144929" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">129451000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities id="Factid_19144933" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">52441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities id="Factid_19144937" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">17546000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AssetsFairValueDisclosure id="Factid_19144940" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">63827000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure id="Factid_19144941" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">199438000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure id="Factid_19144943" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">263265000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Factid_19144947" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">15076000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Factid_19144948" contextRef="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3">15076000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure id="Factid_19144949" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">15076000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure id="Factid_19144950" contextRef="PAsOn12_31_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">15076000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Factid_19144960" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:74%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,313&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,029&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;848&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;740&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;826&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;826&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;17,374&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;12,993&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,082&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,487&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;29,443&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;24,075&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(5,662&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,230&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;23,781&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;21,845&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization expense for the years ended December&amp;#160;31, 2020 and 2019 was $3.4&amp;#160;million and $1.9&amp;#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock id="Factid_19144972" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:74%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,313&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,029&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;848&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;740&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;826&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;826&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;17,374&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;12,993&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,082&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,487&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;29,443&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;24,075&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(5,662&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,230&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;23,781&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;21,845&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145004" contextRef="PAsOn12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">9313000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145005" contextRef="PAsOn12_31_2019_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">5029000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145006" contextRef="PAsOn12_31_2020_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">848000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145007" contextRef="PAsOn12_31_2019_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">740000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145008" contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">826000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145009" contextRef="PAsOn12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">826000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145010" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">17374000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145011" contextRef="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">12993000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145012" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">1082000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145013" contextRef="PAsOn12_31_2019_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">4487000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145014" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">29443000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_19145015" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">24075000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_19145016" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">5662000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_19145017" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">2230000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PreferredStockTextBlock id="Factid_19145471" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Convertible preferred stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the IPO, the Company had issued Series A convertible preferred stock (the &amp;#8220;Series A&amp;#8221;), Series B convertible preferred stock (the &amp;#8220;Series B&amp;#8221;) and Series C convertible preferred stock (the &amp;#8220;Series C&amp;#8221;). Collectively the Series A, Series B and Series C are referred to as the Preferred Stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&amp;#160;9, 2020, the Company issued and sold 19,936,296 shares of Series C at a price of $5.5914 per share for gross proceeds of $111.5&amp;#160;million. The Company incurred issuance costs in connection with this transaction of $2.6&amp;#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon issuance of each class of Preferred Stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of Preferred Stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the closing of the IPO in June 2020, the Company&amp;#8217;s Preferred Stock automatically converted into 27,094,085 shares of common stock. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PreferredStockTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Factid_19145474" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&amp;#160;31, 2020, the Company&amp;#8217;s restated certificate of incorporation authorizes the Company to issue 150,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000&amp;#160;shares of preferred stock, par value $0.0001 per share, all of which preferred stock is undesignated. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&amp;#8217;s stockholders. Holders of common stock are not entitled to receive dividends, unless declared by the board of directors. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Factid_19145517" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s 2017 Stock Incentive Plan (the &amp;#8220;2017 Plan&amp;#8221;) provided for the Company to grant incentive or nonstatutory stock options, restricted stock, restricted stock units and other equity awards to employees, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; and directors of the Company. In January 2020, the number of shares of common stock authorized for issuance under the 2017 Plan was increased from 8,407,405&amp;#160;shares to 10,275,717&amp;#160;shares. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020 the Company&amp;#8217;s board of directors adopted, and in June 2020 the Company&amp;#8217;s stockholders approved, the 2020 Stock Incentive Plan (the &amp;#8220;2020 Plan&amp;#8221; and, together with the 2017 Plan the &amp;#8220;Plans&amp;#8221;), which became effective on June&amp;#160;11, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. Upon effectiveness of the 2020 Plan, the number of shares of common stock reserved for issuance under the 2020 Plan was the sum of (1) 2,547,698 shares; plus (2)&amp;#160;the number of shares (up to a maximum of 7,173,014 shares) as was equal to the sum of (x)&amp;#160;the number of shares of common stock reserved for issuance under the 2017 Plan that remained available for grant under the 2017 Plan on June&amp;#160;11, 2020 and (y)&amp;#160;the number of shares of common stock subject to outstanding awards granted under the 2017 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3)&amp;#160;an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December&amp;#160;31, 2021 and continuing until, and including, the fiscal year ending December&amp;#160;31, 2030, equal to the lesser of (i) 4% of the number of shares of common stock outstanding on such date, and (ii)&amp;#160;an amount determined by the board of directors. Upon the effectiveness of the 2020 Plan, the Company ceased granting additional awards under the 2017 Plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Plans are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions on any award under the Plans are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted under the Plans with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock as of the date of grant. Prior to the Company&amp;#8217;s IPO, fair value of common stock was determined by the board of directors. Subsequent to the IPO, fair value of common stock is based on quoted market prices. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&amp;#160;31, 2020, 2,500,761 shares remained available for future issuance under the 2020 Plan. Shares subject to outstanding awards granted under the Plans that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be available for future awards under the 2020 Plan. The number of authorized shares reserved for issuance under the 2020 Plan was increased by 1,878,800 shares effective as of January&amp;#160;1, 2021 in accordance with the provisions of the 2020 Plan described above. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Employee stock purchase plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020 the Company&amp;#8217;s board of directors adopted, and in June 2020 the Company&amp;#8217;s stockholders approved, the 2020 Employee Stock Purchase Plan (the &amp;#8220;2020 ESPP&amp;#8221;), which became effective June&amp;#160;11, 2020. The 2020 ESPP will be administered by the Company&amp;#8217;s board of directors or by a committee appointed by the board of directors. The 2020 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 481,231 shares of common stock. The number of shares of common stock reserved for issuance under the 2020 ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January&amp;#160;1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January&amp;#160;1, 2030, in an amount equal to the lowest of (1) 1,302,157 shares of common stock, (2) 1% of the number of shares of common stock outstanding on such date, and (3)&amp;#160;an amount determined by the board of directors. As of December&amp;#160;31, 2020, no offering periods had commenced under the 2020 ESPP and 481,231 shares were available for issuance. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 469,700 shares effective as of January&amp;#160;1, 2021 in accordance with the provisions of the 2020 ESPP described above. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock option valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company completed its IPO in 2020 and, accordingly, lacks company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&amp;#8217;s stock options was determined utilizing the &amp;#8220;simplified&amp;#8221; method for awards that qualified as &amp;#8220;plain-vanilla&amp;#8221; options. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:80%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.60&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;77.30&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;75.7&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s stock option activity since December&amp;#160;31, 2019: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of Shares&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding as of December&amp;#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,373,884&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4.76&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8.79&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,492&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,090,315&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;13.40&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(792,845&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4.49&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(429,584&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4.73&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,241,770&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9.89&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8.69&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;99,467&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested and expected to vest as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,585,120&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;10.57&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;8.63&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;84,238&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Options exercisable as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,108,099&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4.54&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.68&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;26,388&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&amp;#8217;s common stock for those stock options that had strike prices lower than the fair value of the Company&amp;#8217;s common stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average grant-date fair value of awards granted during the years ended December&amp;#160;31, 2020 and 2019 was $10.41 per share and $4.46 per share, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total intrinsic value of stock options exercised during the years ended December&amp;#160;31, 2020 and 2019 was $20.0&amp;#160;million and $0.1&amp;#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Restricted common stock units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&amp;#160;31, 2020, the Company issued 26,242 restricted stock units with a fair value of $0.5&amp;#160;million. The Company did not issue restricted stock units in the year ended December&amp;#160;31, 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Restricted common stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s restricted common stock activity since December&amp;#160;31, 2019: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:66%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&amp;#160;Average&lt;br/&gt; Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Unvested restricted common stock as of December&amp;#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,705,188&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.22&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(1,022,234&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.17&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(4,819&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1.95&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Unvested restricted common stock as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;678,135&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.28&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total fair value of restricted common stock vested during the years ended December&amp;#160;31, 2020 and 2019 was approximately $15.8&amp;#160;million and $7.0&amp;#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company records compensation cost for all share-based payment arrangements, including employee, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; and director stock options and restricted common stock. The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:82%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,301&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,753&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,111&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,454&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,412&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,207&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&amp;#160;31, 2020, total unrecognized compensation cost related to unvested stock-based awards was $27.1&amp;#160;million, which is expected to be recognized over a weighted average period of 3.2&amp;#160;years. Additionally, as of December&amp;#160;31, 2020, the Company has unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable of $2.2&amp;#160;million. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 id="Factid_19145550" contextRef="P01_01_2020To12_31_2020_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Factid_19145553" contextRef="P01_01_2020To12_31_2020_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock id="Factid_19145622" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:80%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.60&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;77.30&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;75.7&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Factid_19145624" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s stock option activity since December&amp;#160;31, 2019: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of Shares&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding as of December&amp;#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,373,884&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4.76&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8.79&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,492&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,090,315&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;13.40&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(792,845&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4.49&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(429,584&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4.73&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,241,770&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9.89&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8.69&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;99,467&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested and expected to vest as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,585,120&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;10.57&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;8.63&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;84,238&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Options exercisable as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,108,099&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4.54&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.68&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;26,388&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock id="Factid_19145626" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s restricted common stock activity since December&amp;#160;31, 2019: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:66%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&amp;#160;Average&lt;br/&gt; Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Unvested restricted common stock as of December&amp;#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,705,188&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.22&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(1,022,234&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.17&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(4,819&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1.95&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Unvested restricted common stock as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;678,135&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.28&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Factid_19145627" contextRef="P01_01_2020To12_31_2020">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:82%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,301&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,753&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,111&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,454&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,412&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,207&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_19145988" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_19145989" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4">0.0200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_19145990" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4">0.7730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_19145991" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">0.757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_19145992" contextRef="P01_01_2020To12_31_2020">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_19145993" contextRef="P01_01_2019To12_31_2019">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_19146287" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">3373884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_19146288" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF">3090315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Factid_19146289" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF">792845</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Factid_19146290" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF">429584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_19146291" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">5241770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="Factid_19146292" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">4585120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="Factid_19146293" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF">1108099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_19146294" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_19146295" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">13.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Factid_19146296" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">4.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Factid_19146297" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">4.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_19146298" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">9.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="Factid_19146299" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">10.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="Factid_19146300" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">4.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="Factid_19146303" contextRef="P01_01_2020To12_31_2020">P8Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="Factid_19146304" contextRef="P01_01_2020To12_31_2020">P7Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_19146306" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">8492000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_19146307" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">99467000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="Factid_19146308" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">84238000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="Factid_19146309" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">26388000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="Factid_19146349" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF">1705188</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue id="Factid_19146350" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2">1.22</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="Factid_19146351" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF">1022234</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="Factid_19146352" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">1.17</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares id="Factid_19146353" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF">4819</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue id="Factid_19146354" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">1.95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="Factid_19146355" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0">678135</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue id="Factid_19146356" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">1.28</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="Factid_19146380" contextRef="P01_01_2020To12_31_2020_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD_per_Share" decimals="2">10.41</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="Factid_19146381" contextRef="P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD_per_Share" decimals="2">4.46</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Factid_19146387" contextRef="PAsOn12_31_2020_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5">20000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Factid_19146388" contextRef="PAsOn12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_19146406" contextRef="P01_01_2020To12_31_2020_ServiceBasedOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">26242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_19146464" contextRef="P01_01_2019To12_31_2019_ServiceBasedOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:EarningsPerShareTextBlock id="Factid_19146552" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Net loss per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Net loss per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:69%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Convertible preferred stock (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,961,027&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested restricted common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;678,135&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,705,188&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Unvested restricted common stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;19,681&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5,241,770&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,373,884&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,939,586&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;20,040,099&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Factid_19146587" contextRef="P01_01_2020To12_31_2020">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated:&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:69%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Convertible preferred stock (as converted to common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,961,027&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested restricted common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;678,135&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,705,188&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Unvested restricted common stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;19,681&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5,241,770&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,373,884&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,939,586&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;20,040,099&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:CommonStockValueOutstanding id="Factid_19146592" contextRef="PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5">15800000</us-gaap:CommonStockValueOutstanding>
<us-gaap:CommonStockValueOutstanding id="Factid_19146596" contextRef="PAsOn12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5">7000000</us-gaap:CommonStockValueOutstanding>
<us-gaap:IncomeTaxDisclosureTextBlock id="Factid_19147155" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended December&amp;#160;31, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to the uncertainty of realizing a benefit from those items. All of the Company&amp;#8217;s operating losses since inception have been generated in the United States. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:75%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Federal statutory income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(21.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)%&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(21.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(7.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(5.9&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Federal and state research and development tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4.2&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(5.1&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(2.6&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.2&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in deferred tax asset valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;34.8&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;30.8&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets as of December&amp;#160;31, 2020 and 2019 consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:72%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;48,280&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;25,023&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,385&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,998&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,456&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,740&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,747&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,469&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;64,868&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;37,230&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3,900&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(4,117&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(3,900&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4,117&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(60,968&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(33,113&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&amp;#160;31, 2020, the Company had federal net operating loss carryforwards of $177.3&amp;#160;million, which may be available to offset future taxable income, of which $8.2&amp;#160;million of the total net operating loss carryforwards expire at various dates beginning in 2036, while the remaining $169.1&amp;#160;million do not expire but may be limited in their usage to an annual deduction equal to 80% of annual taxable income. As of December&amp;#160;31, 2020, the Company had state net operating loss carryforwards of $174.7&amp;#160;million, which may be available to offset future taxable income and expire at various dates beginning in 2036. In addition, as of December&amp;#160;31, 2020, the Company also had federal and state research and development tax credit carryforwards of $6.3&amp;#160;million and $3.9&amp;#160;million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2036 and 2032, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&amp;#160;382 and Section&amp;#160;383 of the Internal Revenue Code of 1986 as amended (the &amp;#8220;Code&amp;#8221;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section&amp;#160;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&amp;#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation, which is determined by first multiplying the value of the Company&amp;#8217;s stock at the time of the ownership change by the applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term&amp;#160;tax-exempt&amp;#160;rate,&lt;/div&gt; and then could be subject to additional adjustments. Any limitation may result in expiration of a&amp;#160;portion of the net operating loss carryforwards or research and development tax credit carryforwards before their utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets, which consist primarily of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&amp;#8217;s history of cumulative net losses incurred since inception, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of federal and state net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&amp;#160;31, 2020 and 2019. The Company reevaluates the positive and negative evidence at each reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in the valuation allowance for deferred tax assets during the year ended December&amp;#160;31, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance for 2020 and 2019 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:74%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Valuation allowance as of beginning of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;33,113&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,246&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increases recorded to income tax provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;27,855&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;18,867&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Valuation allowance as of end of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;60,968&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;33,113&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&amp;#160;more-likely-than-not&amp;#160;threshold,&lt;/div&gt; the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. No reserve for uncertain tax positions or related interest and penalties has been recorded at December&amp;#160;31, 2020 and 2019. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2017 to the present. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#8220;CARES Act&amp;#8221;) was signed into law making several changes to the Code. The changes include, but are not limited to, increasing the limitation on the amount of deductible interest expense, allowing companies to carryback certain net operating losses, and increasing the amount of net operating loss carryforwards that corporations can use to offset taxable income. The tax law changes in the CARES Act did not have a material impact on the Company&amp;#8217;s income tax provision. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Factid_19147334" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases its office and laboratory space under a noncancelable operating lease that was entered into in August 2018, as amended in July 2019, and expires in 2029. The Company has an option to extend for one additional term of five years at the greater of the then-current base rent, or the then-current fair market value. The lease agreement includes provisions for a free-rent period and annual rent increases, which are accrued or deferred as appropriate such that rent expense for the lease is recognized on a&amp;#160;straight-line&amp;#160;basis over the lease term (see Note&amp;#160;2). The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The lease provides for a tenant improvement allowance, at the cost of the lessor, not to exceed $14.7&amp;#160;million. Costs incurred by the Company for tenant improvements but not yet reimbursed by the landlord are presented on the accompanying consolidated balance sheets as tenant receivable. The Company posted a customary letter of credit in the amount of approximately $2.1&amp;#160;million as a security deposit.&amp;#160;The letter of credit is subject to increase if the Company were to sublease any portion of the leased premises. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Previously, the Company leased its office and laboratory space under noncancelable operating leases that expired during 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rent expense for the years ended December&amp;#160;31, 2020 and 2019 was $7.5&amp;#160;million and $7.9&amp;#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum lease payments as of December&amp;#160;31, 2020 are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 88%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 3%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,053&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,251&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,441&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,679&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,881&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;"&gt;27,570&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 88%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.5%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 8%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;64,875&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 88%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.5%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 8%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;401(k) Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has a defined-contribution plan under Section&amp;#160;401(k) of the Code (the &amp;#8220;401(k) Plan&amp;#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&amp;#160;pre-tax&amp;#160;basis.&lt;/div&gt; In September 2020, the Company adopted a match program&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;beginning on January 1, 2021,&lt;/div&gt; for employee contributions to the 401(k) Plan up to a maximum of four percent of the employee&amp;#8217;s salary, subject to the maximums established under the Code. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Indemnification agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Legal proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December&amp;#160;31, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="Factid_19147346" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:75%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Federal statutory income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(21.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)%&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(21.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(7.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(5.9&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Federal and state research and development tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4.2&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(5.1&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(2.6&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1.0&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.2&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in deferred tax asset valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;34.8&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;30.8&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="Factid_19147347" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum lease payments as of December&amp;#160;31, 2020 are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 88%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 3%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 0.5%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&amp;#160;thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,053&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,251&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,441&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,679&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;7,881&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 88%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;"&gt;27,570&lt;/td&gt;&lt;td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 88%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.5%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 8%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;"&gt;64,875&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 88%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 0.5%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 8%;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 0.5%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="Factid_19147370" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets as of December&amp;#160;31, 2020 and 2019 consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:72%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;48,280&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;25,023&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,385&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,998&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,456&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;4,740&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,747&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,469&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;64,868&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;37,230&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3,900&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(4,117&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(3,900&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(4,117&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(60,968&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(33,113&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:SummaryOfValuationAllowanceTextBlock id="Factid_19147372" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in the valuation allowance for deferred tax assets during the year ended December&amp;#160;31, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance for 2020 and 2019 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:74%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Valuation allowance as of beginning of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;33,113&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,246&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increases recorded to income tax provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;27,855&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;18,867&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Valuation allowance as of end of year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;60,968&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;33,113&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Factid_19147889" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Factid_19147890" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="Factid_19147891" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3">-0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="Factid_19147892" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">-0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="Factid_19147893" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="Factid_19147894" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">-0.051</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="Factid_19147895" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="Factid_19147896" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="Factid_19147898" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Factid_19147899" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3">0.348</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Factid_19147900" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">0.308</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations id="Factid_19147901" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations id="Factid_19147902" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Factid_19149064" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">48280000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Factid_19149065" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">25023000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Factid_19149066" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">9385000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Factid_19149067" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">5998000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsDeferredIncome id="Factid_19149068" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">4456000</us-gaap:DeferredTaxAssetsDeferredIncome>
<us-gaap:DeferredTaxAssetsDeferredIncome id="Factid_19149069" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">4740000</us-gaap:DeferredTaxAssetsDeferredIncome>
<us-gaap:DeferredTaxAssetsOther id="Factid_19149070" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">2747000</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsOther id="Factid_19149071" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">1469000</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsLiabilitiesNet id="Factid_19149072" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">64868000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:DeferredTaxAssetsLiabilitiesNet id="Factid_19149073" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">37230000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="Factid_19149074" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">3900000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="Factid_19149075" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">4117000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
<us-gaap:DeferredIncomeTaxLiabilities id="Factid_19149076" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">3900000</us-gaap:DeferredIncomeTaxLiabilities>
<us-gaap:DeferredIncomeTaxLiabilities id="Factid_19149077" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">4117000</us-gaap:DeferredIncomeTaxLiabilities>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Factid_19149078" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">60968000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Factid_19149079" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">33113000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Factid_19149242" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">33113000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Factid_19149243" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">14246000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions id="Factid_19149244" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">27855000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
<us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions id="Factid_19149245" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">18867000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Factid_19149246" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3">60968000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:OperatingLossCarryforwards id="Factid_19149800" contextRef="PAsOn12_31_2020_FederalIncomeTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5">177300000</us-gaap:OperatingLossCarryforwards>
<gbio:TaxCreditCarryforwardExpirationYear id="Factid_19149846" contextRef="P01_01_2020To12_31_2020">2036</gbio:TaxCreditCarryforwardExpirationYear>
<us-gaap:OperatingLossCarryforwards id="Factid_19149849" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5">169100000</us-gaap:OperatingLossCarryforwards>
<gbio:PercentageOnAnnualTaxableIncome id="Factid_19150667" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2">0.80</gbio:PercentageOnAnnualTaxableIncome>
<us-gaap:OperatingLossCarryforwards id="Factid_19150687" contextRef="PAsOn12_31_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5">174700000</us-gaap:OperatingLossCarryforwards>
<us-gaap:TaxCreditCarryforwardAmount id="Factid_19150728" contextRef="PAsOn12_31_2020_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5">6300000</us-gaap:TaxCreditCarryforwardAmount>
<us-gaap:TaxCreditCarryforwardAmount id="Factid_19150729" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5">3900000</us-gaap:TaxCreditCarryforwardAmount>
<gbio:OperatingLossCarryforwardsExpirationYear id="Factid_19150730" contextRef="P01_01_2020To12_31_2020">2036</gbio:OperatingLossCarryforwardsExpirationYear>
<gbio:PercentageOfChangeInOwnership id="Factid_19150731" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2">0.50</gbio:PercentageOfChangeInOwnership>
<gbio:UnrecognizedTaxBenefitsOfIncomeTaxRate id="Factid_19150780" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2">0.50</gbio:UnrecognizedTaxBenefitsOfIncomeTaxRate>
<us-gaap:LesseeOperatingLeaseRenewalTerm id="Factid_19152438" contextRef="PAsOn12_31_2020">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
<us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend id="Factid_19152449" contextRef="P01_01_2020To12_31_2020">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="Factid_19152451" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
<gbio:LicenseAgreementsDisclosureTextBlock id="Factid_19152526" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. License agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;NIH &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has an agreement with the U.S. Department of Health and Human Services, as represented by The National Heart, Lung, and Blood Institute, an Institute of the National Institutes of Health (&amp;#8220;NIH&amp;#8221;), entered into in 2017, pursuant to which NIH granted the Company a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; license, with the right to grant sublicenses,&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;under certain NIH intellectual property related to the Company&amp;#8217;s ceDNA construct. In July 2019, the agreement was amended to include Association Institut de Myologie, Universite Pierre et Marie Curie, Centre National de la Recherche Scientifique, and Inserm Transfert SA, collectively referred to as the French Institutions, as a licensor. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is obligated to make future milestone payments of up to $0.4&amp;#160;million per licensed product upon the achievement of specified milestones as well as royalties on a&amp;#160;licensed &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-licensed&lt;/div&gt;&lt;/div&gt; product and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&amp;#160;basis&lt;/div&gt;&lt;/div&gt; of a low single&amp;#160;digit percentage of annual net sales of licensed products. The Company is obligated to pay a high single-digit royalty percentage of all sublicensing income. The royalties on net sales may be reduced by up to 25% in certain circumstances as defined in the agreement. The Company&amp;#8217;s royalty obligation expires on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;licensed&amp;#160;product-by-licensed&amp;#160;product&lt;/div&gt;&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&amp;#160;basis&lt;/div&gt;&lt;/div&gt; upon the expiration of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;last-to-expire&lt;/div&gt;&lt;/div&gt; licensed intellectual property rights in such country. Additionally, the Company is required to reimburse the French Institutions for a portion of certain past and ongoing patent related expenses related to the licensed technology. The agreement requires the Company to use reasonable commercial efforts to meet certain performance milestones and execute a commercial development plan within specified timeframes. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Unless terminated earlier, the agreement remains in effect until the last to expire of the licensed patent rights on a&amp;#160;licensed &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-licensed&lt;/div&gt;&lt;/div&gt; product and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&amp;#160;basis.&lt;/div&gt;&lt;/div&gt; NIH and the French Institutions may terminate the agreement if the Company fails to perform its material obligations, including but not limited to its failure to meet the applicable performance milestones despite using commercially reasonable efforts, and has not remediated such deficiency within a specified time period. NIH and the French Institutions can terminate the agreement in the event the Company becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, or determines to file a petition in bankruptcy. In addition, NIH and the French Institutions may terminate the agreement in the event of a material breach by the Company and failure to cure such breach within a certain period of time. The Company is currently in compliance with the terms of the agreement. The Company can voluntarily terminate the agreement with prior notice to NIH and the French Institutions. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During each of the years ended December&amp;#160;31, 2020 and 2019, the Company recorded research and development expense of less than $0.1&amp;#160;million under this agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;UMass &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has an agreement with the University of Massachusetts as represented by and solely on behalf of its Medical School (&amp;#8220;UMass&amp;#8221;), entered into in 2017, pursuant to which UMass granted the Company an exclusive license, with the right to grant sublicenses, under the UMass intellectual property related to the Company&amp;#8217;s ceDNA construct. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is obligated to make future milestone payments of up to $0.8&amp;#160;million per licensed product upon the achievement of specified milestones as well as royalties on a&amp;#160;licensed &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-licensed&lt;/div&gt;&lt;/div&gt; product and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&amp;#160;basis&lt;/div&gt;&lt;/div&gt; of a low single&amp;#160;digit percentage of annual net sales of licensed products, subject to annual minimum royalties as defined in the agreement. Additionally, the Company has agreed to pay a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-to-mid&lt;/div&gt;&lt;/div&gt; single-digit royalty percentage of all sublicensing income, which will vary depending on when the sublicense agreement to a third party was executed. The milestone payments are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; and &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-creditable&lt;/div&gt; against any other payments due to UMass under the agreement. The Company&amp;#8217;s royalty obligation expires on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;licensed&amp;#160;product-by-licensed&amp;#160;product&lt;/div&gt;&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&amp;#160;basis&lt;/div&gt;&lt;/div&gt; upon the expiration of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;last-to-expire&lt;/div&gt;&lt;/div&gt; licensed intellectual property rights in such country. The agreement requires the Company to use diligent efforts to meet certain performance milestones within specified timeframes. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As part of the arrangement, the Company agreed to issue 125,677 shares of its common stock to UMass. The Company recorded $0.1&amp;#160;million as research and development expense and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;additional-paid-in&lt;/div&gt; capital at the time of the agreement in 2017, representing the fair value of the common stock at that time. The shares were issued in August 2019. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Unless terminated earlier, the agreement will continue until the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;last-to-expire&lt;/div&gt;&lt;/div&gt; valid claim of the licensed patents. UMass may terminate the agreement if the Company fails to perform its material obligations, including but not limited to its failure to meet the applicable performance milestones despite using commercially reasonable efforts, and has not remediated such deficiency within a specified time period or negotiated a revised performance timeline. UMass can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event of a material breach by the Company and failure to cure such breach within a certain period of time. The Company is currently in compliance with the terms of the agreement. The Company can voluntarily terminate the agreement with prior notice to UMass. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During each of the years ended December&amp;#160;31, 2020 and 2019, the Company recorded research and development expense of less than $0.1&amp;#160;million under this agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Other license agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has other license agreements under which it may become subject to future additional fees and milestone payments. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:LicenseAgreementsDisclosureTextBlock>
<gbio:FutureMilestoneObligation id="Factid_19152720" contextRef="PAsOn12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_NihMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">400000</gbio:FutureMilestoneObligation>
<gbio:FutureMilestoneObligation id="Factid_19152721" contextRef="PAsOn12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">800000</gbio:FutureMilestoneObligation>
<gbio:PercentageOfIncreaseDecreaseInNetSales id="Factid_19152723" contextRef="P01_01_2020To12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_NihMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2">0.25</gbio:PercentageOfIncreaseDecreaseInNetSales>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="Factid_19152730" contextRef="P01_01_2020To12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0">125677</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_19152733" contextRef="P01_01_2020To12_31_2020_NihMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">100000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_19152735" contextRef="P01_01_2019To12_31_2019_NihMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">100000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_19152742" contextRef="P01_01_2020To12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">100000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_19152743" contextRef="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">100000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="Factid_19152750" contextRef="P01_01_2020To12_31_2020_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UmassMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:ConcentrationRiskCreditRisk id="Factid_19159711" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentrations of credit risk and of significant suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&amp;#8217;s marketable securities as of December&amp;#160;31, 2020 consisted of U.S government treasury securities, commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to significant credit risk. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="Factid_19159713" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and financial liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2&amp;#8212;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 0px; margin-bottom: 0px;"&gt;&amp;#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company&amp;#8217;s accounts payable and accrued expenses approximate their fair values due to the&amp;#160;short-term&amp;#160;nature of these liabilities. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Factid_19160405" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_19160475" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13,&lt;/div&gt; Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement. The new standard added, modified or removed disclosure requirements under Topic 820 for clarity and consistency. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2019. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-03&lt;/div&gt; on January&amp;#160;1, 2020 and the adoption did not have a material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recently issued accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &amp;#8220;opt out&amp;#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&amp;#160;irrevocably elects to &amp;#8220;opt out&amp;#8221; of such extended transition period or (ii)&amp;#160;no longer qualifies as an emerging growth company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. In July 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11,&lt;/div&gt; which provides entities with an additional transition method to adopt Topic 842. Under the new transition method, an entity initially applies the new lease requirements at the adoption date, not the earliest period presented, and recognizes a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. For public entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2018 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2019. In November 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10,&lt;/div&gt; which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&amp;#160;15, 2020, and interim periods within fiscal years beginning after December&amp;#160;15, 2021. In June 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-05,&lt;/div&gt; which grants a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; effective-date delay for nonpublic entities to annual reporting periods beginning after December&amp;#160;15, 2021 and to interim periods within fiscal years beginning after December&amp;#160;15, 2022. Early adoption is allowed. The Company plans to adopt ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; and related amendments, on January&amp;#160;1, 2021 using the modified retrospective approach transition method as of the date of adoption. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. Upon adoption of the new standard, the Company expects to recognize a lease liability and related right &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of-use&lt;/div&gt; asset on the consolidated balance sheet of approximately $49.7&amp;#160;million and $33.4&amp;#160;million, respectively. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; Financial Instruments &amp;#8211; Credit Losses (Topic 326). The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale.&lt;/div&gt;&lt;/div&gt; The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&amp;#160;15, 2020. Early adoption was permitted for all entities. In November 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10,&lt;/div&gt; which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&amp;#160;15, 2022, including interim periods within those fiscal years. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2019-12&lt;/div&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;, &lt;/div&gt;Income Taxes &amp;#8211; Simplifying the Accounting for Income Taxes (Topic 740). The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles as well as clarifying and amending existing guidance to improve consistent application. For public entities, the guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2020 and for interim periods within those fiscal years. For nonpublic entities, the guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2021 and to interim periods within fiscal years beginning after December&amp;#160;15, 2022. Early adoption is permitted for all entities. Depending on the amendment, adoption may be applied on the retrospective, modified retrospective or prospective basis. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<gbio:RestrictedcashpolicytextblockPolicyTextBlock id="Factid_19160476" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Restricted cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&amp;#8217;s leased facilities. These amounts are classified as restricted cash (current and noncurrent) on the Company&amp;#8217;s consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:RestrictedcashpolicytextblockPolicyTextBlock>
<us-gaap:MarketableSecuritiesPolicy id="Factid_19160483" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Marketable securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s marketable securities, which consisted of debt securities as of December&amp;#160;31, 2020, are classified &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as&amp;#160;available-for-sale&amp;#160;and&lt;/div&gt;&lt;/div&gt; are reported at fair value. Unrealized gains and losses &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on&amp;#160;available-for-sale&amp;#160;debt&lt;/div&gt;&lt;/div&gt; securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&amp;#8217; equity (deficit). Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&amp;#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &amp;#8220;other than temporary,&amp;#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesPolicy>
<gbio:DeferredrentpolicytextblockPolicyTextBlock id="Factid_19160484" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Deferred rent &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:DeferredrentpolicytextblockPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="Factid_19160485" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:51%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:47%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid rgb(0, 0, 0); line-height: 10pt; font-size: 10pt;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: 10pt;;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;5 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Computer equipment and software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;5 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;Shorter of remaining life of lease or useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;construction-in-progress&lt;/div&gt;&lt;/div&gt; and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="Factid_19160496" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Impairment of long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company did not record any impairment losses on long-lived assets during the years ended December&amp;#160;31, 2020 or 2019. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<gbio:ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock id="Factid_19160497" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Classification and accretion of convertible preferred stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s convertible preferred stock outstanding prior to the IPO was classified outside of stockholders&amp;#8217; equity (deficit) on the consolidated balance sheets because the holders of such shares had redemption rights in the event of a deemed liquidation that, in certain situations, was not solely within the control of the Company and would have required the redemption of the then-outstanding convertible preferred stock. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock id="Factid_19160498" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Segment information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has determined that its chief executive officer is the chief operating decision maker (&amp;#8220;CODM&amp;#8221;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Company has concluded that it operates as one segment. All long-lived assets are located in the United States. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy id="Factid_19160499" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and development costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upfront payments and milestone payments made for the licensing of technology with no alternative future use are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock id="Factid_19160528" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company measures stock options with service-based vesting or performance-based vesting granted to employees, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards and units using the difference between the purchase price per share of the award or unit, if any, and the fair value of the Company&amp;#8217;s common stock at the date of grant. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation expense for awards with service-based vesting is generally recognized over the vesting period of the award using the straight-line method to record the expense. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&amp;#160;accounts for forfeitures of share-based awards as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&amp;#8217;s payroll costs are classified or in which the award recipient&amp;#8217;s service payments are classified. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<gbio:ComprehensivelosspolicypolicytextblockPolicyTextBlock id="Factid_19160529" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Comprehensive loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&amp;#160;31, 2020 and 2019, the Company&amp;#8217;s only element of other comprehensive loss was unrealized gains (losses) on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:ComprehensivelosspolicypolicytextblockPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock id="Factid_19160530" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&amp;#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&amp;#160;two-step&amp;#160;process&lt;/div&gt; to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;deemed&amp;#160;more-likely-than-not&amp;#160;to&lt;/div&gt; be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&amp;#160;The Company&amp;#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had accrued no amounts for interest and penalties on its consolidated balance sheets at December&amp;#160;31, 2020 and 2019. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock id="Factid_19160531" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Net loss per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Prior to closing of the IPO, the Company followed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method when computing net income (loss) per share as the Company had issued shares that met the definition of participating securities. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reported a net loss attributable to common stockholders for each of the years ended December&amp;#160;31, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<gbio:PropertyplantandequipmentestimatedusefullifeTableTextBlock id="Factid_19160572" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:51%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:47%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid rgb(0, 0, 0); line-height: 10pt; font-size: 10pt;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: 10pt;;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;5 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Computer equipment and software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;5 years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:top;"&gt;Shorter of remaining life of lease or useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:PropertyplantandequipmentestimatedusefullifeTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="Factid_19164894" contextRef="P01_01_2020To12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Shorter of remaining life of lease or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements id="Factid_19165089" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_19167094" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5">49700000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiability id="Factid_19167095" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5">33400000</us-gaap:OperatingLeaseLiability>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Factid_19167109" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:76%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued employee compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6,150&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,255&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued external research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,772&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,344&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;940&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;619&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,389&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,370&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;702&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;319&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;10,953&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6,907&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Factid_19167111" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:76%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued employee compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6,150&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,255&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued external research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,772&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,344&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;940&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;619&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,389&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,370&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;702&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;319&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;10,953&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;6,907&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="Factid_19167137" contextRef="P01_01_2020To12_31_2020_ServiceBasedOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Factid_19167143" contextRef="PAsOn01_01_2021_EmployeeStockPurchasePlanTwoThousandAndTwentyMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0">469700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Factid_19167148" contextRef="PAsOn01_01_2021_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyStockIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0">1878800</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_19167373" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">19681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<gbio:PreferredStockIssuanceCostsIncludedInAccruedExpenses id="Factid_19167413" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">295000</gbio:PreferredStockIssuanceCostsIncludedInAccruedExpenses>
<gbio:PreferredStockIssuanceCostsIncludedInAccruedExpenses id="Factid_19167414" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">65000</gbio:PreferredStockIssuanceCostsIncludedInAccruedExpenses>
<us-gaap:QuarterlyFinancialInformationTextBlock id="Factid_19167427" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Selected Quarterly Financial Data (Unaudited) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following information has been derived from unaudited consolidated financial statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:30%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Dec. 31,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sept. 30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Dec. 31,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sept. 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="30" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands, except per share)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;24,345&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;20,969&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,764&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;18,036&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,158&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,333&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,335&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,476&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(24,345&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(20,969&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(17,764&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(18,036&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(16,158&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(16,333&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(15,335&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(14,476&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(24,226&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(20,849&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,731&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,717&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(16,063&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(16,128&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(15,032&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(14,094&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(0.53&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(0.46&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(1.50&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.22&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.09&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.31&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.30&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.29&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
<gbio:SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock id="Factid_19167433" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following information has been derived from unaudited consolidated financial statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:30%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:2%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Dec. 31,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sept. 30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Dec. 31,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sept. 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="30" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in thousands, except per share)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;24,345&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;20,969&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,764&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;18,036&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,158&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,333&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,335&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;14,476&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(24,345&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(20,969&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(17,764&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(18,036&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(16,158&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(16,333&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(15,335&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(14,476&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(24,226&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(20,849&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,731&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,717&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(16,063&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(16,128&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(15,032&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(14,094&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(0.53&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(0.46&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(1.50&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.22&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.09&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.31&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.30&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(3.29&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock>
<us-gaap:OperatingExpenses id="Factid_19167480" contextRef="P12_31_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">24345000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_19167481" contextRef="P09_30_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">20969000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_19167482" contextRef="P06_30_2020To06_30_2020" unitRef="Unit_USD" decimals="-3">17764000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_19167483" contextRef="P03_31_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">18036000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss id="Factid_19167484" contextRef="P12_31_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-24345000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_19167485" contextRef="P09_30_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-20969000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_19167486" contextRef="P06_30_2020To06_30_2020" unitRef="Unit_USD" decimals="-3">-17764000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_19167487" contextRef="P03_31_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">-18036000</us-gaap:OperatingIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167488" contextRef="P12_31_2020To12_31_2020" unitRef="Unit_USD" decimals="-3">-24226000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167489" contextRef="P09_30_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-20849000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167490" contextRef="P06_30_2020To06_30_2020" unitRef="Unit_USD" decimals="-3">-17731000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167491" contextRef="P03_31_2020To03_31_2020" unitRef="Unit_USD" decimals="-3">-17717000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167492" contextRef="P12_31_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167493" contextRef="P09_30_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167494" contextRef="P06_30_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">-1.50</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167495" contextRef="P03_31_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2">-3.22</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:OperatingExpenses id="Factid_19167502" contextRef="P12_31_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">16158000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_19167503" contextRef="P09_30_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">16333000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_19167504" contextRef="P06_30_2019To06_30_2019" unitRef="Unit_USD" decimals="-3">15335000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_19167505" contextRef="P03_31_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">14476000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss id="Factid_19167506" contextRef="P12_31_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-16158000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_19167507" contextRef="P09_30_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-16333000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_19167508" contextRef="P06_30_2019To06_30_2019" unitRef="Unit_USD" decimals="-3">-15335000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_19167509" contextRef="P03_31_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-14476000</us-gaap:OperatingIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167510" contextRef="P12_31_2019To12_31_2019" unitRef="Unit_USD" decimals="-3">-16063000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167511" contextRef="P09_30_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-16128000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167512" contextRef="P06_30_2019To06_30_2019" unitRef="Unit_USD" decimals="-3">-15032000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_19167513" contextRef="P03_31_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-14094000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167514" contextRef="P12_31_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2">-3.09</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167515" contextRef="P09_30_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">-3.31</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167516" contextRef="P06_30_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2">-3.30</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_19167517" contextRef="P03_31_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2">-3.29</us-gaap:EarningsPerShareBasicAndDiluted>
<dei:EntityFilerCategory id="Factid_19229339" contextRef="P01_01_2020To12_31_2020">Non-accelerated Filer</dei:EntityFilerCategory>
<us-gaap:ReceivablesNetCurrent id="Factid_19229361" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3">448000</us-gaap:ReceivablesNetCurrent>
<dei:EntityVoluntaryFilers id="Factid_19229422" contextRef="P01_01_2020To12_31_2020">No</dei:EntityVoluntaryFilers>
<dei:EntityWellKnownSeasonedIssuer id="Factid_19229430" contextRef="P01_01_2020To12_31_2020">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityPublicFloat id="Factid_19229436" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-5">646200000</dei:EntityPublicFloat>
<us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList id="Factid_19229723" contextRef="PAsOn12_31_2020">us-gaap:OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
<gbio:ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock id="Factid_19326264" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and manufacturing contract costs and accruals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and costs for research and development and manufacturing activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred. The Company records accruals for costs incurred but not billed. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical accrual estimates have not been materially different from the actual costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock>
<gbio:PatentcostpolicytextblockPolicyTextBlock id="Factid_19326294" contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Patent costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gbio:PatentcostpolicytextblockPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_19326610" contextRef="P01_01_2020To12_31_2020_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_19326611" contextRef="P01_01_2020To12_31_2020_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_19326612" contextRef="P01_01_2020To12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_19327207" contextRef="P01_01_2019To12_31_2019">P8Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_19327208" contextRef="P01_01_2020To12_31_2020">P8Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<dei:EntityAddressAddressLine1 id="Factid_19329745" contextRef="P01_01_2020To12_31_2020">301 Binney Street</dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown id="Factid_19329750" contextRef="P01_01_2020To12_31_2020">Cambridge</dei:EntityAddressCityOrTown>
<dei:EntityAddressPostalZipCode id="Factid_19329760" contextRef="P01_01_2020To12_31_2020">02142</dei:EntityAddressPostalZipCode>
<dei:CityAreaCode id="Factid_19329782" contextRef="P01_01_2020To12_31_2020">617</dei:CityAreaCode>
<dei:LocalPhoneNumber id="Factid_19329783" contextRef="P01_01_2020To12_31_2020">655-7500</dei:LocalPhoneNumber>
<dei:Security12bTitle id="Factid_19329784" contextRef="P01_01_2020To12_31_2020">Common Stock, $0.0001 Par Value</dei:Security12bTitle>
<dei:EntityCommonStockSharesOutstanding id="Factid_19329790" contextRef="PAsOn02_28_2021" unitRef="Unit_shares" decimals="INF">56427399</dei:EntityCommonStockSharesOutstanding>
<us-gaap:PreferredStockValue id="Factid_19334953" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true" />
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>gbio-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 17-March-2021 [09:33:23] {AM}-->
<schema targetNamespace="http://gbio.com/20201231" elementFormDefault="qualified" xmlns:gbio="http://gbio.com/20201231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://gbio.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
<link:definition>1005 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
<link:definition>1006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentation" id="NatureOfTheBusinessAndBasisOfPresentation">
<link:definition>1008 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurements" id="MarketableSecuritiesAndFairValueMeasurements">
<link:definition>1010 - Disclosure - Marketable Securities And Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1011 - Disclosure - Property and Equipment, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1012 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConvertiblePreferredStock" id="ConvertiblePreferredStock">
<link:definition>1013 - Disclosure - Convertible Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/Equity" id="Equity">
<link:definition>1014 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>1015 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1016 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/LicenseAgreements" id="LicenseAgreements">
<link:definition>1017 - Disclosure - License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1018 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1019 - Disclosure - Net Loss per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnaudited" id="SelectedQuarterlyFinancialDataUnaudited">
<link:definition>1020 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsTables" id="MarketableSecuritiesAndFairValueMeasurementsTables">
<link:definition>1023 - Disclosure - Marketable Securities And Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1024 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1025 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>1026 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1027 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1028 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1029 - Disclosure - Net Loss per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedTables" id="SelectedQuarterlyFinancialDataUnauditedTables">
<link:definition>1030 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" id="NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail">
<link:definition>1031 - Disclosure - Nature of the Business and Basis of Presentation - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" id="SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<link:definition>1032 - Disclosure - Summary of Significant Accounting Policies - Summary Of Property And Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1033 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail" id="MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail">
<link:definition>1034 - Disclosure - Marketable Securities And Fair Value Measurements   - Summary of marketable securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" id="MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail">
<link:definition>1035 - Disclosure - Marketable Securities And Fair Value Measurements  - Summary of assets measured at fair value on a recurring basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<link:definition>1036 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" id="AccruedExpensesSummaryOfAccruedExpensesDetail">
<link:definition>1038 - Disclosure - Accrued Expenses - Summary of Accrued expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/ConvertiblePreferredStockAdditionalInformationDetail" id="ConvertiblePreferredStockAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Convertible Preferred Stock - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/EquityAdditionalInformationDetail" id="EquityAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/StockBasedCompensationAdditionalInformationDetail" id="StockBasedCompensationAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail" id="StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail">
<link:definition>1042 - Disclosure - Stock-based compensation - Summary of Inputs Used in Black-Scholes Option Pricing Model (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail" id="StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail">
<link:definition>1043 - Disclosure - Stock-based compensation - Summarizes the Company's Stock Option Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail" id="StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail">
<link:definition>1044 - Disclosure - Stock-based compensation - Summarizes the Company's Restricted Common Stock Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail" id="StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail">
<link:definition>1045 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense was Classified in the Statements of Operations and Comprehensive Loss (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1046 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail" id="IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail">
<link:definition>1047 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail" id="IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail">
<link:definition>1048 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail" id="IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail">
<link:definition>1049 - Disclosure - Income Taxes - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/LicenseAgreementsAdditionalInformationDetail" id="LicenseAgreementsAdditionalInformationDetail">
<link:definition>1050 - Disclosure - License Agreements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1051 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" id="CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
<link:definition>1052 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail" id="NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail">
<link:definition>1053 - Disclosure - Net Loss per Share - Summary of Potential Dilutive Securities, Presented Based on Amounts Outstanding (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail" id="SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail">
<link:definition>1054 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Summary of information has been derived from unaudited consolidated financial statements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="gbio-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="gbio-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="gbio-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="gbio-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="SeriesABAndCPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_SeriesABAndCPreferredStockMember" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="VestingOfRestrictedCommonStockUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_VestingOfRestrictedCommonStockUnits" substitutionGroup="xbrli:item" />
<element name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_SeriesCConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_StockIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInTenantImprovementsAllowanceReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PreferredStockIssuanceCostsIncludedInAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LicenseAgreementsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_LicenseAgreementsDisclosureAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_LicenseAgreementsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="RestrictedcashpolicytextblockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_RestrictedcashpolicytextblockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DeferredrentpolicytextblockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_DeferredrentpolicytextblockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PatentcostpolicytextblockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_PatentcostpolicytextblockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ComprehensivelosspolicypolicytextblockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PropertyplantandequipmentestimatedusefullifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_LaboratoryEquipmentMember" substitutionGroup="xbrli:item" />
<element name="ComputerEquipmentAndSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_ComputerEquipmentAndSoftwareMember" substitutionGroup="xbrli:item" />
<element name="AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_AccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_AccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="AccruedExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_AccruedExpensesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccruedExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_AccruedExpensesLineItems" substitutionGroup="xbrli:item" />
<element name="AccruedExternalResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GrossProceedsFromIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndSeventeenStockIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_TwoThousandAndSeventeenStockIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyStockIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_TwoThousandAndTwentyStockIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="EmployeeStockPurchasePlanTwoThousandAndTwentyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" substitutionGroup="xbrli:item" />
<element name="UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" substitutionGroup="xbrli:item" />
<element name="ServiceBasedOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_ServiceBasedOptionsMember" substitutionGroup="xbrli:item" />
<element name="DateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_DateAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_DateDomain" substitutionGroup="xbrli:item" />
<element name="AdditionalFrom2017PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_AdditionalFrom2017PlanMember" substitutionGroup="xbrli:item" />
<element name="AnnualIncrease2021To2030Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_AnnualIncrease2021To2030Member" substitutionGroup="xbrli:item" />
<element name="IncometaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_IncometaxTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FederalIncomeTaxAuthorityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_FederalIncomeTaxAuthorityMember" substitutionGroup="xbrli:item" />
<element name="FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" substitutionGroup="xbrli:item" />
<element name="IncometaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_IncometaxLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOnAnnualTaxableIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_PercentageOnAnnualTaxableIncome" substitutionGroup="xbrli:item" />
<element name="UnrecognizedTaxBenefitsOfIncomeTaxRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_TaxCreditCarryforwardExpirationYear" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
<element name="PercentageOfChangeInOwnership" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_PercentageOfChangeInOwnership" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_LicenseAgreementsDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LicenseAgreementsDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_LicenseAgreementsDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="FutureMilestoneObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gbio_FutureMilestoneObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfIncreaseDecreaseInNetSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_PercentageOfIncreaseDecreaseInNetSales" substitutionGroup="xbrli:item" />
<element name="NihMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_NihMember" substitutionGroup="xbrli:item" />
<element name="UmassMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_UmassMember" substitutionGroup="xbrli:item" />
<element name="DisclosureOfCommitementAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_DisclosureOfCommitementAndContingenciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureOfCommitementAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="gbio_DisclosureOfCommitementAndContingenciesLineItems" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseYearOfExpiry" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="gbio_LesseeOperatingLeaseYearOfExpiry" substitutionGroup="xbrli:item" />
<element name="TenantImprovementAllowanceMaximum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gbio_TenantImprovementAllowanceMaximum" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LetterOfCreditForSecurityDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="gbio_LetterOfCreditForSecurityDeposit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>gbio-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 17-March-2021 [09:33:22] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://gbio.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://gbio.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail" roleURI="http://gbio.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" roleURI="http://gbio.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" />
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredCosts" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ReceivablesNetCurrent" use="optional" order="22" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:label="loc_GBIO_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GBIO_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts" use="optional" order="23" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:label="loc_GBIO_AccruedExternalResearchAndDevelopmentExpensesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_GBIO_AccruedExternalResearchAndDevelopmentExpensesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaap_DeferredRentCreditCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" order="1" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>gbio-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 17-March-2021 [09:33:23] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://gbio.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://gbio.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://gbio.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://gbio.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConvertiblePreferredStockAdditionalInformationDetail" roleURI="http://gbio.com/role/ConvertiblePreferredStockAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationAdditionalInformationDetail" roleURI="http://gbio.com/role/StockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://gbio.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://gbio.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://gbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail" roleURI="http://gbio.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingencies" roleURI="http://gbio.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingenciesTables" roleURI="http://gbio.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" roleURI="http://gbio.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NetLossPerShare" roleURI="http://gbio.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NetLossPerShareTables" roleURI="http://gbio.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensation" roleURI="http://gbio.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationTables" roleURI="http://gbio.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CoverPage" roleURI="http://gbio.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#Equity" roleURI="http://gbio.com/role/Equity" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#EquityAdditionalInformationDetail" roleURI="http://gbio.com/role/EquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConvertiblePreferredStock" roleURI="http://gbio.com/role/ConvertiblePreferredStock" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NatureOfTheBusinessAndBasisOfPresentation" roleURI="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurements" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurementsTables" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#AccruedExpensesTables" roleURI="http://gbio.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#AccruedExpenses" roleURI="http://gbio.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNet" roleURI="http://gbio.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNetTables" roleURI="http://gbio.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://gbio.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxes" roleURI="http://gbio.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesTables" roleURI="http://gbio.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail" roleURI="http://gbio.com/role/IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail" roleURI="http://gbio.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail" roleURI="http://gbio.com/role/IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#LicenseAgreements" roleURI="http://gbio.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited" roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnaudited" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail" roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedTables" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714718" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_StatementTable_714715" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_714715" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714716" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714716" xlink:to="loc_us-gaap_ClassOfStockDomain_714717" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714717_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714716" xlink:to="loc_us-gaap_ClassOfStockDomain_714717_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_714719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_AssetsAbstract_714719" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_714723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_AssetsCurrentAbstract_714723" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_714741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_714741" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_714742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_714742" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_714744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_714744" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_714745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_RestrictedCashCurrent_714745" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_714747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_AssetsCurrent_714747" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_717317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_ReceivablesNetCurrent_717317" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_714750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_714750" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_714751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_714751" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_714753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_DeferredCosts_714753" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_714754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_714754" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_714755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_Assets_714755" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_714761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_714761" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_714762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_714761" xlink:to="loc_us-gaap_AccountsPayableCurrent_714762" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_714766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_714761" xlink:to="loc_us-gaap_LiabilitiesCurrent_714766" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_714761" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717492" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_714769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_714769" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_714773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" xlink:to="loc_us-gaap_Liabilities_714773" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_714776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_CommitmentsAndContingencies_714776" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_714777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_714777" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_714778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_StockholdersEquityAbstract_714778" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_714780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_PreferredStockValue_714780" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_714782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_CommonStockValue_714782" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_714783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_AdditionalPaidInCapital_714783" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_714784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_714784" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_714785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_714785" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_714786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_StockholdersEquity_714786" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_714787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_714787" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714843" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_StatementTable_714829" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_714829" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714831" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714831" xlink:to="loc_us-gaap_ClassOfStockDomain_714832" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714832_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714831" xlink:to="loc_us-gaap_ClassOfStockDomain_714832_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_714844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_714844" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_714846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_714846" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_714847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockSharesIssued_714847" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_714848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_714848" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_714850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_714850" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_714852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_714852" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_714854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_714854" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_714853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockSharesIssued_714853" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_715536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_715536" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_715537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_715537" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_715538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_715538" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_715539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_715539" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714814" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_StatementTable_714811" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_714812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_714811" xlink:to="loc_srt_ProductOrServiceAxis_714812" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_714813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_714812" xlink:to="loc_srt_ProductsAndServicesDomain_714813" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_714813_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_714812" xlink:to="loc_srt_ProductsAndServicesDomain_714813_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_714816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_OperatingExpensesAbstract_714816" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_714818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_714816" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_714818" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_714820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_714816" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_714820" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_714822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_714816" xlink:to="loc_us-gaap_OperatingExpenses_714822" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_714855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_714855" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_714856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_714856" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_714857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_714857" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_714858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_714858" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_714859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_714858" xlink:to="loc_us-gaap_NetIncomeLoss_714859" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_714860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_714860" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_714861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_714860" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_714861" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_714862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_714862" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_714863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_OperatingIncomeLoss_714863" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_714999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_714999" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_715000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_714999" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_715000" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714870" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StatementTable_714867" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_714868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_714867" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_714868" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_714869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_714868" xlink:to="loc_us-gaap_EquityComponentDomain_714869" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_714869_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_714868" xlink:to="loc_us-gaap_EquityComponentDomain_714869_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_714878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_RetainedEarningsMember_714878" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_714877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_714877" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_714875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_714875" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_714873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_CommonStockMember_714873" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesABAndCPreferredStockMember" xlink:label="loc_gbio_SeriesABAndCPreferredStockMember_715597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_gbio_SeriesABAndCPreferredStockMember_715597" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_715553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_714867" xlink:to="loc_us-gaap_StatementClassOfStockAxis_715553" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715553" xlink:to="loc_us-gaap_ClassOfStockDomain_715554" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715554_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715553" xlink:to="loc_us-gaap_ClassOfStockDomain_715554_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesCConvertiblePreferredStockMember" xlink:label="loc_gbio_SeriesCConvertiblePreferredStockMember_715555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_715554" xlink:to="loc_gbio_SeriesCConvertiblePreferredStockMember_715555" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_714888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_SharesOutstanding_714888" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_714892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_714892" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_714893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_714893" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_714895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_714895" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_714896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_714896" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_714901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_714901" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_714904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_714904" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_714909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_ProfitLoss_714909" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_715431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_715431" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_715432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_715432" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_715435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_715435" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_715436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_715436" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715441" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_715442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_715442" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_715542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockholdersEquity_715542" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_715439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_715439" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_715440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_715440" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_760370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_760370" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_759812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_759812" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_VestingOfRestrictedCommonStockUnits" xlink:label="loc_gbio_VestingOfRestrictedCommonStockUnits_863796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_gbio_VestingOfRestrictedCommonStockUnits_863796" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715418" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_715412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_715418" xlink:to="loc_us-gaap_StatementTable_715412" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_715413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715412" xlink:to="loc_us-gaap_StatementClassOfStockAxis_715413" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715413" xlink:to="loc_us-gaap_ClassOfStockDomain_715414" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715413" xlink:to="loc_us-gaap_ClassOfStockDomain_715414_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesCConvertiblePreferredStockMember" xlink:label="loc_gbio_SeriesCConvertiblePreferredStockMember_715416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_715414" xlink:to="loc_gbio_SeriesCConvertiblePreferredStockMember_715416" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_718826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715412" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_718826" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_718827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_718826" xlink:to="loc_us-gaap_EquityComponentDomain_718827" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_718827_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_718826" xlink:to="loc_us-gaap_EquityComponentDomain_718827_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_718828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_718827" xlink:to="loc_us-gaap_CommonStockMember_718828" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_720627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715412" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_720627" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_720627" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_720627" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_720629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628" xlink:to="loc_us-gaap_IPOMember_720629" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_StockIssuanceCosts" xlink:label="loc_gbio_StockIssuanceCosts_715545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715418" xlink:to="loc_gbio_StockIssuanceCosts_715545" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715446" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_715445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_StatementTable_715445" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_715447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_715447" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_715448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_715447" xlink:to="loc_us-gaap_ProfitLoss_715448" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_715450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_ShareBasedCompensation_715450" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_715451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_715451" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_715469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_715469" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_715473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_715473" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_715474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_715474" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_715475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_715475" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_717319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_717319" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_717320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_717320" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:label="loc_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable_717321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable_717321" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_715484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_715484" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_717322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_717322" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_715486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_715486" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_715487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_715487" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_715488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_715488" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_715490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_715490" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_715491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_715491" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_715493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_715493" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_715494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_715494" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_715495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_715495" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_715496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_715496" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_715497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_715497" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_862053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_862053" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_715499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_715499" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715502" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_715506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_715506" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:label="loc_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses_715507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" xlink:to="loc_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses_715507" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_718824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" xlink:to="loc_us-gaap_StockIssued1_718824" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715349" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_715341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_StatementTable_715341" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_715342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_715342" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_715343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_715342" xlink:to="loc_us-gaap_EquityComponentDomain_715343" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_715343_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_715342" xlink:to="loc_us-gaap_EquityComponentDomain_715343_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_715344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_715343" xlink:to="loc_us-gaap_CommonStockMember_715344" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_715345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_715345" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_715345" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_715345" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_715347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" xlink:to="loc_us-gaap_IPOMember_715347" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_715348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" xlink:to="loc_us-gaap_OverAllotmentOptionMember_715348" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_717442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_717442" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_717443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_717442" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_717443" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_717443_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_717442" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_717443_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_862055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_862055" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862055" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862056" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862056_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862055" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862056_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_862057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_862056" xlink:to="loc_us-gaap_SubsequentEventMember_862057" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_715350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_715350" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_715351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_715351" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_715355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_715355" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_715361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_NetIncomeLoss_715361" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_715362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_715362" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_720809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_720809" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862770" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862771" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862771" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862771" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LaboratoryEquipmentMember" xlink:label="loc_gbio_LaboratoryEquipmentMember_862773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_gbio_LaboratoryEquipmentMember_862773" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ComputerEquipmentAndSoftwareMember" xlink:label="loc_gbio_ComputerEquipmentAndSoftwareMember_862774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_gbio_ComputerEquipmentAndSoftwareMember_862774" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_862775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_862775" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_862776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_862776" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_862779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_862779" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_862780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_862780" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccountingPoliciesLineItems" xlink:label="loc_gbio_AccountingPoliciesLineItems_862791" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccountingPoliciesTable" xlink:label="loc_gbio_AccountingPoliciesTable_862786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_gbio_AccountingPoliciesTable_862786" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_862787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gbio_AccountingPoliciesTable_862786" xlink:to="loc_us-gaap_StatementClassOfStockAxis_862787" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_862788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_862787" xlink:to="loc_us-gaap_ClassOfStockDomain_862788" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_862788_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_862787" xlink:to="loc_us-gaap_ClassOfStockDomain_862788_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_862793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_862793" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_862795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_862795" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_862796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_OperatingLeaseLiability_862796" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_863985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_863985" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_715354" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable_715353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_MarketableSecuritiesTable_715353" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_715363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_715353" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_715363" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_715363" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_715363" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_715365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_715365" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_715367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" xlink:to="loc_us-gaap_CommercialPaperMember_715367" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_715368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_715368" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_715353" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715650" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715650" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715650" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_715652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_715652" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_715357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_715357" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715358" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_715359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_715359" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715360" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715381" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715381" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715381" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_715383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_715383" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_715384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_715384" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_715384" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_715384" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_715386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_MoneyMarketFundsMember_715386" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_715388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_715388" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_715390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_CommercialPaperMember_715390" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_715391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_715391" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_715392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_715392" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_715392" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_715392" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_715394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_715394" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_715395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_715395" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_715376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_715376" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_715377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_715376" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_715377" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_715378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" xlink:to="loc_us-gaap_MarketableSecuritiesAbstract_715378" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_715378" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715379" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_764696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_764696" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862113" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862113" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862114" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LaboratoryEquipmentMember" xlink:label="loc_gbio_LaboratoryEquipmentMember_862117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_gbio_LaboratoryEquipmentMember_862117" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ComputerEquipmentAndSoftwareMember" xlink:label="loc_gbio_ComputerEquipmentAndSoftwareMember_862118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_gbio_ComputerEquipmentAndSoftwareMember_862118" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_862119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_862119" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_862120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_862120" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_862121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_us-gaap_ConstructionInProgressMember_862121" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_862124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_862124" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_862125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_862125" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_862126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_862126" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccruedExpensesLineItems" xlink:label="loc_gbio_AccruedExpensesLineItems_715324" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccruedExpensesTable" xlink:label="loc_gbio_AccruedExpensesTable_715323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_gbio_AccruedExpensesTable_715323" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_715325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_715325" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:label="loc_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent_715326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent_715326" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_715327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_715327" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_715328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_715328" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_715329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_715329" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717493" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/ConvertiblePreferredStockAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_715270" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_715271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" xlink:to="loc_us-gaap_StatementClassOfStockAxis_715271" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715271" xlink:to="loc_us-gaap_ClassOfStockDomain_715272" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715271" xlink:to="loc_us-gaap_ClassOfStockDomain_715272_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesCConvertiblePreferredStockMember" xlink:label="loc_gbio_SeriesCConvertiblePreferredStockMember_715273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_715272" xlink:to="loc_gbio_SeriesCConvertiblePreferredStockMember_715273" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_715292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_715292" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_715293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_715292" xlink:to="loc_us-gaap_EquityComponentDomain_715293" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_715293_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_715292" xlink:to="loc_us-gaap_EquityComponentDomain_715293_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_715294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_715293" xlink:to="loc_us-gaap_CommonStockMember_715294" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715275" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_715276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_715276" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_StockIssuanceCosts" xlink:label="loc_gbio_StockIssuanceCosts_715279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_gbio_StockIssuanceCosts_715279" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_715281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_715281" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock_717326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock_717326" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_714834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_PlanNameAxis_714834" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_714835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_714834" xlink:to="loc_us-gaap_PlanNameDomain_714835" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_714835_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_714834" xlink:to="loc_us-gaap_PlanNameDomain_714835_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:label="loc_gbio_TwoThousandAndSeventeenStockIncentivePlanMember_714836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_714835" xlink:to="loc_gbio_TwoThousandAndSeventeenStockIncentivePlanMember_714836" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:label="loc_gbio_TwoThousandAndTwentyStockIncentivePlanMember_714925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_714835" xlink:to="loc_gbio_TwoThousandAndTwentyStockIncentivePlanMember_714925" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:label="loc_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember_714926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_714835" xlink:to="loc_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember_714926" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714840" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714840" xlink:to="loc_us-gaap_ClassOfStockDomain_714841" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714841_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714840" xlink:to="loc_us-gaap_ClassOfStockDomain_714841_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_714842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_714841" xlink:to="loc_us-gaap_CommonStockMember_714842" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_714993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_AwardTypeAxis_714993" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_714993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_714993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:label="loc_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember_714995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" xlink:to="loc_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember_714995" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ServiceBasedOptionsMember" xlink:label="loc_gbio_ServiceBasedOptionsMember_718835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" xlink:to="loc_gbio_ServiceBasedOptionsMember_718835" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_862264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" xlink:to="loc_us-gaap_RestrictedStockMember_862264" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DateAxis" xlink:label="loc_gbio_DateAxis_715656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_gbio_DateAxis_715656" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DateDomain" xlink:label="loc_gbio_DateDomain_715657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gbio_DateAxis_715656" xlink:to="loc_gbio_DateDomain_715657" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DateDomain" xlink:label="loc_gbio_DateDomain_715657_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gbio_DateAxis_715656" xlink:to="loc_gbio_DateDomain_715657_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AdditionalFrom2017PlanMember" xlink:label="loc_gbio_AdditionalFrom2017PlanMember_717421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DateDomain_715657" xlink:to="loc_gbio_AdditionalFrom2017PlanMember_717421" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AnnualIncrease2021To2030Member" xlink:label="loc_gbio_AnnualIncrease2021To2030Member_717422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DateDomain_715657" xlink:to="loc_gbio_AnnualIncrease2021To2030Member_717422" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_717417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_srt_RangeAxis_717417" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_717418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_717417" xlink:to="loc_srt_RangeMember_717418" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_717418_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_717417" xlink:to="loc_srt_RangeMember_717418_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_717419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_717418" xlink:to="loc_srt_MaximumMember_717419" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_717423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_srt_TitleOfIndividualAxis_717423" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_717424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_717423" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_717424" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_717424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_717423" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_717424_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_862803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_862803" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862803" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862804" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862804_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862803" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862804_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_862805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_862804" xlink:to="loc_us-gaap_SubsequentEventMember_862805" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_865438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_865438" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_865439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_865438" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_865439" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_865439_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_865438" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_865439_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_865440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_865439" xlink:to="loc_us-gaap_StockOptionMember_865440" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_714825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_714825" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714916" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_714919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_714919" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_714920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_714920" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_714921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_714921" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_714922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_714922" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_714996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_714996" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_714997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_714997" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:label="loc_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage_717420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage_717420" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_718326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_718326" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_862249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_862249" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_862251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_862251" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_862263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_CommonStockValueOutstanding_862263" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862801" use="optional" order="51" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_714882" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_714881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_714882" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_714881" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_714883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_714881" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_714883" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_714884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_714883" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_714884" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_714884_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_714883" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_714884_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_714885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_714884" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_714885" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_714887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_714884" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_714887" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_714891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_714882" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_714891" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_IncometaxLineItems" xlink:label="loc_gbio_IncometaxLineItems_862348" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_IncometaxTable" xlink:label="loc_gbio_IncometaxTable_862339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_IncometaxTable_862339" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_862340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gbio_IncometaxTable_862339" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_862340" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_862341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_862340" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_862341" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_862341_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_862340" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_862341_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_FederalIncomeTaxAuthorityMember" xlink:label="loc_gbio_FederalIncomeTaxAuthorityMember_862342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_862341" xlink:to="loc_gbio_FederalIncomeTaxAuthorityMember_862342" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_862343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_862341" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_862343" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:label="loc_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember_862346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_862341" xlink:to="loc_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember_862346" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_862349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_us-gaap_OperatingLossCarryforwards_862349" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PercentageOnAnnualTaxableIncome" xlink:label="loc_gbio_PercentageOnAnnualTaxableIncome_862351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_PercentageOnAnnualTaxableIncome_862351" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_862352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_862352" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:label="loc_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate_862353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate_862353" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TaxCreditCarryforwardExpirationYear" xlink:label="loc_gbio_TaxCreditCarryforwardExpirationYear_862354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_TaxCreditCarryforwardExpirationYear_862354" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_gbio_OperatingLossCarryforwardsExpirationYear_862355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_OperatingLossCarryforwardsExpirationYear_862355" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PercentageOfChangeInOwnership" xlink:label="loc_gbio_PercentageOfChangeInOwnership_862358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_PercentageOfChangeInOwnership_862358" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_865717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_us-gaap_OperatingIncomeLoss_865717" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureLineItems" xlink:label="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureTable" xlink:label="loc_gbio_LicenseAgreementsDisclosureTable_862393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_gbio_LicenseAgreementsDisclosureTable_862393" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_862395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gbio_LicenseAgreementsDisclosureTable_862393" xlink:to="loc_dei_LegalEntityAxis_862395" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_862396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_862395" xlink:to="loc_dei_EntityDomain_862396" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_862396_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_862395" xlink:to="loc_dei_EntityDomain_862396_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_NihMember" xlink:label="loc_gbio_NihMember_862400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_862396" xlink:to="loc_gbio_NihMember_862400" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_UmassMember" xlink:label="loc_gbio_UmassMember_862401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_862396" xlink:to="loc_gbio_UmassMember_862401" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_862402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gbio_LicenseAgreementsDisclosureTable_862393" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_862402" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_862402" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_862402" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_862404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_862404" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_FutureMilestoneObligation" xlink:label="loc_gbio_FutureMilestoneObligation_862405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_gbio_FutureMilestoneObligation_862405" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:label="loc_gbio_PercentageOfIncreaseDecreaseInNetSales_862406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_gbio_PercentageOfIncreaseDecreaseInNetSales_862406" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_862407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_862407" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_862408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_862408" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_862409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_862409" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:label="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DisclosureOfCommitementAndContingenciesTable" xlink:label="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_714770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" xlink:to="loc_srt_RangeAxis_714770" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_714771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_714770" xlink:to="loc_srt_RangeMember_714771" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_714771_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_714770" xlink:to="loc_srt_RangeMember_714771_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="loc_us-gaap_MajorPropertyClassAxis_714774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" xlink:to="loc_us-gaap_MajorPropertyClassAxis_714774" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="loc_us-gaap_MajorPropertyClassDomain_714779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorPropertyClassAxis_714774" xlink:to="loc_us-gaap_MajorPropertyClassDomain_714779" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="loc_us-gaap_MajorPropertyClassDomain_714779_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorPropertyClassAxis_714774" xlink:to="loc_us-gaap_MajorPropertyClassDomain_714779_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LesseeOperatingLeaseYearOfExpiry" xlink:label="loc_gbio_LesseeOperatingLeaseYearOfExpiry_714756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_gbio_LesseeOperatingLeaseYearOfExpiry_714756" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_714768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_LeaseAndRentalExpense_714768" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_717414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_717414" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TenantImprovementAllowanceMaximum" xlink:label="loc_gbio_TenantImprovementAllowanceMaximum_717415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_gbio_TenantImprovementAllowanceMaximum_717415" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LetterOfCreditForSecurityDeposit" xlink:label="loc_gbio_LetterOfCreditForSecurityDeposit_717416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_gbio_LetterOfCreditForSecurityDeposit_717416" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_718501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_718501" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_767113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_767113" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://gbio.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714799" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_714800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714799" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_714800" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_714798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714799" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_714798" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_714801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_714798" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_714801" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_714801" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_714801" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_714805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_EmployeeStockOptionMember_714805" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_714804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_RestrictedStockMember_714804" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_714803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_714803" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_862814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_862814" use="optional" order="9" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>gbio-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 17-March-2021 [09:33:23] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" xlink:type="locator"/>
    <label xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" xlink:type="locator"/>
    <label xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" xlink:type="locator"/>
    <label xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" xlink:type="locator"/>
    <label xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" xlink:type="locator"/>
    <label xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" xlink:type="locator"/>
    <label xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <label xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <label xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</label>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</label>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</label>
    <label xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tenant receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, noncurrent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Noncurrent</label>
    <label xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <label xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, net of current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</label>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 11)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock (Series A, B and C), $0.0001 par value; no shares and 26,425,664 shares authorized at December 31, 2020 and 2019, respectively; no shares and 26,425,664 shares issued and outstanding at December 31, 2020 and 2019, respectively</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, convertible preferred stock</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, convertible preferred stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 and no shares authorized at December 31, 2020 and 2019, respectively; no shares issued or outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 150,000,000 and 46,750,000 shares authorized at December 31, 2020 and 2019, respectively; 46,970,012 and 6,976,077 shares issued at December 31, 2020 and 2019, respectively; 46,291,877 and 5,270,889 shares outstanding at December 31, 2020 and 2019, respectively</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional&#xA0;paid-in&#xA0;capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Used in BS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity (deficit)</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares outstanding</label>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, convertible preferred stock, shares</label>
    <label xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, convertible preferred stock, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</label>
    <label xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and net loss attributable to common stockholders</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to common stockholders, basic and diluted</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share, basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains on marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</label>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total net operations loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income and other income (expense), net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_SeriesABAndCPreferredStockMember" xlink:label="loc_gbio_SeriesABAndCPreferredStockMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_SeriesABAndCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A B And C Preferred Stock [Member]</label>
    <label xlink:label="lab_gbio_SeriesABAndCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series A, B and C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_SeriesABAndCPreferredStockMember" xlink:to="lab_gbio_SeriesABAndCPreferredStockMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_SeriesABAndCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A, B and C Preferred Stock [Member].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</label>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon initial public offering, net of issuance costs of $3,185</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon initial public offering, net of issuance costs of $3,185, shares</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued during the period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options, shares</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of shares | Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains on marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</label>
    <label xlink:label="lab_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series C convertible preferred stock, net of issuance costs of $2,640, shares</label>
    <label xlink:label="lab_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued during the period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <label xlink:label="lab_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new shares classified as temporary equity issued during the period.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series C convertible preferred stock, net of issuance costs of $2,640</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering, convertible preferred stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon initial public offering, convertible preferred stock, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for license,shares</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued For Services</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_VestingOfRestrictedCommonStockUnits" xlink:label="loc_gbio_VestingOfRestrictedCommonStockUnits" xlink:type="locator"/>
    <label xlink:label="lab_gbio_VestingOfRestrictedCommonStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of Restricted Common Stock Units</label>
    <label xlink:label="lab_gbio_VestingOfRestrictedCommonStockUnits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock units, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_VestingOfRestrictedCommonStockUnits" xlink:to="lab_gbio_VestingOfRestrictedCommonStockUnits" xlink:type="arc"/>
    <label xlink:label="lab_gbio_VestingOfRestrictedCommonStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting of restricted common stock units.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_SeriesCConvertiblePreferredStockMember" xlink:label="loc_gbio_SeriesCConvertiblePreferredStockMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
    <label xlink:label="lab_gbio_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_SeriesCConvertiblePreferredStockMember" xlink:to="lab_gbio_SeriesCConvertiblePreferredStockMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C Convertible Preferred Stock.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_StockIssuanceCosts" xlink:label="loc_gbio_StockIssuanceCosts" xlink:type="locator"/>
    <label xlink:label="lab_gbio_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs</label>
    <label xlink:label="lab_gbio_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance of costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_StockIssuanceCosts" xlink:to="lab_gbio_StockIssuanceCosts" xlink:type="arc"/>
    <label xlink:label="lab_gbio_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issuance costs.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</label>
    <label xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense, Total</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:label="loc_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:type="locator"/>
    <label xlink:label="lab_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Tenant Improvements Allowance Receivable</label>
    <label xlink:label="lab_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tenant receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:to="lab_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:type="arc"/>
    <label xlink:label="lab_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) during the reporting period in the amount due from the landlord for tenant improvements.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</label>
    <label xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization (accretion) of premium (discount) on marketable securities, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <label xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and maturities of marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible preferred stock, net of issuance costs incurred and paid in current period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering of common stock, net of underwriting discounts and commissions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of initial public offering costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</label>
    <label xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments of deferred offering costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash investing and financing information:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:label="loc_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:type="locator"/>
    <label xlink:label="lab_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Issuance Costs Included In Accrued Expenses</label>
    <label xlink:label="lab_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs included in accrued expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:to="lab_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:type="arc"/>
    <label xlink:label="lab_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred stock issuance costs included in accrued expenses.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</label>
    <label xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of the Business and Basis of Presentation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <label xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities and fair value measurements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <label xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</label>
    <label xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureAbstract" xlink:label="loc_gbio_LicenseAgreementsDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_gbio_LicenseAgreementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_LicenseAgreementsDisclosureAbstract" xlink:to="lab_gbio_LicenseAgreementsDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureTextBlock" xlink:label="loc_gbio_LicenseAgreementsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_LicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements Disclosure [Text Block]</label>
    <label xlink:label="lab_gbio_LicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_LicenseAgreementsDisclosureTextBlock" xlink:to="lab_gbio_LicenseAgreementsDisclosureTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_LicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreements Disclosure [Text Block].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of credit risk and of significant suppliers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently issued accounting pronouncements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RestrictedCashPolicyTextBlock [Policy Text Block]</label>
    <label xlink:label="lab_gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:to="lab_gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RestrictedCashPolicyTextBlock .</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DeferredRentPolicyTextBlock [Policy Text Block]</label>
    <label xlink:label="lab_gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:to="lab_gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DeferredRentPolicyTextBlock .</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock [Policy Text Block]</label>
    <label xlink:label="lab_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classification and accretion of convertible preferred stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:to="lab_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock .</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:label="loc_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock [Policy Text Block]</label>
    <label xlink:label="lab_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and manufacturing contract costs and accruals</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:to="lab_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock .</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PatentCostPolicyTextBlock [Policy Text Block]</label>
    <label xlink:label="lab_gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:to="lab_gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PatentCostPolicyTextBlock .</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:label="loc_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ComprehensiveLossPolicyPolicyTextBlock [Policy Text Block]</label>
    <label xlink:label="lab_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:to="lab_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ComprehensiveLossPolicyPolicyTextBlock .</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:label="loc_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PropertyPlantAndEquipmentEstimatedUsefulLife [Table Text Block]</label>
    <label xlink:label="lab_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:to="lab_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock .</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets measured at fair value on a recurring basis</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accrued expenses and other current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amoun</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock-based compensation expense was classified in the statements of operations and comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inputs Used in Black-Scholes Option Pricing Model</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarizes the Company's stock option activity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">summarizes the Company's restricted common stock activity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of reconciliation of the U.S. federal statutory income tax rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of changes in the valuation allowance for deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of future minimum lease payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of potential dilutive securities, presented based on amounts outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:label="loc_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Information has Been Derived From Unaudited Consolidated Financial Statements [Table Text Block]</label>
    <label xlink:label="lab_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of information has been derived from unaudited consolidated financial statements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:to="lab_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of information has been derived from unaudited consolidated financial statements.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <label xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <label xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date of incorporation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_LaboratoryEquipmentMember" xlink:label="loc_gbio_LaboratoryEquipmentMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:label="lab_gbio_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_LaboratoryEquipmentMember" xlink:to="lab_gbio_LaboratoryEquipmentMember" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_ComputerEquipmentAndSoftwareMember" xlink:label="loc_gbio_ComputerEquipmentAndSoftwareMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</label>
    <label xlink:label="lab_gbio_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_ComputerEquipmentAndSoftwareMember" xlink:to="lab_gbio_ComputerEquipmentAndSoftwareMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <label xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, Useful life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_AccountingPoliciesTable" xlink:label="loc_gbio_AccountingPoliciesTable" xlink:type="locator"/>
    <label xlink:label="lab_gbio_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_AccountingPoliciesTable" xlink:to="lab_gbio_AccountingPoliciesTable" xlink:type="arc"/>
    <label xlink:label="lab_gbio_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Policies [Table] .</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_AccountingPoliciesLineItems" xlink:label="loc_gbio_AccountingPoliciesLineItems" xlink:type="locator"/>
    <label xlink:label="lab_gbio_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_AccountingPoliciesLineItems" xlink:to="lab_gbio_AccountingPoliciesLineItems" xlink:type="arc"/>
    <label xlink:label="lab_gbio_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Policies [Line Items] .</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax rate settlement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</label>
    <label xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</label>
    <label xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</label>
    <label xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</label>
    <label xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</label>
    <label xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</label>
    <label xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Abstract]</label>
    <label xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Totals</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</label>
    <label xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</label>
    <label xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net, by Type [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_AccruedExpensesTable" xlink:label="loc_gbio_AccruedExpensesTable" xlink:type="locator"/>
    <label xlink:label="lab_gbio_AccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_AccruedExpensesTable" xlink:to="lab_gbio_AccruedExpensesTable" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_AccruedExpensesLineItems" xlink:label="loc_gbio_AccruedExpensesLineItems" xlink:type="locator"/>
    <label xlink:label="lab_gbio_AccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_AccruedExpensesLineItems" xlink:to="lab_gbio_AccruedExpensesLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee compensation and benefits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:label="loc_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued External Research And Development Expenses Current</label>
    <label xlink:label="lab_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued external research and development expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:to="lab_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="arc"/>
    <label xlink:label="lab_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development expenses.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Current</label>
    <label xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</label>
    <label xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <label xlink:label="lab_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance of Convertible Preferred Stock</label>
    <label xlink:label="lab_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <label xlink:label="lab_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross proceeds from the issuance and sale of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock, before stock issuance costs.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation by share based payment arrangement number of shares authorized for issuance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares available for future issuance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation vesting period service based</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation period of expiry</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock reserved for future issuance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compenation by share based payment arrangement number of options granted</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares | Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognised stock compensation on account of unvested options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognised stock compensation on account of unvested options remaining period over which the compensation is to be recognised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:label="loc_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:type="locator"/>
    <label xlink:label="lab_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number of Additional Shares Authorized Percentage</label>
    <label xlink:label="lab_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of common stock shares additionally reserved for issuance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:to="lab_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:type="arc"/>
    <label xlink:label="lab_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of common stock outstanding.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share instruments newly issued under a share-based compensation plan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">weighted average grant-date fair value</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of Unvested restricted common stock, Vested | $ / shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No of Instrinic stock option exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</label>
    <label xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">fair value of restricted common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:label="loc_gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Seventeen Stock Incentive Plan [Member]</label>
    <label xlink:label="lab_gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Stock Incentive Plan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:to="lab_gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and seventeen stock incentive plan.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:label="loc_gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Twenty Stock Incentive Plan [Member]</label>
    <label xlink:label="lab_gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Stock Incentive Plan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:to="lab_gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and twenty stock incentive plan.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:label="loc_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Two Thousand And Twenty [Member]</label>
    <label xlink:label="lab_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2020</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:to="lab_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan two thousand and twenty.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:label="loc_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Stock Awards For Which Performance Is Not Probable [Member]</label>
    <label xlink:label="lab_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested Stock Awards for Which Performance is not Probable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:to="lab_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unvested sock awards for which performance is not probable.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_ServiceBasedOptionsMember" xlink:label="loc_gbio_ServiceBasedOptionsMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Based Options [Member]</label>
    <label xlink:label="lab_gbio_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service Based Options [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_ServiceBasedOptionsMember" xlink:to="lab_gbio_ServiceBasedOptionsMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service based options [member].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested restricted common stock</label>
    <label xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_DateAxis" xlink:label="loc_gbio_DateAxis" xlink:type="locator"/>
    <label xlink:label="lab_gbio_DateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_DateAxis" xlink:to="lab_gbio_DateAxis" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_DateDomain" xlink:label="loc_gbio_DateDomain" xlink:type="locator"/>
    <label xlink:label="lab_gbio_DateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_DateDomain" xlink:to="lab_gbio_DateDomain" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_AdditionalFrom2017PlanMember" xlink:label="loc_gbio_AdditionalFrom2017PlanMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_AdditionalFrom2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional From 2017 Plan [Member]</label>
    <label xlink:label="lab_gbio_AdditionalFrom2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional From 2017 Plan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_AdditionalFrom2017PlanMember" xlink:to="lab_gbio_AdditionalFrom2017PlanMember" xlink:type="arc"/>
    <label xlink:label="lab_gbio_AdditionalFrom2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional From 2017 Plan [Member]</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_AnnualIncrease2021To2030Member" xlink:label="loc_gbio_AnnualIncrease2021To2030Member" xlink:type="locator"/>
    <label xlink:label="lab_gbio_AnnualIncrease2021To2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Increase 2021 To 2030 [Member]</label>
    <label xlink:label="lab_gbio_AnnualIncrease2021To2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Increase 2021 To 2030</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_AnnualIncrease2021To2030Member" xlink:to="lab_gbio_AnnualIncrease2021To2030Member" xlink:type="arc"/>
    <label xlink:label="lab_gbio_AnnualIncrease2021To2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Increase 2021 To 2030 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rang [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rang [Domin]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</label>
    <label xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares Outstanding , Beginning</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares Outstanding , Ending</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of shares | Forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares | Vested and expected to vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares | Options exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price Outstanding , Beginning</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price Outstanding , Ending</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price | Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price | Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price | Forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Weighted average exercise price | Vested and expected to vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price | Options exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual term (in years) Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual term (in years) | Vested and expected to vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average contractual term (in years) | Options exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value (in thousands) Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value (in thousands) | Vested and expected to vest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value (in thousands) | Options exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted common stock, Beginning | Shares</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted common stock, Ending | Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested | Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited | Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of Unvested restricted common stock, Beginning | $ / shares</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of Unvested restricted common stock, Ending | $ / shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of Unvested restricted common stock, Forfeited | $ / shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <label xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <label xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_IncometaxTable" xlink:label="loc_gbio_IncometaxTable" xlink:type="locator"/>
    <label xlink:label="lab_gbio_IncometaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IncomeTax [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_IncometaxTable" xlink:to="lab_gbio_IncometaxTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_FederalIncomeTaxAuthorityMember" xlink:label="loc_gbio_FederalIncomeTaxAuthorityMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_FederalIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Income Tax Authority [Member]</label>
    <label xlink:label="lab_gbio_FederalIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax Authority [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_FederalIncomeTaxAuthorityMember" xlink:to="lab_gbio_FederalIncomeTaxAuthorityMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <label xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:label="loc_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal And State Research And Development Tax Credit Carry Forwards [Member]</label>
    <label xlink:label="lab_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal and state research and development tax credit carry forwards [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:to="lab_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_IncometaxLineItems" xlink:label="loc_gbio_IncometaxLineItems" xlink:type="locator"/>
    <label xlink:label="lab_gbio_IncometaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IncomeTax [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_IncometaxLineItems" xlink:to="lab_gbio_IncometaxLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carry forwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_PercentageOnAnnualTaxableIncome" xlink:label="loc_gbio_PercentageOnAnnualTaxableIncome" xlink:type="locator"/>
    <label xlink:label="lab_gbio_PercentageOnAnnualTaxableIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage On Annual Taxable Income</label>
    <label xlink:label="lab_gbio_PercentageOnAnnualTaxableIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage on annual taxable income</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_PercentageOnAnnualTaxableIncome" xlink:to="lab_gbio_PercentageOnAnnualTaxableIncome" xlink:type="arc"/>
    <label xlink:label="lab_gbio_PercentageOnAnnualTaxableIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage on annual taxable income.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:label="loc_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:type="locator"/>
    <label xlink:label="lab_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits Of Income Tax Rate</label>
    <label xlink:label="lab_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits of income tax rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:to="lab_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:type="arc"/>
    <label xlink:label="lab_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits of income tax rate.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_TaxCreditCarryforwardExpirationYear" xlink:label="loc_gbio_TaxCreditCarryforwardExpirationYear" xlink:type="locator"/>
    <label xlink:label="lab_gbio_TaxCreditCarryforwardExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward Expiration Year</label>
    <label xlink:label="lab_gbio_TaxCreditCarryforwardExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carry forward, Expiration Year</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_TaxCreditCarryforwardExpirationYear" xlink:to="lab_gbio_TaxCreditCarryforwardExpirationYear" xlink:type="arc"/>
    <label xlink:label="lab_gbio_TaxCreditCarryforwardExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax credit carryforward expiration year.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_gbio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator"/>
    <label xlink:label="lab_gbio_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
    <label xlink:label="lab_gbio_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carry forwards, Expiration Year</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_gbio_OperatingLossCarryforwardsExpirationYear" xlink:type="arc"/>
    <label xlink:label="lab_gbio_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_PercentageOfChangeInOwnership" xlink:label="loc_gbio_PercentageOfChangeInOwnership" xlink:type="locator"/>
    <label xlink:label="lab_gbio_PercentageOfChangeInOwnership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Change In Ownership</label>
    <label xlink:label="lab_gbio_PercentageOfChangeInOwnership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of change in ownership</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_PercentageOfChangeInOwnership" xlink:to="lab_gbio_PercentageOfChangeInOwnership" xlink:type="arc"/>
    <label xlink:label="lab_gbio_PercentageOfChangeInOwnership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of change in ownership.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="loc_us-gaap_ValuationAllowanceAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceAbstract" xlink:to="lab_us-gaap_ValuationAllowanceAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance as of beginning of year</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance as of end of year</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</label>
    <label xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases recorded to income tax provision</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryforwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Federal statutory income tax rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal benefit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal and state research and development tax credits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in deferred tax asset valuation allowance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureTable" xlink:label="loc_gbio_LicenseAgreementsDisclosureTable" xlink:type="locator"/>
    <label xlink:label="lab_gbio_LicenseAgreementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_LicenseAgreementsDisclosureTable" xlink:to="lab_gbio_LicenseAgreementsDisclosureTable" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureLineItems" xlink:label="loc_gbio_LicenseAgreementsDisclosureLineItems" xlink:type="locator"/>
    <label xlink:label="lab_gbio_LicenseAgreementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems" xlink:to="lab_gbio_LicenseAgreementsDisclosureLineItems" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_FutureMilestoneObligation" xlink:label="loc_gbio_FutureMilestoneObligation" xlink:type="locator"/>
    <label xlink:label="lab_gbio_FutureMilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Obligation</label>
    <label xlink:label="lab_gbio_FutureMilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future milestone obligation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_FutureMilestoneObligation" xlink:to="lab_gbio_FutureMilestoneObligation" xlink:type="arc"/>
    <label xlink:label="lab_gbio_FutureMilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future milestone obligation.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:label="loc_gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:type="locator"/>
    <label xlink:label="lab_gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Increase Decrease In Net sales</label>
    <label xlink:label="lab_gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of increase decrease in net sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:to="lab_gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:type="arc"/>
    <label xlink:label="lab_gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of increase decrease in net sales.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" xlink:type="locator"/>
    <label xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_NihMember" xlink:label="loc_gbio_NihMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_NihMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NIH [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_NihMember" xlink:to="lab_gbio_NihMember" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_UmassMember" xlink:label="loc_gbio_UmassMember" xlink:type="locator"/>
    <label xlink:label="lab_gbio_UmassMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UMass [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_UmassMember" xlink:to="lab_gbio_UmassMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_DisclosureOfCommitementAndContingenciesTable" xlink:label="loc_gbio_DisclosureOfCommitementAndContingenciesTable" xlink:type="locator"/>
    <label xlink:label="lab_gbio_DisclosureOfCommitementAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitement And Contingencies [Table]</label>
    <label xlink:label="lab_gbio_DisclosureOfCommitementAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Commitement and Contingencies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesTable" xlink:to="lab_gbio_DisclosureOfCommitementAndContingenciesTable" xlink:type="arc"/>
    <label xlink:label="lab_gbio_DisclosureOfCommitementAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of commitement and contingencies.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:label="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:type="locator"/>
    <label xlink:label="lab_gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Commitement And Contingencies [Line Items]</label>
    <label xlink:label="lab_gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Commitement and Contingencies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:to="lab_gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:type="arc"/>
    <label xlink:label="lab_gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of commitement and contingencies.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_LesseeOperatingLeaseYearOfExpiry" xlink:label="loc_gbio_LesseeOperatingLeaseYearOfExpiry" xlink:type="locator"/>
    <label xlink:label="lab_gbio_LesseeOperatingLeaseYearOfExpiry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Year Of Expiry</label>
    <label xlink:label="lab_gbio_LesseeOperatingLeaseYearOfExpiry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee operating lease year of expiry</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_LesseeOperatingLeaseYearOfExpiry" xlink:to="lab_gbio_LesseeOperatingLeaseYearOfExpiry" xlink:type="arc"/>
    <label xlink:label="lab_gbio_LesseeOperatingLeaseYearOfExpiry" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The year in which a lease is set to expire, in CCYY format.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <label xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense operating lease</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease agreement option to renewal term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
    <loc xlink:href="gbio-20201231.xsd#gbio_TenantImprovementAllowanceMaximum" xlink:label="loc_gbio_TenantImprovementAllowanceMaximum" xlink:type="locator"/>
    <label xlink:label="lab_gbio_TenantImprovementAllowanceMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Improvement Allowance Maximum</label>
    <label xlink:label="lab_gbio_TenantImprovementAllowanceMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement allowance maximum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_TenantImprovementAllowanceMaximum" xlink:to="lab_gbio_TenantImprovementAllowanceMaximum" xlink:type="arc"/>
    <label xlink:label="lab_gbio_TenantImprovementAllowanceMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</label>
    <loc xlink:href="gbio-20201231.xsd#gbio_LetterOfCreditForSecurityDeposit" xlink:label="loc_gbio_LetterOfCreditForSecurityDeposit" xlink:type="locator"/>
    <label xlink:label="lab_gbio_LetterOfCreditForSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit for Security Deposit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gbio_LetterOfCreditForSecurityDeposit" xlink:to="lab_gbio_LetterOfCreditForSecurityDeposit" xlink:type="arc"/>
    <label xlink:label="lab_gbio_LetterOfCreditForSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Letter of credit for security deposit.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease existence of option to extend</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="loc_us-gaap_MajorPropertyClassAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MajorPropertyClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Property Class [Axis]</label>
    <label xlink:label="lab_us-gaap_MajorPropertyClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Property Class [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorPropertyClassAxis" xlink:to="lab_us-gaap_MajorPropertyClassAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="loc_us-gaap_MajorPropertyClassDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_MajorPropertyClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Property Class [Domain]</label>
    <label xlink:label="lab_us-gaap_MajorPropertyClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Property Class [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorPropertyClassDomain" xlink:to="lab_us-gaap_MajorPropertyClassDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Future Minimum Lease Payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, option [Member]</label>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option to purchase common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <label xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted common stock units</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive net loss per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>gbio-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 17-March-2021 [09:33:22] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CoverPage" roleURI="http://gbio.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://gbio.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://gbio.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://gbio.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NatureOfTheBusinessAndBasisOfPresentation" roleURI="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurements" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNet" roleURI="http://gbio.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#AccruedExpenses" roleURI="http://gbio.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConvertiblePreferredStock" roleURI="http://gbio.com/role/ConvertiblePreferredStock" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#Equity" roleURI="http://gbio.com/role/Equity" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensation" roleURI="http://gbio.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxes" roleURI="http://gbio.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#LicenseAgreements" roleURI="http://gbio.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingencies" roleURI="http://gbio.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NetLossPerShare" roleURI="http://gbio.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited" roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnaudited" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurementsTables" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNetTables" roleURI="http://gbio.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#AccruedExpensesTables" roleURI="http://gbio.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationTables" roleURI="http://gbio.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesTables" roleURI="http://gbio.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingenciesTables" roleURI="http://gbio.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NetLossPerShareTables" roleURI="http://gbio.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedTables" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://gbio.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://gbio.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#ConvertiblePreferredStockAdditionalInformationDetail" roleURI="http://gbio.com/role/ConvertiblePreferredStockAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#EquityAdditionalInformationDetail" roleURI="http://gbio.com/role/EquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationAdditionalInformationDetail" roleURI="http://gbio.com/role/StockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail" roleURI="http://gbio.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://gbio.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail" roleURI="http://gbio.com/role/IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail" roleURI="http://gbio.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail" roleURI="http://gbio.com/role/IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://gbio.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://gbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" roleURI="http://gbio.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail" roleURI="http://gbio.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="gbio-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail" roleURI="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail" />
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_714951" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_714952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_DocumentType_714952" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_714953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_AmendmentFlag_714953" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_714954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_DocumentFiscalYearFocus_714954" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_714955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_DocumentFiscalPeriodFocus_714955" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_714956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityInteractiveDataCurrent_714956" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_714957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityCentralIndexKey_714957" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_714958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_CurrentFiscalYearEndDate_714958" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_714959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_DocumentAnnualReport_714959" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_714961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_DocumentTransitionReport_714961" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_714962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_DocumentPeriodEndDate_714962" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_714963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityRegistrantName_714963" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_714978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_TradingSymbol_714978" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_714964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityFileNumber_714964" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_714966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityIncorporationStateCountryCode_714966" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_714967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityCurrentReportingStatus_714967" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_718898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityFilerCategory_718898" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_714969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityShellCompany_714969" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_714970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntitySmallBusiness_714970" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_714971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityEmergingGrowthCompany_714971" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_714972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityAddressAddressLine1_714972" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_714973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityAddressCityOrTown_714973" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_714974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityAddressStateOrProvince_714974" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_714975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityAddressPostalZipCode_714975" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_714976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_CityAreaCode_714976" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_714977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_LocalPhoneNumber_714977" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_714979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_SecurityExchangeName_714979" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_714980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_Security12bTitle_714980" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_715430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityExTransitionPeriod_715430" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_862039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_IcfrAuditorAttestationFlag_862039" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_863868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityVoluntaryFilers_863868" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_863875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_863875" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_863882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityPublicFloat_863882" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_714981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_714951" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_714981" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_714714" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_714714" xlink:to="loc_us-gaap_StatementTable_714715" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714715" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714716" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714716" xlink:to="loc_us-gaap_ClassOfStockDomain_714717" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714715" xlink:to="loc_us-gaap_StatementLineItems_714718" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_714719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_AssetsAbstract_714719" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_714723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_AssetsCurrentAbstract_714723" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_714741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_714741" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_714742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_714742" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_717317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_ReceivablesNetCurrent_717317" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_714744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_714744" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_714745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_RestrictedCashCurrent_714745" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_714747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_714723" xlink:to="loc_us-gaap_AssetsCurrent_714747" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_714750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_714750" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_714751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_714751" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_714753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_DeferredCosts_714753" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_714754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_714754" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_714755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_714719" xlink:to="loc_us-gaap_Assets_714755" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_714761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_714761" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_714762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_714761" xlink:to="loc_us-gaap_AccountsPayableCurrent_714762" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_714761" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717492" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_714766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_714761" xlink:to="loc_us-gaap_LiabilitiesCurrent_714766" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_714769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_714769" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_714773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_714758" xlink:to="loc_us-gaap_Liabilities_714773" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_714776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_CommitmentsAndContingencies_714776" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_714777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_714777" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_714778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714718" xlink:to="loc_us-gaap_StockholdersEquityAbstract_714778" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_714780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_PreferredStockValue_714780" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_714782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_CommonStockValue_714782" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_714783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_AdditionalPaidInCapital_714783" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_714784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_714784" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_714785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_714785" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_714786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_StockholdersEquity_714786" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_714787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_714778" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_714787" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_714827" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_714827" xlink:to="loc_us-gaap_StatementTable_714829" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714829" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714831" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714831" xlink:to="loc_us-gaap_ClassOfStockDomain_714832" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714829" xlink:to="loc_us-gaap_StatementLineItems_714843" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_715536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_715536" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_715537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_715537" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_715538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_715538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_715539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_715539" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_714844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_714844" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_714846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_714846" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_714847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockSharesIssued_714847" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_714848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_714848" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_714850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_714850" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_714852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_714852" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_714853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockSharesIssued_714853" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_714854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714843" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_714854" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_714810" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_714810" xlink:to="loc_us-gaap_StatementTable_714811" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_714812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714811" xlink:to="loc_srt_ProductOrServiceAxis_714812" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_714813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_714812" xlink:to="loc_srt_ProductsAndServicesDomain_714813" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714811" xlink:to="loc_us-gaap_StatementLineItems_714814" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_714816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_OperatingExpensesAbstract_714816" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_714818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_714816" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_714818" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_714820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_714816" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_714820" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_714822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_714816" xlink:to="loc_us-gaap_OperatingExpenses_714822" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_714863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_OperatingIncomeLoss_714863" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_714999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_714999" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_715000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_714999" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_715000" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_714855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_714855" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_714856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_714856" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_714857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_714857" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_714858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_714858" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_714859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_714858" xlink:to="loc_us-gaap_NetIncomeLoss_714859" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_714860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_714860" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_714861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_714860" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_714861" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_714862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714814" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_714862" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_714866" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_714867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_714866" xlink:to="loc_us-gaap_StatementTable_714867" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_714868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714867" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_714868" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_714869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_714868" xlink:to="loc_us-gaap_EquityComponentDomain_714869" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesABAndCPreferredStockMember" xlink:label="loc_gbio_SeriesABAndCPreferredStockMember_715597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_gbio_SeriesABAndCPreferredStockMember_715597" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_714873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_CommonStockMember_714873" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_714875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_714875" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_714877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_714877" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_714878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_714869" xlink:to="loc_us-gaap_RetainedEarningsMember_714878" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_715553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714867" xlink:to="loc_us-gaap_StatementClassOfStockAxis_715553" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715553" xlink:to="loc_us-gaap_ClassOfStockDomain_715554" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesCConvertiblePreferredStockMember" xlink:label="loc_gbio_SeriesCConvertiblePreferredStockMember_715555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_715554" xlink:to="loc_gbio_SeriesCConvertiblePreferredStockMember_715555" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_714870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_714867" xlink:to="loc_us-gaap_StatementLineItems_714870" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_715435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_715435" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_715436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_715436" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_715542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockholdersEquity_715542" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_714888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_SharesOutstanding_714888" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_759812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_759812" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715441" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_715442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_715442" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_715439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_715439" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_715440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_715440" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_715431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_715431" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_715432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_715432" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_714892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_714892" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_714893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_714893" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_714895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_714895" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_714896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_714896" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_760370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_760370" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_VestingOfRestrictedCommonStockUnits" xlink:label="loc_gbio_VestingOfRestrictedCommonStockUnits_863796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_gbio_VestingOfRestrictedCommonStockUnits_863796" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_714901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_714901" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_714904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_714904" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_714909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_ProfitLoss_714909" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_715437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_715437" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_715438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_715438" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_715543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_StockholdersEquity_715543" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_714915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_714870" xlink:to="loc_us-gaap_SharesOutstanding_714915" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_715411" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_715412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_715411" xlink:to="loc_us-gaap_StatementTable_715412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_715413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715412" xlink:to="loc_us-gaap_StatementClassOfStockAxis_715413" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715413" xlink:to="loc_us-gaap_ClassOfStockDomain_715414" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesCConvertiblePreferredStockMember" xlink:label="loc_gbio_SeriesCConvertiblePreferredStockMember_715416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_715414" xlink:to="loc_gbio_SeriesCConvertiblePreferredStockMember_715416" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_718826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715412" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_718826" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_718827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_718826" xlink:to="loc_us-gaap_EquityComponentDomain_718827" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_718828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_718827" xlink:to="loc_us-gaap_CommonStockMember_718828" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_720627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715412" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_720627" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_720627" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_720629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720628" xlink:to="loc_us-gaap_IPOMember_720629" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715412" xlink:to="loc_us-gaap_StatementLineItems_715418" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_StockIssuanceCosts" xlink:label="loc_gbio_StockIssuanceCosts_715545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715418" xlink:to="loc_gbio_StockIssuanceCosts_715545" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_715444" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_715445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_715444" xlink:to="loc_us-gaap_StatementTable_715445" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715445" xlink:to="loc_us-gaap_StatementLineItems_715446" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_715447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_715447" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_715448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_715447" xlink:to="loc_us-gaap_ProfitLoss_715448" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_715450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_ShareBasedCompensation_715450" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_715451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_715451" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_717322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_717322" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_715469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_715469" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable" xlink:label="loc_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable_717321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable_717321" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_715473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_715473" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_715474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_715474" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_715475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_715475" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_717320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_717320" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_717319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_715470" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_717319" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_715484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715449" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_715484" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_715486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_715486" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_715487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_715487" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_715488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_715488" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_715490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_715490" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_715491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_715485" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_715491" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_715493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_715493" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_715494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_715494" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_715495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_715495" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_862053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_862053" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_715496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_715496" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_715497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_715492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_715497" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_715499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_715499" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715502" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_715503" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715446" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_718824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" xlink:to="loc_us-gaap_StockIssued1_718824" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_715506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_715506" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:label="loc_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses_715507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_715504" xlink:to="loc_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses_715507" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_715274" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_715278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715274" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_715278" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_715370" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_715371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715370" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_715371" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_715332" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_715333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_715332" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_715333" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862098" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_862099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862098" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_862099" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_715302" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_717316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_715302" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_717316" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConvertiblePreferredStock">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_715262" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_715263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_715262" xlink:to="loc_us-gaap_PreferredStockTextBlock_715263" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_715250" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_715251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_715250" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_715251" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714807" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_714808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714807" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_714808" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_862274" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_862275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_862274" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_862275" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/LicenseAgreements">
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureAbstract" xlink:label="loc_gbio_LicenseAgreementsDisclosureAbstract_862389" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureTextBlock" xlink:label="loc_gbio_LicenseAgreementsDisclosureTextBlock_862390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureAbstract_862389" xlink:to="loc_gbio_LicenseAgreementsDisclosureTextBlock_862390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714708" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_714709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714708" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_714709" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_714790" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_714791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_714790" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_714791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SelectedQuarterlyFinancialDataUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_862827" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_862828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_862827" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_862828" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_715387" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_715397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_UseOfEstimates_715397" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_715403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_715403" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_862656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_862656" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_RestrictedcashpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_RestrictedcashpolicytextblockPolicyTextBlock_862657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_gbio_RestrictedcashpolicytextblockPolicyTextBlock_862657" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_862658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_862658" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_715404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_715404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DeferredrentpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_DeferredrentpolicytextblockPolicyTextBlock_862660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_gbio_DeferredrentpolicytextblockPolicyTextBlock_862660" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_862661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_862661" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_862669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_862669" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock_862672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock_862672" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_862675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_862675" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_862676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_862676" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock" xlink:label="loc_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock_862681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock_862681" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PatentcostpolicytextblockPolicyTextBlock" xlink:label="loc_gbio_PatentcostpolicytextblockPolicyTextBlock_862684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_gbio_PatentcostpolicytextblockPolicyTextBlock_862684" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_862690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_862690" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock" xlink:label="loc_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock_862691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock_862691" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_862693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_862693" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_862695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_862695" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_715406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715387" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_715406" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_862726" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock" xlink:label="loc_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock_862727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_862726" xlink:to="loc_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock_862727" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_715335" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_715336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_715335" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_715336" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_715337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_715335" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_715337" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862107" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_862108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862107" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_862108" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_715315" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_717314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_715315" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_717314" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714874" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_862147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_862147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_862148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714874" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_862148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_862149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714874" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_862149" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_714876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714874" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_714876" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_862279" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_862281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_862279" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_862281" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_862282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_862279" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_862282" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_862283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_862279" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_862283" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714711" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_714712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714711" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_714712" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_714793" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_714794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_714793" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_714794" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_862831" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock" xlink:label="loc_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock_863787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_862831" xlink:to="loc_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock_863787" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_715338" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_715341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_715338" xlink:to="loc_us-gaap_StatementTable_715341" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_715342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_715342" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_715343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_715342" xlink:to="loc_us-gaap_EquityComponentDomain_715343" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_715344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_715343" xlink:to="loc_us-gaap_CommonStockMember_715344" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_715345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_715345" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_715345" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_715347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" xlink:to="loc_us-gaap_IPOMember_715347" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_715348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_715346" xlink:to="loc_us-gaap_OverAllotmentOptionMember_715348" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_717442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_717442" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_717443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_717442" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_717443" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_862055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_862055" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862055" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862056" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_862057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_862056" xlink:to="loc_us-gaap_SubsequentEventMember_862057" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715341" xlink:to="loc_us-gaap_StatementLineItems_715349" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_715350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_715350" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_715351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_715351" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_715355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_715355" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_720809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_720809" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_715361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_NetIncomeLoss_715361" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_715362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715349" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_715362" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862769" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862769" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862770" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862771" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862771" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LaboratoryEquipmentMember" xlink:label="loc_gbio_LaboratoryEquipmentMember_862773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_gbio_LaboratoryEquipmentMember_862773" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ComputerEquipmentAndSoftwareMember" xlink:label="loc_gbio_ComputerEquipmentAndSoftwareMember_862774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_gbio_ComputerEquipmentAndSoftwareMember_862774" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_862775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_862775" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_862776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862772" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_862776" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862770" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_862779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_862779" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_862780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862778" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_862780" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_862784" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccountingPoliciesTable" xlink:label="loc_gbio_AccountingPoliciesTable_862786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_862784" xlink:to="loc_gbio_AccountingPoliciesTable_862786" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_862787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccountingPoliciesTable_862786" xlink:to="loc_us-gaap_StatementClassOfStockAxis_862787" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_862788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_862787" xlink:to="loc_us-gaap_ClassOfStockDomain_862788" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccountingPoliciesLineItems" xlink:label="loc_gbio_AccountingPoliciesLineItems_862791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccountingPoliciesTable_862786" xlink:to="loc_gbio_AccountingPoliciesLineItems_862791" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_862793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_862793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_862795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_862795" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_862796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_OperatingLeaseLiability_862796" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_863985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccountingPoliciesLineItems_862791" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_863985" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_715352" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable_715353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_715352" xlink:to="loc_us-gaap_MarketableSecuritiesTable_715353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_715353" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715650" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715650" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_715652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_715651" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_715652" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_715363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_715353" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_715363" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_715363" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_715365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_715365" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_715367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" xlink:to="loc_us-gaap_CommercialPaperMember_715367" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_715368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715364" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_715368" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_715354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_715353" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_715354" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_715357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_715357" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715358" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_715359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_715359" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_715354" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715360" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_715372" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_715372" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715381" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_715381" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_715383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_715382" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_715383" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_715384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_715384" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_715384" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_715386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_MoneyMarketFundsMember_715386" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_715388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_715388" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_715390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_CommercialPaperMember_715390" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_715391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_715385" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_715391" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_715392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_715392" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_715392" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_715394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_715394" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_715395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_715393" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_715395" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_715373" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_715376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_715376" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_715377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_715376" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_715377" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_715378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" xlink:to="loc_us-gaap_MarketableSecuritiesAbstract_715378" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_715378" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_715379" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_764696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_715374" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_764696" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862111" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_862111" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862113" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862114" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_862114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LaboratoryEquipmentMember" xlink:label="loc_gbio_LaboratoryEquipmentMember_862117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_gbio_LaboratoryEquipmentMember_862117" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ComputerEquipmentAndSoftwareMember" xlink:label="loc_gbio_ComputerEquipmentAndSoftwareMember_862118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_gbio_ComputerEquipmentAndSoftwareMember_862118" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_862119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_862119" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_862120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_862120" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_862121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_862116" xlink:to="loc_us-gaap_ConstructionInProgressMember_862121" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_862113" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_862124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_862124" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_862125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_862125" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_862126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_862123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_862126" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_862129" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_862130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_862129" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_862130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_715320" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccruedExpensesTable" xlink:label="loc_gbio_AccruedExpensesTable_715323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_715320" xlink:to="loc_gbio_AccruedExpensesTable_715323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccruedExpensesLineItems" xlink:label="loc_gbio_AccruedExpensesLineItems_715324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccruedExpensesTable_715323" xlink:to="loc_gbio_AccruedExpensesLineItems_715324" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_715325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_715325" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:label="loc_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent_715326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent_715326" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_715327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_715327" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_715328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_715328" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_715329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_715329" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_AccruedExpensesLineItems_715324" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_717493" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/ConvertiblePreferredStockAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_715267" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_715267" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_715271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" xlink:to="loc_us-gaap_StatementClassOfStockAxis_715271" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_715271" xlink:to="loc_us-gaap_ClassOfStockDomain_715272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_SeriesCConvertiblePreferredStockMember" xlink:label="loc_gbio_SeriesCConvertiblePreferredStockMember_715273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_715272" xlink:to="loc_gbio_SeriesCConvertiblePreferredStockMember_715273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_715292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_715292" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_715293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_715292" xlink:to="loc_us-gaap_EquityComponentDomain_715293" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_715294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_715293" xlink:to="loc_us-gaap_CommonStockMember_715294" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_715270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_715269" xlink:to="loc_us-gaap_TemporaryEquityLineItems_715270" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_715275" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_715276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_715276" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock_717326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock_717326" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_StockIssuanceCosts" xlink:label="loc_gbio_StockIssuanceCosts_715279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_gbio_StockIssuanceCosts_715279" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_715281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_715270" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_715281" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/EquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_715253" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_715255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_715253" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_715255" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_715256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_715253" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_715256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_715257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_715253" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_715257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_715258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_715253" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_715258" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714819" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714819" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714840" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_714841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714840" xlink:to="loc_us-gaap_ClassOfStockDomain_714841" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_714842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_714841" xlink:to="loc_us-gaap_CommonStockMember_714842" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_714834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_PlanNameAxis_714834" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_714835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_714834" xlink:to="loc_us-gaap_PlanNameDomain_714835" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TwoThousandAndSeventeenStockIncentivePlanMember" xlink:label="loc_gbio_TwoThousandAndSeventeenStockIncentivePlanMember_714836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_714835" xlink:to="loc_gbio_TwoThousandAndSeventeenStockIncentivePlanMember_714836" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TwoThousandAndTwentyStockIncentivePlanMember" xlink:label="loc_gbio_TwoThousandAndTwentyStockIncentivePlanMember_714925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_714835" xlink:to="loc_gbio_TwoThousandAndTwentyStockIncentivePlanMember_714925" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember" xlink:label="loc_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember_714926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_714835" xlink:to="loc_gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember_714926" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_714993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_AwardTypeAxis_714993" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_714993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember" xlink:label="loc_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember_714995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" xlink:to="loc_gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember_714995" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ServiceBasedOptionsMember" xlink:label="loc_gbio_ServiceBasedOptionsMember_718835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" xlink:to="loc_gbio_ServiceBasedOptionsMember_718835" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_862264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_714994" xlink:to="loc_us-gaap_RestrictedStockMember_862264" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_717417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_srt_RangeAxis_717417" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_717418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_717417" xlink:to="loc_srt_RangeMember_717418" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_717419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_717418" xlink:to="loc_srt_MaximumMember_717419" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_717423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_srt_TitleOfIndividualAxis_717423" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_717424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_717423" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_717424" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DateAxis" xlink:label="loc_gbio_DateAxis_715656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_gbio_DateAxis_715656" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DateDomain" xlink:label="loc_gbio_DateDomain_715657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DateAxis_715656" xlink:to="loc_gbio_DateDomain_715657" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AdditionalFrom2017PlanMember" xlink:label="loc_gbio_AdditionalFrom2017PlanMember_717421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DateDomain_715657" xlink:to="loc_gbio_AdditionalFrom2017PlanMember_717421" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_AnnualIncrease2021To2030Member" xlink:label="loc_gbio_AnnualIncrease2021To2030Member_717422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DateDomain_715657" xlink:to="loc_gbio_AnnualIncrease2021To2030Member_717422" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_862803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_862803" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862803" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862804" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_862805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_862804" xlink:to="loc_us-gaap_SubsequentEventMember_862805" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_865438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_865438" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_865439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_865438" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_865439" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_865440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_865439" xlink:to="loc_us-gaap_StockOptionMember_865440" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_714821" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_714825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_714825" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_714921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_714921" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage" xlink:label="loc_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage_717420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage_717420" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_714919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_714919" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_714920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_714920" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714916" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_714922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_714922" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_718326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_718326" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_714996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_714996" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_714997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_714997" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_862249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_862249" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_862251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_862251" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_862263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_CommonStockValueOutstanding_862263" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_714824" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862801" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862182" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_862183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862182" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_862183" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_862184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862182" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_862184" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_862185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862182" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_862185" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_862189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_862189" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_862190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_862190" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_862191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_862191" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_862192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_862192" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_862193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_862193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_862195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_862195" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_862196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_862196" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_862197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_862197" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862200" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_862201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_862201" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_862202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_862202" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_862205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_862205" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_862210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_862210" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_862211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_862211" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_862216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_862216" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_862219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_862219" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_862221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_862221" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_862222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_862222" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_862224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_862224" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_862225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_862225" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_862241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_862241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_862242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_862242" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_862243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_862243" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_862244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_862244" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_862245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_862245" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_862246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_862246" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_862247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_862247" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_862248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_862237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_862248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714880" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_714881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714880" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_714881" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_714883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_714881" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_714883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_714884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_714883" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_714884" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_714885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_714884" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_714885" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_714887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_714884" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_714887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_714882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_714881" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_714882" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_714891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_714882" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_714891" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_862337" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_IncometaxTable" xlink:label="loc_gbio_IncometaxTable_862339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_862337" xlink:to="loc_gbio_IncometaxTable_862339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_862340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxTable_862339" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_862340" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_862341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_862340" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_862341" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_FederalIncomeTaxAuthorityMember" xlink:label="loc_gbio_FederalIncomeTaxAuthorityMember_862342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_862341" xlink:to="loc_gbio_FederalIncomeTaxAuthorityMember_862342" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_862343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_862341" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_862343" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember" xlink:label="loc_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember_862346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_862341" xlink:to="loc_gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember_862346" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_IncometaxLineItems" xlink:label="loc_gbio_IncometaxLineItems_862348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxTable_862339" xlink:to="loc_gbio_IncometaxLineItems_862348" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_862349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_us-gaap_OperatingLossCarryforwards_862349" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PercentageOnAnnualTaxableIncome" xlink:label="loc_gbio_PercentageOnAnnualTaxableIncome_862351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_PercentageOnAnnualTaxableIncome_862351" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_862352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_862352" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PercentageOfChangeInOwnership" xlink:label="loc_gbio_PercentageOfChangeInOwnership_862358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_PercentageOfChangeInOwnership_862358" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate" xlink:label="loc_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate_862353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate_862353" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TaxCreditCarryforwardExpirationYear" xlink:label="loc_gbio_TaxCreditCarryforwardExpirationYear_862354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_TaxCreditCarryforwardExpirationYear_862354" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_gbio_OperatingLossCarryforwardsExpirationYear_862355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_gbio_OperatingLossCarryforwardsExpirationYear_862355" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_865717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_IncometaxLineItems_862348" xlink:to="loc_us-gaap_OperatingIncomeLoss_865717" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="loc_us-gaap_ValuationAllowanceAbstract_862318" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_862319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_862318" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_862319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_862322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_862318" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_862322" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_862324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_862318" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_862324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_862300" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_862301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_862300" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_862301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_862302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_862301" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_862302" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_862303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_862301" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_862303" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_862304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_862301" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_862304" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_862306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_862301" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_862306" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_862307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_862301" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_862307" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_862309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_862300" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_862309" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_862311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_862309" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_862311" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_862312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_862309" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_862312" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_863977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_862309" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_863977" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_862286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_862286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_862288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_862288" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_862289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_862289" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_862291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_862291" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_862292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_862292" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_862293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_862293" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_862294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_862285" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_862294" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureAbstract" xlink:label="loc_gbio_LicenseAgreementsDisclosureAbstract_862392" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureTable" xlink:label="loc_gbio_LicenseAgreementsDisclosureTable_862393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureAbstract_862392" xlink:to="loc_gbio_LicenseAgreementsDisclosureTable_862393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_862395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureTable_862393" xlink:to="loc_dei_LegalEntityAxis_862395" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_862396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_862395" xlink:to="loc_dei_EntityDomain_862396" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_NihMember" xlink:label="loc_gbio_NihMember_862400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_862396" xlink:to="loc_gbio_NihMember_862400" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_UmassMember" xlink:label="loc_gbio_UmassMember_862401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_862396" xlink:to="loc_gbio_UmassMember_862401" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_862402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureTable_862393" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_862402" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_862402" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_862404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_862403" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_862404" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LicenseAgreementsDisclosureLineItems" xlink:label="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureTable_862393" xlink:to="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_FutureMilestoneObligation" xlink:label="loc_gbio_FutureMilestoneObligation_862405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_gbio_FutureMilestoneObligation_862405" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_PercentageOfIncreaseDecreaseInNetSales" xlink:label="loc_gbio_PercentageOfIncreaseDecreaseInNetSales_862406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_gbio_PercentageOfIncreaseDecreaseInNetSales_862406" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_862407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_862407" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_862408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_862408" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_862409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_LicenseAgreementsDisclosureLineItems_862394" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_862409" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714748" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DisclosureOfCommitementAndContingenciesTable" xlink:label="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714748" xlink:to="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_714770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" xlink:to="loc_srt_RangeAxis_714770" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_714771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_714770" xlink:to="loc_srt_RangeMember_714771" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:label="loc_us-gaap_MajorPropertyClassAxis_714774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" xlink:to="loc_us-gaap_MajorPropertyClassAxis_714774" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:label="loc_us-gaap_MajorPropertyClassDomain_714779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorPropertyClassAxis_714774" xlink:to="loc_us-gaap_MajorPropertyClassDomain_714779" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_DisclosureOfCommitementAndContingenciesLineItems" xlink:label="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesTable_714749" xlink:to="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LesseeOperatingLeaseYearOfExpiry" xlink:label="loc_gbio_LesseeOperatingLeaseYearOfExpiry_714756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_gbio_LesseeOperatingLeaseYearOfExpiry_714756" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_717414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_717414" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_TenantImprovementAllowanceMaximum" xlink:label="loc_gbio_TenantImprovementAllowanceMaximum_717415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_gbio_TenantImprovementAllowanceMaximum_717415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="gbio-20201231.xsd#gbio_LetterOfCreditForSecurityDeposit" xlink:label="loc_gbio_LetterOfCreditForSecurityDeposit_717416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_gbio_LetterOfCreditForSecurityDeposit_717416" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_714768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_LeaseAndRentalExpense_714768" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_718501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_718501" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_767113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gbio_DisclosureOfCommitementAndContingenciesLineItems_714752" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_767113" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_714724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_714724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_714728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_714728" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_714729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_714729" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_714730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_714730" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_714733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_714733" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_714738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_714738" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_714740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714721" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_714740" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_714797" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_714798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_714797" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_714798" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_714801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_714798" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_714801" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_714801" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_714803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_714803" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_714804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_RestrictedStockMember_714804" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_862814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_862814" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_714805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_714802" xlink:to="loc_us-gaap_EmployeeStockOptionMember_714805" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_714798" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714799" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_714800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_714799" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_714800" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_862836" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_862837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_862836" xlink:to="loc_us-gaap_OperatingExpenses_862837" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_862838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_862836" xlink:to="loc_us-gaap_OperatingIncomeLoss_862838" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_862839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_862836" xlink:to="loc_us-gaap_NetIncomeLoss_862839" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_862840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_862836" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_862840" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g108483g02c06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g02c06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &-*^8U0X0DE-! 0      $4< 5H  QLE1QP"   "('@< E  %4UI8W)O
M<V]F="!/9F9I8V4@57-E<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX
M.$))300E       0]]%OU.<,5KE=:2M"S384G#A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!E;.5@        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              7@   )T
M  $                          0             "=    7@
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7@     4F=H
M=&QO;F<   )T    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %X     %)G:'1L;VYG   "=     -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 8 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M         0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I))))2DDDDE*22224I))0>YP(
M#8UG4_!)2V[<[:#&DJ-EE=9BRYK(:Y\.('L9'J6:GZ%>]F]RA6XC)(<1&P^7
M<>*!U#IN)GO8^ZPMV-=7#2W5EA;ZU;MP=^CN8ST[$A751OHW&@N <UX+2)!&
MH(*9A#YV6!VTEKH@P1RTQ^<LMW0J72/MCX@M;]&0UPMW-']9^0__ *WZ=2+1
MTC%IR&Y'KND ^QKMC02[?^B;4YFQGYKJ_P!)_@_W$:'=%GLZ :XB0^0>#"1:
M0)+P!YA9#>@8]; VO)@UUMKI;#6L::Z[*:7EE>S^;=;ZW_&J./T"AM;/6O:;
M&!L :L:6.]3<QKSLW._>]/\ G]]U/H_S2-1[_@JSV=D-+@"'R#J" FK<VP$U
MVM> 8);!U';193NB5LR,:RF\%M5GJW"TSO<'&QEGLV_I6-=Z3?\ K7^#K]&Y
MK>AAU];J\D>D/5+@^'$&P;=U3?YO_._Z?YBH=U6>SK/]C'/?8&L:"7.,  #D
MDIW2P23*R7_5[#=3Z1R7DD!KW.+7;@U@I9OW#Z=3?=0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ TP%@ P$1  (1 0,1 ?_$ !X
M 0 " @,! 0$            '" 4& P0) @H!_\0 7!    8"  (#!P<9!@0$
M!P   0(#! 4&  <($1(3(0D4%18Q4=$B-D%6=9&A&!DT-5-45UAA<7-V@9.4
MEI>RM;;"TM/5UA<C)#)"L295HL$E,T748I*5L^'P\?_$ !P! 0 " P$! 0
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MBX57<GBIL5MEW/<[#8;GN=N_?.EUL.OQ<5WZCC7J =]@.;"I=#-LH"CD=SL
M -^V4(E>*O:U:UCK6IZ\FX?7EEN-?XNK37TJ=0JI(!/;"H^]I2HZ[J\A'615
MO7:_5+&[D'#BW6,ADG@/B&>NI*';K+N5N@72:DENS-91[,4,ND0R=:Q,ICKS
MT%ELRJT6\DDL2H.E'W&W8*YV Y;X<O14:,%1TJ2SPZ[8C6K5A826:^IO!5A=
M92(H:\S.QL3CU^>[ED&Y,TW;BBVW2=D:U@F%UE;>I![2X;M+;LB5*CJZ)H+*
MS[?&F-Y]!.<7L<?L.<M98^W(VF'=4"!>TYBB+5C)(*H(2KEO!KZ54GK67:!(
M1)4U*[1DZUIK#Q4^N8STQ&U=(N4)BD6Q(LS;%E()4&SL:U?KW*<2V6G,=W2-
M/U*/H4DK++?]'$H67K+:EGXS=6-JT35T4@." S#*U?B#XA$96D[ F[C!6*F6
M[BTWSP[!K%E2&$>LA6Z.3=C^KSR-G1=JRSJU(K:M9Q:J?5HP[R.DS"K'C))&
M?+>)=.T[C/72&2.:'2*&H^E-.S RS^@K+&8BH01$6F?<DLK+V8*>(V0ZKJHD
MK6I+$4U>QKFHZ4*:UE0B&N-0>&03!BYF!IA/((R-W4ON^:;HG9%\VUOO@CV?
M>=HU.U.]I:&WIL,FNX2#B8IWK!:<8:R4<5]NZ9/U963B(PQP@G"]D:'E0G(I
M^<SXI53QS/?J%6O3H:W5@J31+5OT:WI+R.ZVN#60)"&4(KMMU (FX<& X]N1
MC:;<LWM5\-W+-V"=KNG:E;%6*)(S3ZD5?>$%7:1T3?IDS#F)$8\CR*K[ YQV
M=_D,WEV*-PCT>8<C0S4_EY<A%])%[>WEV]$.7L]@^QSQ@]AOW.Q\A_'ZA]7L
MVR9L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S08Z/
M5EV+Y\ZEYP%1G[.U C>26;H)MX^S2L>T2312 J9"HM&J"?, Z1A*)SB8YC&&
MLK1-82222>SR]+O( DS(H2&[8BC5578 +&BKY;G;<DDDF'"AD#NTLVYFL+L)
M&50L=B1% 4; ;*H'U^9[G- N<01!JN<)>?'D!@]5+N!#D ]G2 1#F':':(=G
MLY(]#7YQ;^\R?MS<(1_WDOG[9#_GFPZ6+T:@X#KG"_\ X])?WCE8RZO:FTY!
MTS]O1#V [ #F/+RYOCC$:\0\C]R=Y'+MWV[<F[[=NP_+FQ5XC8%CW\V/(_KR
M7,V9ZS4)77]$G4[(E-TRK2Z5Q1C6]M3DX"+?)V9"&^5"4^1RU5++IQ?_ *<1
M^"Y60]K<$QS<EBQ&8C'/*A@+F$I(ZF(O^/TR""G/^EQVY>W?(\E6M*)A+7@D
M%@(+ >)&$PC[1B4,IZ@3^ARWX_T=L^Y6A4>=\8O#=/K$QXW1+&!M02<%&/PL
ML'&&>GC8B=!TV5"6C6!Y&0.R9/NO;-3/71D4R"NJ)B6)X^GTYI4Z+M)%PD=>
MD[;!GCV(X,P50S+L3L-SVQ)4JR];JUX9.NBQ3\XD;K1IRX))R4\T3F_%6W"E
MF( W.:4MP]:%<005=?2^K%:V#YE*! GH57&(\)1T>$2QD/!_@SO7OUK%E"-1
M==5UY& F: ?O<QDQW#4;XDZHNVQ)Q9.IZ1+SXLW-EY<]^+/ZQ&^Q;OYY'.DZ
M68NB=.I&+FLG3]&AX=14X*_'AMR5/4#;;A>WEFPR6IM6S,]6[3+ZXHLG9:<@
MT:U*P/ZI!.YFLMF"@K,&\#)+L5'D2@Q6$5F23%9!-HL(JMRIJ")LUK;M)')$
MEF=8YB3-&LTBI*6[,9%#!7+#LQ8$D=COFYZ-*26&>2G6>:N%6"5X(FDA5#N@
MB<J60(>Z!2 I[KL<Z,UI33MD@(JJV#5>O)NLP3U[)0D!*TZOOH>(D))TN^DG
ML9'.8]1HP=2+QTY<OUFJ22CQ9RN=R94RR@F])>NQR/+';LI+(H621)I%=U4
M*'8,"P4 !02=@!MMGB33=/FB2"6C4DAB9FCB>O$R1L[%W9%*D(78EF*@<B23
MOOF^!"PY8<M>+%1I8 L:$,6$!BV"(+$%:@R+%%C@2[S".*S &@,@1[V!L (
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M]&R?;5OW^5G\Y7@CZ=B^YZC_ +/'QT_A&^F;C?Q2OG]$X^*?B'Z-D^VK?O\
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MW6.X2:$27@:TDH=VN3K$6I"*-2F,X63_ +Q)$ %10GJB%$O;CTNU\XF^T?\
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M!;M'_P"XF]O_ -1O8=O?@:90/_V57[M!_E'D_$U7K=0A%$Z%2E$U"E.0Y*O
MF(<A@ Q3D,5D)3%,40$I@$0$! 0$0''I=KYQ-]H_[<?!FG_,JOW>#]WE#NZ5
MZ4U?\1SN*X(4*KQMKU]",+=3;-$0D=$3U=GXR=B^]GT9+1S=L^;#T%E4EDB+
M=2L1004(8Q2&)T'A>];^&J4)L2M#8=H9XG=GCDC>-^2NC$J?(;$C<'.)_E"T
MC3?BIJEM:=>.U0CBM4[$4,<<]>9+$0#QRHBNNX8A@#L0=R-P"+VZO,ZF=::[
MEY)0[N1E:-4I)^Z4 !4<O7T!'NG3A0?9.LNJHH<?9,81RAM_@[5F-/51+$R*
M !L%61E4?H  SM-,+3:;I\TC,\DM*K)(YVW9Y((W9CV\V8DGZSF\^#R?,_\
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MSV]6];PKZMZ[H5=DR%3DH&EU:%D$R& Y"/HN#8L79"G*(E.4JZ"A2F*(@8
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M,#WVIV7WH'^?8])D^96__+?[G'7;YM8_5%^^QXP/?:G9?>@?Y]CTF3YE;_\
M+?[G'7;YM8_5%^^SHU)8R]>76.W7:F4LER,9NYZKKT1&YSWJ%>H571Z8>SU:
MRA?,8<UZ:Q:LS%60FYJ1*/QY+_\ $;79N+,N_P"1B/KSS4/*$DJR[V+9XMMR
M'_:YNQV)&_Y"<Q%H^1'7V,W[.3\E9S:R];SCW8?_ )J&,9(F,9_! ! 0'R#C
M&=%]%Q\D@9M(-&[QL<! Z#E%-=(P#Y0%-0AB_=Y<_JYZC9XF#Q.T;CN&1BI!
M\]QL1[AGB6*.92DR)*C>:R*K@_EY _5^K.E$UJ"@"*D@XIA%%6-TUBLFJ+<J
MIO8%7JR%$_+_ $](1 /8Y<\]S6+-@@V+$DY4; R,6('N!).V:J]2K44K6KQ0
M*W=A$BIOMY;[ ;[>S,YFK)&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&0S
M=?7O&^XK3](R6,9,V,93WC9.^8:>":AZ&WNTM'3\>1$RK9^Z&O-'15N^Y<6\
M8NW=N$#'1;,5D>F+;FZ36<D,1$,XCQZA^!!-'IRZA-%9B"%EE8UD<-SFXPLD
MC*>*QLNY0EU9P0H&<YXH##3>HE06Y(YDX[AVZ(8'E+QC978=@I&_'<AF!"]M
M:TE*;EL%;HEOFZA1=:UY%%HK* K&1%;7=135SWNHJF+@E@E4C/F:(KII+-ZT
M<QU2D(Y*AT':L?09-9GJT+LU'3=(JJJ-,.C#3+Q*Q0L.8L3+SB7F RU221M)
MP]=M>EOJ$L%2S-6JT(@H,BF..N2BL5W!;K2*&0;A66 ]QLQ!Y&\Q3%.4IRB!
MBF #%,40$IBF#F @(=@@(" @(=@AVYW_ )^6=/Y^65YV/Q-:YU?=$*586ML=
M.$6]7>VB>@ZZXE*S0F-VGE*S4GMSE$U2#&-YZ;259M#-F[\Z()F<O2-6@ N,
M*>_!7E$3B0D"-I'1.4<*S.8XC*V^ZAW! V#;;;ML-B:JWK%2G8%:43LP$#32
M10M)#56U*8*S677Y,32AD7B'VV+.$3ULL/DW+7&,8QC,5-3L/7(:6L,[),XJ
M$@8]Y*S,H]7309QL='MU'3UX[6.($11;-TE%53G$ *0@CGEW6-6=V"HBEF9C
ML%51N23[  -R<\22)%&\LKK''&C22.Y"JB("S,S'L%5022>P WSPEW9L:S<8
MO$'PW!6PM>FM53]PN>KJ_=81\NSVK>*U8ZNO-VA1Q$)IJMZ'#OHVN0\C%-;(
M!)N6J=D;6I@S.V3.FWY"U/)JEVAT^I5K/++725&(LS1O$9)-T *PHR1HR"0\
MWBD$JC8;9\QU.W8\0:KH9KM8TRA/9MT(K,3LFHVX)ZCV9STN)6G"Z5(7CZ_X
M>6O.+"(NPSW&IU2KNN:;7*566I(JKTV C8"&:G5$Q6<1#,DF;4BKA41,H8C=
M IEG"IA.H?IJJ&$QC#G61QQUX4C0!(H8PJ[G8*B+L-R?8 .Y/Y3GTJO!#3KP
MUH%$<%:&.&)-^R11($0;D[^JJC<D[^TG*,;_ +3L2AT>Y3UATU3;;&R+I1 )
ME"/8F(W:2C@Z;1^\EX282FG1VQ3(_P"(/"1*@+F(H:0$P\S?.?$D^H4=/O6;
M6A4+D4C%182*/U(YF(61YZ\XLOP7CLYKP$,58R^_F-8FM5:EJ6;3*UF-R5,H
M1.RR,0KO)%()FX[CUNE$02/7W'+.'A@B)^.UU7+]!:M4E*U8IJ6LCJHMY=%E
M:H"R"B^K[R=K"]F?QD=/56P,U%G"D/.2[-Y&NG3UQ'KR;=9!).P\)Q+-H]"^
MNFE.4DDPB,A$R2I'+2ZT33,G5@EKDJJ3-NJDE2XXG.NT!]*US1=,ENJND:I6
MB6"*U+'8FJ7*]9&IUC9,*36HY8:H%>&4031R5TB20(8Q*T_%A[/+1[ZJ436#
M[63">73//7"[/:T_<1:"(D%%2KP$18+6J_F&/1#P*24&*@8A8J;P@/ 2[Q7Z
M&*A%%')7J415BG=7FDG*2<3&5,?3C,DQY1$ P*Q2*(@,@[;9;U--T'2^4\]J
MKJ7%DDCTZE'=,=B6,\HA;LW*]80U4(')*XEE(]2,0[]59_KL#&U:!AZW#HF0
MBH*-9Q3!(YS*J%:L4"-T155.(G56,4@'65.(G55,=0XB8PCEO'&L4:1H-E10
MJCS.RC8;GVGWGVG*^U9EN6)[4[!IK$KS2L  "\C%FV4=E7<[*H[ ; =AF30;
MMVQ#)MD$6Y#JJK&(@D1(AEEU#*K*F*F4H"JLJ8RBJ@@)E%#&.<1,(B.554&R
M*J@EF(4!068EF;8 #=F)+'S)))[G(X55!"J%!))   ))W).WM)))/F3W.:5L
M.5G(F#;+5\KH\BYFXEB5-BE'JO%$'3CH+)MPE2FCR*'*'1!1R'0( B("!N65
MVK3V8*R-4$AF>S!$%B$)D97;9E3K@Q!B.W)QL/>,BW9)8XE,(8NTL:;((RQ#
M-L0O5_!@[>UNPR&(C9-ND(:R.%94595A&TX\>W8-(%N1=>5@JHYF#H1DHBG,
M'<DDI*4*0SE,L:T.'>[GJCH"F7GH-7ORU[CF?E8CAT\PQQ)50%IZM)[#)#,!
M9YB::8#JKT8R.+[%"HJH;]F2*PS/O)''5Z8185#-)!5>4B.3:4L)))0.0$:[
M%6V*]MR2O5BK9;4G:Q3<R,766TQ7X0/!Q9F7<NY>VH,6 %C1,V>2CEFQ@FSQ
M*,!9H@Z4,=$ (J(FL!J=NF+PO;/+!22Q4K?@18G=Y]06.+:'\').\<55)!#R
MC20DKL&.\D7)X%L^D@-)%766&$<.K*SR6@D>R'B\C+'"K"/=0Q)7L<QM5O5C
MD'S*#M,T$$O%EG6TG+JPI(;P[*M9*./#MDF\ZR(FR!S79-J_6:(MDG;IPHJ+
M-1-!FN4^FCJ=N62*M=L>C/"+23V&KBOZ3/'-"U=%2S&!&9*<R2M&L:R.Y8QD
M+&PSQ5N6'=(;,O2:/KK)(8NCUI%DC,*A9E''G7E20JJAG8MPV5&&;YK2P/K%
M!J/9-^=W( Y73<('/"<FH)NG*:94V\2 .6I#$3* )RH \$4Q-T0 1$UIHUJ2
MW5,LTIDEYNKJ36V39W  2 !D! VXS[2=NX\]YM"9YXB\C%GY,&!,/J[,P&RQ
M>LNX'E)ZW;?MOF9K?RE>?;/<_P!<Y[)-#Y"3\]U+_$;6;:OR;?G%O^]S9@K1
M\B.OL9OV<FY(SFUEZWG'NP__ #4,8R1,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8R&;KZ]XWW%:?I&2QC)FQC,)964G(UV=CX5Z$;+O8B0
M:QD@)>D#)^X:*I-'0AY?[E<Q%.8 (EZ/2 !$ #(UR.::I9BKR=&>2"9(92-^
MG*T;+&_M_%<AO([;;COFJ=))()DB?IRO&ZQR;;\'92%;]!(.><=0DZUKRPS%
M+WKLUQ(6]NNV=Q5,C95::?$,LF+@3*S3A-5M!+OR*I.!(E)Q#M!H07CQVW:F
M 1^5Z<(-,L3TO$FKO-=5XW@T^&=K$H)4ON;#AEK-("KCA/7D5!U)9%0YQ-+I
MTYIJVKZ@TEGFK1U8Y6E=>0Y<C*P*Q-("#LKQ.J[,S!2,OMK2U+6^LH2BL ]K
MR155&K%L]5<. <L$ *5HZ0>.T&RSTBB/1 [HB:C554#BT>/V_0=J_2]*N&[4
M28UI*R[E(TD+MRB4#INLCJK2*R[;N 49@>#R)L[=C3G-B!9#$T(W*JK%FW5?
MQ6#,JE@1MZVQ4G<JSC9CY[<1EEI%6V7Q4-[_ %5E?6EKU!PU1\#K5W:G-.?[
M"D3[(N$4T8P4M'G),E7C9M_%O%UX9-PY;&03 Y2@J # O20Q6=0ZR+*):NGB
M.!I3"9F](F4*C+Z^ZN58E 2.V_GG*:O+6@NZX+4"VA8T[0XX:;6#6>W(;UR)
M$BE0]0&.:2)F>(%DW4[=QO7_ &;PF\53TYY9A1YV1U<Y923=MPWU_BOO4P-9
MGEH!^Q0MXV.V%A"6-LXF%XR3\53S9&,2I#&5:E=A+O&Z,.?3M1/K"%VK$,!0
M34IF*.48=3J2<.H&8J1&7"IQ.V_(@5EO0]<+]7T:::@R,HT2'Q#<8P3=-U])
M](L"#TA7=HSZ,TR1P=+J1B1Y748TO#'Q^FILHTA)*PUG3Z]QBY<.&Q?>2KK8
MCNL-5DS2<+&;<[U=N("&?,RF:FIJ=MZIPN(O2S<=S%BIX^#]9Z3!'D2J9E;T
M W#U^D".2+:(8JA&X,/5(/9@Z_BG5\"^*N@PCDFATTV8I#HC:LS7G@4J9(TU
M7@[P1.HX^AK8[G=EN0J3$<?2^#SCEF(&T1E"MUIX7JN^JJ48^I]KVW*; 7O,
MZF]*NNI&JQS^>=:S0>-R%;NK%"38R*Q>FV+$"@X<.!Q'I>KNL@@EETZ)HP#%
M)9,QE<-N>/%I#7W'G(C[D'8KMN<\P^'_ !-+'.E*S9T"NT"H]>SJ+Z@UJ4/N
MW3*23-IP9?5-BO8:1AVZ(_'&6JW<W]E['L01-]@B\.>M0-8TKL.NMUV>^VO:
M#)]).G4-"B$HF%?1@VZ:C0LF]N,//24D@Q30+',U'3E8OJ/0K$[\94] @_"=
M4U[<D\MA68E4/("/@ 0&,R2,P4; $L3L3PA;OR+%9A^!*7X86Q1U:U<L:@CL
MQ2%^HJ5Q#W4RM:ALR2*O3"IR9AZ'Z)X*M?:2M;6^N[??=KW>'@?%6IV+9+V"
M>*4JL])T4(BK,("!@6$>4S1T:-,[50<O$HLA(IDLSBP[RR[IZ5!4D$QEFLS(
MG3CDL%"88^_J1+&D:J"#Q)V)X^J"$ 7.KTWP[5TZP+;V;FH6HX?1X)[SPL:T
M!WWBKQUX*\2 [\2YC:3@!&'$8"Y.FV+FSJ$&U"3AY62B9IT,9*NHURK'>"F*
MR8E4=&E/[IJU<"<Z96J3Q]&IN^2R23L7 (MG'C6+L=.NHF@FE@G8PS/%(83%
M&RD%^L.*H^Y 0/)"')(5RVR-9WK"01 2([1RMTW9&*%%([MU.RJVY'$,\8;N
M Q;932>PN9"YVJ,K'#SM()0[!+ON=J)Y0M=E899%R1,RTG#*IQC)XBVZSJ'Z
M+6,*X;J%Z$HDNJLBH;YW<6U<N0U/"VL&41@R6:1G6I/79& +2UR((Y$7EQD2
M.#FK "97+*<Y.RLUFQ%!HFH!PAYSU>H()(F5@"TD)$:%5_%=5C#*>TBDLIST
MA8I*H,FB+@4C+I-D$US()@DB98B12JF22#L33,H!C$('84H@7V,^L1JRQHK$
M%E10Q4;*6  8@>P$[D#V9VZ@A5#;%@H!(&P) [[#V#?R'L&=K/>>L8QC&,8Q
MGST"<^ET"\_)SZ(<^7FY\N>-A[OJ_1[L8$A!$#"4HB'D$2@(A]81#F&8V'N&
M,"4H^4I1Y" AS ![0\@]H>4/8'RYG8'S&^,_H%*7GT2E+S'F/( #F/G'EY1Q
MC-3K?RE>?;/<_P!<Y[(5#Y"3\]U+_$;61ZOR;?G%O^]S9@K1\B.OL9OV<FY(
MSFUEZWG'NP__ #4,8R1,8S#3\VSKT3(S+\YBM8Q@\D5R)@4RZJ+) [A4B"9A
M 553%()2$*("8YBEYAS#-D,,EB:*")2\DLB1J!Y;NW$$G;L"3[=A_7FFQ/'7
MB>:5PB1JSL21W5 6(&_MV'LS\Q7$%W;O<*>T)%'AXBZPSUBS;QR+)OLBD.QM
M:\HFU3\.%DR,[2DF@@C(]>V;)) W<%22YJB)A V?:]&_DQT]Z$;:S-8]/E:0
MJM*Q&T2Q[_@SQ:$\B5\P'^OR&<)=\76#.#IZP>B\!L9T?J._;<+L=@/,@D>6
MW;+"<+G=P(:Y3\53N):F1="6E%DF2.Q:>N]4J2#M<X)(&G8&34?R<*Q,H8H+
MRC:7E&[81ZQRV;-@.LE3:[_)C9IP36](GDN)"&=ZM@(E@H.Y,3KLCD>7 CE[
MB0.\[3O%L4TJPWHT@+$*L\9+1\C['4DE1[=P=O/L!MM^@%HZ;O&S=TV72<(.
M4$7"*R*A%4ED5DRJI*IJ$$Q3IJ)F*<ARB)3%$#%$0$!SY2002K JRDAE/FK
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M.VWA!HT= 8AV[M--@NNV5;JN&K593J"=?5EAO0UK3P!)&0R1I,H,B*2 73D
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M,"(&D@=K_P"*><@1%$G2%0%":-!_E#J:[J-72XM/FK2V0[$R2Q- G!#(RKL
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M^XK3](R6,9,V,9PN'#=H@JY=+I-FZ!#*++KJ$2123*',QU%5!*0A"AVB8Q@
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M'7V,W[.3<D9S:R];SCW8?_FH8QDB8QFK7*KQUPKTG7Y0@G:R+8Z F* "H@J
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M?M#VP/?P-E_ QC'C?M#VP/?P-E_ QC'C?M#VP/?P-E_ QC'C?M#VP/?P-E_
MQC'C?M#VP/?P-E_ QC'C?M#VP/?P-E_ QC'C?M#VP/?P-E_ QC/HMNV@(]MA
M><OJM&8!\#<1QC]&^99C:=CJ&*"L\Z-V@(AWJTY"';YFP#Y \_/M^H(XP2/>
M!OY#]F2'%IRDFX2>RZZCERF1-(JITTR#U)3** 3DF!0  .JH;R"/(_EY!RQF
M/K^K^WS_ ,LG#&9QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&=!VW X";ES P>J#D',!\_G[?J8QFM.HDBW/U &Y^?H^R//M 0#R#
MYO+S\GE'&,PBE8;''U2 "/G$"A\ A]SF/;[V,9Q^*K3YW#WB?NXQCQ5:?.X>
M\3]W&,>*K3YW#WB?NXQCQ5:?.X>\3]W&,>*K3YW#WB?NXQCQ5:?.X>\3]W&,
M>*K3YW#WB?NXQCQ5:?.X>\3]W&,>*K3YW#WB?NXQCQ5:?.X>\3]W&,>*K3YW
M#WB?NXQCQ5:?.X>\3]W&,>*K3YW#WB?NXQCQ5:?.X>\3]W&,>*K3YW#WB?NX
MQCQ5:?.X>\3]W&,>*S3YW#WB?NXQG:1KB"8@)$ +R'F'8'+S=@^GGR]_&,V!
MI'D2$/4A['(H<AY]G+D/(.7F\@_=$,8S:<8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8SC%),P\Q('/WO]N6,9T%B@50Q2AR .
M7(/KE ?]\8SBQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC.TW3(<
;#=(H#R$.7/G]7&,[A2$)_E* <_+R]GEC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g108483g10s25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g10s25.jpg
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MM;:W)#=B>#-2H;'1&B4Y6(*6E[+5*$178V=WDKC6U__$ !P! 0 # 0$! 0$
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M_@_F_(?53ZK_ (2P_P!CA^MX^E[R/^_M+^A_W1Z!B/X/YOR'U4^J_P"$L/\
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M0*D@K989R1.4\LJ2*UEB; LT;-&1VK9/CJQW99:/-='-!?/5\Y=.IM+S,D8
MP!@# & , Y:/A(^[)=JSX[\>(QXJWAY8;+MNW-"*&*21<1RB54I!50()>]%D
M9Q=5E$5>])1PJR6 I56A#!V86*O*?%6BNV[>7<9S>B[?GVFM_P 'KPYZMSEV
M7=K-MQ65)I/3Z$&,]#0[Q:*D+S:;&:04AZP67;"1Y&PS9C$OY&R.XQ5"6*FI
M$L&+EBI*#(LM:]5TXI1]:5[/DEJ[=N5RL8W>>B]IT"\J? ]X>[+T]8HW0VMF
MNFMO0\(\=4"Q0=AL[F+E)IDV.LPK]QCK!-R[)]$3:Z:;%W,E23G8LZQ)%!\X
M20<1K_EAB*D9)R;E'BLO8[:^)=P5LLGVG#R8)2 E1*(O(B:A9 0$2F59R$9*
M1SGIU*<@D7:O&3M'T,4Q%4%TNI1*<H"'HZ])D?I.\,-POM_\4>/VX9=4JT]>
MM6U23LRQ"E*FM;&T<G%VQ9(A0 I$5;&PE#HI@'[&D8A!]2CGE5([DY16B;MU
M</8;Q=TF2;RA(P"E3OV#F?Q5(_HBV ?>+^QL=^ M/T=/ /=@# +=MOVN2OX.
M7^^2R8ZKK7B5GZK[/%%Q9!88 P"W:W];ROY13_\ B2^2]>R/@BL?M?B?N+BR
M"PP!@# /.[=MF#5R^>KIMF;-NLZ=.5C 1%NV;IF5765./H5-),ACG,/H!2B(
MYE6K4L/1JXBO4A2H4*<ZU:K4:C"G2IQ<ZE2<GE&,(1<I-Y))LE)MI)7;:22U
M;>27::L]R[8D-FV XHJ+-ZM&+*)P4:(F(!R@(D-*O4^O0S]X7J( 8!!FW,5J
MD(F]H5<?R+Y<^66)\J]I2\W*=+9&$J3CL_"MM;R5XO%UXK)XBLLTG?S%-JE%
MM^<G4]W#8>-"";SJ22WGR_A7)+O;SZ%AO/PQU# & 6I-7BJU\QDI2::)."?M
MFB(G=NRC\Q5&[0BRJ0C\PK%3*/OZ] $<VIX>M4]6G*WWFMV/>[7[+E)5(1U>
M?)9^'O++4W=3"'[2IS2H=>G>FQ0 G\O15XF?I_['7[V;K9]=_LUUR?NBRGGX
M<I=R^)5X[;-'D3%3^-3,5#"  61;+MB^O_6< 51J0 ^<3KE#Y_=E)8+$15]S
M>_"U)]VO<O?:56@^+76OA<R"W<MGB)'#1PBZ;JAW)KMU2+(J!]TBB9C$,'WR
MF'.9IQ=FFFM4TT^YFB:>:::YIW/OD$C /\$0 !$1   !$1$>@  >HB(CZ  !
MZB(^[ ,?S.T*9"G.DK*E?.""(&;Q:8OC (#T$HKD$K,I@'T$AW)3@/H)?0>G
M33PE>IFH;JRSG]77HU]AFZL%QOU9_D64KOF" P@C"2RA>OH*JC-$PA]T2D67
M !^]W"'W\Z/\.J<:D.Z3]R*>?7W7WGJ:[TJZI@*ZCIEIU]YP2:.$R_SA([(K
MT_FI&'[V5ELZJE>,H2Z,XOVJWM)5>/%->WX>!D"%O-4L!BIQDRT4<']"M%Q.
MS=F'YRD;NBHJ*B'SBB50OS@80$!SFJ8>M2]:G*WWE]:/>KV[;%XU(2T>?)Y>
M/N+LS$N, 8 P"F2<U$0R0+2LDRCTQZ]HNW*2)E.GO!(AS =4W_"F4QOO9>%.
M=1VA&4GT*_>]%VD.48ZM+Q[%J^PL1UM^BMC"4DDX>"4>@^RQ[P2]?O'720(8
M/OE,)1^81SH6!Q#^PEURC?V-F;K07-]2^-CS);GHZA@ [B10 ?WZL>J)0_E!
M RQOO^A1_/DO 8CE%]4E[[#ST.GN]FOY=)=49>Z?+F*1C8(\ZI^@$1<*&8KG
M$?WI$7Q&ZIS?\)"&',IX:O"[E2E9:M+>77>-\BRJ0>DEGSR\;%V@("'4!Z@/
MJ A[A#[N8%Q@# & 6M-7:JU\QDY2:9H."?MFJ1CNW91^8#MFA%ED^OS"J0A1
M^[T 1#:GAZU7.%-V?VGE'L;M?LN4E4A')O/DLW[-.TSKI7G?2:*R6J]O+:9>
M!;D[X)Y'QK=R[CC=P I'BF]DF1SQIRB99M\KS&:A3(D3.@L0K7[M^B[RKQ6%
MJ4O)O:]52PM5J&R:]2>]+#UF\L#.3UHUF_\ X>[O2K6HI.%6*I>7C84VG6II
MIKUU;)K[RZ5QZ,\FLY75WG3QNL"J:"MQ?5U=40*0EBKTPT2$1^91ZR;2$<@
M?.=P\2)_Q9]^<)+A?J/,4XOHZR3E:M]5N3 )2I62"LT</: O8&58RK8AC (@
M115BNN5)4.@@9)42*%,4Q3% Q1 *EBXL 8 P!@$<=G<C=(Z_EH)*S;&KR+V*
MEW:LA%Q:ZMAEF8&@9IH0CN-@$9)XT4.Y<H) 1TBB("J4Y^U(#'+>,)-.T7FE
M9Z)YKBRK6<7RO[489?\ B,\>V:IDV[?8$J0!Z NPK3!-(P=?VP!*3L:OT'W_
M "D2FZ>\.OIEO,SZ.\L5.&\0KCE**$(]DK=72F$ %69JSE9,G7YSA7W$ZKT#
MY^Q,X_>PZ,UP3ZFO?8$DZ/NC5&RNPM'O]8L3DY>_XM:2:*4R0G3KWJPCL6TN
MB7H _*69$#J!@Z]2F ,W&4=4UUH&17OUF[_!E_[H^0"GUS[7H'\31?Z"A@B.
MBZEX%9P2, U=^-#*OH;PT.3;J/6.W7<1^LHI10AA*86,WNC7,1)HB(" B1U'
M/7350O7H9-8P" @(@.E+]9'M_P!+L'\/8SCW\*O6,!M_Q!N,-(L[-O(P9KQ(
MV]Y'NTRK-'QM:T^R[):,WC=0!2<LW3ZI-D';58IT'3<ZC=9-1)0Y#=-1VA)]
M%N_+WA_#Q/T3,X@<DOPE37-=BK[Q:VHP8MV]FNE:VA2[&]22(FM(QU"?T>5K
M0N3$* KJM#WN?0!943*E;F;( 84D4B)]-!NTEP35NV]_!$<>BWA\;^P\'P=>
MXOZRCR_;MUQ!!RKH)8$3@"B9%2EW0110A# 8I#JD!$JAB@ G*BD!A$$R](K_
M &/\W_I)^?GO.NG.<# & , 8 P!@'&O\) _=6:/#YOJ>VG^H]]_\ SNPOJ2_
M%[D93U75[V3N^#;HE+QUY". * '5W5%HF-Z=1*A1H8Y2B/3KT*+@XAU'I\H>
M@ (FZYXKUX_A][)A>SY7]O'W'1UG*:'YD'))!-KR)WXV2(5-)ONG::":9  "
M$31O,ZF0A    "E*4"E      #IGK0]6/X5X(YWJ[Z\3N/\ "1O5/B/#9XOK
MSULK4,1&N7-HH>6G8J.*FHRV?>&QTSF=ND2D.GY0 <AA Q?WP .>?63=6=DW
MFO!&T6MU9\_$V-PVRM=6-T5E7K_2IUZ<0*1I#6J"E'1S#[@*W8OUU3"/S !!
M$<RLUFT[<[,FZYKO+UR"2E3OV#F?Q5(_HBV 1%VAS8T]J9LE"-7;B^6QFS01
M7A:PH@=BP=)H$*9O+V!431[10BA3HN&[$LJ_:+%%-TQ1'+J#>N77KW?\%'-+
M3/YY_"Y RZ^(KNJ>.LE48VKT-D81\A1NQ^B*93 >O0%7TV"D4L)0Z=!) -_7
MJ(@(" !907'/V?/>5WWT$>9;E!R$FE#*O-OWA$QQ$1")F5H%,!'W]J,$$<D0
M/N 0A0#W  !EMV/)>/B5WI<V>!MR-WRV*<@;=O[M-0  Z,I9)*80. & W0Z$
MLL]1,'<4!Z&((>G3ITZABRY+N%WS9(ZA^(?NRMJH)7!M7MA1Q1*"_MK%*O31
MDRC^U;R<&BC'I'$/0RCJ"?&-T 1^5W":K@N&7M^>\LIOCGXFR+2_+_4.YE&L
M0SDE:G<'':0E5LYT&KAXN/H*<))$4-'3 F-U!%NDJA**$*90\8D0!$*.+73U
M%U)/H?3\^PE/E2Q;M;^MY7\HI_\ Q)?)>O9'P16/VOQ/W&,=K<B]1::3.G=+
M6U),@F"B-8B ^-K*N!B]Z?6,:F$6":Q>HHNI9:.9*" @5R(^F%%O3O)<DM>X
MUXW_ ,2RQNE%VNLJ%&1#;J8B4O<7"TM(*$'KT5+$12[!DQ7+Z="*R4NCU#J8
M#@/:%U37%]QFYO@N\BM8N8G)"R'4%SL^7C4CB/8WKK2*KQ$2CU^0FM$,&CTP
M!U]#K.EE?NJ#T#I91BN'?F0Y2?'N+19\D-^L5P<H[BV*=0H]P%>6N7D4.H?]
M9K(.G+8P?\)D1*/SAD[L>2[B-Z7-F4E><&ZY*L.J?<)",M$3(F;E>/CQS:'L
M!FK=4JOLA'T0FT8G06.0GM/M,6NX<$3\H[D"*+@?Y%^EO:LL/LFAL3#572K;
M5E*>)<<VL%AY1?FY9J26)KN*;3^M3HU8234VGZ& NZCJ22DH:7^\^/*Z5[76
M3:?(KM6N\!;D1-&.1([3(!G$:Z J3U /<)O+ QBK) (@'G-SJIAW%*<2''L#
M^9*V'J4']=?5OE-9Q>O<\M'F>Y&I&>2>?)_.9=V8%SQ2,BQB63B1D7*31FU(
M*BRZH]"E#KT    $QU#F$")ID*910YBD3*8Y@ ;0A*<E&*;DW9)?.G-D2:BF
MV[)$5;KMN7G5%F,&=:'A^IB>8F;RY%Z3KT[EER#W-DCA[F[<X")1$JRRI3=A
M?8P^"A32E42G/ISC'H2T;YM]ARSJREDOJKEQ?6_=XF)F[5V]6!%HW<.US]1!
M)NBHX6,(CZB!$BG.;J(^H]!]1SM<HQ5Y-17-M)>TRLWHKGNDX*9ABM3RT:\C
M@>@J9L5XB9!14$?+!4024 JI>P54P'O(7KW!TZ]!Z5C4IS<E"<9;MMZSNE>]
ML].#T9+35FU:^:OEES/[>UV?CDA6D(.79(@'45G4<\01 /OJJHE3#_\ EB-2
MG)VC4A)Z6C*+?L8::U376FO$_N#LLY6W .8:1<,S"8!42*;O;+]/3HX:J 9!
M8.GH G3$Q/>0Q3  A%2E3JJU2*ER>C74UFM>HF,I1=T[>!)NC[:C;$9&-F2I
M14P<2II' PA'OU!Z !4#J")FRYQ]"MUCF X]I4EU#F!(ODXC!2I7E3O."S?W
MHY\EKUI=AT0K)V4LGSX/KY/V=1D"RVB(JD>>0E5^PH]Q6S9/H9T\6 .H(MDA
M$.XWJ'><PE22*/<J<I>@CS4J,ZT]V"ZV_5BN;?AQ? TE-05WV+B^KYR(D6_8
MT_;5%$5%C1\2(B"<6T4,5,Y.OH+Q4.P[P_3IU!0"H%, &303-U$?:H86G1LT
MMZ?&;U_RKAX].9R3J2F\\EP2T[>;Z? M&*AY.<=E8Q+)=^Z,43^4@3N$J91
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M<5<%PRZ/GY]VOZ\<8-\:_56">UK8W#1$3?\ G6O-!LT49(.O1<[R"%^5HF<
MZE*_*T6+U JB1#_)RRE%\>_(JXR7#NS,%.6KIDL=N\;+M'"8B!T'**B"Q! >
M@@=)4I#E$! 0$!* ]<L5*U"5&UV4W97:S/SINH (0\/(27;U$  3BS;K 0.H
M@ F,(%#YQ# )KZF\/S;%S7;/]@';ZVKQA(HJD[,A)VEVB(@82-8AJN9O'F.
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MO)="R2[DNO,ESK;A7H36ZS=^2LJW*:;"4Z<M=UTIKRU2B!@.C#IMVE?3,0X
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M_HBV ?>+^QL=^ M/T=/ /=@'R4016Z><BDKVCU+YB9#]!^Z'< ]!_DP"@VP
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MKJU0E)VPM5Y6:H3?G(QE5]O"8I58J$\JD4E?[Z7%=/-<\UK91TSY@=HP!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$]...E5X7R=@6QH9&4
M61$:W%."=JL>W<)B4\J[2,'<F]<HG,FS0. &;-E%%E2^>NF5K_1?Z+_(.IL_
M<\H]LT7#&5*;_P ,P=2-IX6E4C:6+K1:O'$58-PHTWG2I2E.:\Y.*I>1C<4I
M_P#1IN\4_KRYM?970M6^+RT3O,3/MIYPP!@# & , MV9^RM2_'CS_+%@R5I+
MJ]Z*OUH_YO N+(+# & >9[]9N_P9?^Z/@%/KGVO0/XFB_P!!0P1'1=2\"LX)
M& :N?&BBWLMX9_)ILP1.NN@QUA**)D 3&!E#[JUQ*R*W0 'H1M'LW+E01]"I
MHG,(@ "(:4OUD>W_ $L/+V>UV.0+PH=E5_4WB&<8+E:'B$?"FNLO3W#YVH5%
MHS<;*I-HUO&.72YQ*DW:HREL9'<.5C$0;HE.NN<B29SATU%>$DN5^YI^X/X>
M/N/T0\X@<D_PE;84!)7OBMJYD\06LE0K&T;K/LTU"G691E[DJ1#UL5B%,(HF
M=K4*PG B@ <Z222A0 ABF/TT%E)\VEW7^/9VCC\W^?'LSI7P=FH/[*ER_6;M
MA41:J:"2\TP@1,5%"[I.=,ASB!3G(4$S*%*(B0JB8F  .7JK.V[DGZVJOR*M
M-Z.UN7_/0==N<Q88 P!@# & , Y7/A).F)=4>.7(./:*KPK1&SZBM+LI#"G'
M/7"Q+?2R*&* ]"R29;N43'$A2*,$2%$QW  '9A9>M'G:2\'[C.:T?80!\&GQ
M%*3PEV/>Z7N=209Z9W$E JR%FCF#N75H=NK8R",;..HF/2<23R!E(Z6>1\\$
M4T?2B*K2$=-F3A%L[3-I7I.HDX^M&^7-<ET]96,K//1_/Q.ACD]XU?#+4>IK
M%/:EVI![HVF]A7B5 IE193+QLI/.6QTXU_:Y5S',XR#@HQVH@[EFSEX2;=-D
MU6L9&N7)C"CS0P]24DI1<8WS;MIT+CT<"[FDLLW\ZG"B\=R=@EG3]VHYDYF;
MD5W;I82F6>2$G).3++*"5,HG5<NW2QC=I"B9153H4O40#/1T70C(_20X0:?D
MM"<1>/&HYQ S2PTW5E7:V=F8 ZLK7),BSEI9=0_;%96&3DFI3^@J%2 XE*)N
MT/*J2WIRDM')VZC>*LDB4^4)& 4J=^P<S^*I']$6P#[Q?V-COP%I^CIX!1;O
M<ZSKBEV_8=TDRPE.H=7G[G;)DS5\^+$5FKQ+N<GI,S*,;/9)X5A%L73H6L>S
M=OG )"BT;+N#II'#4_FG7ND;#B/H@H%QJMX@O:!:#-4^PQ-EB0= W;/!:C(P
MSMZT!P#1XT="@*P*@W=-EA(":Z1C >BV_:Y*_@Y?[Y+)CJNM>)6?JOL\47%D
M%C0QRN0=ROBDZG3M-)UC'Q$0WXA$KFPE=H\Q3>TP[C?-GG8>/W-1-6Z,DN.<
M7:I7:-?=0'&6*VQNW7+.7V)'1,\^F=N)N T]2X^?#YU_*Z]5Z\<K*W#1MWO:
M][)Y<M5OGR2A;M;^MY7\HI__ !)?)>O9'P16/VOQ/W%Q9!8C["<L>,-EV273
M=:Y!Z;L>VQMMLH9]9U_8U4F[XWN-#AG,_=Z\\JD9*.IMC(U&*:+N+*D\9(!"
M*%(SD3-WJR+9039I7::5KW:MD_$D%@@8 P#S/&321:.&+]L@]9.T3MW31TD1
M=NX05*)5$ED5"F(HF<HB!BF*("'S9E7H4<31JX?$TJ=>A6A*G6HUH1J4JM.:
MM*$X33C*,D[---,E-Q::;33NFLFFM&F0EV9Q7<%5<2^MEB*HG$ZJE7D' )JH
MB/4>R)DG!@353ZB $;22J1TP 1]O6$Q4B_!?*O\ 1!44ZN-\EIQE"3E.6R<3
M4W90;SW<'BJDMV4<[1I8J4'%+_O$VU%>G0QZRC7OT5(J_P#-%9]L4[MZ(B'-
MUV=K;LS"?AY&'=E$>B$BT6:F.!1Z"=$52%*ND/H)543'2. @8IQ 0$?BF/V9
MM'959X?:6!Q6!K)OZF)HU*3DD[.4'.*C4ARG!R@UFI-.YZ4)PJ+>A*,ES3O;
MKY/H>91LX2PP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 7K4M=72\+
MD2K5??OTC'[#OQ2%M%H>O0PKR3CRF9!*'4WE L9<X%,":1S!VY[^QO)?;VWZ
MD8;+V;B,1!NTL2X>:PE//-SQ57<HIK-[BFZC2>["3R,JE>E27UYQ3^ZG>7\J
MS[="<VJ>-T+35FT[:U6]BL:(D6;-B)F&$B5R]!*H@FL0JDB[2,'<DZ=)))(F
M[3HLR+I)N<_H'R/_ $6[/V'.EM#;$Z6T]J4VITJ:BW@,'46<94X32EB:T&KQ
MK5H1A"33IT54A&J>5B,;.K>%.\(/)_>DN-WP3XI=KM=$G<^L'", 8 P!@$?9
M_ECQAJ^R%-.6'D'IN(VZE9*-3E-6O=BU5+8I;5LLJ2M"K_T$_&@V49:U-%DY
M*(9!&"LXB!&8$I8LIWA1-G:]G;G;+O)!8(+=F?LK4OQX\_RQ8,E:2ZO>BK]:
M/^;P+BR"Q8^QMDT74=1?7W9-ECJ?3(M_7HZ5LDN*R<3%N+38XFIPJLFZ226+
M'1ZT[.1C5[+//(BH=LNI*3#QA%-'CYN!7J[9:Y;XAI8:G/PMG@'XN 8SE=E6
M,U$/1:.5F3H&DE&KN63@6SQNX:. 17/Y+E!9!3M52.0H%1>_6;O\&7_NCX!3
MZY]KT#^)HO\ 04,$1T74O K."1@&.]N:RK6Z-6[#U'<43K5?95,L=)G 2 GM
M*4?8XIU%KNV9C@8J3]D#D'C!?IW-WJ""Y! Z91"4VFFM4[@_-RY.<<-E\3-U
M7'2FT(Q>/L-4D5!C98B"R,5;:XLLJ,#<JVX4]'4).M$@<ME"',LR<E=Q,@5M
M+1S]HW[DU)*2T>G-=#Z5^>C1"SR>O'YY/YSN3LH'C<^(7KV@,-?LMIP-D0B(
M]*+B+5=:1 V:ZL63=($6I5IUXB4LZY;$*7I(6AG.2+@2@+YVZ^>CI0;O:W5D
MNY9+LL+=+]GP\;])K<V'L;:&_-CRU\V)8['LG9EYE6WM\O(BK)3<U(K^2PC8
M]BS:I 1-)),K6,AH6*:(,F35-I&Q;)!LD@W)=))6222X+1$Z?F=UO@]<+IWA
MOQ3:,M@Q_P 6;=V[-!L;8$6J!1=UA%:/;1]4I+M0@]#.X"'1,^ED1 18V.=G
M8\BSANU074Y*L]Z66BR73S:Z_!<-"%?CQTZ%T])M;S,D8 P!@# & , PMR&T
M'KOD[IV[Z1VG&'DJ?>(L6+I1L9-*4AI!NJF\AK%!NE4EB,YN E$&LI&+G160
M%PV*@\;NV*SEJO:,G"2E'5?.9#2:LSADY=^$=R^XL6B6*PUU9-T:N(Y7/ ;.
MU?7Y&RMUXOO,9 ]KK4021GJ9)(HBD20))ME(('9C(Q,_+I%\\?0IUX32NU&5
MLT\NYO)^/-&+BUPRY_.A#:E\5^3&Q95*$HW'[<UIDEE2H^1#ZUM[HB!C&[1.
M]=%B :1Z"8^JSI\NW;(% 3K*ID 3!HYP6LHJW2B#I3\+OP1[1K.\UCD5S#9Q
M+:?J3QI/Z[TFS>LI[XML30Y'$79]ARL>JZAE',(Y(G(0U7AW<DB$DFR?S,DF
M9BM!..2MB%).$+V>LO<OCW<S2,.+[OC\.\Z>LY#08 P"E3OV#F?Q5(_HBV ?
M>+^QL=^ M/T=/ ,(<K9,87BYR3F2S:=:-$Z"W%)A8U:TWNB4 +#7=C=!-J4Y
MVU?-;8G%"E[>>M.63QO.E0&+6:N$W1DCB5JNM>)#3PG%ETM';4KSJ]Z6OZ]-
MW<E5E)7C]-QUTUBV%EH;1+P$8S9D72Z SV;.2A9 +3<;,2LLU(VVV&:I*JKL
M]2%PH)DDFK7M;CKJ^%W8V36W[7)7\'+_ 'R63'5=:\3.?JOL\47%D%C1#RTG
M:K(>+9QWIUE5IT:O#4'C-:()-[9=&U>:NDO+[WW>WCH^9A-K[WH-FVNVHLG5
MF,]KJ.UCJO9MKUO;)^9G85!M9[-7DUA9)[K>=LUW)/6S[<U?(WO8*ENUOZWE
M?RBG_P#$E\EZ]D?!%8_:_$_<7%D%C0SP9UTLARXM^Q$-57NJ6!SL[DQ7+5--
M^9*$G6OH @MW\B)6G?&_%R7E9.XM*U)V?8,I:XF+='3AHVVWTU]AVS2)4C6J
M LWPX6CP6ME?/L?=W;YL%1@# & , \CU@QDFYFLBR:/VI_V[9ZV1=-S^\/E(
MKD43-Z"(>I1]XYC7P^'Q5-T<30HXBE+UJ5>E"M3EUPJ1E%]J)3:=TVGS3L^]
M&/W>F]6/3BHO1*Z4PCU'V5B1B7K_ $;$6Z8??Z%]<_-U_(?R1Q$G.IY/;,4F
M[OS.'CAU=N_JX=TH^PV6)KK_ /EGVR;\;GC^D;J;^(\1^=Y^M9A]'_D;^[^"
M[Z_]X>DXC]K/O'TC=3?Q'B/SO/UK'T?^1O[OX+OK_P!X>DXC]K/O'TC=3?Q'
MB/SO/UK'T?\ D;^[^"[Z_P#>'I.(_:S[Q](W4W\1XC\[S]:Q]'_D;^[^"[Z_
M]X>DXC]K/O'TC=3?Q'B/SO/UK'T?^1O[OX+OK_WAZ3B/VL^\?2-U-_$>(_.\
M_6L?1_Y&_N_@N^O_ 'AZ3B/VL^\?2-U-_$>(_.\_6L?1_P"1O[OX+OK_ -X>
MDXC]K/O'TC=3?Q'B/SO/UK'T?^1O[OX+OK_WAZ3B/VL^\?2-U-_$>(_.\_6L
M?1_Y&_N_@N^O_>'I.(_:S[Q](W4W\1XC\[S]:Q]'_D;^[^"[Z_\ >'I.(_:S
M[Q](W4W\1XC\[S]:Q]'_ )&_N_@N^O\ WAZ3B/VL^\?2-U-_$>(_.\_6L?1_
MY&_N_@N^O_>'I.(_:S[Q](W4W\1XC\[S]:Q]'_D;^[^"[Z_]X>DXC]K/O'TC
M=3?Q'B/SO/UK'T?^1O[OX+OK_P!X>DXC]K/O'TC=3?Q'B/SO/UK'T?\ D;^[
M^"[Z_P#>'I.(_:S[Q](W4W\1XC\[S]:Q]'_D;^[^"[Z_]X>DXC]K/O'TC=3?
MQ'B/SO/UK'T?^1O[OX+OK_WAZ3B/VL^\?2-U-_$>(_.\_6L?1_Y&_N_@N^O_
M 'AZ3B/VL^\?2-U-_$>(_.\_6L?1_P"1O[OX+OK_ -X>DXC]K/O'TC=3?Q'B
M/SO/UK'T?^1O[OX+OK_WAZ3B/VL^\?2-U-_$>(_.\_6L?1_Y&_N_@N^O_>'I
M.(_:S[RL1NJ];Q!RJL*16DE2" D65B6KM9,0]PIK/$UU2#]\ARC]_.["^2'D
MO@I*>&V!LJ$XYQJ2P5&K4B^<9UHU)Q?3%ID2KUI*SJU&N*WFD^M)JY?I"$3(
M5-,A2$(4"D(0H%(0I0Z%*4I0 "E /0     ] #/T48QBE&*48Q248Q222622
M2R22R262,3^LD# & , 8 P#0U$Z[6F_$HV-=TM57MO9ZMR*9Q]>MU=YD(:U8
M.:19-:<;I;8D\MQXGI5U,7&#ERT"$;79M5VC& OL70&<*+3VR/E%W M?)+*R
M6>6F;MGJ]<GTVT-\N"I;LS]E:E^/'G^6+!DK275[T5?K1_S>!<606(2>(PJ8
MG#?;S<MOK-#&46UO #:KHDQ"G1A;'MJB0)T[7,24!:6-*KDD62&*F]F.:]+I
MZKC7SG9'L2HU4  3'5=OA[>A<7EQ/!X;DHO+<1*,NYLVN+<Y:7;>4*XFM/HM
M1U8=Q7MZ;'@G#+7\NQ@*LSME4C%XY2.B+JWKT.6WMFQ;">/:*R"B";Y[A+)O
M*VF783A>_6;O\&7_ +H^""GUS[7H'\31?Z"A@B.BZEX%9P2, 8!%GE-PPX[<
MRJDWJ>^*"TL9HL'!JS:H]=2%N]17= 7SUJY9F7:]:HKG315>1+L'T#)*MVQY
M2)>BV0\NT9R@[I]:>:?9[]>D&EJ5^#8Z&6F5'$)R/VW&U\5A,G%R=;ITQ+D0
M$W4$C3K5.$9G4 OR06^AXA>ORA1']KFOGW;U5?G?+N_,C/GPY<>?#N-C?$3P
MF.'G#J897.F5*6O^SX\.Z/V5M-\RLD_"+&*(*+5B-91L15ZVY^4HFC*1L&2P
M)ME#M#S:R*BQ5:2JRDK:+DLK]?/3JZ!;M]W5\W-F&9DC & , 8 P!@# & ,
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M,O\ W1\%2GUS[7H'\31?Z"A@B.BZEX%9P2, 8 P!@# & , 8 P!@# & , 8
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M&6[<6NWD=LIY2&4C&53C[KJF0$!!M$P?L1:^5K+ARO?+.]NC3I?,V(X*C &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MM!8$'"R0$4,*ES8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MS[793^A3_2$<%9^J^SQ1<6"Q;MG^L&7Y157_ #+%9*U[)>#(>G;'Q1<602,
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M62[/]*"[\WXOPT-G69DC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M/GG+&1CG2#UB\;J1#P4UVKML=5!PB</4JB2AR&^81SQ?*#_P';?_ -HVE_\
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M>Q8JB1.6HTYR:=UEGV(A>]^ULV"90D_-=YX"(\W^8@B(B/U4>_ ZC]P-J6H
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MN_5WMZ_&UK6Z'K?LZ1&.]?.UOS-ND=\&BK:2A1EN8,X]2 0[R1VD&$6H8/G
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M8!]P@("'H(9R5?UDNM<+<%\WXZDKXZ]?S;H-EF9@8 P!@# & , 8 P!@# &
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M1AD;92[R6-1>"<4F9[;KF?M5$G5T2%*5T\J=FGX/VD%4F$O((I%=*B#)6 ,
MA;S7YRZLX*TVGWC:<)9IZ(MMAEHD4JQ)Z\BG<1$5NKR]PM%C6-L>\T)A-!$0
MT.J#.I59].WZT23IG&5.JS3HRY6XE)N]N"OQ]R=NMV7-F4M9;;:;VT'!;980
M@5MC<V#Y^RA!N.OK\M'M&EC>Q39-Y:M56J\:]D)%1%@1>2;U>WV%C$2"KF%4
ME'+R.<FP4FK)KX\USLRUN2/*)MQKE]9EG-7WV^5?8*EQC7<YKXL-)2M8GZ[&
MQ<S#,'-<F)"$"59V**&SN3O(^8]NB/H;%0T._CW3^1A!=*_%+KR)"6,_F1D>
MIVG)YD_4C]B@=JA.ZQQ)NTY>H]IR]>A@ZCT, AU')6O9+P95Z=L?%%RY!(P!
M@%E;&UQ1-NTFQZWV958:ZT:VQZD78:U/-"O(V29G,10@'((E40<M7":+Q@_:
M*(/XU^W;/X]RV>MD%TY3:::=FM&#FKY"?!OX.6G9"<XQ[T+4XAZNJLWH&V(A
M[-M8CS3"I[/'WR 4-**QR F\AHVE:M)22:!""\G9%QYBQ]U7^]'M7P?'MMU$
M9]?C[.SD8(I'P;'>;R40)LCD;J>N0@*E%RYI%?N%UE#(@8!,5!E/-:"T*J<O
M4I3J/SD2,('%-8"]AI=>/"+?6TOC\]>3/H7M^'SU9] /"7PV>-O!6,=.-90K
M^R['F6(,+)MJZG:2-RD&9C)K+Q$3[*U:1M7KRCE,BQXJ$:(*OO)9C/2$VX8-
M'*6,ZDIZNRY+3MYOK[+7)^?GYY7)_P"4 P!@# & , 8 P!@# & , 8 P!@#
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MORTOD_=?N::?$W&R"9$:U7T4D4&Z:4E2$TV[9R9ZV0(2<ABD1;O#E(=V@D4
M(DY.0IETRE5,4HG$ E:]DO!E'IVQ\47ED$C & , 8 P!@# & , 8 P!@# &
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M?FC8T7TE)&1/*2;V9D55'\N\?R3I9Y*2+UZLJ[>+J&5<'Z& @%*40W?-EX8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
08 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g108483g11a64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g11a64.jpg
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M.<-/:T]^)&P#L#:8/.U>H*SKE.M?AK;C\*:[5-9EIKV<C)6)<[Q8XW!T3Y
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M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%KZT3MBQR%DR]4U^(L^;MUA_
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M=L@^)FBDZKN?QA]'N(G(BSAD[<+!9$T"FD'K-@50W?K\M>??9U_%9++/?
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M)]/F,(+2UW6JE.]SEW 6$E;0WN<I5BIS#VLKT$Y,M6#06[0=)EPX@BQ)L_T
MI"@PHV-A \=#M]M! $6/"BFNUEG&VPT6T18L6^UW*BSA?:+5!)/:RZJJRF^?
MO54[[ZZZV5/-=IA$PB81,(JXKU]B>BJUFTD"0_R_4W$,B@\X>=37T?[4K/SJ
M\E,.C!8* D-@0B("(3=)3J #SDD !]R:Q'5;ZX)&@J#]@/2-B'+PI  ^I_
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MG.;M^VAK>!!UV._/7IW^=.I:&$Q^0L083*R9.!ER]$0^DZJV"*&<,K<)G6;
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MPJWZ$;V(:B\\85%8M%PI/Y'?.]*2R(V%-X1Z*D]A1E.<T[*)XI(Y?+X9Y>,
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MM]5<SA13"*(7R#?YA'M[_A"]*_\ HS-,*3/OM_S-_B%OFH?\DU7_ .[N$_\
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MN_Q?ZOP_P+9L>_!]O_TZ1^S7/]FOIK(?8F-_X8)(_P#R;=R']7@V&:_)7_\
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M%AEK-N2,=&RNUM5D@<ULCCX_O+I#&0"!"X N#MM'LOMQ]F67Z.Z(Z5R=W&=
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M<2  /4D@!7J]>Q;GBJU8)K-F>1L4%>O$^:>:5YXLCBBC:Z221Y(#6,:YSB=
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MD9<8VS.IS0F5L9>XL:\N#2YQ: 2=Y;&XS&X:!%1:(1\)%(P"9I#@D<C8I@#
MAAZ&MZ18BA MNU'CF:.M[TDV:-T4$];WKCC7URY'&R)C8XF,CC8.+&1M#&-:
M/(-:T!K0/D  L&W<MY"S/=OVK-VY9D=+9MVYY;-FQ*[[TD\\SGRRR._XGR/<
MX^I45H3Y(<Q2][1N\S?UM6$WN <V!36JIF HY:MR$9![E7$(C6D@=1!);L7!
MVLR.,A72TJ5?FVZ_&IF\DRB7"FM?%C3'<L6WW+$PL@,EK2QU/ ,;/$\&/X*S
M)2V$2O:W<FW@_I3)I=GD.N&7>FL-T[7Z8P>+=@97V<=FL?:ZD;EXKEGW(Y&W
MRLYZQ1\;(OH5I)@VD(JSVG[/CIAQ"DY&H/"H9I[J'P^+1/1+;?9'4:CXD%I_
MMI^?])M[H6T:_JMM?U+G]/\ G_)^']0O^/[?RJ?=GQPQ1;\**./EKEX;&LY:
MWK?$#>MG6_+9UYKD+F2R.0\/W^_=O>#S\+WRU/9\+GQY^'XTC^'/@SGQURXM
MWOB-:)]3^<2?IR%!X&E=5@5 "8R:.2LOQ 059&'$F*0J61J=0K9%>Q8-,U&*
M,:E\4%&T$@70ODIUPJ//:*"5>V'6)D*+K\38?>IJS!)'*[P60.+W0RQS1<C/
M%+H1RQM> SCR^Z_DTEJZ3HOJR'H[(6,F>GL7G;,E.W1@.3LYB!M.'(T;F-R/
M@MQ62QXD=<H7IZSG61.806RUO!G:)1G#2A:T?=14[8</A%KV9&A,<9.+=F]<
M5VK/CA:.-V_+>2N7PB+BV(@HL_0Z+)MHVP#"!3U;KD(.&M4T$$KHIUSX;YHH
MK$\;8P;,L$!F>Z,#4A<V-H:XN'(",-:TGX&M&@-;)U+EX_?:V+O9#"XBW/;D
M9@L=E<JW&5H+;WEU-D<]V:6>%L3A 7VY;$\\;0;$LKRYSM7^YO-$1]=>7;0H
MJ<G9''(W(V(@X[+1-08D;0<P4\,FXU)OV8'%6&D'9&/M6K[2C)13IDLOI#M!
M?::R>/EJ$>2Q]BG,][(Y&M>71\0\&%[9F@<FN;HN8 [8/PDZT=$;GV<=7W^A
M>LL-U)C:U2W;J23UF07A,ZLYF2K38Z9SQ!-!+R9%:>^/4@ D:WD'-VTQQ^';
MS/$?-'@^GT8B=DAWF]XU!_2<EW(U!BFQ$MM6IJX4- P?[8.':XC@_85OH6F_
MT^)\Z56_5D76]\;XPNF:$5#$5A$^1_OC(K\GB<?ADL5H.;&<6M^!O <>6W>>
MW'TZSV\]87^L/:5GG7ZU2M_9FYDND:8J"8>/1PF=RXKV;/C2R[MR^\/\8Q>%
M"=-X1,[[M$S?KQM,(F$3")A$PB818NA!X4U.=2=M#XNWDG:SASU(4(^)1.=.
M'B:J+MQT63:<O]K.D5EDG"NW&U%TU5>%>NN5.];MB&(/\011B39/B!C0_9&B
M>6N6R"0>_<'2S79'(/K"F^_=?4#6,%5UJ=U8,C+71M$!D,0:QS6N8WCII:TM
M ("C9[O'4N2\GW9Q>S.LGD/:P&5O!.K72BZL<;SE*.%TX6X'[ENMC4Y5P<5;
M)QE1OO17]U51X%[_ %??&MX.7;5=CK0N" Q"&0M]X\/PQ*(W>$1XGPB0/(\,
MCXN6N/==;[-9>H(NM^G3TU)F([[\I1CG^Q'76VWXTVX#D&2^XD3.I&LUYN-?
MN#P&N,PX KB^ Q],#O(M&<48TK-I%7-=PUX=U52483 +S]6*A.9LX*_PGK0]
M27=FTU^)1V[^IC]T35X*[_5<=ZU3#MJMQM3W00",PQ.?[N(PPS&-GBEWA_#X
MA=_O-_%R^]W5SVGR]02]==2GJ-^8?=9EL@RM]M.N.M-Q@NV3CF0>_?I10%8M
M-(1ZK^"6F#X"%@_IX)Z'+>B_*<MJZBFMB0:DI;+)S)I&M:D1ASARO.JIL^I'
M !B#-MU'_:T?XEHN4K$=;[;$6OYA35--XGTKJUD&77W<=+7J-FBJ2R32/-B.
M(DRUK%4L#'-)VP2MDY;(<-M&CW6QZ.L]*P=*=;4<SU(_%9+J*C1QM.HW"WK[
M6-QN;PV=9:DLUG"(-M&C-2;%H/B?QG>3&0TS]WK6];UO^S>OIO\ \-YN%Y@J
M(_C H7X^:V];>U"7EU_6KJ9126BH/7:,0O$O8Q#FAR]->;I7.%QXE[/Y/P<C
MJ5[NC;(C-'3,BZ#2;AQ"DSK%!GH$CR& IX:#)95U P&6*5L, CMNG=[HZK1D
MF(:9I.;!;+PZ4AQ9)N+F  P?2?MBZE]J.7Z&]GL764>79C[M&;(Y5U_IR#$Q
M'J6#/]6T<:V6>/%TS6MNZ997DAQ[)(F6*99D36D=(;+KW,Z]?-B81,(F$3")
MA$PB81,(F$3")A$PB81,(F$5*M*>2O>$$]^(7?8-L2*;T[)I9=AZ9\+7Z84A
M["(OS5\#JD@HFBVL! -%EA\2DOGMR'4?2<J&A)&$6I^K_B0R:A<A:%(D:UK1
M[>GR ]=_CY?]U=5A13"*(7R#?YA'M[_A"]*_^C,TPI,^^W_,W^(6^:A_R35?
M_N[A/_30S"BMB814F1KY?@LG]S3_ ,:1J$O)[)8Q+)Y!(X"BD;(#91)IG 7$
M^2D@9<[*I2,A845&FL/9F2<M?KICR L@0Z8,$' KA)]RL?4S),M-BXXG321R
M30L9'&6ODEA,PD9SDD;$QL8B#W2N/%S2[0!;W^B+GL(L4_9QB^O[F1CQE2Y1
MQF3MV;MN.:G3Q^39BW4[#:U*E-D+$]Q^0DKPT8FF6*:*(2RN9.71=1\B7QYS
M3VR JF0W@,MNP9C$Y<VV!K7S))J+B5>53 I++Z]W:S<G*+Z<Q>761.BL""%$
M8U*FNPT><2H,&_45W#Q*A#LS'-X67+,KOMMLS2QR_!!0DJ1PUX9)(/> Z2X8
MY9YG0L=PD'!AD8W<$3>7._[*O:GCO9W:S=7IR;!8NA>H/]ZR_6-/J6]E<WDZ
M=#*_8CH:73+;E#$8V#)V83<I/]XM-I6+''+7YQ$*\^ZJ\=Q.L*OKB(5?8OI6
MI.XA XA&&7#BWOXS(L&P&/CA:+8S")EU9]"-3O'+7_WYW!X2VCC@IMVJ(^\=
MTTWSN*^,CKUX(Z\]ZMX<,48W9\5P#&-: ^*7WBF'C7Q^#$&%V^/PZ7F&:Z]O
M9C,Y>]F<3TAG!?R=^[(68+[/BD?9M2S.?7R./&&ZF?6//^[#(Y%]ML(C%C4P
MDW2M\O,&^5(3:7GEGYGLJTK&B?UZ2#F(N.@4%)H6OON3]"$3W[>0# C$FZB7
M!I1H5%1:,#41_3EJHU[6Z2WKENI8>H6V*0H3V)X^X:Z-L,3A9_2<>>G-8Z3P
MN>G-CC:&[&MKZ$]A62]B\V%ZIDZOQ&%Q5[LZQ!=ER>2A?A-4Q.ZMXL5BS7IB
M\:X?!/=N3.E#'AX:"%>3&?/<FD\;CZEXW==<Y(J!!*A:+B)6E3L78%>F#?\
M<6G*=+MH7,3;/I?\B3QA-YY-&;O?YN5>5&ZVT<ZR.E)(QAMV[<SN#2Z-L@K1
MAQ V-51%*\>A;+-*#WWL'2^<KG5-.G;M#ISISIW&PBS.(+EBB[/W98!*[P7D
M]0OR%"O(&\7,EQV,Q\C/AXZ<T.4)?3'Q)>=+FN2KI^'\MT*^#1;]$G.5B5H7
M!6)*8C&[::)\!'46K8$[C))TR.'P<U7FI9[U*I6]#=1.1K=1]33GK57^G*5J
MU7F;CZ;FQZ$I=8LUW2M E^ QP,,;BU[V2^*X^)(6F-YX':]#Z0]N/5?3^ S.
M,GZTZFBL7?%.-;#AL#F8:$SWX]QL,NY>S'=A9)7K6<>W'01BE2CL"]4 M#@)
MW_\ 9Z*PC_'T#:TKJU-+Z](0*3:<VW3/?6O\%)LG")47:RF("&J?U39@:DL:
ML@:.]_D5&N>M?3>W]R=#WIV)*_RADW9J_0>%(X21-'HRM/ P>K2O-?[4P9$\
M>I\+2S1=V=DZ99@^H #]YYR-*!]*_8>[XI+6=Q.8LN^Z)6#R\[WKOY)/9M1?
M*)6GFE-&O&*+B7T=$EA .<VXI )(YLHE"?T)\T.3(Q[L<FGI\Y_6QUL**LT6
MI5\.*D)MTS8DNN*R6=RE;/UZ&H #+4CXLELF%YG=$&O>WDSCK9)8&N #BUSI
M=!R^J.A?9+[/\[[&LOU>YV5E<RAU'>$]C'8-N3J,Q$.1\2K7E,5H2D^&SP[;
MYX9'/ACE@BQP?)"O16%\\MC98=,+YE"]X3$6\0*!1Q44F"J&$%&RG*S5Y JD
M3>E1+<D.<<:<"9?/"EA6.)5[<)BYLQ'K:'I=LVD'N$MR0VY&D.8US>%:)P[@
MPUMN:'-/=LLSIIV]PV4 Z7RG8ZI?7@EH=-4V].4)HW06)H)S9SN1A>"U\>3S
MAC@G?%*P\)Z&,AQ6)G:&F;'22M\4Y$K1HM:XT;KW/++X/H"NP*4<XD([F$\@
M%>FB[@+^R;!;<[8N"3)N85^I/;K]QYWWPYX;];;9<-1ILBUXT_,-X!G-OA<#
MHEG#AO1< X_%O?KKLL5O4<S< [IX8W$&JZ<6G6S5E.1-IOB-;8]Y]YX>(R&1
M]=OZ'AX) +"\!ZW2N@BY15;N44G#==/M%=!=/A5%9)3G?"B2J2FNN%$^^-[Y
M[X[YWSUSO?/6MZWO69) (((!!&B#W!!\P1Z@KGFN<US7-<6N:0YKFDAS7 [#
MFD:(((!!!V#W"HQH?XF0=.?)C*/9@H/+AD>7E%DS.+H\6- EH^SD=H,+8$2]
M!6!BZP%%&D-T'F,:;04,SE7)6/OFA58\3.,?TC7GDJ?3C*N>DRC6RM89)Y8_
MT\)8)+ L-E'@M@:X1<96"%HD#F$.+W/  /TAU+[;[.?]D%/H">Q0FMMIXG'W
M7'$Y-MJ2IAI<'/0>,G-F)H),@;&/N/R5B2D8;4<D#:T-:3Q'F]/.N7S<F$3^
MW"+4E=414E2DSIFNH2-BQ23?CZD#UBX)K+%U$DF;=-=_M\^=<KN>&P]@UY==
M<_J--&31K^7].W23XQX*E>LY[H(FQND^^07$N( &SLG9T -^>@!Y +>97J7.
M9R&M7RN1FNPT]BK'(V%K8&N=(\MB\.-A:POEE>6 \.<DC]<WN)VWF0M&F$3"
M)A$PB81,(F$3")A$PB\HOR^CO-E ^GR$J?FJXKV>G:%F-_'9%??N/W[ 2=N=
MHRUR.7HVB(50=[1@/ 'I!U'FY#:FPCN..R!43Q&X$8[C\D7'%=9R(T!L; .F
M-/ZR1W_,]O4CLO1_YCNVJ?0E'5_9U,RR/3&#% +$<W(1F9-K!8#2P5J@.-QI
MQ,FKM^G(2L:)H. Q8IT\<K/7[-=RLNJHKUWT5L@@Z/8K?>%1,(N*^<]LV3QX
MFT=$%&C5PYX8,=(=/7O:"/:O+1GRZ7:MMNG/7&D6^G#ILAM;OC2RZ*?W*<D5
M77QIS<E8]@?)9-#%<3ZI")SW8+5<UY:*$3;3R-],_$GC<<FC($8-+9U%>%7Z
M+-,LRT(E9=/H8_9=.5&KWIRQ:E-W8,[@_#YC?_,[Y@']RM/PH)A$PB81,(F$
M6+SC_P#@N7__ -+R#_\ U+O+<W^ZE_\ +?\ ])69CO\ VA1_^V5?_P"=BCEX
M$_S%?%W_  H>=_\ TBB&86'_ /9.+_\ NZE__6B75^TS_P"<CV@__C?JO_\
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M.N'*'26E>2J/,?B/XJ&?@NWK6N*01 KOY1/&OK&#C8XNE*JDIFAQ$2LQN0Y
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M_K0@X)$QXMTBHCV+#PF.QR(,6F^/V8*T364Z5**VQA$PB815W>(_\O?RE_\
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M+G.<0?DT $D[XAW&]8=98_HVI5LW:]FT^Y.Z"""L&!Q\-H?+(]\KFL8QC2T
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M:HIL&-Q1,:[.\))#T)U';, @PL=89\5MDD;:]UKI86#C#,S1LU1W($1<0)8
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M4L]V9CAO4-*6ZZ1]:O"SC"P0-KB5L8DDC#W$"R#-&NQ5//R&_&^:LVFK2/\
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M!OSI^Z]@4"KEL,6,<M-CTR#A!EVXY<JII=$X'_#^VS^9=]_64T#_ -VGN?\
M\MKY ?[MF$XGYM_;9_,NA0^5/RRZDY2$M8O[)<S,&#!R<U$4/CR]XK2</&Y.
M^/BXW(2@%/SIT5'@Y"3BDI' RSMHBP+/HV?:,'#AP'(IMB<#_A_;9_-]0N^_
MK*:!_P"[3W/_ .6U\@/]VS"<3\V_ML_F70C_ )4O+)<W(8R*B_LDG(XCT*YE
M<?'_ !X^\7IN,='66R03F0BFWG15^%Z,CM;?BM$F[;9%EK;III9#6U,)P/\
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M]M26R U9N(7YQFCZ37%#YG9]>Q,I.Z^$."%55YU!ADIF9@KLH[' UG<HL2*
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;&F<J:R?9YZ0XD.SI!<KPY75TIR1;[PB81?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g108483g13d64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g13d64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X3W%:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<Q,V0V-#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @5%@Q,S4N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(# X+4%P<BTR,#(P(#$X.C(U.C(R)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(# X+4%P<BTR,#(P(#(Q.C(U.C(R)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF
M(WA!.^* HB Q(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L
M;W<@,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI8G)I)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @
M($--64LF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!I=&5M<R!H879E(&)E96X@
M9FQA9V=E9"!F;W(@0U,Z)B-X03LF(WA!.T5M8F5D9&5D(&EM86=E(&ES(&QO
M=R!R97,F(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C M,#4M,#E4,#<Z-3$Z,3<K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 U
M+3 Y5# W.C4Q.C$W*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&5$871E/C(P,C M,#4M,#E4,#<Z-3$Z,38K,#4Z,S \+WAM
M<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E
M($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO
M>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I
M9VAT/CDV/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!
M0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!
M05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!
M04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+
M)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF
M2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&8O.$%!15%G05E!14%!=T52)B-X03M!04E205%-4D%F+T5!
M84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G
M241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1
M341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!'
M:$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51
M;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%
M)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58
M<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*
M,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
M445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&
M5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ
M6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B
M6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI
M26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q
M-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T9867$W
M)B-X03M&6&A8-3<O;G U>#AG96)B5%-.1G1D3VYT2C=#3S=D-S)/9#5"23@P
M,%I!354P4SAE35$W64Q28GHY4"MC<U!Z465,,4)P*VE5+S1W)B-X03M89CA!
M,E4U17HS<&E:=&HO04IY>"]--#ED3S!59C@X3'8O<W!X-#$T,GHO>FQJ*UI9
M+S96*VIF.4DY,R]!3FQ74$=V1W1L+S5Y,"]-)B-X03MQ3F52,#=2:5 K664V
M+S=+<U)+,&E6<68O43-8-6M%8F%D;R\O4U!D9CEL5T<P,G%X9CA!3U=F-6MY
M5G!P*VII;B],=F1F.$%:5F=-)B-X03MQ45I0<4QY>'%6>'%N;'939%1U1E)B
M:2MS-V4U;5=-14E(;6E6,D-G;&I3<F)63U1$2DUS5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER)B-X03MS5F1I<G-69&ER<U9D:7%25VYN0W=U9DY5,VQP8F$W
M:G9)8EHW=C9X3D0V541X>'ER13-P;'E(8C0S,EE*>%!9;D951F-E9DIB5%=.
M)B-X03M/,'4K.'4V<&%0<71Y8E-Z=4AB5#5),EI585)N2W<S8W-O4E51<U<Y
M4&(U-'%I9DQ8;2M46"M%,79O9"]B861,-FYP86QC3EI#1B]4)B-X03M9<'-K
M5GI,3TML5%-S63DV67%R6#-M;3%S9DUA-E1D:$E,66%D3G%C,F]3>6E/3TY)
M2F\T:7)"9T%"*SDU8VDR,4U6448O.$%M0D1")B-X03MF,V1R6F%.<4]S4E=-
M349Z8S-M;B]62DEH1F-Q6&I:1F4T:FUL*T939C-C8F4R2V\V4'HQ-4]B4V10
M,6%45V)/,C O5E9$-F9.8WI2)B-X03LR-&QQ3VEI56]3=S=R,4=+<#1#0TMJ
M8TA&6%EQ*U(O*V-U,$HO35A4:C(O43A0.$$Q1EA/4E!.:51U.'@P;E,U6CE$
M9615<49B9'9P)B-X03MZ1GE4<6)H-6-T6D%&2U!4-51553)'2GE->FM#-#9:
M2U-+3'1J-&DK2T9F571!=58P9S-1:DI60CA452]S=UDX=G%P<G@V9T=F0WAL
M)B-X03M2<TUY;DY8>#-+43%"-FYP9TUB4E9V,$@X9VUV:U1Y-&8K,5A:9CA!
M54]M5$1.0RMD4$\Q=&]%2&]18UIT5&Q&6314=45"+V)E;C1$)B-X03MV;4AQ
M.5=-46]F53!:<W=G4$Y&85@U>#!#-U,P9R]316(S<WEO<&I&451)=T92,' Q
M>6505EDU54PS6GAY>%!63DY4,6)3=$MS,G9D)B-X03M5=DE,0WI19U!C,U5I
M47A+5TY&0F1Y<6EP,D<K6E19<S!N5SE&,6TQ3C-P1B]B86IA:'I'8FDP;6IN
M:D1G06QE8UI:86=%8EEQ=74Y)B-X03M8,"LP=G)'=W5*948S<5132EI2.%=0
M3F]O>DLT<4%65VE+5#A21TMO2F9.+VPQ=DLS*TML=38V1#E83C4Y8SE/6"LT
M07%8.5!J-G94)B-X03MT>')I<6)O>75I=7!Q<D%%2#)/2W0T<3=&579V4$U/
M:3)D:$YF>EAK6G1,95IB5V5736U52D\P<7=E;7=J-6M-2EA#:V1U*TMP:&EQ
M)B-X03M':S%45$ER*TA4<&)U1DY1=45A4S-S,FM15%-);C)M4TUN:W=8=5%-
M5E-I-B]-5#AV-U,U;'1B<GI.<$YV9%<W=$900DQF5WE32DEH)B-X03LT<VIQ
M>F=Q>6M524]+;VU0>F@U4VLQ46%42')D9RMQ:SA2<#8S54IU3U)&865K1S4Q
M<'8P>%924&XW>4M,.#9E9DUE;&DO178Q8S)H)B-X03MV8F8Q=E<U8U!4.5!N
M>34X='5.2S%X5EAT+TXO;$\U,5(Y271T8G-*.59J9#0U3E!J=6]8=49E36M/
M<&E6:31:4T1Y1DYS5EDU279M)B-X03M%+VUN1G%O.'8S<#!L3D]F4WIF97)9
M8T]B,U-3:6)H.6$Y8C!G<4@Y:FXO:S1Q:F)44DY7=F9Z0G9F34=P5R]P5U=M
M5W=S4$PP8D]J)B-X03MC+U=P2F0S5D5:*T)C:$EH>4%01F5M*TMP1&\S;&4Y
M9GIR<$]R,E!L5U!Y:D9:<F-T<FMS5#)95R]-,%I226Q7>F1M:U9:0TIF56U2
M)B-X03M$=#!Q8U9B+T%$2CAK95ED8SAZ5T]Q-EI&2%!&<&QJ231T3&AK*W$S
M:S98355Q,F1W:%!,:DEQ1FQA;D980VLK1T9586QX-70P+WI()B-X03MR1W R
M+VQE-W4O,'9B5T@Q8T,T<T5J:&QH:F-34C-$3F-">'=-;35J4G=E,6-#<UEU
M+TDS;FY49DQD<&]L<&)V9$TK:WHR.3-C-EE.)B-X03M.5FUU-W%E4V%A1V54
M56Q:>&%F=F9H14LX<3EA8EE697%A0F)81G)O3VTR,7EV1S5G=%E9-6Q*1%5D
M23%6:%5%9S=J07%0>%8X<2\X)B-X03LU6%)+,VXR>%DY4G!%6"]55&,U4FM0
M<6%:;F1I;FM-4E U9%9#069J64]$.#@Q,G$R;39F5R\S;'!X*VIT3U9I3T-G
M:F-I=54X8VY')B-X03LT:7585#=#=%%I:R]00GAY4GA&,G!7.%5M;#-51DM)
M,%1I;BMX3TU#94E&3TTQ24AZ94ML84\V*T1%9F-C,V(P:3!X;WI623-'3G)B
M)B-X03LY0B])<74S:T1Y.'%.=V,V5EIH6'!7:"MR2E$P4%=M5#9-,VMF;793
M3EDP,U=*:S%2;6UM;5EY3&1(8U-G+W1!+W=!3S)C>G%C5314)B-X03M01GHW
M*SDQ5U=%:$QD5CAP,DXV=FU44S5$8GE"0F-X175586Q/43-R5$1P;TAX23=D
M531O;FE'>C!4.#$Q=5<P1%16=%I%:75M,7I2)B-X03MH0DQ+:&QJ5U$V:D1X
M6C0Q84UU;U!6438Q.%(Q>G!N84M/=C9X<65G86HU6G4O36UR=U)72G5R<4Q5
M3#9#3U-X<W%08D]91FY74V4U)B-X03M59D=V=VPU2V-Q53-X5FIF;'96<&17
M,7)Y<F908U,S555V;41Z1V)35UEU5RMR8V)R,$9!:RM*5E=0:498<TYS2W%6
M=B]W0W-T2"]W)B-X03M(<% K5%IW2V=033)S*UIJ-7(Q;3!K,6EZ,%-A,U-Z
M2&QL.5$Q<693-&5*:%(R;%<P:FAK:'91,#-*6D)),C,R9'1J:7%A-GED5"MS
M)B-X03LK9&1B6%8Y4FEU9$4Q87IJ,#(R:G4U;'19,$YV6E!):'1W9E-K5U0Q
M5W%(56IE;T%*2DI62UI.679.6"]!1$QN,'EB5TQI,75B9GI!)B-X03MQ2VXV
M6D9L0S)N47=,+V]Q861(8U)4=DDX=31946M.,34P*TA!<E0R1VE7+VLS>FAP
M;'9Q130Q5DYE5DHW5U,O;G5*-%E',65,,%IV)B-X03M2;FQL-$TV='E%<%=R
M.5-7=W$Y1#AO4GI72&UR>D9O83-D,6171FY&65A&<TPR-&QU-45E-%-54V=3
M>G,X;D9J0T=O5V]$5VQ"=&=6)B-X03LU<#5K,5!6-S-6=%<O34=Y,%,X=DEV
M3"MP46I3.55H83(Y06%D<%IK:#%"94PS161X4U@Q<FEV0TIG84PT5D)6-E)Q
M5GI"9&9M4C50)B-X03MU8F1X2D)0<%=R>5)31&]Y3SEG>6MF34A!<D=5.'1A
M.35M=3EA,'A%=$QB4C103D,S.'5O;5=2<C%8=%)"3'=G9SE%4F]Z8U%V<65T
M)B-X03LP2BM(0W))3EE9*UI0>D9S3D14-'1,.'-Q;7)A=#1.97E!<EEW=%5F
M<TQY;E K=W=+.#145F%A;&)W3'%7;C9H3%DK9'(R85!Y>D%N)B-X03M(5E%:
M3E)N:DUZ4V5T2V9445-E;U(V0T%R,69X5F911TMU>%8R2W5X5C)+=7A6,DMU
M>%8X;B\X04]752]P+VU(<#8Q,D]J=VXO<#5U)B-X03MC<FY'>3%Y1S=Z9GED
M<C!L;EI4>$-H<6%I=EDW-6@V;D9:8T1764]):&)*<C!H;6-L;35-9'I8=WA'
M4%I),'=P56@X=WEO,4]:,SEZ)B-X03MG3TI%=$M#;3%V-7!-;&Q,13E$>5%Q
M<%!88T@S>6\T9#=C8S95:5%E8S-*<&1Y:F]/5&9R>EI2-4\T:GE7:#A.2G K
M:%AK1"]!2E%4)B-X03MY,R\R>3=,+T%+:#!Y65I)>E@Y03 O5SE087IV1C(V
M>%-J-V-B.6U5-51N=U)Y4F]S2G=%:%)2='!".5AT65E/6$PP:U9/5DM6-&=#
M)B-X03MT37-I2T%$24)6>5-867$W1EA9<3=&6%EQ=S)F.'(Y2FYU2B]5,4<O
M3VU83V]F<&4T,&9L8B]6;G5X24IU6F8P9G)02#%&0C1I8FIT)B-X03LP<&ER
M37-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9F23,O3UA,
M52]-<E1F*S).1"]!3E)6>FM:24QX,U(U:7)Y)B-X03M,6'(R>7)-1W)+2%-U
M=VM/141:449N<D=V6$=K,&DT3&=J;V-H2TQ!>%-Q.#-U,U!I82]J;#!E5&1(
M:W-",W=P9F]B-4$O-5%0>3,O)B-X03M!3G-U>2\V:#!Y4U4K>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<U=T9DU0;40O;%EC;FPV
M.&AT13 Q.4]K)B-X03MV-U)O5$DX+S=U-%-&9E5D=4-$:TA*2VA.=C5J:7%3
M<C4K,6TS.#<R*VEZ,VUK86AB>4<X8E5R3%1V5F4V,#)',FI,>'E817!L6E=,
M)B-X03LP0VQ40VAQ9'586$964%$O>D$X>GIN>71Q;7!W5UDP6'IF2S!6;F%W
M4GER9%=N3T8W:3)-<W)Y<VLS3DEZ>C1X<'A04W5+<&PU;C@W)B-X03LO=T-(
M+T]6=&%856MK;&I0<&,P<T=M,CAA>5A&>F5#-6AJ:5-%8D]Z;%AB-&516'5E
M;%%Q-C0Q;GHS9C8Y<71J;W(V9&%*<&QV6GER)B-X03M:-FAB4WEY>5-82T\W
M4G900F1+:V9(:'AQ<V(O044T<3%9+VU93&IY=%IA-RMG=%)N13%T3&,S.%9O
M<U1R86DS9&\U=S!S,&M#4T98)B-X03MJ86EX.&Y)1F5/2W-X=&)M0S9T66)Q
M0G5C139,3$4O4W%/07EN9C)/2W%U2W9K3"]!2GDK2B\U5UAP;B]!1WAO4"MO
M<35W1EAI*VYS)B-X03M5;4\O6$E41WI#63)8>G0K.$\K25%&=DQ99G)X5%,V
M3FE'-B]2:6=Q1GHO93<T47IJ>55W8VMR.40O>2\O=T-51#AT+SES=7DO=T-O
M)B-X03MD34M5*WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W-49GEP-6QB>C!N;5EA=EI#,U,S87=&:#E1;#4O5EAM)B-X03M766HQ
M+W)L4%9Q;$]F<#AF.&I&54YD95%D63%45W1+=DYF,7%++W,Y1VYM=4Q/2TMY
M1G9C=5IO,FDT5#-!;&1744DY0TDT:S5B5C99)B-X03MQ;S9$*U=D,W X=6<R
M.35R079T1SAS33<V3%I#,CE+54TP8E%X;35N.5=14RML2$EW6&I';FEA-'%I
M+T](-6,R,VU85C1D56MV6',W)B-X03MU>G1(9S R9490,S%T9$=:2EDW<4XK
M42MZ-EI6:W!2;%EG;6U+=%,K569/0S9N93,Y:C5G=$Q76%4W93%H=C-/;E!*
M24AT:UI7:W1Y)B-X03MB=%5J-3AY44A2*U!V:7%4870K4S%N8S9D639B6C-L
M=6)+>G-$<#145DQ*9%-+<WIT23$S0GEL:%-+-61N4$M1<3-A9T=+=E%.2G-F
M)B-X03LP9G!D;EEC+U8K<5%2=V5P5&IY.4Y!;DML5%-T4$A&559I<C5#+S5Y
M*T@O25-T3G O=T)7840O<4MU<T-V15EI4DM.*S)!;U!*9DE3)B-X03M7=T)!
M8492:6QW2G%C54Q*<6QG>'=H25=R6$-L*VE(-68O.$%+0BM7+W=$=&PR6"]!
M1D1P:%90<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7(U0R\U>2M(+TE3=$TO-UDP2"]5
M5F,T1F5(,6]A,7A697I$06AQ)B-X03MV:&ER5E(T-'$T:V1E,D97=5-N;V-5
M:"MH+VM$+VQ!+TQF.$$R>3=,+W%(5$-&2V99<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6'E(+WIL.2\U36Y49BLR3D(O=T)25GIG2W9$85EQ=4E'2T=G359C975+=30W
M)B-X03LT<3)56'9V9U50,$\O3"\O04I14'DS+S)Y-TPO04MH,'E34VXR2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03LR2W9+
M3D@O3GI58FY79$QJ=7)N4RM'<#9P3'!C,VPV2EI6,5=X04UG:&QN6G!31W%9
M:'E(;TE0:49'3TMP>C5-.#4V-7%/<GA73W4S)B-X03MC1FQE5$Q/,&5J4V%2
M9C)->$54:T%X6&0Q33!-+T9!1V(P-"LO8D955#5N.#<O-&8X-5<Q<&134U-7
M32ML>E-W86)B>')*8UA.-$QM)B-X03M'3TI)4G,W3U9D=F@U0F4U-E9#<G)J
M5V909"]R,G$R3VEV<#%O;6U7.6Y+=&YQ1G1,3$Q*2F-O-W1'.#A&,'%2.&5(
M1W%X=CE/2W17)B-X03M0-6U#-#AR5U=U+V],55IX3F)3,TXO1F%,138R;W0S
M84]C3DQ.2D%K:%8T,F]S9DIY0EAJ:7)-8E<U9W5R5T<V9V)N0D]I>7A0,'%J
M)B-X03MG37 S.6II<7)I<C5$+S5Y.7(O>7-R5&8K,DY"+W="4E9Z9TMV1#99
M14]X5C)+=$AR:%8Q85EQ-G!*02LO1DPY1"]Y+R]W0U5$.'0O)B-X03LY<W5Y
M+W=#;V1-2W Y:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER1DI02T=T86IR5FAF83ER158U6C94)B-X03M/.3%P=&QA,FAT9C,U
M5F\T-6)I4G W:C%7:E-1.&5+;W1D>4\R2W),5'EB<FLK=C98<3-M2%=O=%0O
M46=M3VUX45=F,5%M5V5-=W1,)B-X03MC3C8P=VMB,&U)05)55W!R5'!I<3-Z
M:"M83G0U;#%E2%9*3#$W3S=S-U(T3DYN:%0Y.6)84FU35T\V:F9K4',K;59:
M2U5:5TE*<&ER)B-X03M5=FQ(>F=U<#-T+UDK64Q3,6PQ3S-T66(Y>G!Z>5-"
M-UI'5G!,8VTW5DDK9DUK0C!F:C<T<6LR<F9K=%HS3VY73VTR9#5B;7ES-T$V
M)B-X03ME13%3>5A5:7)--U-.9'=C<%E5:7586GIY:TMT,F]":7(P1%-B2#E(
M-EA:,DA0,69Q:T5C2'%5-#AV5%%*>7!5,')4>'A61EEQ*U)0)B-X03LK8W90
M+TIL86(O,GAO9CA!<4MU8T)1.$]W2S-I<EAY=W$T:F9&5W%D<U5U;T]U0E$O
M42\X=B\X06Q!+TQF+V),<W8X07%(5$I+;C)+)B-X03MU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M2TY8.&XK561A=59U=%DP4W<Q)B-X03M+-E)"16LY-6%W>GE#345S14132WA#
M9W-45#-X5D$O.'%Y+TQB+W%5.4<O-V@Y<B]!3E4X5F0O>7)(.'1V*W!4,&(O
M=4@R=B]!1E1X)B-X03M6,R]+<V9Y,2]W0W!4,&(O04QH.7(O,51X5C,O04-R
M3#AT=BMP5#!B+W5(,G8O5E!&6&8X<7@O3&(O<54Y1R\W:#ER+T%.53A69"]Y
M)B-X03MR2#AT=BMP5#!B+W5(,G8O0494>%9K5G9B=U<P161V8GAP1&)W;W-C
M34UA:%521D9&5E9&04%!2T%$1E8K2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @
M(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A
M;F-E240^>&UP+FEI9#I!-C5".48Y,CDR.3%%03$Q.48W0D8V.#8W030W,S V
M0CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT
M240^>&UP+F1I9#I!-C5".48Y,CDR.3%%03$Q.48W0D8V.#8W030W,S V0CPO
M>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X
M/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I2
M96YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*
M(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI
M9#I!-35".48Y,CDR.3%%03$Q.48W0D8V.#8W030W,S V0CPO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#I!-35".48Y,CDR.3%%03$Q.48W0D8V.#8W030W,S V0CPO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD
M:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CA$03E!
M1C8X1#<W.45!,3$Y,T9&03$S.#<T-38S,#=$/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 T+3 X5#$X
M.C(U.C$U+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I!-C5".48Y,CDR.3%%03$Q.48W
M0D8V.#8W030W,S V0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,"TP-2TP.50P-SHU,3HQ-RLP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T
M<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^
M"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO
M:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%10
M9SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE
M3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A
M<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@
M(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @
M(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C,P+C P,# P,#PO<W1$:6TZ
M=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#$P+C P,# P,#PO<W1$:6TZ:#X*
M(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@
M(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%10
M9SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:3PO<W1&;G0Z9F]N=$YA
M;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB
M<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N
M=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG
M/E9E<G-I;VX@-BXR,SPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S
M:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A
M;&EB<FDN='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO
M>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y
M86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S
M/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA
M;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y
M<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O
M8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( & !! ,!$0 "$0$#$0'_Q  ?  $   4% 0              !08'" H"
M P0)"P'_Q !)$   !0,# @,& P4#!@\    ! P0%!@('$0 ((1(Q"1-!"A05
M(E%Q%C)A%QA"@9$:(R@9)"4S.,$F)S0U-SE25UAXDZ>UX?#_Q  = 0$  @,!
M 0$!             0(#! 4&!P@)_\0 0!$  0,# 08#!P$&!0('     0 "
M$0,A,4$$!1)187&!D:$&$R*QP='P,@<40E+A\14C,V)R0X*2HJ.TM<+2_]H
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M=N._;[9UW&U'L,@GQO\ .WHN^"6S$7_/SO=>D_[*N261X6=)15--%%.XZ[N
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M[RN1O>B*^Q$1)!+B+$CX@00;Q8@VL?-3+*')0#N>-0\B;6(8JP 8SCN C@0
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M$26>,5T;F,+O#6-B,B,E;X^VL$E3MH-Z>!3";Q5A2R2<5*"5#@2!!,X R,S
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8B:(FB)HB:(FB)HB:(FB)HB:(FB)HB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g108483g13s54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g13s54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4H%:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 U+3 Y5# W.C,T.C,Q*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 U+3 Y5# W.C,T.C,R*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-2TP.50P-SHS-#HS,BLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%E045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q=W988EAZ>G!L=G%M
M<TPU:28C>$$[5U-X<S=A-G59<D@V;D-'<DA&33A1374U*T5M3W4R+TAT6$97
M85EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%W+R8C>$$[
M>G@K83-L3'E89%%7=7-V4#8Y>$4P-DI"2#9L15%/86YD979P=&EQ62M4=E!(
M;"]Z9'!X=G1);%EO2&1'9VQ!4UEE;35J3$9+:SA3>28C>$$[;6AX5E X5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<5,K9'8K54TQ+W=$-UHQ
M,R]!36U(>%9/<U9D:7)S5F1I<G-69"8C>$$[:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-65U-1=WE5.5)&96QA8V=$4W5X-C1Q;'E):659=4M+1E@V;5110V=Q
M6G%N<#1N1E4P>%8R2R8C>$$[=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+<$PU,B\U47I8+T%0=&Y89CA!>5EF1E94>DQO*W!A<EER8C)'<7IA4DMR
M:#)N9R8C>$$[5E=:9U R5%=H<#AJ;'5,24EM>4]*0D9P4')N:S=Z0G%';U(S
M3G1R.'1N>&ET-'I+<70V9TU,35I#158P:"]F8R]I<6TS155Y<VQ+0B8C>$$[
M4&M8>F]:+U90;39F:TDU;%%R15%!,&IL,"M$,4-P0TY4<G52.%!3;4MQ:2M6
M4'I!;3!/>70U9DTO=T)4,4]*2D)D6$5-9G)Q>DYC*R8C>$$[<79%>4-/=$EQ
M2E9L-V)D5&EQ;%IE4F9/3G!P13%H2C5L9E5796(Q26YU9E=4:6AH:U%O>DI*
M-FI,-FMI4'@U1#=.2S!/>7%Y,R],6"8C>$$[6%!6:RMU95DW:31T,TQC65,P
M.5%R4U)/0GDY659O26E+-V1F=6)1>E!2<E,W=$Q"64QU6#%P:$I-=V)K>C!2
M-5=E3D]4+T4S<&]W4R8C>$$[<#A-0U5B:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<50S9C%V.4Y3+U4O5"MT9E54-E!R8W94-65R='DT-S K5T-6,71Z67EU='5A
M6&%L828C>$$[+VU,3D9P>C)D-5E7,7I%>$]O>$):1VAL6#%O4T%P6E=C9G5L
M;')V,W S-4M)8U9E<FXU36-82'<K=75,>35)0U=Z+TXQ=$]V;%,K,"8C>$$[
M,4QU5TY6<VU#='EJ86="67-52V-Q,4Q64F@T05I.<U58,"\X-5!2:D@V4C S
M;BLU3$9&64=Q13AW>&%.<7$T<%=G0CA+0W16551A3"8C>$$[*V%O;79O3&AR
M17)%.$ES8F]G0DI5-45Y17%T6$1C86,V<5 X;GAX5D,V9%IF;DQ(4&-3-FIF
M-F1.2$IB>6E+0T)A0DQG47-)4W9*0B8C>$$[=#9V1716:CE!,GA6,7IA9FY&
M0W-B5VPW63-#3R]W0SEJ:U%,36MB4%)F:3-J3$MR5EIU:&]+3#1Q<E8P<C@T
M<#<R-W5,<E9,0T=!4R8C>$$[1F)3,'1664%W2&MD,FM2<5-D040Y4%EH;%=6
M*UAO=DU%8U5Y83%):S!O.452>4I10FE,94U3;&%5*T5Z8VE/5SEA.7%91E1B
M1EA9<28C>$$[-T9867%H=%!N=4IO1V5F:'I%<W%$9T-"4T]2:TA5;F8T8VI!
M:VID:$%K:F1%-4IM:W9N8B]L1$YF+S=:,3,O>5EF1E4V>%8R2W5X5B8C>$$[
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A625!-9FXS>6@U875)<F)8
M9%1J<TIP-#)L:%=54#A!16E63$5&5DDR-#<T<6\V0B8C>$$[-6PP3'I"<D)V
M9$=V63<R,D9Q>4=33W5Z3$]624E)0D<V;G1I<DIC5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&EQ0VEM;D]S,U5*:TIG:B8C>$$[=#1(4T]I,$134$U'3F%C=6M9
M-S5!13A22&M0,'192C1Y3VQ$.4M-5C!9:TMW2EA:9T17:#DX;F):84<P>B]E
M6B]W1&I08V8X;C-Y128C>$$[3UAX4#-S26-V:69V63EQ2&UF55E0>D0P=E%)
M=E)B5#=U,FQL;DY4-G=L4EAA;$M%8V%+=F-(-3$K1V).3'9/36XU9R]O9E@Q
M;&DP=B8C>$$[.4-F57(V:G$P+S%N,'91;31':$A$;#EI=C T<6XQ+W$K<U<O
M;2]3=$U33T$V5&9W5'1*2S-,,6A,04LX5F\S1VQ'6'%V:FPX8V-4:B8C>$$[
M378T9VDY,"MY:$QS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)#+WI4
M6%5M,&I4=G%&,&).,#%#1C5*=G)%1G-J249C1TYM;B8C>$$[6E$S3&Q8:4YZ
M5&%H;V-)5E!T6CAO*U8Y8FUJ;C%J4W)854IO:V%/2U,U:%-6;%)W47EQ5T)O
M1'E.8T-O9E-T2#!R4TY:*W V6%IW,B8C>$$[3G(Y5F%4,$QD1FI4;DI.>5IU
M2V=#<$IX5E!S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ06<O-#<Y-2]Z0U=V
M+T%#8W5-<D@Q;C-$.28C>$$[3%50<E!U2"LK6%=%8V%85V]L5D-L<FA3>$%!
M2B]C4CEC34)U9F8X06]$2T$S4'8O045"9G!N*SAZ+SA!1V4T+S50=FI$;#A4
M.39W-28C>$$[9D4O97=Z5S,P-R]L8U!L,DHU<$)F1W=U6DEO0D=H:DM)<VEK
M=$E:07EN.3<R:E!Z-C59>EI(-3(O=T-533$O+T%,6C$S+WE99D%Q:"8C>$$[
M-7)P0F9E6#<X1#1O3E-31FHO:UAC56QU4B]W8G)L*TAC4T@Y2#=T,DI:1&Q$
M2C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5B8C>$$[9U@U>5=D+V0V
M1'!C5FU)=5@V56=--U144G="6793;$1S<&M+:&E!9G-G.4MK-T$T47)08T-P
M8B]!3DY*+W="1V8O33-&57EX5C)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R
M2W-7;#AZ45=F;795634T2$9J0F(R<U9X9DHX85)317E32TI&55964TI0=&1"
M5&9R;4MC=T=1,WEO8B8C>$$[=45D4TDU6D%J,&=#>C-C*V%)=4YA6EHW:3$P
M<FAD86IE>DLQ<E$X;VMJ.4-)1V52;"\S5W1D=C5J<TUK8VTU161Y9C%$9&Y,
M3'522"8C>$$[95(U9DEB*S<W,%0U5#!P3DTP:S)Y>79/=VYN36MS:'%765-S
M<%!T6&HP>5=#2$1'=DUS.4YI-$E69#=N-S).871A=F5F;7!P17)79"8C>$$[
M.$5S:TMI-FIJ=4)A:V5H331:-3!+>&9A9FAW8714;#=E>5!Z="]Y:&UV.$$O
M8D]U+W=$:W<K0E9,>C9K:#AO-FI.1TMY5VEP94I4<B8C>$$[5S!K5S0R+S5&
M-69P:BLX2&YT.#EM37539DDV=6EU:'%J04UP2&-(8UI147EB>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMS028C>$$[+TXR35A.:G Y:$YA=UA6<DY*
M2R]'831T8F8X069P2'=H5VPP-D(P8C%71#A!5SA-2590+T%$0C4U.&XK5C59
M8EA7.5)I,#5P67DY=28C>$$[:G$T57AX9SAU2E93=G=H96U"5DA14$TK9V59
M9%IA-S!7*VEV649T4VIT1U151EIY<'%P05EF16AP='941E=467$W1EA9<3=&
M6%EQ-R8C>$$[1EA9<3=&5VUD1F]'64%S84Q5,'%F05DR='!F<6UO0WAL*W-4
M4VQ,4T,R;FYM44)A3C924VTU1F8R:C!/5GIN=S<Y2TQ6:VYW-VYK028C>$$[
M4VQN;%=Y;70W;39A-T@K;3-L=&(S5C10*TQ:<&)H:78K=T9%2'--<7=2;VTK
M6D%**S%P,#!#0V(U:T%N-&U8.6E+,$11=$PP,BLQ828C>$$[5WEH15181G=V
M<4%D2V5K<C!59&AY:T\R5'A9-'A-<3<R941"0T5P1TEQ>6U';68W>E X03A:
M-VHO:RLK5&AY*THK.71H>2M**SEI*R8C>$$[<F$Y1EDO;5)P5VQ#0S9U2CE4
M=&EY1F)M5DQE35)L*V)E:%51=3-#<&)L=CA)<#A85V).3U!/,R]!0VAM=B\X
M06)/=2\K5$0T<6UE;R8C>$$[5VE8=&AC,F(W2F-X4$-X.7!&2VXY95-J2VE$
M,TML;FMU-F$V.'!A5$LO.$%E0S%J:FQ(+T%"6D5V<'8O04U-<'EZ55)R269E
M:5!*3R8C>$$[<W!3-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&5TIF;5(U
M;79F3#)M-F1D,D9V1F18:S$Y1F)X>%-R>5!'4DA$1D9$23-,.6XT5"8C>$$[
M,S,R<FEQ86%N-5(X=#8R,%9X<FUK,FPW9')%23)-,&%Z0E%1=TMQ6%566#DT
M.4YU*TMQ5VQA4'!7:V%Z.50P=7IH<V)8-G$P;F]7-B8C>$$[3$=N3U-B:WIC
M5D%&4U1I<699<3=&6%EQ-T9867$W1EA9<6AD5'9(<S=.-VA)>$LV<VEH1V)G
M1'IC2CEO0G5N2W94251L=VDR135C228C>$$[=&)F2W)83VXQ04Y,9VM6.&91
M;'AL>DAV+U%6;GI(=B]!149J,G58:T=Q*UI.3S!7,C54>$EZ='%K:UDU4F]K
M6E-54D]W,D):-&Q"2"8C>$$[9V9F369*251M26HT=4IM;4HU27='+SA!3SAQ
M,W!024I)+SA!158W2'E(4#9P86YH559O2DQJ=#E)>3A(,6XS1#E,:V<O=D0W
M:"ML6"8C>$$[<W8X065M+R]!3TTV+W=$2FE,1$AM9F8K9TUO.'HW+S!"8G!,
M;SEQ-5)G=SEE-#-"<B]U.7IJ:D\S>% S<FI/,WA0,W--=3=N5#(O3B8C>$$[
M*WES-&\W,E<O5S)A-75*:#9(,5='35%V1VE&=E-A9FDU66YH-FER>F\Q1&QJ
M3D4K9F9.4U)A8G(R:4QP96]3>6Y48FMI.5-!9E90:28C>$$[=%I:4#<U;E9D
M9VQ$-S!'0E=B67%X-WE6*S9T9%1S04M,66%N9'A2<C1*2DHY6E%F47,T>DDQ
M2$U(=FE0,69O67A:1&U/>61I<G-69"8C>$$[:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<D-0>DQI=G!F,%A$66%,3'$Q>&1Y4U=K,&E46$U-54YT3'=-+W(O049D
M-'533T5!;S=5<4]H-B8C>$$[67%Z8T%#=$(Q,T]+<&(O,#!N+U)N+WI.>%9-
M<U9D:7)S5F1I<G-656],<4-C>6E*:51#-6EK<4-T2$%"23-!<C$V:D%*06]%
M9U5.4"8C>$$[9%%81VI4,T5G355,47EL>$M61D9!24I99VM!8F5/44UG66MS
M1$E'2DHU360Q5'I*8GEA1W1T;S%U*W!Y4FDS5FUH25<S5&DV9D,P-R8C>$$[
M9D)886Q&<69(365E56-&4C,U9FDS17EA9T=&67AX.'583#5Q*W!A3')E<%A'
M;B]P5%5"0D%:>4=S-T1N1W!8,&Y,2SAX64\S24M6,B8C>$$[0S=(2E1X>6M2
M>$AR,%I:34TU:V-5<48X;RLW=B]S5&E#>G1,3SET3&$P:%-#0T\S;D-2>&=+
M;RM/2'--=4510T%/-"]O8VE-0D5G028C>$$[54M0-D5X>7AT56],65)35'E"
M,EEZ=4I'1%5O0T9#9D111'-O-C1"1W)9:4Y7<3175'-64UAZ="]Y:&UV+W=$
M8D]U+RM41#1Q;E=+<R8C>$$[53!854EO+WI".'AA6#A83V%+,'9L<4YI4D5)
M6DXO:TDO=T%C>7-K9C-56F4X35%D,E8U:7-N67$W1EA9<3=&6%EQ-T9867$W
M1EA9<28C>$$[-T9867$W1E5I.'@K979+6&QQ5TM,6&14:7-*2FQ:-&QK-45S
M<6=K;C11,UI4:7%(,$1Z3&]8;4171&4V3F5X,W1S3%9K36MD9&U78R8C>$$[
M<5%144-.,5!B1E=3-'%S;&UH:55.2S9X<5-&1$U1;W%E9S-W16=)2D$U<4XQ
M9'1"8U=C45%/3'%5>$9I,4].26YL<E-H<B]D,'=3;"8C>$$[4DAM>&Q+:4(S
M+W%33S8X,658-"]-<TYU3&MY>G!B>4-144(U;$),;U9$3$9Z2$E!3C)Y:5=A
M06YZ-D].3%4T>&LT8C-R<'8Y>6Y$-28C>$$[;G-:3F5V63E/<W)M.75Z1$%'
M4DEZ14MG=G4W5&5M1D9'6&8Y94%::'AN:$)*44Y417I):4-4439F<G!R4C5V
M3C=N54=7,G-9;4XT-28C>$$[-%-3>7-13T-52'=*42]0.$UC6GEB-T1M=4DU
M=#EO+U8S;%-T9$5U-WI1;6XX>%AA>5)*2$DS,4<S3%)7:6AE6'A/4U$X;FHX
M4C1J=R8C>$$[-S1":DIH8WHX3VI'3T=5;UAL4'=(,"]T*T]Y8U!A3$HU8W0W
M97=J5F]X2&)M0D5+:&5#<VIF0U-12V-2-#5A63-!0654:SA0-W-#4"8C>$$[
M:VIR>4<T96$P94956EE:=6-V3FEP-&U.,"M':715+T@P3DUS:T19<&Y)1WA3
M;SER0SEZ2&-T>3EA2E=20TA93%(V8V=60C1T.6MD4B8C>$$[:$U29'!-4F1Q
M=49K-T9867$W1E5L.#=F.&]:<B]W1#)Z<G8O04I-4&EQ9%EQ>&YZ5D1&<#)Q
M85HU;5)E3%=S:3)7;WE$871N8W1W*R8C>$$[3#)I;5I(*R]-;D-E2TIH,S=J
M,VHY:D4Y-TIS>&U4<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ5C8Q
M-5<X=#8T67IR1VU7,B8C>$$[;T=%37-2=5EK;#1I4497035!,'%$:7%&,')2
M.4LP:E=F<65L,F-.:F$O5E=K.4,S4EDP-7E48VUB:6]!<5-C5E1U865'0TIP
M<#5&:28C>$$[:5%695)Y1E5$>$I/=W=%9V)L0DE!<W-D.'DV+TU&:G-D1VA7
M+W="43E7,V518W%24DE:1DM'4U1O0S=5;W97;2M9*V),,&IU9&Y%,28C>$$[
M1V,O5$%C571V8U!E;S9L-5IU3"LK,'E85W)M4R]!=4<U,C!-9G R<V%'1GIU
M;S5-9FI#:7)V=FM:-%1):FE.-R]":FLP>&Q+2FUE3"8C>$$[9FPP-4@X8FQ0
M;W)"8F4W9RMR47A15V--36M9:FHK0VAD:TDT;W$X869"-#5K0TY%5GEC;U%O
M:6A10599-%IH<44X-T)F4V5/2D5O4R8C>$$[5W%H8VUO;T%0="M/14$R4WE!
M4$53,V$R8V1S6GEJ37AU2E=M9FM184UW06].:'0X3TU9,6%X:E8K838P=&AB
M5S912S=30DLO1SE/4B8C>$$[<5-D*TE59"]$1TUA1DQ'3D-L6$I-;EEQ-T98
M67$W1EA9<3=&56PX-V8X;UIR+SA!,GIR=B]K=RM+<#%I<48Q5%1R9E5T3G5T
M4'525R8C>$$[0S=I94=4<%=J<5)55C=J<4UL0UII45(P56A,+T%#9G%.>&4V
M1$-,=S$Q0WI,5U8O,R]F,C4Y3C(O=T)N45 X051L;65)171U4C-(>"8C>$$[
M4D4W2C%L2UA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5T+S9A5"]!
M2TTO*UIU2V]$>FI0950R6#9&,#!T*VMD454P36)"5"8C>$$[2$%H0FMK2DI&
M2R]91RLU3UDK;TI)-%DX>31M<4I-94-0,5,K=V9J6DU,1%$W0S$P,DMY4D=#
M2U9L:V9K4DDX<6M.-FMJ2V%S>%E63R8C>$$[*U=2>$%2<'5H:&I'4$-%>'EX
M=&1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)'9GI!,694-UAY-W%';7I3
M:U@R<#)&.4A944MJ=28C>$$[,')2,GI-=UAI1#!(:FEQ6DAZ4F]);%=),V%I
M5C%:;&HT=GE+<5%'24A'=$%71F9N:7)H-6\P17ET14QT5$MI<7I2.%@U0E=*
M0VMJ:B8C>$$[5VA+;6YY>%9I,&M.;%EA<F8V>#5C,6)J93-K;V953E!U;%HW
M859G;TE&5E0Q25<T=%5-2RLT<&U537=L15)M3F@Q2$YJ6&,Q6B]M3"8C>$$[
M<D=Q<DQ(6C981G P:TUJ=WI83CE+,&M3=D=11T-*0VY/5#<Q2'9J3$9J:GIL
M9G4O1WDR4W,P+WIF-6DP>7A2-RMA,CAY=W)Y36QX628C>$$[<3!&>G-X<E--
M;W--;DAP4E-P*UIX;$A&32MN,"LO:W4T4EHO3FY11C X,WHR1W!*1#99;$9B
M8G%P<%1C354W,2LQ5$%.2U-A16\O3B8C>$$[94IF9&9M=#5E=#=+3S=.<'%,
M<$E505%7<DMW3#=$9'EI.69!+TQ%855K,6-F;79%=G90>E(P1S)A1F9Q96]3
M=$\O<&]%=%=&0U)89B8C>$$[,4-N-%EX,'A05U!Z6&E1."]W0UIK-'9)26].
M075N9VPU;#-L;71O<'%+0G9(0UI'-3=N97),5$%-34LS;4PY>%AI4&-R2BMA
M96EF6"8C>$$[4'%K*VXV;&)Y*VXV,WA7,W%$:GDT+S=O854Y9F%N=F@O3$=R
M16\O4#EA.%,Y=GI2.'-M-6UT<F5/.75:-%%P84]/,&Q5+T5+:F%54B8C>$$[
M.&8X05I5>"]+>7%Y66=E.65*0S)F-6\K=&-8850V1&5X>%<X;G!O.%114W5F
M:#4O=D4Y4D-J8U=5,$)B<FEC161Q;5!T6&DX;&94+R8C>$$[04TQ9DQD,T1*
M33EV<49Q:V)/<$UT<$LK-F1D-$)-0G8T;D=7;&M/<U0X4BML94I/.4,X,39,
M<FQT0E!94W-28T)J1VIO>4Y24U%A,28C>$$[1E R9DA+8VU-=VQ24T1A8C5"
M3'-666YB*V-V3%8S<3AT,5HV;&)3<$AB4W=G3DMS5EIO6GEJ2E=4:BLP<$9C
M5'E15R],;71A3TEP="8C>$$[5S%056)+3%4W.#AP67AD44]S34M%:4M*6%9U
M2E5,.%))-FMN2V-51'9+6#%&;S X2F)Y;4MN3#=/-&9J<6Y*.'IE5W@Q,5=Z
M2&(O928C>$$[:4QV+T%,3$QN26-F33-L<T5!-G1:9VLP2"MK4F)M;&8U<U9D
M+VEB>3-7;C96<S9N8T0V>$8O>E9I<G8X5&57-C O4W1N56)K9E=)=B8C>$$[
M*V%S5F-033-L<S%P<3%M86)';'A&,2\T3$989C1M.'0P<BML<D]N:CE9:2\U
M<7A6>#AZ*U=G3U(Q87I!.&9R159.+SEL:7)J-6TX="8C>$$[:6QD5G,Y.6@O
M<$58+TY72W4O>$XU8G)4.4LR9%1U0CE9:2\U<7A6,RM*=DQF27(K;')0:T)5
M:C9X1E=H-F9T93)+=4AM8GDR83 Q5R8C>$$[>C(R4"MK4F8X,5EQ=F<Q+U%R
M:599<F95<E=A5GIX4T]/84YM2CA!07A*>%9(-'$P5E5K16=%<CEK*T=+<411
M6$HQ0T\T17=&<VM5:R8C>$$[8C(O0E-3-TUH5GA*.6]C47)!<C!.9F)&5D]'
M,3%"9%=U<FU3-40R37-52U<Y<4553D<V1GI)>&M!-4U'-4Q12'!1*T]+=&%F
M839J0B8C>$$[8U@W,V0R3&U'968Q3$M-4G)'65EV5%)F5$Q,.7,X,5IU4CAA
M9'-66&%:8E@Y=D1+=#=C<&13=E!,2D<X8U%H0WA/-6%/37%'9FM54R8C>$$[
M:6QQ+T8Q>%9#,C)N-C=&-6)E>&95:V97:D1+:V5Q0T)&5EIN-65N3#9!*T$X
M0U)693E09D965S5S3E%L,$TR360W-D8K649J*W9P1B8C>$$[1U%*06]$3TE8
M1%(P4#AP1DU68C%M>C%/-W1O63E/=E9S6E5U24I:6D=I5UE01$A)<E-X8U<R
M575G241D5C9J1EAA:&%A<$YE-F1,828C>$$[6'$R,71B5$TY+V)M2EI$8U)'
M2C%6034S:DMU>71Y6'=P:7%J<4=N-C5.<3%N8S)E<')B5TU,2V)Q>DU#4T=6
M44I/645H*TI/4EI/;B8C>$$[.'9Z>%963FIQ;C981C),.&95854K<&5I;&%C
M0T0K.2LS.75J67%S<S=(5V]T675,;30Q05A';E-)4D)A96EI3D<S2V]R24)Y
M64MU,B8C>$$[-7A66G!E;F$U8C-6*SDY<5EU-$QG9S)C87=2>$Y$4G!+:W-V
M.31E1%)R=B]!0RLK2W)B3%1F34U7:C-D<F-A<VLR<%-H+W%T*VQS:R8C>$$[
M87=S,%-Q1TU02FQC:55.26%N971-5E)7:3)M<%=L:C9/;S-G=G)G4WES<S9X
M3$-"13AJ3D9(=U1B.3-'46QE.4XY.3A64C)+=7A60R8C>$$[-F9P5VTV8F)V
M8F%D8E)754QV2DUY44EQ3#9K<D9N96=&3U1-831Q:SAV;')5+SA!078X06@R
M3%533#A7:3)G,4EQ5DY107909VA7;28C>$$[,V)P.4<R2V]Z>D)P1CEQ5FIA
M,CEP96UZ;&=U<F$T:VUO5TQP0DMS:G!11E(X9D=M.6-66#9P<&0W9#9N;SDQ
M1&5#0S(P-C1K;G5R628C>$$[>&@O6$0R,'-#3'I*0E1G,'9,8G(P>%9A,FLS
M>#@Q2G)(,3%V<4-73%=N-DY++T0V>E1,2C8T875X-')X27!V=#!P=7%T,#-3
M3E-T=B8C>$$[34=S-FIC,R]!3EIS.5$K<D-X<WEN13)Q=U)L6D8U,5!-4T]X
M9F]+5E!81E944W1(;7-9.5)"=6UK;'8W<6$V5GE#9E-%;T-O:6AM8B8C>$$[
M6E9593%F1$95='-F3$=T5R]K22M86G1:95A6>F%3,C4Q<TIX9C%:03-'6&=3
M,S)E6&II<EAM6'ER<D=Q954T9$9S9%IK<TPV1TY%3R8C>$$[<$--35AA3TEO
M1UI+:CES:519.5)I<F5Q95=.8G9,8E)5:#%Y5S)N,'HP+W)5-F]#8FQL369.
M;4)0=VQL4C$V.4A/2W(Y5#AU-GID928C>$$[86)(5C=F5FYG<TQ927,R;FA4
M4G=O;#5G34-.<$1*2'E$02]92'1I<F]F3%=R>"MC6DYC3W)U,6A+<DLR;6Q.
M=5!P4G)';DE%07%K:28C>$$[>5-#<3%"8RM*>%9V469,=71A9G%7<UA&-W)5
M;#EB86EW83!G36%O,7-F5FUA;V5P1&XP-5DP1E8V4FIT:7)8:V9Y-7)79S9B
M3&$V="8C>$$[<D0V,5!*27-G=5I%.4UG*VMI>69$>6(W8VES+WIB=60X5EI&
M:7)S5F1I<G-69&ER<U9D:7)S5EE.<59T*V%K1#-5=6Q45W,T3C%*2B8C>$$[
M2$1C3T<U46-P5VI334))=VYW3D5V>$UF:5=V46Y#<DEV2SAF;61.3V1F36-L
M=DYF:6%4:$IA9W%H:'%/1E9),E!8>'=+;2M+=7A6,B8C>$$[2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%9J+VUM,3@S4WI7:VYL-F5+27A,2UI5;6)J
M1S!P84UX1U%"2%IK-'))<$-L5#A13B8C>$$[9'-644AL:&9Z3R]355@K25=S
M9C!D2$4X8W9O5D5K:V=#37-O;T-!0U=:94Y2<W1E-$=&5U@T1F1I<G-69&ER
M<U9D:7(O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4
M:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @
M/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!0;W=E<E!O:6YTPJX@,C Q,#PO
M<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @
M(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/DUI8W)O<V]F="!/9F9I8V4@57-E<CPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E
M871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT
M(CY0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD
M8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z
M(" @(" @(" @(" @(" @5%@Q,C,N86DF(WA!.U5S97)N86UE.B @(" @(" @
M(" @(" @<G(R.3,W-#@F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# Y
M+4UA>2TR,#(P(# W.C,T.C(T)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @
M(# X+4UA>2TR,#(P(#(R.C T.C(T)B-X03M38W)I<'0@5F5R<VEO;CH@(" @
M(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C
M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T)B-X03LF(WA!
M.^* HB!$;V-U;65N="!#;VQO<B!-;V1E('=A<R!S970@=&\@4D="+"!I="!H
M87,@8F5E;B!C:&%N9V5D('1O($--64LN)B-X03LF(WA!.^* HB T."!H86ER
M;&EN92!R=6QE<R!C:&%N9V5D('1O(# N,C4N)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($%R:6%L350F(WA!.R @(" @(" @("!!<FEA;"U";VQD350F
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@
M=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @
M(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @
M(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R
M;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @
M(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @
M(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+R(^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXW,C N,# P
M,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XU-# N,# P,# P
M/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T
M1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @
M(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @
M(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%10
M9SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DAA
M<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R
M<')I;G0^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR
M9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE
M/D%R:6%L+4)O;&1-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E
M<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I
M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;&)D+G1T9CPO<W1&;G0Z9F]N=$9I
M;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I
M86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N
M=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG
M/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S
M:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R
M:6%L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM
M<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE
M/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.CDQ1D9".#9"
M.3DY,45!,3%!-S-"1$(R-C4Y.#(T,C0R/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.CDQ1D9".#9"
M.3DY,45!,3%!-S-"1$(R-C4Y.#(T,C0R/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M-CDV13<S14,V-CDQ14$Q,4$W,T)$0C(V-3DX,C0R-#(\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)
M1#YX;7 N9&ED.CDR1D9".#9".3DY,45!,3%!-S-"1$(R-C4Y.#(T,C0R/"]X
M;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.CDR1D9".#9".3DY,45!,3%!-S-"1$(R-C4Y.#(T,C0R/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z-CDV13<S14,V-CDQ14$Q,4$W,T)$0C(V-3DX,C0R-#(\
M+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8Y-D4W
M,T5#-C8Y,45!,3%!-S-"1$(R-C4Y.#(T,C0R/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 U+3 Y5# W
M.C,T.C(Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY,D9&0C@V0CDY.3%%03$Q03<S
M0D1",C8U.3@R-#(T,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,"TP-2TP.50P-SHS-#HS,BLP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO
M>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $: ET# 1$  A$!
M Q$!_\0 '@ !  ,! 0 # 0$           <("08% P0* @'_Q !,$   !P$!
M   #! 4(!@8'"0   @,$!08' 0@1$A,)%!6W%A<A-C@B,3=8='=XER,D=K:X
MUQ@R-$%1LR8S56&6LM89)RA"4F)Q<I'_Q  < 0$  @,! 0$
M 04"!@<$ PC_Q !/$0 " @$"! (&! H&" 4#!0   0(#! 41!A(A,1-!!Q0B
M46%Q@9'!\!4C,C0U='6AL;46-G:TMM$D,T)28K+A\1<E<I*B"'.")D-CPM+_
MV@ , P$  A$#$0 _ /W\   (@TG9X#,+=B]-F8*W2C[<+^^SNNR<##$=U^OR
MK"EV>\'>W&9<NV32(8NX^K/&$8V;FD)N4DG!#,(A>,CYZ2B ]_P_S2^TJO:/
MM&LMJ54W&SRN7;<DYP[6E<C=U!S"4*(N6@/235JB&]WH$//:+$D4S28;T>W3
MM8N%R=TYI;H: D#UA&6?I<C^C+E^*[;_ "V]_3O\%N6.8^DLM?Z30\I26NB-
MITZG*7JB/7F9:,TH]D@T(9&P.T8[2W%7)GBL^QAW"+]]6/TGY86B"A3+QI/F
MY\1&W3?W??MW)Y @
M
M                \&;J]=L;FNO)Z&CY9U49XEHK"[YN1=6#L2<3+02<S&F/
MSO6T@2'GIF-*X)\#\:23M'X_*L8 0Y*>4O-TU7] JDMBF=R-=U2RI7#0XAY7
M&2[2V61"5<3J$K*D.3IE%D9M[(RR221DFR<E+S;TB/'$W+*/!.[][Z=NO8CG
M8D$6WJKQ(V;(I-V[<_H5!NW03(DB@BEE;--)%%)/A4TDDB%*1-,A2D(0O"EY
MSG.< +M+Y?:BXX$
M             !!.B^G, R6<GZQHVL4^IV2K4.,TV?K\E(][-1M&G+BTSRO3
MRL6U2</5$K+?'[.G5AD@@K)66RN$X:"92#_O4."=G[F<*;W5X\*NV0/Z-RDG
MWO*%-P0<GM+,D<;+$H%_:E+8>4-WD:B@2KQ4I9>QBSM.;_1Z,D9K\,_#&+IT
MD&SZ].SV^DG7--.H.Q4N)T/,K3&7*F3:LJVCIV).KUN=[ S$A79^,=(.4F[V
M.F("PQ,I ST/(MFDI"S<:_BI-HU?LW#=,1]_K['=@
M                                        I[M/\6'BK^T>B?RM:@2N
MTOE]J+A 0
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MV26M4QUI",'SZ97D%%3E#=/FZ;+9;>;Z;+O_ !VV^1K8!B
M                                            %/=I_BP\5?VCT3^5
MK4"5VE\OM1<("
M               *A>K?WC\??XO:9^56R@2NTOE]J+>@0
M                                           %/=I_BP\5?VCT3^5K
M4"5VE\OM1<("
M              *A>K?WC\??XO:9^56R@2NTOE]J+>@0
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M#TJ/C%.F68JFZ(?E\5U^'5K^"3^DM(!
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M9R7?+D3^<K:/:=;1<:@SBV+%FW#[_4=>
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M[-$&]_H6R^_WV[$Z@0               0CJ_P"_?F?^^Z=_X<O0 J=1_/-
M_:UW\BUHU3B+]+\!_P!J\S_ _&9-PMC:P        I[M/\6'BK^T>B?RM:@2
MNTOE]J+A 0
M           !4+U;^\?C[_%[3/RJV4"5VE\OM1;T"
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M6M0)7:7R^U%P@(
M            #D'NA4&-<V=E(WBH,'E)C&TU<FCVRPK5S4H=XB=RTEK.@N]3
M5@8QTW34<-G\J1HU713.JDJ9,IC< _KE^HG7B,=RZU+L@XJ_;PW8\L</UXO2
M^=X7MO1;<>?75J_#=X7L^0AHGG>\YUW\>\ %6_24Y"V5[XNGZY+Q<_!2WK2D
M/8J:A)!I*Q,FS6RG9>HNX^18K+LWC97G[4UVRRB1^?M*?O )7:7R^U%T0(
M                                      (2N'].F*?[,;#_ .3014Y7
MZ8TG]7U3^&$:IJ?];N%?U#B;_DT<FT6QM8   0CJ_P"_?F?^^Z=_X<O0 J=1
M_/- _:UW\BUHU3B+]+\!_P!J\S_ _&9-PMC:P        I[M/\6'BK^T>B?R
MM:@2NTOE]J+A 0
M         0#JWI[&L7L4=4+S.6A2UR<+RR(UJB9;JVM3S6O'?KQ;>=F(C**3
M=7]?B'\DS?,(N1G6\<TEGD;*-HU5VM&/R-A.V_\ U:7\2<8R0;2\;'RS+[S]
MSDV+20:??&3V-=_=GJ";E#[U'23=I(Q[GZ2I/KLG[5L]:*_,@Z;HKIJ)E$&*
M'I[[//==H]&7K8*;5/-%7KZ;/.G+6*4L-A8K^C%J'ZD\F^C>P6Q1<?CBZ5&?
M6.*\_6K,;O=_T@V@EM@Y+,S]I\.QJTM%.QFFDNN[[]/);J2W77X[[=.W?W5
M??8I^F7M:;U$MYPMN4^0.6JUK+/W4TBPLBWF;4,(YYF9QQ<X34<>:.S>@LK1
MVT=EV4EQE#*M_P!3_7RK<Y YEU[[;^Y>]/=]>_N79=NO4NW ^9+MA47XUY>;
M-^ S;_[0?8=$<8]FED[*X=46>]V;U+L,/58@\I2*E,SB] BK@TKS:;0B*C&N
M7C>1<-*RT9K-TBB&]^;N^BZOOTY5[_/Z=O>;0 8@
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MDY1?A0A#:.RV]E/9]=S' R9Y='BSC&+YY1VCOMM';KU;?P?7NB[(TT]@
M                                               &-_OB;=0>_MY2
MI:Y 8%:J_P"="6BS6F]>FEO.=<U.EPUUMZ\?2*V1OG-Y3M<W1Y+\;D;+;)3[
MREE#+1:L6/K,US2)8S<9)=.J;Z[+9-]7M\5U:[+NWY]#5?,)SMGS3/++UE9(
MWMAHU2G.QUR*4MO8=EH"/?\ 65J*5-(I;(U^\?0G"E23+R43=<XF3G.%X,3N
M0  %0O5O[Q^/O\7M,_*K90)7:7R^U%O0(
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M;;;ZLKM+;6*ZGWHNNI?OW4N=[_\ O[>2VZ;&FXYN60
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M=734NYQ2.IZ0M\WUM!3[68SY+NK\RJQOJVPOPGE/F66-\[_OQ54[_+Z,21@
M %0O5O[Q^/O\7M,_*K90)7:7R^U%O0(
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ME"/[_@:@#FI9
M    8E?:1]HT1Z"S>?T>)B92N]RWZS16L>I]+\QZ'#NX"?N$?-3%Y=9NC(DG
M\D3KE\?1S.XVQ.K-<IDY.W<@[:E^L*P)LQE'=I[?O6ZV^'1[/I])L;1VL:QI
M=090L1$P$.SJ]?:Q,# NFKZ#A(UO$M$6$1#/62:+)Y$QK4B3..=-$4FKAFBB
MJW3(D<A>#$Z@  !4+U;^\?C[_%[3/RJV4"5VE\OM1;T"
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MHKWM65J6W5I)>>SK<WV,K3[NR5TZ6_\ [\5!;_O^O?H:@CFI9
M                                         8N?:-:,7(=B;3D3=_4E
M1E]#\]N*?9%O+4IYSD4XRMU^Z3W8FY^AX[;L&U.2Q?(*HZOMA5;>D8B7_!*I
MQ[<F,G7TY!K&JS0SCVV>W?=;I_3MLUN^VZ>_D:5^9LY>93A^=49UI5AU5O"U
M6OMH>R6!QFC[C.!1@XUM#UZO2V497C=6G:E",FZ36MSJM%834O&_1?RRZRZQ
M2(C%]^VWU_:V3P!  %0O5O[Q^/O\7M,_*K90)7:7R^U%O0(
M                        Y!YH5!C[*VIC^\5!C<'O4.,ZH\LL*VLKOKHI
MCM>-H)9Z247ZY(4QT.)-3]6*4QD_FYSO1Y99N%#(CBSR\6&5/;DQI9%4<B7,
MMX\M+FK)<R3:VB]UV*RW6M&ISZ]+NU;3*=3MY%5IUN?BUY]CL3=:KPYVK(GS
MI-PY:WS)-QW1]'4]#@\ES>\:995.$A*-6)BROR<.5-1T2+9*N4H]MTW.\,\D
MG!$8]BG\.F5>.4$BE,8_.=PU'.ITW S-0R'M3AX]N1/JDY*N#DH1WZ<]DDH0
M7G*27F?+B'6\3AO0]6U[/>V)I&!E9]R32E8L>J5D::V^]M\U&FI;/FMLA%)M
M[&=GBW/)RL$Q'2+PGTVG>B2[UNM\<*$,58CB\_H"^KT87BO>KMVD?6OPQ5..
M4^4L<]?2#<B9/Y7S:1PI@W8ZTG/RU_YAKGX9UC-DUM)2S/4IT5]>JC7C^&U!
M_D3G8DENSB?HMT7+T]<*:YJRWU[C;^F'%^L3DFI1LU?\#W86.N;VX5TX/J\E
M1+946W7PBEU+][!B.6;U4G-)UBG15N@EOG4;<>I&2DH=X<GT^24!,-C(RD')
M$+_)X]C'398Z?S-UNJME%43[EJFD:=K.-+$U+%KR:7NX\Z:LJD^GB4VQ:LIL
M7^_7*+:]E[Q;3[%Q-PIP_P 8:;9I/$>F8^I8<N9UJV+C?BVM<OCX>3!QOQ+T
MNGBT60DX[PGS5RE%X=>F\Y]E9#HV7^;<WONR:=B]D=(J4V]*5!2;N]"9VEE;
MZ=;*.3063-964=5_/TYR9XL?K-Q%0#]%RT:Q3=@DXYR/B#!XJTS/T[0<#,U3
M4-)ODGBYCQ7;F84,F&5B9.&LV,6[948*NN3?+*NF:E&-<8)GY.X]T/TH<-ZW
MH' VAZQQ/K_"V=.+TO5I::\K5='JU"K4],U'25K55<IY%F%HL<O*YVZIX^'=
M&==>/"F,S=/)<GHN(9_7,SSF%2@ZK6696K-N7Y5'3QP?OU'LM*N_E(=_+RCH
MRCR2?*\X=PY5/TI4TBII)]?TS3</2,*C3\"I4XV/!1A%=93EWG;;+9.=MDMY
M63?64F^RV2_6_#G#FD<*:-@Z#H>+'$T[ J5=4%L[+9OVK<G(LV3NR<BQRMON
MDDYV2;2C%1BN8U?]^_,_]]T[_P .7H ?#4?SS0/VM=_(M:/!Q%^E^ _[5YG^
M!^,R;A;&U@ 1KK.H0F/U%M<K QE9&.<WK*J"1M#)M%7I977-2IV3P#LQ'KMB
MAR/CYZZQK^8/Q?KE*(;/E639Z\(@R<'T_=^][!=?W_N6YEEY/QS'L:]&5"Y4
M&V7ZSV36;!ZUR&TQURI6>,J16;)B.FS1[Z;"H& ^ZK>>:+,75G)'+3J(Y?U[
M1XUM"6?2H9]IR#N\.ADVVOI7SZKIO[^B_P MET-EP,0 *>[3_%AXJ_M'HG\K
M6H$KM+Y?:BX0$&9GVM,<[;^15]+C43+RV$ZYCVPQ14^?Z8CN"NC"OG62[SGQ
M)U!I:'2JA^?#Y$"+'[WX%Z.C^BRR$N*XZ=8U&K6]*U;2;6^W)?ASR$G[^:>-
M&*7G)I=RNU1/U7Q%WIMJM7S4U'_^YI-&2+.7C8^6CUBN&$HR:2+%P7_JKLWJ
M";ELL7_]JJ*I#\_]QASNRN=5EE5B<;*IRKG%]XSA)QDG\5)-%@FFDT]TTFG[
MT^J9]T8$@                                                 &,
MMDW/U)2M&MM:=XYZQM,.RL_M!BO/T_,%;%!2\19;%'.?+IZ]8DGB3IQ$UN)6
MFR,.LU&Z4#QP9-V0YS)]*,MNG=;]-NJ73K^_L_\ KN:BX0RLT;A^-1UT2?H7
M%AE.>,K8A*F^>31LS6HPZ$\E(FZ8_3/TY0CHCPW3F^9QQ3OS&^/QZ,250  %
M0O5O[Q^/O\7M,_*K90)7:7R^U%O0(
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MDDDDMB<A;FVD*:5_23YV_O#N'Y,:6*G/_/\ 0_U[*_E6H&JZ[^G>"?VUJ?\
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MJF*^"JN@D_-+<QPI^)B8\O\ ^*$6_?*"Y)?_ "BRUHU<]0
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M5C;KZ,5=.^S3?<K=+>V-.E]\?(NI>_?=2YWO],VO+MMV1IV.;ED
M                                         4@]0[)Z(S.YU*/\\Y\Y
MW.=D8,SR0Q-3-+5#1DT@647;\FU/6+VQP^/8XL@GQ5-:N76$NU@L#=H1W6X$
MG$G1G0E;>?U[K^'=_7\RQN17^RZ'6'4E<LPM>1VJ&G']<GJE:5XR31Z_CT&;
MCLO4[/"KKQ-PILH@^16A+(S*R4<=*Z82D3#3<=)Q+(02D   J%ZM_>/Q]_B]
MIGY5;*!*[2^7VHMZ!                              !Q">FYLM<#YXC
MH-'5OZ?3\4HZ=L@3W G4V'953AZR5_V:+U.+YV2/PS+G2,.=>&^#?G5!Y%J&
M \IX2S<1YJW3Q%DTO*34/$:>.I^+TK_&/V.D/:?L]2ICKVARU-Z+'6M)EK*W
MWTF.HX;U-<M/K$M\!7>M+EQ_Q[WJZ4_C7['M';CUEL0J]_B+K?\ <K=O]^<_
M%3/].X_[)S/[Y@FK6_UVP/[+:M_-M%)J%L;29D_:':G-9DO3&5.*LMI&M9)M
M>*9FT;&Z1VYN.D:!YLB$CLU"_$R3R/A>3,JQ5YSO"OF+8AOA\_#<T#C?4;M/
M>+#%W>?J6FZKI.GQBVI2RL_-T&I.+752KJ\6V#_WX17F<%]-7$.5H,]+ITQ2
MEKG$G#G%7"N@U5MQMLU/7-9X%Q8RJDNL;:,7UK(IEMMXU-:>W-N7@PS*HC#\
M@SO)X/Z9V-&JT;"*.4R?3Y)2B:7WB<F#D^'/E6FIM>0EE^?#G.+O5/ASG/V<
MVW1]-JTC2\'3:=G##QJZ7)+;Q+$N:ZW;R=MTIVM>^;['6.$N'L;A/AK1.',3
ME=6D:?1B2LBN57Y$8\^7E./E++RYW9,ULO;MET78\BX?TZ8I_LQL/_DT$?/*
M_3&D_J^J?PPCS:G_ %NX5_4.)O\ DT<FT6QM9"FE?TD^=O[P[A^3&EBIS_S_
M $/]>ROY5J!JNN_IW@G]M:G_ (7UTFL6QM1".K_OWYG_ +[IW_AR] "IU'\\
MT#]K7?R+6C5.(OTOP'_:O,_P/QF3<+8VL   /SD>6)"B>E/1M3AMNS/.9G1+
M'7G6@4G0;%Z*TG9/7^8M6$-0]%9O:LWL5<J\5@=7A+J>X8IJ;K%H^D5F'V;,
M9_-Y""=.YOKHHR?1;)O;W;;+?=_'KTV:?5[/W(_1N!B !3W:?XL/%7]H]$_E
M:U E=I?+[47" @ #+_QU\:+[8^T<R%3GT&KZ_P"7[E!)?S$>?K1J+F0MCQ(G
MPYSX(RWX:U74YSO3N/G*;OQ)SINE<6_Z;P;Z/=6764,#4]%O??D_!F7&O%@W
M_P 57BSBO*.VW=[5N)[&9J%/9>)7='XNV+E-KK[W%/IW[MFH YJ60
M                                          !@']H[%XUM&MV*P2=9
M6V",PNK0]1N2US\Y;UIN!9':(=W8)>ZMK!IN:UV>95]"PYCJCE_JDG386R6'
M.+#FV-6*:>0):Y(\CQDGLNG[FM_J^#7;SW>QMWDL#VK95F=8[/1UJ[7,^ID#
MVSP[%C&1%C[$5R-C^ST7&Q9CQD?'3'W?\08L8XYF+1LX2;M#&;II]Z,200
M%0O5O[Q^/O\ %[3/RJV4"5VE\OM1;T"
M "$FG\1\_P#W)5'_ '[NPJ8_IV[]DXO]\RS5*_Z\9G]E--_F^JDVBV-K(5>_
MQ%UO^Y6[?[\Y^*F?Z=Q_V3F?WS!-6M_KM@?V6U;^;:*>!OOJ7(/.4<S/?9U=
MY:9OY4JEF]6:]L&AW%XLIU!LT@:TU/QR8CES_JQ)&0.QB2N.E;'?<<J)(J?'
M6N(M+T*N+S;G+)NV6-@8T7?G94V]HQIQXOFVE+V59-PJYO9Y^9I/Q<8^D'AG
M@BBMZQERMU'*VCINA:?7ZYK>J6RER5UX>!6^=J<_85]SIQE-J#N5DHPEE*?(
MO6V_>Y,$W30ZNEEU/0D3Z=5LEL]^D)>6J%(S>4S>"L[H\*DQ/%PEKLYK16I%
M[$H)1KARJ1PA+E;.8U/BW.'IG$VM<7Z-K&=C+3L6,WGXVFY&;.VW&Q,&S!IR
M)>$H.NG)R'D43G4E7*34HV\LJUO^=WPUZ2.,O2SP?Q;K>GQX?TR%[U[3^'-0
MUB[)R=,TG0\C0\3/L>+&J6/BZCGO/P+[<>$<><Y*<,E5SH7-O&.QGZ^*Z7RP
MMV6_XTT/#75VFU@KZR>RT3GM\FZU'.;8K4F4$G)VN&K;^LQGWE>)?]='D)9L
MG$MT./)<[%FNW75H\R^,-:TN+JRY*-.9"=E>#F78\)9+QH4JS)JHGCU\SKGS
M.=L55%<]KA!QD](UC-A5QEPO6\75;(UXFL56Y&-HNL9>#1/49:=5B1R-1Q<&
M[ Q^>>/<[)79-<<:$/%R735*$Y6+%X;N0II7])/G;^\.X?DQI8J<_P#/]#_7
MLK^5:@:KKOZ=X)_;6I_X7UTFL6QM17W8W%D)=L'<PE N%N85729.UV*1KI*X
M9K%13O)]3HB7%^35CAG*SK\9N<0L9%HV<<Y'%>N/J=50(W5I=4E>LO1Y4X65
ME0QL^S)OG1ZORUURTW4<-;^-?3)R\7*J>T(RVK4Y;[I1>F<3SSEJO"%F)HVI
M:E3IVN9&HYM^%ZCX>/CV<-\0Z1'F65G8MD[/6M4QI.%5=FU"MGOS04)6"%T;
MF !5_P!EVB^T_P YWF9S8U];V525SB =2N64B:TC2:U3+;J-+J>E7*BTBN5J
MY3=@M5)SB;M=MA&L=4K*NB_A47G8.43;'9K"5U?EY]WLM]NG7=>?Q*:>=K'7
M(ST]GL+A$G[WL= M="TUOL2?K3+O<1:I#2</^BLO0K-7=']AYU$+UJ>>R'+%
M"*4JD7%I6YIG++O5Z7UY"14BP$OL]]M]UMMM\=^S^7D_XFM8&( %/=I_BP\5
M?VCT3^5K4"5VE\OM1<("  ,OY?\ ^[W[7&HOB_Z*,]!>09RN&3[_ "2O+AFM
MU-83N.=_9Q15K4F+=N4O[3$266-W^3\GPZ35_I_HJRX/K9H/%E.0GYPQ-1P_
M5U'X*65.4F^F[2]SWK9?B]5@_+(Q91__ #KFY;_1!)?2_HU '-BR
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M(J%Z'HW"^GZ19++D[=1U:[KD:MGR\?,LE))25<I;K'J?95U;/DVA999RIGZ
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M-H>2\C>*[[N5U:Z+JU%>2*S.]C(T^[S60Z=]O*^*B_W)_)-_$U!'-2S
M                                             ,5=<A-4]/;=><4A
M(NW*5+.;A;-1BX#56-=D6L?8*JX7S1T6 LN@8+H5&I</ID!I]JM.25O0JYZ3
MA;A5HUQ*U1;SZ[J\<ZC1EV2?3K\>_G[_ ":Z[;=?>:Z9I76%/SC/ZE%0TM78
MNKTFJ5V-K\])-IF<@F$)!,(QG#3,PRD9AG*RT8W;)LI&2:2THV?/$%G2$B^2
M5(Y5&)VP  "H7JW]X_'W^+VF?E5LH$KM+Y?:BWH$
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M?Q(91_<CZ!_W\\S"IN_3NG?LG6O[YH!JF9_7CAW^RG&?\WX#)N%L;6
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MVX)R\U*2BI->]O;H7C&EGM
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MI;RC8GVVWBN:/,NK\UU7ENNKW-^QPHO
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M)2S4J:I< J0TQC;:I/'TE<25R[/&AXZ2G8-29?R*YWW^_P# CI[6WN7;JO\
M9WZ_!_/YFVH&(    !]=XJX0:.EFC7KUTBV75;,^+)M^NW":1CHM>.%O]$AU
M=3A4N+*_Z-+Y_G/_ "2]&,W)1DXQYY*+<8;J/-))M1YGTCS/9;OHM]V86RG"
MNR5=?BV1A.4*N:,/$FHMQKYY>S#GDE'FE[,=]WT1&F3:)*Z7!RTW(TQY3"1M
MJMM22;/9N)FE7K^D6J<I=A6(>*,=-!NA/U^10:]5[PSML5%V0I2*\+SP:;G6
M9]-EUF++%5>1DXRC.VNUSGB9%V+>TZVTHJZB:COUE':2V3V*+AS6LC7<3(R[
M]+LTM4:CJ6FQKMR\?*E;=I.H9>EYLT\=N,(1S,*^%?-ULK4;$DI;*2WCMK'M
M'3]\X1:,F3==V\=N5"(MVK5LD99PX75/TI$D4$2'554.;A"$*8QN\YSO1[YR
MC",ISDHPA%RG*32C&,4W*4F^B22;;?1);E[;97379==.%554)V6V62485UUQ
M<ISG*32C"$4Y2DVDDFV]D9YT3V[Y1SJD7>5L6YT);Y]=UV19Q-=F$K78I-G-
MZ+9I"%<1M?K?)27=M95FL@X9OB-.,#(N$%E722*I%.Z/A<6\-X.)F67ZQA/?
M5-4LA71:LF^R%V=D652KHQ_$ME&R#4H34.1J46Y)-,XMH_I7]'>B:3JN1F\6
MZ/+?B7B:^O&PLF.HYM]65KNH7XLZ,+!61DVUY%4X3JMC7X+C.$G9&,DSZ"WI
M3UAOB2C+S'YO7H-3D$U$4=D]-.'%18&;+EZGQ]!9U#G<6>2242Z=S&2I%WS$
M_>)??6"?.F2-B]>XDUE.'#^@RPL::V6J\02EBPY9+;GIP*G+(L36\J[%*4&]
MN>"ZH^$N.O2+QE&57 7 T]&TZZ+C'B?CV<]-I=<UMXV'HF+*>?D1E%NS'R8S
MNI?L^-3'?E=0?)7A+UG69;5C2/KF2SY-G8RU5^O059*].IZ<B6S5^^=NR7R)
MB$6+0K668E:2#0QY%ZJ5=%\V10:M#JZQPUP=Q+CVZES\3VX2AD+&G+#=F9*Z
MVJ,;)RFLRNM0CRVP49QWG-J2G%1C'?FOHX]$7I'P,CB)W>DF_155G?@ZZ>CR
MOU>S,R\:$+KK+%J^/C1IK5>32J[JM[[I*<;80C77*5UO^AQOZO\ VOW]OI^]
M_G^YP=18?_S\.)D4^7_W?#^;_P >_ ;9_1;6W^5QKK3_ /13BP_@GM]_>=5_
M\,>,I?ZSTR<8OW^%B:;3]7+&6WV%)_+7V7,5^M#8?^D/9F^KU:F6AI64J\PF
M[?#-IJU.:I0M":SLZ1HXC3R+%O"7)K'=9J.2%-)LUC'168_2*;4^'?1W4M1U
M3\.9"U+'Q<B./&B%V55&W(EC8>;&Z[EE7XD(TY4:^1R2=D&VG#9'*O1__P#3
M]C?A_B;^FV?#B+3]+U"K!CA4Y>IXL,K4+-.T?6J\S+5<\=WU0Q-4KH\*5B3O
MJDW&5/*C:RAYIGF70Q*]G%(JM&A2?)WL=58*.A&RQR<Z7B[HL>W0Z\=&^/>J
M.G9EG*IS&.JJ<YC&[UC#P,'3JO P,3&PZ>GXO&IKIBVNG-)5QCSR]\I;R;;;
M;;9^J-(T+1>'\586AZ3I^D8JVWHT[$HQ*YN*V4[%3"#ML?7FLL<[)-MRDVVW
MP^:_TH>BO]NZ3^3V?CR8'Z0US]<Q/Y7A%3H7Z?XV_:^E?X9T8F\6QM9"U3_I
MRV7_ &2Q[_YM%%3C?IC5?U72OXYYJNF_UNXH_9O#'\=<)I%L;40=!5[2VNZW
M>Z24%1T:)8Z11:='OF-XGGML3[0YO39MO(O*ROG<?$)<F3Z(5HLT1N+C\*+$
M=<D<RG7_ !LSJ*:,^.L9>793AK#OQ,/%A.&7=/)7J=VH71G/'E@PJ7BO.Y7%
M94O#\+F4K.?EAJ>)A:]7Q=JVJWXFD0TC.TG2-,IMIU;,MU*+T?+U[+A?;@3T
M.C%CZT];5<JX:I9ZNL;G4\AW<E4XBW-L
M"GNT_P 6'BK^T>B?RM:@2NTOE]J+A 0   &57J--/S?[=\K^IV*9(VDZUUWY
M,VI9$O&[)/EI<*3N63;[J?.($^[65!P>4DW)2_0BH%JT^KPJI>I=.X9;XAX,
MXGX8GO9F:5R\4Z,F^:;]6BJ=4I@G[3YL9Q\*J&_-=?.>VZ]JKRO]'S<7*[0M
MWQ;O=[76J3\ORM]Y/M&*6^W;54<Q+0
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M65_*]I2KALDEL8^B#T3\-<'O6M3HC/5<^6LZAIN+E:KC8-V1IU.AZIJ>#"S
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MA8E55%>)9D2PU7D5Q5\W1#*NKDYM^,I1G/VHIN6A9FR
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MM<R3\FF6L&KGJ
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M.FX&%;?TNMQ,/'QK+ES.6ULZ:X2L]IN7MM^TV^[W.F'H/>
M                        %/=I_BP\5?VCT3^5K4"5VE\OM1<("     #*
MWS!_^'/W/ZC\N./]2I.SIMO6>+MS?%%HFYL"Y(/6(1B3O>HE.E8&Z2D?&-OE
M^ZPM?5==2*FMSB?3N)?_ -0<$\,\2Q]O,T=SX5UB2ZR<<=._2KI_[6SQY-66
MR_*OR%'?==:S&VQ\W)Q>T+O]*I7_ *GRV+X>TO97E&'FNVJ0YB68
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M5[_*ZW517BX\<?$JJIKIK\/'IA%5TUJ*VA!1@O9@GMORK?;=[-GZNQL+'TW
MJP-)Q<7#Q\3'\#!Q*JUCX=$:X-4U*NF&U=*ELI<D'))RDDY=^ Q6I7>DUJ9A
M;LI55W+V]:)<&2U6<RZZ'$]$O]HT!VR=<EF+)0IXMY9E8MLJCPY7;9H1TKQ!
M58R!/%I6-EXE%M66\9RGF9N5!XTK9+;.S<C-G"7BP@]ZYY#KBUOS1BI/9O94
MW"NFZMI6#E8NJRTZ5ENKZUJ=4M/LR9P4=;UG4-9MJL]9IJDGCVY\L>N44U97
M6K)*$I."F$6ALP
M  4]VG^+#Q5_:/1/Y6M0)7:7R^U%P@(     ,NOM)XY]EYO/7MFMM%U9;RYJ
M4=R]E9)FZZDL4TU9K4+\QZ5+^6Y52.YCDF!52J(L"2LH^^!>%5X?I?H[LAJ:
MU_@W)G%5<2Z98\'G>T:]9TU2R\"?7I%-1LE8TT['557UW6U9J*=7J^;%;RQK
M%SI;)NFW:$U\7OLH[]%S2?OWTYCI%C+Q["6BW:#^-E&;61CGS50JK9XQ>H$<
MM';=4O>E40<-U4UDE"]Z4Z9RFYWX=X.;V5SJLG5;"4+*IRKLA);2A.$G&<))
M]5*,DTT^S319)II-/=-)IKLT^J?TGW!@2
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M?&OHOIECRME=3.$L>$(0C"%O@*IQWCX.Z]B4"=A<&W
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MK-5U<<:2VLIKV4FTN>$7M%*.^^\8\J;[=-^FYM6..EP
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MRW/UK-?B9+=NR<Z,9R]7Q]E&,HPE?R1LOMWM"-A.@
M                                  !3W:?XL/%7]H]$_E:U E=I?+[4
M7" @     _E0A%2'24*4Z:A#$4(;G#%.0_.E,4Q>_LZ4Q>]YWG?V=YWO.B4V
MFFFTT]TUT::[-/R:!033OLT?)MZAFR=-SN/P:\PCODM3M1PU%'/;K5IQ$O\
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M:KKF73&<ZX9N17DT54*,I^'7)0DW9A472U4'1C]#
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M6'?FJGIVUTPQ?_5)U_U7MR+=/O._$O.)N<L<+=+S_P ..2][_P#J_P"\5O\
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M2MO8MEVR)UA607KI)KJ!/Q$D(M*HMY)6+*Z^IQDH_01=F0X3JZ9%.F+P0>Z
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MU,X4&+[LS4] >I/8V1:%[T@*Q7/UI%IN2^5)OS7!Y]D<Y.M\O7V.R^HJ]>M
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M(A]&_O\ :_IZOJ6B @
M
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ME4CE43534+PZ:B:A.]*<AR]X8AR]Z4Q>\[SO>=YT"#^P
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M#,HVR5]^\*@TFXQ9T(V?N^_W3)Q
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M"MT$4>$3*,3V
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M1U#W6!Q"I:E)-TH.&L-]E(V,G26\1ONMO/W_ $[^[?ZV_P#*_8$
M
M
3                     '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g108483g14a64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g14a64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )J"^F(@X0DE-! 0      $4< 5H  QLE1QP"   "+@ < E  %4UI8W)O
M<V]F="!/9F9I8V4@57-E<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX
M.$))300E       0LY>]O6?XE(8D@<U(-?/DQSA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              Y    4H
M  $                          0             %*    Y
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   Y      4F=H
M=&QO;F<   4H    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   .0     %)G:'1L;VYG   %*     -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$$0       0$ .$))3004       $    "CA"24T$
M#      <,     $   "@    ;P   >   - @   <%  8  '_V/_B#%A)0T-?
M4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$
M &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !     -,M
M2% @(
M        $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K
M<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M%&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,
M  0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I
M9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M     !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y
M-C8M,BXQ
M              !865H@        \U$  0    $6S%A96B
M        6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8
MVEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W
M=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                         &1E
M<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P
M86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@                            !D
M97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0
M=FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M3 E6 %    !7'^=M96%S          $                        "CP
M  )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@
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M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M-D=38V=UA(>VP<?Q,S=#4F)T=K.UT>'_Q  < 0$  @,! 0$
M 0<%!@@" P3_Q !2$0 " 0(#!00%!P@'! @'     0(#$002(04&,4%187&1
M\!.!H;'1!Q0B-3:SP2,R8G-TM.'Q%18D0G*CLC,T4F0(%S=#1&.DM2935(*2
MDZ+_V@ , P$  A$#$0 _ ,_C & , 8 P!@# & , 8!UKF\M#(26I>75M:$YI
MP4Y2AS7)4!)AX@#&$@LU4:46,X0"S!A+"+8]@ ,6@]@BWH#ZJW-M0)@+5[@A
M1(S#$Y1:M6K(3)AFK# $I"P'G& *$8J.-+*3@"/8CS# %E:$(8=; YN , 8
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MEL(H6=S&,02Q*=60]NE14LD#*C4-$<8UZ^<,B**/3TL0II.JTX$->CC$!X=
M<&9=9GBA7[+6SK+X)RT9%]I1ZR)E'X:LXJVZ78#?"*G4MQ$VF\CA F+4B9HB
MVDN1+D!_-0&(#FDE2XZ-"F)V,0$D-06U7M\U? [FJ>1II=6]F1AJF$+DB5.L
M2%.["\I@*D2D2)R3HW% HT >RE;>XI$C@@5EG(UJ8A40:4 "HV , 8 P!@#
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MPF%B*-TTO\S=) Z,_ERA"*4;:52+:@L0BS_* %L.X;OQ#;?'M?CQ+Q,$# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M24H?K*K5[2]/&N.3L+L-(U%R;1\Z77HWR5&PK(7M:SD%%)F0;Z2)VT^#;CA
M(-TB HV(&M@>!J#HN7/6](\%ZN76K5JUWXK=0Y[YD3!V0IY26CE$.<W1X6D1
M-@\LREJ=R0E.N2$C,="T37H1 @@5B+++$,"1#G/PEF?*R[N ]G1J61B.LG$K
MD0*XYDV/OI;TE*6(;8A0C9XT-M1*4Y+KL206]&.1Z-+H!@1><:$'PX!B&-41
MO]:@XY]-BLD=M/<1I;J812S(Y4D\X@6'!+BC401S9\?Y1-;,M]')932@:ZB9
MK\\*6IR8'9:[RH+F)[7#88TW-:-8!D"6;TH.4L'L#EP'BO/N(L_XY<V;-W<U
MI\<>:-12J<1.%6HJ5(79TF404Q-R.3R4Q;(DA;V4U29J2H&_T:P) EK36L*\
MP"_SI:<#5G3GXKH./+E8C=9[J.=S&PG:2,\2]Q+*0Y3,Y >I969BV\OAA34U
M>8@)2*#%9(U !;'YBB#H"< '!;^%$Z0]5R2=0'<LBHZ_>>&3;QG3P@(7;W8%
M25%:*>>&2$XS:+3+IC&@)$B  #@)P\\WK8DP2.YF 1ZRCHR76_3V8RTFU*N*
M227K&Q#J2ITAY4J$>16L<3+2E%?G; R[+W.3QJ@[(- (3!H(!;&Y@WO6L Y5
MD]&FY)K2/."L$%HU>B>>4_4C0\U8LZJB)/YE&8,EES%(A0]^$2S#5&2?:=M5
MD!$W$J6C1YX-^>^3&8( %%K(^I_9O*>0=Z2%!+:$E%+<A.2:_D2_NEEAY#'V
M? 2Y"^'R&55VP02"VI$:GFJ-8Y:1B8YK*#6^1LH0#%HD[:9&5H"9/J/\%F[G
M_P :#:3#.%-73..S6$VG55C)VD,@]Q-C0)8<>RNRAD$O;=.J0]N7N[.J)TX)
MC"BG/:XD9AR4LDP"V. \.^I+;%NMLUYN\O:[(JN-U'8-4BH?BBRSN*PNV5-B
MQMPC+G/[9,FKF(DY^:BE2=V8&QM:EB%I=$A.V<]F3&O!#V!:=6'1LY8I(UPQ
MXRW%R%HQ_P"(?!6^VR_*V=(-7DN8[\LMSC4A>Y)%(I-].#VIAL4;&]9)7Q.X
M.L><'I>X(STVC235I(5Y0'AY9T4.9#C +!X[1Z_>/!/'QVZ@NN=D86NL5L(%
MIN*IR?TR]PKV1G)CU4794#(B":>W.36E>U;\[$)M*S6) <<20!(56W3ILB%V
MSU7+#53NL#D_4$60@< (=H2?82"%(HU7,CA;DALR$R'3*QS%I<U3YHU0P)'C
MS-R:]*4ZI4D--#V=-%I_'^7+0$=_&KH&VI6[];2*36Y7--U3:W&*R>/TZK+C
M>\72^1.U998<?<6'5S2>+6M)!,D(<8\:H0/S="XGZ3:@N"4UO;G)D:#CDZD"
MK_3OZ,%B<3K^IRVK/=N/CNDX\5T^P"#O]?&\A7FQ)ZN>FATBIDRD0+'LU5 :
MR$;%EQ29TAL'BSW'5BW1YJ#33LE$>6'FYD5X P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'YVU\FOVL _< 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@$;4XZA&HSU$*(X&-E*3]4GM1#:!\AO&0H'&+U^W
M.T!J7=KIHW7BE8TGI[/=--I[81,%#8X-K9$!O#:F&M=';:]K0 7,%\P>*)UH
MCI GDI1)US D!T4%4Y5L00=C^Z=-X_.(]J%Z??=%M[(\F9Y5K]'>>E^3'XR=
M>'?8"XW7KUK?RX P!@# & , 8 P!@# & .^O9W]?R8 [ZW[-]\ =]?+]_P#-
M\N .^OE^_P#F^7 & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# +/KCXKGVMRSX;<G"YL4QD<4"^08#H:./C<#9SN\
MZZ0P(&RWW3PB#'O<UM'Z4%XFAZ]+:,\SUMN\/G(@(*.HM5S#'>N-TOY_'V5@
M8=R&;0Q+(@,PXHUJG^1+G6^%RB0O3(ALM+)W9R/3(B$Y\K74HN0&A();C;7+
M6%DQ0P#*8UZ]:W\N , 8 P!@# & , _@8MA#O>M;WOL+>NW;MK>M=]=_P^SV
M?M>W!#=FEU_ CEC_ % 71^Y1*^*XN(W)-IE;=I(]N<P<$=6[AC=7#I+'^',U
MJJ3TED*7K<,>':-.VD7DF8U^T4GWM0RD#V$&_P!LL%EPD<7\YPTE)J/H8NKZ
M93:3<'%TE"\8O-)Y\MM%)O0SDMBRCLV.T_Z0V>Z,IRI0IJ>(]++$0HTJ]3#J
M^']'Z6G"JLUZBAFC)*;65N1L O%K7R]M=_5V[]]>W6N^\_$81>'>1:\\;9YF
M5%8''[WA)Q0[-![LMZ!<?PM=D5G+Y9(F:;S%+/'HZ8F.S)8$:0*(TG:XXWH0
ML06W3CYX)2JTY[*,+3E9# 4<)6CB%7IUI3HT*N(3A548.--1^AEE3;NW>SO9
M:*SXFQ;$PFRL72QWSZCC*E3"8.MC5+#8FGAX^CHRI1<5&="LIS;JQ_.RII2X
M.S)(X2EE**)QU--W%F=YD4R-)<K=(ZW*6A@<9&6W)2GM<R-2U8XK6QI5N8%2
MAO0+'%P4I$AA*<Y:I,+$</'O+FGE3C',\JE)S:6C5V[:V>ME8P%1TW.;HJ:I
M.3=-5'&510_NJ<H1A&4DK7:BKOLL6E=0&#+YAQ9ME[9K.M^JGRL8%/K08'ZF
M;'>ZT?5C[#X#*%K4U/;JQ; K=HN<M&2J<&(9A)*Q0D0G;- 8E+%GZMGRBL7A
MH3A2J*I6I49PK1C.&6K4C!R:E=75[IZV[>#R>PZT:6TL)"6'PN*CB<11P\J>
M+HPQ%/+6J0@W&$_HJ>MXR:>5Z]3^^GW"G"(\5:>>WNS+;M5^LZOX#:<AD-Q6
M&]63($C_ #6OXFO=FAE=GW8UK7%4RPLY2V,(3CR4*A8O/"<8:K-WMCI+YYB(
MJ%&FJ=:I1C&C&,(.-*I*":479N5OSN+5KZZ*-N5?2[3QL(X?#8:.'KUL+&GA
M:,*%)1H59TU*4*:4<[M:4DM=-$7MY^4Q0P!@# & , 8 P!@# & , 8 P!@#
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MYJ7WL2-]$ENUM.W"V&YW_P#$1-CWE:'/8P!@# & , 8 P!@# & , 8 P!@#
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MJ;K],H:FB6;:N-\VEZJ8V),VU^.366UK7'T2?#8X)M!&V(IO)?B1+GE4%6G
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M"KH($=!D#34D(,8:="J=.9&A0T9%?[TE[Q4H<3&*-B S^:!VRBVW;UYKOR6
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M *M;3OQ_LWW\?4;'S*S.?!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MD8,X4'Y%KM2HJP_="%Y+I4L!?HD^'!BAC8;.!IGH4A J*"W#>6">+ & , 8
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M4U_ O86-X5;9%=?I4OO8D;Z/-NSM-VMIAE_ZB)L?,K0Y[& , 8 P!@# & ,
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M:I3 4 ZEVM:L7I9=M:UWZG-6=^VNW?\ I?N3'M^7 )4M>S7?V_'@# & , 8
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MXFQ[RM#GL8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M"]A9.\22V3B$N&:E][$\[YMO=G:;?_+??Q-CYE9G/@P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , L\N[J"\).-LQU7M\\HZ6JF=>C
M4CP.(S*<LS7(B&MP\IM M5M(U EJ(A<$HPQ$-821YT4'9Q'E"NP\ NCB4KCD
M[BT;FT/>$,BB4O8FF3QB0-9X5+8^1]]0$.C,\-RD&]@4(7)O5)UB0\/[$T@X
MLP/J%K /08 P!@# & 07=2MB7;YR]+"2^\!"1MNN8=;,G\U-MWBVK'(7"@'(
MQ=J@@,(F+<U%"E2<.[#-=2I,"+A?4I:0UB&ZB+< //GJ"='7JUK7R8 P!@#
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M=AT+=:UU1^,G;_AK4^A>PL;PN^R*[_2I?>Q/.^J2W:VG;IAOWB)L>\K0Y[&
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MQ]H1M7ITE/$+"1A'^TPHSE.%/&3K)).65QIRULW]%-F:GT>][WTFN-????\
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M.C"CL^<EB*F&E3E4EM"G9)46ZL))MO)547JKQT-@%E?E&# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!Q5RU,VHU2]:<6G1HDYRI6H-
M%H!2=,G*&<>>:/?J"644 9@Q;]6@AW@&$#S]NCAWRGM"'\HJH3=32,.]PM<V
MLVPH'0K##V0,SX]T+!Y+1+URY+:ID<O/C+(]5I-)M6<>DZ$[6GR/H7Q*Z-C
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M=>4%L.M!V(??>]:UK>]ZU@'YYBB\@%+M&EVF#H&@I]D%>1#HOP[!H)7A\ =
MV$.P:T'7AV'6]=MZUO /MLDK8BQ[++V,KOY(6P!V(OOK8=^ 6];V#>];WK>P
M[UO>M]M]]8!], 8 P!@'Q\V3^<;5^0)\ZV3I/M3Y,'E]D!'LP).SO#Y396C!
M"'HOQ>#0Q;%K7?>]X!]L 8 P!@# & , ^)R9.H$2(].2>).;HX@1Q0#-DG:"
M(.CBMC"+99N@C&'1@.P]!&(.MZT+>M@?; & , 8 P!@# & , 8 P!@# & ,
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M]+%CW]9*E#"6<TH$AOHQ3)W!PD*I*(8BU+VO6NJC1BY4>>,"K^ , 8 P!@#
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MN;+JM+]?4EI_#NYS9=4O%_W<W)/6_P!'_%IPU)^L@@8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# 'R_?_<]7Q?Q_A[X P!@# & , 8 P!@# & , 8 P!@#
%& , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g108483g15e64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g15e64.jpg
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M@% * 4 H!0"@% * 4 H"I#0/W]/&3^^C@'Z/VHL24!;?0"@% * 4 H!0"@%
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MXR5K6Y6MM% %K>3E[$6).SY+=GT4!;?0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * J0T#]_3QD_OHX!_V18D_7JH"V^@% * 4
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MP7U8"X^@% * 4 H!0%2.@GOZ>,E]]% /^R+$GUT!;=0"@% * 4 H!0"@% *
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M0GPZU81!2VB92$(HG-')IM \?3#HJ>J$5I5R71AL3AO%;Q)"!X@IX&60$JZ
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M#N[$_'0)=[@J4K?>BT6[/JOU+?=UEKE#\B@% * 4 H!0"@*D= _?T\9+[Z*
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M77ZDQTW9\>E2?M"!0"@% * 4 H!0%2.@?OZ>,E]]% /^R+$E 6W4 H!0"@%
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M<M/')/DSO:N-)W:?*"S/1#>^310W;Q?K_9_NY>3R:84X=;O #O\ M3Y5M_\
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MNI>R)+6O1Z,<-@C4+2*!"V:&944U8#DT5L*.#-S2SZ\ZBJ(3/8KMR5RQE6,
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MN)LS07>Y67C#<Z-A"+2EL!KPW)W7&]'"A&*K/$#,^2'FNMA.0R4J@R$IIIY
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M=<7,\)18B\W'.U)*P#$3P@3F3?,W1TRZI@!D%;TU]NU>@M@H2* 4 H!0"@%
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+"@% * 4 H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g108483g20k14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g20k14.jpg
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M+*R77WUK5I.V6$].]<VIMWNDJVEMMMAY]:M:2A2.*>>.GC,LILT6&0)))V
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MC#0P[*=JVO:6F&4H:;UM:E*WI"=:VI6U;].][PUK6-#6-:QK19K6@-:!P
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MG'+@22?'@7QUI)T6-7WB%U^73_"&[+6W>_FK$XA^AWA\7\O\?<GR-XCKOJD
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MB&Y'LX\-O7^S2/)Z LDH,SOW-#Q]DG)R-891T:$9#0$TEMH9#:!W'B+^XO\
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MWR' UD#M2\3XV?J!EXA4D>LB@\1<</S\Z!0C@;'\W;/OS6(<A+O+(V%/\KQ
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MAP'0)Y#A?4\7[/$_4X2PX#H$\APOJ>+]GB?J<)8<!T">0X7U/%^SQ/U.$L.
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MXC@LE!1XEB=5+3BGJV,J:"E?*W"8Z2HKI*G"'MI*>D?/.) QC;;V<<UB2I5
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MQDSQ?S(8,+R'RCQI6W!?I,Q:N1;!PS93Z?R"GCUBV\RUDB?>C;*(+$0M;<9
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M#IJ_Q;78CCU/X?\ ",=/6R4TT<N-XG,#)A]'3->-93-?&X!\T@!8YS'$M?\
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MW$<7=B,&..9!205SB6438(99ZN-D@N'QQV?3M9.UXDJ&/GD.K <VTBZ?B/\
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M9.^M/JV ]MR/[/XRXGH.Z9\!U/9.^M/JV ]MR/[/XRXGH.Z9\!U/9.^M/JV
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MVMPAAP<AS3XKA_\ #*MU(9)9'QCYS-324K@[3>WY62.=IQN#0^.9KBV1CP0
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MTQ)A23<+79E&ME5T&#%&G"8O8,X581-R2X"/R_I-K7(VWV \.=M_.XMO6/\
M5Q W<3SY#Z7]EQR\$?47XO5;Y0-"FI8IP2$JO(LVQ/0=OD&!GC7XMHB1:7<
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M@[5;V9>@A/5!B<*X]N2:M'V9N*F+:S!$%UB.EQ'PWR26/K;:-N7<+M63M8<
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M&FFT(3K24ZUA19#")A$PB81,(F$56VQ!U5M(7(80!LG$.PVJQ>P8L5\^6:B
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M0UF)T.J9)"R:GD,CF1Z6@)X7V<+O8Z]M5/-UG[Q9_P#^S:_?_P#2N>!^"_\
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M.(]>R7/ ^G=/*DU][)7M.)^4XL.(]>R7/ ^G=/*DU][)7M.)^4XL.(]>R7/
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MP'S58(^9.JULO$U0:-(V ^C2<G+!7>):CHNK$4YAV)(B0TI>Y(X_!#!)E"R
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M4CE^1NVLR;Q[8F CRK)<Y#FRNM[1Q'>T57B^M.]N;LA<-T[=AI@-M'B[0?\
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MW]$S/+;L-S],LO7Z*Q8B)C8&+CH2'#9CXJ)"&CHX$=.TL"!!LH8&':UO>U>
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@*SC?M/\ XH_W@N4;/J[W*WEJ?\EM_P!U'_16<BX%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g108483g21o57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g21o57.jpg
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M 0$! 0$! 0'_P  1" $6 ET# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MQQC'&,<8R*6"[5JLY],J2;1*RG"DPF$KDS,XSCQ3E3+.%992K'TH6_EI"O\
MPJSS(!/D,P6 \SD3C[FI;[V&G%E(B<Y\/7D0?%G']_.(KTE[&/\ _3X_WN9X
M-[/O&1YK[_W990\C *Q6YHV7'FQ'?'R/QG$NMYSCP\R<Y3G.4.)\<86VO"5H
MS]"TIS]'(Y($'RSN\9G'&,\JVMH]CKMU&V]W&A;L;JT"7IOLC>J5J 5KNHR
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M2CEC=&AM<G$B1/RX]N=J^Q\")V>BBJ"&$Q]&]W.G.E*"0J%H&2K3?ZOLV_\
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MBUF<R2!(8>G!%-*3V7DU[1'97=VV'9)8-H_;_: 0W%KHN"V6F4S4.P[2#K(
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MNM<'LSNUC?%RJNS01O5K$>_]*Z>&HU?/Z_O@MO[\!+<K=DEIM#]9;FR@5@0
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M+<9&G8O3V15ZG3#U(8X(ID0)*T<(581(Z[<S"B*D;$!@H&Y)[YT*>E5:+7S
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M=9U>YJ&C=OM;=32,9LG9%;2+3=HTC6)X?>(F<Y16AL2JFMG#,E +L,H^;JL
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MIB6_"C:U[2HX]1IU:CL:MYHTJVY)X)XK"/:>L+"/ J"-.2_K*\JK/7</'+W
M8[VEZ_--H^I7]0C5;VE)-)?TZ*K:J3U'BHQ733DCMM*9I.+D17*[O4N1-%/!
ML&9%U%A=F]^U#9Q[8NQ<ZU*>]=<NEUA!T^BV"X+I88;O[M"1H!F<0'F9+J'[
M#70UDDM1;M!<BQ+C'!#I+X2OPX[@E/9.E:=/4BK5O2D":GKL<D]B.#KR/IVD
MI9159 -HI9(@3 W)H#(ZB25CS/FEU_6:NH37;QHR"70_"LT56I-:]$B36?$$
ME*5W25B#/!#.0MM"JVEA1FB@0&(7Y<.UVWYVSY^HM55K6"[ _P!PRG6<38;M
M,LKX(<!"=*P':DO;"L"O/MSB9V(6FEZFR!B3!462S'A(DD1DC,N:WSH='I+4
M6[<EM",:*NJO% L0D:2379-(2%&E^JL914G,C*Y&[<58<5/8M>(]3?4'TS3J
M^GF<^)Y-!CGMO.88X8O"D/B*2S(D!#R3+*\E80J\:L%7D\;<F%<C.S^\%ET4
M#5 *B2#)FR_=++82-;<L^Q+1&&P.I_92FZ_"BPS,:>LCB%;$[#3 C FR0L#0
M!K41==C2A5>C5$SLMI5#AZ1<DL!$B\+0(E*&M$7?6-+GLN[[J%Y0^C%C(5>2
MPY/5(>4S)I)X@U82"GIT--I99O'=J274K%ZPL:>'-=JTXHX@KF3A9%X(L(DC
MAI1A3 K1P+6E[M/[O[@V]M'6E;U=KX"U6K _U^E7. 1INS+B1$53;6F1&[[?
M:7=F5Q0;6%-71@I\%58]8MSJ[ 8)&!-B3'9B'ZD"LN)]!I4JEJ6W9D,L8U)8
M&2>K KS4[ST((A5E$EN<6)(Y)C+"!&B(\9):*:2*57Q9J>IZA0@T^E"*\YT5
MK225;]F2*OJ6E1ZM9L&_ 8M/K&I%-#7%>R>M))+%-L%GK13^I?/)9]"QQC(]
M;:E6+[63U+NM?$6JI6@7,"6*N'H$<F&-""#*H\T>1@2VW8\J+(96I#C3J%8S
MXX5CP5A.<6PS35Y8YX)'AFA=9(I8V*21NIW5E92""#W!!RBS6KW*\U6U#%8K
M6(VBG@F19(I8G!5TD1@596!V((RCB73WK&9K]?JYG2U),A*S+L4T5%,0'BCV
M7;>T/8MC94A/DR"-@A6A@0&8L0X_+)CS; ,&R3C2FPHM,3?36M5CDDECO3I)
M*(@Y1@@V@+&$HJ@+&T)=S$T:HT9DD*$<WY<E_#.@2PPUY=*J2Q0-.\:RH9#O
M:""R)'=F>9+ CB$Z3-(DHBA$BL(HPLZQHK3^*W;Z?C7E9^6+]6@].N8/X!/M
M]DJU?K;50" RC/F\) \96&6@D1G.<>E ;2SC/T>/-?Z0N]6"?TF7JUI7G@DY
M?6BFDE,\DB'U,\I,C'UL2?7FX=(TPP6:OH5?T>Y!%5M0\/J3UX8!6BAD']TD
M< $2CU(-L^;SHG46RK(&N%WH80]: ,+ L>=>3*B$EADSTE$ 2<D=)AK.5U!-
M.2**\;R0"(G./2TP,/OO..*^H7:L3PU[$D<4C<VC&Q4.5*&1 P;IRE#Q,L?&
M3B .6P&V+>CZ9?L16K=.*:Q"G328\EDZ7/J=&1D93+ )/KB&7G$')8)NQ)R[
M&IM;1I8Z?'I8)J8)V&;VR-DHAXP["V38PA^MG;HPKS?@'2@&TV$5+F?3ER&7
MFM>7'J^.(&Y:*LIGD*O6CIN.79JL4D<L<!]L:211NJ^ID4^K+1IM%6C<580\
M5V74HV"]TO3PS5YK0_\ G20V)XV;UK*X]>8^I::U)4: 8UK4J-6A^M;0V=]V
MIL:*F75"4&UQE13<# F2N2/2#)P750U!HK38=N OX.-#:BYPUR4UZY-82U-8
ME:U$8^$Y8B9&A;E&W,;-U$;ZW,DOR^L6)[Y76TO3:U.6C6J5TH6!-U*JJ&K2
M)87C*G28M&(9$/'I*!$$/%4"]LP\'KGH\=7#-3C:VKJJ]8M?#=4GATMJ4028
MUR')6LN+J!*3/DR9DP-!)WFW3(T=^0M3;Q\AG"_!W&$S;4[[2QS&U+U(K+6X
MV!"].RZ0H\Z!0 LC)7@4D#N(D]F5IH>DI!+66A!T9Z2:=,C!GZM&*2Q+'6D9
MV9FB22W9=59CL9GV/?.\C0FGF]B3=L,T$''V 2D+G$[#%3*BK*%' &*HLX3&
MQY+0<C8<UA**[BQ31[YQ(-I@4DAB"PRPC!U&Z:RTS9D-9 %2)B"$02]81HQ!
M=8^M^MZ:L(^IN_'D2<G]#Z8+KZB*<*W)&YR3*&4R2&'T;K2(K")Y_1]H.NZ&
M80A8P_!5 CEFZO==+Q6Z52+/J:DG:QK"I.:\IM?DP/-!KE#F"@@N514QV7F\
MOU B+KM;;GU<E\4%)8! I4R#(?%CWF+8M6U.O+//%<GCEMS"S/(&^M+85Y&%
MC<@[3*\LI69=I%,D@5@&8'7L>']#MP5*EC3:DU?3ZIHU8&3=(*3QPQM3"@CE
M5DCKP"2O)RBDZ,1=&,:$0VO=,='"-RWC=Y6H K+<;+;J#;*V\4#Q_+1'=<:S
MI^N*K"%>5U3)-(--3<LE<EEHSTFK&SA237\P)+STM^Z37+[T8*"321010V(9
M0CG^N!:M36IF?<;H9.MTI0A FC15DY* HUH?"VD1ZI;U:2M#/9L6J5F R1+M
M3-"A5HUEC[[2=$5C/ TBLU>6:1H>#$L9L<ZN=?;&P%CE]4U9Y%>DW&0(7&CR
M1LF.G85ED7&]CW98R5#ES0EPM4EX_9*_/>D@C!3*)<X<^ZRRINB/5M2B,A2Y
M,.J(0X)#@^C1""NW%PRAX80(XI% D1.RL-SFU+X>T6<1+)IU<B%K31E59& N
MV&M7$+(RL\-FRQFG@<M#+)LSH2!M*06F]3UK81K98.F@X.Q3<(E'(V)'K/E&
MQ]@GP")UH<U)D/, XME+!!9&Q)#1A[=B*!Q\XQ\=,'QGF:9+MR6LE62>1JT;
M(5B[!"T2LL98@ R&))'6+F6,2.RIQ5B#LPZ9IT%V6]#5A2[*D@>8;F0),Z/,
M$#,1$L\D4;S])4$\D2/+S9%(CR.MO7]C:+>WT:KI+6U<FIEMC6[ UI)IBQ2
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MH:3VIXM+T];%E+,-N1*T(DECND2VX92%WX6F(FGC.RS2,9G5G<L9@4T]JDY
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M)QX)U*.Z';=&93L0PW4D'9AV8;CL1V/F.V?68W$D<<B[\9$5QR4HVS*&')&
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M;X$,0V BC "NH 11LLA!D4=NRN54N/)BH+ [#.,?7*\)9B1A8$,-CCWDR(#
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MN7+D>0((;<\@1Y'?SW&PV/JVS/%>)3BO$@@KL.)!WW!7;8@[G<;;'<[YTG
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M,8M/<B#5[3=<8H%B-ZZK>O=1V,198,::,LQVX[=VW;-.5VHII%AA"3\5J;;
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M4M2EYP@^=;1C*LY5G"&VR*6VTXSG\%"$I0C'@E*<)QC&&,^?887Y0:_2(_\
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M36>QA0,$!E 8&PR9NP"QJ(U;H4MB  @K(QI?MM'9M1JSN0AZQ8NH)/V(K#@
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M\+\&,E/&,P(>S@3\ZSC0Y)F?.IAYJL6>.TEY*Q!Y^N@+8T-D9=;;0MY==M(
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M(JXS#/[9MDP9;%[&;LH"MXL!JT0R^VL%>PU$'Z\HLA&OYC,[C?R&W;R]Q/N
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M9&PP_HW'9:/;![V'X4/_ .\JVYRS'>3%A8<;3G.<X5\*QXYSG/D_CRP?,_\
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MWU">238S09J+2[('F(=G^PMEC(<,% 1)];666\/B2W'M]:G<CSV&Q\M_O/\
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M;4\RL[''E8V\C]SJ^JG6A-C8Q;SNO<EL7"!&3+#1UC\AL@R>%R#*1L28J.C
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M757MB;8GFK\Y'4O*1[EN276/:PAJ&IEM"$X8S%?>(K?R[BLYNNZU0\6O-O\
MCU;QVHJPJFYCIC>T*L>;5DVJI^1.'/E+,[->^(RJ3[?ZZLN9P>_KVQE,TGH#
MUKUW\2[40=Y%D$*MF:T=5M?94^R:Y1>[(Y:[JSJNR$;1+.:U9MQAUQ=E139X
M?!V(MR"4^*B//M.]:[KFK:B;7I5Z=DN^B>E0QL(()S1B6&H98(0D+&"-%$9*
M?5(W &R[06.--N**./+8[;D<SNVQ.Y&Y]FV4O-I%KZR7#<I*I:Y[J=@JW'UT
M3V4'*Y[,'K@T<MUQ/8JI34-)HMGNT)^.5JP&.B[#+/-;G%H3#LIH*_,.-"(D
MSII!1UJ+238U31]'L(\>C/":<]=$IU:QECU:[-"CQS3V)7-:1RJL\@1Y9%02
M.E9+1<^,<D@.\F_('=F;8HH)W 4?6]@&X )VS<P3J"O1!.O%.VO<T/Y,(.&Q
M[![=6PYI$C.,S(<Y0?8,M5NG-7R)%EH:'Q ]CFGA,5E;XX:G,*4M#WF679F4
M$/Q+ ,@8A@NY+J"JOQ*@L.2JP7NRJ00+_N^.WY$C?X$YR3-%UV:)L0=RZ[J9
M8LMF1:I<N'O#:<,L.F(5)5@772\:U-$:W6<_%+PNKA9,($M+<9*X"L18_IQ\
M\9KQO'J/N#9NVAMZU[W)W?I2C3A0$3L+5U9FR3 NSMAK-7"<B55BY0XF3K D
M:K8<A6B92FPX9!UPJZ8S(5(=(M$>YINHZ33I7(+N@Q:G<L"5:UZ2]:@]#$E9
MXE(K1$1RM%,4L(S$-NK)N-U9*W5V92LA10064*IY[$'8L>XW&X[>W?,Y8NOT
MND[STIM/4M S9S+\1&K]V[&M&[+P'M;6J P:RSZT0-07$F$[H,P+(64S#3<9
MCQ >IZ N/):98;* *:T\,VFVJ=_4[\:4T:SI%%(S/3EO321)/U TR+5Y0J29
M4C<MLQ.[ 1S9((<,J*2Q =M]F"J&*^HEMB?(GM]N6U/U11:;383Q[9&UQ%8U
MZ6F["GV>Q[ZV2TXS''L)F$$W2U%+;B26I,&+#7(E ;'/DUF-'3)<=B(:<?RK
MF112SR1PPQO--*ZQQ11(SR22.0J(B*"SN[$*J@$DD  G;)$@ DD  ;DGL !Y
MDGU 9<=?*!3H4:<KA>(? G(K9H.;'DFS XH-+X]QASAI-EZ1'F#)+$E#HYV*
M\Y$Q"4PB)G$=+6,)(Y(9)(9HWBEB=HY8I%9)(Y$)5T=& 9'4@AE8 @C8@' (
M(!!!!&X([@@^1!]8.0JA?PJW7_YFBO\ V:U)S2K_ -FO?]Z3_P E3ST&L?\
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M;#_L,>A> /YZUS_,H_\ 98^3NBO\L&Z_T+&?L_CZ-_15_A'XF_T;#_L,>A>
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MRIQZ36?19\6T>5&?2;\4_@)\,[D[[DG<[GOYGOW/M/<]_>?;@*HVV4#B-EV
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M><)QEMG.6FLY;3X(SZ3?BG\!/@W/?N>YW/?S/?N?:>Y[^\^W 51ML -AQ&P
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MDTEZLLFW+333#:&6&FV66DX0VTTA+;;:$X\$H0VC&$H3C'T82G&,8Q^+'.N
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MBK01"PP0ZJEN(,[E$)*U3$W8[\VD4!VD.J2O((!N_( L3MO^KXG8#?;]K<?
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M4X4'-$2 SQ<BN266)4?U>[.-8H:%5KR-$FD:Y.VI0QJ]6666:@TM(R/QY6H
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MMW5I8H"5$O5*VSK;=- KURJNX:9)G,#12@V33$.RTY9/$I*I9EYT49'N0R[
M:',0/F0]K0M9.B7C:-*GJ,$L,M6U2O1+)#8K3 "1 2&,$NRCA-'NR=U(=&=&
MC+'U%X\V0@A@R$@AA\=MQW[@CO\ NR,W,5W"W1$D:LVQUN=C:E;BZK.5RZU+
MLN'KNW(^P-?'&K'-)WE=.^4A14$8.!0,IX;39-=4F$X3:8PS*?'J";%34:&F
M&IJ- 2?24LFIPZC3GIUK&GUZ-J/H0K0-IYWDE$$TP5K//9T59>2\C/@JSEE;
ML@X%&5B&+*>1Y<=MAR _9]6_P&(Z^7_[J 1DJO._M.5+"@4 AK"9IK7UJU[
MJMO/ K"]B1OX5L&PFY%J!,E(K3P-C6TP7-AK980;9+,?%-L-YUB3PTD'H^B5
M;DDDM@7$O6[#=:M5:-D^BYJZQ)7>2-U$QL1D@APG-RIQ&)?.1E[#CQ4=F((/
M4#;[@$;CB1OZ]AOL-A=W3NS&PZ^?K5#UWLG5<H#9*%:JI=JALO3.#5VCUJT!
MCA^DF1YYXQ"K(2R#XD\(1EYR:4_$=\'HLB$_+%R^7IUNO2L/-9T^MJ4;5K4
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M_P!-_P!\Q^X,[6_R6?Z;:[_XMX_DH\??S#_XGI'^_P"/Y/O%W\U#_/\ 3?\
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M_O=T_$#AYA.]M=R:].*UL+D^)-P9@.')MM3-6VHYD3X[GHNLV 37YD4/[?\
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M:^!2*B%I,I6L[21KIX[*F09V( L3%CCWIY!TB_'3%E1YH:"X7FH&J+-O/U@
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M\2^+/-_-HS6MN 6NRGR1;5#UC)L$+^_1KC!3.)E"$IH4=%$G4L$L/N,=O?\
M#\AW^S<^KU;Y+P6L>ZK)BU'++N"H&"+6I;I6->N,2H X8/NUDAZADC"Q:NP=
M/,CT3!9VHWY6;26DWN%&A6(+[9KQB+BPAB;!(]0^>_\ '[O7YY)*_1NYD,3L
M%PYN.IE#1BE; ':_AN0ZU\#4;8^"UZUJ\K+*C]-A72<Z 98V:J\&9X0E72#D
MJJEPFLX4%R=3Q;';MV_I\_?\-N_MW/KRH@>H/N@8@BWE6YZ.]70INR'@89VT
MMRB9F4:KNR<18EOL#O7UI,L2S<+E7",\7"#-#FX5-@.U:'5T88",L=MO7O\
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/CC&.,8XQCC&.,8XQG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g108483g25k44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g25k44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4F":'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 U+3 Y5# X.C,P.C0W*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 U+3 Y5# X.C,P.C0W*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-2TP.50P.#HS,#HT-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$Q,CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%C045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&
M6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&5TQF;69Q9"]P;FMB53<V
M=VYA,W4T9E$Y3UI.;5AL8U)Q869.5TEX5C1L3C5V.$%Z3VAH5V%45B8C>$$[
M8F=2=$9(34<Y4TTO=3566FM*<#!Q14]X,S9E27A6,RM,=GI3.55W+W!'-TUI
M.&=Y.&QQ0VI"1U@O5T1-0G@V,4DX8U9D3#5V+TY#128C>$$[:U-A;F-Q>3AE
M86PP<6Y*=4DU:CEN-'1V:7A68D8U>"]-*U=1>'AA;&1Y3V]1<T9:5%0Q535O
M3G4U6&5N6#=S5E97.#%F;6MS8S!J828C>$$[<&-,2$%W5U9Z2D=!0UI$1#E)
M-7%255EQ:')4>C$K6D8R>7!B87)D5$\U2V]I<W!9:U5R4F%6+V$O=T$V2$96
M5T1Z:"M:,7=Z3$)Q="8C>$$[>$MY8G-Q4U)K9V-U04Y"-'111'AQ4$59<6](
M.'=0>D)616MF5S4P4U)U24ID0U(W;%%#=RLW1E5W+WA$*V)0-E)B5'8P:F1F
M5S%6;28C>$$[15A*87-&-699+VUQ54E&35915"ME=GI(4E5:=%AU3TUN2&=2
M26AR>4I!<%0U8BM(9D96-F5C+WI.:VUA1U!63&PU541--DLV17%Q9R8C>$$[
M37AA;E%+1S-*.2]!-'%S2&YJ.'EI=DPY2S-82#!Z3%5S;RM!349R=5 U:4(W
M;D96>F5D4'I,54M4<3%W435+<%-333AI0E=G<#$O="8C>$$[2&E+<6]G95IF
M>F%-+W="6$8W9D=B:7)M4&%O5FE1<$\R=U!%-'%I=DLO;F)Z=R]N2%-,0RLQ
M86571V4U=&A*1U="5C1P:7)$=#!:1R8C>$$[1TMV;V9&6%EQ-T9867$W1E5U
M=6)F5TI,:5%X,UAO,B]*1VE%4TE7-&]0:E)J24@O04QW=#%!*TAI4$4U3455
M,5-J36YN="M0=F1B4"8C>$$[<FE-;VYJ:FM2-#%D:4=(3T]6-4=,<#!65U)%
M6E%P<%4X5%AC-&YH4DAJ-G)B0S0X=TUI:2MT25DU3UI$3D9*5F5"0DE.1'9Y
M6%I34"8C>$$[<$AS>45E:%=%<VXX44-T<%1A<3!,1%564EI6-&A3;C=6559M
M2F]33FU9<CE&93E!2E8P6EDK2W95:F-I,D]X5C)+=7A6,DMU>%8R2R8C>$$[
M<V,O35!23#-84$M..7!.:G<K=#-2:45):V)I<$UC>5-.53!0-TM(1EAK3&9K
M,RM:1%%M0G T5$-A5FE.>7A5.%%Q<CA.2V)"1D$K428C>$$[>%9D2"M4=C5K
M4GE3>7!.04IP=C=Y6#%Y6$HY45,Q-49A9S@Q1%8V-'%P4R]K<BM957I-.#!K
M16IT.7!N=4-X4'I*6#-X5F0O>7!N."8C>$$[>'9J2')1+W9+97 O<$QF1E)3
M9W)T=CA!0WA(>7A68VXU3R]M56I3<VQX17)4<7E434QL=UA6>4=:5TY.=WA&
M5%A&5FEF:W0K66-C=B8C>$$[<E)Y44I-4U0V:3-$0G%S2T4Q07)V6&9&5V]V
M>58O34M*=6-5:T5B8D1K='=Y;C131UAO=EEQ0U!L:7)8+TMK=E S<4-1+U98
M8TAL5B8C>$$[-7564U!%37!"*VY&550O>7%4.'IQ>&M835%E3C5*16Q&=W=K
M1%-H5F,X=W9,-&=G2%A&5DM(.&UF>D5H3EDS=&@X16M90FUQ07-Y;"8C>$$[
M2D%!5DDK2E=/2W%A9FMN*UE#17-J5S9K<59*135"2W-#1T@R96A"3F-68F(X
M:R]Z0EIL6FYT>7DO6DIN2DDS<G0X3TMT3BM36#5G328C>$$[<7%Z5S569#%5
M>FMG16=,=#A09V](,%EQ:6]F>6PO32M+8C%L=4E':SE-=VXQ2B]50FI)231&
M6%9L2S<Y0TU64E=G9FQ.-3)S=DY';28C>$$[871Q0G0R:71B;4(U4W-T4T5J
M6E%!<6A13FQ!04=+=F-C5F1I<G-69&ER<U9D:7)S5E%-,&Q.8W1)+U998W)7
M-6(P451W8FI*8FIK4B8C>$$[-')Y;U!M8U92,DMU>%8R2W5X5C)+=7A6,DMU
M>%9!4S-19E9O8F1A,&DU1B]#<%$P*S19<6HX5F1I<G-69&ER<U9D:7)S5F1I
M<G-69"8C>$$[:7)S5F1I<G-69&EQ>68W02]W0F10*TI$1E8K2W5X5C)+=7A6
M,DMU>%8R2W!F3S!9.'=74T9+>4<P=7ES;2MW16QT5694569D:7%9628C>$$[
M<3=&6%EQ-T9867$W1EA9<7-M;%-'1C5N3D5J575X-C=+2VY&5U!A3DTP,F]P
M33)Z4T8S24A3<D%N1E=367$W1EA9<6QL>&-Z<C5M<R8C>$$[3%98270U8DLY
M;&MJ-T8T-6)656(V0DDS,S1Q;65+<%AC-DYC4UA&>$Y&9E129E=!2W)Z:UI5
M9$)X47AR>C1Q3TQ.>4%(>$AI96].5B8C>$$[549C848U:5-/4CE0,7!O-W1V
M5#-N:DTP5$-+1E4T8TA:=4A*=WIS>6)M=3EE3S9Q85=.:&,R.7I.3DQD=F-,
M3D9#<%(V,$5S45I:2B8C>$$[5D9E2RMO0W165E%+:79F1E5B:7)S5F1I<G-6
M9&ER<U975"]92"MU;B]%:&EQ+T9867$W1EA9<3=&6%EQ-T950DU:9C W6F=,
M5TPV<B8C>$$[9&,S<#!B,4QF:4LK-')I<5!X5C)+=7A6,DMU>%8R2W5X5FIV
M;E!64'$Y<D19<4MV94@T;7(Y;%EY<% S;BM/2W%0;"\O97%$-4XO>"8C>$$[
M131Q>6I&6%EQ:$Y8<W!B+T%%;3ES66)H-T]7-V=L9VIU-"]T>$Y):%533'50
M:5%M;WA6:E=J841D-E U:S!3,FTQ4V4K:F<P5V4Q5R8C>$$[1U))16A2<F,R
M36)34FA%.6(Y-E8U34I*6' R,GA6;4=+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%9:4#A!64@K=6XO16AI<2]&6%EQ-R8C>$$[1E5O,5=W.'A4,SA-*VYA;W1N
M87@X4%5T1V=345-F17=K<34K2F9G649A9G1+3S%15E5V:3!J>C-Y=6A,<CA0
M<'E8>&YT0W1R2'II="8C>$$[4%5$0S-C;C1:0G=5<#!6:%AL>DY!=4MP;F]&
M;G(Q<D1/=7-A9W5O4W9)1$$V>'!(=VI#2T-09U9/<FAM.7$P<6%6>%9.3593
M2%AR8B8C>$$[5UIT63 T-EID<&%S<T8R2F<V:'53=5E50D91,CA434I"=#A2
M6&E307A)5E@K6&1/.'HR8W1Y9&$Q66%L1DI(8G)B2C958V)2>4I(+R8C>$$[
M04M1-6%.2751:VM0=VIJ.$E(=FEQ9#1Q-T9867$W1EA9<3=&5T%E9"]W1&Q*
M<F8O04IH:R]W0U1K;4MP=C5F+T%.-F]0:S,O04)%-"8C>$$[<7EJ1EA9<7A8
M>3%R3C-F96%V349J2GI33%,O46I)6C-C4U-41U)U9$AJ:59!<V%)04EX5&1I
M4S-W;D95>75V*U5V,'HO=&XV:"]Y9B8C>$$[<W-65&I&6%EQ-T9867$W1E9'
M-&MD2F):5DY"2DE68V5).4XR+U=O>75C:41(>E V0S)1:4-*95$O4T9B3$=T
M,DMU>%8R2W)*+W-$+R8C>$$[048P+S1K359E3F9M8BM8=FTS5V9/175O5T]L
M2%5B2C11:78Y86AJ,S1C86-:4W!49S(T0R]#9795=&A69"M76#5F.$%M>E)T
M5FYM,28C>$$[2%-26GA.86U)5&5V1$E88WE),C12,G Y:VMB9E0P>%8V3BMI
M<B\X03,Q+W=Y+S%W2W-M,&I61VAK5TIF5&Q:4TDU1'A92WA'>F-A:28C>$$[
M=$0R>%9,-"],9FUH3$]/13-W339X47AT8V5K;%,X6B]E4V-7:UE6:UAA;F)R
M:7%,,#=1.5IT-TM+1S9K*W1Z;T-(=4-%479U8595328C>$$[4E=L069(1E52
M*VER+W=$,S$O=WDO=T)C5EDS*UE(;"]6.50X=#-E:C)-2')A;&1O<VQV0GI2
M95-15'A'43AM6E9(2&M/<'A6;$AK8B8C>$$[4SE1,')Y:G!7;C9I9CE.=')D
M56U5='HT;G%%-4%K2&=0:#).3G1T<U993$(K4T=Q4GE,2S-M-C5L;&=%>C)F
M<5<V1EDW:35K1C5.328C>$$[5C4O1B]U4VEH=55886=49V524$U+<'4O-5-7
M,S9E:#%/3%9R;$QE,'-,2%1B4%1Z57A*1EE834YW1V(T>'E:+U%P-&(Q,WA6
M;BM+=28C>$$[>%8R2W5X5F=(;F8O04I3840O;4=4+VLU2FEQ8BM8+SDV;U!K
M,R]%5&ER2TU69&ER0E!+3G1Q>#%J>F9&1')3,TM4=7(R36=!84]Y;B8C>$$[
M:V4T1'AI,DYX3CEG.$A:<4HV:$HX1%)6361,,'4Y,#-8=$-T8G95<'13;6<P
M835G:VUM0VIN2D,Q:6IZ9$=K-5-S3U1C-4<S4%A&5R8C>$$[5EEQ-T9867$W
M1EA9<3AE,3=Z5C5H:3%Y*VEJ=G!&:G0W<5I95D9+2T9D:T9.=C545$]),69A
M1V-:<$%33E)K82LP4&)A5%%95&AI5"8C>$$[15=9:2]S96IE4S<R-G9F3$YN
M9%A5:&UU2E!5-7E.,5!'5C%(5#)'9%(R6&QL:S X6E-.:S,Y-659-U1X4G@U
M-5)I2T%R-V=N95HW9R8C>$$[3WA6,DMR2B]S1"]85"]I47A6-'8U+V)Z."]M
M;3A.=DQR34YO:5-R06UN9E=H0V%*5S,T96EH4G52<#9H3%9Q4TYG;W%Q<B]L
M:B]J;B8C>$$[-B]C2%9:=%AK:4YU=$9V>&1!0UAK0S-(,6%R,V]+1W4R-$=+
M=E)+-G(O>&8O=T%0:7$R5G1:16)M2EI8;$-K;W)&,55T5%E&9T=O2R8C>$$[
M.39(1E5V.$%R4&Y&67)A5G)74U)M5T0V>F)O>%9L6F<S<C!D;4MK2CA0169J
M=G-Q:F)36%A*3&1*3&E+94-::%8T951/5CEI>3=6*R8C>$$[5TMQ=&16+S1V
M+S1F1E=.9FU#9DU!.'0S6C!Z-C).64-,.55.=#9N,6XP+UAI.5@P*T@W>FI3
M;DMN=%A&5U<K5&IQ:#AQ85-D5CE4.28C>$$[22]6679R4'(Q.5AN>$@Y-5@T
M=5@X,60V.60X5EE$0F0O=T1/44)K5C4Y4'1L:6=%,'I2>'I7=DMC>5-#.&=T
M=U-#1CE+3TDR3'1T=B8C>$$[2GI"96YQ2W%J=%-4.#5O.5IT;W)A4DHY26ES
M<D=+931T,7-X3DQF971(.6)N2WIL44EV4SE3<7)1;EE,42]%1EAP1TMU>%8R
M2W5X5B8C>$$[9TAN9B]L2F]0*UE:4"M4:VU+<'8U9CA!.39O4&LS+T54:7)+
M359D:7)#9DEC2U-A.35I=6YH,%5Y>#-,47!C859B1T<U2$M2,VQ3."8C>$$[
M;%ET>FM*0TUA53-Q5#)X5E!R<B]!2E,O5% X071N-F@O=T%N-TQ&531X5C)+
M=7A6,DMU>%8T5#5J+S532%90*UEU9B]!2D].;FYM="8C>$$[+W8U+S$U9F4K
M9S9,*S5H+U9J.7HQ6#AV=BM547-0.$%N="]Y969/=S=(+WAA4'@O,U)E4C=9
M+WAM6'<O,TE:1&UZ9%DW1EA9<7-N*R8C>$$[=U X05A4+VE1>%8U4#4P+TYZ
M>D9O+VUA-#!U>&AS231)43E0<F]C>3AK5V\U8UI9*U!Q.54R*WE63F0V0E9%
M+VPO.$%M:C5G.'<S8R8C>$$[,$XX;&=&:F=%;U<R5U5-<$Q!55ET230V2#<X
M5EIX*VTW<BM34#=J+T%&>%93=79-5C%B,C!S+V\K<C9332]P4DM7:V)I2SA5
M6&QU>"8C>$$[-D%9<6PW960W>C%9:VHP,F513UE!-V5H26Y!6$-U86YN>$@W
M=F=053,K1W9J=&EQ6E$V.6534DLU:%=.;4941S0K2E0S0F]Z1&(R2B8C>$$[
M1TMR+T%.3C-8.&MF,T@K=4MS9C@V*V)T4S!843=J6$Q72T8W=7I2631K;%9J
M1U)03D5R8V=R2S-B86I9<7E8>7)Q,"MS95<Y3C%3-"8C>$$[:E=+93AT-#5P
M55-O54UY,5!'=%13=E1F1EAN,$@U;"]M6DI)<&9Y6F11=U)#86$V63(X<DTP
M6'%#-71O-%9$:7-R,D5C:4U.*TYW528C>$$[5F=P4'!S<6I.5S@U+VUJ86%V
M8C)-6&PV3C=D8D=Z;'9,-4EB;65.<C975D)C45)#23%646I.>%IQ<7!&6&%L
M8TMV4W-#=7A6,DMU>"8C>$$[5F=(;F8O;$IO4#A!;4=4+T%*3U-9<6TO;"\X
M03-Q9RM49CA!151I<DM-5F1I<DAR3%%R*S!I,7@T;W)71R\Q044R.35B.%EP
M;EE1."8C>$$[14TX<&AK<7=K<39S>7EC959/2D$S5E%7:S)8;4LP.'DV3D1Q
M.2]"92MN;S%X1E=/1C!L339.67)02DI-,')#45-307-T26MO3W1C5B8C>$$[
M6F1I<G-69&ER<U9D:7)W;GI(+WEK3W%F.'AC+R]*>',X.#%V.2]0*W9,-S,P
M2%)F,TU0-G-F=65Q+VPY+W=!;VA99C@Y=CA!:S@K9"8C>$$[:#)0+T%)=$@T
M+S=O=DDY<V8T>DPT9C=K36AZ6G5S9&ER<U975"]92"MU;B]!0DE9<3AO."ME
M9%!,1G(U=FPP<"]+1G)R5V]+15=A."8C>$$[=51"15=D:S5+<74X8W!A:6EN
M>$5B-T%E2W%4-E0K83)I5TXU071P-4AT8D0V-C!54FYH;6I885AI>3$T,C1R
M<W=.2S15=E8O,&IA9B8C>$$[.'-39F@O>E1G43<Y23)N+T%#>$HK2"].3TMU
M+U-.<"]Y>$HK2"].3TMO2%503C-L+U0P:V4W:6EJ15@Y-&]"9&=#:E-!.%92
M;7!X:B8C>$$[63%P,E!H:7%*:3%Z5$I:6&EJ=%DR:VHK,F]P=#A26"M8*UI3
M35953#5D3W9P1E<V<UEP<DPP,U-A>FM66&IK6FYJ9$A91F%F0C9:<"8C>$$[
M=#-X5DA1-G1"8G=2=U%7:7A147%%:6E1:%561D9&5E9#,$%!,D%'2W9.3%0O
M;DE3-G9*>$)B95=V56M*04,O6%%.,EE)3GI!0G5Z028C>$$[66%3:4EF>C Q
M:65666]02V)Y>71#3&=*2&5":C9257-'25=!,'%"<T1V.$%E355*;#5'+T]Q
M,3AZ-B]$;S!U;%!9>EA+=6)E4EIH3R8C>$$[<&%.1$E1,W=21F9H52M/3DMN
M6&UR.#!.0CAT6$YX0F5W6$5V,5I9>DI,13%Q:65P23AA*VM$4%!#95-R3VIS
M4T]!5F@X6$EH4T97-B8C>$$[<BMB6&MR5$E'931U2G9R05)':G-X0DE(:VMK
M='ID3$1(231707EE:TXO,VQ&2D%99VM65E-P4'HV.&M,4&-7=#AL,W Y-UHS
M9W-,=28C>$$[,75&9TQX4VUE3S-*6F]:<%EY:71)>$I6:G-J.7=!5E52-3,O
M04]5;6<O-6AK+S5/4UEQ;2]L+R]!2'%G*U1F.%)/2W-O>%8R2W5X5B8C>$$[
M2C=R+T%*4R]44#A!=&XV:"]W06XW3$952&5F;5(U1W,W=5,P=71:=#1R;4=2
M;UI9:5162D5*1$LQ0G11<5)M4DA36E-,1514035).28C>$$[-EE(>E0U9D=H
M9G W-CE'9$@O-6)257 O965L,D9F-WHT8W@X,S=U*U!A;DDP,D-E95EH:DA&
M23AK:S S.#%F2FUO86ET:$9D.$I:2"8C>$$[155$4'@T>4]Z0E963TQ-,WA&
M='%G6FE1,6M*1W0S835U=TY6:FAX;4]W1FYY5#-69DUE:395-G@S.3-(0DLV
M.#!I9&=R371A5D930B8C>$$[;#@X<UDX>3@O;#%%269544AA5C5J,%A66&%/
M=W4T-3556&LX84U'6E9R4W!O4TU96EEY-49C5V]H:RMK9W9'+TUF.$%Y:T]Q
M9CAX8R8C>$$[+W=$>6-B3T$Q=CA!9GHO<GDK.3E(,%@Y>D0K<D@W;G%V-69F
M.&]H668X.78K5'HU,DA9+RM,4BM0*S9,>5!B2"M->2M(*S5$26,R8B8C>$$[
M<DA9<3=&5FLO=T)G9C8V9CA31TMS5SAW9FQJ-5<Q,U9F,')D3&-1,S5O6&UT
M-6YJ3$965D9A;31"0V]"5F%9<6PP6#5+*U19-4E:028C>$$[,30S,60Q:VE2
M-V=L47E5<'14,D%X5FU(-DES=D)V=GA6,S9)<W9"=G9X5C,V27-V0G9V>%9$
M,TAL8E%B;FXY67,T-795-"MP-FEQ,R8C>$$[3&AU=&%G,30Q,GA65EA19$U6
M,FM73&I)*WI/3FE10U1U9FU4:7%J2G Y<75P45%!:TQ*1$Y)57(Q2U!%06$K
M,TTT<6EF,%!:941F9B8C>$$[:7)#;V9Y3CAK478V:TQ8<V(Y;5,T2VY9,4<T
M6'A'2W$X4#5.*U9O5T1W,U=O>$]&.4U-;#(V:TI5;FI51'!6:6%9<6IV3$@U
M5RM4+R8C>$$[04,U9FI59%!T;F$K44U)<#5P1V-O1TA&=4DR559"<%=L8U94
M;E5V2S-L:E9*;6XQ4%-,2RMM6D)%,'1Z8E)435DQ64]Q1FY6:GA$028C>$$[
M34(T-'%T=5!+2&Q/-60U3&Y23$-E4U5+<W)Y5W-,;&Q32F]61$9L3E%S5'-G
M+WE34C!X5EI$-4PX;E%23$1";T]N4E%O<VE,1VQP028C>$$[<6A::TUC9T%#
M56\V3WET-&=K2$95:3@Y5U1R<6QL9D-P4U)04EE5,D)2:7<S+WEU6BLW1E5D
M-68O=T(V;U!K,R]%5&ER2TU69&EQ1"8C>$$[,6XY2B]O:2LO4EA$.4MF5C5F
M<4AQ531E=G=0<&-Q.75D2S1Q;$9J<%AM85DV5G%6,V51=S,Y=G U=#=M0V$S
M17(K<D])2&U,=D1.2"8C>$$[1U-*25 R1D,W-UEQ.'DX>F9K3G%&-35H1CA.
M634O<&TO;F4V361K,T,R5U-/834U;CDK87(V:4Q'2S S66(Y:G,X9F%C;WA%
M835">"8C>$$[-6%C13-B354O3$Q55B],.&53>G)%2G1"+W=!9E@Q3FA*+W94
M.5HV9E=/4#)T<S%U<U!J:VLW5S=,<WI62%-:635):7I'*V9M0U P<R8C>$$[
M5CAV+T%*13-D<'):=E P>'=/;%AS3#)X97I01V-2<$90>D@W-%58;35J,G(Y
M:R])82M/:$%)3G91-FHR<WDU8V-O1T5F54-/=E55>28C>$$[,WIL*UAM<659
M8FA,,F)665DU3&5%>'!&1EIU959#5S<S0C-.8W5Z-EE:1%I,=W5R,$5C-4)*
M27!F-5,O3')5+TQD,TYD5RMR47IT4"8C>$$[2#9B3$I:=4%">416,G508DA"
M<&AJ3F=R<$Y"2$%345-B4W)84'DT,6E45C1*;'8P;$=Q6&MO=5A3,&9J8G$P
M53 O<4XK+V%Q.#0Q:B8C>$$[,TDS66(Y:G$X,UE52GI-=4DK;VLO3C9V1#(U
M3T5"15)(<$%(>5IN-6,P5%9D2'-,97=A*V=U3&%$;E=L<SAC:F,R6B]T974T
M1S=F>28C>$$[-71D2G!X:'AI04XQ*W4S5C9R54A.:TUY2W8X05939#5K3T\W
M1EA9<7-N*W=0.610*TI$1E8K2W5X5C)+=7A6,DMU>%8R2V]35DLV="8C>$$[
M8E V8D=L=D]05D$K1F%V0V5*4&DQ3G9K8U9294MU>%8R2W5X5C)+=7A6,DMO
M4%=,25AU;7IW57$U6&Q'0E-V3F9I6'(T:U5X5DDO3"8C>$$[+W=$=E9".&TO
M=T-);D9755EQ-T9867%H<B]58E-W:5=7-5IG2DA%8U-2;SAS:G5A;FEK8UED
M,DY!5TY"<V]*3W=*>%9J6&QG95ET4R8C>$$[,6E85S=M.60Y075966)R430Q
M6D8O8S-+35AH;FE%83=R*S=A<%ES0U!H96I33&EQ6C8W<CAD=7<P-C!L0V%L
M9&QR94,T9&5C1G9/."8C>$$[4DU*;DY62'A/54%J0C5T>7%">$1-1E9,>61P
M1W5A8EE4>6$S92]73#(W:SEA849'1'=1<T9#<UDR.4]%,6PT*W!*4E94;51X
M5E(Q5B8C>$$[4W)8<FY5=DTQ,49P=6A866AS-U=E238U8G5,:3)M;G-P<&5+
M>E<P.%IH9%)70V)I5F%J,'(X4T5C,5=2,V0U0F]'9T<T=7!:<G%+=R8C>$$[
M9U535'9X86%49T%V3U(O,V-A;&IU-W1X4F0R67%O2D-R1B]*-BMD3EHQ6F1E
M,714<'1H1DA*2&%714XR,'EZ;5)L26Q:15=/2#!G9R8C>$$[4' X=50Q63%A
M9UA&5V19<3=&6%EQ-T96:R\R0B]R<"]X25EQ=GA6,DMU>%9*2DY',6%3,DU0
M-E%:2"MR;45Z2S!N37ET>')0.7%I;B8C>$$[.3)+24)T5G0Y.%929&IP.7A!
M<T-Z>E!/.$Y3,'AK:RM.;5=J37E%;&1Z,%AO=F)&54)$;V5R>$9+,SAK:7AU
M<DM';6LK2D)W2$)Y828C>$$[,4HY36YK2T-R2#1D.6Q5,W9O3&EE1E5G;45,
M0C%C=%)J54EE6$@T5U$W:T-V:4MJ=FAI85E4:5-.:U Y5S%9:31M.5I%;6Q7
M25)1028C>$$[<S!59D%6:V]X05!*,EIH>C0P;T9013!)37)$2&AN=6(S,B](
M-#AT;79,.7!Q='!P<5<K<%A!=5HP;T9K0C5(9T9!;U<T>#AJ544O6B8C>$$[
M.70V8VDU0T-D:UE)>6I'<$=Y;4]18FY9<3=&6%EQ-T9867$W1E5L9W148C8S
M>$%O:FQN5&%G;WEK,$AY3S)+<#%I<G-69&ER13E7."8C>$$[;E@R<BM:5$QQ
M5GI&9656*T55>3948WA2>F-B>4]Q1F\K55DT23!8=W1Y6BM82G1L,D]+<W-)
M<4-+,#DX5EET-4\X<&%H<&]7+W="9B8C>$$[=D8Q5'I"-E Q5G(P26=!:E-2
M>4A4-$594U-X;4U3*U!"05,S1&M657<X,#94<F5O,G1O=6HV;S)L6%9T9'A4
M=DM&1'),0W16;&ED4R8C>$$[1%93<CAQ9GI!8FIR:7)6;&%A1C51.'9*1T97
M,W,W65)I-6YJ:4IA4U9Y<V)4>6E-37I/-U5,=3%F1FHQ3TMS9C V3S<X*U<R
M:C9T<28C>$$[9&DR;#)D;DDP-U=4=CE94S1B:VI1>3(X.&-K46]H:B]!3'=W
M:T]J15)T=UES>7)/;%5+07%I:6I9061!359D:7)S5F1I<G-65U0O628C>$$[
M2"MU;B]%:&EQ+T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<6]Z>&HQ65IJ6#DP5W)116UJ3%1O2SDV67$S.28C>$$[6FHX2"]W0U)B
M+S!X5C,Q;5!W9B]!2D9V+U1&6&9762]"+SA!:U<O.4U69#E::CA(+W=#4F(O
M,'A6,S%M4'=F+T%*1G8O5$989E=9+R8C>$$[0B\X06M7+SE-5F0Y6FHX2"]W
M0U)B+S!X5D0V:$)P=6\R8W1L9C(S,7$P;DA'5T-71FY2:%=U-$LY:4MJ1E9D
M6C1554MQ3W%Q2TMO:B8C>$$[8T%!9&@X3TMT+U=9+T(O*U)B+S!X5C,Q;5!W
M9B]K5R\Y359D.5IJ.$@O-49V+U1&6&9762]"+RM28B\P>%8S,6U0=V8O:U<O
M.4U65R8C>$$[>51+-%965C9L;#9O-#9-1#%)>%8O.6L]/"]X;7!'26UG.FEM
M86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!0
M1$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E
M;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO
M;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIC<F5A=&]R
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3YR<C(Y,S<T.3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @
M(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ
M;&%N9STB>"UD969A=6QT(CYG,C5K-#0\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z
M9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @
M(" @(" @(" @(" @(&<R-6LT-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @
M(" @("!R<C(Y,S<T.28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#DM
M36%Y+3(P,C @,#@Z,CDZ-3 F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @
M,#@M36%Y+3(P,C @,C(Z-3DZ-3 F(WA!.U-C<FEP="!697)S:6]N.B @(" @
M(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X
M03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B
M(#(W(&)L86-K('1E>'0@8VAA<F%C=&5R<R!C:&%N9V5D('1O(&]V97)P<FEN
M="XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[)B-X
M03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R8C>$$[+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C
M.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#HY,S,U-D0Q0CE$.3%%03$Q.$0W04)$.#(U.40Y,#4V1#PO>&UP34TZ1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HY
M,S,U-D0Q0CE$.3%%03$Q.$0W04)$.#(U.40Y,#4V1#PO>&UP34TZ26YS=&%N
M8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.D$U0C-%-T-".48Y,45!,3%"0T9!1$0T,D9#,C9$0D4X/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#
M;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @
M/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O
M;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z035",T4W0T(Y1CDQ14$Q,4)#1D%$
M1#0R1D,R-D1"13@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C M,#4M,#E4,#@Z,C8Z-38K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HY,S,U-D0Q0CE$.3%%03$Q.$0W04)$.#(U.40Y,#4V1#PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,"TP-2TP.50P.#HS,#HT-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP
M34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YU=6ED.C)F.3,X,V0P+6$Q-#(M
M-#(R,2TY9#(X+3<U-V8Q8C<Y-#%E-CPO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HY,3,U-D0Q0CE$
M.3%%03$Q.$0W04)$.#(U.40Y,#4V1#PO<W12968Z9&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D$U
M0C-%-T-".48Y,45!,3%"0T9!1$0T,D9#,C9$0D4X/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S
M<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H
M;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H
M;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T
M+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G97,^
M,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE
M5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R
M96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R
M=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP
M5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @
M(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*
M(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^
M4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N
M,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^
M"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W
M871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!"0)= P$1
M  (1 0,1 ?_$ !X  0 !!0 # 0             (!08'"0H! P0"_\0 8!
M  8" 0$!" H,"P8"!@L  0(#! 4&  <($1()$Q05(9&5TQ87&C$U4516MM48
M.%=8<75V=Y>QM-8*(C,Y04-5<I2UP3)A=);4UR,F)$)2F+?P&24V-U-E<X2A
MLN7_Q  = 0$! 0 !!0$              0(#! 8'" D%_\0 5A$  @ #!04%
M!00&!0@(! <   $" Q$$!2$Q41)!87&A!H&1T? '$['!X0@R-[44(G)S=K(8
M0E65\146%R-28M/4)"4S-E16DI8U15.45X*3HL+2U?_:  P# 0 "$0,1 #\
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M=D@5JG3JJD3KUZ.A,O(48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MF(8H^4#%, @("'4!#H/ER%//>U.IP[V?JF'4X=DW4@![XG#I_% .H>4>@>7
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M>&93A*8#=@2F W7IV1 0-U][IT]_KU_HZ=<E'H*K4_0IJ%$X&3. ICT4 2&
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M#+BA3AA<4*<;:A3:3B:3B:A3QB:A3B:5:)-Y)GMR&A@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@&A/^$#_:T:9_/DC] KC@'-IQZW.UTHOLB;%NX=S,Y5*=
M&UQH5 BT<^?U_>6H]AR<9/"=9,R4++5>DV"*=]A)UX29ZDQ40[PZ561+UZ]<
MGD'P]>N[FB2:?)[2,%+*5^HP]VC=7U78&KGFKV[R-BG]CKU?K%#Y#,YRZN$#
MRZ,>O<XS:>YV]_@(WPTB+CP!)B>78!'-E,N>+>/'6OPIOW;]U9E@E\$N6'EW
MU+9M/*9NUUU9ZI5]@;'GK]):\IU%>[<D$G,+9+BWC]E7RVS+.0DC6&4L"$,P
MJEGBJ?'J/9!>0E8UD]B7:;. %I'$;WO2RR:K14T3QHWA77(BQ[^#Q6;33KQ^
M6="W>17(6L;1H%>JE33;,8EN_I4FA67<!;"R5,4JM%<55W%0\U,[+M%5CX%X
MX>&$S"CT^J(65&.@Y6P-(Y]"LXX6[IFL<=,'XUW98%6+QW8Y?/%//<_FC,BG
M(/7]%K.KXZQ6RU;)ADM5<<FS_21(Z.=:^B):H7VCWZQV('ZUD=1AK(XK%<F:
M:H@O66TV#BU2D7).R5]OWM]73')8NC3W:4TXY+'/?&MV:I2F/'-]RU:SPWTM
M/E= -4S0!]Q[EG'TK7=_QK[;[Z+=L+-&LMGHT5Y1J>$<WNSJ5?056FZ=+2SY
M-.:2CXJ8N\LI6XY=%NX>RQ9K!;GFL>]Y5TPY![\\73?AEB\,<N*W5HW3Z&W+
MVB,F6D$8Y(T?!T5]HIY.U8*M9G\I#3.IZEXDG[#7'DKL^3U^U):9M:7G7 0%
M"K\M833[L+2H+Y!Q(3#7&M=]<\5GO7?3GK?@O+JOA\,;M^4"TW0YN LFR=GL
M[99^.KO7%DM0.9.5<3]LB>0<GLROLIYT6Q-)"5AG&O7;BE(2;PSD\.G*J0H,
M#P!5QPZ5;W;EEA1XU=?#-Z#&N_C1X;GOSKJN7+%FN=G1%>T[=:,C?;SK2QRU
MA4FW+VFQBCUKL6O*5.2@4Z-9W32S5URV8,WSMPL@@]3E(9PRL4\NY;@\9,FD
ME%2JKEO]4^NC#KCZW>?=JB4E@Y9ZSL<_5"=\<0="\'M*!H9G4+7*6'6Z4[HJ
MW:H;Q<*K8=LS=7&NLGUC8&6AJ)!TME8(ROPTG(LXQ]%,(5*X4?%4K5;G7+!\
MJXLF_+C2CK5K6M'QW8U;UQG7^2%0U=2FM(UM+W!V^J%*N"U5OLE 1L(]>;+M
MNW=*7D#(0:,].#$5*#A-2-R,SNI1^\D)IW(.'$8Q;R(H(&UB]6L*UW-9]]5N
M6%.!*E*:-5IJU2J]=2[+3RATBS<+VK7U,MC>Q+ZPH%'B:^H[)5XRDO5]H7/<
MFR1KD]#O7[\8R%LZE/J](!1HFXDZBXFBS)6CE($G;<L=[RSW;L'NWT"S>#Q2
MK5NG'&E-^Y^!A5/;.LF'*LVYH>)F8FC2]B<W(\8SCV2DM1+);Z\J[EEZNQ.^
M:LWY=:WR8>2-)%9['#)-*["JKJ1BZY_!YAXKAG7AE@M^_,8[JX/CZI7&B>*P
MX&7Z!R2JU1>LUYG<FX+"]A-IPE[MU@/ N%GW("EQ=6KT,EJVWC)WM=XE"PQH
MJ=A(A*S+SD&[KUSF7+R(9.&J4-('2N2WY/?5_!:8;^!<<G6FKIUUKXXO(I#+
ME:W(TC8 MALK"LU_7^A651@GL,A8ZI5]E:TV#1;'+VHE/=2[6,D3(P<9:8]!
MZ<Z$C.1[X*^\6:1KPX-ZJ+3>]V*?+&KQPW9ZD>-:I[J4SKOI6E%@M*TKO15+
M3R4I,E%[3@H:^[59-+?:]&7U<BSFSRL!:9F@Q%UA[W6T&UDO,S8XJK2I[/!/
M*ZC9Y:RK@UJY&T@+<$89HVE-V#U=<JT[L.]8\"\77@NYMUI6M:;OFSW0?)RB
M6G95XM6V;9L96-/R<U9NRFNT8)M;'XT;6TULLZ&OT6,A:(AM6"DBKO%A!-&2
M[B"B4&$BT3;D[#))R66YNE,:+?G6E.#P5%EPCK59T^%*Z8X]^*6=3]0'*:KU
MVV<?[E"[ VK7(+6%SKLE;-0P,>=K7Y?Q?M2RVZ?N;%\WN#&+>3$_69M)%PE)
M0Y)-65,[@57Q:XDT?#=<M*MJJI\MR:HM>!<N+IA7NKIFM5RK@O5-HBDMN;'&
M4N#BPA>M:;SIL7>[8JI&.Y6?M^M[1%U^1EW$N_>JL5K!+*LX9PO(R*O>4Y8Y
MG;E,@*')-?''F\%36M<*;RUI3.G)M]^_X[C-M9Y=&9.(:#\+L]EK411^.-9K
M6OYEPFA4E+!1D:K!;);J-EY0L?$M[975;[63SY"$>OH>Q+-GQVK18Q$*Z.O.
M)]SI3GW5\"*N%:Y+N:K6O!KTF9!0Y%ZKU5L6V4FF7J_U*F:NV+IJ(H-VHT<Q
MFI"]:TTNK>4[[6'IFME@VX16V;U;)#9**"KV0K3U9R*4RW7*VC#@6&[&F]ZY
M/KEW\F.&+WUICC2CW:XK=PRKCQ/EA!J2]'BDK-L" J$#K[=D0W<Q31,ZM*V?
ML;8VYYZL[.A(-.;9(OYJ%K%\@8Q:;2>LK%$(*S*, Y!PS:G>3!9T>.NY9K#7
MY<55C1?X\=[3W4IQT1D2B<P=?5VVUN84V!MN#D*M>M#6*W[!AJZV<6C?<!K*
MNNX6RP=R0&Z,ET2.'#E-&&0FY6<93,$FJ_LJ1)Y!JR<-:I/!\E5[N6BX[A3+
M%Y[\\.6JWO'+?2E IW("@T>L<<=B2I'1KJKM:GQFR%8\T7)2[G2O'V]EM=67
M4BQ? H1U8_9' 5=M'R7@*:K?1,0LD=1N_.L>T\..&+[LG3#NJUB*XX9X\<%R
MY^-5Q+<HO*6M']A-BV%=MIJ[&J=*FX%:T(O[6X\;]_W"%X80LV]JVPJ):YV-
M9UMP^]CS):S,8:-L1&#=\W/%H)KM#IC1*CY5P7'*OB\ACA7/#EBZ/P7&F^F1
M4U.94="*R$=1)^]5:KN(CE0+:&B44HED2R[0LUHGM22RC%E* @+NIK/:^^:O
MQ%1S3I1FH\KIA=)^$+*5>:W;UN7/=W)TY"N&">&%*4Y9X;N[@?$WY3T)U/PT
M[,NKF::4=5!_+6Y*,:OK%$VQIQ/;Z;?[*9J.)IJM+6NM[4,-_CG"T@RD9=>-
M1EC2K&8<@HC-V=<UFE_6KOI14Z\6T.[CO>ZF[-UQQQ>.6#(VQ>QU83?D#L<^
MR[!<5X*9@GX;&NM>DI67?JQ$0S9I*2$*>V'G5V#(S8D0Q=-K2QL#>':M96--
M$RR#5BUM:NG"F:UJ\:)4T\L"I9>.-=*:Z:]^)FJ^;RU_,U*_5VA;%V_21E;7
M,V&035)*S?MO,)W65'JOL8M$N]O)IM*N5JT05P+5F=O>VY=C1KD8'*[VQ-'S
M>75RR=%3.F->>/%JG%M9Q=^/#+-O'1UPKCR>61H?F;#K;2WI;I.:L1%;;;J[
M):EM4ZC=7IZ;1ZM8[3-%H(1-!V5096'AYE::AYE6+8S,C77$Y74/'4.[4>^.
MH^+3##BEUR?7@5Y;\>#?3_#Q*,MROI2VM8"ML&$;!&2=))VRK-*;:2QSUV.]
MG>U%+34&:&UQU]7G2<,:-BV[MW1G]KC$6*M5:S+Z"<)231R^OKC\,AZX;O6.
M.=,"W+1RFB+K!WI.VS%RL<_,!R1B:P^F2 _-%539;[4S_7]=07<22AHN%AW%
M6N"YH5B3Q; JR1?%B"@2+KO=5$ZX84JJXX5K3&CR6"KSW$QQXUIG3=2JS7')
M9U,XTKDM5ML[6MB-CM5J+'FOFT+AJ\\Q(1L2\J]8EM$[)J2,+2',G9X:.K5P
ME+$_IKJ'CHZ<@RO9Z,9299DLRU;G6=ZPPPWXUQU2UIN69>YO?3!4Y98ZXX>%
M<1[[MB3IKR(F)R^PUOE+C&\<*576!)Q.4L31O!PR$TIXX)[)[D+F8IT12FT%
M=I5I9IAF>V6LP&=)/'[R/8S=ANJWAK3U75C&O#_'UR7AKZR%.VGN+?\ -]ZL
M_*?:/_Q"L&5Y]T/P1%EWQ?%FU?(48 P!@# & , 8 P!@# & :]>8=5VGMFU0
M5.UQ3)"85U34G&YH*=7FAK$0SW.2558:E4;OEVJJ%@&#1@;JK8H!!0BB;6PP
M*ZYT@=-N^=X=F[18+OL\ZTVVU2Y:O"TPW7.DJ6I\V*Z_=J9>.U G62IKG652
M)S6,4F<H4]F*GAKVEW;?_:.\+'=MRW9:+1%V<NZ/M38;8[3^@V6#M5^D1R.S
M;AFQ0;-M_0X;'>L=OL4$::EVZQ1S'#[R77%MJF]D[#VE6.4D-JB[)575KW5]
M::MI8DC$V%?7]VK@.M[(I:[=1034Z1%+9D*=V1$"JFL>DT46Z2@M52J=?(DV
M&Q7?/N";>%C<^\(+?/BBEN7-DPVRRSW#<[=MAF>ZE5BL,U0MNBD7I%$VMI-=
MOWA:[[ON_P"[_:#9>SE[P6'L].[/V&5+M,%HLULCN6]K"H^U\,-R1R%:[6H(
M;_LL4U0PMNW]DX((88G*:>5>/]&LZ6TXW7UBKTTRH_$-C<8+7$S+,WJ49:%M
MBR"Z.O)" ?."@A*GUSI(%*1(NVZBQ4']KE&BHD<(G*7H+WM5G=WQVR1.DQ6O
MM''9IUNE2XH',D*Q00NV0SH(767^G7K_ -*@AB57!9Y<2P:.X>Q]T7A#VAD7
M-;K#:I=T>S:5>EDN.U6F7.AL]OF7Y:)D-RSK'-C_ -7:8KB[)[5TSYD#CV9U
MY6B5%[N*&*$_5EV-L2*L'(QY-R^]DK!57M@;:ZUU0*$U7K<AKI.JU-2&N<'9
MWVKK<Q?SXS;Z>>NW1YF8?-W;60A&].DCQ;6+7DBQ6*;)N6&3+NAR;1#)BMUM
MM=LB5H@MKM-IAFV6=(@O"RS()*E0RH(85*E0-1037:8/>1326Z^[\L]L[<S;
M9:.V"MEW3;9+N*X[EN:7'89UR0W==L=EO2QV^;V>O*3/MSM<ZV39D;M5LG03
M)<ZRP77/<B"S/"[+;^W195""ONP]Q4R(D+9R!8MI^FT%Y:KM.5VM1.LY77SC
MI+Z4:33Z);REGE(]E9O:UA!F$P81DBHY%X9\Z_3CNV[5':9UDL=UVN9!9[GC
MBDVFVP6>R29TZ9;H+8O]5>T4J"8Y<B7''(5OG*6W',EJ%0PPP=KRNTG::*5=
M]CO:^^U-U6:=>/;*5+MEUW+-O"]K78K%9;AM-S1J&V=DY=LG6:7:;?:),FWJ
MX;+^DP0R;/:(IGO8I\RX(3;'*)SL?3;&0A-@LK(O&5V,VO5I2%[- =24AQKL
M-T?2<,G%ZS-$PT&CMM"$KRE@?[C-.)VMM.UA&M#7P;KEX9MWW##8;SC@G6..
M1#-GS+OGRIM;9#!!?<JS2Y<QS+>YTR;%=KFSU)@NMR?T>*5/BGJ?5'6V/M%[
M0([][*R;19;[E6V99K#([26"T63_ *EF3Y_8.V7K/GV56;L^[+9;)!VF@LMA
M=MG]JE;%>,NUW?!8G8G*B*[!NK_>ZQJ)%&W[CL=FGU;>WV')W'6K"J2^N[=)
M<=[]X:PJ3R1UC7DJ\@VNAV3))=LI,-FSQ5"$&5<LY!5D[XIJL=DM%XMV>[)%
MGDJS.QP66W16B5;;-+ONQN&*TPP6^>Y\45FVHW#$I<44$,4U2X8I:CAZZR17
MQ>]U]G9<-Z=J;;>5LCO*7?%HO2XI-VVJY+SM'8F^U-E7;-G]G[#!8I<%Z12I
M4$V7%:8()L4%D_28Y<Z.3,MF@V[<M=K'%W7<!;]A/AW;K^@5)24NU;2:6+6=
MQU3,M+/NPDBE+UB'D$SS>M%K-5:ZO-1[ULA,TV#62=NW$HL]D.>U6>[9T^_K
M;.LMB@_R5:[7:/=V2>XI-NLUX28K/=6PY<^; _=6Z&1:)RE1P1.7:IJ<,$,M
M00?G73>7:>Q7?V N2PWI?<U]J[HN>[G:+VL$$JW7!>/9VUR[Q[5^^@M-WV6?
M"[7<,=NNRQ1VJSSI<%INRQQ*;,F6B*=/VJA[P=??Z!USL$]@SS@# & , 8 P
M!@# & , 8 P!@# & , 8 P#2)W<_7=_V;Q_U# :XI%NOTXTW"$N[AZ97)>S2
M;:*;TNS,UY)PQA6;URBQ2=OV+51THF5 KAXV1$X*+)E,S!R__8D<J?O:]\_H
MCOOU#EH^'BO,#[$CE3][7OG]$=]^H<4?#Q7F!]B1RI^]KWS^B.^_4.*/AXKS
M ^Q(Y4_>U[Y_1'??J'%'P\5Y@?8D<J?O:]\_HCOOU#BCX>*\P/L2.5/WM>^?
MT1WWZAQ1\/%>8'V)'*G[VO?/Z([[]0XH^'BO,#[$CE3][7OG]$=]^H<4?#Q7
MF!]B1RI^]KWS^B.^_4.*/AXKS ^Q(Y4_>U[Y_1'??J'%'P\5Y@?8D<J?O:]\
M_HCOOU#BCX>*\P/L2.5/WM>^?T1WWZAQ1\/%>8'V)'*G[VO?/Z([[]0XH^'B
MO,#[$CE3][7OG]$=]^H<4?#Q7F!]B1RI^]KWS^B.^_4.*/AXKS ^Q(Y4_>U[
MY_1'??J'%'P\5Y@?8D<J?O:]\_HCOOU#BCX>*\P/L2.5/WM>^?T1WWZAQ1\/
M%>8'V)'*G[VO?/Z([[]0XH^'BO,#[$CE3][7OG]$=]^H<4?#Q7F!]B1RI^]K
MWS^B.^_4.*/AXKS ^Q(Y4_>U[Y_1'??J'%'P\5Y@?8D<J?O:]\_HCOOU#BCX
M>*\P/L2.5/WM>^?T1WWZAQ1ZK_U+S ^Q(Y4_>U[Y_1'??J'%'P\5Y@?8D<J?
MO:]\_HCOOU#BCX>*\P/L2.5/WM>^?T1WWZAQ1\/%>8'V)'*G[VO?/Z([[]0X
MH^'BO,#[$CE3][7OG]$=]^H<4?#Q7F!]B1RI^]KWS^B.^_4.*/AXKS ^Q(Y4
M_>U[Y_1'??J'%'P\5Y@?8D<J?O:]\_HCOOU#BCX>*\P/L2.5/WM>^?T1WWZA
MQ1\/_4O,#[$CE3][7OG]$=]^H<4?#_U+S ^Q(Y4_>U[Y_1'??J'%'P\5Y@[!
M>Y"U&UT3@UKNJW:M3U0L\79]C^,Z[9XA_!3D?X;=IB09^&Q4HW:OFOA;!VU>
MMN_H$[^T<H.$^TDJF<QY]R7@DB+YOJV;-LA1@# & , 8 P!@# & , 8 P!T#
MX@P!T#X@P#QT#X@\V 4IS!0SR7BYYU%L7$U"MI-G$2BK=,[Z-:S(L1EF[)R8
MHJ-T9$8V/\,(F8I7'@;;O@&[T3IR*;,AES),,<2E38I<<R6FU!'%*V_=Q10Y
M-P>\CV6\MITS.GCLEFFVFSVR9(E1VJRP3Y5FM$4$+G2)=J]U^DP2IC6U!#/]
MQ)]ZH6E'[J#:KLHJO0/B#S!G&=0.@?$'F# *.YKT&\FXJR.HI@XGH-G*1\-+
MK-DE)"+93AXX\PU8.3E%5JC)FB8P7Q$3$!P#%L"G:!, SDAFS894R3#,CADS
M8Y<<V6HFH)D<E1J5%'"G2)RU-F;#==G;BIF=-'8[+-M5GMLRSR8[79)5HDV:
MTQRX8IUGE6MR':9<F8TXI<,]V:1[U0M;?NH-JNRBLYQG4C & , 8 P!@# &
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M1<POOQ<O(I)S-@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# +;@?A"W_ )2)?1BM8!<F , 8 P!@# & , 8 P!@# & ,
M 8 P!@&+]PNG+.DF<-)!_%K!:M>I \C9ZIUIV"3C8%807;EE;LT>U\$7B"BC
M-U''0\;3;5=:%K:K>QR$4X2 R>7W@_ 'ZL \X P!@# & , 8 P!@# & , 8
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M;RVJW_)!^ GZSX./=#^U#_*B6.A?A.:_%J'[47,+[\7+R.0DYFP, 8 P!@#
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M# & , Y_M8=TPY/O(/V\]FM-:-./M?YBJ:'VB"?'G>&O$Z%J>3W#M;0L'L.
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M2$Q#6KU8+[U_QRT3JFT2%UUOJFETNV2L=/1$A/5^&;Q\BXB;1>9G9E@C#+)
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MMJB(H>50H@K#1/95'7<JX>M2-M4>&+IDNN'&G,ESQ";<FZ?RUXTOK?=]QS5
MN!JO-(STC/WU:G/E[SJ%_=V=>5=23Y6*?2$<DY7:+) =0JSV&D%&Y!!HJ"4;
MA<+HDGIOSY"M5NJN"7#"F+X_3'J6\>37]L2GI!WZ[.DJ]7XLYJ+1>"'CR:_M
MB4](._78J]7XL46B\$/'DU_;$IZ0=^NQ5ZOQ8HM%X(>/)K^V)3T@[]=BKU?B
MQ1:+P0\>37]L2GI!WZ[%7J_%BBT7@C"UIY*053W)K31CV2N;^[[/;3CR-4B0
M.Z@ZXVAX"QV)HI;Y):4:J11K.SI]K1JR+-I*.)-U7)COR+-HR5=YJD6RXJM+
MF\=^'K.BIB9K#M;-$WRRS7Q\\C]2W)*#B=XU+C\>0NCZ\VVJ3EO(\CP,M6("
M/AB@=!C8Y965;KM)FP()23J"CF$?)J':0[US*GBD'$2>2+:HWM-=[]?$-P[6
MSLK+'!:5Y>O&P+#S0J%5B;E(3]A/$NZ3M.'UW*0\E=63!\6$DMK:^U.]V0N5
MRNF+&HPDML*/>R#ET0J)2,UF7AA7"I#$JAB>-72E:XYT;IA5[C+BA6:AKM4I
MA6F^F7K<2%JFR6%[K\9;*5>4;76)I$[B)L%>L02\/(I)+*ME3LY!B[7:K]Y<
MH+-EP34,9%PBL@J!%4CD+E[2S;KI5U1M;+R2YT1</CR:_MB4](._79*O5^++
M1:+P0\>37]L2GI!WZ[%7J_%BBT7@AX\FO[8E/2#OUV*O5^+%%HO!#QY-?VQ*
M>D'?KL5>K\6*+1>"/!IJ8.'9-+29@Z@/0S]T8.I1 Q1Z"J(=2F # /\ 0( (
M>4,5>K\6*+1>".:7NP6V=J57E+46=7V9L*MM/:5J;\6L!=+)#MA?&NFQ$S/!
M0CI-LD+HR:"!#+B3OIB(I%$PE3(!>IEJM:XYKP=/AOS.#>^Y9:PI]V+9N5[A
MKR:VYR"X_P"QH+;UJE;U*:HN\9"P%LL3U:3LCNO3\+XP;Q<Q*.14>2RD2\9/
M1:R,@NX?':/DF:RQTF*'1$DGAOQ\6P;NLR"+_+;D/,<;]7-K33=;/=S[/M-I
MC:9J_3\7.)UR5V'8C1TQ;[#&QTRK%S2;->OZTJ%\O*G;C'!'3:J+L1.V%T#M
M 5*OGN7/3&B[S$^_.>](U)1N/^R:77_;6I6Z8UEMF9G(V=+"MZ#Q.BXVK2VS
M>2CH#Q4H,O7=;,-@Z^>2<$'BQ9^WLY#)RK51J*2X)-UX?'3FZ/P*[?\ F$MK
MYERKCY+7A76P=#2VKHW5]*0M D'>Z?("-@(#C^[829H QZDGL7>CRUZ26[4=
M8R0TQ1IF<34E&:B3,@4RXYT5:4;KIC3'/>?CF!S9K/$"/I#JT4J]6M>R-=@3
MLZ-.U[M*W1-;J6N=1;$V/.SJ\]3*#98DABS5/@*PJPE'44ZCHZUC=))-M6H&
M6=H@E7+XI9NF]^N\K-.Y3S]DW[J+1DII6ZU5'97&VY;U=;"LP&K<.UL-+D-"
M,I?6D'3[ SCMANY&()O)FI9Y:V5FE(P+^-;UYNSFIXUH94\*8-Z-+Q3?R_PP
MK,7!!@# & , 8 P!@# & :$^<WVT]E_)^G?Y*TR+.+G\D5Y0\OFRBT#^J_ND
M_P!,IE9Q<_DB7-;_ )(/P$_6?!C=#^U#_*B6.A?A.:_%J'[47,+[\7+R.0DY
MFP, 8 P /D 1^+ .0[GQ(:HY"=T'L]D4TWPZWBF;4VO-01%#[H3M'<G%BQU*
MZTNY[(<3JFIH"YT*M1$[#6P+-%D=R4&\M3:Q+Q$=)PLFT:JN$'VE6F<2QW8K
M&G%8_#FS+SR63S;63PX4QZUW'4AQZ@3U70>DZRK4Z?0E*[J;7<(I1]>3*]BH
M--/%5*(8FJU(L#I)%S.5* % 8JN3#A%)>2B&C-XJF0ZQBADT1GT3W0;56_\
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M5SB;WLO9FI]H:%J&@5M%;?L<AL.GA58*5MDE,-[22PO7L;=8E^G9CM*]!2D
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M5424*(&(80$!P"H8 P!@# & , 8 P!@# & , 8 P!@# -"?.;[:>R_D_3O\
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ME?V/?PQO;^,[S_*+A/F]]KO\2[J_@Z[?S:_#9;GM:>K P!@# & , 8 P!@#
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M*Y6;*.H.=28,4YJ'78RA&;8CLJ).&);+:TX4Z'-"VU5JG++S,I9#0P!@# &
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M6<)?^BMU ()E"IIFS%$HH7"EFL_I]2U2IFZ:X4Q3PQ>=#>1[1T]_;$1YGO\
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M41$ 54  ..E!55K3A3Z@^ O\(]<G YB</0."9!44$F]C& B8"!1.<2Z='LD
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MHH6G1HS!GZ9V2, ISV8B(TY$Y&4CF"BA1,F1Z^;-3G* ]!,0JZJ9C% ?((E
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M:CA;6W)G2YBSAC3Q./4>ZP=T"'_:Y$S!A^,:=K<1\XTX<]:?](/;'^W+1_\
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M7)=LYM\EK6UN&21T6:]DTSJV<6:HJ& ZB+963JKI1!)0X <Z:1B%,8 ,8!$
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M40$2&,4>H"(" *DD0ZAR)ID.L8IECE(4IU3%(5,IE#  "<Q2%*0HF$1 A2E
M>@   ?O & , TS]T,UPYAMKU?9;<%%(RZ0B4*]$0$Q6L[6A(0I1-[Q"/H=TR
M,W3$.IE(]^H B'4" 81H']5_=)_I@BSBY_)$N:W_ "0?@)^L^#&Z']J'^5$L
M="_"<U^+4/VHN87WXN7D<A)S-@8 P!@# & ?)(.P8,'KXR9U2LVCEV9)(.JJ
MH-T3K"FF'])S@3LD#^DPA@&A?@YW0OD7;[TZEN1\U"[#USMCA5:.<U$JFH=.
M3*=WT]"5;=;_ %NOIUA&UZ5M%BW#)/:\]A7S1Z$0TL[JT1LI&,H]9%XV12TU
M3+<Z5>]_*G/0B=4GJ6KN3GI0;ESFX4;S@M!<Y7&N])T#EG7[_)+<'N3;9]'R
M>V834C&E),HI;6Y7THF^<5*;*Z69I*)QY6Z1G9DP<H]M1T:PS7]9;J\>(KS\
M'Y$@>0?=-=-[!T)N^A5C1?.UW9;OJ'950KS5QP2Y1,T',Y9:9-0L2W7>.-:D
M;M$5G[UNFJY7.1% AC*JG*F0Q@_5N"U2;!?MRVZTQ[%FL5[7;:[1&DXW!(L]
MLDSIL2@@K%&X9<$34,*<435$FVD=/;((IUDM4F6JQS;-/EP)II.*.5%#"FVJ
M*K:Q9Q>^TSR3^]&Y@?\ NO;L_<O/<K_37[/?[6M/]V7A_P  \9_YJWS_ /0E
M?_<2O_[%OUVC;IMZ$FZJ7&OE!:&T)/S54F7%=X[[;FD(FT5I\I%V*MR:T;5'
M*;"?@))%:.FH=T9*0BGR2K1\W0<)G3!_IK]GO]JVG^[+P_X _P U;Y_^A*_^
MXE;O_P QO3[C%O"2X9V;?\GOKC5S7KC._P %KMA63Q/#?D19CNW->D+>XE"K
MIPE =G9E12EV(D.Y!,JPJ&!(3"F?L^%O;)VX[.=L+-<$NX;9,M4=@GWA':5-
MLUHLVQ#:)=DAE-.?+EJ/:<J.NS6E,<T=S]F;IMMV3+;%:Y<,"G06>&7L1PS*
MN!SG%78;I3;ASP=>!M>Y?]T<U3N#C!O75]'T1SI?6^]ZWLE;KK-YP6Y/QS5S
M*R3,R+1%=\[ULFV:)G4$ ,NNH1(@>4Y@#RYZU]I[OM-Y]G[VN^QPP1VJUV.;
M)D013()<,4R*FRG''$H84Z9Q-);V>?\ V)=JKF[$^USV>=K>T$Z=9KD[/=JK
MJO6]+1)LTZU39-CLMHAF3IDNSR((YTZ*&%-J7+ABCBR2;.3?VM]^_>H\O_\
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M57+ITYXA<@T&[9N@0RJ[APNK0")(HHI%,HJJH8J:9"F.<P% 1#T)_HL>V/\
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M/$ 81 @'BF*YW9C%CW($9.W*A ,LE]X/P!^K /. , 8 P!@# & , 8 P!@#
M& , 8 P!@# (:\MZ0#UA6[ZT1*+B%<&@Y90I?XYHR04!6/.H?W^]LY$%4DR_
MT'E3#@$?*W_)!^ GZSX./=#^U#_*B6.A?A.:_%J'[47,+[\7+R.0DYFP, 8
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MN=:M+1ZX<VLJUR+F^/-8/<M_)/3%UZ/N@![P &9*, 8 P!@# & , 8 P!@#
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M+6G[BXREY@]81<P\L4C.QDS(6)DZB5&TL]E!E5WZC@PMTA*45%AH3F;BL*"
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M 8!;<#\(6_\ *1+Z,5K +DP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M'$Q2@7)@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
6& , 8 P!@# & , 8 P!@# & , __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g108483g26l36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g26l36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $TJ^23@X0DE-! 0      $4< 5H  QLE1QP"   "('@< E  %4UI8W)O
M<V]F="!/9F9I8V4@57-E<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX
M.$))300E       0]]%OU.<,5KE=:2M"S384G#A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!FI5@@        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              0    0_
M  $                          0             $/P   0
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   0      4F=H
M=&QO;F<   0_    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   $      %)G:'1L;VYG   $/P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$$0       0$ .$))3004       $    !CA"24T$
M#      (V0    $   "@    )@   >   $=    (O0 8  '_V/_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ )@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M=K71"!9"4N'Q)#,W4V)W@I(75G(8)8.5EK+3U4.BTO_:  P# 0 "$0,1 #\
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MW;+:#([OZ/G;G=>UJ#':FQN)U[B-!VM+:CS%_1V*QV&U*RUF*=Y#\"_4N!@
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M1V@-/[F:4M6<=:T]I>UJW4]C<3,V*JJNALAI>A1?7S.G[=6]F*V3)-=*;'S
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M!2,_4,SVG[Q'6>[[JL#EQ =.5:P@Y2#_ (GXGK5WZBJZ.E*.E*/OTI4"LO\
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M@CY,8F/,T&Y>W4Z@F)T[;TP9<F1)BRE);$F0RXI:D.<)?4XHE.%9[M&2?LG
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M 0^F*X@]X#P[!*N/C'XUB\)#,D^TB"[K5P9O6'2TS:(WLEV#)E$' ]IP11'
M^:/W>O;IVC['=Y>G9D6;<)C3/?R9[[;Z@Y.=![Y*5\"4E 2EM22D8RK&20K&
MGW6R:SUUIZY]I;:8>@-'7FYOKA:2MUY:?C3EGA+$Q,&)<)SD,2G O+<KN.!2
M!Q(0@H%7=$J&;:X8G%UB*44KF/NS5R)65>[5IK?*6N2%G8,E[3*CF>_B"**K
M7.:G&Y)9Q%;;=2&4O@L\0)!PD.\/%T QG<X\JM7[3UXL4'1EPNCFH+_JMEY$
MUR!(F6&5;8MH8=4MOV)^(A*XRD\!6$.2DNN+5P\"LA-5/5<M,=/B(5H$(39
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M'8G/NKX? U[F173HW:[<G4QJJEM]1ZQ8UU=Q=*5M#Z4HZ4HZ4HZ4K7U\2/\
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MP*+=8)JUZEF !0P!5&0IP08O/D(]6_SK[<M/O1YC:FYK+)1); &&W@DA:?=
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M7-JN]TO)%JG0]/-W]DWV-IRTJ+-J8M$@@VUY$=IIEB.MY:))4PAE 1PI SG
MMUF;!S6-%6M=JF<(<EL^)B":X.+B'"7LQ">_Z9@?(<"N)F"[NL6ZV]2[@U(A
M1FY*0YQ(BNXX59.Q(4%#W![P',8P,\JR] 7WNK?(.HM0"+J&,+BRMN2S[9%5
M A,*>(+2FG&B\MI#J8RBUE$C@4E;:L+31F:WXH U#<Z@V+).5*#>'SR/(OSH
M7"6J:+86OM'F6+*'-F5C'!]>3J.WS;V]%@W"<;+']T'NB>%*?'#83C&!L.F<
MX-;)V::P[/-$3[_>;O;Y.J;9J&.\Y8#+M$=]$'4#2\H7+[]:\,.*2Z"#WH2
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M@<B-U%-3*34(=S\NHA,UFQDBMK$ [Z8 ?J**](6MJ;JQF\7 H&HP\AQ^RJ0
M8X_5I4\"1@=VV"Y@# .2!GEX&L==7=GLDU)H#3ZK1>M!,-3+;$U'-M,6 ESV
M98EXBEN$M:GD]WEA:EI<X\$*00,=_P#H>/\ >CI7^;36#'_3&-JS/_/'7T.\
M<KST*P:_/MK= /I^ K*^HJY1TI6M'XKV0MXKTKIOX+2FZ&K=<U-TM#6MM:NT
M6I\)I#5N*U]3',W,'G1SFI<#JC3R*5 *]P"KYC3^5J7;]C'U1JS9;78"E1P^
M"=I71^M=E\QZJ\<K<*IJS<Q^4T/G:.O=>X_<.R;=*:XUCJ3*:@7G<1H_16(*
MYJ74.M<K;OT<+B P6+FM7Q^+%7@M0:E;O>E*.E*.E*.E*U]?$C_8OM-_GB^C
M;_:+V^Z4K8+TI1TI1TI1TI1TI4,/3=^V_P!7?](^G/ZOGU\^=D7^T3MV_>^V
M?P]VNZ=J7[ ]BW[KW3^(HJ9_7T'7"ZAQZU_V?[=_TY[4_P!9$]<$_I"_LOI?
M_F'I#^(&NX]@O[2ZF_<#5W\,74Q^N]UPZCI2CI2CI2CI2CI2CI2CI2CI2CI2
MCI2CI2CI2CI2N1CXFHS'K2WH,./F9G12%=XPSO0>A=+DQ(R<^1"R9,-9X)$6
M& ]PE$<=4+ (R>G+Z^[-9D99+2QMN!X9&2,X//._CTY<Z@8T"BPB@B0\DK\F
M1M3$S"52'8PP ?JE@\P"5Q,2QQP4_0!S%KZS4;8R/$\\D 9/,8.WAYD^%*([
M)N0;$HG&$KCPV'6EV3!C%5:P@5:!-@2LB)UB9)3#[(@A$XXI45 [ =.F/P_/
M&?3)K+AM-.K4'N( '*>$A)VP<'.1SSM@>HIT$U)\#JC;E+'6HFS1I%7HQ9=6
M7#NVI;5="S\I%PQ%=XHA=M-BLPD,E#%24H*N9QRVP#\^>W+/H?#-6)#:$/*0
M@_JP-B3DDG;!(^9/(<P/%GXPE8=PQ#0BO98")* KMB>03Q/M,B/$1,C'VY[>
M)ZJR>63MG'R\-]L=/6K/"!OXCF =SGD#CPWSY5ZPS<XG6'.:UG,2QC):P>9+
MB \DR,"$$R%KYA0]Y\#!3W0&>6^!OXC(R>OQ]? U'G\/GC_"O55W.4P4G%J5
M#VH<1+^<)(3#"IM6!28HA@PZ65%<&<!YS.$*\=8)'08SN=]N0//K]^<G%482
M<#)Y;=,@[^6V-O#?'/DCPLUG,8VO%LE,-B5N>#+35 ;%H58ET15\LQ$#"(6O
MS=I>/DBDI*B!G8YV!'+!\=\YQGTH "K&^PQC/PVV/0X'GT.Y-3%QX>]2JXJ
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MV)7\Q:?)\SW$4\\UU1C&=P>@Q@Y^'^7D3R/C%L[(!BY8 F,24>,8B1GV$R3
M3)1SQ D(S/M,^\S/2FPWSR.WCSVR-ML?CZBO6-<?;XU27#"@1]YCA,>%G!%/
MTQY@9Q/WXB!C[3/5"^6<#.?NP=OCX?G5U)XC@XY9& 3R/0?Y8.?"LLT.,?IK
MI-RXLHLSJ;3W:$1+JU@8RM:92ZK,R;1@EB0^!H.6?+%1!3)=6SN3\>=5 9VP
M?4=.?W<OE7=8G^15_DP_F_P8ZOUC4VL&0L&(X^KB)Y_C'O'_ "]*=4^!5CZ\
M^5:COC!,,O3OIGF/U=Q,9QVS(%)%B\CS$%[]O,S[%'N///OQ'6LZI<<1$;;0
MHI]I!:44$I6E*B6\H4/LJX21G<??71.S&8W;-2+N3D&/<FK<VIP0I>/9WB\"
MR.^RAP*2CC"PG@/$I(&W.N9A;36VS0%13\K2"W\P9'WNLM,EU::9F"AA6&IL
M67+$UFA7@B(+OF8YS97KO;)=SM"ERQ;XR%3(A*U]\7B4D\;A&%H(., #IOTK
MZ.UI9M,:LLVG7BIK3]UGS@>(L--6\!XKX6"LK;S':XAP-D<*  1GAW$3 ,(U
MP U[E0;E\U0WRA=6U 05@)..(A3H&&"$6$2L <IT 5@M@AW65+C1E/OQ%N71
ME+TM"FP7DN.#WTY4X5)(SR*3C<[X-<_G:=C6!&HIJ-0M7)_2=U;M"Y31#H2F
MUK*FE1I"7E<.[JE!:3[Q"" D)%#U+<<,LUE&^L!*39[FO6VHR98#U'8-AJ9]
M4^5)$4UIY) P4S$8(TMIM,N0J<DLA;:5,O.-H>0VZ5'B4 0WP)P!R4<\O"LY
M':[KIN<'[3=+G>;??X[\>;;[I>I"8BRF*IM+;#);=00>% *.$X.2%'.W@5Z0
M+"'(AX"?<AMBJ%B5E/,1-8YB9+F>([VK(H_PXY@NO.6Q$M,CW[VU*@N*"&FH
MD0-N(XSPA)6B2X-RH#[(Q]QW.W1+O>+!I]N'8+=9IT23-E36G[OB.\@&2YE3
M"H#0PI..:CGBQX5Y6F*-HJS_ ,4M@2FV[>3O,0-,.Y3H370I"*\$X)A5<*JE
MA)2:N2.62IDQ;D[!NBHI2^N.GHX5*VV..+ !.V#@=,]:\[5NF+-JRQQ;_/18
MK6P@IMMJMEO;9DW6Z7UI/"_W;X[A18"TGA92PM2>//&>'!MF9BU?E^./'UF5
M\G3;3"6-FM=M&RN(-OV5]L@S%TX8RJA;&?,/<D&+6(+, 7>YF?-*8\%GV<QT
M-+(:]_C!7Q>\ =\*&_3KM61I:T0M-ITG>+WK1RPW&RWEVYVG3DZV_P"APT*5
M%[J:IA=Q9S)?7''>2$H05]PUT12_S+5J@ZM*(JJS=3&6E,AB%+PCW+QIOK+@
MC.*M6+%9LPN([5),BGQ\\>HU<I=BM,A<5AQT.+BMK9?27D*2]*9:7[H2/LAP
ME/0$> P=4_JK:-1ZQU)[?J=NZLW.+>)D=Y3B&GER417YB$H4M]XALNH45-#)
M+0*,YWJYU&(N 9D$(:-9+7"SLDTCDOF65@YD89V*QP4GL'WY<PP+]7W]VQRG
M[DW=H(:CQ4)B*=!#24.\:T#.5<0) R3C'@<[8.HZATA;]*VC0LR3&ML]A^Y*
M>FPH<=M)?::>6>%U(+O'QI&%\:?>*L8Q3,JC'4(PV0^;R$.1XK.7?AZ)) 2B
M)!@T[2V):U;)DD,.J8IL1!CSS$=:C)9N,^SL:<4AB2N8P@)EI9)""4Y"G%<2
M@59YDJ&^^,#!Z):9%FC2]1=I=CN#.G1;(T\QK.TM$2,D(3F-'4\VI [T E"H
MP9!XCCBS5CG&9^U8HXT;5&A&.9+(M8IST8UN-68KK%$-7+VWC%13;7)E$,,F
M=Y2\NM N%HU='_1^FHLMN,JUNR)7M#1<8;?#R6L!7 YATL]VM7=D[!7,$YKZ
M3T=JSL-M,F?K"6PWJ5C4MOC6R.S?!%G2X5TD..(DNMQW6U'NGN^9:0X%()2E
M2=^(8NV9)(.M9C$8"YJ#(U++<-Y:P15!+ DG04,>HI-$2Y!"8D"ES\SRT3 8
MZ]:XWB*B=%NUNT^;W<+?'5!GRY#:I,=N9W*VDOI92PXH+0XO*!QE04>'C&<U
MHND=(:E'MUENVM']"=G,R7<M06=E4I<=N=%-Q=;]ED152(K*VY"D.)1A7"@)
M1[JPDI..9>KJ1]S!WB/(PFGX;62G L#MO9"TZ894BK+!)R:Z3A;G.,5RL":Q
MO(C$ZGJ&!JZ5+LLJ7:)29-S;81AMEUMK(*%J>"$Y2Q)4C92LN%2U8V3Q5V#L
M\N?8[:;!J\6>=:9++BISJ6[E[)-;"8"GHL]#B5%OO8SDLMF.@E(;;(2"LD*.
M<=R:[JU0TD^"ET+,DJ8:(@2;),8$@"9B>$R]$R3>Q2C>P9[8['9Y;.G[I$LM
MR@K[I^ SW+SYXY;<Q17WCTE]2$]XV2$A*.%'"$JRH]/D>]P'+SI'6VM8@M[+
M<5QY@NVN*(SD9CB4Y;X,)+;BS';84XYQH2HI6AQ(2E&,F@Q&X;4*M9&BVIX9
M<Q4@L&K:<."9(H9$I+M\9M&(D8F8CWXGK)ENVV[3)< O3H+\-Q"S,CR>X0\#
MA24M<*/=!V"P'%<0X@<#:O&TJJ]Z0TK9M3VRS6768UY%FVEE$VW"9-MUVBH>
M6I27N)Y2"EHMJ< 0E16 <\L+$F&2;'RME*!(8,N&&)2/;)"^)394<R,\NK'+
M"'D9@@Y"<2?#]G[M^XJ<G16A[BBLEPIQS+BN/B)SGECEL,YK)TKJ>YR=/W'0
M]N@3OZS/7!<QV/,<6]P2F%AV5':3W25(B@(=X6,'A 2"H@4DMB5A3\$0JL?*
MJ==00:KKK<1++=FPU0V E22A"!B5*EL2!*EGU]8;C;BE1)T-EIIF*HR(K(;V
M="BE:1+ (#^ D [)YJVWQ6VVN^>U150G;:BWWZ1(+,R==%!^W0(I<(=1!MZV
MF0A24D!M0E#[('"#2#3A)7\RQS;B1?\ +UJ"9K2A UB8JW8"3B"%C"6: (B(
M8/QQQ[]:]9-21]-Z@F7B[RV&'Y#@<@(E)"H\9S)[\1&5K0&?=* HH42I)X59
M3N-LU'HNQZTBVO2VE-)F#;].=[?+KJN'"2[,O\LLI66HR6F6BA,9<92UE4N2
M4AYLX'![V*[BIJ1I?7%^E:KS=/2F6QGS BFS4,JBE 8GV"0U[:U \I""YAC1
MCNB8ZV2V,VJ[:I;U3;KPS^DI+S:7N[X0VXAQQ <2E*7N+]8C]7D*(X<;$;'2
M+[*UE:M 'LWU39I%UTU$%YOW>29;JUQ5&%-3;WE3'(ZVXYCRPTX(W=%2B.[#
MR"[Q([YM$?WH:6_X.X7_ *+I==D=^T/_ %)_"OC)G_5I]!^ K*NE7:.E*UD?
M%FWAUOLGZ6<=J?0.KKVB<OE]X=NM)W,_C;.B,;?KX;,-RSKX5,YN'AM0Z8T\
M\IH(8&:N83(G4E7:M2A:RRA2LJ^&'JW)ZS]*^%S&5U3D=7OC5VKZH9;)ZIVT
MU?8\2<H4Q6'+[3:7TAH^5)(R[:]?"JNI(BB\^PZ>_I4>I'X?F:I]?FZ/J"VE
M'TWY[9[5FGM/:4U%ZD=I= ;E8VSI<<]J?4V"UAJ>OCW8C$9&XT\;@,>ZG%L<
MG>''V,K,E7''VJ/#6DJ:T^W/B)>LNSKO":7M;J'IK [E;A/PFY6:3H'0IV/2
M[2I>HW=3;'$X3$V+VF+E*FW5>C]':<@\AN56U6<7\C8S&/951<J+0I5FPOQ,
M?7@[;:QN2657EMP<3CQT[CMG?['FGZ^/U/I:/3OK3<D-]'XY6(7J\+N0UCA*
M*@FKFZVC55:+\8O @=IS#5&?K\?E^8KZGJWUP^K/3T[@8/ ;VY#46"VTQ.I-
M6[?[E,T3MM:L;TZKQV"V6RU3:W+?ANC:V!R>/KY+6^HL8RIHK':>U*]%VFK\
M6^<Q0OE4U+;XA&]N[62O;5[57_2_N/B=NE^K_P!(1K]0EG4^W[-"6SK;X: R
M2(5IVOGV:V7^(7QC"UX;A1\5M@N?(58)L*5NAZ4HZ4HZ4HZ4HZ4J&'IN_;?Z
MN_Z1].?U?/KY\[(O]HG;M^]]L_A[M=T[4OV![%OW7NG\114S^OH.N%U#CUK_
M +/]N_Z<]J?ZR)ZX)_2%_9?2_P#S#TA_$#7<>P7]I=3?N!J[^&+J8_7>ZX=1
MTI4??4SOD7IXVNM;CAIP=5%6S6'Q$8DLG.(@_P 5:U4O^<BED)'P>/N\?RT^
M3GCO#CGKFW:MV@*[--(O:H3;!=RU/A0O8U2C#!]L6M'>=\&)!'=\.>'N_>S]
MH8WZ3V4]GX[2]6LZ75=#: [ FS?;!$$PCV-"%]WW!?C9[SBQQ=[[N/LG-:X_
M[;98_P#$<G_T]/\ ^%.OF#_VRW?_ ""W_P#4"O\ ]37T]_[&C?\ Y^7_ /3R
M?_V];?+&J,+BM*EK'4F4Q6F<!3P@9[,Y?-Y*IC,/A<<-,;ENWDLK?95I4Z5-
M4D=BY::A"E@3&$ Q/'W!$?\ :8L:24\!D1V7^#.>'O6TN<.<#/#Q8S@9QG K
MX@EL>RRY,;BX_9Y#S''CAX^Y<4WQ<.3CBX<XR<9QDU$3</XB'I1V^S/Z-CN9
MAM>:A;H'1^YU'$;;9;3FJVY?1&M]V\%LMA<YA;RL[5P^70.LL\!Y!5#)/L4L
M+C<GDC47921=R*QZ^A[L^K7:'9/?7T\>G[<*WFL1K#U._P!D&OMGFHQ]8]&Q
MF-NUZ3.WI[4>;9D$V,-F=3-UCBZ.CE?AMJGF<HM^*9=I9%^*K9)2HZY+XE^A
M'93%X;;KTY^J3>K)7-+;I:URM7:_3.T#WZ7TOM'O3K38?4V4S5?6N]FBK-OY
MS6NA,V_ X_3"=197(X1E"RRA5R-D\6E2IB:>W\V@U#M#H??;]/M-:>VLW#TQ
MIS5NF=6:QR^.TCC;&*U5B59K#A;?G[5%-'(-HMDG8ZPT+5=R+*6+@Z[8%2G>
M+WVV/S@99F%WDVJS 8&CI[*9T\7N'I'(!A<9JTZR]*9'+%4S#HQU'4[+E->G
MK=R4U\T=JL&-99)ZH)2G>>WGV>TK:KT=3[K[:Z<NV]4QH:K3SVNM+X>U9UK-
M+'9*-'UZ^0RM=KM4SCLQB;\:?6!9::64QUJ*G@NUF-4K -V/51LCL_B=:W,Y
MK;!9_/[>KTN_5FWFCM0:7S6Y&'I:NU7I[1V(R-[1S<]0R5''3EM38HWW,C%-
M,5&$Q!6'$BN]2OJ>G=R]N=7Y[4NE=)Z_T3JC5&C+ 5-8:;T[JK!9O/:4MF1
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MSG8X(QZ,'M;MMPTE==.L:$7)-VF%V5=TK7(FRPI0!F2&&<=V\I&Y:+*", %
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MND*T6]-GNS*IEPD-QHZ77FFPTV77"$A;A!"4YR2-JT3_ .Y3]2?_ (CMS/\
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M6HK"$J*D[W2C#'G99-[YO'V,A#L+*%#$%A7015+0$':Z5V*UA1C+9CEG<//
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MS.YZ;>(Z9'@=Z467YUL.V0^7)8K$!B8:#&\BZ8CV*3[H]^.)CGB.E.0V.<[
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MC;_:+V^Z4K8+TI7S[<G36F]Q=#:OT!F\A352U3@<K@;)S:3#:A7ZC:P6@#S
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MW2A.WAOD^O0;>&Q/+!Z#84E8[8 38B;!-,%K3R0P,R,R1%'L7'/$^\1Q'/\
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M7SZ^?.R+_:)V[?O?;/X>[7=.U+]@>Q;]U[I_$45,_KZ#KA=0X]:_[/\ ;O\
MISVI_K(GK@G](7]E]+_\P](?Q UW'L%_:74W[@:N_ABZF/UWNN'4=*4=*4=*
M4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*5R-?$R2DO6UN^;X:1*+1[$B;)^6@RV
M]TN -%,\+AHS!1[3WS]YCJ#R/0XK)C_ZMPX'(<SD=.N?\\>M0.&./I;7R_TC
M[O1C_G5#/;)]C4U;9W$C(SR#BJ$N/>)*"F(FT!R)(Y]>O7SR,Y'K4C<8WR/
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MR<+4IBU68F!I-JS'RUVH,&R(5:!@HEA168@.WC BZ30)S:WY*BV?LY4<8/4
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K%3&W%9,]TJ4,F4RI7W'I2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2CI2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g108483g27s60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g27s60.jpg
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MJ/=M0GPF@')@Y!N9SF !P02+2%]H?EI9?#!<6IP)+['TSA675DJ0ALCN2E!
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MM#;)25#LNGU75JFCJ![0PU(AHN8-A9D&1[$$C(4O65/^F!H.:ZE6;+M@:X,
ML6$W+3NO<@F\6E=67G8*B4N-7I0JR*":C"_6UTYRKII/U+1J)I34EJ$NHF&%
M^^(0EO-QA)4@-*?46DK*TK"?+QZ/CC3>+3^T&D:XH;V^+X+7BF:OASN%/Q'!
MF\C:7>4$D&-/$I^(*6]OBEAJ>'N&_P ,.#2_;G;N(;NB)MD%3'GJMTX1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7.D]:B"A_UDNH=YQIJ1I6'6T-H4
M2^D*P9C<*)00I.U$GM)!  23^.?)OC:KLJZULEH/A23 !/@TS,R+"+^V0)4[
MK-2JSX7IF@[8]OC2Z\#[Q[I,00(C!FRU[Y1QO49T]+M#H51DM^VE"TMQ%/ +
M /<$EIOM4L'PK0'[$;^/G?2>J#3^:I6I-EQ,.> "#C)D2+B\#YWY[X9^)J>C
MI;-7K*=P6N:21CT+KW%_G:5B9/PQ>GZB^N50:DPA;NVTHB/MN)2KY 'LGR!L
MJ^2!LCX'/H%+XET1H,'C4Y8 V;$6F\@Y@?.PP3'5GXST%9[?#U6F<)(,U6,,
M6@B9).>V!W500\"WY,8<9C4*8]&0HA';3I"RI[9_WTR6TMNH=23M6B4+&@I!
M&MPG_%W2J54"I4:;F2YS1(F "V02TB2 (((@7E2CU_I9DU-52IL@N<2"YNXW
MEKAG)AQ@$<"5-8> <JO=K0M>K27&M);#].?:0X0/ZG%-1=:4>XC23^0D ^.:
M5OB;H]G#5T6TW&[6N VMF8&YP[C^]U5UOC7X<I.=/5*,,@<=H@Q)_0YB^54,
M/I>RU6I\;OL>KLAM;?NNLQI2@?;!]M38<VH=B5*"2EI"D[)2!L\BU?B_H]&G
M4=3UFG89.R:M, $V.YV\C:3!_$?Z'GNK_P 1/ARBQKF=3I'C: \FTV 'S%P(
MO%UEQ0>GZX;0L6N2:C0*NE8I:^\RX3J4L*9&EN.*<0%?_H=?&SOP=<57^(=)
MK=?2:W5Z5[WU1/AUF.<\/FP:TF0,GG$!?,-1\9:7JG5M*S3:MHINK%HD/ N6
MP))#9,$Q\NTVC]-BG/M>JIT5N.,R6F6^J;$2&EK.N]*+QIWVGNT2$G?V@?OY
M!WS[I\/5:3J.BWU:>^T, ).Z(!$"P.+G)F(A?;=,'#I[ W4T:@=3<YS?.'$3
MN.V"&[N!(B.+A=*SJVZN;(Z6;,^MJ!CU[(5=C/ILJQVY 0_/>3W-?K%94V2]
M3K:@O#4F7H/3WD&GTX+?]]Z)K\<_'73O@OIYJ52S4]5U+'#IW30Z'577;X^H
M(\U+24G?C?9U1P\*E+RYS.5Z]U_3=#TVY\5=75:?LVF!N\W'B5(,LHM/XG9<
M1L9)DMT#XMZ]\RXXRQD#,M2CT/(%WY$I<>CU,W2:HBG4NG0YZ9\*#0HE*GPA
M3X$'M$6'!0I4=ECN5VK?<=>7^7^B_P 3OB#I'6^J=?JMTW5-?U:BRA6.N\;P
MJ-*G5\2G3TU.A5I"E2I_@ITP2QK>"XEQ^5Z'XIZCH]=J^HO%/5ZC5L;3?X^_
M8QC7[VMI-IN9L:W#6CR@38DDK>AT+]45V]5%B7E==WV];ENS+;NYNWHL:V_U
M/Z9^,NC0*D7Y'ZG.G.^^'9:VQ[;B&_;2G[.[:C^D_P"&WQGK_C7IG4-;K]+I
M-)4T>N&E8S1^-L<PZ>E6W/\ &JU7;MSR+. @"TR3].^&.MZCKFEU%?44:-%U
M'4"BT4=^TM--CY.]SS,N(L0(BR\(_4WFFZ.K+)G3[C[$&&)MAX8J&&F,A9#O
M[J(NNRK]DP<K6^JZ)DG'^)Z)TZWY1KIF6Y2&9+<6!6\KV:S7:JAB&[4*)%?<
MJ$;Z.NF@1,F;V@1]9_HKJU#JIPW(LJV[IM*]J577LD1LLQL4,*@UYEB]+BPY
M1+OJ]ZTEDNTV.["%#39%Q?6NU$T]I]%->%.?DN/10\2"%9KI"ZM[MZC+IC4&
MX[7MR@,/]#W0MU3J?HKM36\+JZK?\PO\UVTD3I4A'\OVS_@[1OY><*347/U6
MI_J4F5VQ?9(1'U(^D+YL7KOQ^S9MQW#F:0NV:TUU*=5V$;)M+'MDY(RC=]UV
M_P!-V8[SQ]*NJ)8N/+=O>]I46GVW;M+K]_W!$H@M:UGZJRY4IE)AS:>APD?R
M&?43G"JJ\_4-Z-+!D45BY,Z4!+=?QI86:8-2H-"O.\*$QAK)L^N4RS,NUJXK
M0MJNT&V\75*?;M3C3LA7%4J5:-O+_3C<E8I"*W1%5 FT]NX^8R/?T52WKUK]
M-N/LGQL.7)>]>-_R;RMK')I]N8LRY>U$A9$N^WHUWVYC^KWK95B7!9%$OFIV
M;,BWJBT*Q<4&XH]ER&;OETV/;;B:H208GY\8Q/K>WO98B.>J]BFN8[PEENUZ
M'==!L2^NL6ZNEZ_59%QKE"B5RDQ;<@]2$&GU>Q:8+8BR[WN>[;KP=1H-&M2V
M(ES5^%(NUNRJY0J?D%)H<4LEI!CT!XYCU]5G+3NJ+!]9Z?;LZH:)>B*GABQ[
M6R/=UU7(*/7*54:#3\1_S WD>G5NUK@IU'NB@7+9\ZUK@I-?M:OTBEU^DUBE
MRZ74:?%F,K:26(,QS_?'U[K$"Z^M;JAQKTUY/ZKLH=(V/[7QG;.!J_FZS+<B
M]3$^IY-#T*#3*M;EBY@H3F!:?;E@5BOTBH.2:K4[#NW,-/M2IP)M%?16&TQ:
MQ,+( ) W9<!,6CN#-Q[@?VG]Y=8'4#9&-;)N*5AOI?O"_P#)_45CWI]L*A8S
MZP;UO#&8FWS J,QZN7OD]SI)HU:MF5154\!=O4;&=WNS(DV),54X1<$?A8@3
M%^9D1@3W_LOV@]8/43D;$=[WAB_IPQ,]D'"V3<T8NSM;F0^IFJ6GC:VZ]A00
M7J@K'64*+@2[:GD"!=L6H-*I%2N+'>,X]N.Q:S&O1%$JM(52)A9@3DQ:( ),
M^DV]I5K:UZFUXUJQ)V3L-].42[;3QUT283Z\,W4K(65W<:W[0,99OM[(-W46
MQ<;6W#QO>U/OO)-$MC%=\SZNBY+@QW:!J\6W;;C7*Y(KM2GVP3;>"?S%H($B
MT7]KC$JK+M]12X*?4<@9"LG#- O#I3PUF/#6$LJY>EY2GT#(B*_EV'B2=,NO
M'N)1C2K4FZ;'QDSFZQ!>,RO9-LZNSUQKX1;E"GN6I 1=)-N)-R"8CM.?>+1/
M"QLR5<])H66>L3.'1?=E<=J_3]TK=93&19,S+%XY!IN<NK5ZFTJ^;&LBU;&O
M&[;DA5=/3G4;-N6GURN4*CQJ#9=2OB'A.T'0S;F0K7M1^N4S /)$>@QVYM[Q
M)S)QQK.0UT'$E:Z?K8BVE_B5?3GI]7W2<AV/U296RO8741*R[DR^#!QAU*Y<
MNZ/85SX\&0Z1C"[I=^W[;WZE.O:RKJ@IIUCWB_#I6)[J?O\ 960.?_;(B ,$
M7^@P#VR-K/IF5>H2^GNZK>KTFH(NJP>H+/%F75;/\T3+[L['=7C7]4:Y'QMB
MB_:E5JS4KUQ79-#KU&HEGUZI/4FI&/'DTVHV7C>=3I&.;3+#L^X!]_4C@]P+
M>IR=AO"U7-\]<>\567ZPW4S5V(S;[L+_  5?]MYLK;=4K!>-P$E ([_" G7S
ML_D#GS'XOT'V_4:BB'P7;!V#(I4\F;2'3-LFQB]WJ=+1ZIT!N@U%>KIZ>VL2
M^D8<=SZE@.\FW'<<K#6O=;U]52'$B4N%3J,EN(&Y*85(9:?+C:3]SZG$MK2M
ML >XM"7=))45$GS\STG\/]$Q]1]5SZKMTM<_4/>T F3X8WENPC$P>"+%<#T_
M^%/2?M7C:G5:NO3,EK:SY:9,C<!%Y/)Y[66.M<ZF,DU.H!,FXWG&'.SL1&0T
MH%Q2>YQ7O%(0&4+"FP4_>I:5D) 3L];I_A/I.GIAHH.):UNXEPB>S1$S!&9'
MS5^[X ^'-+4'@TB'  ES,$S>38&#;N;XA1]"ZA\FPPXQ'NBH0V@I2DI#X[%;
M&R2%]J2#K_C>O/D P-9\(]*KU 7:9A!L)8TN !D"1R 3Q/IVN--\-_#K &U:
M.X- +@63)B'$2+DNR;QS8E?:>I;*B);;K-YU8K=VYVHF.-NZ(4L>5'V&2H)T
MD.J2G?CY(WO_ /$.E; PZ2F0 &C<QA! M< $F+D[1<7P2H]3X%^%JA<]G3-,
M]KR2TFF-QR3,@ &01)B0.Z]6.K3+\5^/)B7M<*%J6EP)^I="@H'6U.-!QE9^
M/N)'_.SS5_P5T=['TWZ+3.$$7IL<V_&UX! Q,6@Q"J]9_#KX8J-:]O2=-$#_
M +6(,Y! D3;Y>RN74^O7-59M"9:%7KJI5.F1U1Y4J1#0)JV"5(4VF2RV7%DE
M.RIT@J2 1L*Y5Z;^&?P_I]=3ZA1TE.C7899X9=LW0/-X9<&"QL&BQFVY<S3_
M (7=#;JVUVFL&4:K:S*!K$4FN#MU,-:9LTB8FTB(,1]>F#5:I5?5%Z(:@M:"
MV]U08E:#FFFW%L/7C32XDH2!H+UY\%6Q\C?/K71Z6EH.TU$3O:6D-,D%PLTD
MF?-Z7,'V7T)M'P]!X+7.#*##?:1N,Q$FQ'_(72OZONC^S.J:T V]]+;V2Z!$
M>%EWL&"5-$E;WZ!< 927Y]MS7U*4I #DJD275U&F)4I<Z%48OQY\!=/^-=!#
MBS2=8TM-PZ?U';C+OLNKV@NJZ.HXDD &IIWN-:B#-2E6XKK_ ,/Z;KFG@Q1U
MM)I^S:F,<^%6@2^BXY%W4W'>R?,U^@3%O0EFW)F5+_PZ[_+MAWGCFG,52ML7
MK)J\>%,@RYJ(4.51I=$HU;348DT.(EPYK:$PY410=9?4K:!^8.C?PT^(^L=:
MZIT _9.F=0Z3296U+.HOU#*=2G4J"G3J:>IIM/J16IU)%2G4 %-],AS7G"^5
M:'X8ZEK==J^G'P=+J=&P/JC4NJ!KFN<&M=3=2IU=[72'->/*YI!!*WK]!_2_
M>_2S8-Z6K?-;M6N3[DN]NX8;]IRJO*B,Q$46!32S*76*-17DR2]%<6$M,/->
MTI!]WO*D)_2G\,_@SJ7P7TSJ.BZGJ-#J:NKUXU5-VA?7J4VTQIZ5':\ZC3Z9
MP?N83#6N;M@[ID#Z?\+]$U/0])J:&JJT*KZVH%9IH.J.:&BFQD.-2G3.Z6DV
M!$1>;**MGHJQRGJVSGU39$L+$5_W+?,O"<W$UP5^P:%7\@XLDXLLU^@3WZ-=
M%<H\JH6^_/K"H]7ISUM5&,XTMA#SRFY2$*'TI=1-HO$DGM>/[?N%BS8W0/U%
M6_7<-6M6LAX8>PUT\W?U>UBPW:52;V.2KRI?4S;^8*?;SEW*EN(MFVI^/7,F
M,4FJ0*,FX8]XLQ'[DCU2UGF6K7EEDD&3>2 #B)$?SCY>JR/Z1.D>Z^G.Z8U?
MN&ZK>N!ACH?Z%^EA3%&8J33INCI2_P PG\TW,DSF&4?H-SC,5'_0&B14&?TF
MI?J+#'?%+I8)GZD_6%B[<OIM9(8NZULHVU<]HW3==M97Z]JY(LJJ9-SEA2WZ
MSCSK0ZAJ!G:G>WD?"TN/>=(O''TFRK8IL^E2:%<=G78U.K3<AF%-IEM5Z 60
M[([[> ?PB,&UY]Q]56E>].JMRL5]7&-[1J&-K"IW4-Z:.*^B"S+>H;=WS+6Q
MY>-C4OJ[CU6N_45URJW%-L-<[J/H1HWU4^I72Y%MVJNU0*ENQ5/ED.@M/9Y=
M[SM_LL0$6'FFVNOZ^[I?Q9DN_J14NM[$5U6OBB?B[J:HN-$4!&$L,X*KW5>U
MFRV@>D1^I8[LF#>US4RUKP2_>%9-K0*'4NS)\BT':)C^_P#;T]_Y3PGY<C$3
M(G),1F\B3CY K-_'O15F"VHF'K/KUUXTDV7@;K[S-U8V;5:5_-'\SW/8>9*A
MU871+MBYJ7,IJ:52+OMRX.H^F4F*]2JG4:-5:1:TZLNR*;-J,>C1<K!(XFX
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M5.H"T[()(!&C00'0X/#@; 2!V< TR#G<T-,$"W*W<'@2YS3, S<YC\1CU(G
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M=<]S=2[[E]R"VX#0+3B>T2(DFWK5[4=B8X$-2BGR0E(9;4V K>O:4X%A8&M
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MGVCVJ;^"2$_.CY"O&OWYS.IZD36:65")<0X\R#P"+#C.%>#K&FIT2TGS1F<
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M$X1.$3A$X1.$3A$X1<Z[UVOH'/5#ZEV94-MY:D8DTM17LA6$\=^/D#[0$[_
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$"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g108483g28p75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g28p75.jpg
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M<8&HM<$:,C,U-C=#86AR<W1VB)&AL;*SM+?1\/_$ !P! 0 " P$! 0
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M")2T=YWM99@"6K8<.KXE$RLM>15]"!P^*.@RH)BU8)$4R@H81' XF/1\6/"
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MG&^F%,I9-Z[B]F/RY3&O.ACB:$<%>Y^XU?M?W[W$:C[I6\;W(M-DR>+X7.+
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MOFS"1Q_"C08D+@RJKG]%\6:G3E]F>FD\/6*^G7&10:<!/$^73'P-)TRY-B(
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M3,L0PSQAX9/%',P2,='(&2,#VA\;P'L> X<S' .:[+7 $$+7EL.KM:!1V]&
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M,_YL*U]5;>(IW:Z>PKI/VU;23M!0S @8H.YX&($)6G#21XK-)-7DHCX*,#0
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MGVRVVKM23C2I-KLTV14U^%LD**B5DW.%LI[>HJLJEZ>-]?2^+.N^ORVFVW,
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M) WQ@$K7<GD:7:GJS)9AU9GY0 7FL8-/JCL1N!*11UO)0+]RF.V4'S($/()
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MDY>+N6T+B\G;"4691\U.ABC^_;UO_=;%JKLVO*NDE.]NI57\U?O)_P!=:DO
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MN+GR22/)>][W$N<]Q+G.))))7WM:UC6L8T-:T!K6M :UK6C :T#
MP%YLI$"Y0"-PTH[W;(2P <"KZ-7#=$GL.(,=QI%P/PX3<:Y6:HO],X6W:N4$
M%E4,KI;Z[XTW\U*P+K_2T5ZWT53G7V#/CY2%TA6,&JB)DI4['OI,_CD C8V+
M!GD@>B18,6[-.1XMNJ3<C@PIDL\W64:CF:.VC=,G1;>X11MNNFJH[4-H3%S\
MP?J+4%V(IF\]6D"D,=R3&V32<I%V-#XW-$'8R0;M Q)TW8[G@V6X<Z]"N<;#
M2PI19%[@BDEPB<(HW!*:JF6=CF_<:-2]_(IDWI SUJ32 R&.EZ\VBZ-F-YT7
M6V2'C')+,R&RP/L(=+:R;5@S:I.A[D%@CIEVD121X1>0<D &,#MS$E-B(\(2
M=#F2A0X29B1R;PP1:!Q+3=\_6;MM'10L_8BQS?97"KTB]:,6VBKEPBEN1:=H
M+KQ">N8RT!,')2@FVMJ][>[#23>4OA3Y9G-;IECJ8RH:%V%!0FC:,,2CM1
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M*MM]I6L( 1)G2D6CS.)5:_HF*504A$ED D^4)V$9.*+E7DG;BA\BU(3GKO\
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M*9Q6UJAJEU+97%&=96 *NB35&]@P2W8>1,EV<$K;>L0UQ3>MD+'#3^6-I["
M)VK@UP#9Q8<3>4R-R!E)!P7#E8#S_7/;KG ./GG&.JE;UCZLQZF8\"<&(I!
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M/3.?D-AY?[J2-]V00IVCK@MH3'E9:3K.LIS/1\91V=:['GD3C1(ZW%[;L&A
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HN8V9_P"DU5Y_LZM__P 737A7/W&_7_5=.7"HG")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g108483g31h01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g31h01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %%R^4A(X0DE-! 0      &$< 5H  QLE1QP"   "  << E  "')R,CDS
M-S0Y' (% $!-:6-R;W-O9G0@4&]W97)0;VEN=" M($=E;D)I;U]3+3%?=7!D
M871E9"!F:6=U<F5S(&9I;F%L('1O('!R:6YT #A"24T$)0      $.P%GULG
MP&O9:\FK8,,>A;@X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              &(   '"          !
M      $             !P@   &(                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     "=L    !    H
M ",   '@  !!H   ";\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( ", H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C
M\P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
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M(#XY&/CD;ONQ[7,< YI ^M)=%;U>Y5(KZ#F3/Z# ;T'(/@Q#>!'TG*/R,4?
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MLM<^)8,_IZ&^+E4S+1C7Z39?$R2)#^[.JP0]_P"]>)D/]X=1N10A3B!3"!A
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M3J,RM=OILC.-HR9HE%KVE6U64*>.AX6E6>1NT9%S;V=>E1B$FP.<\MAGX'>
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MW)3OW#@#O-V+(876\LLBA4J_I%$FUC"( C%6V ?K^0\>0%%M(*J@)?(>HHD
M2C\A !YE*.M-'Y-P;CM4Z=O/=V1U<UCIY#_Z<=ES^7>.'<;\P.:QM_1VKL6T
MOR6E]0T&#MDN87(UX]CV'K):S&$'M!#MB.8.RS\BA%"@=,Y#E'P(&(8#%$!^
MP0,41 ?/XO _/FR-<UX#FN:YI["TAP/H(W!6N.:YI+7 M(Y$.!!!\A!YA?OE
M2A.$3A$X18ZWM]4=SKBKM;-7W-E:%.=U7T)F-6FVQ$R)J*'<12;DS]$I$U4C
MG,HW*!2*I&-X*H01QD6:P\V0EQ,.5QLN4@:738V.]5??A:T-<XRTVRFS&&M>
MQSBZ( !S23S"R4F&R\-"+*S8K)18N8M;#DI*-IF/E<YSFM;'<=$*SW.<Q[6A
MLA+G,> "6NVR+F36-57.SW4?+.U=+G*C?S62-7F8IA"DL5:GW\?(QC%A-MYT
M@-8QPH[K#I55R@=%566@9%0&[A0$S)JI-5$->U!IK':CJRUKO7QNDC9$+%>9
M[)(V,E$PX8R75WDN!:3+"\\+CL00TCMOHEZ:-8=#F?Q^<TR,7;91NV+[L7EL
M=7LU+=BSCY<<XS6XV0Y>%K(I&O:RED:S#)$TO#F/F9)PW57I;DG4BJ1=:H"U
MJFG<6C-M@LEIL#QY(O&L[+FF7+=>)CQCJJB""_ND4'#. ;._<H@*KA555PJM
MQ:=TIC--5V04C9E>P2M-BS.][W-EE,KFF)A96&QV#7,@:[9OC.)))ONF'IWU
MKTU9JYEM2LP]""W)CYO8K#8V""M#/CJ(H12QW;(M9F3K(^-\D5C)30\<A#(V
M1LB8ST;;U4D=AMNF2R&JOZA4]JP=AUZU.I-*C$3#J9I3)?5C"\KUD?/4EZQ.
MJMM>L+<'9HV8;)G9Q:_P9_=.$E]F72RKO/\ LRH&T16YOKEJ4W>M VYO3E9B
MSN8"O4M1B]I5@3L;=E O*Y'NG]6C)X[=O!23J.!])L8L"O$CR$FE[Q4HVY^O
MDVY^O]"GKI'@^IX93-24V:3HCZ_:QKRFF2C3.$T/JM!MFN593E,;&-'36C9L
MV?.%F.7(S3QPA2H4B2\N+$0?'9GDGA2KH\(G")PBTS>V[M=@IO6W)YR!2L,D
M5GO\<[GJU%6&SU"!LE:C,@V.8FD[[:ZMV%ZQNZ_3:PSCCWY])/=2:QB$A48P
MSZ'DFP*&:E!&_+]'].ZOSTFLGURZ@]9K:$:6')9L-S*>3BR24W,$CTI:H1+Y
M)H66LENO\])%137*0K^5O5R>.P %U;1.BH$FY*5\F]]7X/:]9ZM:Z*T!$V?K
M=J%KNJ<L]K2$O.S56MV*ZIEDM2(R7,X;KPC!],7V M<F'AVRDCT]FT<L3K"T
M>,B*IC;V6-3C*M@%=2U:T6Z8Q';;=J!-/TJ/96C5W]8O77^Z8K8L_BKDB:/=
M1$6#VPUV=AO*;AG$P-*K-/*P<,X&(>M"+*\)]FQ1:;BTCE&ZSC'7E)&^(7<7
M-9C)[-H"/<,.K%?Z?-THZ&;VZ?D$E)+*H60DI<Z\XX2);K*^DXY)NI%1"Z)/
MG]?T+(>P6/Q^(9]EMGRJ_;#2TZ1KO3?,H:IQ6IV_ZB+TZ?[*8]FMACIFH.)!
M>'FU;!4+)-1\R]DD'#M^L].^56%X1-8A03MMV]H'_=;$N%*<(OF>O6D<S=R$
M@Y09L6+99V]>.E4T&S5HV3,LX<N%U3%31001(=5950Q2)IE,<Y@* CRE[V1L
M=)(YK&,:7O>XAK6,:"7.<X[!K6@$N<2  "20 J))(XHWRRO9'%$QTDDDC@QD
M<;&ESWO>XAK6-:"YSG$!H!)( 4$_=5]8B>1^Z"Q<@  B8WZI5.    \B(C],
M?8'XQ^S\?V?/F(]L6 _?K%?R^K_:K4_;_H0 GVY:5: "23GL4   >9/A6P&V
MYW)[$'M;UD\>?N@L9$/M^6ET[YA^4/\ ?C_GX]L6G_W[Q7F^SZO]JI&O]"GF
M-9:6V[=_9_%@;>7<VE/*)D%4P60%,Z2X J51/TF(J!P Q50,7R50#E$# <!$
M#%$! 1#F8#@X!P(<"/%(((([B"-QL>T;+;1PD MV(/C C;8[C[8$=NX[^\+]
ME3(4  I"% H"4H%*  4HCY$   #P C\Q /D(_;R?T[_'Y?2FP&VP VY#EV#R
M!?KTE\ 7TAX    \!X  ^P #[  /Q!PIV'9MR\B 4H#Y I0'QX\@ >?'S'Q_
M!Y$1\?OC^4>$0"E ?(% !\ 'D  !\!Y\!Y_('D? ?B\C^7A%YX1.$3A$X1.$
M3A%I,]N99):F]?L1MU?U"'QJ?K._?2\5H3VX)52;C!0Q?822<53FRVL8HC:+
M5:(-24K<57G=_BXQPM* YEQ:Q;9W.0I%?WH?I;/6^GG7*ZI:!!Z=+O,CHK"Y
MV^ M,5<VCW0(>N1L9>FKJQ0LW9&#^6CK2VE&4L9.>EC%?HK@>0>C_NI4BYS4
MNJ.<ZYL><;I8YO0X^^916K35Z.>NW!S%PD(SN@)IV:58PJC9VSC[7*,D&\2I
M<(H(^SH0B1X9K*H1CM^U=D6(270SK?:9^R6'2JY9=E5M$"QK3Z(V6]6S2ZTU
MA6TA!S;R/C*Y:)5]$,F<U9*U 6F79%:G8K6*(CY-JU9JM40(1>[6>BO7G:'$
MX]ND+:0DYR&SF"&8@KO9H*9B6&70^GUJM#!R[%^20CGB]6V31ZQ.ORN%'DU"
MV9TB\6,X2;N4B>OK\JLW$TFI04=#Q4378=DPK\; Q$,@DP;&&.C:NW4:UUHV
M543.L1*$;K+I1GX03,BN' H&(9=8QR+7 UH]*I/M;L_2IM0J]23E?9Z;6\DT
MZS 1,"21=D[(844CI^6+:-0=N"E44*5=P"BH <X ;[XWDBVC\(G")PB<(G")
MPB> _)^__P _Y>$3A$X1.$3A$X1.$3A%JN]J5O&O]=Z=C-]R&SW*N2!]$?P,
MTW@:9&7*NV-E-P"L?'PEB8R,;*G&4-,.&4A5&K!LT>OG+"3]$L@DU6C)<BD3
MM)L/9W.+9U6=9''1T]6KZIKL??J0^H;]Y<K#9Z_U9VC4*%'NYAM*+1](AU]
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M5"&*( ("'-MQ67QF<I19'$7JV1H3.D;%;J2LG@D=$]T4@;(PEI+)&N8X \G
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MJ@N=;D:\MKMW:R/AX7![GY^<5?:]3F;0K1VI,A:JR6VOM&5\=6"G,TECK#H
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M4$TV)A@P&0N2.T]D-59C+Y;(24X970-H3.BR,@HNF$1OQOM8R:])"6MLV9'
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MJAQ;5K5;)5;34;##QU2A&\7<ZA(TZ4F(5"K6ML4)> C2OU'4?&+MT')$C@!
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MG/?FJVNCISX\'9\;OG*\I&]@] ^9.2I3A$X4.[#Z#\R[S^'_ +"N0?FNS_\
MFG$\^QL-]Y\5[VT?HL2]8]*_M8TY[PX?\WUU*/,DL\NJ+VJ_;)[G^="X_P">
MG7/&_IA]U3I"^%V<^GS+V"Z(?<MZ/_@GA/H,*@'G6Z[&3A$X1=BOV8O[6-+^
M_P#MO^3B>>GWU)?N2L^$F:_FTUYF?57>ZN_X.8;^=<6PWGTTOFI.$3A%K_\
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M$ODCJ.<.4#!Y 0\E4$/("'V@/->L5K-1YBM5K%:0'8QV(9(7CL[62M:X=O>
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M^F'W5.D+X79SZ?,O8+HA]RWH_P#@GA/H,*@'G6Z[&3A$X1=BOV8O[6-+^_\
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MYSZE_P!$O")]S)W#_=*M;_DY]3/Z)>$3[F3N'^Z5:W_)SZF?T2\(GW,G</\
M=*M;_DY]2_Z)?WAX12YU(<[@?)I&/["S<S9]"KFN[O46UML%2@*/*W'/ZELE
MWKN6V]Q7:M%PM>;$L^=1M9FV[J(C&K&3;O4I% AB.@.8BL[PB<(G")PB<(G"
M)PBU->U\B*S*8;D_UDUE3"$$]ZK:B>L24!(3.=5M6-I=_L3!IL*\-?<QEV6?
MS,W!Q+-BBC<V<9+Z3^I_#S\7/0KY[%."*Z73<Z2O4SK4JB]O4BBKAF6*I/\
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M_3^575RG4J/MN>U75<VDW<Y0KO%(3M3G7M>LE8--PCL3"QF&D3;8>"FPBY-
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@<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g108483g32r93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g32r93.jpg
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M 0$! 0$! 0'_P  1" !! 6 # 1$  A$! Q$!_\0 '@   00# 0$!
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M5-_40?;1_$ECN/44?$ZW\H@_I8_[SCSJF_J(/MH_B2QW'J*/B=;^40?TL?\
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MF9)&L2$WRDM9(U6KV)4[TE<B+\G>Z=N_S\>WRY;DQ;,W[.K\U'*'=AXV_DI
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MJ(5A*]N!QMF'9^]/_2Y]C-W3D7,-A&+ #$DEC 8K8B0._P D2:)'/\VR.^A
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M\TGE8UR?-JJBHM#2TLS28[#_ )1NO8\XQ'CBI$DC38D[,'#WXI\,+V;2Y<K
MW-6KN5;W]P(D:]A'BBJ]02.S$G\417.A>R*=K4<K8Y(V.D3@GI)(;N'IQ_S
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M9L'M7=#S-:C708=T^RN<B(BN?'M'*WH]53LJJC$8WNJ]T1B)W1$3MI%^[/\
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MULSEAADGGVWN;8(>7Y>(!N8@ZUQO3&9[1U9;86;HO,@ @\!UW@-G91[#"!Q
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MG/#5T@1(E<*R!LCE5SD(%CC9')YO^DZ=G@4UZ(Y)7-\HWY05T\3B7/>]KL'
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M:1 PP(6C BC!CL_ @%@B'A;_ .K%$UC$^I._9O,2YSC=SBX[R23UE7  R '
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4_M-3PHVC@>]J4.%*.$1PB.$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g108483g32u77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g32u77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %9*^52(X0DE-! 0      %T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   "  << E  %4UI8W)O<V]F="!/9F9I8V4@57-E<AP"!0 7
M4&]W97)0;VEN="!0<F5S96YT871I;VX .$))300E       05 37$ 2D;Q78
M:7>!KT-6PSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M    #@             _@   .$))30/R       *  #_______\  #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              (O   '"
M   !                          $             !P@   (O
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   (O     %)G
M:'1L;VYG   '"     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "+P    !29VAT;&]N9P  !P@    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M9$55-G1EXO*SA,/3=>/S1I2DA;25
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9'V1$H@ @!CHR3%4RW';W"K("/\ ?<]]3S'/R^/S^2N7(\KWROY@>>>G-<G
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M69!RNN%?]0HN!,!N!36Y >>1ZB#SW'CG@>>P@';U$1 3:+'P7V@*'_</3/\
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MX#GOVU+CYV\U1?0 'CK<&Q-N5M=/EK?C[% +,DW15&YB<(+"!3$*''XL1XY
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MU)W#7N_B&)DDS8MXQL+P&E=W+:9-L8Y9BFV)D1/U>1P,+"S4[=_)1B'B\V<
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MD9KA9Z>F[^0-Q.&9N\ZTSXJP%XWK7<.X>[>(S-BYO)Q7;4\A681X7PODY#N
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MHL!0Z0X,@X @&#J*?IZBB)A'CH-1!-3324U3$^">&1\4T,S'1RQ2,NUS'L>
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M"$*8A%B^TQ96[182-402,1=-(%%0'J4\H!( ))*E)U!T )3=1! I1ZVYU#\
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M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBP]GM8&V",X.#" %;XFR2L81+U
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M7ORX<.>5_,999'-:S?PCCJ/*_P"2DC7K@F4I"JJF\LX$4 1.8H=0&+TE.40
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M8* [***3@R0.P,V(J)> !443A-[.UC:W(F^FEKY>LE;7 (L3Y97OEP&NF67
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M<\_#T[<=,L/CKU\;<^/!/>_V?E?/C\CX6X(:4$1 1-U=^.XAVX$>Y2@/3SV
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MHN7W' \!U8JN3#GX@(?2T9'B "7@WO<<<]!N%0%,)^[9!^*KPYO_ &^G?_\
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M:\LHVEY>IR4#*L1NK3KL[MOQS?7RTFX>VIMB&N3^6D$&$^JZ3:.:Y4SII +
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FFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g108483g33r43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g33r43.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1904&AO=&]S:&]P(#,N,  X0DE-! 0
M    %C2^5H0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Q*9F@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              JH   5=          $
M                 0             %70   JH
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   JH     4F=H=&QO;F<   5=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *J     %)G:'1L;VYG   %70    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      ,'@
M  $   "@    3P   >   )0@   , @ 8  '_V/_M  Q!9&]B95]#30 "_^X
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ME=+(/6>LP08MH!CL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A0D=H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M
M,#4M,#E4,#@Z,C4Z,3,K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @
M(" \>&UP.D-R96%T941A=&4^,C R,"TP-2TP.50P.#HR-#HQ-BLP-3HS,#PO
M>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P
M,C M,#4M,#E4,#@Z,C4Z,3,K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @
M(" @(" @(#QX;7 Z0W)E871O<E1O;VP^5&]U8VA5<" W+C \+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @
M(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM
M<$U-.D1O8W5M96YT240^>&UP+F1I9#I!130Q1C0W1$$P.3%%03$Q04(Y-T5#
M,S8W.$)%,#<X-CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DEN<W1A;F-E240^>&UP+FEI9#I",#0Q1C0W1$$P.3%%03$Q04(Y-T5#,S8W
M.$)%,#<X-CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.F-A.#9F-S1F+3-B,#DM-&1E92TY.3-A
M+6$T-S)C-C@X.6)E9CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z040T,48T-T1!,#DQ14$Q,4%".3=%0S,V-SA"13 W.#8\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C M,#4M,#E4,#@Z,C4Z,#@K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I!130Q1C0W1$$P
M.3%%03$Q04(Y-T5#,S8W.$)%,#<X-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-2TP.50P.#HR-3HP
M."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.D%&-#%&-#=$03 Y,45!,3%!0CDW14,S-C<X
M0D4P-S@V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(P+3 U+3 Y5# X.C(U.C$S*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A
M<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I",#0Q1C0W1$$P
M.3%%03$Q04(Y-T5#,S8W.$)%,#<X-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-2TP.50P.#HR-3HQ
M,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A
M;F-E240^>&UP+FEI9#I!1C0Q1C0W1$$P.3%%03$Q04(Y-T5#,S8W.$)%,#<X
M-CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M
M96YT240^>&UP+F1I9#I!130Q1C0W1$$P.3%%03$Q04(Y-T5#,S8W.$)%,#<X
M-CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.F-A.#9F-S1F+3-B,#DM-&1E92TY.3-A+6$T
M-S)C-C@X.6)E9CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O
M(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY4;W5C:%5P(#<N,#PO<&1F.E!R
M;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO
M=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*
M(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O
M;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$
M1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #N > # 1$  A$! Q$!
M_\0 'P !  $$ P$! 0            @%!@<) P0* @$+_\0 5!    8" 0($
M @$-"@H)!0   0(#! 4&  <("1$2$Q0A%3%!%A<9(C(V.5%8=G>UM@H8(S<X
M5V%QE]4D)S-"@9&8M];P)C1#1D=B=7C!4F>AI;'_Q  < 0$  @,! 0$
M        !@<!! 4( P+_Q !0$0 !! (! @(%!@@*" ,)     0(#! 4&$0<2
M$R$4%C%1\")!5F&1U#(V-W&!DZ'!%1<C)$)VE+&VT352=7>TM>'Q""9T,T1&
M8F1R@L75_]H # ,!  (1 Q$ /P#W\8 P!@# & , 8 P!@# & , 8 P!@# &
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M""A%D%T%B HDLBJF)DU4E4S%.FH0QB'(8#%$2B X!RX P!@# & , 8 P!@#
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M4_,,4"HX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , _!$"@)C"
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M(Y9G\?ZL<;W+\S5-_%XR]F<A3Q6-@6S?OSLK5*Z211+-/(O#&)).^*%G<O\
M2DD8U/G<ABC7_)32>TK 2K4.\(S\\HV=O",$X2RL1,W8=A=G]1*0S)H H>(
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M+1&UYB:V["N&<VF882/>R@C)K>7ZA/+C;4]NFGW&UU)E7[J7J':GN''EXZU
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MI.#AS,TDI4L4L\E$_7-CM8YT *@0#R/<6Y^T:W5#2^G_ -T/0_$>KGV!<;9
M\9^2/3=KNA9:EGOUUF+S-TV#6Y$W.O"5G\7GI($FE>EGD4Q5<G"+;-4!2;%
M]KJ ^)!$WFE<=TDQ\\GA\"W<@#YI/ (E\*GW9?"(E[&#PB(=AP#EP!@# +/V
M']X%Y_,^S?J5[@&L?H3_ ((O@E^A=+]JK+@&VC & , 8 P!@# & , 8 P!@#
M & =5P=Z4[4&C=JNF=<"O3N'BK4[=KX#"*S5-)B\*[7!0"%!LJJQ3$AC'%T!
MB F<#M8 P!@$3]6_RK>57_H>AOV6L.5#JGY7>K7^S^G_ /RK(EM[5^27I/\
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MRWZYF-6WQT[23@[):*3(5.T.'* I?P41.3<$L^462% O\''OW)B>4'VJ/@#
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M-4T%G)(W852?';(NG[.*;*KE:RZHHIN)21CXU!10"E6?OV;-,3.'2"9P,IX
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M-M& , 8 P!@# & , 8 P!@# & , I,F=@1>)!XI()JGD"E8E9*2Z:2CKR51
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M<K)V,<GZ4*QFZ:8P!@# (H<S/XGH_P#2KI__ 'BU_P#Y_J_%\PJ+K;^)4/\
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M-X%VD@W;H)%(DB@BD0B:229"IIIE*0A2E*  !K.Z$_X(O@E^A=+]JK+@&VC
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M P!@%G[#^\"\_F?9OU*]P#6/T)_P1?!+]"Z7[567 -M& , 8 P!@# & , 8
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M_P!*NG_]XM?#_P"?]65%UM_$J'^M>F_XDQQ;71;\<K']4]R_PWD25^6Z5*,
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M[,3)+=O2]ZM8BL@K0L1&5Z=6+E4AJU86LA@B15[8V)W*YZN<Z^<[QPA@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!%
M[E_*\OH;3#][P=J^DK?OHL_ IQL-R!DK/%:Y4K2CE0+(X=.ZB^CYDLJ@T!,T
M40CD&YUA.#@AR@ 8!YGF?3HZH2G(IKR>DNF!T/ W&>XM[N^O2,COHZY;4,@6
M0<W-O6%+F>F#<2/O'-(V$]>-*_'P)-B[&5#UF/T_W>?[/[C'O\E^?W?Y_/\
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M>,JH)E4*:X"H2LX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MUZM^58>VP>,%AD6:1A*K,ZCN5<O)%BE#N99"NR2E<GB%'W$J:A#'^0 8QA[
M]>.H6)7C8^E>1LPLY1][3<UC<\UZ(GF^+&VG8W((B_T6.15^;N5?(SZD=/\
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MM0:-VJR9UP*].Y>+-3MVO@,(JM4TF+LKM<#@0H-U5628D,8XN@$@)G [6 ,
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MA5-XF!"F(+83& Y .U@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MP]&8)*+67:"JB"GF !#/H3AVZ1?!(/Q:72#W^?M:K+\\ VT8 P!@# & , 8
MP!@# & , 8 P#HO"/SJL19O6K5(CH#ODW#([M1XU\LX"V:J%>M 9+BH)#@Y.
MD]*!"&3],(G!0@'>P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MI1*@0:H(K $J8TD\:KIE(43-_'%)O) !7 "MQ1%4Y *M@# & , 8 P!@# &
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M%>)K9=YA:WLW632W3E =WJQ+NYJ:CZC-M3^A2DG;ATQ&5<)G. *E*4#>-@#
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M.%_">_RVSM!ZZL45=7U.#6T+,739NQ]FGH6L@E_CX:WUPCL"SV)&DTSXR!9
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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?@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g108483g35b35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g35b35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '^"^@6 X0DE-! 0      '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  AR<C8P-#4X-!P"!0! 36EC<F]S;V9T(%!O=V5R4&]I;G0@
M+2!'96Y":6]?4RTQ7T9I;F%L1FEG=7)E<U]R979?,#0P-S(P7W8S+G!P=  X
M0DE-!"4      !#M6B4K-$O.L)A8;KBXS1C[.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             #%@   E$
M 0                         !              )1   #%@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #%@    !29VAT
M;&]N9P   E$    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MG2+W8S[@'.#I&Z1_AFV-L;=_U^G[7_@Z\RBK]&DSKF9@VBKK5+:ZW<9E0(8
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MQH@!@JO:&- _-W/9_F+;0X1=]5@QQ$N,ZR/7_O5)))(KW_\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                          #_X4$7:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(P
M+3 T+3 X5#$U.C(X.C(Q*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @
M(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C R,"TP-2TP.50P-SHS.#HS,RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C M,#4M,#E4,#<Z,S@Z
M,S,K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL
M;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z4')O9'5C97(^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E
M+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @
M(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N
M9STB>"UD969A=6QT(CY-:6-R;W-O9G0@4&]W97)0;VEN=" M($=E;D)I;U]3
M+3%?1FEN86Q&:6=U<F5S7W)E=E\P-# W,C!?=C,N<'!T>#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @
M(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3YR<C8P-#4X-#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V
M=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/G5U:60Z9C4P8C<P,6,M938Y9BTT-3,Y+6%C
M,#0M-#4Q-S8R,C0Q8S@X/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C,U03)#,3,R-#@Y,45!,3%".$8V
M1#$Y,#$T-3DT03DX/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HW-S5!-$$P.3A#-SE%03$Q.3A%-T%#-C-#,4$V
M,3@Q-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,"TP-"TP.%0Q-SHP-SHS,RLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C,T03)#,3,R-#@Y,45!,3%".$8V1#$Y,#$T-3DT03DX/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 U
M+3 Y5# W.C,X.C,S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D
M(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HS-4$R0S$S,C0X.3%%03$Q0CA&-D0Q.3 Q-#4Y
M-$$Y.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,"TP-2TP.50P-SHS.#HS,RLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.F8U,&(W,#%C+64V
M.68M-#4S.2UA8S T+30U,3<V,C(T,6,X.#PO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C,T03)#,3,R-#@Y,45!,3%".$8V1#$Y,#$T-3DT03DX/"]S
M=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)
M1#YU=6ED.F8U,&(W,#%C+64V.68M-#4S.2UA8S T+30U,3<V,C(T,6,X.#PO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.F8U,&(W,#%C+64V.68M-#4S.2UA8S T+30U,3<V
M,C(T,6,X.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O
M<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO
M<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #]
M +X# 1$  A$! Q$!_\0 'P !  $$ P$! 0            D&!P@* 00% @,+
M_\0 6!    <  @$!! (*"@T("P   0(#! 4&!P ($1()$Q0A%3$6%R(U05%A
M<7:V"A@W5(&1E:&Q\!DC,D)65W1WE)?!U-4E)BDYEK?3UB<S-D5RI:>UQ-'Q
M_\0 ' $!  (" P$               $" P8%!P@$_\0 5Q$  0,"! (%!P4)
M# 4-     0 " P01!1(A,4%1!A-A<? '(H&1L<'1%#)SH;,5(S,U0E1RX?$6
M%R4V4E5B=9.EM-)TE*.DU @D)C1#15-C@X22M=/_V@ , P$  A$#$0 _ -_C
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A%U7;YE'HF</WC5DW)Y]:[MPDV1)X#R/
MJ56.0A? ?,?)@^7SX1>-&W"I3*XM8>TUR6<E'P9O&S<8^7*/GQX%%JZ54 ?/
MR\"7Z^$51\(G")PB<(G")PBM'LV[91U\K#*Y[#<XRC5B0G8ZM-)>5*Z.W5FI
M4%SLVGI9MW2Y0%!JZ=N' I W9LVKEVZ51;H**!@J*F"DCZVHE;%'G:S.Z]LS
MS9HT!WY[+B\6QG#<#IV5>*U4='323QTS9I \MZZ4D1LLQKCYUB2;6 !)-@L(
M.['M 97IY<<!GG=,@+EU[U$\@VM-TB+ W<VMBX!-NXCW%4B4GB;>4CB1JQ98
M[LR;EG(I"+%)['.S,_C>-Q/%ON:::62)LE).\,?,Q_GQYAF:X1ZYVY07%P.P
ML!<K3>F/3F3HK5X%,:2"LP/$NL%55PRYZEA #V/I6,?D?&V,B5SW!S) <C7-
M=8ND%SO1:5J]+@-"SVQQEKIUG9$D(2=BG!5VCUN83$. _(BC=TW6(JV>LG":
M3ID[16:ND4ETE$R\K%+'/&V6)[7QO <Q[2"' \01ZO0MZH*^CQ.D@KZ"HCJ:
M2I9UD,T1NU[;D'D6N:06O8X![' M<T.! K;F1?8G"+SW4K&,4W:SR09-$F"
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M%F'SSSZ&J$[U_GK9"W@KD"B!EG+WKSV2TJ[F3)ZUE6&& H "G&E3/D8?,D'
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M"[6^<0#N[74$*&G, ZWZ)[#:YM>XOR.OM,M@            !X  #Y   'R
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M-7LRA7!_I.+D#^\*4AD0*0Y$Q(H83)F.!3 17%* E*4HF$XE* "<P% QQ
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M/_6%;?\ B_X.:3\OKOSRI_MY/\RZ3^[N,_SKB7^O57_Z^."Y^W;M/^.#4_\
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4 4JZ?")PB<(G")PB<(G")PB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g108483g35w02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g35w02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %YJ^8$(X0DE-! 0      $4< 5H  QLE1QP"   "  << E  %4UI8W)O
M<V]F="!/9F9I8V4@57-E<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX
M.$))300E       0VMTT@N)R>O)<ZZ#L7IO L#A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!EY5@@        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              =L   0;
M  $                          0             $&P   =L
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   =L     4F=H
M=&QO;F<   0;    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   ';     %)G:'1L;VYG   $&P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 2 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M8V75DFT5AX]!_IL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\;X>2/CC?NX'B0HDR34T/GKDPM:K&<>!FOHNW9_:]#0(3XF%HUE0E$"!^P"
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MD7DUF;#&[=4C8]5W7=\%@-DSG'V?_4M L9# 8. UE5;$T$((MT^B+KI^DO\
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M=$3HB=$3HB=$3HB=$3HB\XW?9>[@>\;N3V+MWXTQ]AG'^M7MDXDSVE:-W?\
M /%^9Y8#4L)Q[R#R.[+:ORQV+\P\AZYD=7P?*NG5<A9XYY2J5:^,R^&O4\CC
M\[;:VF5YRJ!VV^*]%6*KS4QF-JDHTE6H4ZY)9:.\:I376N5'=8(,N&N1]2M&
M(G8F):0P1S$%%7]$5'.1Q\>GF]3CY+1TE^;*?WW5D0LJ!^_]UI9 8G7'RT2
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M*#@B\P?,//WU+]#T;A_'U=]YEVC>Q[G>^33W;)I_"7P8[E#<M [H.(-3[;=
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M_:QQG0UW2="_UF\3[7HVQ;!F,AL>M4.2,KQOG\9G79/'UL/DMCUV]7PI[PC
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M)%W\]ED#!>DS/=-P;$0?CV])F=Z\07K^[UG\^/SX\=$7(?U'_IXK](9WY]F
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MTMGWUW5%+**OR&01@T8Z<G]]#$MJ8N\I-VS7E:BR2 4#WG]HUSJIUZRUV4#
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M"HA6R&=HW_LJ4LF<<$ZSA45J5OY1$HMA44@W1X\>Q^8_GHB[!^B)T1?SXOJ
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MY=OWT@:.%Q_#'*2,+@6X "Y26^W7<^'G8LVM+UBU%G]H "_93UAZC'@O3WF
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MS'ET]%5EQ?=[J][(4T8[6MGK7&OL1-FO66H:<V%5B=)09*)[F&PO53($53$
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M@IH Z:TI*#CUDH@!^2!-/@UI*887@INWWM[?N-/"JQ_MG"N1L9MCLQD7JL6
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MT[.3DLXX';^,L?FOTI-G$%5*S7A#A36M@ZO;"*BY1:< ,7,6$L;9D4?VS,W
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MC28B^(O<=^NBK&)J+15^SMV3F9@F/<\YE1%"A HF?!^\O7,B#/(B!Q^[S$C
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MY1!/PULCCV(,E..N_'UB Q4\A.P 0LA*5L:+)B"CW/P4Q[1/@>B^"Z0(I_\
M$1;7I?Z51GN-5?7<\;[</=^C8:&]+U\!77C:^!WT\HA(UEWJKD@;5.4G'55%
M;)E8P8@"E/L"H@)B"B8@)&('\^8F_-;!*TZB*:5_G$7,=I[>S?=/74^<HD,5
MO^B:*BE.WM.8W"RYF=\7*]D66#R**D)3-,YKT:\?VFW*SVS"OAA<,<5<H* D
M2 /4(_;^(GS6P6]8$44K3\HBWINJ1>^_Q!08W/G)\/+^J K>V=;6XYZ$+ECO
M7Y4%]B\S9$DR$C,)=BZ5H50M(TQ!XD!3!>/>"$9(G&PIB?<O/5^:N"#^0C"M
M*#TB-[CPRH*W[YZZQ"M#$A?JFUSINL=+DWKFK>?>3RP=D+*\I5#*MKU5663C
M::HD"L5I 95 PF9^%0C/NN/)J'S$3Z]!T6P727C=TQ$N2;T^EEGPSH;*^NL0
MI^?#R&<)M::5J3VFV^FY7*QWG\VU:K:9[%4''NL0UBG8S&_,\6)\KAA"N)CU
M? _!^Z(F1F"GQ$=#T5P8'^#Q:5H/RB*3EVC6R>N<0M]9#L?ZIHM7APTWJ+3W
M=<L+2-F[DJ*_L$6"K3^G42):;'LQ3S+T$$'$Q$P7N7QS/F(\SXF?-;!@:&!%
MJ;C\HB_$4 I>M\[4"GKJ?_IL[##8#K0[AN %*VJ<U3W>\SE:22\-L^WA%6:H
MI1CZJ 37%! UAM^/R0B1')%$R13/@!*/Y?-;!:?H(F^GI$7M_I4S-N.M;"C&
MI_\ K&<?JFB^@%1;LT-ERY#O>YE67Z>&T5+ DRV;%GBZ7RA,(-;VC))D9 W"
MXIB9G\KC\1'0]%L%RZF*#<$^D13D#N=OT-^"GKJ?%/K&'3]&S6E!<7--_%4S
M.]GEL&#1;LHR#A5!"S'5B6<&U<*@O=4A,B *$X_ >T!$#X")ZGS7P76#%S_K
MXNN5!6N6=:9VL0AQN?\ ZQE]\)@%CK4:$5R-,Z65H?W9\BV89%C-I)3A.S6E
M="H# 7'VZ9]H$)_M'\DC*_P!P,D0?L_%^:^#7K BTI4?7Q:TMQI??7@GKJ?_
M *;*7%.I:38;Z4[-^^ME=,?W';.Q[HN[2VL2V$\6G46Q$-<)N</X#T$5$PH]
M0_;+/7^1\SUD.BN"7/4QK5_EXHJ;6SJ*=]1I53UUB']9#S(/U;*"_F37@2IN
MGN/S:DL.=SR!RVC--IS7KG\E>W7.61"Y(1!4M=$A/Y("F#&/Q)1?FK@?]3%-
M,Z3$33,W=H=]/)7UU/W.VRM-83*#.E<AK6Q/%;R?3@Y9R^X<\'K>0S%O)5JF
MA;/>J?<G)1\9Y'#LF5^)D9 66&P,E^X?\(SZ1$==%TAP/#,/P_TB5AQ&13,0
MH=71GO!8YL3:JUQ(K5HOIDNRPO$9N:F>JC.:6=6]UF-::@MIE?4ZY]RT$^M*
M%,^\WTLS8&3X>T/P:H)7CXK^XMA868(8"7' *9(Q)A#!\>L%)1^<^G1(Q*4I
M3^!MSOG&BBM*'+/,+ZQT;_@<;_M!X?Q&:CX^V_4O>J + "M9M(K0"6.7Z)^(
MB]H"''[&7JE7@_$K)3(&&"<1 KB/#M<2": FXM6N\#MRM<4(N35>D(%1G3N/
MXT[MQ5E=62"8B'U?[K0DP>I1_!+U^BD+-?Q%\OQ,@%J<1*)DR!F4$$QRBI-2
M#8:$UL<S6MJBM16F=!=8D<1WC*HRTWT[U868<$77DI%=4FE?R).D(D\!, (9
M>+( "A3; J@8\L5987Q@?K,Y;=0*DD@D@[61S_-[:< 6B]%CL#:)  J*$4SO
M>^E:FG:;5NKK3U!B66)JS%1(R]52"L2WP=G[3^T+ E<03$5EC6LR4L7!?*0S
M[RJ,3&%!M5<?HEU&TL"Z]"*T!)JTUK<"]"J(=*AMA<-%36]*BN^UCI6IW'*-
M#7G_ #"Q-M1E]M[576+ -E@!Z)00SZG$@UOQ#YC^U*UB!^ @BC4,1I&RYN1%
M0!2A)-=<P-XNZ]J+EI0UKG6AL3:PTUM2E32U#57K7H9KSD,R5"MG,;7R-&WD
ML1D7W%U\HJM=BQ^F6[&/96R-6G95+T2RC;JV_@EH)L+:"6!1$9UC'F&'M:X'
MJR2UCP*5:XM<UP+OS7%CFD5JT@E'-<6%H?LD@T>*$L.]NT"VK<[C>*9K=[<3
MX;H:%Q%N^W\9Z+I&][/B>9-@C2<%&UIUS8=)QVCY"MQ1G,[A;N?RF4QV3RN_
M"_#XF[5R>.C.XBLK)V9-1CD6^@B-D_1Y"9CRDO*S$9D^\P8?7-@Q)<07&2B1
M8;HKW@OF 0PAS3$8T/.8<NJ9UYBS4*''B1H3'2K>M<89B,?UH$RUCPQK2&PJ
M$BA+22W,%HYM,Y X%QUJEM6/N\>Z_F;..HSMR,E5V2NK%GE^%&8VU5T!*!>"
MLDWDIV2_J*K!'4K,?@X0*, O)QUG+.P^&X1FB6AQ##88^T(OT"^2+")5C:[+
MC,F)U@NT58 .J#@)%9-.!AGKG,J\0RTLOLS(<#&<0*CJ0W8L":&IV]E88X+P
MVDV]5Y9Y=WS !NM'B;7];FCI3;E]&%V'9MTVY.OX.WL#\39QF9C"88&6\CD\
M?C+V-MY%U>C0G*5EVG&772$O!$*>G(\(1VR4*$84!Y>QD2-,11!88SF/;$ZE
MGTGN#'M+G!K=IH*VIF+$VY>!#B&$9A\0/B  N8R&PO=U8<'-+W6:"X'9%3LF
ME%G=7$>W\V9_BW!XOBWBS0U;QD=N93V7B[)/V/'WJ.EZE6VW9YS6"Q&Z[G$9
MC5L3"[-;#X^MB<QEK&27CG5[=HT-7S'#IG$8LE#AR<E*]>9@"-)Q'161&P(3
M9B*'P61X_P!;!A5<&L#'Q"\,(<XBG%Z5"E63#S'CQNJ$,EDPP,<QT6(8;*/=
M#A?0B1" 7$N:T-)J!G.#[5[.-RW'N*/,9'6=?WG"<B_9V^3./<IIV:P%OC3
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M#=],-IDX@<K,0=%BR0CP]B()R=EXHAQ7]4'2TM'<YX: TQ6/:T.:R*T;#B:
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M]F1%O]P?,DR1&9\QU*T)J=Q%+4O85KOWT&>F3V<^U?B\I70,6+>0.W%A-!L
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M'&#$V]A^P:[+]DM.RZS2 ;@@@BY2(QSV.AM>Z&7-<WK&TVFEU?I-#J@D6(/
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MUTC@)F)/R4S(^0B??V$"]?:?'QC$ ?6$]0T_+9PV%C^41!4Z<FF55]ZPD_\
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M+( ,)\*H&RQL(,(<"6O#P2ZI-12@YVS36/)9+PF,=#?#?##HAZQKZ;57.>7
M@@;.R1LT&9)KSUNX7 VN)\9QMGN%^/=JI:]FMXO:)ELEG^4<=F-5'D#(T,I?
MFJ6 WG'T<K7Q=JE0?COUREDV3-507BN VS#:9)XF'S$.<C0W1FP&QFMARSF1
M.H!#2=N"YS2X.(/5EH^D* 4"GI#3";"?+PWB&8AAN+XH+.M()%&16AU*"FT"
M;4)N5DOC7O*Y'X_YFQ7-E*AJ]W)T]-T/3LWKCZMJSJF9Q_%^IZWHF!LW$SD!
MR4W5V./L1M).3<4=+9<?-JC%:J"ZT81L*@1Y)TD]\78,6/%$5I8(K71XL:)$
M#7;):&D1HD(@M-89HZINJR>BPIGTEK8>WL0X990ECQ#APV,VA7:J##8\$.%'
M4O2R@$\Q(S''VE<;Y+%(J8W1<SNN:PV0379&49;WB< BXVV4.93*JJ<$,5"K
MJ2TX.S-@W1Z2&[#@,AS$:9!=MQV06.!V=D"#MEA;;:J3$(=4Y 4UKKOBET&'
M!(;L071'M(KM5B;)(-210;(+0 ..04-IY+6+)&1&\V#6 GD2BCYUFYTK)?KX
M+U R(R]OW",#[?B8B=BQ^)[22:#A:FEJ&U5P\2#V5UR%,K@7IK6UQ:GL7\+=
ME<U1,Y8X6-,DEX0(-(9JB!_A9B"X3!''M!>QSZ]"18BQKH*4\\\C:G:EA>VZ
M]*&H-]2:VJ0:G7)6VSY;98P3<9(>@*R6E"CF8;)22Y&9_:*3$6Q/^."D?SZ3
MU.17<I45TUKQ).@%-0*&]KG2L;RF.&Q<A\6&R@I/U?[>KD0#C(U_$8C RLJT
MK5 >WRS$I/P,S,RGP\5D#2U+TK0#>:<+Y5R5.AF277^7&WA41-.Q9KBD8LM8
MTBJU#_(RJ"&&IAD>8$((O/GQ^%QDK87(R&=\AQS&9R-3[..Z34*NF5;WBPVN
MU[DD,$R5*=2)APN)D6F,$HI4,P"P@9B(\STWJ"EKF];'?6MK"PYRM]X6I;KC
M9@D-M56F#\:BQ\D*KK^]A#$POS B,1$%$",^2_='YF?!#VY7H,SD:7-<SD*5
MK3<5?DX,K2RMJKRFT?M%8X)Q?:&H/<3]H*(F5I77_;,?M(I&?]T7CSSN4KE<
M4).6N^MLA>XX5.J[6/H^U;-7NU@&0*EEQ+O9DI0S*R;.4U'PR6',G/D2\#'G
MU_;/C_/KS'2S_P U-.GI4+_^,1=S@1!GC>_4Q+'3Z3*^SV;R3Z#.3NTKMLYG
MVC^MN4^&M)WG;/TVGA_U_/8TK61C%X]CVTJ,/%RYA%9MFP:AB/VDTY\SYZ^3
M36&8?.O$2;E(,P]K=EKHC=HAH)-!?*I)[RO=P9R:EVEL"/$A-)VB&&@)M<C4
MV'@% F_3Y[*G3Y;VV<8,\_%Y]\(<Q/P^/BF8FQXF0\1XF8_/^?GK6& 8*,L-
ME1G_ ">_/7DW7-ZTQ'[9'_Q[LEQJ^GIV3)]H5VU<7!! 2YB,(?K*S(B,/6;,
MQ D1D4Q$1^9\_P"[H< P4YX;*G_A]G'@$]:8A]LC_P",K]CZ>O9-#5OCMJXN
M^50L!;)PAR0"V0)@QYLS'J9+"2CQXF0'_=U?4&#4(]6RM#2OU>[+5/6F(?;(
M^[\_L^ 7*/T^^RP2@H[;N,/8?'B9PA3,>H^D>/-B?X&/$?\ _9ZGS?P7^S97
M]7]Z>M,1^V1_\950/8-V: N4CVZ<:0N2@Y",,?B2B1*"_P#://F) 9C\_P"7
M4^;V"$U.&2A.5>K%:;JUXE/6N(Y>F1Z?WRJD>Q+L^#W@>WKC>(9/DX_1RGS/
MCQ_G8GQ_/^7B//Y_G\]3YN8%_9<G^J"OK;$OML?_ !E<+.PKLW=ZPSMUXS*
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M]SRR3UIB7V^<_:8W[ZK8[.NUX1D8X.X_]9\^8_1@F/W#ZS'Y9^(D?Q,1^/\
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ME,,C\#$1$>/$_CIZOD!824J*7%($+]U/6>)?;YS]IC?OK[5V3=IJ2DU<!<<
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M2([#T,6Q?$V3]ER\H]M^W<H*;+6.=+(G.^#DC:<_N\_SX_B.I\X,7'\\=O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g108483g47s43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g47s43.jpg
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MU D6-'&R-H$C)+1"0W:V\"5$18*#A8:CPO'_Q  ; 0$  @,! 0
M     0(#! 4&!__$ #L1  ,  @$" P8#" $$ @(#  $" P $$042$R$Q!A0B
M05%Q89'P%2.!H;&RP=(R%B31X3/Q!S1"@N+_V@ , P$  A$#$0 _ /[^,8S
MHX33V@([1#^P!_;:/_K9C&11DD0$0$2 (>@*H /:$H8QG'>B'O.ZDQC&]$/>
M=U)C&-Z(>\[J3&,;T0]YW4F,8WHA[SNI,8QO1#WG=28QC>B'O.ZDQC&]$/>=
MU)C&-Z(>\[J3&,;T0]YW4F,8WHA[SNI,8QO1#WG=28QC>B'O.ZDQC&]$/>=U
M)C&-Z(>\[J3&,^[S0]-,/[JE_(!QC&]&_JB[?<4+]X[.T&W&,;T0$-O&3[J
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MC' ^@_(8W)&>MA[NY\=C' ^@_(8W)&>MA[NY\=C' ^@_(8W)&>MA[NY\=C'
M^@_(8W)&>MA[NY\=C' ^@_(8W)&>MA[NY\=C' ^@_(8W)&>MA[NY\=C' ^@_
M(9]"%C0':#8?]UW _>J.,<#Z#\AG0.WR+&8W>EY4H-D513$QS\RAU"\8.,8Q
MND39S#L  Z6W9C'IQ^OY_HG\\VMNKRA0 1$3 &WI>AT@_P!^EM_OC)R/(CL0
M$0Z8%.(?[ &,955>7,>_<F(CL",?" >AM S;:/3]W^^WW,8RY<8QC&,8QC&,
M8QC&,8S\[GO\1W3HLC38BNZ0:Z7V7NNFBVJ#"&H=:K5CFFL.A6Z%8U8UU&(V
MU%<TP@EJ- -'B2'*LV2A)!PY>)M$$%G/I5]F-KMN]-WI\$AMC49]BM9H7-=F
M0<,8D";'5HRD_$P*@*6) \4_MQHA]24.F=7W*[>@>HSEIPA>RR$=.S3:8V0W
MC*-Z*LJ]RJ0[,X4!FPN?XD.G;)U3RN=*]4U8N[773"B0\Y%C1))B$OJE 2$]
M%K/FY;FC*1;2&+'+QE@++Q\<_CI82QZS$KLBR"4CV8V66Q&WJ!H0VMAT?WA&
M[-2BS<*? *.U.X/+L9U=/C#<<$U;VYTD;5#=.ZB4V]OI^G*L_<Z)XO4(O9"P
M&T*36/89V%4FZ4^ H&! ZL_\4'1M"!I\JXT]U:1FK[HLTUMJ=&5C*FTNTW"S
ML^M#4RM1T%*6V.6>V:ZLHNT66 .U,M5U:]5WL@XLJ)):L!.V'LINFET&SIE-
M;>;0M<-8PG2<P]ZNZP8+&#/&5>>+"ME42/9;P\9]O^EB.M1M+J(MN=*7JVMI
MF>LFW:5:M/5UTC390ML;:3V+Q*]VN8:[T;845U_&]7<'OA&T#A,0-UM>FJ<N
MM5Z?J"_H#:>DD&*+"W]!UFJ6MM;:J9F_?*.ZC-1=OCE8.1?)Q[J103.^38%C
MW#%TZY'4NF;/2J0CM=@M;678,U+%H]U;1,;<JH6TWBPHJE@A^$MW!E'HNB]<
MTNO1V]G0%3KZNZ^DMJ*@39[=?6V5V=8J[E]:L]J9C1@C4 +A.PHS7[G.SLXQ
MC&,8QC&,8QC-$U'4%*JN3@(@(/8O9L^4&_Y8QG*IJ&.U1$?4I#Z?..T!';T^
M?8':QD \\_KY _Y_'-YQDXQC/ 5__B*:/:=W.4H\O3]574M$V2^U5=TUJ[1C
M".Y6AP%GGW!8BQ6&7A*]+-Y4E7<QZ+UE*JL8!\]9?SHZK#3HMTU]%K>S6[M0
M382VF$>4+ &S-14O6,QWRDE*(4\8,59 U%5O %3P#XW<]M^F:6U33KK=0:LK
M[>N6775(M75AL7(E>U91HM!K-,.M"D7=/>F@G<R]Q1^'[H[<+66G/86^5*31
MDIV%EI"P5Y0*Q$3=;;- E8)U9F"KN*&Q(S+K^71J@+%MS>514"0K[%OL6RE_
M9W=C$W5]>R=LW59T_>NE22E!)@K^$9CQ/&X\$J1VT8YEU/;'IFSL>ZO+<UJ*
M]I4>T#[O*L%7Q(ML(6EXXJW@'6[O>5H#XD47SS3)S^);HW6FE)/.U&\1TIJ)
MI,TUCJ< :2TU>S#^L6$0=T1H=O%WY\5.8N=?86^PMD4CN&$(RHM@1GY&/=/*
MNE8<\_9;>JUQ.VNRZVXVE:G;M*BVE\.P>6UE^"%6C(D@-1MB1FK!;>%JU]N^
MEP75-M;;G3=Z:O5->/B:#U?7M\6FG;/<?BNU%-FZJ.Y)+IW6SS9M87[FM_Q$
M-*[;=&NFD'1=20U)?/--(YO19U.BUBP(R6H&DMMUGE8R71G;NR;P4GIK5:3.
M1=^92SAJHPN(Q];C1DUG@N4,=?9K;C [5-C5]U5=MCL3]XK,KK;D=%'F9Z[&
MB;5MB;Z[(&[H=U7"!>#EA[;=.V=I=".GO^_NVA,:=AIZ]UIN].V>J4G5;;:"
M--#6U+)NI0J4V>R$_$+]PGU;AXUVV*TP[#1C5X(N_36C=>KDNFG1'Z!I76^E
M-=0:H,LSC+J\DH>+CJJH^D+),/6A&$6>+<-2*NG#F/3=UK[/UC[P&WM+OUDW
M:53G84A-"YUK]C/!5=VKVK)%)9PX8A0&[;ZWM?#9.H4Z7U,3W:=+CKUXTW!I
MU;57<US19[;O*<]<NUZT4*ADRKWLTP_O#//YZ_&,8QC*<L:YB7TJ8"/%-$L>
M;T-HK/.?M%'[ QC]?K]#+2CAVI;1Z8D3'[#8QG8XQC&,".P!$>D'..,9X4D/
MX@VC"<?+2L'7M3;%&1^D\OK+'R"52+7FEGI[#3N[:FQIJX:X2->5<O;%7:,_
M&(3?HQK?EI.&4?.F;-RX=-/0+[.;W<B4KJ2=]R>BRFWB&5GV8:K>+X*T"K.M
MU[RI<\*X4%@ ?(O[9]+"5I*&_><^FTZJE!K>"NQJII;6_,P.T\"S7AJ/X8<3
M :DN]D5BR]CH?PZM..$!J3':<T.BZJ&,^I#F[O+3)5Z+;UVM(M;SJ5I\I W#
MD)US+UJQEL>E=GCUXV2BTS-)+H6'='1E@?,V5.H>S^UTW6;9V-C4^&X@LDJY
MK4F&KL"D>9A*R,MN3!U<]R<N.4*EK](]KM'K6ZFEIZG4#WZC;;;%(S$(*NYO
MZ1CM=MFI"_C].V$,WF.U^V3$5[T3VUG"SU>,8QC&,8RF[&N8M^!(!'8,.Q-L
M]#:*[P-ON](>;&58\#GZ?Y_]\<_^>,M&.':0HCTQ2*(]L,9;.<CU WP3_P"(
M8QE15OSP_P#[9(?Y-,8R[<8QC&,8QC&,8SQ#PB.%I/Z'ZG1FGS33^$FXZ;IE
M2L*%SE;FI&0]:<V#52/T^G974-E#U^QS-)H%,AI%O:G-ZE6 5V;6Z.KX2D&Y
MB73U7O=-Z//?U7V3L41YWM,P2 9ZB>HVS--9GI)+[-Z*9#71O$F.VG90.JCR
MG6_:.W2=^>DNE*J5U=6R[5-HSE!K]132M3=24;5U=/5DZ[!W*)X%3WQ\2)DS
MFKV_\1)NTG+PQL^DTW"Q-9=7L]9ER*6@$]2XJJUNS#7#Z?[\HU?1M\OJ/?M/
MKU7*3&5A69+,0?\ )LTV=*S%D=5B&VS[-%IP:6Y-WHNOXLR(\ZKUK+Q1L^'L
M4,$U=;8U[7>H3LIX\R DA5^>OMLJ5W$V.G5C/7;;]WISL<;\]>%_ ]R-M."[
M-=[=TMN&K/7-O$E[K4,:[#:\J<J'#9KA;C'4JP\$:GZ>5VVPS-/5FQ2((04=
M7K9?=6*-I1K1&VNOSFG%>G%JHYD1DY1Q<KO%U>.N[.CQ#6;0;2CY!C#[M^A4
M\!MB76+[-9.QTYKS1J1UM38W-%XUGM4F+!.Q!#7>SP;8=D)12U.7J^U4!LIJ
MV]FM71ALQ3]I7?B*0V=WJ.IT[JDMF-M&%CKL_?5MK;GKIMIJ26JK1PD;.0X1
M$JOP?](]4Z]P4-.YM.U2=X@YK2R!EXR7FJA%Z<:(ZDZ@1,'%-:U2)UH:S2$%
MI](:<,*C-MJJ^A)FTU^ D64>=R^BF^J>FH.I;NI7K&S,Q2#SVZ(Z3N^UOZNL
M]':MYMX*OLKM/:9LM)QI16;M5SOCKE#T;IO48^SNE7WBFU&W3HTG6VJFCTG>
MW9QFL-2JG8>.D^BFM5==Y5V(Q=$+/)>N=<(FIT72JL6*N<&[1"64DM='U2@*
M[I_*-6M6U"5B*L:>=W[1N<7TMBX^P3+-G-6.KMB2K* =S=WC9>@5B1F)NRQ2
M+N1TRU]NLZ]3WT"=/6U*[*%JZP>WAKK;LQMNTT8I*I[&HLX.FS54G)R*-UO6
MT^G:]X=#Z33Q.L/K1AI45=?=,H&K;O2ZGI\TM55I> \5(M7;G32UWK78D&ZE
M?A_'H]"IDC1= *G*R4VRUG=6:JT*T/&T>T/I"];U6GOJ\I&Z<\M,0UJHD=":
MB"_D8J(<06D#)"3@&=L9M&)3W'LZ+[%UV.HV1)MHB5MB*EF]]7QK+4/M<)2.
MP[ZW:KN*;C%:&)+9C/MD=33U7U.C:]*57JAOKZ>PRHIZ;0:VJ\#/1YK+9TYR
MWN]YR:/3%%(IL(BC-[TYX?EEML9>YJT:--JA#42:T+CY"74N$FO')P6J>I-1
MH\[>I-W(TN';1=/95RR/M4J5*"NZ2LU#A5I2;4JA%%3M<&U[.RB^O.6\;4V$
MWV5!! Q?4U;;$X($V*%[-6:ZETX4RV'"3%O+NV]'VRV-F>Y78Z6NM+3KTA'H
M=JC((]0WM;4KN5=]62SUEA=^H:E.YAL:4C2IU@3V_I6BLDX2270536073(LB
MLD<JB2J2A0.FJFH01*=-0A@,0Y1$IBB!@$0$!SRY!!((((/!!\B"/4$?(C/=
M@@@$$$$ @@\@@^8((\B"/,$>N9,C)QC&,8QC&:!J9_I)UV;%_P#7H8QG.H?T
MB/P4O_ZQE5]/R_M7/S9I7\175"\1M.&,X.\(2<MHZ=HP[ ^I%C%A;Y+4-#20
M)&!H,BKI4W">G-%7.ILNKKJW52:M*4PTZLBQ7SM5*=3J/K]CV:U-=[ANIN4C
M[T7;W:?,4UCN=E-A1MGPTWAJ(-#@EKMM2': 9FWSO5]MNH;2:O9T27B[/N0F
MGOURNR^Z.F^)'3<].7QJ]*;?J>K@A4U$T;_&S"PUM8>?Q1=1S5:>NL+P/K^_
MKU:>+JR2;J2GV,\YJTM0[W<:=;86%_D%=:38G4I[9.[,A4;/JK$23B0:$G9%
MDVA)+,/9/6%9PIUK66E5'85633%4V->%HTI[R K<6)@_!6SJ%)FC&BZ[?_D#
M=]WMMS]F=QXP<^(&I9+'7KI[FUK;,I>YL:)_VJC;3E7UI49U%J(L:;)8>%9;
MG[^;4B^"/I[=31<_J]7G!4+ G-/I"5B-2-$-,"HQ$PPT]E*I.#?Z_P (R-F9
MHZ5E04C?Y>U#H]P1C+- 66)A\4^CQ5)]_6=F'=/2H.9F:JCZV_M\NC;*6G[M
M7I;(G,3W>)K7B7E23OL6]HMEWJ9^S>EM&=NIQ;BXJ[TEO])T.)UGI5U[>^0Z
MVE:D74S,-W4VA.\MB<>KTRX;$4PB*@XA."= TY(U^TOA'M>T_ DM):;:9W2D
M5R3U U5G8FJ:?HRU7KU!<6:"KX#9H&FL[/')2#AG(HECE&!;[?0F9[!^L4N?
M=MJBTV?@7:VH;%4UM.;VV3.U-A94K^ZK=I-P"A[N[,6A[5SG+6:7LW+5'OG3
MXO#2XI30Z?M:D*;G4;2U](5UX:1O&/\ W$=5=B8=D=?#*9!TKX5X6S3FR3\7
MP$82EO8&ITJ[+U-:,(T3D]7;+>8J&=1T4DCI>Q4E6+&F:HUR]QE\;,CR4FM9
M[36G$3%2$/-.E;;G1S'9E-_:"FPM+7@*ABQ72EKO0,Q.VP5FOJ5UVURW8GA1
MJ*.M)@5Z=[1#9T;W3V0EJ-+7U-HZQF%%.I;&Y.3),#IZ&B3U>H0W4W%0TH=C
M8@9S>56.+4_ACS#"#C&-BX#%;M5_AU;A):FZ9OY>*L2VETM'0\;JH3>DRUTY
MF(]TI;UXB:GXV?9,^)8'E1-9(-&PNVZ" 3J=$0T9I=?K'6<175VD1Y>](SMJ
M? C;2,/ %)S>;-S,7\*AD"3D=0]I[3C-;^R4-C<FVU3?T'K.YT*3G/J -*IH
MV1CLM.MIV1.+/K>/$68 #90X:%IA6TQ(-."%%1E6KFIL-IU"SPRHQ\2R<Q6E
MKBS(W>4Z"H+A_ 4Z@PZK!E,S32)>(P52"6<0[A^X8*0 8OV'%RB-UIWM75?9
MI,)W.RON"1@H;8"UOLN&::%U-+=@<*&%#G_ZIV)+1T]F4GKPWY:4K^)V25I]
M/-QMOV:3/'5TIE4M59,(ZXH9-1E,!:,=PU[_ &*Y2%3JNCT9+1[6U:.0,)?3
MSUZ0H6H45=WA:UJ99M/+"?2XK.Q1&E=V4:Q*KENJ+::BW[*57<0JRBC!+4;H
M6M*"VMNLC&.[2FN)ZYV-9H#Q=26S(;9:3[D 7 (Y1U= * !FZ">U>[;:?6U^
MEI1%V.EQEN^-N#2W)[C>!OWT[GIP6TNG;169=3VVG1*$Q)*"IXK^)1J1(0E/
MGR\&"1D"ST26PVZJ0-ML$C?M+X*'CHF<GW-PK:FF[<-Z6NKN+#<-%:^Q>*/]
M2H&JNTBFAY6019-MMO9C56EY?M9%\-_"A:D9+K[='=YS$:#:/P1J)PWJ,O;K
M4L#\:(2>=/VZWGEJV_Z?HXM/QMK7ELV?<Z?&23M9MF!T!S39UVOM=*BC%M^.
MLX!E1PB_I]IY9W5VH%&N;Z)4@7MMI]9L[R"54465A74]"LI5Q$JK+-V:JJD<
MJ[.S.HJT:J',B)CMT#"*1?*[,A#9V(*XHL;UDM   XG1D#@ L & [N Q Y]3
MZY[_ $MAMO3U-IYF+;.M#8:1))DUI)0S)*J24+%22JD\<E1Z#1;-YX*?R2P[
M\^S!FSELQO40^ G]QL8SL<8SS!PDM=[QHDC6%Z5H_,ZOFDX?4NPS<; R)F4J
MPC-.J8XM8-HQL$;(!)R]D=)(0,2Q3V.E'SI+H5I('XR!>MTOI\-\V%]V>EV/
MJSF]%[D9]JXCRY[E[4D":.Q^$*#R5]<X'7>L;?21KG4Z97J9I+?M6<7[*)/2
MU6V.V:^&_B5NP$9(/B+L.U7/(SQC/_Q%]8X^:7@ZKP8XO4I$3QT1 W:GZFS1
MM-KQ9)]34'<"5/L[K3#EI"&7/0GD5(RBT8BVCY="? RZC>'C363MS]F=)D%*
M]5?5/#/2%M2?O6O.8UO$-Y+M\*X&P'5>[ED,^!R[^%Y:_MOU2=6CK] GO#F<
MI;>MU"IT-N]CN"(U=ANG\O(G3:=*-,*E18=Q62&^@J<+G3U]7[I-L^ O4RHP
M[P'.B<%8:FSA['JC5B!6KDK/QU?=Z8B^K[YC3M8+)J+,0#9*5?0#.1GUI=1L
MZE)Y1OL?L;:6D$/7[%J*1OTG9GGJUYK 3:J[?;56MI2UIT)1:,LP@(28.H?:
M73>.U9?9'7 DW=TJ-]99;'4-;C7VC9(MH%X.FMU.^[6*BCQ5[FO:U+%;]3X7
MZP7JW0FC&A%=E6;FPZ&QT+J(FM8(2IZFHZG:DTNNZIS49;*]IK*P<VCI'<N$
M%7I:3%E-3*\M(N]4GDJ6LNXXKB?Y_P"Q1[O&F_U"J,);[/K<2I;5.KK7KJ3:
M-=M*3.Y'IU47NG,(HU%0U#D3ZX]IB-S9CTOI$:(U^DI+=!M+6WQU#?U(=0K/
M8CHTC8=-VNM1K3LK4T=NHM4:[3#7TXO\1C4Q1M$/&/!AD)MP\@Z1.R]+AK=.
M+ZBP,=.1NALY-2;JNKZ=HLE&4E&ZK6R/TR3-,-U;M9=+Y*)5/$"^L2M"S'V9
MU07#=5$PM+S2[PF-:CH_4)S1:C:+=R/IQ;:XF? EMJX#]LO>=7_KC?*R9.@/
M9GEJ6KJ2V;'>C.L^D5K1HG1"%73J6S/0!JIV[]/>1,B]_<_T>TDNZ^INE6F6
MI#J'5KKG4'3ZF7=Q7USN%%X)>UUR-GEH=91VSCG2BL8H_,R4.YCV+@QT!,LS
M;*"9$GF=S7&IN;6J'%1K;-]<4' %!&K3#@*S !^WN'#,//R8CS/N>F[9W^G:
M&\TC!MW2U=MH,6+1.S"=C)BR38F9?L)9$8D>:*?(6#FMF[C&,I2R^>&3Y&C_
M /J'N,JW_$_KYY;$=Y@OQ1?RQELYR74#?!/_ (AC&5%6_/#V;/\ X6_$!_N9
MJ \VSW.GM]/& >?3+MQC&,8QC&,8QC&,8QC&,8QC&,9A3;H(G<*(H(I*.UBN
M'2B:9$SN5RH(-2KN#%*!EEBM6S9L5103'!!N@B!N323*622> 22 . ">>!R3
MP/H.23P/F2?4G(  )( !8\L0 "QX"\GZGM55Y/GP /0#,V1DXQC&,8QC&,8Q
MC-"U**)ZHZ*'3Z-B_P#KV_Y8QG.I%$K5$!]2E_;T1QE5''/\/Z#\OL<WK&6Q
MC&,8QC&,8QC&,8QC&,8QC&4Q92&-?R& -H!$L=O^RSW\C?9[H8Q^CEK1O40^
M G]QL8SL<8QC&,8QC&,8QC&,8QC&,8RE++YX9/D9A_U#W&0?0_8_TRV([S!?
MBB_EC)Q)C_P1#9TBG-]FSI>X.P>GZ&,9YVDV\@ZLKPD:\=,G*<:X4*LR76:K
M  .&B9B\L@8B@%,"@ 8 '8.P-NWT&0#Y _@/O_[_ %Q],TE]&:@@H826RVIE
MVB&PE@F  !$!'F KOFYNEL#8&,GG^OTX_P ?^LZ_=NH?MPN'UBFOW.,MW#Z?
MV_ZXW;J'[<+A]8IK]SC'</I_;_KC=NH?MPN'UBFOW.,=P^G]O^N-VZA^W"X?
M6*:_<XQW#Z?V_P"N-VZA^W"X?6*:_<XQW#Z?V_ZXW;J'[<+A]8IK]SC'</I_
M;_KC=NH?MPN'UBFOW.,=P^G]O^N-VZA^W"X?6*:_<XQW#Z?V_P"N-VZA^W"X
M?6*:_<XQW#Z?V_ZXW;J'[<+A]8IK]SC'</I_;_KC=NH?MPN'UBFOW.,=P^G]
MO^N-VZA^W"X?6*:_<XQW#Z?V_P"N-VZA^W"X?6*:_<XQW#Z?V_ZXW;J'[<+A
M]8IK]SC'</I_;_KC=NH?MPN'UBFOW.,=P^G]O^N?!C-1!Z5PN']OYAFQ]WUV
M79LV;1'GYO<$<8+#Z#^/'^ /U_'G@O!WMTF*+NT6I=$0(<4G,[+K)&,00.0P
MD4=&*)B& IBB(;0, "&P0 <9'(/]/+\/K^/U]/X9Q3A;Z@)01M-L1*78.Q*>
MF"E](!V$=!LV[ V;/OVXQR/F/P^0\^/L?D/SY(XS-N[40>G<+@/_ .13?[G&
M3W#Z?V_ZXW;J'[<+A]8IK]SC'</I_;_KC=NH?MPN'UBFOW.,=P^G]O\ KC=N
MH?MPN'UBFOW.,=P^G]O^N-VZA^W"X?6*:_<XQW#Z?V_ZXW;J'[<+A]8IK]SC
M'</I_;_KC=NH?MPN'UBFOW.,=P^G]O\ KC=NH?MPN'UBFOW.,=P^G]O^N-VZ
MA^W"X?6*:_<XQW#Z?V_ZY]+&:B"/^K[B(" [-E@F@YP#;LVB] !'9Z/-TPYL
M9!//R'Y>?\N!_+_'&%2NW554'1['95'7%*3ESS,J9QQ"B82E%8SD50(43&$I
M=O% 1$2ASCC'\!Z?^?\ S^AP!D+&:AD >+;[@0#" @ 6":+S<^P0$'8\P[>8
M.EZ(#C'(^GE]/+^I!S[NW4/VX7#ZQ37[G&3W#Z?V_P"N-VZA^W"X?6*:_<XQ
MW#Z?V_ZXW;J'[<+A]8IK]SC'</I_;_KC=NH?MPN'UBFOW.,=P^G]O^N-VZA^
MW"X?6*:_<XQW#Z?V_P"N-VZA^W"X?6*:_<XQW#Z?V_ZXW;J'[<+A]8IK]SC'
M</I_;_KC=NH?MPN'UBFOW.,=P^G]O^N3V,7J"*A!/;+:<O& -A[!," CMVB
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M+\ =K&0/,#[#+JQDXQC&,8QC&,8QC&,8QC([O^D==CK=[-C'KF1'J27Q9/\
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M7V]?/D>OS&5[O+GC^?\ Z'/T''/)_/+;H%LE7,7%/Y>,6A!DD^5<PR[LKT[
MBBIRMU07*DAL,JW!%T=(R""J951;N$4W"1@)4C@D>O&2#R.?3^//\\NW(R<8
MQC&,8QD-KU>1[,)^'L<8R9C&,8QC&:=:I-5 J;! XD,L055SE'8;DA$2$3 0
MYP XE.)]@@(E*!?,F, L9YLDIS4=%Q(BPBXD[-I)/&R!UH:;6,NQ+,5E!JY(
M+>3(\7,G$2<ZY<BUB5DG#J%$&)E$#E,K<!?+S]>.?,>7D?P_#Z_/\Z\MY\#S
M!/'/S\_O]/S^7S&6#396T(("_G4&#)Z9VJ*+1@+@"#&\5/DDGY%E5P!V)^7X
M_(JJ)<GR"I016$Z*53QSY>GZ_ 9(Y^?E^'T_\Y?Z*I%T4ER<Y%DR*D]/BJ%
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M .(1>,A?0?8?TRZL9.,8QC&,8QC&,8QC&,8R.[_I'78ZW>S8QF1'J27Q9/\
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MD(S1]"W4TH]'=59&THF_$C1Q)DLR+$M19\)KMH[9)^"JL'J-59*RV9NZ<PD
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M1!5RZ=.54T&S9L@F95=PX75,1)%!%(AU%55#%333*8YS%*41"0"Q"J"6)
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M_% Q!,0Q#&T&5D/:PX/ /'(/DP##S!(]"/MZ'SSL(ZT4,AY!+ '@CS5BK>1
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MKHU *ZQ/)* TE2!\FT7KL412UK"LY6&H]HZ <> Y'=K@J=INVB:]=*@IL*)
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MO_D-_P#B$7C(7T'V'],NK&3C&,8QC&,8QC&,8QC&,^&*4Q3%, &*8!*8HAM
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4'&$/]@[0>C_<1Z>WIXQDC&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g108483g48d06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g48d06.jpg
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M4U24EK/4U?$T-39#8G)S='6T)3=66':"DI6BH[*UM\+2_]H # ,!  (1 Q$
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MO?VIW_HU_P#TFM>[_P!R77_5WO\ -JJSO5S_ )N&C/\ [5X1_P"7X/(_1/\
M>?3/^HVW^:37/=#_ / [I?\ ["TS_NC57XY*5U-.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*50>PMF85JNGA7V=7!::KL;B+00"@J+N\D2[B;'F2XL$%?C];:V!"FCP)9&N
M;%^)$"K7$:]PVNU;N\MK%M+MRX6T+<2T@AMUTJ<4%*2D(:0XLDA"C^&,<R1,
M5K&MZ9H-LU=ZK<*MF'KENT:4BVNKI;ERZAQQMI#-FQ</*4I#+B@0WM&T@D$@
M&U?\VNB/]9<F_P!E6VO]QN:7W[IG]]?_ ,0O_P#1:@?XP.EO\,O_ /)_J'_5
M5/YM=$?ZRY-_LJVU_N-Q]^Z9_?7_ /$+_P#T6G\8'2W^&7_^3_4/^JJ?S:Z(
M_P!9<F_V5;:_W&X^_=,_OK_^(7_^BT_C Z6_PR__ ,G^H?\ 552ZW[7:-DU-
MI&!D>3$-(KIH L35FV6J\I8Q1C9[.P=K4]GN1/+G(U//E51/*\L<US35-N)#
MKY)0L ?8;_)*2 /]S>M8;GKWI==N^A%W?E2V74I'W!U")4I"@!)TH 22!D@>
MM6TT'V0U'ANDM3XGDEOE%9D&.:_Q6ENJYVL=HR70K.NIXD69%=(A89)B'4)Q
MO&I8T@P'^OL,KV*CET]*U>QM]-L&'EOH=9M&&W$?8KY6U:&TI4F4VRDF"")2
M2/0FH;I7K/I_3NFM!L+U^_9N[/2;"VN6?N+7G/*?9MVT.(WM:8MM>U:2-R%J
M08E*B,U=S^;71'^LN3?[*MM?[C<W_OW3/[Z__B%__HM3_P#&!TM_AE__ )/]
M0_ZJI_-KHC_67)O]E6VO]QN/OW3/[Z__ (A?_P"BT_C Z6_PR_\ \G^H?]54
M_FUT1_K+DW^RK;7^XW'W[IG]]?\ \0O_ /1:?Q@=+?X9?_Y/]0_ZJJX>NMQ:
M[VN2]#@EY)MCXR^M9>QIN/9-CLJO=;CE&K?DC9-34\@K98H4EXWQQE8C1>7N
M9[C]]JTU"TOBZ+9Q2RR4!U*F7F5(\P**)2\VV3N"21 .!GD3,:/U'H^OFZ3I
M5TX^NQ+(ND.V5]9.,FX2XIB6[ZVMEJ#B6G""A*A"<D2)N;S=J;IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4K&[L3_ ,OZ[_\ Y(X+_P"7,WY#ZO\ BTG_ +8M?\U<UQ?6/]NZ._\ 332O
M^Y:I62/)BNTIQ2G%*<4IQ2G%*<4IQ2L;];_\XSLO_P!VZ._\L9-R(L_]]]8_
MYFF_YEZN,T;_ (9=:_\ 0=+_ /<KZLD.2]=G3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI4#-K*VR6$ZQK
MX-@ZMG!LZYTV)'E+ LH["CCV$)3C(L6< 9SC#+!\<@3#%:PC6D>BVJ0A>W>A
M*]B@M&Y(5L6 0%ID':H D!0@@$@')K$ZPR\6B\RT\674OLEUM#A:>0%)0\UO
M!\MU*5J"7$0M(4H @$S'<NK+3BE.*4XI3BE.*4XI3BE2B)04L"VN+Z%5PHMS
MD#*T=W9@ P<VU93A-'JF3CM1'R&UX)!Q14(J_",I&L\(Y>8TM-H<<=2A*7'0
M@.+ A2PV"$;CWV D)G@$UKMVELU<7-VTPTW<W893=/I0 Z^+9*D,!U8RL,I6
MM+<_A"B!S4WYDK8IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H*RBR)M=/AQ+&542I<*5%C6T$4(TVK
MD' 00;&&&SB3ZTLJ$1[9,<5A!FPB%$QDN)) I O4K4M].["Y6K^W'U1]8+L'
M:&R*[$-M=8#1,CVYG5OGV73['*^JF 9;DUC+L[)XX<!+;(KBPGCH\;K*'%**
M.6/2XQC])05U;50U7$SMXX[".Y_>3D]S6W;BK:<4IQ2G%*US_46U?U(L=4W6
MY^V-9G&5U&!8Q/QC <)QC9>T<=EY'GV7RAP\4Q[6V!X%E='$R;>&:9(^GQ?
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M-5;0O,5K=8[8LL3'7V4G(*_6V7Y3,JH=99S9@!1*Z:8"D'F/ZOF.1]:IWO\
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M?W+_ '&Z-(BDV3ASX4N&X?E#Q987-."4-R@,)XWB\M?YYV.BW;%\?M;!E#S
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M.6==5):>+-%Q^_[\U=B02<?#(S.(![?/UJT6N>H';_*-E[9V/FVK-WT3\O\
MI@]@>LCIO8OM)KS=&:9+V#SO(-;W$=*6JPW+\AP;7NOLD+47!Z*5C\VCK2K"
ME%R;#\ >REA6BJR!&1@@X!B(]P#/K/T-9;Q>HVWI-A]*:-(HA4E=UIZX;8U9
MNRUK;['VS<"NLTZO8?J^L#2L#8H2^5N74\F..1C:6$(#H$:P,4<)025521\7
MN1'YDUC;T9Z,[ U._J1JC?76_L1;V74F3!6CWC/[QR\TZL!R+ ==Y=K_ !?9
MVK=!RMR3<MJYV54ES)JPX-<:5Q"GPF+F%S"CV<RKK!BL4?M_?\ZJHR201\4X
MB")Y!,1]9SS@XK.#ZC"=R<CPW -5=5]79/EF'[,N+VL['[ UWLO6.O-M8-JV
M##@?)B^II&T,FQ>IK\SVH^?.Q]NQ8\NQF:RHZ^XN:FFDY5.QF?6*HG;DGZ#,
M3[QZ#,=S$XFK@ZJL-G8#I7KYANO^CK-7T>/[#Q'4]CI^WV_JD":)T744]E"_
MQ=J;;%)V<T.;OH&P:B!&P2KN(N8W3KB3/DV4<L26^6JF).?>8.3^_>L<?JOV
M>;TB_3HN=<875[%S:I^I)JRRH<&M\C!B$7*9$'KYV=DR*<&33*^S@4MM*@BE
M-H9MG%;4CO$KDM9E=7.E6,55R>%YCX?_ -DUCUEG4;M7O"P[#[ZR#30-4Y=O
MGN?],S.J+1]ML/7N0Y3BFF.E^V-<W.99YG64XKD-GKPV87M0+,KD.+XID^22
M!8[CN,TT:PM;Z1^7B4D"!,PE8F#$J2<#OS D@?EFJ:[+=9._F\-GYI39/ANU
M\ZJ*[O+U\VSJG,JWLG@&#]8\=ZK:RWAIS/@8W_@/7Y!5Y;F6Y<>J\8R.;D3]
MBX9(@S+4<G),/V++GPL7PJ:H"!F?YJA$9D@B2>(SB#QVR2<F,=TKV*QOOG#S
M[2>G-E]>M2Y1M[864]K;:YWIK?..M/8K$Y."9!1XMG. Z3C9'>[%U_V#R7*X
M.LKK(\@KL/U14!K*7(X>67&RI<B+(G*2-N3)@;>9&>"2(CDQGV(S5OM0=*=]
M8IUE^D9K:^P>JBY9U1[5?XJ;NK6Y)BDH.*8FNJNUE ZXA38UH:#D4IV3;.PE
MBP\</9V*FLR3U!\-=82(JJ$B50>0!\\C]E>N:],>P5ODV]["LPV 2#FWUE^F
M/;_&W)E.+@^^T3J.AZCQ-B9@\1+8;HD^KF:LSEK<;F-!DUNZH86MJYK;*L?,
M4D?#[)4#\R5$?K%60W%U8[Q T1W;Z:Z^ZVT>?X_OWMUL3LEA?8B9N77..8H?
M!-H[SQW?=ABMMB%K8?XC/VSBEA&GX'5QIF/UV S*JOK+U-@1EABHIJJ@B0KB
M !&>0(GTSS^C)S6S?L!H+86+8YV"WAUJR'>>9]E\DUIG-9J?6V4=EMB-T;!V
M'DF/_D6-VT76&8YNS4>-P,;LW1,C>L2FA$ R%8?E*,LYS$(J@,P#$3G F/F!
M)_.L#HWTOMU]:(?0K-=$]C-W]@,@Z7["PO'HFG]D?RS8MA3M&;*K0ZQ[)LQ2
MZQ;2FKLTF78\4M29_5 V'M#*2WEIB49]E^?YN6IN!*NW [@0E.[O\7(R.Y^6
M .>PK&;8'TZMY98#N-@^/]#=:56^MV]R=S[BT7]1BPSO2&/97I;%\YV;"R?"
M,_JLDQ2;:=E8MWA%2&7.@X765L&-:RI#L>LI$*HL+(O% H8R8  VY^+V/:"8
M]3&>:V'0L$[:=/>S?:'.M/=>7]LM*=MLJP;<+XN*[6UEJW8>I=ST&LL4U1G$
M?)*W:EMC&/9+@&<UN"XIE%9<XM>R;_&K-+^H+A]C#?6S%5;@@ F")'K(DG\Y
M)GVBI1*ZH=L>R_;*7V(V_L?8/3,.LNN.%:=U+5=>,IZ_;:'=76T[%^Q>S!Y]
MIO'0^RPBK(=QCVH=>P;./@. W60DU_<6 4-C%C"^_4! $0#)DS/; X(]_P \
M=ZM;U]^FGV#QS7VF]77O8C8>I(_0G=W8JLZH9C!Q[16T![0TOLL$-^JMAYCB
MV08K9XWCVQ=8X3EF>:7JFQL5Q9:>L)D4J@I8%-?5I%54J3), R 3!(@]Q\C@
MGG-7Z^F_U*[0]>.K53K3;6]LFILMC[:[%92W'XV):4MXM11YYO[9&:44H%O1
MX]/!-?F5=>!V-.CR)IY-!:9G.Q9@:V#10JBO512@3@#@#OV 'KVX]^>]7MVM
M]0G3FE=C_P $;#P#L11XA%S[#M7WO8&1HW,P=>,:SO/I]-3XI46^RYD:((M;
M97^1T.-ES.EJK? JO(K0--<93 G@FABJI&)D<$Q.8'M_1S&8BH+L5]0G!>L4
MO9)MBZ![<S\)U12R,ES#;6':(M,AU-%QV!CT?);>]BYNEO#@2:ND@&,"WE?&
M-D.P@3X;D<2,JN4 )B(S@9'])J"V;]2C1>M#_:-PCL%L292:>Q'?>U86J]-9
M#FDO0^JLYK["VQO(=R C%C/QJRGUE+D-DS"JM+_//RS';BT;C#ZT 9<A50DG
MN!. 28GY5G'AN88QL+$,5S[";N#DN&YQC='E^)9'5E4U;?XSDM9%N:&ZKS*U
MJE@VE7-BSHA%:U7@.-RM15\(JVN/C\7!\34^GN5SG_.DSM,&()HWD860</79
M!M*@U]W-:]C7-&-%>0J,1OA$<J1.IEN6$.)W;@Z0/9):"OE^(?[)JH$F ))P
M,QFN+X\ OQ-FSQED2E<L)@/D:J(\C3.D-$5'.6*02^'(I?<JJYXU5I7?MA#=
M-(<++92F(4$]P#R?_:.?J2 !4@FT5Y25J1&XJ R#,$X,$QQ(!D\9-2]@GQ,>
M,:;%D1P_FH!/"(I&?="1$3Y);3_L]T5KW!*U'(UOZN8Y5:_E7 %NGR5 NH;)
MG:?A)!@ PF8)B <YXXK#Y8W)2YA"B >^)YQ/ZL^E7JRVLUY.Q6HM*6GEU\S\
MO:GB(I#?F) N4)9R*Q!_,H'^Y2,*X#2*UG^<Q4<O.V+VIV]TI%P9;WDA3A2(
MSB,F"1$0,$C S'67MG9G3D*94%JVPD ?%.V<X&/=6)&!-4GB\O\ A\X7Q(D#
MYE5L"[!;25/ O*:2'R>!*:XCEBI-4C/90M_R"4P9&%8<+>2EZQ]Z,02K>VLN
M6KS>U*K9_P#FN@*_%MCYJ28CXL9>A^K=1Z'UUK4&K6UU"QNV'-.U[2-21YUA
MJFC/CR[K3GDMRYMN4++@6!-N^PQ<MP^VD*ARZ^8R)9Y5AQULL6BMDF/ (UR7
M&.36D8B5MI#9\A10BO>-(MLC'U]@)6C>X4I' ;CM];\AUK3=93Y-^2DH=4DA
MB\28*7FG8V!;H^(M$[P2!&1'4=5^&=@_8/=8^';UUK/1UT%N/V#BVE]4=).-
M N?9NH=.E#;]@X/@MM4M$OI2Q#REH4G-M@!LX 9L24)?D,57%:41ON/#D:<;
MXWKX1@PHUIU$]R(X;O+$]E1R] AUIU(4VD!,"%@B#[$F!)!,XG';->.O-;'D
MF#N0"E0(@I.)Q$B2.8@?6IP&89Q!R9;10Y,LT@1D$UJ^2*)K_G&%KO!"'<UP
MOE>/XQL]FHXGL[Q8HK)5Y8*@E,DR('Q'DDP(GC)CY550"TPEUF0(@O- CUG<
MH&8]1V^@_3)*1)K2K6>3L<5J"*83WJBL>[[@,5WAGD8O*#<]7?(]?+'/<[U2
MR0M$!Q.1)^( 2.022",#O]?6C++B0F$J6#)_D_Y7' _M>Z<C&/2I* )  ES(
M_P <R.3]A&N&D=8ZF"]XC1T>]5<KWN<QJ.3^IZ*JHU53UN21&TR((DF5),8(
M*XV]AW_,<Y'F5*:5\)4-I*@C^46W!Y<0C<IKYK"8^=7>Q3%QPH%3F6?QVPZ0
MB@;6Q/0SKS*I#"O,-L2$I$4,0(A*R99%"D80O0 WDD%1J<MJ>J*?<NM'T8AV
M^/\ ;;@*2&K%L@H4/-D(7YH)@(4H@HR)@'UOH_PYM="TJVZ\\2DKTKI%+B#I
M^BO)VZOUN\0MQ&E:<RD+N;*R==:9%[JKC;"6V'0VRZ5/$#MM_#2[<CYDW<&&
M%B@KY=)C:7==" C!,93RLBK8"HV(QK5B,CD%% -A/)'B^-SU]D55@O#[16]*
MZMU5QK>X'M#;3<O*)5ONA=VZUDJ))45A4@@0 D@8@GPC4=>UWJCQ&ZIU[6%6
MZ&+UBT9TG3[1E;%KHNEZ:U;6%AI-NA8!4S:6C++#;I)6\&2ZX=ZR3UB<]LJ5
MIQ2G%*<4IQ2G%*<4IQ2I'<XQC>1FHI&0X]1WQ\7O 9/C)[FI@6AL=R2+!L*R
M-D-$2='.^HO(];;6E>"VKW1YXH-E81!R&@F21D4J><4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4K0+W5[T]1=[=CR=&-G=F-':1TIH+8VL=A]L[S:NR\3P>]
MVAF. 9'1[0UUUOUI2Y#9P+2;3"RRBQ7+-V[#"$536U-;#UICDNQR'(,GDX<_
M?]_W]JO"51N )D$" 2(R"21QWCU/.!G*KOJ;^8W='5_Z>=2OWV.[4R%G93M0
M,/\ 5!&ZL=?<BI+F%B%NUOHX<+>N[RZ^U\K6':MAB-;L6,K"!&5.*H, J],"
M?4SGZ"2/0P?8XY7?9#2/3GN+]5H?9[-:'79=YXWU^VOHJJS"0.!/WKAM!UFJ
M=/W6#:@@R40^QLPJ]F8=?U<C L5%:9*V7EU4=M0\-NT[U5@D)([8)G@R2"?0
M9YXP:V#_ $W=9YKIOH!TSU;LBOF4V>X+UKT]CV745BUS+#'KZ%A%.VPQN>-_
MZBFXZ=SJ26)%5@I$ @QN<-K555%$%2B."HD?(FN;?\6Q!^\B="E0)7D#_-.H
MB@>-I0O>SKJB(/Y7(-'E]48PBM>1KD1HD]B?K :X\EG[*H@&?/Y, 1Y63@D@
M2)$@>O8C/:M^8LYB(Q$S,^_(C'K]*XZ(-E*K:9:\\))"&^X"9;,,972/1Q'1
MR1QR%:]ZQR*UI%097F<-?9_C]4Y!3;;URFX)@8(+:C!,!)$C@X)F8 /(&*FI
MVM!DB8SN5WD[ACTSW@GO5 W4$[OLR3Y$J7':YYI#('R-8 35&ST.$K6A1/?Q
M[."I&J)4:U6)R?M+EM;1"$!*QC<5 [I]@)X(Y5])J,6GS72V3'EB9 F2.<=L
MSG\\37NPTJ6.&@HQ4)7EC%:R1-62R0]?4(!1$'ZB"!PT:BCD^/F4;E4C7JC.
M8[E ,E2T@*"LA$<Q,F22<?S>#QS6U9K4I"@-Q""(!42!VQP!\HCT,8K[8B4]
MVRR+.(2P%':P0_Z"J0C7(C&/*OAI4*C6.<1C%&YKWL54<Q$Y9:*AM;:0(!*M
MV8)(X /$3W)Q&(K(X&]V521GL(]1 F!\HY/I508983:VU/?0Y+J^P2(TT:/
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M0  223  &223@ #DU<A"W%H;;0IQQQ24(0A)4M:U$)2A"4@J4I2B E(!))
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M]"T=K5NI4A()).>XQ,9/;M'YU)".,=AHSH\8GRUKR $I'-A-"]K3(^&^0C9
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MDH+8W G(W0__ #DNZO\ ]8:+_P#Z$PWDUI/^_74__6=*_P#M%K7EGB)_XK/
M;_L3Q"__ "-KE8:8EN;96%/KM3:S@7K;':G:[ZB^1W.0XQB-!F^1UE-K'L3<
MM6JHJ+*<HQ3'DG75EG%?)E65C+LUATE);BB4II4P=G4\W;ZE>VI1I]BAW??]
M0=9/./,6[-T^VW8ZPY\#3+[]NSN<7=(4IQ:G-K;3@2T5*"V_==;Z%Z5UX776
M75ESIYM>C_!O^"[I=CIFK:UJ6@:7=W_5OA?8$7FH:AH^D:SJ9M["TZ>NFF[6
MU9M _?ZA8K>OVV65VE[>VHVAVVS?*=!:JLI^+:.S?-].]@\VV+-N-?Q<KLPR
M-4;2UEA&%W./X\'.9-11&S.ES.)E%A26-_DL>G@7,JG^4EK"B6$:4:ONH;I_
M2+!:V-+NKK3=8NKU3MFE]P*T^_L;6V<99%TIMDW+=TE];2WGTMH<4WN+B4K'
M 7O2/@OH&D>)'6%K;:QX@]/]/]<>&6@=+L674KVC6CC?6?1_5O4&O6&IZFOI
MYJ^U%O0=0T%[1[:_M=-TEV^N;!J^V)L[AZV>LG;=R^P68Z^UJ;#'+2[$R'JU
M/VNROP#2.8;E;F>YOXDM,.QS#)L&G?8-UE@N26N.6TF!=Y1(B /\\MBY;"#B
M-M^91;G4NKW-G8JM9;O'M!5J 1::7<:E]IU+SEVS-LM#97]AM7W&7%(=?4D&
M5#[0D6SGF=_9>!?AIH74W5+>O 7_ $QIGB_;='*N>I?$#0^A%:%T)]U6>N:I
MKMO<7R;4]6=1:59:I9-7-AI#3SC9;94-$?<UNR%K=*&/>KNQF^*K,MNNL*"D
MZ8:9R+(<#9BP 5$B[R$79"BM75#PY!(@45BW)\=?=6=Y6UYSWM:M/C,E&P:"
MOF/WP-5^^-7;N=1WLM=-::\]:"W ;4Z\G6VG"V0\I#*_/9+KCJ$*+R/*85\+
M*%GCWU>'@\+O#F]T+HD6NI:AX[]>:9IG4:M7<<OFM/TQ?A7J-FF]2YIC=QJ-
MJ=)U1.GVFGW5RVWIUV+[5F9N-2N6$^'3O-MQX;"Z6:WS;+<3RW!]R=/5RW'Z
MFGPPV-6&O9FJL;T>"GA#NR9!;FRF-=8UL7X;\]C$A%_B&G2RJ!U=7.6DC4Z<
MNM2MD=,V5U<6]Q:ZETY]H:;:MBPNS78,:6&TATO.%]+K-Y#I6E!\YO>V$-K\
MI.7QQT#H;7+CQYZIT#1M9T7J#H;QP^Y=2O;[76]5MNIF.L=5\07;ZX5IZ=-L
MD:.[8:KTOOTUNU?N$?=E\;6]5=WEN-0>HKZ@63DS[8U1J>@=LYU]HS6UAV+Q
MF1K35>WMH"!V,?9O@=<*S*G:FP[+$QZL8S&]CV%B/)WUT>=$L*N3%0[(YWCU
M>KGS=WK>GM&]\W2[)>LL*LK#4;\#6BLHT5M_[OM[CR4 ,WJW _L"DK;4D$ D
M3_\ !JTA/3G3%[UEJ2>DAIWB%U5;>%VKM=5]9=$=(+<\+A:)N?%.[T8=::YH
MWWI=J.J]+6MJK24W3EN]:WC3Q;4XVE5,[6F1NV&W]#9GA.D]7[TB9YT;SW/:
M#$-MY;(Q&KQ*SN\[U<T=K M8N#YK+C9ECT^>_'#LB1\<L8BEL_CR&M-%49<&
MH*3U!J.DW5KI=CJJ;OI:[NV;?4+@VZ+=;MU8#S$.IM;I2;EE2RR0E+"TRY#R
M"F#*]&L.^#71'B-H.O\ 7W5WAX_TY_"#Z<Z<U+6^BM$;UJ[UJTT_IWJ\JL[F
MS>ZAT!AW0M2M[=.J-EYW5+5\)M-VEW;;N]'[T0+$>R>2]6-8;E-9[2UUBW2P
M>2UF*;6#&FU^Q]SXAL(.H]EY3F5"MG=4.<V^#LQR,RG=8S\G@PPYQ)R.-(E2
MY\>VY72?L^M/Z#8ZD7+ZSM^F0^BWOPE:+W4[>\&G7UQ<M>8ZU=.6OD#RMZGT
M)%TIY*E*4'*M\1%ZWX5:5XP=6]"HM.D.J-8\>EZ5=ZST:MVWN>ENA-;Z:<ZU
MZ4T;0M2^RV&H]/674"M3=5?"TM](N'U]/-:6\TRQ;.655/W+Q_6A*S5'3+%A
M;"QG7R4&SMJW3=18+N/;-GAIZ$5W1ZA@.KM7X]GF2T5+%W5E#LTHPR8D;&ZI
MVG5Q2)]A!'7TS\_4K-D6[#IJW^V,6GDWVH.?=]KJ6H.6Q:#K6G(*+%F[?::3
MJ;_VIH*2EA'W;]G3L0$-5$^!6I=5INNLO';5U],:MU-]Y=)='6!ZVZBZ%Z,M
M-=;U%>GZCUM<"ZZOU/IS2=1OWN@M(&@:BMIY[5+P=<_?+XN;A5S?)HW=/:&'
MOOJ_J[',L%F&(56R=.9EF>_)M=@^?'8+*-8AFXM;Z+<?'\>ER,>L,@W+46 <
MN#<MJTAZ]P_(:2X'!?ET!X];4]=3JVAV#%P+FV1>Z;<W.K*1:W9BXL0JW<TH
MEEE196]J3:Q<!SRPFSMGFG0C[2BISH3PC?\ #CQ<ZNU/1EZ'K=YTKUSH6A>'
M#%SU!TVV5Z1U:MC6+'Q##>I:FRUJ=MIO0M[:N:*Y8&[\_J;7-+U"Q7<)T2Y2
MK8MU!R*LRKJQUYN*D\J3$=IS7E<\TROLZP[IU)B]92VB+%MHD*:X8[.OEC!,
M^!8M@%HY\ \J!)C2C=ETZ\BXT'1W&RI2?NVS1*D+02MIA#3F'$I40'$* 5&U
M8 6@J0I*C\P>-FF7>C^+_B;8WK;+3XZYZFN@ABYM+ML6^H:O=W]H0]9/7# 4
MJTN6%.,>8'K9Q2K>Y;9N&G6D9&<F:\OIQ2G%*<4IQ2G%*<4IQ2G%*<4KC^_%
M>.>X?06*AG"#*L.R[9*,()A2 &WK\][&(5/0OM_F.$Y41Z._5'(GCG)]4)1%
MFXI&Y3:;LHQ,%7V<3Z@\0>Q&:M+B4*0#_../I']5<@OVXX)B-I6#>CH+V2)
MYS([ /\ 9%&T?W*K$7XW%(AVH@7$*YR,>YR(YW'-EF[<#5TZ4)2H%*8(492)
MDG)P,<@".,1G=A: L0 01&,1 ^7;,08/?)JD,BAS?OJB:,(:^6V.80Y 3$1I
M) 'HY7O$UB^?5BO>Y6J1/"JUGGSXY(:?]F::?1YRG@%A0$ [1P!) ^6(F!6N
ME$*!4>_ '^R/U5ZL@2#A>*1'*>5*K5B2'RFMB*.2DI\MY83([D,0SC*K1-4?
MLQA5>3PQWJE5E&[>V0 %;@/Q3\*1!D0/AP>1B,\UN!Y924[PE*1(!YGT$<G,
MS@U*9L.P2<VM#!1A%8(07!4L:$%S6C,JH<J*Z0GZD^1PW*A"*YS6+Y1O,MNX
M@MEQ2C 4KG:I:C@3'"3&85V,[JB;YU+A22I/P$''!]!$X,G,_LJ>X^",6Z;,
M&PX9AJY(HAC1'?=L0S!&<:01OM\B&\B,J.<]([6IY8KF*FO?%S[%MW#;YI,D
M93()  $8@@CMNSD345=OJ%J8_#O/?,08CYI[^^)BJS@1B-M7!BV+7)-<C)P6
MM>2$A6^"#&BE<]3E^1JIZ'<B-^-$:/U<OB*N4H7;I44 +0 D*X,$>T8P.  3
M!GB;M+<5O!.4P1WG,$<8$9X]>157LA(K)@UE."#YV/<)$5L-Y6_N,P@!$1CD
M=(148]B>0M3PQZ.7].?*RDF05<DF<^@Y,R! ]S\\]7;N*"D@' B00>_;@=OU
MD@R),]KA.;-A-C13B62A%*Q'QD+)(TKE(C$*]&N$-'JX;GO:B,8JKY5CO.H]
M;IN=WQ %.<R0#!)X]0!B"9C,Y,HA>Y609!$^YD<>V1';Z9-.9#$<:<]I$:8!
M(YDB%5\B(])+_D6(DV9'5P_^-)Y(Q?#&-5I&#5KE=R7TI#3+$D;HY"0E6.^T
M*Q@ #D3$36EJ*T[%S B,S\L>I$_/B?6H K9H:BNFHS^L-8L0SQ-*\0Y;2N4K
MVO>UC6?.,2,:0B.8A'(1RK[*CL:/(5=/0% )5*)4D!0,QNB9">8&8!&)QIZ8
MX@^7*@#N]LY)/? _1D5U>_ABX[EV-O:8Y3K_ ,&,$#?ND<XBC+F-5)#Z%7RB
ML8Q?C>U517/:CD;X3SR5Z)=)ZZUEH[3.@M+&W@;7[%)!S,DJW>F:Z#6% V%H
M 9_E2?T.#]?/?CG$=BG/9ZYFG%*HNCUU@V.82FMZ;%J:)@7Y=:U#\3=$9*HS
M5=X6::XKI,&9]P*5"LWV,[[V-)0H9#91AD8X;U;S6:L[5FU^Q-,-)M-CC?V?
M:"T6W2HN(*%2%)65KW),@[B#@U/:AU1U#JFOGJF^UB^>ZC^TV=ZG6@^IG4&[
MS3T,(L;IJX8\I;+]HFUM_(=:*%M%EM25!20:M/0]1^MV,4^44-)J+%H59FN&
MS]>Y8)66$J3D&#V+ AD8K9V,V=(L9-**/&CQ($%\OXJJ" ,&K2'$$P+8YGIW
M16&WVFM.MTHNK9=G< A:E/6JX"F'%K6I:F@$I2A!5#:$A#>U( KLM1\:O%35
MK[2-1U#K;6'[O0==MNIM&6%6S+6F]06JEK:UBTM6+=JU:OUNNN/7-PEG?>7#
MCEQ>%]Y:G#>BHP_&:&\RG)*>FAU][FLFIF959@:])-Y*HJB+05!IJN>YKGP*
M:%%KP?&T:( +$<CG>7+)MVS#3K[[;24.W2FU7"TCXG5--I9;*LQ*&DI0( P!
M7"7NMZMJ.GZ1I5[?/W.G: S>,:/:.%):T]G4+U[4KU#$)"@+F^?>N7-RE$N.
M*(($ 6[O^N^E<GI1T%SKZF/7@S7)]C0GQB6-7:UF=9I96UOEF44]]5385[2V
MV0S[VX);2*JRA_>"LI<0K70RNC\TWM'TQ]H,N6;90+I^]3M*VW$75RMQRX?;
M=;4EUMQY;KA<+:T[@M23\)BNGTWQ.Z]TF_5J5CU+?-W+F@Z3TO<)>3:WEG=]
M/:#:65EHVD7VFWEO<:=?V6F6VG6*+)J\M7PPNU8?00^@.54N.ZGUSB<[%[+'
M<3K*NQPO&,BPW&)P4D/EU.-9;<4609-5B.<Y2G9>WF-4=K9R9;I$R7/KQR2R
M'$(=Q<[.GV=NIA;-NAM=LP];,+&XJ;8N'&GGT DDGS76&G'%*E:EH"BJ2J8K
M4^L^J-9M]7M=3UF[N[;7M6TS7=7MW/*2S>ZKHMCJ.FZ3=K;;;0AM6G:?JVHV
M=HTR&V&;>Y6TAH(2V$8=;:Z&X[F63U-MA8-*U^.4^J(^J*##MKZ3E;8K==QQ
M9'DV1R,OU=)C;(P:1B^36Q\E:&[++2V=/3'L;)%F5C8$L%CSE_THS</MN6HT
MQ##>GIT]FVU#3%:@BS2EY]XW%@4WMJ6'W"_#I5YA5Y+)2IL(4E?N'1G\(O5-
M"TF]LM=<Z]N=4ONL7>LM2USHWK]KHRZZG=7I>D:6UHG5[3O2W4+6KZ39MZ45
MV"&39"W.IZJEYB[-RRY:Y&XWUOUC3CUO8W=9(S7.M;:MJ]1Q-DY+.FFS#(\6
M@4,FADMRV9%DQX^0GLV6-U8G6UCRVQ+2]N)U<D23/D%),LZ+8M_8ENMJNKJR
ML$:<F]?6M5R];I94RH7"PH!Y3@6ZM1<"MKCKBT;5+43Y=JGBEU9>JZJM=/NV
M]!Z=ZJZPO.M7NE=*MV&]#TO5[G46M19.C,.M.N:8W:&UL+5O[&XRIZSTVQM[
MHOM6S2$U[5:NU]1R, E5.*U<&1JS$I^":]*%A4?BF(6D7&X5A0U2N*[T@RHN
M(8R K2H4JLIXB(1%0BOVV[&T:-HINW;0;"W7:V9 ,V]NXEE*V6\X0I-NP"#)
MAM.>9YR\ZNZEU!OJ1F]UB[N&NL-:MNHNID.*1&LZW:.ZJ_;:E>0@;KAE[6]6
M<04;$;KYXE)E.V<5&&XO0W^6Y33TL*!D.=S*F=EUN%KUFWLFAIHF/TSYI2/?
M_3K:>%'A1 "04<34,5HON),DILC=LPT]</MM)0]=*;7<."=SJFFTLME1).$-
MI"4@0!DQ*E$Z5[KNKZCIVBZ1?7[]QIG3S%[;Z+9+*?(TYK4;Y[4[Y+"$I3\5
MU?7#K[SBRMQ9*$%?E--(19FXZD=<;Z/1Q;/5&.FC8V'*8U&$!K> .NA9MDI\
MPRJN"VOLHJ.J[K)9)K:55F^2N20_U#&$!K!-C7>G]&>#27+!DI9%PEH N("$
M73YN;A "%IEMU]1<4V91)PD#%=U8^-'BCISNH/6G66IH=U5>CO:@XXBRN575
MQH&E-Z)H]TLW-J]%Y8:4TW9,WB-MT6DRXZMPJ6:BR[KEHS.<8P_#LDU?B4C'
M->L8+ *^NKDQ]V# 9#97?;X=.QY]58XQ&+ $*#(C4DN#'E1!"C21E"-C&YKC
M1M*NF+:V?L+=3%F +1"$>3]E 2$;;9;);6PDH 0I+2D!20$J!  J,T3Q1\0N
MGM6US7=*ZNUIK5.IE*7U)<W5T=2'4+BGU77FZ[;ZFF\M=7>1<K7<-/:@S<.,
MOK6ZTM#BU*,\U_I?56JC2)&N<#QW#C2Z*HQJ0^C@MB*6CHK7)+ZMKW(URM^,
M=[F.57DDB(A[&ZR"VMK(LNPFFD.RVFFV%@5*L[1FV*FFV%%I&V6FG'W6T?(.
MW-PZ3RMUYQQ94M1-1W4G7?6/6#;375'46J:XVSJ-]JS2=0N"_LU#4;/2M.N[
MD$@'<K3M#T?3VDDENUL-,LK*U0S;,-M";U>M\&I*?+L?J<9K8%)G=SE&09=5
MQV$;#O+K-GD)EEA+"I%:T^0&,>19K'^%DB5(D2G-^XD&*_(W96K3=PRVPA#5
MVX^]<( .UUVZ)-PM0GEXDJ7$;E*4K\1).E>=4]0ZA?:+J5[JUU<W_3MCI&F:
M+=NJ27]/L- 2A&BVK+FT$MZ:VVVU:!S>6F6FF0?*:;0FH:&BJ,7HJ7&<?@ J
MJ'':FNHJ2KBHYL:MJ*B&&OK8$=KW/<@(<..&.%'.<Y!C:BN5?*KF::;8::89
M0&VF6T---IPE#;:0A"$CT2D!(]A4;J.HWNKZA?ZMJ5RY>:CJ=[=:C?W;Q!=N
MKV]?<N;JY=*0D%Q]]UQU9  *E& !BIMS)6E3BE.*4XI3BE.*4XI3BE.*4XI7
M(9^*M^ 3.BDN2T;A"#VE WY&/<T4B6G780)#U:U6L&%6N1[E<UZ>Z*/SX=XX
M_JU:DHL4I$J4;DQZA(8) ]S(@=R!6E=QN9!G_C(/IA//M7(S CK$K(]8  [)
M@(?RDF([X(Q2_N.1A7JUS54*/;X>)SO*)_\ %Y\>?@ARZ<?(*5+5E)D[0D!/
M<B9 R,#CZ[*7%!I*,$ R#![DF"9S$XQQSZ"G0FMYD6 -DNO>L0\AA(HV(1Z0
ME)\C"'.\;2#(%&^&HWRZ0(J-5R._191QRT9!2A"@5H!"L?B[@=L\>T=^*M2\
M%$) S)F8(^1X/;U[\34#?02SSQI<*0D5\:>+RV2I8_S+-*Z5+]1,1Y"DC-$1
MQG.5B_ \3?/E4;S:MG;=#;BG"2DH^*()! *4P8$ DQ/Q1P8-4N?P$R09@0?6
M?7^G/UJ,E133(\9LGWFO 83%"%K5:H%?Y8015>CFQ0HJL<1Z^R/5K%\*JIS1
M:?675I9VI:,E)5)5(Y20!E9P0(B/BKGBXM2E(48B8.0<XC(Y)Q'UGBHO'H%<
M25'.]9(U Z5$<\GB.R.Y/=R*>/\ H0XRO*,;21R_N8CGN1'(BI=?OO(0&AL(
M*D*(@J4<_$$JF$D $G=G$9[Z]X\AEDMNDA)DB(*N#!F""8F?D<351DQMP&QI
MIA@;#"Y7O6*912/NGM(T;%>Y%\(-'-;\A4]V(C_W*]K?,2O44J2MH2%'L4@R
M,'U,R> !G$>E;6E*2YM*#\!22)YP1WQD#TSZB)JJ%@M6O@N'Z BO%\03V#D&
MH'N1&""\H%4I%<]41IWHUI?=I/#6HJK$?:UMNJ0XUO*B5#8,[<[B 0 ( ,@=
MAP.W6M';D&3QP9[0.9Q]?3WK]*WX/M(I#2A B1"-#)B/1ZM5P_B.)$1'*YTE
MSAC&WW<]6M(]W^<B\M,+4XZF4[S)2HP1(^0XCV'M K:;NFVMQ<D$\$&!)'[>
M8GBI%9R5/$5'O&.;%<1SX_A&1B.1ZN"BA(WPDCU<YJ*Y/^+]6HG[?#=RP&R$
M@*V&<DC=$9,@00,<#(S-1NI7*2R >2D[B(Y G!/&  1VY[34$.66%41@2A&C
M%$!SD8\[9;QA(_U8U0#:BJIG,1XFJCB/:J*BM\*J7*9\RY4II04%* 40G8DD
M">3@;02%'@>D$3%6-PVA*5%2@29&3^J#ZQVY[Q74[^&$OADW+O['8J%2'_@]
M57;&O8YC!G=FE/%.,?LGMX0CWJK5\*Q?T5//CQT71-EY?5>J7B@-ZM(3;R#)
M4D7%HN3&#!! /$<5T3MW]HM6FP92A94.9SO!_3[=AZ9[,N>NUITXI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5K/W!OGM5@7U"N
MG^H2+J&EZP[YR/=6*"KJ^)?Y)MO+CZ[ZW7^U%R;(+VP'2X]KZ!79M7-H*O$L
M?KLNFW-77%R*US&"ER/%*A5P *5',B#[9($1WYGM$#FK>_48S#NAUYU[LS>V
MHNUF%U<6?:X3@VA.NLSJ_09A?YEN#8EECVO-=ZX#L&9M.JG6#\RV);AF3[0>
M*.+C>.RK.9^7SHM"0IE$@$@9]S/;F<CT]\_6K%[T[B[JU]W L.M^SN^_77IQ
M38GUGZTY9'R[8VFL>OZ3;6X-D7VV<<V.2DN<TV/@]=C5-6S<'QX]=6'FR$BB
MR*."09A?5YU5"9 (2HF5#'8 )B<'U]JWN07.?"AN?+%/>Z+'<^='8P8)KE"Q
M72PC&0PV"DJJF&QA2L:Q[6M(]J(Y565R5?BGXPI4?HJTQ7L8R9V1>\+&M=]R
MQ$T%_2]7C*,C_D^-6!>C4,GLQ'M7PO.#ZV=+7W:8D*%Z"?2/LF3D>ISG;R0>
M#$ZFX6U6T3GSC _Y/E=NX$Y[9SS(Y*8U2TK2%-%+)862XWP07/80H4<B+\0"
M,1@G,7V;\2/1ID8J>RL&U7>=JNOC 3\,1)(XD!42DF0<&2)$\3-6,WB?*<E2
M21A)*A,C!"23R.X'!Q',0[*-\5SH\8:Q327S N4H4$20<OLX U.SR%@UCKZ>
MGE%]QHWS[?N4+S>1NA82 9W A*8()@P?Q&3\SSB;6[I(6D_#$\@I'&/;Y<<$
M_26P:@'VKYQPR'%6&\(@N>][@2 3!MFE<BM<I$^-C5(K$\E<KF#3PU?&1^[4
M1Y:%""H%4& =R);!S@&3M& )!/&-VXNVO,;VJ04E)"@"@C(C,8G@F>"3[ _B
M?42GC)"L!_"0;A-');':@W@*B%_J(QOLW]OJKF"\/15:XB>7>>9K6[#4/-#<
MD@DH)R%)QB>8X^* 1@'$URUS<I-TE"""0LRE/($]T@F!F,QR1S4VQVG1TT<9
M82';$C_<",[^H$@I/_&*Y?VM:4)1HPK#>"(USBHK43RMM_=ES:L.!)<5\24F
M%).#!"94!M48]P!B15^IK9+"E'RS""<E!^+;.W_G2(CD&9]JS)!L767S%9#D
MPQ']B1_9CAH1ZN&L1S1HYCPA1OEA!N<YWZ$)ZL542)=>80@[4J+Q(@KDDHC\
M63NF8^1SSBMW1'FPRDE*0G9S"4B21&8CUXYS$Y-7&USC&/6EX*%>Q)8J.5&F
MG. 37?,LD:/^ ?\ 77T:$?MZC5OE7"5BM<Y%1.0E[<O-H+J5E2TN)3\)R$J/
M(@@\\S,&< Y$E=ZFEE VJ2 1^+<!!!. 00)X)Y.1(J@+5B@NE5@VPH,*1\@A
M1WK'<4C50:HUS_99'AB(KVH-K4>C_5?D16<FF0XXQ$A2EC\9$J2" >>4DP(,
MR>8 ,U"W&N,;=I*U*&#!*@#Z@ ^L9'.?:J9N(WSV@C1QM>8D<[/43 G&=3,:
MV/(5$:CFE^)7*1">KAHYOC]R*J;EL2EM062D)4G,E"AM)"@?^221D$@_(Q4?
M=ZJZZAM+:R3B962 (F#DY,'D<?IAYD"<VJB?="",L8B#"=@5&\9F"5@T.\;7
M>XOC\-*XKOB$Y&_N3RY7;;=PUN*0B0?BD;0J#SV"C, )Y.,>@UK>]<#FUQ8'
M 0 L)QRJ!.<QW).9S72;^&#*->TW8@;'2%>_KY!?(8_]L=IQ;%QIBJ%BN<J*
M]A&/=ZHUOERO_<A&KSM^DFVQJ-RM$[C9 *W [H4\TH23F(2(GUKLM-N2\/+)
MG:@J.9_GQ]>>3G'O7;'ST&I:G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2M4W:[5'>?/.WW6+<VG--]9<CUQU1R7:&18X787:/
M8^O\OV>NW]%V&L+B'<8]0]2]D56O?X1N\@LYE?(AY1G_ /$];50B'#C4FV-&
MJ57I*0E0)/Q #"08@@_W0]/2K_[FZ[9[N[MKU;S_ "F;B[.N?6:OSO;,3$TL
M;*5DN8=HKNO3 M=7-I2%IATH\2U3@-YL&\HK;\[?;&SG)JLS:2.*C#8*_?\
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M3&/8X;E5RF8CD<J*JH4"C]_*HUST<GGE$+:6ZH@C<$DA!VH*=JAC;,QQ"P0
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M>3OJJ-"Z;UAYI_J"]U"T58;C9"QM_M"73<1]H\\;DE/E^0P6X)G<YZ5HR_\
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M3>EA4B=^K%9,3,'R( .(@8CTYCG>D>D//#K5_?XA>&2T-TD*E"BX>,D[HC
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..BE.*4XI3BE.*4XI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g108483g52r77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g52r77.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P ET# 1$  A$! Q$!_\0
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M1X<"U(\66D)N<M>Q[/;!BL%I0IJTY81Y&%"$:+"]!8WG8K)T#B>00;4@R$3
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M@-#R&0VCXJ^D\EB1Z9%47 U E6]F-'4NI?7"^^FS!<:Q[A;FK0B/;,Y1*69
M8&8V#V=8EM(Q+(>5A99.8.U\W#9'G_(T??N\^YV<+'0$6C4>0;5:S&*@IKCH
M]DR-QW&D++FP<4%DUFDNROU=45V7 T:,>PX&^JZWBK$6VW?(]D%'([3:4'M
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MZ!1$3'SKY<6"8&1+]4,6<P*@:ZNG]&'Q'Q9:'9\I2#,<7+S=G18\*(]UGV9
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MVRHB32L)3KA=5L7K&).AD^.I089%5(%.6:\3/QBLF36+9#*S]X#* )=?&B*
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MG1[0M"9LK2"8G9<0JO$*-6S)OK\5$;00W&>T525QF<2:?G);,7V/0X[*UX1
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M=*R 2'C[$O<[0 B;&C^#F=M]4AO2O"9ZN@N7I6_['UOS*ZG@/97R/LO,S0W
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MA&0<#(LAMU(4NQI(.."[)&50-(JBP"86JTB ^&!10][DW:/(C7(/'!U238Z
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M9T<^D9S]F*ZGR/AMX5IOI)MGW\X4O_1SI\'+0]>6_./_ $2?%QT_&,UHV/\
MQ&=\+,*K_>]^WC_I-L^_G"F'Z.=/@Y:'KRWYQ_Z):^+?P@?;.C?TC._LQ1UO
MD?C;L0NI;?)=G_?6WGJ<[D&7UINWUIV<=4Z_6U1HU:)P=+?G7_HE#[G'3\&A
MFM&_I&=_9:53Y']VZZ\4DP#^<&7?H[T^#5HUIK2U3_K7_HEGXN6GWVUHX?\
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M%+;K+Z;]]M]MUMU*5I6E,U&0[=ZBE6C%MU/+@KQ4^O8_ -1%7J8MW8*^K8_
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ME="T6T:(N'9ECV2"QG!QW'5C5[9!,OK2>= GDH>15"0PDCB'+4#58U<-AI5
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MUINBNL*^7TOI_@O_ %"P[W+[&FGPW<;J_P#9P?MU*M^1M&=U-_S9#FG7W?\
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M$HI%G%7T_>IH_$<WB44BSBKZ?O4UA%?HM,](=/<4Q/L_D]_1:B;.GP3-%MN
MYAW+&DOI$OPKO<IK;,3S>(6(FSI\%C+..OI>_36W?)_&'BN:D6<=?2]^FH_
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MU(R0,BGIT8R/)JG+5!3EV!&D3]B+VU!2T".?FU+;!3)R[2TXW'"MV1[$#2<
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MC-FJU^DMKUZU?UK7\M?0XJ4UU;Z(^NU<G>D?KL5E@EKSM/)2?9^[1GEK^_\
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M0B3C0TQ(,*89%,!KY:'.0WS+H9=#E61I6-!C0(DPZ$R.V+#$%SW1&@[<PD(
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MG@K_ ([2KZ7E/V6F4YB9L+;J;Y-EOB_9'C/]C]3[*VE-:<59=*TKY'&PK_\
M%)\4G@K_ ([2KZ7E/V6F4YB3L*UI2M9/ESK_ .LB,?V/U#PL:4 D<795Q/\
MDD;]:0^Y)X*OX[2K ?YWE,K_ /-:;;S$?82W4WR?+>__ +R8QR_['Z?97TI_
MBK+_ )G&_6D^*3P5_P =I5]+RG[+5?[B/L(_Z3Y;_.3&/['Z?97TI&,*RQ_N
M<;]:6F^Y(X*B:&-I5A]UY3D_V6K[>8B["%:;ZR?+G'^R3&/0_P"I^L_98TI]
M2R_YI%_6D=[DC@J!H(VE6'W7E.7_ &6KO[B)L(?Z49<_.3&/['Z?98TI]2R_
MYI%_65KXH_!1]L:5?3$G^RU!=<Q+V%DK[;4I+ENZE;=]:UR/&;MU=]:<=(?3
ML4IKHWA6TH(O99>/VI%Y/Y4L.]R3P5 W1]*C=]V)0]UEI-O,3MAFM.O),MTZ
M_P"R-&J>[$-#PK:4:P'%V72E_P"](W+M\J4^*3P5_P =I5]+RG[+5]O,3-A>
MN_?)LMT_]1XS3W8?H[A6TH%*0[+/^Z1CW32?%)X*_P".TJ^EY3]EIMO,2MA6
M[?OD^7.MN_SD1CT?^I^H[A7TH '[G95XOK*1N3^5)\4G@K_CM*OI>4_9:;;S
M$C83KOWR?+G8W;\D1BG+_P!3]3[+&E)PA64?]TC?K2?%)X*_X[2KZ7E/V6KO
M[B/L(_Z3Y;_.3&/['Z?97TJ_BK+_ )G'_6E1[DG@J) X[2J\C_.\I^RUUG!_
M,H]BS!&3XKEF,.YF>D\)(6F8VA,)X*)!F!I"E>D2]6 P,&O<O1BMW3+"CERL
MU1=V).;FRBJ*-UGKK5X1]([7D)BSH[I*# FF&%',M+.9%?"=Z</7B1HH:V(/
M-?JM#BTEH< 37Z31;W-?!IH?;UG:1V?"MN<M"RHXF9%EIVE#CRL&:8#Q,SQ,
M"4E3$BR[OW2#QCW0VQ UYAN<UI'U$ZLA^ZHWU\U\;KX)?OS2-47C;MY2H;XP
M)N0W6E!U:\_;UJ/6U:]GD5UIGI#I[BCB-4WCKY5B+2HOGJ>63#L_;C?DK]\U
MT=Z)^NU<D^TN*YZGEF/[/VZVY*_?=0@ZE*7T%W4B?88$\]3RT'=G[=;<E?ON
ML@$-=4$88\Z)]# G?3RT'<=/MYMR_P ;K"HQZ#W%.ZLA^ZHWU\U\;JT.1ZBH
MJVF0^^GEJ-XZ?;S7E_C=1=OD?D^"?U9#]U1OKYKXW1880":FEWB%2XR'W5\M
M1O%7[>:\G\;HNE1F.L+6^JHONDP]>-_&:\A<$_JL*[IC_7K;QFL,! -12_<B
M?U8$]U!WKUMXW66@ZPN.W9R%$^A<3NIY:#N*GVZV\;K"IQ/.>]/H9$;J>6HW
MBI]O-?&ZM#D>HJ*O5D/W5&^OFOC="",01SKI#V]'BG6&0_.T\M1O9^WFO+7[
M[J*'T^D>"NZLA^ZHWU\U\;HNE1F.L+!O"PJKE2M"8^M*\YNK1XVK3ZG;V:*:
M[,]$=/>5R=Z1^NQ+M+"N=IY9C^S]N-N6OWS4 .N32ZF/4LIUA<32E=Y0=3K]
MNMO0^^ZCP2;@3=ERE%(L,"=U?+0=Q]NMN2GWW4?CT;T3[#(BE*[RHVG7[>:^
MA]]UFA. )Z$5_5D/W5&^OFOC=*'(]2TSTAT]Q3$S(?K^6HWL?;S7T?ONHM1-
MG3X)G5D/W5&^OFOC=%H$4%XP&T+'$"XFZU+G2@Z[YZ[B>MJ]BG(KK;,3S>(6
M7D&E#7'#H6.L*BZ5KO),*=;MQORT^^:V[Y/XP\5S3["XJE:[R8^G6[=;<M/O
MNH\$BX5OWHGV&!.^OEH.XNW6W+3[[K%"&WBGG>")]I@1SU/+0=V?MYMR5^^Z
MS0G 55&WF\0F]60_=4;Z^:^-U:'(]145UAD/SU/+4;V?MYKR5^^ZB[.]$]'>
M$[JR'[JC?7S7QNBPP@5J0,,>E0R)46JP>))$F"JE[9>VQ--XWOOONJG=2EME
MEJE;KKJUZU*4I6M>Q31=*C,=84P9]2K^"E_-KHHWY7XQ\%JYK]<!WXU?_3H:
M*-Q?S^)70M%M&B(T1&B(T1&B+F>2)<"@(,I,)+<L@!"IL%2[U!K<[ZFCW+]J
MQ<%WEEGSR0H.FZJ3,O*[[!XAH]?J4N3;74KU8:-)Y=RY/%7 <F]<"B^UYL]2
M=DX*-IPQ%"4%WC>I:1M58^P4Z5E^3H@DN@J3L0N58D;\.Y"E3 A8G5C?C\ K
M/'+AM&%42-T<02W*M]<JT\"H6N%U+_Z@3U5%>4T6Q/=I?##&'P^?<('#N+3G
M)J6)(^1;1\S;568]73,?()O6KQ@T<C P%Q') 1.GWZ3<0.!AGYE1W<P3L64K
MB"VN>'7_ %)JNJ0,0*]%/&HIG4+GI?;GV=@S1\NX*GUGHV6;1L+?!6T4?U,-
M#>RU&9#,<J4<-U[4$$&2<< H%(P]6=6(25K)(NL/NJD4NO;<VTOKD:<]*K5'
M WF[S2;\0XB[EY1SKTG )Y'\BBB)$2Q)BW@(\1BTFCTA&VC)!&9()HW4>AR[
M2Q1RVJKTH\8$V+X<](!S 8D,-!B1 219O%HL$4RO%13Z_P!BZ#:BENIY$GQ4
M^LMY/2T45>@I>=)^HM_JT6F>D.GN*OL12WU\B3XO,6\M/0T6WX#G\"F]!2\Z
M3]1;_5HC,#S^ 1T%+SI/U%O]6BVM9JFGOKY'9QU^LMY?2UY"\=/Z&GYW9ZBW
M^K6&8'GW(M-;3R-.LA&L9)MBELF!1,/,WERP-ZW$+AC9(J*:4&%UD+&A5XBZ
M$.+7S<?>XHSZ*V364M<7J(I8;>X5OQKMV'K6O.H#4TK3'ZT7GPEMN81 HG%Y
M,PG$:3AR96_(52<2M7ICU1E2:=2&TEO#ORJ3EQ+U\?2X?&K(LI)++C B\$;4
M"&UVH];*:AY.2_'FYJBJW8EM28O#1,)+"@Z5M$2!+(C$V(J!;.#<(:8>DCB)
M9:D,N0:$7#%&-X[/-[&APL#('4WZ+T<_B]D@8/VSE0FJ2X@4Q%+Z8W@<_)LV
MK6HWMIX1E+Z.L1:$NY^2%(FT;+.8O1%!@'R(MB]KC*7D]SR]9O&<C/<SXU8Q
ME1%%R:1=GWZ4D"@.!\YK&2Z,! //_;U4-=G+@O85J*6ZGD2?%3ZRWD]+18'I
M]+O%5Z"EYTGZBW^K1=5XHVQ]L#&>QA 1D^R&'D4@I(Y-;&(_'XJT8+$R!"YH
M\).5UER;T>P9#V+)FI>X74<7K7+*MD&[5:JM]R/U&C.C4]I/./DY*) @\3 X
M^-&F'.#&,#FL: V&U[WO>]P#6AM*!Q<X4%?S#A/X3["X++%E[9MN7GYWRZ?%
MGR4E9T."Z/&CF%$CO<Y\Q&@084"#"A.+WN>7%SH;&0WEQ+?FG3F]VSY2E*?*
M/R]UOO\ "?CW7W X(;8!<3:MFWF[S9KE_P!2OP7XX^A?WJ:3_/LK]=3:<WPV
M>MU-^#LO<7GT(^/M3[#]L5K[ZV;C6FI-=7]Z5^.3H;]ZNE'YRROUU,IS?/9Y
MI2E*X-R_UOOT'^/M0\#]LU-+5LS'U9K]"A]V1H8?^ZFD^S_VEE8TO_RS--MY
MOOL\4INK@S,'6^^P?X_U/L/VS]U;,^;-?H5/CCZ&?>II/\^ROUU5_N^^SO\
ML&9@[[!_C_3[#]L_=6S/FS7Z%5ONR=#&FOP3TG-U/[Y97ZXK[>;];.]*;OE&
M9@K_ /F@_P ?ZOV'[8VVK9OS9H__ &@CO=DZ&$U^">DX_P#J65^N*O\ =^]G
M?]@O,'?H/\?:GV'[9^ZMF?-FOT*Z?'+T+^]/2CY]D_KJA.>;X[/2]]MUN#LO
MVTI;2VM*K0C?6N^M>P>]'6V\$-L &MJ69T-FOT*P[W9.A9(IHII1TOLK]=2+
M>;V[/EM/\A^7J_\ YX3\>Z'@AM@N!]]+-H-A;-=?]Y^M%GXX^A?WJ:3_ #[*
M_75]-=CK:_QEMH8Z+Y!QX'D("D=D:T6D$?E;,>B3'$K&30DW617&/2#!Z/?,
M7R*C=PDXL6HJFY0<-4+D;;E?A-*-&Y[1B=A2<[$@1N.@"8@QI=SS#>PO<P@B
M(QCV/8]A#FEI%"TM<0;OWK@QX3["X4K$F;:L.!/R0DIYUGSLE:+(3)B!'$*%
M'8YKY>-'@QH$6%%:Z&]L0.#FQ&/AL+1K>NTT4NOY$GV/K+?1]#7SK@*-NV;E
M^CDDXDGG4A-%+K^1)]CZRWT?0UA$SH*7G2?J+?ZM%6XCG'>K[$4M]?(D^+S%
MO+3T-%T?@.?P*;T%+SI/U%O]6BK/1'3WE0GZ25$.LFG3Y^WZRWT?0UIGI#I[
MBC_1/1WK#V)I\]3R.SL_6V\E?0UT?Z)Z.\+BI%J2?/4\CL[/UEO)7T-0^AT#
MP1/L12YZGD2?9^LMY*^AK ]%W1WJU.9ZT^U)+?3R)/CI]9;_ %:R@QZ#W%/Z
M"EYTGZBW^K115M12WT\B3XZ?66\OI:+M\C\GP3^@I>=)^HM_JT6&8GF\0J7(
MI;J^1)\5?K+>3TM%U6L]#3\[L]3;_5KR%XZD=#3\[L]3;_5K#,#S^ 1/Z"EY
MTGZBW^K6&WN%;\<>8JU.9ZRGT22W4\B3XJ?66_U:RAQ/.>]2+44MU/(D^*GU
MEO)Z6BBKT%+SI/U%O]6BZ0]O1XIUJ27.T\B3]1;R^EHH?3Z1X*[H*7G2?J+?
MZM%U6">I)],J>1V?6?66^=V^AKLST1T]Y7%_I'H[@EV)I\[3R.SL_66\OI:@
M],\@NY,%E.L22K2N]-.O7\Q;Z'H:R_$<WB5:D8$CI4BQ)+=]23X_,6^AZ&CP
M ;A2[Q*BD6(I;J^1)\?F+>2GH:PBOZ"EYTGZBW^K1:9Z0Z>XIB:*77\B3['U
MEOH^AHM1-G3X)G04O.D_46_U:+;<!S#N6-(I)4M2W)IT^>N^LMY*>AK;,3S>
M(6(FSI\%C;$T]]?([.+S-O+3T-;=\G\8>*YJ18DG6M=Z=E>MYBWEIZ&H_ <_
M@4J1@:)]B*6^OD2?%YBWEIZ&L?)_*\%:DXDGI3[$DN>IY$GV?K+>3TM90;>;
MQ"=T%+SI/U%O]6BBNL12YZGD2?9^LMY*^AHNSO1/1WA.Z"EYTGZBW^K19A[>
MCQ4$HDG0<^K1.RE:-%ZTK2RVE:5Z'=UZ5I3K:+H@9]2K^"E_-KHLM^5^,?!:
MN:_7 =^-7_TZ&BC<7\_B5O+IXS966JO739HE=?1.U1TNDWLNOK2ZZEEMZM]E
MM;ZVVW74MI6M:TMNKNW4KI0G 56Z@8FB@\( /=L1[),O':M#D>HJ5&8ZPCA
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M*GDZAN3*8<=W;]Q5CUN5!QX>E10$ZU]=IV=(2IY.H;E?;AEY=7=U68TZV_\
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MJ72R6W%BT!/3F/3K$F)."9FM!T;'I "WM(FJS_&&/P[9DHN21:O7DF=Y,LD
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M]::W6K?0@7<IO-.Q>71/-(1TE>AF8.&,T:S7,.,(;#KB<HB%RC>$RY]LFMY
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MC OC B$#-)($AR[AU*HBY)728TVEPJ]$NDJ:%LH?$A$VAIX<_P B/')N/5!
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M+PMQ6X8@K%EC..2ZK>H1 NXL8%KS"0NZT\A;='[!#!.CUHV-.7%C.XD6H@-
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MJ4Y/IM$6L&XG Y*XZ;D<:B)]UTDY&],FPP8JXZG/!QD0[8=&?-EU.DG0F12
M6Y:\]T!<<=,LE4[FQ-ZDNH,@E3F5".0'&4G(JEY+"H)(2R[<8S7*'(Y'RQ%9
MH%4+K!FJKU^S<.5&XE:0'E1B%ZM4F"ALNHUM2N)/*K2@.(!Z%:D8$CI5@_'.
M*1CX@3'0/'H\D5CK>'DR#*+QMH^)1)JS9CFT7?NT&*;AY'6X\<.8(!'"B@Q%
MFP9-4VMJ#5"Q/+A>V@VWW;+L4J<S=A>DE,2X6D#"\4>QGBXV,N=)O;AQ>&1,
MDPN>)O9*23=W,WHU9O5U81F4O?V.*I]%M>RJ2.K;Z+G":CJ/ %*#/P2IQJ:Y
MU/-W7)!3"6 CZSMR>Q'B TX?(4;/5R\!A9)9XVZ.[==+NE7HE:]PATR_?..A
M+77I]'>NEN=Z(X6NOR1YK:#.M!R[4UG9GK*RCO$N$BE[V\GC/%A&\@>1E+^]
M]#(D[O?2=!R<>(2-W<X&J5<GD7DGDCI(NM6\@FYD)Q>QQ:J6?W.(01B".=*G
M,W78GJ[.Q9:N/<4W%!9NL'Q[4T#7HZ"EZQJ-U*"'5KD@]HY%D*LNFQZ]'A8H
M[HLT614HY)$%Z7=%>.;U(J'&HO-*BMYPKM62&Q/'HITL^&1J&#7RSL@06>,
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>EV=V"V&QO;;99;2RE*6VVTI2G%2E*4I2G'HMK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g108483g54m92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g54m92.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( )(
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M[J;>6^M4T[#O$6V8<O=MNNVV<U<WZY32477D:+--RC3<6XM&JE130:N62!S
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M"]1PN 1-K&9L<*Q+,D>6!%B=0&!\9^'&.K.,G@DCU[@]M5I#WR6MBQP/''<
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M^>WS&JNBP.Y'S$^A09'<Q]^2@-RDJB*9H^4E0AX*0>>Z04CU/KDZQ/M)$1S
M;><3_5^R.$.BPS;X1Z9\;JF*0KSE?!T84H=''PXSQW]/Q/XG4*$*0#DCG]_U
M:(JQ3X4*)!CE: M24K(SZ82#\P.._P">=5<2"T#<W]/W4Q@[%::(4/I'PCGO
M^>K*[ "#(!OOY+,">"\,>%-L) &,;;F ,9SC_$5\9!.?SUF9^D?>ZH?H/D%<
MYU90FB)HBQ=7M)0B(\7;=3$ZL0U2EC$@C&0I.WBT^#SC/<]C\M>?K0>)U!N
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M.UAZ+4,O[PJ70,@Q(HA]6<@"($H!*#G(!/H1R>2<:4GAG.<PPF(R1<";Q/\
M?>FI:74VEY_V;2+#WC-[7N+9M&5+*]D?DURN^3<1"ZD#W7;-'EU JAA95%N2
MR5IB)AJ68ZT*\I04L(*(9Z$K4DK0#O\ #G<_-4W<9WV!MTM/3<+F:DMY*(:Z
M6MYP!:WZ;SDSU/2UED(==5:B:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(NJY2^=
ME)\(5(W=ME.B*]/LXA^Z/IL3)B7!]REZE]1T"#5%E;M%-FY6I%O)!JPITS G
MS*>Z18<91%R1EW"85R*?.U:WKV:3ZI5-J2Z-4:DSW%2'+(2-61(R%453)R;H
M\W.0):?^BZK2ZFF5C1$1U4ZIT^?2A4I.RL:*10[_ &RB (ECMDL8@_R%S;PD
M'.,%;98V.<>I3VXR <:PU'EKZ8'^7/Z!OTMYJA<!5ICJ*A [M:#XJ&78MHR;
MBM*_ZE#E84S5:-/RHEB2?@A1 KJ6$@X)*UIY.$]OEQY#C^I?I^+:-OYCF47,
MYG<LEI]Z'3U$"8\[;_+O:_V@K\*]K?971/JLI:'BS=8VN7"'.K4PTT6L<<<U
MP6@221C"ZKG&FXIB'&_R6HGK)!3 "4](4HG))R#@ Y&#SSP<:ZC=?HVED5V"
MUY>)O(ZV\/0+V]/7:1KA.H8 !@NO<0.@.#\%1%LNOK7\<G$0D$)*T(!\M( '
M4E*>5E*<%2$Y)QG&59.PWB&FFU9AF\$@9,3VDVF%LGB&C _[FSW<!\\>),9\
MO0%F;+U!T2-9GZA#BI@4^GS\<D]2 D096+$&3Y1RH8X&<J.1QA1'G>,<8%"H
MQM MGGI\[K.L7"&@!P%[S@ =9"\#[:^W>@]G]5PO0MJ-?J.(ZG3T:3.8.=RU
M*U-CG$!P('O #W?U$!>7J9 A2[LC2R$%0]^B(1DC)"8B(15S@KQP,??W&O5U
MCS:*DZ8+V->1^QV,$]<;V7T@N<=)2+B U[07=< V.V^T?)9>#P>X0@>%_L=@
MCJQ"V^LE ZB"KX9:*.2"03QW!(^1UL:5W-IJ+K>]3:;8N)^YOU633NYZ%%W_
M +4V&W=HZJY)K869-$31%CBO'L:TLX/%-WMSTR@34.A6JM543"Z#_(1OL:M#
M+08JE#. GK3DX'*D\Y(S\PXMJG4O:+4,YA3+N*\.ITG P7@<*HU'-O\ JN7V
MW#2(L5R_Q"XQ4X'PW\+:>G#W.XS[15=-JXYG,;0=J^(L)$1R&*-.29;)[@"P
M6R&?'<K!JBJ93ES<]#J03",%*OC3T*24J*@".G'(ZAD\]@!K+Q+6G3<6H_G5
M.6D:$U-PUSG2" )DGO,"ULK:XGQJEPOB-!M;4TV4JX#RUUG\T"1)B]Q:#/<R
M3Q>5LP^Y@QD)HT7KAE:H@ZH:2@<=/PJ6G"224\C((PG.#K<J\=X<TL JDR&@
M0'N__G.YV$W/7>;[6<!(-2MQ-E$20&?DOJ'W>CP>4R+D' MX\P;=AW?'JDC%
MGZ:8$DA7FQS#C0(D5:0$E24PQ$4<Y2. GCGC.L%7C>F%*HV@7.KD$,YVN:T"
MX#BYP;B3%[VOB/'^T?XC>SVETE9S.(LJ-IRPD4JC(JF(:6 .)$$&1:X!( *D
MY^RU4KZ'\27<[(I@JEX<#;!'AH@GX2CHN0P\@PTX"0?,['D*SV(QKT?LT\U>
M'4W.=S5&EP<[,RYPGF_RF,CIN(77X#JQQ+@G#N)MJMJLUM-U1G+,AHY")!,B
M0\1.8*EL;Z]\=-VVT93$8YEZM>=PTP3,DB-"3,4UD4J;\V#!<57AK2J#.5*,
MJ'%-"HB@M$5<,U&JI33T2TI5_$_B5^)%'V1TYX9PWDK^T.JH\],. ?1X;0J<
MS6ZNNT@MJ5G$$Z;3F0XM_-KC\H,IU^-[3^TS.#TSI=-RU.(UF2T$2S34W2!6
MJ##GF#^53-B1SO\ < :_S/LU\1AR/5S6>V^N)@1*K5:NJ+0ZM<NHOF9G:I4I
MZ%)5.KS-;FZ/%;>8LQ.1H"DQ(*JT>@Q2L1U!(0?'?A_^+.LXAK. >RVKX6:]
M:N3IJ_&*O$GU*]:H*=:N_4U*#M)[SZCFGF:=1O/-:%Q?9WVNK:FOP_A-;2<[
MZDTJFL=J7.>]P8^HZJZF:-W.+;C\S)F=EZFWA[J7C8V\.WNU3;>=G;:4Z[[*
MOR[JN_;P,5^7#D)2<M'5+'TVCMFC4!AOM@SD*;<*+KU2>FJI/U.:EY6$W84O
M#DRN=5%A_HE?2@V03!,$"!;(<9GR]5V57MX5O92EP)>EP7 MQUR]%Z=N#=,U
M1(":8;M64M'=N[KCC5%*:PJ-!:$:@V;=*:;4(:XT[.3T6E2462E43D:<E"KU
M[?N!]5P#93N8N+N I#OGGW ;4&-0K2[5GO)"@TR;IZ%5F\VWEL71=R(Z9FI3
MYB24)RU>;AT> E4.))4P0I6/'G(R#-+*2(/Q^9'T74-D/%'M77+?;5Y*Z\:-
M]J=W+-[.W#=*LM4,^FLABW0W:-1FS#';L1NN!^RUR9^5<CI=M,1#4Q6E<"FL
M>B5ZA56X%<;](CQ*J@IY3>, GK@9.(_HKL^3\2NQBY)PUNLLR]+4:M,8UZGX
MUG:Y&919>C7/I^WQ^4*V=U:6PY>GNVI5\UBA/-T-VF4X/&B-"D.F5JJ:VUJO
M6:#3JS4Z:41/3]K3?U^!5.I/B#SCDO%:RTM"VL7T@1WG>"Y=EWQ47'7+#R,Q
M;=S6T8S??-8G(\G0+R.>2<E'E*6Y)*=J<S1JNN8ATN3J46A2CBJZ*?0ZB4P(
M)YA:+7O/E\][*H[)-[<?<4W[9-FX;%>3+NF][1N6Z])K-1;--H5O;EM]B/6@
ML-_U>W(@NQPN27D6@XGDRI">A/2D-B-6(#FI5?:/UC;4VFKH*"-_#XQ/[QX7
MNN16TO?N#O,Y;COYE25G*'M]MM>:[EEPWG-37K/78>\6QKHKUM;B/B3=U+<$
MHU&?!EKF-9STEM,F<8CIB.!O465KDZ]VY'KZ*;1R$18Y@'XB1\Q?T7BYG^(S
M=^J[,;;;H')<';8WYNZ]?VAT>8G'/9J\ML;;V*@[AI^BH>,\]W%<.\%.E+GT
MMGR3@@HIKB:E?9% B1*1,U">G8LG5Y*!)O!6Y021>T[B3'E;U7:%<WG[EXNT
M:8W1-&B6&F$LUU7);"&]-4VXE4E-U\^V[N3-L+1RNVVHP'#1(S3@;C3+R,>V
MM<<$K=.2C5MT-^1I<F[&M&@/>I% %X^QU)%\"Y[=+JB/[Q,*G:V^CC;3VCVC
MDF@W;WO^S4_8Z'$K$#=%)M=G6.=-V:+N(0B<<\.DU>W+XJK630*/1)6WDG39
M>A.*EN)%T:C6I&HLP$Y;2)Q,[9B+;^?DN)O#Q2+@;9X-NIW=.PF379:^5H&#
M>2W<O92$XJ5'9:7.FKQ'1;EXS+NK+CAO&;:4/ZK_ $;<6C2S*E7:NIU<1+?-
ME-+EU5$IY)F#@D7[;V^6W4KL.I6Z:M>>4!^.#<Q6J;<*!N JC-<+K;]E+W6Y
MJ$&HW3J]AH#59U3A0'U"I[;(I+)L^P[4/QR2\Q9]T4>NQ(M6:-Q'>[IMQ315
MGX189Q.?B>G7$+T+L$8EO6#:]WTVV]U478HTX\Z'.3M:@M%R,V6EYR':*U\C
M2(TI3G76*].QZ<Y&3*-%W4"9;D[(6QAM:NT"1M2VFVQ9.CTU)'7.(^_L>4&Z
MC:^V0*ABP^RY"\=2KF7<* 3C/2VF2%8^9'4/PUK51S5M/)@?[@/_ -#]"L#V
MDUZ!&WYC2>G,&_0%1 ]E+K:+?I;_ )1TU"3E:?-0I>85"G8@2F,B#&6B*$)Y
M*UX"2 ,'CN!KQ7MA0KOU.C=IZ;GGWV!S!S'F,<H.PD<QF#VW7YX_'[V9]H>.
MCV6J^S5&I5UO#N)O@L+@&TWTG0][F^\T![6S< 3.8CTS.7NVRTI2LB2FB"L*
M3!DRL%2D@ I,12E*'4G@E7;OZ9\XS@_&ZH@:>HVX()#6FQWLT3$VC&!T^3T_
MPU_&W6N!=QBMIFO:TP_7.#:?*)#0&U"1&\C @&8"X^=S&W=$;HAT:64D@I"E
MTN6*>,!(*>3D'*@0<JS\7RULCV>XS!EKI'2H)G)B^]K>?=;@_!K\87-)?[6N
M!F>5NMU7,.X,$6B]X](YI!OW96>:CF-"F)2E111*@/(ARL*67&6N57#1#2(*
MLK6I:@H=2 G 4#R=:;^$<3IUJ#*M*H\NJL ))<![TR21 : "#[TW&UUP6?A)
M^)U/VIX'K>,U3Q*A0XCHBZN=34KAE"EJ:;JKR'N]TM8USFEUN8")! 5FWZ21
M#<JYZ&H*A^^Q5=8[%,2)YJB!P00I(2,9X)]>WU@LG3-I.RVF&VZ?2^>@DX7[
MR_*>_0LID %C0!U\_KCKA9?'P>YM$_X7^QR=A#IAS6WQD1T#.<)B2L50YP/0
M_+5]'3-+2T*9,EE-K2;"8MM91IZ;J-"C2<9=3IL:3BX:!A7)-;*S)HB:(L9=
M[10[JVT_%<W;RM*J$:! =+4LK0JLE"OAB4]=F+73J9>*!P0F++0HB0?G@YXU
MXG4Z2CJ^,:BI6HM+Z.KIZBF8DA]/0TM*'"2;FFRY W<  %T.)</TG%>&>SCM
M;1;4/ M;6UFC>2015?J-54]^X'*UVH=RQ%PTDDA6*6T^G,WZ1/TJEU.)*2,X
MM,6,(2R%^8DX04J'QI/.#@Y(/Q C(U75\.TNIK4JU:E^948TM'-@B;\S<$;B
M1 ,WF"&LX7PWB&K9J-7IJ=6II[M!;(=+0-_>$" "V)CJJ.AY.),2-%-;J!*U
MK"B)R-UJ6H$ J/6"4A/Z79(/(^9V':'1N#0=)1$-!$-M N(&!?&"5ET]'042
M6LT6G%(%T---KH.]S<B;P3UM*WDB^W7)*@1H%>GX)AJ"H<1,U$^%0 *0 "03
M@GCA('!!]<9T&D<7,.FIWN3RWOO.1?OWPM;B7".!ZK3U#6X7I:_.US'-=2:&
MW$DD-$.(G)VR" I2/LE=7GJ[O]W'52I3D2=G)K;#.JBQUK*BHBYC"RK)[E9Y
M*A@9'2,]/'?X:QFG8W3TZ88P ^-I/S)ZF23-UHTM)I=%I=/I])3;2HTVEK:3
M &TZ8 ;#6- $-&W:%-KW;;1V1NF9AD:B(%!N#0I:.IDOB'+A<Q3XRNJ+]#UA
M,,"+46W/1N9J4),:2C+-0IQ1,"-"FO->W7L+P[VTX=^55Y--Q33-<>'<2#)?
M2<9)H5X]ZKI*KOUT[NIN/YM*'\P?PN/< TW'--R/BEJZ0/\ IM2!)83?\NI%
MWT7G]3<M/OLO(=YVVM^'"P;435K[KN:HON5O"U8:Y^LT>&X6Y.LU%>5+S]+F
MD2T&7;(GX]+B0)A4>4Q6A'(7"7$B@A<'7E/8O\).%\$?P;CFLJ\39Q_1 U=1
MIQJ])4X>-5RU:+PQK-'^:ZB6O+Z?_(YKM+CEJY/!/9#2:!VBUU9^J;Q"@.>I
M3%:B[3BJ6N8X-#:/,:9#B6_[DP1)F0O>-<M(UG!=^W5[)^+5DO&V#'NG;]MP
M9>;@0Z+$H5WZK:^L.N)4Y)4I$F)JH0INTC632)B#.RL*3@Q:LB/+SBIN N3^
MRKVTV(V)!^$_N5YRFMAUKYNZ:+FQGY>#W&3NI<:]E%M:AS-N';&@7/NY9][V
M4N*ZI"GH9H=DY'<C6N"Y*FF0KSPK-);[EG9FHM20H4I5*]3:N2;1;$>L^7EG
M>5VM8[;-;K;])UF18LPY8\&NL^TS(G2X*G)U"(*-9FW%*M<T5P%2M,IXASL5
MM4B5BUF.I,2'.U14::EX$E!6F500F<_<W^<KI^V>P2UMF:O;FHVM?-SVA(L-
MA6.MW5F]"-K7!2[F4C;TU:6Q[>5)[3SOM:XG127"&E1:50'%5K6.*VRW#3Z?
M(0Y^$I<C)+ER$SGJ3X3F%U]?OP[6>^["KME;>L5&2<C>8U\V0SHCRKJT4">H
MVXNZC+NC=:EN:<H[;GYR NJQV<F@MJL0J)6Y%LRE2BS%<9S^DX4>B3Y 8^(/
MP^[_ $6EMXV,N9C45B?7AY)M[-68O?7+DV)9]DYYC5:A,!@NE@TEI/JTCC<M
M7L%;N1N$W;C5U;U=]=JYM8T'NWXCKEJ2VGG!F&_*5^8*2Z<#(@SO!SDQL,F8
MDKTM:_:G;&T=5LQ6&K,.F+-V)LY<RQS*%6JLG-P8S,NN\+4O=T1JZB!2I14_
M6X=9LZTTTJ>EER$O*246L0(TC-1)R7C291)@C8D'X @>A5&HVTEMM>XCK>;-
MNK>IFM%^/>KW,>MD&\Y&M"M*X;AN*" Y'2N%4&34;C4,N:HI+@<S8:MQ: QG
M$Y(]0K=::T].UBLQ*@2;8'C>?G';&%Q"WFQEIL2V5L;.U*\]\KC6YLI7+!UJ
MT;>?,W:."&%#VXS\C.V_HU/JC$M QZS6J5,0J31:<XR[Z@XZK4I*D2JI2J4V
M?CU*>GR3G F9[SXSZ+F]^-K,C?5^6MN+$O/>:V->L\'',,V5MW&M5/-Z!7'-
M*0J9..^;;EU;4W/HZWI(443U H#JE)62K- H5><]*I,W*RKGKR*@0& 1 ,QG
MMWRMU7MK;=?+^ICTNI<6YMV*&VXE<GF7:EYQK?2ULF=7'.QJQ;>ON.0IS+MX
MT70XJO4&:YW=1Y</]VO&F4*&[:[&;5-HL>)(1) D]+?W/TVA=9L?P]+"MR!*
M2[\F7MN A4!FLVVK"3?.I-QS?9Q;:WZ:VEJLMI_5MJM 3$"437YU-5=;N#IN
M*ZQ I0=STKWT-2O="$SL!<FW?^MER*9V>TNKRJ)=T70>+HF8E]*3?VH5ZJMR
MVGUJFW<WJPVJHW4RKC@,J'4: *#3FC0V12:@W(E)J4C;N!%:<M,0H*:?-TXD
M]AZVM'7XS*YSMGVTM7:^T*^SFDXG*XY)Q.2 YY^:<@HD.875H+6;;4FJE$@T
M"D461CUMR0FQ+N5ZUR+*JGW4]ZLX7-/+AQZJ9: 0F?L_51/_ &S!*XEE]C<)
M$0PPNY5Z>H@9ST-AA*'J.Q_;K#5(;R.B8)W\/V_E -^A&TQ,_MYJ M39V<@J
MC0841<%$1*BOI40%DJ'5P.1U$]1SD<8QR-5<&ONYH,=]SD^%L;64/:Q[FEU,
M.(/4'S%NL8ROF+#5%B*$8J4DJ!R%$'X1_K'*B"?OX[8QJ9AI: +Y,#^/G\+*
MY%I #0(M !O\KG$7F?'\BH3+*ZDE1 25$**2>_3@'I&/Q.>.,:EKRWI'@/#S
M/C_*J)V,$20? $_>RJLD9@9,.8B0TQ4*!AP^H#IZ22%8("LE0]!]^<ZQ/<TN
MDL!.9.>WPB-E#X>V' 3,S VZ#;Z?*C0>OWM4!40D]2@%D*^$IR<E)QG/XG]>
MK$VF-IB;1F)O_*L'$#EVZ8VC;^"5F!/!=P/"FV$])R/X-S P>>WN2_GS^>L[
M/TB\VRH-S.) .VX'2RN=:LH31$T18N7VD.-&B^,'NLE"<HAR-A^D?$1TQ-O-
MJ(I!2"!^DK@GU&>^N%JF-IZQU6)+Q<0 9#>7/@.D^2[;/]SAC!CD>1X^^3<1
MU/IW,64T0T"G1,!"4X0%%()5U'(RH#!)) YYP22#@9UR7./YPSO&1XY\[=H.
MR[-'2T_R_P QP!)8TD01L!,_Q.>RH<.70)7S4XZO-.<YPH*.>W8'Y'@Y[:VJ
ME0FH!<>XV(-P !Z3MVP!8XZ6FHNH$AC0?S'YD CFCM%K ]2<0ON!#\WSD8(2
MA!B$X/"@,  _%P>Q'J?3C4$GW7 Q+H'<6,FP,W\NMUKO;0I.--S.<NO&PFT@
MB;6.Y\Y4K[V1.F&%O.W#U8HP%[<HTG#7V!,6XK,BQ$  ^GD@_$GNDD8^+70T
M==O^K_T\W%(O;)N0(!-^L@D#;M9</7&@U]%M)P+WBLYS  .0,-*!$G/.;V (
MZXR$.NTM--$31$T1-$31$T1-$31$T1-$31$T1-$31$T10M_;*O\ ,UL:^?VD
MWK(^9_Y+L'C]O[/RP5A/)>+D?*ZG8^(^3E )DE%4>( .0E8[9]1SCGM^O[O3
M0"=X^_O"ASH,X][X9*^@(AC*!AK[J^(I[_JU"NUP$YO?;U,QXE?:X:E)*<$9
MP.0?0COQHI<ZQMM_["?A*JTL50824XSTHQD>H Y_?MC[LYQEI))L)ZV[>JQE
MP)L,[#;J3C?SGNJ&"J'.&*K"@M<0@ G*0H*XY^6K$2WEG8"?!2!-NN%F!/!<
M.?"DV$'Y[;F ?SD5G6=@AC1T$>JEP@QT 'P 5SO5U5-$31%BY_:.T'^.(W:1
MD@JZ)&PN4I&>H?P<[3#/'?'.0<8QG7!USO\ E"F,Q,D@"XYLS:)A=RA'_BSG
M_L.PV=/<Q.-Y\59+EXP5*+A@X$1 "L=7PD9(PD G@]^K/.<:Y3V>_,20Z>YV
MN21XB!>TKN::JU]+\O!#&B3V&WE_/5:$*"A$J$\#*R2HG/Z9''2,CTZB,I(]
M<>F1SN9\[<K6QT@&Y-NMLXBT%6HL%.D1((YW$F;B23!'?^H6M"A)A)F4<D*2
M$'",904@J 4H<@DG]H)U!=)9:!S<V9-L;G89GYK%3HLJ:SF>"YK:,00!-W'K
M%NN9E2[?9+H<E#W)7KEX<!4.?79"8FUQU$8BR:7JUH)AA&,@ICQ4J"B<8Z@"
M<\8- :M7VB#S4'Y;-(]A8;^\7 D@X)AHG%R.D+PNLT=9G&JU<56_Z9E*K3;1
MAW/S5*E,M=.(#67WDVMB?!KVZRIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HBM^H
MOS=YU19VB,-\6JK+KI^[E%DX$O1V-4ZW1Y]A0Y"@O=R3=6BR]S(RVU6V5;6G
M7,FHM9FI]=/=;L;M-H<G2*%.U6!3$%-MYQZQX;GX+T!MPNG4;L,YUU.M.-D.
M:L->[=UV',5!@RZY&BFFM)\UFF-946GQW,[9B4J$VTX=#J$U$BUF)#J9FTUB
M3EI*0J$K*PB&WP'J 5$Y]LJ&;,['/G]I-ZL'Y9;#!UAJ@DLC ))]/OS4%P:/
M,1'8%0$:,4B<C=?($*)GC.3E)_<_,:HZ8L8N/OXPJNV_^0^JJ\5> ?+1E6<C
M(2 KUQR2>?PSJ@:6F21&#<^ V\%+2TD 'XS Z3;Y^:V*O,\]!6G *DY Z< X
M[$CD]NQ _7J\CTF-S:;#=7<(!NT6V^,_=HLMVGJ4H#!P20 !P1V.2<$?>,=O
MQ.GCFVW>W4>)'3LL<B#<;QCRCK&.Y"HDZI,":Z5)/*5%.!D C()Y(P<GTR?[
M-2K-<+$;'^_OZ+, ^"W_ $4>P?\ JVL#^XKUF;^D?>ZDW/D/D/OYJYYJRA-$
M31%B[O:.X8_C?=W,3XD@RE@DJ*> O.W.TX(X(/? 4>#VQGG7GM:?^>#((#1D
MX(:)R(Z[]5V=,]IT7Y(D/YB\]""8L9F8[*R%!2B&!#6%I/DI5B(1CJP"1G/I
MG@>AX&>QT*ES(/\ D9+<D2;X[S-SC!NNCH^:7O:8:YONR8-H!D>. +[Y6O ,
M'RRDF($I7DY 4"K/'PJR<* Z3P ,9^'6-P=S6C B#!BTXM;/<F^+;+:S6TB'
M$DASY\G>,GL-LJLPY9(BK05 A2!%2D@@8P4D8&0,G. ./F!CG ]Y# 8N'<I(
MB^.L;V,S;K*SZ"*]:LYC@!2H&J[G);[H))#8DDP# M-U+']E&0J!O*O7**.
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M,DI25#;C:C[CG&1Z??G(UR]3_P!CI(;GX2?G:86Q3IU'-EK20-__ -C^VWJ
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M(F9(!FT$>7]A=/22YA#6N<0, 3&9./([6O8B+'4*7DUIAXC=( PKSA#Y)."
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M=7#79=RS(W%Q( BPQ.TSB]9;%'J,U&J EX)B+A1C#4I('3U"&I2B%'  )4E
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*1-$31$T1-$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g108483g54x17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g54x17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %,B^4R X0DE-! 0      $T< 5H  QLE1QP!6@ #&R5'' (   (@>!P"
M4  536EC<F]S;V9T($]F9FEC92!5<V5R' (% !=0;W=E<E!O:6YT(%!R97-E
M;G1A=&EO;@ X0DE-!"4      !#%Y9V$,<94)9V>B5'TF+\R.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE- _(       H  /_______P  .$))300-       $    >#A"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              G,   ;4          $
M         0             &U    G,                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   G,     4F=H=&QO;F<   ;4    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   )S     %)G:'1L;VYG   &U     -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
M   '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG
M;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O
M;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/
M=71S971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H
M=$]U='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$
M$0       0$ .$))3004       $    !3A"24T$#      *.@    $   "@
M    .0   >   &K@   *'@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E
M &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,
M# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.
M#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,_\  $0@ .0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M          ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<(
M"0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C
M)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3
M=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1
M  (" 0($! ,$!0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,S8W.45U=G>AL;6VN HG4V)C<Y*RL[?&X?#Q_\0 '0$!  $% 0$!
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M<N , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MTL)AZ*'9F52 >RC[F_362AV?X-[>(!_ !!]\ [#!RXCV%RGR^YAZ!E5.OU?
M?JK9AZ)_=]^Q_OB; ."P4N   W2P&'HH=BQJ0=B7Y-^FM%#L_P#>#X#^Z!1]
M\ Y-!RPCV%RL!0[,/0,ZIUT/P'O6Q'HG]WW['^^)\ ZE@I<  !NEA,(%* B+
M*I@(B7Y-T6M%#L_P8 #Q_P":4H@ X!V&#EA$1"Y6 O8F'H&54$  WP >5;$>
MB?W??L?[PF#VP#J$%+AUW<[";V*'8LJF B)1 1,/C6BAV?KHP  %Z[\2E$1'
M .1@Y81["Y6 ON8>@9500 !#H _56S#T7Y+V(B(_Q";O /<9-UFK5)!P^<R2
MR8& [UV1FFX7$QS& 5",&K)H42%,"9?1:I )"%$P&.)CF JL 8 P!@# & ,
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MH"4L11%%H9TD!8[WC=L;8NQZ13%'SBO\F]+?35XI7G7UC?+ >1KV\];[ N(
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M]D(0EB6Y3MA=C/RY3J_#*J-T(USDJZKJZVVX[N9^4'*C & , 8 P!@# & ,
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M(HR%5%7*FNFZ<**H*,:ZHN,8[\,YHNC & , 8 P!@# & , 8 P!@# & , 8
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MO"9=VW=VPM2!OJ:K39?60W>7VO=FU#ICBRNII"<=",,2$KK.5CZX]KC&0!O
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M/ZG@(?;=>'J#Y^/\/G^KKOWP#@*13 ."@5*M <#>8'""C/(#^($\^_M>_+P
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M7E^KY]\ ZA2*8!O,*E6@/WWY!!Q@&[\1)WW]KWWXB)?] ]?& :V-D5VO0OU
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MVZZ9%D%T3E51625*!TU4E""8BB:A#%.0Y!$IR& Q1$! < ^N , 8 P!@# &
M, 8!@KD3LFN:HUM)W&9.7\89'*G3$$E4T9%U:E2'"/29'.4X@@4H**S)1350
M5A$W[=VBX;K';K 1!X(:^>R4Q;=Z7M59S<;>+U2NA)-E$73F+D7QUK!:VHK$
M*FLA)R0%B6RK, *S;MG29A!M*-2F V9X P!@# & , 8 P!@# & , 8 P!@#
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M=G#H7/?9 ]S!\E#YZP#@MSIY@[+:JX8.BCV6;C1#H_L0>P<]=''V*/P;]N\
MY-<JB4>C6FNE'LP=&FHT![)_&'0N0'LG]X/DO[]8!P%SIY@[+:JX8.BF[";C
M1#Q/_ /8.?@_]T?@W[=X!R-RJ)1Z-::Z4>S!T,U&@/9/XP]W/R7^\'R7]^L
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M5O\ O5@#^NEPY_SLN-'\_P#N[ZM^/Y_]M6  YI<.1^.67&@?]&]]6C__ "K
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M%(=P9."N\4W.G 6M!N510J?D90(J91+X'D8A10QC$3]0KB/644<,E"@J[;/
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MW\A_I_8>^QZ  3H/?V ?<!']_?\ Q$!]^A_]?Q\@=@']0AWT/1_?K]Q[]O\
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MVS2($&QIRY:SOE5A@>+?;-!EK#5I6(C@=./!3T&PO'B(+K>F?TDO(_@;Q\1
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M8!]P#*HMKGUY_BT^^_U[$-;IKZ[G[&>"1@# & , 8 P!@# & , 8 P!@# &
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M*ET%X_\ '*]K2>81R$#/-UG$.Y9@8&B,E$(K-7Y_Y_N^O0CV^?/[G_/8G_\
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M3C\P&,T\ /I8WY)8&IZE!,W9"I('-(%&H*J0HFFADE/1-]QY_>E*Z #*^ ,
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MO]DM+7)N5-?).9AV]5KJ<$1U+)),VTW*R#AN,@H!/K & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M6;&&9QSS:="FZ.UG(F-E:_)1#Y"ZQDN:8C"2T7%@:.;,Y!C+OVAP^W;/(\B
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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@ P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g108483g61b88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g61b88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6?9:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 U+3 Y5# X.C(V.C4V*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 U+3 Y5# X.C(V.C4W*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-2TP.50P.#HR-CHU-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%E045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<7=B
M>C!0>B8C>$$[06@Q>3!V4$Q.=F-85G-,6#!:;V]:8EI9,6M.-V)3=7IX6%5S
M4TU7=%DU:U9G0U%7-U9R;&MA<F1O>3AD9W@O1S0O4F)#.50P:C@K.28C>$$[
M571T36=U6G)U,VQ7-71$9E,R9'I:5WE#,TYU<3-"<D-Y4TY)2E=K3$1D4'-&
M0G-C;41!3E)'53$X4#)P<$%0>C-F4G96=6A,2'%52B8C>$$[=3(K<E<W-E=$
M35-B3DQD4DI*2$MI<CA6,#8O1'EO;U9Y5%%S4%)B3#DW6'HW=DPY<4@P1U0O
M;DE0.4QA6"ML66YA=V$T:"]3:DTR;"8C>$$[27%X1C0O5T-X>&,U0VEP-F=Q
M2D]B2&EA2T%66E!!<U1L<U@K:#=$;$QL3WA6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,B8C>$$[2W9,+T%$-W!8-7%J>D9E-G(U5V4T:VA30S)I
M<TQ73S5I:FI-:DIC97,U:75*1&(X568P=5EE174Q4G=D2TYL<T1'<4QJ6E)/
M>5EO928C>$$[*U U-71E=3A+,TM13DI0>6EG3VM'3E8K=$E9=E%-,S=Y;C%0
M;4(V:'(V=C)V9WA(07 X4R]W0WHX8W9T4D]P85@K8D8S-59U=G)5,28C>$$[
M>$IQ>EA/;65N6C)%.71:=#E8:6=T,G9J1&-)63)6<$IM;54X,W X4'=J:C%1
M63)P12M%,WHR+U)F-E=3+VQR<"]M:7<X<TQA*V%(;28C>$$[;3%P2C5J8UA%
M,#1U0DM#,5DS:DE*-$IW;T]&0E%G-V(Q>45Y3#)B8U%K22MR;7ER271J<U9D
M:7)S5E$Y-7%/;C)1:DXU8WA7=VU9<"8C>$$[15IN5U!M>6\P:DMV26EP16-B
M36%D9U0R>%91,'I8.4,Q5FY84SE2=&(Y;S!J;&M&=$Y(3593645X=65$3E)8
M0VYI92]B1E5F:7)S5B8C>$$[9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F53
M84YB,B8C>$$[2&XW>D)Q=6QA<G%L+V5N>3-*4$A-:VMD;$=G:W5V<G5N3W-%
M:T5%8CA$16I/45AF8W%#,TI'1TMS;#%F>6IP;FPO>4Q,8F%+:E<Q>B8C>$$[
M6C)T;D%D46I):74U;W)(:7%E=DY&-E)K+V0X9U%D='IT,GA#<S)X5C)+=7A6
M,DMU>%8R2W5X5C)+<49X<49H8E1143-.>D9$3F-S528C>$$[=&]P2%9':UE5
M<455:T9J=4]M1VQ86&0U85=D=3EZ951X,C%T2%%Y5'I-<V%+0V%$:WI%06)N
M04%Q*T]33U=.6DDR1'AU07E/<$)6;"8C>$$[27%#0T]O3TMR<U9D:7)S5F1I
M<G-6465Q-GIP1VM7:'9.5W9R9E0W44U%3GAD4W!"2'EB;W9/47%T5&EQ<EEA
M:%EA:&%26'1H8WA8;"8C>$$[;DU/54YZ039Y>$]+,'%R;U-P1E(R3TMQ5CED
M4W<S5VY2;U)X=6)H;W!A:CEK5SAS;3,K>6I'2V]Z1EA9<3=&6%EQ-T9867$W
M1EA9<28C>$$[-T9867$W1EAH+VLR>3AZ4GIF;6)*-60Q,G<Q1'I24$M(:$9T
M1W@Y2SA35S1R1$ET=VM-4%-K84XV:C V='1X1TMS<&UU9GI&='1"."8C>$$[
M,E-E6C1R95A4,G5P;W1$5THO5'5285,S1'AO,'!H0E%O<U121D90>&XT:$IH
M5C909U8R2W5X5C)+=7A6,DMS6B]-6%9,>E0O04,Q228C>$$[9%!L365P,T5S
M54YK1F)G>D]81%!V43=#3E=9*W=Y,T-!6F(X;4UY83(U;TA4=$HX,E-E83<Y
M-S-6<G$S='IA,B]!5W-F*VEI6&-/<R8C>$$[6#%K,T-%9T)E5$-.4W@O;#-Q
M6E-J=VEH=6=!,FID4CAJ<F4S*VY8:C9J9$\Y;$TP,'AL;6XU4V-K2V-9+U%L
M=#0T9G1(9$4Y=6Q14B8C>$$[2$M10T\Y2FA:0C=L4'IB-5IS:C58,6-X,TXO
M1S8R:WIH:&985"]9:DQC4W-K:F]686Q'0DA42$A/<$$W3$M.:6U55SA0;W=2
M=S@S:R8C>$$[.4Y&5#%*1'ED=4EP>5DY>64K5FLR5U,O07)S5F1I<G-69&ER
M05!Z>71R,C0O3"LU5T-7=W0T1FYG93EU3E-7-6%+3T9:0E)K3F]K:R8C>$$[
M<5 V;D0T=U!H5W!Q3V]64G5I851R54@U6%=L;&]';WA387I,6DQ,86%L.5EE
M93,Y968X065T2DA08WA88G9$>6,X3V%-94Y"=#%#<28C>$$[>GDY62ME-U0Y
M1TPU=3%+,#%#-V)5-VQO;719:6Y'0G)78C!53#!I0DMJ;%@Y,S1B;6Q3<7I8
M1EA9<7@S4W9-*W-8=74S1VY82&PR."8C>$$[<W)72#=&+TLP6E)U;E=H-"]W
M1$%/*U92>45Y<6DU13A-4D%316=4,TI0<5AN8GI8<"MP,U5384A.<4U#,V$R
M,%5%3G)D>&U/26AI<R8C>$$[,S%O2E!$4#9N2%E):7)'5%-2>#%Y,7@P<G0O
M>D\X+T5X9E=023%X2#8X<%1G:EAB=$5O5D]*62]5*TPX,DQ52DM!52M,:5!I
M>%8V1B8C>$$[;S%Z95A7:C).>F5X9E8W,F4S:6MU64]*6&A+-D)N5&DQ5TA&
M:5)1-'%J359D:7)S5E-A-W1R6B].,FU44$5J5%(R5C99-5-O3$PK."8C>$$[
M=&PR8G%.;EEF4V9(2D$W251N27!E4V528G%Z.'$V=BM93W0V*W%A9EE,96UE
M6%4U23=T5VMI93EU*T%C4U-34E!X6C9*.5=J-&M-2R8C>$$[:WEC;%)6;$=R
M96(O04-Z-6<P9GI*<'5L,S9Z,VUK23AE;U)G4U)E;DES:W%C3V)P>%EL-V%1
M55AR5'%!46-66FYI<G-69&ER<U9D:28C>$$[<G-663-"<#EN-6IU-W$O=F]H
M4'!Q5G1.3FI9;FEY231-."MX2#DU3$=!=BM39UEB3FLW<$1*1E5+;U5B04-G
M>4-867%P6&1N85AL=28C>$$[.71D=U(S1G9*5#%)6E96,&%H<4MQ=TE/-'A"
M5F9(2$A&1W-C86A),$%6155!2W%G54%!2%%$1E8R2W5X5C)+=7A6,DMS12]/
M<7IT6B8C>$$[+TEK.7AC>G=7-E=6>&)4*W!D5W-D-4-A>DQ'>4UJ,G5O;&5A
M>45+-G=K:'%6*TAK0W%J=$(Q;7HP5#AQ.4XQ:5)V<CEN<"MJ45A,=B8C>$$[
M67A#35-X>%=Y<U=H:6-7-%5&4E5+>7!19%%-5E5T1#@X85 U<T]L,VUM4C-#
M47AA;F17>$TX6$5&<F4R;E)I1U5U;$-4.$E,0G%D<R8C>$$[5EIL:7)S5E-A
M=W103FME<513,S)O,FLK;DYW.4LS:G18:F-50D0P67I.>'%A9F$U9E)L:VI'
M:%$S66='+TII,VU(>5(U-W9.43%/-R8C>$$[,'9Z06)-,VPU1$I::C$W,$,R
M9VIT+U1*.4PQ2'0S<$XK.453>$ER,&\W34<K1W1K:&9-6&QZ.#9B;')'1%%D
M8W-T4# X5S!-3B]$3"8C>$$[2S@P;DE2<7-O:FUE,64T6BM18VE:<%%4569#
M<D%S5E5&3BM8,S5T4$%K3G(U;T9J1DY$2F(S0TYD6&0T.$%L;75+4U%Z>7)(
M2DDX3B8C>$$[=F-G2U@T;&U21%9E24]+;V@O2C,U=UA':5AD;DYR,79B-FYC
M6$@Q>&15=#=Q-6]R0S-A25=Y=TY#06M*8TEX-'8T:TQY,TMR35!)+R8C>$$[
M;#=6.40P:#=F5CE4:S%3*VYM33AK<GE4>7%H2TEN<'AT8U-44'@K1&QT>%=P
M4$9&1S)+<VAX5F@Y=$Q0<3-N<7HQ2T]:,#!U,W1,>28C>$$[3WA%8FYJ8VQ*
M255L;%ED1$57:T%4>$MC<6M&8W5U;T5-87,R>D1+5U1X9CAO9$,P3R]V=E!M
M;E0V4S%H86%J2S!&-W!H=#1B6D1!8B8C>$$[<3AI0W!083-->7DX5E5W<UEL
M:E)746=C;C5S5E=C*UIF2S)I-F8U4#%U1%0W6EE&=3=H.55U44=C.#=Q4UI:
M<$I+:VLQ67(P1S-A;"8C>$$[35%Q=C5M:3$V5'I*;U,V6F1*8E)0.5HK<T=1
M>DUP-'AG<E='3U-*2DMD=5A43%EC4$-B-7-49&EK0C5&,'I63&91,EA3.5ET
M2C=F-B8C>$$[,V1G;')22%-O=4A!6E!Q.'-!2$E!3E$Q,D\R,4U/5U%*-55I
M04E(3D573&5C679.5W!R2DAA6%5F,6$Q84YF<E8Q1$5!-6Q5=7-,2B8C>$$[
M8V]R35ET=TMD0G535&=01'=J=E-,=GEC9%@X-5(K8B]!2W9,64-45&A:97%B
M83%U25A(4#%E4$U.3D9B=GEP*WE703DX4$1(:'4Y-R8C>$$[4EIV>5)7=F5C
M3'I39$IU8CDY0G938F1/65)Z0U9)0DA,:S%U.7E5;T17<%=N-CAJ1$AX1W)4
M2U9#,$9R6&UY-G4W<E1D0W-,5V5#8B8C>$$[5W<X53$U3$9D5S=7>4EO859O
M>$Q!;DYU2$E)86EJ54HR>55C97A08V=Y,T$W,EA7,79"8E<X5G1B;TDT2557
M3TM.9&=Q24M+;SEG0B8C>$$[;$Q.9$Q,1D1',&MR<DA'=3=/-4-Q0C=K-&LP
M:T,Q3V$Y<S1B4G)Y865/3WI24%9E-60Q5TY9=TLX>35014Q4975+0T=O3E%S
M2C=*8B8C>$$[*T,U:6QS6%0Q575K9%=I361+.'<T4$5R5&5T8U98=F-7-E!%
M:GEO<GIK<D-P64%U47!9:%%F=$AI<$\S8D965$9867$W1EA9<3=&6"8C>$$[
M;G8U,2MD.64X;6583$17=$EA1458.&-&,TAC471.1SA5<U5G1F5,43AA4'AA
M<&Q192\W2E9::#5:,4MB5E!,;6PV;$]533$W85%8128C>$$[<&E#:5!L3$=R
M;F=&:VY8:E4W56MB+U=06$97.58O,W4P8B]M368X039G-VI&57AX5C)+=7A6
M46@Q0W=M=5IR5T<U:6QU<F5N,6E"2"8C>$$[5G!)*U<V.#%"<71E,6-.2W-U
M3E1S-V4Y=')+575,:3<U96=Q>'E-<#1#<E9D5DM,469Z15DP<4MW2S=&6%EQ
M>$\T,4Q63E8Q;E5V3"8C>$$[:V-Y3$A&36DS53!+36MK3FTX2U-K335D:#9K
M-6M-86-1=D5+>CE137,T84%+3%1V.45V2'%D:F,R>GAW5V1L8GDR;W1"169S
M4T=-:B8C>$$[9W=D46Y(,%9O3T(R<CE%3#)3;4]"6&@O;'92.5 Q-BLX.5=F
M;&DT;3!Z>E!A4GI7565S139D2$PV,'0Q2T-Z>3).<6QZ4C-T05A.=R8C>$$[
M5$Q2:5)V.$%&:7)+<FI2+T]E:6584$YL>'%U<G)Q<TXO95-Y861:>4M:1G1B
M3V4T9C16:V(P,S5E;$MT1C-23T$T,7)H5FXX,FXR128C>$$[,7I$9%17,%5T
M,6(Q*W)Z=6ET2DAY,F)G>$96<C-P:F%Q*T)52$1P8TU7<5A/<$-35G!R<4]/
M2C0R87-95TES5C1R5&)D,E P-&(R<"8C>$$[5C,V37,O,&PK:W%0.6(Y3#!/
M6'%38U!4<GEP-F9,,"MV9FI81SEQ5E9U-T\P=DQD-V$X9VIU8F%39VMG;59:
M15E!,4A*5T)",T=!1B8C>$$[54AC-E9,2G%7;EA537-C3G990U)48BMK4U=%
M:6A!1EE/;U1I0B]+8TE/>7!J9U9)4$]S4&Q78E)P22]-:S97.6M1>$1.25DS
M*T=H4"8C>$$[041D:G0P04]!-&9%.4Y--%IJ:E!%179A2'EG=FMN-G1P,7<P
M;6MU.7)!;'A:=6MS<5134U%X=W8K.#5+2%)J1WA$3#@Q-UEJ2'=B228C>$$[
M;FM->GA(<7<R8GEJ*U97<38O<4YX9&%V93-U<'%K<6%H8U!"1U!384)&.652
M-VA,4E!46C!G655,:%-#-%)E=5-9;TQ1=%,O2V92+R8C>$$[36)8,F=386QQ
M3CEP9S4V;&)X=U$R=W1&:6A.<DI.9$IC4C)5<FQU6EEG8S(U.&E&2$IQ<7-P
M,#,X*R]Y+W="4G9,5WET-6)J-C5E3"8C>$$[*S9T;FI22D),*S5!9UI797%Y
M1G)I9R]:*T(Y-F-3=U9F<2\U-&54=$M59E=9-W(Q5U,Q:VIJ26=I-4IE4DI+
M<D-396%+2VMA>6]*2R8C>$$[=CA*665)<7%Z,C!U1G5B5T<T5EA26FM74E5K
M2$8Q1&=':DPR27)U35968U9D:7)#+W=!,69-<V9L-U)T4'98=#=A9C$Y46AT
M235,>"8C>$$[62]29V5:2%9:,VQL9$9H0TAC=E)T=FAP=GE#<5!S;'5F378U
M9E)X439W=W9B*W<Y138U86-&65A(1# S;FHK<GE-;3!O2B]D>3 O;"8C>$$[
M86Q$:7%',#-Y.7%M:U@Q<#EE,74U,6(V,7)&-611<$]&0W=25#(X-U)W251Z
M:S1W9U58-#9B.4)S07%N6&UJ5T1O,VPK.3%13D5R5R8C>$$[<V9.9EA*0TUA
M9T)#5C-Q>%!%935Y8TE'4F]);$E!5U5D83-553EP2&-2>7!01S8X=E9H4$Y'
M.&5"5W126$EK2E,T96).0V$Q:75%;28C>$$[9'9R0EE7,75)6FAC4VQ$4G94
M9TM#5F=/-4,P1TAH2TQ35%-B=GI69&59=&%-5FQ"65)-,7)X83=C>7EQ=G!S
M3C1O4U5*4%=N<6EN5"8C>$$[-5=315)%8C=O0DYL6G)%4&U.9DY/9W$K=#)5
M8W@K<RMN04Q1<7(O=7A7<4YC33=F-T9X:D5X-%1S9V<R3C$O;D<K.#%7;FPV
M-$UL;28C>$$[<R]&;W@Y6C V-FQT-70U1DA,,'EQ;%)466=3=#DR3TM-5$QN
M4UI%9V-M439:<C)L6'(O5F]:5$AE2718<V)G3D9C<4(S355L2$DO>28C>$$[
M>%94,DIY<WA)6E=P86YQ,7HY6B]2;6MO:RMP14)P;F9E2S%J8G!,3E%G:VXY
M:4U'<BMY,5E)2%5O469L5%%2<%8Y<E1M,VQ%;#5C<"8C>$$[2V(K6F\R935!
M:%5&:G=9;&8S=G%.>#1Q0GDK154R17!Z2D%(8V=205I&;&)*,DMV2V9+3&%N
M-4TP;GI0-70X,C(K=GE4*VQB>EA*=B8C>$$[-3=,54=-8U%D,U<P4WIB.3!I
M5%1Y17$S1D94:61V:6]Q;D8W-2LP4'I";VYM;3%G:75B5DY(:VLP*V$X=6]U
M1G9,9$I,2D0V54UI4"8C>$$[.%1C;VPR3DYN4V\S2S1Q>C=&6%EQ-T9867$W
M1EA9<3=&5W!),&M2;S5&1&\T2W5J0V])3WA"0GA6479T3S K+W,U3$<K=&]R
M=7EM6"8C>$$[:DQA>F]S:U1Q3C9-:D%Q4G0S1TMO1WDX;RM63$=95#)7:3)&
M<DU$25),1&)1>'176E%S:#5+;U!X<6]$94E'*TMO94QY0C5$:%I':"8C>$$[
M.'0V6$<P8FE337!:5S9L6%5K<7=O;7I$:V%(1E574$Q(;&]3*W-.2G-H35=H
M:TUG=#1U6$\R47AW3EAJ5W-33591+W-J65EQ=',O2R8C>$$[9FQ7>&IH:7-T
M1W-B5TLS:SEA,U-',FAJ5T]5:TAM9U911F(T4G5..%946$9867$W1E=!9FY,
M-6HQ>E%V3#EL8S9,<D9L;W0R.3)6828C>$$[-C%),'0R:E<S;61O>5!3;4Q-
M,T5C04M%<T)V,DMR3&9,36QZ2C5C,'53-G5O<C8U93%H33$Y0DES,%4W1TU6
M;%-216E6,68W45E);R8C>$$[4&AI<5%A3#5K,5A82DY-;G8Y1'5D1V%05DQQ
M0D5U1#EP26)A9%5K;S9X4"LY2'A#:49F.')&5U)A+W!:,5A2<GI443AC6G4T
M>D8V:R8C>$$[<V9R2V]B671W-4I5:CEN9EDW-4M-<4YO2711;3AR95@U;%HU
M9$UT1W5M6#0U,&E72GDS:4A7<VDW+S574$56<$-E4U!+,%AL-U-0<28C>$$[
M>'0T63=T,UIR:6%*,FU-;%=*6&Q)-E)S84$P<%1*6F-H;6)21TY#:S-T.4US
M-V4Y=6(R24],:3@T*W5Z4U-/<#1#:3!2;4M,469Y9R8C>$$[6D,R4TMW2VAT
M4C V,#%',&4P=3%:;TA)3$MK:GA%.%159D9'>4XQ2&IH0G!6=6]A4G!U;S(V
M,CDY8G!C4G!V2#9G<7E.4VY*2"LP<B8C>$$[9C513F-14T954$PS;"]4.4(P
M,6)#>#5M34TP:VMS<F,U6DA9-W9).4)Y3DM$-4%$2EI*;5)S<UEX;U5M5U%:
M3WA6,DMV2'9Y6#!4>28C>$$[<DIQ=FY6.4U45')N4F17;&E:8E,R;'1:-'9Q
M-W9C96UJ=U)V27E),%1,.$UQ4C<X:S1F0UAD5FXS;3-3<D-(>6IQ,%9R8GA7
M>5,X<B8C>$$[<5E24G%G95EY0U8U1T-G5F0R1E-X,W)V:4945S@Q>E-,3R]T
M=%!U<G5/1SEV3G)70FI2;C-P=#E/4DUW1%(U<S0T<$5%9V)"9&(V,28C>$$[
M;SEZ82]7-V4O=#5R6&PV9C%I3U9':C5J9FIZ0DLQ.7-2345886Y(24=I1&%#
M:S@U*U9O-W%7,&)5-$1D4D)E54-T>F,X9T-O4E9Q6"8C>$$[2G(P5W!Y4&EX
M=7):94)/<G):3'HU,G9$<FAS671!,4=85&A(>B]39F]3>&=T5#=0<%-P1V5U
M,U=V=%1)*TME2W%.9#=:*UA(0F9%3"8C>$$[-VM6<6YN:E$Y37-:3#(W4SAJ
M9VDT.#)A>75O>#A40E(X56MA3#%08S1:6E)%5V(K5$A(<#543D-V;49-+VU*
M-4Q75S!H9E995FQV5B8C>$$[1'=R56M!159P27EG<$=F14]2:C0X3G0K869Y
M=5-I835.-G8K64AL4%,W4G)Q5RM3-&I5<40Y5B]F-W-A0593<2]26$=E84U2
M9&]X-B8C>$$[86-Z441R6#AW+TID>F1V84IQ<TM4>'AI5GA.>6A52W="*S-)
M1E%T.%$K14Y8-VII33A#871:85A)0F1B2W0Q-3<X;E=S.79"3')&="8C>$$[
M-FPP,T-,9S1K5V])2'AS;DI52'AD5TEW;DY%9%52,"M19VM!-TPW<GIR-5)T
M8F0W:6)73%0P,'!Y-%1*23(U-#=+:%IJ=65W>$]7228C>$$[1C)I3T-C:E%"
M5&$Q=5E,<3)I=6)D>$I"3VEY4D]+,%I(2$I4=C1G-4U'>&)8245':7%954]X
M5C)+=7A6,DMU>%8R2W!09%@Y:F58=28C>$$[;'1A6$56>7-/;U115$=*,6-*
M3$9A,T-Y4G1X2F\V3G-Y;F-(1E9F>D1R='!O5VHS1W$S:5-35SEV=S5P0V]:
M>C9J<D=+06Q2,6)X>28C>$$[135I27-T;4Q%6GE%4C%1:65C=$5.:VPU2CE:
M9V=E35-"<')3-6I&0W9+;DYO*T).4$)V;&<X559B3'=*6%<S>D-(,&XX=W9+
M*W%7;B8C>$$[,7$R=4I!;DEP=V%'5&U34$%+<E8V-4=/94UH8DQ*<%IW3D9B
M6F9M1C5F=DY4=3E.:&IV5&,R5E!707,W:&IU86994D=K6"]:2TU9-28C>$$[
M-&MK8C=,3%-Y:D533E5F3G$Y.#9854]P,G1R0F]'<%A.<E!8,4QX64A654%.
M05-R3%AF+T%#=4]*>6M'<4M9-$%9:VU5464U5C%B>B8C>$$[-6]/;%=2=DPQ
M3'E+145+4SEL9%)I<F1">6MJ4E K1W=Z>E)I3$XO2FIJ,#AP;6A8>D-U,VY(
M4E):4&5O3'%7,U-->6U33WIU;E1I1B8C>$$[-4@T>$AW-F8U5S)(>%)6;SA#
M5C%T9G9#2#!B>C=O5W(R279B4T\Y845S>3%&;F-Y8G(Q*TM&2D8O2$)$34I#
M>&9Y5&PP,&]':EAZ0R8C>$$[,G<X*V%F9EAT-UHR,FXV:3!T:31346TR6E$S
M3&M+<E5G:C=04G=P.75T0DA-0U-!1'-M96U-44-33B].5FHX,%@P;78R96UR
M;V0X;"8C>$$[<&-Q-U!Q57%C66]Y:7-W1&-E9$ML94DU161C4&E(:4%O;SA%
M8T)L>$-X,%I";')1:V9M<GEP86$Y-5%V+TQ+4#E1=')U,DYR0SA!2R8C>$$[
M:45!05)L56IA4#15;U!G<4%2.$HR>%9H;7$K6$Q0>4(U5#@V-C5E-C-Q13EP
M<7,X.3=,0D-S8G!".6%N:TE30T-8:W9*;751<VHX:"8C>$$[>31G+T141E4W
M=DY&,$A63F)T-V)69%)A9E8T:$PY56ID3%-11D(X6$5&<E963"MK>7E.2#%5
M3EAC9D59>7AG-VM--%IP4D9!,6%+,"8C>$$[,SAU3D0P,E!H6GE01TMK.&I$
M6D\K+U@T,W0R8CAC:DA&16-G>6YN;DDW:V]M>CAL,FQL9GHV:&%8:SA&-6-+
M16UM:FIS,4Q+=$M#9R8C>$$[=#9F<VI*0T518D$S67EY>4EO;EE-8FHX.5=Z
M965)=DMJ86IQ,&0U3E!.6GA-,$=N;4EY=U%'-60O559'2W(V649&6E$O=T%3
M;6Y%9R8C>$$[-4YG>D-B43=I94EX5#9R9%-X3E1L1SAD;7EM:'%+9S(Y3W5!
M9T9)2DA*0S-V;#9.1D8O3&54>E0R36).8G0V3VXK;V]55C1X=3A#:"8C>$$[
M2R\V=T=$:$8X:SAC9TMT0659-WE(4V9+9#=R,G98,2]$63)55%0S1G!.2' P
M:W T1VE)07-4>$8S86=4-"MP1E--2D%+26MJ:V@O2B8C>$$[9'I:95E)8C-5
M3$A53'1,,GAU<'1+,4,T83)S66YE93!+<$E62W=U5$=A07!6=6Q-2$-,=6MM
M4G%R,E0R-#AT0S5M9VUU8BME96$R8B8C>$$[;&)34U$R3'1'>$E.54Q7>$MN
M-%(P>$U195E54TDR0C5T,VYL,7(R,F4Q=DY2=4QM,FMP-FM%,%9L26IC4T=&
M5F$S24Y#2S1K03=&128C>$$[6D=*<T=I>$Q8+WI!,&)Y9#5H=$Y"=4QQ*W57
M:71"9'E7<V-.:C9+,F=%<6=+1D9S-FU-44Y*.$E)-')4-U1+0U%%16LW;#9,
M:7)S5B8C>$$[9&ER<U9D:7)S5F1I<D)D5#AT84IP970V5EEA6#585S185V(W
M54PV.3%5<#8P1G!D4U<W=5IR;%=Q>DQ--31H3V%,<TM%14M#<6Y':R8C>$$[
M861O5C9B<4<U,$MZ=')Y>&PY1S1J5T=/4TEL:U=61VIL36-F249*1G)645%E
M,U%K;$%41"]$6&QZ+W$Q5V8X03!J>&8X,#1%<48Q-28C>$$[9CAU,G1L4$Y&
M;W1M-U%X=DES4S)Y9D5656M,4T]/4CDV9G-Q5#1!-$%+-4I*2C5S4B],<2MJ
M.'=Y-FQ"<6YK4G1!:G-X0DQ"4&5W;"8C>$$[:&-.9&,U2D5J.6$S=#)P0W<T
M.39#;%%V5$-H;3,K1W9,;B]6<7,O*VME3"]!2G!X5D(V:F\O;'$Q1G5',&5Y
M65A%.&-(2C1),6I8;28C>$$[97)T=V%L86-51E!I8W%U,TMU3E=T,'A$>C=R
M;6YA3$AP-V%&-49M.'I.8V5T2S4P*S)#2D-B645E;D\T:&MO>E-F0UEY3U=X
M,C5!2R8C>$$[4W)/:#5B.'5K06Y38E%%.6I"1E5F8W5"5R\X0418;'HO<3%7
M9B]34$8O>E1I<G8X3F584"MR5EHO=T134$8O>E1I<D=0269M3%4W>B8C>$$[
M54AS6F9+5C$U9G1*-V53*V5A6&%&2C!U<$Q-5S18,#1G1V5+,U=F-&5Z94)6
M;59:>&EQ:&971FIF,FMT;F97.%8S851R>&UT<#!74R8C>$$[3C$X1U)G5EEF
M4$951G)M;EAT=V)A-3 X=W)E,C!I06UC17$Q=5I9-4IO=U%'0TTS;W)2*T1%
M53)P5V])455:<'HS<C9F879F>')&9B8C>$$[3D1',3%%;39R2U9"9%8S8EE.
M5VTU=T9)4D=+<V,Q>7<X=658.4\Q5'I28C9(6G9Q5FI&8V%I6E5I:&AM;&U3
M1BM41V9J5E=D4U9A428C>$$[.6EA-UEQ=VY3+SA!;DEV>35C3$=L.7!T,4)C
M>7<S33AA5WIW>GAS=&Y:3&5Z8UAK83-A;D9I:4U50W-2,7!7:7%O4'HV<W!T
M0W1D428C>$$[9S!S5S X:C)C5C$K;$QP8DMZ:6$Y<W!R-4%,<U)Z8R\S8T-G
M9G5X57E*,W%!<6QV;&YZ=C54.#,K6F].3&HP-U5:<E156F)Q,3%$4R8C>$$[
M=%1J=')I>%4R8U5C-TQW6FY94GA31D-N22]!>F-5:D%D:6AT1F)V6'10,'I4
M9$YH8414<E-'>F=:,FQA2S-J4TI$235Q-VQ504A*:B8C>$$[,5!F06Q%-'$W
M1E5T=B],4&QZ56)X8C-53DMS-WDY5D9I5S5N=#1P6E)(2$HV<4E(9%,S1EI0
M:D%R<S(O6$95>7A6,DMU>%8R2W5X5B8C>$$[,DMU>%8R2W!,8V57<39W9%9S
M-RLV=$HU2&EE-'0Q:TPR,'9P.%9F;$$S=SAN:%5*>4A39TDS-FTP56Y70DQS
M5F1I<D)0>DHX-&5C+R8C>$$[3'0Q66YY+V\W879B=D1,3F114C)L,V-023AC
M,75G9U=A,S5,8G,P37-S9V533C8X3TE&5&EQ-SAT=E Y.34V<SE51W K5S5D
M15-X6B8C>$$[8E,T=&)X>DE8;&1737-44G9&15%%47!8:TXK6%1B9%9K3V@R
M1W-733 X1C X9'A:=5=E2S1:,V$T*T4X23%L2DA'5#EY<3%B-%18628C>$$[
M.'I6>5-G2GAG4S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%O,C%J6E=R5'1A
M,CAC1%A5:&YU5VE254UK<%5+6DI/24A*>7%+3U(S;R8C>$$[0FER:EDR4G96
M=GIB>&TK4TYO175I:2MQ26Y93S!996Y,9U=517)7;%%-5E9S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5E=397164%1#:V-V,VY+=C)A2'!4=EA&5T$V-61F;3EB*V)B='1%
M<S0W>E%3;DM"8F\R<28C>$$[>&AL:%4X27=K<V,Y5VM1:FY),4)Y*WI286Q3
M9W9*=FU4.#1.5W8W3S0Q4%)O-U13<FU'4F(X4U)',64S;FI%,W K:DA.25IM
M.5-S6"8C>$$[27-R3#15,T]+;VUX=5!Z;G-T06UM=4QA,S%45T9A,6IG=&Y.
M=6EU<F,U8FU6;6IE0E9+:5994G5D-"M153AU4E910V%P*V8U5RMR<"8C>$$[
M3FQX95!N83AV45=22E=614UC9$QU4D]+35=K0FLU8W%B,'%&5E9&4C9R*V5G
M;6-V;SEH>"MR07%+>&U0,7A"2DQX048P2'%:=45*2B8C>$$[8FHK,$M#=4MR
M8FI6=GHS2VA9.4@P*W9/,%EU;G!O94QO6DQL879D>3=2<T)'5S0Q87!+:G9I
M<4]45U!Z:#E'9&TP3WI:>%EY4&)I<R8C>$$[87,Q-DQG<D9'-B]82%5),792
M;6\U;V8R:CEN1E9S,G,O;DHK:71+:V@P3WDO4U4P:S0Q94II:%-'3EI"-DII
M+S!X95IE3W8W6%AR>"8C>$$[>%9,-'1E+U!%,RML3F0V3&%7,71.25E,-DY&
M5V%.0DQ)<7!->E(S17-N-W11>FM50S V<U=90E98835R+W=#9#EH<70U4%DV
M2&)8;28C>$$[:W))>7=X<W%-4DA(2DE%85 P<FMZ<S!Q1DML;S9!+W-Q05-Y
M<DMT1TAN665A.5$O4VI+,FA#1TU76E%1<D=:9E1H-4=)2U=N2#=Z,28C>$$[
M=5AQ;BM8:C-X47EB1EA9<3=&6%EQ-T9867%S;#EB:"LV0VPV:C=D44M6,S9E
M,DMS33@R>F9M6D0U:FAK.'110S8P;U=J;5-'8C9Q<R8C>$$[2#%L5FQ+06QN
M4S19=35J0C1L5E5$=E4X5DQ'<E!Z5"MF5C%Q5E8X=C)Q>%<P9W0W=3)K47=2
M;6]J6G P;6MM+V4W.#%8,&E62&9K828C>$$[67%N>7EF;3%B,T=V5"MN1&1X
M4F97<$Y"=&XY065Q6DQH5G1O;C1V0U%);UE3+TIN0E!Q-S%+,$-Q5FI6+W=!
M+U1*8U1P;W1G=%EL328C>$$[5G!,-E)26D9L2VQ59$QW36558CAI-S!(=S!#
M:G%Y<F-E<2]N,&LX04]J,E1W<$)!<G-Z445V331I.61P3TYZ2'9'9E4T.$])
M.6IT:28C>$$[<4HO5&8U,R]!1FUY539"62]6-4=I1CAW35EA2E-K4FQ+5G94
M>4ED<%%"5&]O-C%X5F1O=7(O;E0V=&Y(<6UI,FYO0TM96&LT35%L.28C>$$[
M4DEJ-DI52F1&1S5Y0F58=W(Q26]O2$EQ=$IR9C4S3F]R>DYO1F=M<FUE1DDW
M57-H:45":F8Q6D=C6&TW0U5,.$DV2V8R=#9+;TQ7=B8C>$$[35@U-G=00DQA
M-D)B1S%T,DPS2E52<S T<3174# P=5HU1D)6;S8X45-(0C,T9%959C5S,5@X
M-6),5F<R9S9:85AU;7=W2W-J37%&2"8C>$$[:TMO,&MO6#9W;'A60TA#;W%N
M8BMC;C1657DP;30O34\V,3=33&TK:5<S,&EE=VIL,4LS4EEL:FIU6$5R3D@X
M6F$U.5)#65)T.$9!,R8C>$$[9D976EEO9&EQ>50Q<7 V655J;"LX-58K>E$Y
M2V0V-'%W5V4W+TXV,S@U,W$R=&AA,W9L;6%E15=R6$5S55AP47)#9E9+=$A7
M6#1P828C>$$[9F)2-F1H5$952$YQ,S4T4EAM;VU,4F)/84$S178Q1TYN:%I"
M06MD27%0.$%764@K2C%"*TY+;7 R:F]&2VQU,C%B.#=P<BM1,V5I,B8C>$$[
M;'!A=V97;6=J:&%'4515=#5V<39Y3SDP2$9:+U,R5E9R,UI2=&EQ26XQ3#@T
M<$Y":EID2W199%A.-V%I5DEF4DMR6FU&2DQG<C9L>28C>$$[>6QH3GEI3S0K
M2&12=GE#:$-W-C$K8VPY;V5S>%A':U)71W-W47<O;S!7:&E"8656=FE0<5A,
M>E<W2D=%<31&4U%W54971F-5;VHV+R8C>$$[*V-6='!&9W1T<&M&-7%$>GIX
M-F<Y+TQB,5-/<4-#9$)B3F)P=S-C;5 T;C9F1EA&5R],1C,K8TQ8<U K24Q3
M0DQ)=V5L8T-)5R]Q3"8C>$$[2T9N6EIO,E=D9WI%<D5R07%&<3)W54M3>7%!
M,$HO>G)F5SE/3W%X>7!P63E&9%15+V]Z8T-/14\P9G!&;G$P,W%&*S-P+UEO
M+TA&5R8C>$$[<C=84'IO<V12<V]F,&)&3EHS5W%4,F)826E%+T-Z;&M2<F5E
M4F)E449$1VY.95155VQ/67)V:7%/.'0V;"MD5#-&:&)A,W!.:$1B1"8C>$$[
M,#%V<C=M<E--1CE4,4<T4E0X47HX54961D9,5C1K9D-Q<6AB878X06YH2$)A
M97)O='!.3$LS3S@U;4%E;7(S36Q557!D<"]D=T-0:28C>$$[2TY7<#50555+
M<DY02VQZ-6MU9$)T<"]-;'!&639Y+U V,6$R-T(T,'!)=U-H1'ED62M*4'A(
M1D-B67$W1EA9<3=&6%EQ<VPY8F@K-B8C>$$[0VPV:C=D44M6,S9E,DMS1#@V
M,T@U=3(S;4%84&Q/,6=V=$M31TI0<61W.$-),')'6#%84$EX>2]#06Y3540O
M2F)E:7)T4S%0.#19="8C>$$[5'8S<SE)=$I,4E1B4C)-26MJ;6I).4M6-3,U
M=DQ:>6LK<C9A17-Q.%8S5D@S2E5O6%0Y6"]00S9V8E=,571%<W)#,$XQ6FTU
M;G1P228C>$$[<$<K<CAL3C!#2&YA9S0Q,U97661"6#=95E97,6(X-35T2C$X
M2%)R5S,Q0TU)=6=.1S!*36=A5FQD,S5856E":VEO>7$Q0EAX*WE60R8C>$$[
M<&%A,2MA<VUR-G196'5K4E)7155&>DIP9#%B8T9U2FEP-%%!4WE35#)Y4T]7
M-69'=7=5,51C1$9+;F(S+W=#8V1R<&0P-S9:2&9A;28C>$$[<39A3%I*6F)5
M4E!Y=&PK=C=2=$%56EIW,5=,<W!Q06DP0DI53'(S5R]W034T<F4R83$P0WEU
M8F<R:79D25=J:E589C%G<3A3:S-H;R8C>$$[;F]F17)B-SEF-5%P83!N5V9Z
M<V)53DYJ,4Q19$]7>6UA=7!Z4GE"1$-N27)24CE9;4Q(:4$Y440Q<%1A=4MO
M5WDQ9C@Y1FMM32MI,B8C>$$[:W%V2D,X878V0T)%8F=S>4M9-WAJ4DM-5C56
M3%9*<4M#37%Q,2]Q=C4S:E1T2'5R3%)B1G14;&IU13%E=V534#9V13-R1#!(
M5G971"8C>$$[:RMK=31746IC.39554DS4G(O.$%.<34X>#)3879P;'!:845!
M:VPS3&)U:D]42F%/>E)-1VML8CDQ8VQ5-4E"5VQD,4]+<S9X5C)+<B8C>$$[
M2E!7<6YP:%-/6#=Z;%@W3D0P<#-R:7)"3F-N+T%$87-D5C%&.41G:C%3>6QD
M:EE26&=T9VMA<D1%>7%P:FMT2D)Y;&5:8758*WEV,B8C>$$[45,K2W!F4&-F
M;FQE,G5O;&)A3%,W:%IK1VXK;CE5:T1W>'A85$TS1C5:=413>4,S43AN3D]O
M,G)I;$@R1W,O;D4W6&DS96A78U%I<R8C>$$[;6%Y8FQ',W$S>6]V1E=+,U<P
M8G9Z+UI',TAF8S!646(V.2ME-DU2+VAZ5'!G<TU4:&QK4F55>G-H:VIO,3,X
M25)'66-T-FM6-D=M2R8C>$$[='AA-2ME<G=O2#AV869&3E-D-4=:,%I$=U-S
M35E#,VQ1,&IQ5DHS041+97I$1E=L,40X-S5T3W9R;5148F4R,4M.3$DR3FI(
M.5=-1"8C>$$[=4HR3C!#>EA$<W=A2&I7<DI4;W4T-4965FUV4'IH,4A3=$IU
M<E-+,W-,>5@V-4AQ5G5),5)5-4]L=F)3,'53.&YW5F4U04A52T5)2B8C>$$[
M3S9R9&Q,*V-%9'1-6C1F6'5G;'1*1TI46DQ'6D5S6FUM:55234=P2F5*16I/
M>D0W9G=G2W!9<7)B;E4O>G<Y1W-E:S9E6DER;4PT628C>$$[,E905W1Y<DY*
M6#%*-5%L1U%+84=V>&EN,E-3<78Q4%4O=T$W171897@P<7=K=6]B,'AX>#%2
M635R54I+4%503S4U54QE;7DO16I6<28C>$$[0W1".%-Q5V59+TY(-3976FET
M<DQY+V%Y1S9C5WDS<U-'54I)>E-+2D]#,T5V<'%65D@U4VII:$Y'<FEQ8F%0
M-6TO3D$K9')B4CEB,"8C>$$[4T<S,&%D<FQH<45%36MG.4M.4UE/8WE44U)2
M37A89FM.*V=55GA6-D1I:#)+=7A6,DMU>%9:3#8S1#DP1DPQ2#(V9U5R=C Y
M<U998B8C>$$[-7!U9GI0=&1D33-L>7IG=CE,2S)S470W:5-&1D):-51C>3E9
M-6%Q;VI!4'%51F1O,G%74E9"5#9Z*V-Y=T@P3D5S-4IQ>3A055=+328C>$$[
M14-+27@X9W0O2G@O94Y+1%%T.6QE9V)K1DMR3$HK83!0;5!5,U)"8S922$1)
M,FUO0F%,2$IC3&$Q:4)5=7-W:F%F;'E$4T$Q-%5B:B8C>$$[>D]+;U)T5R]/
M*V$P:C0V4%I7,3)54FY8.3!9,6Q74T=Q;"]R:VAA3F]Z3'EP1T=&2T%N6FEQ
M<6%$<E@U=VY7=$YT9&(P:3!G<TPS,28C>$$[6DQU9%(V:E<Y2&MC4D=31U9K
M+W4Q4E9,3#%B.7)I,DMO5S0Q;C@Y1W5R1#!T1'1K='=%92]90S)R>6)M<W-9
M:6$K8FU&<7)O4DML4R8C>$$[3C9!;%%Q<W5T8B]0=%IP6G)B44Q*>'=H:E,R
M9#105#5+:FUA54584W8X56Y%2T-F<S R0G)I<71(<68U-#-4=7,K:U=M;G%I
M,W!I828C>$$[0C1*3UI&<DHY541M4V0V9C92=S9,=CA!=&-12TUQ=G5.4R]0
M1S%G84<S,'EW,4=73F5-5GA)<5)E<'=L85!N2E,X56,S:E9:3TMO1B8C>$$[
M*T]L458T<W%I6CEB+TYS,W1V6E<K:U=F4#!583AU;E)V459M=359=5-(-GET
M9CA!4C!36#!G4V9I,UE'9UI605,V,2MF3'AS:V5G,B8C>$$[0V5P16%40C0P
M94]1>'ED06)Q9$-6:T-C4V1I3W1+:TEQ<6%N9"]N6$QP,6\X1FA(1&8X04<V
M1GEL<$I:;VY*<F5&-UIM1GDQ>'DT>B8C>$$[3DQ'46I,56=.<W5X5E=A:F-F
M;E=B=&XP>3 O8WDK=$EK5GDQ9VE22DAD>5124FMX=$DW>517>7!$+TMT86LQ
M2F1&6"\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4
M:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @
M/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R
M;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @
M/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^
M"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y-:6-R;W-O9G0@3V9F:6-E(%5S97(\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C
M.F-R96%T;W(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D
M9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F
M875L="(^5%@Q,C$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @
M(%18,3(Q+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,C,P-S(X
M)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P.2U-87DM,C R," P.#HQ
M,3HQ,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P."U-87DM,C R," R
M,CHT,3HQ,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M)
M;&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP
M93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03OB@*(@-# @:&%I<FQI;F4@
M<G5L97,@8VAA;F=E9"!T;R P+C(U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG
M(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!#86QI8G)I0F]L9"8C>$$[(" @(" @(" @($%R:6%L350F(WA!.R @
M(" @(" @("!!<FEA;$U4+4)O;&0F(WA!.R @(" @(" @("!#86QI8G)I4F5G
M=6QA<B8C>$$[(" @(" @(" @($-A;&EB<FE)=&%L:6,F(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C>$$[
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G-C%B.#@N
M86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(R,S W,C@F(WA!.TQO
M8V%L(%1I;64Z(" @(" @(" @(" @(# Y+4UA>2TR,#(P(# X.C(V.C0Y)B-X
M03M%4U0@5&EM93H@(" @(" @(" @(" @(# X+4UA>2TR,#(P(#(R.C4V.C0Y
M)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A
M=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @
M(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@
M:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@
M8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @
M(" @(" @("!#86QI8G)I0F]L9"8C>$$[(" @(" @(" @($%R:6%L350F(WA!
M.R @(" @(" @("!!<FEA;$U4+4)O;&0F(WA!.R @(" @(" @("!#86QI8G)I
M4F5G=6QA<B8C>$$[(" @(" @(" @($-A;&EB<FE)=&%L:6,F(WA!.R8C>$$[
M5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M
M96YT.B8C>$$[(" @(" @(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C
M>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*
M(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM
M<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%10
M9SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/E1R=64\+WAM<%109SI(87-6:7-I
M8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/
M=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @
M(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXW,C N,# P,# P/"]S=$1I
M;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XU-# N,# P,# P/"]S=$1I;3IH
M/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^
M"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP
M5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I
M86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N
M=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG
M/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S
M:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R
M:6%L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M
M93Y!<FEA;$U4+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;"!-5#PO<W1&;G0Z9F]N=$9A
M;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,SPO<W1&;G0Z=F5R<VEO
M;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&
M86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9I;&5.86UE/F%R:6%B7U\N4$9".R!A<FEA8E]?+E!&33PO<W1&
M;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI8G)I0F]L
M9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO
M<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S
M:6]N4W1R:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93Y#86QI8G)I0F]L9"YP9F([($-A;&EB<FE";VQD+G!F;3PO<W1&;G0Z9F]N
M=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI8G)I4F5G=6QA<CPO
M<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO
M<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S
M:6]N4W1R:6YG/C4N,# R/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP
M;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^
M0V%L:6)R:5)E9W5L87(N<&9B.R!#86QI8G)I4F5G=6QA<BYP9FT\+W-T1FYT
M.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:4ET86QI
M8SPO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y)=&%L:6,\+W-T1FYT.F9O;G1&
M86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^-2XP,#(\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93Y#86QI8G)I271A;&EC+G!F8CL@0V%L:6)R:4ET86QI8RYP9FT\+W-T1FYT
M.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @
M(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C
M:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT
M240^>&UP+F1I9#I$-D$U1$4Q0CE#.3%%03$Q.34X,$0V-SDX-4,P0T,P-#PO
M>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^
M>&UP+FEI9#I$-D$U1$4Q0CE#.3%%03$Q.34X,$0V-SDX-4,P0T,P-#PO>&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YX;7 N9&ED.D-&035$13%".4,Y,45!,3$Y-3@P1#8W.3@U0S!#0S T
M/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I2
M96YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*
M(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI
M9#I$-4$U1$4Q0CE#.3%%03$Q.34X,$0V-SDX-4,P0T,P-#PO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#I$-4$U1$4Q0CE#.3%%03$Q.34X,$0V-SDX-4,P0T,P-#PO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.D-&035$13%".4,Y,45!,3$Y-3@P1#8W.3@U0S!#0S T/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR
M96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D-&
M035$13%".4,Y,45!,3$Y-3@P1#8W.3@U0S!#0S T/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 U+3 Y
M5# W.C4S.C0U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$-D$U1$4Q0CE#.3%%03$Q
M.34X,$0V-SDX-4,P0T,P-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-2TP.50P.#HR-CHU-RLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K
M970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  $0@!$0)) P$1  (1 0,1 ?_$ !X  0 " P$!
M 0$!           ("04&!PH$ P(!_\0 5A   00# 0 ! P,!! 4&!@H3!0,$
M!@<! @@ "1$2$Q05%B$7&"(Q(S=9EM@D,C-!>;@9-D)1<7<*)2@T0V*QM+6V
M)C4X.5)56&%D<G-T=8*#E:2RU?_$ !P! 0 " P$! 0             ! @0%
M!@,'"/_$ % 1  (" @$"! (%" <#" D% 0$"  ,$$042(083,4%1810B,G&1
M!Q5"4H&AL? C,W*RP='2%B3A-4-S=(*2HK,E)C1$8G6#D_%%4V-DA*/_V@ ,
M P$  A$#$0 _ /?QY$>1'D1Y$>1'D1Y$>1'D1Y$>1'D2 %J=3V'"/D2Y3Y,$
MBH@O6]WTY>E@2XL_'%UIDR-5L@,5 ( "3<ZU#,QJ^SE;4H@_ %'#G7;7],[9
MYTQG.RIPZK.,S,QF<6X]V/6B@KT%;20Q8=)8D:&B& 'N#.:S>8RL?Q1PO#(E
M!Q.1P>2R;W9'-ZV88K-0J<6*BJ>L]8:MR>W25FQSKY N>Z[5[+1D3J8ZJ<(A
MJW.7SJRC.SK\#&U8CK-8EB(Y_6IXD:RH;;&'Z>,L<,GGU0WWWU_TOJU\9DVC
M!*BO_P!(M:N-M];-+]#]?;ZGUO3UV/PGKD>)N,QCSPM-^_#E>+9R733O2Y='
MTBGR/K#S2:_M#ZO2W;OZS7I'\D- !KB"4<"CUX69,G *L9-.753TW+[!C5*@
M;CT:+UT2N4Z!;+H0M*0L7J)71+"9)RR#84+OT&HY/9SZR<5DM0V0S8]2!KDK
M%UZ5-D-1L6BA6(\SI(*[V 6^J"3VGE;XJXVO/KXZNKD<O(->'=DG"P+\JGCZ
M\_1Q6S[*E(QQ:IZP-,5K!L8*@ZI4KT?\I?0D5K"*1RK9Y+I//+'^2JR^8G%M
MUAR"2E6]<5I7I1=L2K:)P,P;D8*QKM55W8:0]N\63=SL"WDS@<&1> UB^FZQ
M>(Q7N9[JD2JKBJLOR+LT)YMM@V+7M55:J@:(?0U6_3LD, >*Y;QCRE&'15A9
M-UV3E^+,OB&S</@K+CB8F*Y5\2G&LLNJR^0WT^0"0<FL6LE8-;/+.A_R?<YA
M9V)J>0/+;.;";1B_-,UZ"2IPZ*H<7TH59#FZE7R27I**LHS,US3YJ/+C4FCR
M/10T11#%C[3=%3?34GB,IJS<HH7JI?+KQ?/4Y+8JECYJ5GNZ!02I)#NH)52>
MTZY?%W%5Y"85K9MG1F4\3D<F,&Q..3E;%4?1+;QM:KS8RI8@#546N*[+%T=?
MX,^57G61S6[('"H%T[8IKGV3S."62YKCG>P9T&86##K%'UEB C2L99$6Q672
M<Z13)QH4VSG\D4;/Y.<6!B63A?0>'REKQ[++<2I<I*[:O-RJZV-3U&[S6#D%
M411IR?1R$4,3">,N*MR.0QL?&Y?*LXR[(QLLXG%9636N5CY28GT9'J1ELOMM
M</4B_P#,*]]AKK4L/R1^6#F'2O)[,S@.\HC+:YN& T'(*(E=2FA%\*6U:K;1
M]6D/&07+E9L^=SD=^I(QYW@ZF-<LF3I59XWS^GT<#PV7YM=:MCNEM%N0N2ER
MMC>32=6N;==A6=!QT[!([>NH'C/B/HN3D65\C1=BY^-QEO'7X5B<C]-S &Q*
M$Q]D,V2I+5-YG05!)8=M[W.?D0J:  ZAW+5;TL_L^[6<[*PWG4)2,B?]!-P5
M9OUQTXD4DK[==MK'X^&72;[M"[XQJRE#4D,=PY60MGJ:N/.OB[K&O NQ%IQS
M6MF4V0HQBUP#5JENCU,P]0%^H0PLZ=&9.1XHPL:O!Z\/EFR^07)LQ^+KX^YN
M3%>&Q7)LMQB1Y5=9UTNU@6X.C4&T,#).T/>5:=*U#!+SIZ0?R>N+&#[&8T8V
M9/!KA1-!Z[%DF#\:_10>CBH8R/(A2X]REHLR*#W;7?[LI?=MB9./=B7V8]Z]
M%M3=+KL'U 8$$;!#*0RD>H(,VW&\CB<M@X_(X-OG8N4GF5/TLA(#,C*R, R.
MCJR.C %75E/I.M^\)G1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D
M1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D2M[Y3.M[/XPYH#VO46E7ZRXY=
M54UA@E<;$Z_@  3/C2XPI(3:4>E,.()(!T4]7BKK)M%LU;)N%ETE==<8UVG#
MX5.?EFF_S>A:+K=4%18S5J"%4LCCZQ.M=.R=:G*^,.:S.!XFO,P?H8OLY#"P
M^O/6QL6I,JWRWML%5U# 5CZQ;S % )(,UB#=RRNNZ=$2NZ'<;[,E\HE<\U"F
M/C"J.?V[70:'08/#G!?29$7$WFXR/R,40D65'&A29C%S;0F,:QV/O70TNM[T
MLXY+;VKH#X"(E?4O+W5T6M98SA?+ KK9E8+VU6W20Q9@I77CC^(;L7!2[/:K
MGK[KLGR[/".#E9N*E&.E!<7L<C(2JU&M[A\A#8K(*JF9',V(]\JW*[2%4!+X
M,A<5WD.EX@<L"K*ZHVHI78UH/(1$U\L9C*#D.&H(N@ J*%DW 0KN07T7<EV;
M]H#0+Y8.]T:+P^8;,E+/(H&)8M5UN1<E5(L?O6JNWVBXTRZ'V2I;IV)ZV^,N
M'7'XR_'&=R#<M19E8>+QV%=EY;8U)Z;[K*$ :I*7W6Y<@FP,M8<JVN6UG\LT
M.FW7-_<_R2G+=@574U6L<LS^W.35O.PL>#1I6OI58THE%NZ& +%&K86L$C>V
ME=GC2V?YR[4W9,VR+S[$,>UW"O7A8V2M]%EU]K5?1TMK9F?S4J1*.ECYU@9O
MZ55_JQW)(F'B>-:,CG.2XNW!S<;#P,2G+_.-V+DUU5U-BW9=MV=YE2##QS75
MK%LL)^D,2J@-VG1ZG^5_EVV9$QC;8/>E?JRNKIG=%2%K9IJ4U\!OBLX '5D<
MGE%-DS.N$Y6W91Q/60ILW.@@FZ!K(E$&6[/?*NOE=PV72A<MCVA+DHO6F]+6
MQK;&Z$2]5^P2WU=CJ ;MO?:9>%XSX?.M2E:^1QC?AW\A@OFX%V+7R6)C)YMM
MV ]FA<%JU:%/0YK(<+T]YVWC[M^H.X8P<G%) ;91@XAM%W#":6!6A^"1>9;2
M-H24>-X$8,ZZM9>I#2H<G&)JL'V78A9&TRR3=O6Z[5XOCYW'W\>ZUY#4FQBX
M-=5JV.G3TZ-BCNGF*RO6&T64[T"")G\'XAP?$--F3Q]>:,9!24R,G$MQJ<CS
M5<L,:RSZM_D.CTY!KVM=JE>I@0QJV3^4OJ,3S.Z[".P.IS%.TOWI:- =.AXU
M%9IB5@^<0<V&P>/6E"E5)X02S*H@0(M5I<T>#2P^1($6JS%E&&HXB[4VYX?#
M.7]!6VY;[^.JR<1F9.ALHUM8]-@%8^HX!Z""I31!+D@'C_\ ;#F*^(;G;,;"
MLP>/\29O&\O753?Y]?%59*XU69CGZ0P-]#,K7JR,EH8%5I"L98K\?72MM]?5
MK/.AIC&XQ$:8G-HRMMRF+8!S@Z:FZ+C#]>/";"L9<L<?-]C,]+,")82*&A03
M<4#29K?D,)$VSQ/6<GBT85M>-6[V7UTH<QB5-:Y#@,U5050>FL$ EF8EB1]4
M@B=1X9Y;-YS$R>4OIIHX_)S+APJ*EBY%G'4L:DRLLO8P\S)=6=$2NL5UA>]G
M6&D^/:V=+'D1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D1Y$>1'D
M2K7L/DCJ:PNM><>M^6)[04;E]%UO:U>N0%_1RPY%'"Z%F;C$UGR#:O#,>)95
M9LVKG5/\AEIHDYR@ILD\2RHEIM\'-PZL/*PLRO)9,BVFP-C-4KJ:>HZ)M5AW
M)'Z)[;])Q_.\+S&5S7$\UP^3QM-_&XN=C-7R565;58,SRP6 Q;*GVJH=;L&C
MKLPV)#_H'XP>X+8/]F.8I?',T9!_(+3=!".C=2->V2])QNUZ-K!I"E65-ZXD
M2[876\X+-G"CPK,EI+*HZ (X18"GY@;H1?YV-R_'TK@A\;+9N,OR6Q=6U /3
MD6]8.1]0$VUKH!:PB,PV2%/2-%R7A#Q#F6<\:>2XFFOQ/@<;7RO5BY3/5F\?
MAC'9< >:53$R7!ZGO-MU53Z1&L0.TA87P[UWS_U%8-Q<X6[0:-?](1;F()T"
M'MB%SHY+XN4YW@[*ME2]-JQPV*#O_P"51)%]G#6;+(M11AZBZT;N&S/],XQK
M.0PLG#KHRJ,GS<5\QL9J;*U1QE6&W5_6I8=#Z_JP2RC6P29M*/#W-\9S.5G\
M5G<:,;EJN(3E*\W'R;+Z7XO'7$+X#565HWGT!NV1VKL(8*P7I.BQOXL;/",*
MN:+V9 UMX'\M\P^1!]NDTD.-7U>2)21;M(&T^]CC.LS0P7;8<+K8T!XSHO\
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MM6#<7F5YW'+YJBF_&IR;*;4?%\@7+956*W9T=?)/GZZG"!>DDZ+$EIX/X"Y
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M;DIXMF?*LZLL#*9$P:.(E6=F%F9$@I*8'#Y",.5.A=@C1N,P2.N0X<5![@W
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MX[GX>O<?</;M,R"YCZCJF;49:U:(T'-)P!I"\8;=(F?3VPX:#(6ET+=,&O\
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MNG;MTJFW;-6S=/95=PX75VT21012TW4554WU333UVWWVUUUSG$@$D  DD@
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MBN%_KG&&V!]*1J>N<N,[8^S*.4\;Z;_77?&N<9^G/#@>7']9@VXXWHG+:O#
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MS$]R2229V*(E:*E:JB(H554 *JJ   !V    ^4R_J2TJ.M/HVH0?RLT" )2
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ML%EG+%)]E'3+M-DX<-VKAPTT<?DU;++M6RRJ.--U6Z.^VR>NG.MGIV5V>DD
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M=PJE1T@[.I:'CICMM7_H?C5FR/U_R_<>I.:D,8_S_P"=^WRHK]/^KZ_;C?\
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M_F' 7^H;-Q3['%Y+/J ^ZL9!J_9T?P$RO]L^:L[9B<1R2^XY#@.$R6/S-S8
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M?_K;CNQ$?I__ "Z8]])^C<Z/_P!5P&_M<18/X<G/AGT_P:?7PWS2?V/$]!_
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M*EOC^F-TXQ8U5V!&-==?\M$=@V4-,8^S".-/\/J_F/%7^HR>4Q?E3RF:5_\
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M4>NJY1W611<[K(;Z+Z:;8U_)^$N+Y'#LQ5%N,UC5D9 NOR+%\MP^@N1<ZGJ
M*DD; )([ZFXX'\I/B/A>3IY"Q\3/KJ6Y3A-CX&%39YM3U E\+&IL7RRP=0I
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M.,E'<?YZNZUND5:E@[XI_&I]68:QZJ US5-D&V[E"0LR5@?@*2MQ'!,CW2Y
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MK1!TRGU5AZ@_N(/N"".QG0_5EH\B/(CR)$KMT;TJ8YXE8WD2+5E(^@71 !K
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MF$\D5!0YLU233?2 @;DA9SLZ+'#+X@]6WU\K&5W+*@12>P!)/WGVV3[  #T
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M1N5OD8%SC5'%%\R*((#!#IN1KLY;O50GI;&5E!BY7=T[J&"M) .T1=8W0/0
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MFWD 9#C&0]01\C'1L]I2.S^.)K#G3)=TH;B0YRL;B+ >)7+PV<JR@,B9B/\
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M;3KX%H#85=)*59C<8>?IT*LE^XQ22PK3_E7Y/V@QN&%[.L9WRZ^K-+\;A/\
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MB=B;E$X8:JB6@5NS4D>">R#!8.D[=M45D33 G8T*=VM"J=)@Y ZDU@2#H0.
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MCTECL0<B]:\LS68%CTQ8IE8<WA\!4AVDYGK.8B%-C41,0>.R$+* K4@8 D"
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M)\]*PV<.70"- 4HZZCGZ55)=$[7SGSH9K?H7JRU#+9ZPC$QFS492,??.PSQ
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MVF=<I90SG>=]B-#O[^XD:[@[/;V]C-Q]$F4<HTM>0"BJ%A<OJ^^)!K'>%@T
MK^,U'-W<2?5KU8T3517+S)8'/(BB,)[L<Q)"'STNY)1R%?Q^9IN'X;:08T.(
MF[$*=MBOCG4))>HYM8%C6NVYF)%IR'/SYQ!381 94$3NXP/!0^S8"8.FHU((
M]*9EM5HDC#B<SAS!2*,B'\=/K GR)T/D6L+U"6!04AM&-REHRAM;?(K$5'\D
M_.DX  K$ZRYSE=$QQ1D4GMDFQ;(A5T*)*Q4&^G$N<1V.QM("].J*#V^JB)^
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M8,9&?G3;S'>*#-MT]G;C11UELCC]O?$]5T2/B5%6+&HK74BG<3OJ>@9+T/T
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M .K[#R)V[R(\B/(CR(\B/(CR(\B/(GYK?]$K_P#L]_\ _7/D3DG/?^H.C_\
;U05I_P#4L+Y$Z_Y$>1'D1Y$>1'D1Y$>1/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g108483g63z71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g63z71.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5, :'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/D5L:6YS/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!46#(V+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,3DR,3 T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" Q-BU-87)C:"TR,#(Q(#$U.C$S.C X)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#$V+4UA<F-H+3(P,C$@,3@Z,3,Z,#@F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!
M.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE
M87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R
M;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L350F
M(WA!.R @(" @(" @("!!<FEA;"U";VQD350F(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(Q+3 S+3$V5#$U.C$S.C$T+3 W.C P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP,RTQ-E0Q-3HQ,SHQ
M-"TP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(Q+3 S+3$V5#$U.C$S.C$S+3 W.C P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX
M;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED
M=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ-S8\+WAM
M<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M
M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S
M54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F
M(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"
M9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$
M07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW
M14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9B\X04%%46=!<T%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%
M0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!
M04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$
M0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F
M(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:
M2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:
M6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M
M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%
M4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D12
M1&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S
M.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM
M9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F
M(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!
M07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867%L;FU/+W8F(WA!.S=,5&95
M,#A1;3EK;&EH:$4U6&E42DE&8FER4U%E;S-'<%9055AK92M+<UDP,WHQ<7(V
M;$)"9'A7,'-%9VAG;&5)>7=/;'A*9'DR-V,F(WA!.V]P5EER>$58>$IZ3D<V
M37<S=S!Q1V(X>CE4;2MR>C)7;%)35WA%<&UJ831*;F0T-T$S=D-.46=!1D-O
M1&UT5%551WAX<%4K;3@Q6%8F(WA!.W@U379V35=L,CAB0TM/-&US:$\W0DI)
M;T-W17)C5G(X45%S<3EX5#1H6%E+;4=Q87I.<'5J,V5P5%%+-G=+<E%):VA"
M:S5H44]D5G F(WA!.T@K.&%N-UAW-RLR2W-F='9/5W53*UDT.5!L=&)71T%V
M8G=4<$A0.$%75U-2,W9K9FDV2V<S*W!J-U9#=F1A:VA3<F0U-34Q0S$X>3,F
M(WA!.T]K>3(X4W=(56)3>'-,;6I(,5!6:70U3&A(*TQA4E9U95-D:4%D=F@S
M5E%7;&5D=DYD>C5A=3E83G1"3UET3%A5160W4S=S655L2T<F(WA!.U(T9S!Z
M4R]7048S1'@P52M)<EA&5V9X3UAI4GHQ6E%45#-'0E8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+<T8Q6F194&UY65=Z-G!74FDF(WA!.VE+:7IX,C!56G1A8S!F
M.$%E,E5I.#9S439R2T@V1VQ":%9+.5 Q<GIV1G!55FQ$1G%$6$5-04EL;'-M
M0D51<S1/:E!%<71)<S-R554F(WA!.R]%4TM(86U+1F9Y-7%0;D9D971,1V$T
M=7!D4#%#939M170Y0TER:%E,4U9J>4UB;VI+<S9Z4DI4:6]8.6M+9'-5<'%*
M<&TX,UAX5V8F(WA!.U=,84-+3GA,23!.>DQ"2S='4&HY5U%W>5=W4TE+9FE!
M-7574%5#<%95=E!&>C5N3C5C5V5N=F925SAT:5)A0WET5FY75UIX34IH3$TF
M(WA!.WDO=51';VI+55E%,3)$2&)&54=,,U=P=$$Q2%1);C%74%4U<#=6<DLW
M83%U:UI91U<R1'-S:&E72E-0:DQ*="LQ5F5U2V]8-G8U-S$F(WA!.U,Y;&EU
M64QI3U583GEJ1#8U95=&="LW<S=/3DIO-6):6D0V8GEI5C!4;U-7-S%X5D\Y
M2%<O5'I9;'908V%N2DIB5S13.'5*-#=K5U8F(WA!.WI*-DM#:T%#0S%25EI7
M8W54>DQ'9W%-5EIL9U8R2W5X5C)+=7A6,DMQ3C59,E8Y8E!A,W1V2&17,&Q0
M56=M4EI),F]A:7%S0T1V:7$F(WA!.T1K.'1E5VUG14UM;%=:=#0T:D%S8E<X
M4E)995EK35E"5V=4;4$S2'!89D9714PU=SAJ>F%O:T9R<'$R6'%+3$]Y,3(S
M:7123$5J<G<F(WA!.U(P0D1.2$A3555*6&)K3U-G2$-R3#1(,&%Y;'102U,R
M>G1#8D8O5%(T<7=',V@T4DUJ3W=#=5-*0E926"]+<%560V]76'I4-4Q3.74F
M(WA!.V1-;$DY8654,$QY33)K>&IK97$R-45K;G!E;7=&56I,1G%#<6=N8UEQ
M;&LK<"]L:DY:>4MM;5=T-4A:3$9%='5,1E%05&ML8THV4'(F(WA!.TI':E(X
M,6MA<4=M>$EW<6ER9GI0*U@V,DYL2D9(2$AB6$1*3F%Q;&TU4EAH-%<X8VQ9
M-#)2949%:5-3=$YG<6YB1E=4:7ES:%I#>$8F(WA!.W9'3$E2*V=,6&=V<&5L
M>#0K;G=P>#0X9'5.2U5W2W)!04%!0V='=T%X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%9I6&YN>F)Q3VLF(WA!.UA/;398<$U556UQ86\P;G!V4#A!,V-A
M4D%&,DDU4FEV>%8K,3!"*U=&54XU53AY,V5S84AE-G9.8E=D=').=$5K63%'
M565N0S!%:V$F(WA!.S-%9G%-0S=O1D5N2C0K9$\Y9#EL569(-6LQ<4QY+V)8
M<W1N1F,S,3-D:3%T;')*6GAY2DI+56EM2W5,:#1G>3!B:652<#DR2W!3;C4F
M(WA!.VTS:C)+>FI327A/.%@Q=%EN=2M+9E9H8F974WAK35 Y-51B:%-N*U94
M1VQ83BM9.3-(<CEL879:;V1/,4%Y<D)+0W=:9E%J:F%1;"\F(WA!.VE6:GHY
M5D98:4]203-'3DMN9FQ4>E)C834Y644Y;6QO,$UD=DUG:FXK<T)K=6]Z26Q4
M=VHT<T9P56(O3VTU0W-G>%8R2W5X5C)+=7@F(WA!.U8R2W5X5C)+<61X0DAC
M5SAS16]R2$UJ4G5"=%971D1I<GIA=R]+>EA,92MT27!B*T]44S=/5C)3<E9,
M23AQ5$U$0C9)*THS:%5S9E<F(WA!.TDW530O1&AT1#!/8E192F14='126FU%
M.7)&3D1';TDT1EIZ1WI&:%-T4C9)<'8T-$5P5$XU2S!Q860U;6QN1%-02DE1
M1U-L6F)I1S4F(WA!.V(Y:BME,E5$,G(X=S)Q539&-4)N:'4W=515<&E,55)P
M8C9B8E)Z*W8V54M,8TE">F%#1%E,9&YI=$=)<'5Z65953'HX='!)17-R3%(F
M(WA!.THS:'-%8V97:DQ/0E-$-G=T=UE5:%<S8FMO9%=:9C-I54IP=79W-#)R
M4&-#=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5DIV33,F(WA!.VQ,4B]-
M8TU%96])9E5T;4PR.'E"0WE%,#5$:DES:4U$>$91>6MB67%T,&)Y9&]M;&%4
M3'!34F97<D\T2F%E2S5#4$<Y93-P2W%1<4XF(WA!.W5I;U!(1E5F839.;SEP
M8E(R=')9,CEV8E)0-G-515532D=S9TYE87%O0416-S1Q;'5U95,Y1C%F5#%S
M1U)B3S)"6&MT=$1B5DE24VDF(WA!.T%'5TM8:'=5,%9K-'-V66I&57<O465J
M8TEL*V]W9C90=D%416I&1'I%;DI3=TY$-F<U,2]M,S8T<6A03&YL8E0Y0D8Q
M.59D<$I,>'@F(WA!.TI.27E14F)Q2T%"3&5/0TUD>CEM<$HS>%9/8U9D:7)S
M5F1I<5(K6F9/5VIE6%IT3'0W.'E.8V%X95$R1FY"0V]D*V,X:7AE;W=*6&HF
M(WA!.T=J4TQY8C-!,TI!>%9-<EA69$QU-4=I=$QY0S1L459D27!%9&=+,'%1
M<$]+;W)&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3<F(WA!.T9867$W
M1E5$<FUT869O;6LS3W$V9S5J=$Q63V-H56-M63E&4D9'-T\W14MQ:G%45$95
M3&\O;7I1=%4P,U1B-DLV:F=/<3(P1C%A,G,F(WA!.S=X<%!W=6M74TY7:D1.
M.%9'06]#9"MM2W!X:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%5
M83DU43AR*UE*3%=45W1-=#<F(WA!.S97>&M383!M;%%'4TXT,U=18U@K,7A,
M24]3,31T,%E%67%K8T9H63)F-7%2:3!T-')C4&]C<D]):U9!>"MU4C=N:4)8
M0W)-.$-U>%8F(WA!.S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M;U16=$@P;E=,1U-W,5=Z:'8W2U=N<5<Q>$=S<UI)3E%E3$%I;T\T4&)&5T4F
M(WA!.RMD9DQ0;"]2+TPO;#(R,'I4-&)A3W@Q;E%R93%+;T1):V%A:D%O6#%'
M<34R-FMM<#<T<3E">%8R2W5X5C)+=7A63')'.#%#6%9,,C(F(WA!.VY725%7
M,T@P;5%T>E!Q1&MV2W4R=S8T<6U/2W5X5C)+=7A6,DMU>%8R2W5X5FEJ+T%0
M:S%O4#A!=&A3+SE2:V5+<W)X5C)+=7A6,DLF(WA!.W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W-2+TUZ+T%)-4=K9CA!8F8P5"]U<%%9<7DW1EA9
M<3=&6%EQ-T972V584$]0;'(F(WA!.U9F3BMU-E196'%Z-FI:;%)C,C13449$
M8FXP6F%L;$,O1$EE3WAY,F5'55EI4D=X4F)+.'%3-T9867$W1EA9<3=&6%EQ
M>%1Z<C4V4&PF(WA!.VTK,&4R1FMT,FUP5')&8U-'-6IH84-.<&]O9E8Y3F=Z
M=6]A8U90=V]/:%E->4MY<5<V5')A87(K869*8DLX<W92,%=60TPR0F]#,RLF
M(WA!.VQX+T5G8C=3*RM&5V4T1F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-64V9Z8G(W-D1O3GAQ8U9U=#-.15DP:'18;5<F(WA!.S-%:GEY
M3$=Q*V]W8F8T=&Q65V1U:7%Z14%Q<T4X>BMD-&1C,$QY<39A8F51;E5D53!'
M-SEB,'I*87AL-RM">D4Q>79W1FQ0=R]01E@F(WA!.W%E2W5X5C)+=7A6,DMS
M33AR95)03&UJ961F34=T,D5,<'%&*V56>DDP:DUP3GDO<GDP56UG<DE-=6YN
M;$M):65144%Z4$M5=7A6,DLF(WA!.W5X5C)+=7A69W9M-SAZ<%!,5W5W85AC
M-E5:175Y;W1*,6YQ6%4P<7AJ4T]1<%$X:#A21F%(1%-S=G8X05(Y23%#5S)L
M=C=',W4U8DXF(WA!.R]6=$I*-&ML84=4*V5-=4-58C-'0E=0=B]W0U179R\W
M655V+T%&1U(T<7EV1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@F
M(WA!.UEQ>&IZ,S5Z;#AP-F9(<4Q72#%U>4I+>GDK<TEY:F)C444T>4\Y4GE0
M=VI90W!X5D<V4&5A9C5S.')W6$XW65)V6F%J1U1.65A+:5HF(WA!.T-O66II
M-GE+;V(W3F0Q>%9*+WI$=')A,3!$4DQA,FE30S-H,3-1,&AH:55):4MU<%%!
M2W%R44%$=T=+<WEX5C)+=7A6,DMU>%9,8D<F(WA!.S(Q1U!68BME94]&8F$T
M-&5I,&-R3R\W<V-2>55X;T)58C=-85EQ;5=+=7A6,DMU>%8R2W-3:#@X6&MM
M=B]O<S)&<4DO<D)G.6-A;&$F(WA!.W1*44U6-696>"LX-6)F638Y<TMS5R].
M939I8GIB;S%H2F%7,'%.1VLW5'I197)*.$TY071495=)0SEE>CE30TM':%%R
M,6)!<D9(+S@F(WA!.VUT0B\R=W!F*V]Y4$975C1Q-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ>&9Z3C5X=3E',4)B4TMY=')H5VE75#%*=%%T<E(F
M(WA!.W%K<TME;DXX4DAW+V%X5DQ0>E0Q4&@U2G1R:')7,VUA-VYT,$U5-FDU
M:E0Q;$Y3=$IR5DA)1S%F5E5%9D]M1E4W+TPY23 X;395<V$F(WA!.TEI:4=G
M5D8T3#EO,2M(,7)R9798.38R+V9!<4(O37HO04DU1VMF.$%B9C!4+W5P45EQ
M>3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$F(WA!.S=&6&IM:S9/=B]+>5AL
M=#!L,7%!6#AS,&PO6D(T66).+U99;4]F,5EM:&PT1W%N,' K5E(Y9UE523<X
M,6],065B9$9N;718960T,6HF(WA!.T1#67A.36]N2#=I,U%15&E36F5:8VAM
M554K9%%H3$EF>D(Q5'I,86%L-69G,%<T=31%=4QO0RLK<C9D2F91;4E01U<K
M<U-P2$U95C0F(WA!.V,Q54%+5UIG96%Q<EE&475K4RM:6E!Z5% V8W1R3S-9
M84Q+3&(V;%!,8T)O+W)K93AN<7=W8U<Y:%@U-'%Z-T9867$W1EA9<3=&6%DF
M(WA!.W$W1EA9<3=&6%EQ-T9867$W1EAK=C5Q-EEL>C5P='!94RMP,U)T;S!F
M47)26E9U*TAQ4T@Q:$US5GI%;V)C05-H0CA0,CDY:494=C@F(WA!.WER2S O
M=T%!5V-D,6)S:5<P;')X86%54G)B348T97!C>7AX>C!607A$8U5.5'0P3TMT
M>#,Q+UIF;$I"9#91;#=A,V%W23!#5W1T*VLF(WA!.V)R-'!H>45-6'!Q2#5G
M;F<W4C!514]Y;6A'2W!.-6EU=E!%,VPO>6UD5%,P=4Q..50P0G(K+V,S1G)E
M=&,O6#1/6"MH4U<P4V]/9C@F(WA!.WI+92]%9$U#=E8X5F1I<G-69&ER<U9D
M:7)S5F1I<4(Q2%5:-U,T<S19-U5Z+UA*1$5(1'%O5F=J4V(Q+WE9,GA62%EQ
M-T971&%"*U<F(WA!.SDO;VYM2V)68E18<$1B,T5K>E,R3%<X6D)I;G4U8GAO
M=SEA:CDU8TXX5DLP>%9,=GI,,#-Y;DYR1FQR5W)A<F)1;7A:3$PV=DQ9>#8F
M(WA!.VM5;%EM-%9U2D1T0S-!5C551S,P659E;%E&66\O=T0U3F%$+T%,655V
M+U5:2&ER2SA69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F0F(WA!.VER<U99
M5C5K+TQQ-C%8>E1(-6AS=&%K,#(T:E<R2'!#0DIL3#)N,6HP,E!):G1E4%5F
M3$966#AW=$LP=E5F3$M71W,V;D1B+T%&64,F(WA!.RMM96%#3V8Q:W1&<DMF
M<7)61'(X5E-!1%1B,GA6379):#!Z+T%!;'!W,'562C=&55I96DER8U=A9D,W
M2U%,8T)F5#1S0TM5>%9,+WHF(WA!.TTO-#5':V8Y="]24"LV;$)I<DQS5F1I
M<G-69&ER<U9D:7)S5F1I<5AA<B]V9&\S+T%$1U O=T)19'AI<5DT<3=&6%EQ
M=RLY+TQM,C$F(WA!.T1Z5F0V-V8S,&MI>7AO;&Y$179O>5<W<'<K2EIL8C1H
M5D-E2E=N>$AL>3)O8E9M1T)72U O=T-45V<O-UE5=B]!1D=2-'%Y=D9867$F
M(WA!.S=&6%EQ;#-M6%9"<%!L>E9D5EE/=S K>G5,;VE-<4A):&EA5#13-%IA
M+T1T545E,E-H2&EK0C-Q5T]F;$HU,V)Z;#55+U-R<DM*23<F(WA!.VAR855Z
M;4MP9$52;4LK:VMA:&%V<T-+*RM7-FI$-&-Q441B3DUO4S=&6&QU:UAN;E9V
M>G0Q2T-F4F]9+TPO;V=,<5ET=TI#:6]X:6(F(WA!.S%Q,2M/475V5&5L3S):
M8V]9+T-S2#%S9#=E<%II36Y9<3=&6%EQ-T973F5B+TIA*UIB=E,R;G4O4W-R
M0U5Y6$9M67<T;4)+:U5F:V@F(WA!.VIA:45C=#EJ=%$P3TMP,W!E;7=A8EE1
M,DU$4U!"04-S6FQC>4]&2DI!3$AC.&$P1F0X5EDS*UIN+TA),&HO='8V2B\S
M56]-5EID:7(F(WA!.W-69&ER<U9D:7)S5F1I<G-696$O;7 U=#@V84IR+VQU
M1%%.16)63&5A6C-N;%=#96)G+T)O=4Y9:E%F=7!(9F8K5W912$UR5#1O4T(F
M(WA!.TUJ5$5L-E9M2WED:7)S5F1I<D@O0416-5IF5TQR43=Q1F=S,FLV:$9D
M;FY*27%M2F8W=T)&<6I0<T]*66)B,$EQ87%P1'!';6%N668F(WA!.VUM4F8V
M>&-A=5ID1FQA2G)I2S)I.4IF<FMF=TPY6&EH<5 X05=Q8U9:.6ER<U9D:7)S
M5E=814-4=U-14%AH2VI),4]T1T9$,7A60S8F(WA!.TYO.6YP1FEL:F%C=E%J
M<'@U:T4W04PQ04A965-B5D<T1F1I<4944S="3#4W.5E13'E10EAM<6%K0W1!
M9#9B5D]+;W)&6%EQ-T9867$F(WA!.S=&6%EQ;&YM9E(Q,7)Y.7%';$4P3C-!
M.&%(;3A9-6M65&LP6D1C959/43=J66=J8D970V5C+TPK<S)/;"M6,FPQ;6(V
M<EHV;C5F=' F(WA!.V1*4T\S3G,P:V0W8F]817)20S0K,750:DAY>%8V9&ER
M<U9D:7)S5F1I<G-69&ER<U93-U9F.3=T1R\U:D@O-F<W:D95>'A6,DMU>%8F
M(WA!.S)+=7A6:6HO05!K,6]0.$%T:%,O.5)K94MS<GA6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W-2+TUZ+T%)-4<F(WA!.VMF.$%B
M9C!4+W5P45EQ>3=&6%EQ-T9867$W1EA9<3=&6%EQ;&UR:3=.-7!J=U=K;'=K
M1G<P<WIX=$5!<6U#5TPO9&IO5'9+1'0R>%8F(WA!.TTX5F1I<G-69&EQ538S
M-7,X=C9(8S).='%T,DQA8E5N.4\P57!)+TEH:U%L:6ES15AN2VDX;F]T5T%R
M=4U64W O=T1Y83!(+T%'=W F(WA!.V8K;WE01E=6-'%X:GIX-5@Q2%@O04Y$
M9E5R;U=V-D\Q0TLX=4LX4#-K561E55AX4E1F87(W1'AR:7)*.%9D:7)S5F1I
M<G-69&ER<U8F(WA!.V1I<G-69&ER<U9D:7)S5E%7<S9Z<'5I-F),<5=P4VU'
M>FA+0C-#4$DS2U)X1VEQ:UED,UHS8TMQ<4-35&ER1F903W R3W%E5U!,*V\F
M(WA!.S)%=W5,2S<Q=E%P<F5:86=-:C9J05%A14%J-4A&5V(T<6QV;512=C S
M;TXO<$@Q;5=Z*W91=D(Y86=.2DDK67!Y42M)>%92.&XK6&8F(WA!.SA/95<W
M3%)0<FLR;V95,5IF<FQY87EY8VY:-G-D*VY+;4MP>&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5EDW-6\X:392-6MV9$]V3#8F(WA!.U=E2U14;5!&64=65FUJ
M37---6EM-4LU2V5R87AT.$I5-V1A13%646HO;$XK6&(S2G57,%-%>G-#<&9L
M3%=H4$DO="M/2W)V*U969FPF(WA!.SDO,5I99CA!9W!F*V$X8E9!87(K54AK
M*V8V;CE2,#)'1#!R<4]7-G$P=GAW3%AN2'-X*S%T:'159B]Y<7(X=G8K<DQ$
M+W=!1DPO>E@F(WA!.V=T6&8X<7$O3#<O<7EW+SA&3"]Z6&IA=$@X<79Y.4A8
M4F]F*T-K+S5R>'151&]8-5%E5#=84C=3,S%,5%EB<2]I:59B;31$>3!D>#$F
M(WA!.V)D:#$K5T<Q4B\X07EQ<CAV=CA!<7EW+SA&3"]!33$T3%8S+T%#<7(X
M=G8K<DQ$+T%-1DPO=T$Q-#)Q5U)F:SDU5$AM4S5V;7-)1S F(WA!.VE3>F=G
M9W-U8W15=5DU6FUL;"LQ5#0P:VI8<BMZ:7%:+W=$2W%V>2LO=T-R3$0O=U5V
M.$%Z6&IA;W93=GDO.$%*,FLS.%=O861P:V0F(WA!.W9E43AV4VU6;DI8;7!2
M=7)%8G%X1TMS9WA6,DMU>%8R2W!:-6HP0S Q+U-:3DYU<$I916%31V%/-&=+
M<DQ&3&)Y<E!&26AD6%=Q>5(F(WA!.W%F:55J>$9-5E-)9FQ*-4)E>'-R4S8P
M>&)W5TU554U-,#=U6D-)4'-->%5O0V$W.4U65F8K5E9F;#DO,5I99BM#;"\U
M<GAT55!F.$$F(WA!.S53*U)P8D<T:71D2FAI=5I);E=#571,4EA+:TLS,FHP
M3T<Q5V%4*U5F:W$S,'%Z9W9T3&AU3#)'0TM/-FY$4S!K;%9!2&9D:#EP<6XF
M(WA!.T)A;W8O;%98-69F.5=72"]!24M8+VUV1S%D+WEQ<CAV=BMR3$0O=U5V
M+TYE3G%L=6XO:R\U4VDQ8E9,;34P*T-A=W57:&)4;T$X=%DF(WA!.U9324Q)
M1#A8-V(O1C%W,G%:9CA!2W%V>2LO-G-S4#A!=U5V+T%$6&=T6&8X<7$O3#<O
M<7EW+SA!0E,O.#$T,G%!,5 X;V9*,#@Q9V(F(WA!.U!464E%9W523&5Q6&PO
M95%E;DEP:C)9+W1S<"MJ1&%O+W=$-596*U@S+U9L:"\T2U@O;79"874O-596
M*U@S+U9L:"\T2U@O;79',5HF(WA!.UAI<G-69&ER<U953#8K=&)',&QV3'51
M4E<X0VPU2$Y4441W07%35#!!1S505$98;'5L,T@U:F$U-6MV4$U':E10+V@T
M35@P,D\V:S0F(WA!.T-89W%I4S%-2W,P5%)L+U554S U2SE+37DQ04MV5V-#
M=7A6-7(K63)R-FQR3B]B95<O3$5-5W!A:$)+6DY3<V)T1F%X:V=#34=76GDF
M(WA!.U%Y;4]4:#A38FAJ=%9G5G=Q>E1Y=G R;S9D<$UD;&94;31-4DET,V1M
M:VQ716=&635(87!D;S9L3U935T%"3SEC0W!T:7)'=E S;5,F(WA!.T129$-K
M2#%X<DLY=E S1FY02$=*;E)M259P46@R4$%.,S9T44%->$-L5DEV>30P8GI&
M0DTY-V57-S)"171X839G<W!#:2\X051L9C F(WA!.V(T44EQ<$A,44M'96<Y
M5W!9:EIC2W91<T-U>%8R2W5X5C)+=7A6,DMU>%8R2W9+9D]U<S8S<F9M0DQ8
M>71E,S!W,#9A2T<U<V)!:3,F(WA!.T1.24QH2DHS=4M..$5C;VE!-69$.$PO
M0S1Q34MV4TY$+U,T,'5"9%DY339K9UI,:#1F-W1Y:D9226\O6CE244@T.7$P
M=TMJ<U99:"LF(WA!.UI(;4-E>#!K85IP;#4Y5C$W53)32WA:54UJ3'EC06LX
M9#$U-V]R049Q;6]"-&UI<6PK6&UI83592DID,V-3,D9T9"MR-G5L<6=I55,F
M(WA!.W!*4TLT:FA74V1)1$Q&6#%9,6-I;T(V:S166G!G5E%V<C8Q<V)35SAU
M-4)&8G=+6&MC,4Y!4$%#<$I044%B:SE-5F54-D9(-6\Q+WHF(WA!.U,K<C)Q
M>7E24V],=7<Q>5)6=#0T4%1U8FA(,#EH1T-B:4HT;&E5<GE92V559UE.445Q
M.69W2S=&6%EQ-T9867%L2&U8>E9P4&PR>E<F(WA!.S5V,EIN;&19<F$P:$%A
M86%2+W-P1W!+:G-D>5%",T]+<V(Q=E1T4#@Y9F]7-7-D56MH:6$R4RLK;TY7
M2GIB6%$K0S5157%*;S)88FPF(WA!.WE3;%9:84Y80W).-V%#2S-T-')E2E%S
M54M,2$=Q:%9!5E)104MO5E)S3V=&34-Q;4MS13AZ-C=&-6AN=F9,;FQZ5EI,
M6'I"<"]0,6\F(WA!.T9,44-E36\P53!C8W)+>3@T+U5$2S%$4G=/,5-#<5IF
M;#4U8FLP6%$Q3GI%,$8O9&-8=6]'-$@P,E%C94-&5VQ92516=VAL8TM7254F
M(WA!.S!W2WEN1E=--G(U-3AV4F$U1C5A86%:-S8X<$$X='%+:3-A8FUS9D]1
M1W%S>&E91&E$46IE9WA625!+,VMV>D-N;7DT,41Z1S<S5#(F(WA!.WA34S%V
M*V-B>%1L54U16#!I5'<T.%)+=C=S36IL9TI'5FIH5C9,9U8R2W5X5C)+=7A6
M,DMU>%8R2W%.-657=&QB4UA6,TMS1G9#=DLF(WA!.U=6>E)62'54:7)$6#@P
M-D@U,SAT,W1N<#$O8V%5,7I+;&Q"8WI2*VU895=)6$5)1E1V2$Y%9#$U2WA"
M-"]#>$=&5U$K5B],.$=H-E<F(WA!.W1Q9T%L:TEK;F]E441L44]#>496:V1%
M031O6D-7-&=#=3)"53-X5FI8;7IZ4F]L;$I(;T8Q<4PV8G%/<GA.2%HS56%S
M9E):+V=J:TPF(WA!.T0T5B]E9$MN-3=9<6MV:UAY:')6<G)T+W$S;4)73V],
M2S5I;35P3$9.-G<S9$MJ:W9P+T5K8D)9,C1.=UE-1D)*5FXK0E5I.#$K9$XF
M(WA!.T4X<U<P8S)O33=Y>D9H0F%105!.2G=2<$=+<7A504MI35-724<S:FER
M161F.')E64YF,6UW;FIU8FDV.'188B]!1FU";&M73C=68FDF(WA!.TY34U9C
M;S%9,EAL169J1D=A3F\K2C595F5J,C!%5G9B>%<X4VA9;U573TY60W%!<6EG
M0591<6I99$%+6496359D:7)S5F1I<55E85 F(WA!.TY/:BM79$U/<&%Q-W)B
M.'5#:4M.<%A:=4IC,%9!5#A+27I(,D)X5C5086%*3BM:;753>C,Y>$PK:C=E
M3FMN:&5%4DY#6E=J64EV<7<F(WA!.WA35#)L=VM235E01C1N<5169VI!<3EO
M<S=23%<Q=#=C3SAV,65*659M;%!+5F=O07%Z9'DS1W X5&=66'A6-34U-S@Y
M3$LX,VQR46TF(WA!.VUU3E-N4&]4>5=93%-)5UEX4$A'-C=24W)8;#9J:C!X
M>$MS>4U14594=GE0-4M444Q.6G(U-#<W6%I&-%A'<"MM<7E'355#>#AG05,F
M(WA!.T%Q2TLY-D1S04%&6E)I<D,O=T%Y=E!-4&PR>5-Y5T\V82\Q0T]15WHR
M,%5J3GA4*SDY2U99-5EX3W%%=6EV.$%$='513CA64T0X=2\F(WA!.TE1=7(V
M1'IN9C-B>5AS:W,Q>&)Y=TET=D9/<S1&2FA#1E(T4%51;%HT5W)Y:TA0,TI6
M-FYG5C)+=7A6,DMU>%8R2W5X5C)+<60Q8W<F(WA!.S)T=$QC>G1W9V=2<$I8
M;U1214A*:E%64%%D<U9E3F5A9DYH.#DV;D9O5VM.8W)9=DE),FAE1U-"6GI&
M26MK.&9R4W<O-E!C;TDK8T4F(WA!.W%-4E%K9D-X531696LK5&9*=&HU5S!L
M.4]T-6YU56MM831K85%+1CE2:4-75TY11E%K:FLS2&)L53!&8T-S9WA6:FYM
M-WIR<'9L*TXF(WA!.UE'8C%D4VY!.4,Q4F959FEX2RMO67=53&=C4V5#;FTY
M0W%68D97369L-351=G(R4G9-;FU1=F1V4$MB;E1B4SE26&5",F%P;&I:;%(F
M(WA!.S%2=4-M3E=514M&-4%%2T9+=E-S0W!B-6LX=U=0;#=2<FY6-SA31S!T
M44=M34UB>7-Q:V=&:7%":GA7=%=065EQ.&<P+W=!=E,O;6(F(WA!.W)%=#5Q
M9'A/;')A3'A:1$@V171T2S!I4VU.5VMH:6MN='!66&YB<V5,=W17;S553T98
M=#A59G!X2DAY6BM#:&5B;7)'9W!5;GAW2W4F(WA!.WA6,DMU>%8R2W%.-64R
M9&QB=F,S:S97.$53.'!*6E=#2W%I9W%39FYI<GIR4DYB;C@V835R1VQZ=TYC
M95AW56Q347EX3&,R1G=J3VLF(WA!.V9";V%-:C@W8W-58CDU1S%$5FQF-%-R
M3R],*VE7,F@V4F(V6&)/.&M&<T=%8E-"03%'8W93:V%X;T%/5D%&54-M0E5W
M>%9G6#5V-E F(WA!.S5Y,5115G1V3#=O.7)*5U!53%1I=VU.5U)O<#1P15E-
M4%)D2VQ6,TER.7%G57%P:#5%.&Q(4DQ:3#=5;DYX<CEW:B]7-795:V1%860F
M(WA!.VA*2W%+>F5N>60Q57E/:4PV:D1L45EQ>3-&6%EQ:'12,'EW,4="64PV
M0EHT:VM384U.,5=32F<V3W!'-%I71WA'2V]N1EA9<3=&6%DF(WA!.W$W1EA9
M<3=&6%EQ-&M!5DIO3VTO:61H:7)Z=E<O4#A!4% U=W-T2CAU<VPY2D5Z>%A6
M<#9S4'!824MU,&=#-WE,-E@Q9&Q%=C)!+W<F(WA!.TU0:35!<7EB>34U3C!R
M>3ED,VLR;71+:TXR<U-#,&1G,&-3=SAG:7AM;E!I03%&1$UE23)79S)W2VXR
M2W!8-6YH.'=Y-DAC<C5E=4DF(WA!.V)B5T%!,7)*8TIZ:DI69WA2:#(U9V-E
M5SE+,7A6-3<K5B\U8V%N1$-M;RM:>$E*24I19$]S1VQM<D5K8W!N:E=58RM,
M<D9+>$UA3GHF(WA!.S1S3U-U43)&6'$R0EA9<3 V2S9L2$%:5T)$2U)514AQ
M0TU654Y/,#9Y,#)Y:7-B1TE15VM!-'=W<EAI:3%R>%=V441S3S)+;VI&6%DF
M(WA!.W$W1EA9<6QU<RM:3D,P5T8U3E1V66)C<$1,8VE&;E@Q6&EG479+,&-D
M96(X5D94>$=+=DUB-U%T42]-<E@U6DPV2U-X,#-42EI93%,F(WA!.U%X*VQ0
M0VI+=D]J34A6<&I);GAO>3!#;$I),T)"<59E=%=D<71R8E)W<3=31D966&UK
M;UI*0W%H96-J041K>'!U8T-Q,DMU>%8R2W4F(WA!.WA6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5D0S*W!A9' Q<V)R54QQ1WIT;$E6<#=I4EEO=U=.04-Z
M:T1C-'$X,#@K-G)C*V(W=B\F(WA!.T%!:G!50FQS;6568C)74TYW<GI78WER
M.$QR4FQI:FY!4U-24&E2:7 T<VY,0W).=DHO;%-(>3-P2S)+6$5L,'=:-4,X
M=G!G25I31V0F(WA!.TEH1VM3;VAB-'5)54-U.4U#<#=I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5EEL-6\X:3-/<S9L3&0R;7!F55DW*S%3=S%A4# F
M(WA!.W9695,R:F0S2&]38S!-3&XQ5U9J4FQ+;F1D<U9:2'!M;#9B<&1M;&QP
M=')&6C)K9&5%14MH149456UG-VLY8U925TMU>%8R2W5X5C(F(WA!.TMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+<$HU<3AV5#9Z8C)B,FQY='!Q3VY8074W
M1V%73#9X1#9N<'9%5FQH-5(X,5I*5T=Z06HF(WA!.W%$:7$S>70U43 S44E8
M:U96=617=6%T<4]Q<V=7931D;DQK=3%78FE#,49"63!!07%A67%N=4MU>%8R
M2W5X5C)+=7A6,DMU>%8R2W4F(WA!.WA6,DMU>%8R2W8X02\Y:ST\+WAM<$=)
M;6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C!&,3A#,3(W.40X-D5",3%"
M.$$U0T(U130P.#<P1C$S/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C!&,3A#,3(W.40X-D5",3%".$$U
M0T(U130P.#<P1C$S/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ
M-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C!%,3A#,3(W.40X-D5",3%".$$U0T(U130P.#<P
M1C$S/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.C!%,3A#,3(W.40X-D5",3%".$$U0T(U130P.#<P
M1C$S/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP
M1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z,$0Q.$,Q,C<Y1#@V14(Q,4(X035#0C5%-# X-S!&,3,\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#,M,394,34Z,3,Z,#(M,#<Z,# \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C!&,3A#
M,3(W.40X-D5",3%".$$U0T(U130P.#<P1C$S/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 S+3$V5#$U
M.C$S.C$T+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU
M<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0
M<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN
M<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I
M;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X
M;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@
M(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%10
M9SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,S N
M,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XX,3 N,# P
M,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\
M+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@
M(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4
M/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP
M93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/F%R:6%L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT3F%M93Y!<FEA;"U";VQD350\+W-T1FYT.F9O;G1.86UE/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&
M;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B W
M+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86QB9"YT=&8\
M+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N
M=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @
M(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT
M(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @
M(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D
M9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB
M<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!3P'I P$1
M  (1 0,1 ?_$ !\  0 " P$  P$!           ("08'"@0" P4!"__$ #<0
M  $$ P$  0(#!P,"!P$!  4#! 8'  (( 0D3%!$2%1896'F8M]<A-C<7(B,E
M-#AV>+4Q&/_$ !P! 0$! 0 # 0$            ! @,$!08'"/_$ #D1  (!
M P(!"0<$ @(# 0$    !$0(A,4%180,$$G&!D;'1\ 43(G*2H<$&,D+ALO$'
M4A0C8H(D_]H # ,!  (1 Q$ /P#OXP!@# & , 8 P!@# & >9Z]:#F;L@_<H
M,V+!LN]>O'*FB+9JT:I;KN7+A;?W71)!!%/=553?WS31/3;;;WSSSWW ($C?
MD0KEV/C<X)TWT7%J(F!4 ,C71\F@ )A49!O+";4/$Y*\31F;NR([#)00(BT0
MLLDU>A@JJ91@[=N63%T@Z4L/&NVO'K[.RQ.DN,8GK<>N[-B8,>LV'2F=V'6X
M0BL[E=6:1#V;,]F+QN@*5G IT=CS=)ZX12;$%G(AKX^7]8*.46NCEN@LMJ[^
MNW0D:[EG38S[ -63BWHO7\ZIROC;8RL<O&522(0]8<T:+CFA2+0&36,25/+K
MOVJ[)DH!BA)!HJR:DEE2:C-NJW1;JJNT&_#S2_(VX^3?X-IX!B$\G\)J^)&Y
MY8DI"0R'1QDH0-R.0D&XT6/;)^?_ -5<.-]?-UUM_P J+1HCXJ[>NE$FC-!=
MRLDENR,&+49<L0Z$J>&7+ 4S*<.G@]R4 >2!@F,+[,6Q-\+\6>#TG3WQILNJ
MP5711W<>KZMU$ON4V[CU5NE6FG#(FG=&V,A3#;$GT6JJ!3.S)P0W$PVOXN<F
M,I)ILWA!1@ C@UR6+.TV ]!R_>J(,FJRFC5FW7<K[Z^)(I;J;:Z^LC!A0J]8
M89N;2C&38][+U*8"7KH^58M$X]M##\J(P]BV^\_4=B'A[PH,<++L=A?C1-CN
MBKJ147VW;)V+3Q@DIN.$]AB5T=7U%0-H4%5-F/RH4ST<<E$:@)S5FTWBK,Y&
M=(YKX/E!-8BW="5) 1E@,+'E6XX@W<EGFJ#]8:C[HXW)-RUID-I-)ZF626]H
M;%;7:TZ2:2!24NZ<G%X).6C)BJ%\B$ /Q>-FVF[M4F@[\/+/Y:,W',_!^S)=
MJF\47)-5$DD5T6G28$WC6)(F"ODJKYW7H.Y#G/75\-I(V'#27VXI!6<4>P<1
M$SOC7=C+3/L0L:4R5K'=4'B#MX00CCKQDTVV<N4TTD]]M4<5.(O/AZ[43I8L
MX>MH[8;@D?<?5E)T::J6+S25MUI==\^@U?5Q$0"K$K(SCR>R09&1\D_3OOF^
MS:%"711NZ.29;?5DW;^:M&'A(V\&"'\_!K\DC, 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , KH[2Z!E]7672==^W/'^5JNL01/"4DZ0E,-$2T<VE\<7C"$6J
MMB^EGNU?0HE)6!@_)%#\X;.FKUC&51H9--[]SOE4;-\%V\.HRWQ2S=]G$P.:
M=+=#T!RU?-KF9%7_ $R/B#V,>T/=U?"0S@9/ 4GU9-BSNQHE!Y+Z$%N(*;W>
M#%34<*#Q,C3= UD@X]7[]/=:5E:.='U^-BWN]-(6?O?AB^A.J"7M$)]+9; V
M0R6 I?!H)6]A2L!*0?H=^&#6GK+]HTR=)^.G.OAM'>$'D3([7;;T<LDWT]66
M^OY[J:CO:[O]A.>R)[33W_\ N6GR$:I\]#0%JV44N^!*VG#(+7<!>R6<MZW:
M[L4'TTDPE-VW9QP(U>DF M/8B4T>%B[K46 :%GR;A!%#^\3I(FTW=IC6/7?H
M:_Y![+'V]'8 SG9,BO++GL;JYM51#:*+1T65B%(VR>$#(^_0508NQ$L95]L'
M);"S UH5(-A1YVZ\\?#2"6AJ/M]U/5ZL$Y[6^Y..OU<F#6UK1*U])PO#U"#I
ME +&E56ER#MEZT8OI5"E6K.3Z@U]E-_U,:),+N@#A_IJFG^MB2[+37;[+U3>
M%(!WA9W8=*1$MT#*Y] A"7_6T'"8%RDTA(@YK/87)+/9P.* &MCM#*LL=V_,
M8LY]G314(EO'P3S;T22BBP\85>(U0X7WGA?L7GO:?%PZO#50]\K8L0!3AH?F
M$[AJ,?F0US 5(TF\.FXP2$Q.2>R</Z90VA$C=)ZCI8F)2\^QD6XI17P(6]\&
MO?R./?RY"FE+7ZRKZJID_K_R*VK9<OC\2:SV:AJB@!&<*P"%D'!%L+/2]PW6
M9M&/IC<,94# &3@C+"[82_=C@#EJEHLI8M-EM.O5Z@C<6R^&>[B1=D_>!<].
M;]C56@R3^"Q3B$9T?5=J(Q)RN%*'))';0D@F0D2)$E]HI#';"+1UA'6SB/M7
MKF5MI<'+:^ZLT4T#4+C+4=4>GV";QPF="<O/TN-V!0U)3R3+I.I)-JBK:72!
MTW;HLT')N20T*9++HM&^NB#5)9^]<*)MT--44--M4D]==-=?/#LWULI7AP7V
M[:-R5S)(O?R(H5<_D'EUP55(AP]J/!VM4;8X= :%QK%NFDQ2DE<RH8I%9F%3
M01WT9+Q@YJF[0-+O/3C*Q9/KX7F.LS+2<M3=KCGJ[8,5C'171]NZ<%Q]A?L>
MI=[>W'TAO*R9BXKB#21(S,@OM2(H-& V1JCQP=LZ]FQAQZW'+IZZ^()Z:-]]
M-//4["72M*3C+Q?^A+^&^4YQLGLS8\$O3JEU+^I.?H5-JGZ9L:KX73\EKJUV
MX$?"8^$,VF>.@CL4M81'9*\ .C$$# W%A#Q@$@#(R()XF(<:-7Q!JX10K.Z3
MGCC;P$N\0XC3?MO:^3;=5V#=4.ZP6YKL*U0M\BR-#/;B(25I  \"DM8&V$U!
MQ06".MHR^7!.H[838J:(Q-!ZW3DS12'&/%7IEAMN\:QQ$XO'^NK7:W653,9L
MMMWZVL\$],A1@# & , 8 P!@# & , 8 P#%IT\2'0F8D%XR0FJ+"*R%XM#1#
M9L\*RU)J(>+J1D8T>KMF;H@>TT]%,FSMRW;+N7:22ZZ26VZFH%#;FSH-2_.P
M*SN0NT4IG"VS&+)13@.^%H!;A$J^<DA;)CSQ%6GB#2]H/*0:JW@ &#7(R[4
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M9=&@:$5!(AX]*]"CTWI)P8Q-AJR$R'4R2(E]33!!N2U*/WK_ ,<^.W2ZJ@&
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MP\39)J>-?%]UE5!6VXX*%U>F5H_*/_S?\1'\RR$_V.N_!:<5_*O\Z2X#!D8
MP!@# & , 8 P#Q$EWC4<_<CF/ZH0;LG2[$;]RDR_47B2"BC9C]XOYL@T^[6U
MT;_<K:^I(?4^JIY[II[Y@$-*EZ;N>R+>F%5F^6W\'1K<K&Q=A2IS<D$D#,#[
M+(DG+P;@>+%M='Y[19BY9MW.C7U#=JX7V_-^?1'?WT6.*^_D38P08 P!@# &
M , 8 P!@# & , 8 P!@# *?OEA_WW\2W\V6@/[27_@W1BOY'XTEP.# P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"G_Y1_P#F
M_P"(C^99"?['7?@U3BOY5_G27 8,C & , 8 P!@# & , AW1G_NE[B_^54'_
M &-CV 3$P!@# & , 8 P!@# & , 8 P!@# & , I^^6'_??Q+?S9: _M)?\
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M+((J>Z>[I:;:BT8K^1^-)=O@P, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M60G^QUWX-4XK^5?YTEP&#(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M:AZ.8:::<9],B)\L/^^_B6_FRT!_:2_\&J,5_(_&DN!P8& , 8 P!@# & ,
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M;*Z>N'_V2"^FV_N@U6[77)J_\(G79X_HZ2L',8!3]\L/^^_B6_FRT!_:2_\
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MYR:KZ--?PUPNDHJ5X5Y.W)\I3RM%/*4RZ:U*G.6KYO*)'9ZXV, 8 P!@# &
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M^;7\Z6_X;Z?F\_-KY^/F 5"?+#_OOXEOYLM ?VDO_!NC%?R/QI+@<&!@# &
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M?/< J%^4?_F_XB/YED)_L==^#5.*_E7^=)<!@R, 8 P!@# & , 8 P!@# &
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MRJ_XDI9-C,AE1M?ZBV_GCLT:(._$_P B/B_B*22>@AD^ , 8 P!@# & , 8
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MXEOYLM ?VDO_  ;HQ7\C\:2X'!@8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M:[HJ*:>^;8!L' & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MC7C<2,,O(\U"KZI*L8JJXC0X4KZ)6TZFU9:=WKJ+5L&1@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# *?_E'_P";_B(_F60G^QUWX-4XK^5?
MYTEP&#(P!@%4OS%_';+/DYY1"<ZPVRH]5983<D0L_>2R8*2/#5F4:CDV!K"O
M&(ITT<^.72DK0<)+[*^I)ZLU-=M/=M]/?!NBKH5=*)LU$QGL9G?Q1\-R3XZ^
M,81RY+)Z#LHU$Y1/Y O+(Z)?A!;Q*92HA(6[9(>2<.G::C))YJV6WW6]U54T
MVWT\UU]\\P2NKI5.J(F+9PDN&Q8_@R, 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8!"GY&NHS'%G$'2'3T;"C9#)ZGKY8I%!!K5RH%=2TV6%Q.+;FT63AF\
M<A6D@/C7I=HT>L73P<W<M6[YDLKHZ1&J5TJDL2R%/*W=-MU;..[:;^0"S(7,
MMN,(-SI<[V]:VJ*21G0K K^@A.0%P1"KH:ZL$L[?UY*0;P,+?1MN](28(^9$
M'0MJ\0<I^"NE-4NF?B;4-K2-82O) ?Y"_EPX#NZ6_'<3J^XI=)V-'?(=3]WV
MDOYSMTT&_9>KXO75P SLH]3D%."537C$I)P37]&CR9:0N?OOK,Q+ANV=JMQJ
MFBI=*8O2TKTN\K9^)9'^_I^*S^(V6_TM=>_X%P9]W5LOJI\Q^_I^*S^(V6_T
MM=>_X%P/=U;+ZJ?,?OZ?BL_B-EO]+77O^!<#W=6R^JGS/I<_/E\4C)NX>/.E
M).T:-457+ITYY?ZY0;MFZ&FRJR[A=6A]$D444]=E%55-M=$]-=M]]O-?/??
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MI@M,Y<M^N$QGA! (F38[*"Q'Z@<>?7\\'#'?NBOF@U2TIG6EKM+*\&1@# &
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M)($7#4Y.)M*TE6C./1ELPT5)*/-DU/=UR26B3(-KN@Y(/V.JJ"FXJ3<PL7?
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MI/7,EC8(8;L=@H__ .I$'G95V(<;?AYH]&*FKTS*4=!VX2IV:;<:-1N= 6#
MP!@# *E_D+#59UA:W-/ A2[  L@:L@/T%T/0"FL\5]M[EZ LS(DE"IF9K_=K
MI#A4ML<_!U(XSG)^-@9N0 /&33V0.Q>D<*C5+B7&D)VLY5[\)Q=3IDJ%Y69\
M_P#0@#HCX7BL"MRQ5*>[A[(8U%.XMNX>O?CMI:M).Z6YTLY*U)659E1)YE8W
MCZ/5B! &BDF-!DS*!AJO&$UV)D;<IKE+72E?]V[5*.*N]+[M'2AR"_OE]S94
MJ?3XE(5?X2/.(A::K=5BJSDLGA!DI#EK!'_IJJK-$99K4$UL06T3^CNR'RAL
MS79L7""K) <W$N,:=6W822P08 P!@# & , 8 P!@# & , 8 P!@# *\ODPF)
MGSG%_0=7]"P_GGI/JD]'Z4YY/R20&(^4-28Q( SJ9BXP0C(B028(5<5TA)QC
M&9BQ"OD0.EP#_P >,R:XGZXU3F6FTKN%-MXQ$[V*3!NW(7-_3G=WQ0VW$;3Z
M$H2Z3_%+?FWDUR:E5Z6*PF=UPB?+7Q/*^/V#(U9+%XC7:<;!6K+)\^EXS2O7
MVFQ,019EBP]DN-7:IK5FI3JLL76-7,*4IXJY>=\>L9OVKJ?E_/G0;^3S$KS?
M:LAJ.KKFE>FVY:]*'; HO,*AGY$C_HF7D8B*R]O6$V))^;>N9O7LA4=+NG^S
MMRJ,U0W*U4M;/7SZFB>6#(P!@'C(D1X<>^+%GS,6*%LW1$F3(ND&0\</9(;N
M7KY\]<[I-FC-HV24<.G3A1-!N@GNJKOHGIMMX!RD2+6\YOV+<W?%&]C<]0+F
M&W8"BG2/R5]&AP)V,T6!BDL(UB1XHKBN;+DE<1 (%LRW!SF7_P#644%=K2N%
M#=G"!R3R$NHY*#I:$FFVG>E:_P#TW>\.(TTBZ<GN PEQS61<>_)77%9#(4X[
M993FJOD/JNLT'(RJYH0B"]EMZ?[@AH(LJTU';G#L"8[/"V^S@E**]N<0ZTU*
ME6[HL:"J/BI;_;>F<WB:>SJB4\2=$N#F, 8 P"H_O^.U+V#>'-G!9NYX_IXV
MFJ'1/3/.2FL]V3M;G:+B2T:$QB;2"OU&3:+M3=JR>#/HS&YU(H^&G+@0Y<MF
M\A=1]D +C2<)N+X3V?G$W6.XJ/Y%2HGJ.!W/\-1>$V]81&@^O>U1=:6['=G#
MQ_\ 'A651VI+&7+DZ6M>4%6)MG-M)8.6CU;QN,EBLD(QUD2;'&24(;N&[H;<
MIJN<JG_]/HKI?F;9ZSI3Y&(WL2YNJ/WIP,D%O\5&/V7M;QLJP59'I;#B3^)O
MIR-_3%56:(FQM J,^$LT_H[L1LE:LG#5DY;K-$!S<2XQIY=F"1N"# & , 8
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MN73IRJF@W;-T--E5W#A=7;1)%%%+791553;5-/37;??;S7SWWP"L[N.KK.N
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M272104E]4J15$BA[%FX(/2*[(2U9#&[O=HT1\\'+\8,[P!@# & , 8 P!@#
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M1"JTM=QB+O!@T<L^'M9B!D[)TZCXW32VNE\+2:E-I3]]=-^)SM4C+89VATH
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M6.EV$6%BFC\LJT9MFZC]RBHYW31TUV4]_#W\1&V\MOK-JX(, 8 P!@# & ,
M8 P!@# & , 8 P!@$;8SUK1,LZ4LGD-C+E6%_P!7Q2,3DW I$$,1QT?A4K9Z
M.6DK@#PTR9,+"CHQ95,5)"T1<%F4=-J:B"RS5]YLCJ+#B=)B>/';A.=#GHN2
MF8'0;9KP_P!E'Y+SO7M96<=L;XC?E&CB"K83SXM)S;D_'Z"L^>Z^I,($7K\@
MZWAZ(>>$P]>7#58X6QT>1P]&@#Q(;3UINVHKIW47>F<VNG@Z N:J< @X?7ML
MSF/\[R[ID]6(,/9W0]*5M&XRWL==Z@/)&78&1MD',A>1 Z49M#"354OZ+?ND
M&Y-N+&)_:#V(P]E,)V3>/!3V$I\$& , T5;?15.5 =A5>S6W:I@-J6]^NBZ6
MB%D30;%5; DXIEHIH.&I.5?OW;?5ZZ&M'6P]LY=;K/FS%@@Z*.V;-<5)O1PL
MPIA')62[YZ^[AY\M/@;KF%5Q!.N5.EDV%:#"CCV$<^=-R6A[C!SF=\!V896=
M*#X3-S\7;"VD#V+E/0-Q0,W"E'QKT@7=F9..JII355+;IB[_ )4RHZ5MGG5-
M.V"UKAOA?697ET]=%S?'_6?(O-]Y5Q2D3<<13#:H+:B$TN:LC4J+F[^*0"',
MBM31#UH/+AX;%4F+%$Y(=QI::EAH=X31W?C#JA)*IMIM])2K.(4N'F7M?4OF
M9,F8YFT'CVC9@P8-D&3%BR02:LV3-JEH@V:-&R&B:+=LW1TT1001TT212TT3
M3TUTU\\\&#TX P!@# *M.H?CP?33H6']=\OR&#U=>+TA%85TI%I[&U9-1W6-
M")$V;8Y&;BA3)/;4E84+!^N2%5SU!+0NU>LVL5,OO "[$A&QI5?"Z6I5VMZ7
MPX/5=JAD]ZIHNE*)&G0U(U#65/!Y.=6E$B$U?!(Q A9R2.6K9DX/%1\6%BF;
MXNNT9M6ZQ!PBHZ4203UW5]\UP1MO+;Z[FU,$& , 8 P!@# & , 8 P!@$>>D
M>E*[YJ@!Z42PL(=S#R"6Q+ZVJSPX.'3>XBE1UM([0D$0K\4YWW?&S/D=C;M9
M?P>R>^,$U4%G*?GBR&BPJ4_E[*8E]YS(3(GTUW;-_CG.VS;?-JLD[$B]B6UQ
M/T5R0 /1N[N"KN@57N+8>Q*0.#,OD/MV4B_%#EJQNX"=:A?7,IU5:%F,:>#A
M"9&._!Z<'Z_O)TA)50FG3:I-_N3<;*'JLYR=3=5@K)>4M!XYTFI74QM1Q!A
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MHEZHQC0=X_217)"8DW#!B3EHU<.6:VS9MLD.;J;A-MI8EDPL$& , 8 P!@#
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M82WC$ZOK>I,K!D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MS-KZB*ZJFH;;6;MLEK@@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8!X28P:;&D QD<Q+AR[%V,*BB;1N_&DQK]!1J^'D&+M-5J]
M8O6JJK9VT<I*MW""BB*R>Z>^VOH$7*!X2XWY8E$HFW.G-5/TY+IDBHTD,C@L
M,%!2[H:JY3>JA6CU%'U8/'E7B+=TI'0NP\'NX:LUMA_JC-MLD*ZJGEM];;)8
HX(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g108483g64y37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g64y37.jpg
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MQYQIKOF70AZ9JL?7]@?]UJC_ ..6_P#]O^7+F?(?E3/D/,_A/K^P/^ZU1_\
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MG4C#:;%*;M7B6,,K,,P^ECJ:[!9'UD>%X/7U9IH*E[*>GFI7SW=+>:D8TR3
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M61AUJ(J4B--%G1K%O!)[]IB97\[96Y?SIEK?1;CI[,AL,S&!(T&:;*91H#Y
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M0T=)\*YGP=)!+$Z6.!^VY^\8R:5Y8"Z,MDD^=SGN+G.)!6ZW-[6U)PBIN_\
MS!'_ ,FF?SL'EX'O'HY<?^?_ %^ZN7(N2<(G"*F4'_#TG^9;Q_O:P\IU\&^@
M4&GB[U*U<_$6Z>O'??A7WYU9UM%*5=K#5EQJ%9!)B(AX15K0AMT]=&WVWTTR
M58 T1*8327?2&4HZ&*??2'???7/]EJ^GPWM!AE95D"GBG<V5Y%Q&)H9(!*1R
MB=()'$ D!I(!("T']4L"Q'M)V![28/A0<_$*FCBDIH6.#7U#Z.KIZUU*PD@;
M=5'3OIV!Q#7.D#7$-)*_D6\F:)8>K>HK.=<]5P)5^K'B)U<NJ8[Q*R;5J\=)
M]/"KNT5MI4+C3C:O8Z2Q5BICU+F):RCWN^VF(<[0L88?;L'J8JROA;3[;FTL
MV.UKIC'(QDU/B%<74;X7O:ULT50QYD:^,O813@DW+2?Q)VMPVJP; ZR2OW4;
M\2H^PV#Q4;:BGFGI<1[/X#'#C$5;!#)(^CJZ"6%D,D-0(IKXB0&FTH;^>#E:
MZ\KAW7=ZL=VWBTM+FRY[5ZST3!6S#+J#J^RT2_C7PMFHL-?/ZD65ZQU@P^6R
M.V43W8NK#DU-';1S9T![M'-52MJZ:*GON8X?@JO>.@V*ZLAJ:5U,&/BE97.E
MBF:P11L,8;,1/+ 6B1K]/*3"Z67"\1J\1+?C)ZO]ZP@4\=<)<"P>KPW$VXF^
M:"III<#BI:ND?*ZKJ9A4E]&Q]#3US)'TLO\ 4?\ AU="7KKGK:H7BTI*;18+
MDBMUHS2$P5W'MD>O9-V,OJ*:[236Q?1]'B2OLPJ^2NQUN6]6ZA0AQW'X8BPY
M_'>U&)4U55ST\,D]0:>6"'XB1U.83\)3MII! ! ZH,<DK7R!WQ3(G;1=\/<M
M<W]@_I=V;Q'"\)H<1K*>APYM?3UU9^WP1X@RM Q;$),3IG8@75D>'BIIZ:=E
M*^+]K?40B-K&U^R)(W^F/-37K*\1F&GE,E0=JRORN\A0[7?^MVM>U6/_ ".M
M&\]57^<ED2=AE$E5>3>]]7;"=/'U$?>F]31J4[GJ\K:R@3M8ESC*+>V'"9)*
M3=B@)AIJMDNW'AD-I78!')2@-E IZO:KFS$3U9?(RJ;NGAFTS>>42#M#%#B)
MF=BS65%90RP;N;'*C:IV=K9XJUSG4Y^+H S#'4H-+AHCCEP]QJ(W2!DFYSKV
MM2;T.K[2N'6S;R,W8C^"%WL=#@6=G^31BS;NF.JNT==RIIUNMDTY5WR)H"0L
M26!%+:Y77TUD.7[V_?=IMT*2HIRZC@J689L'M!#%4%])A37_  &^BDDVYX80
M&P;1>'R1R"'=[437[@!BRV)4E8V/$:J@DQPR-['U<]&(\0QY\9Q7X::&#=4M
M34DNJRT,='%-":DR[,[V&JO(JXPO'D_U7W!K8&2/N[LKJ)[W_P"1UZV4I$UD
M=G5=)U7T?Y 0).NMA10Y9Y.NNV"X>IFG40619DFO:%<<:Q'3-;C4%^?HRGPJ
MLHMVV3#Z6MCP[#*?;DDBC;+)5XAAVW4W+@T55&TUC:UVT)#22QDM#8)WGY25
MF/X=BF^?#BU=ADV,8W5F.&*>5U/%AV$8P(J$AK2?@L2>,.?AK=DP_N$$H#S+
M54T9V6\,R^\U2&[]=^0"N_?G"MLZ[;EMHNI2EY%85G9"+1I9@U-FKKNR()1*
MYVXJ[0!KU0'<;,:-UA/UDK,7@ $J/GQ>-B@?)!4X<^GW,K98710-?&8W4TFS
M$Y\4D<4FU+1OI'2SEFS458JGM<YP?;.=EG8O'#5T.,LK/BH)(:EE15NCE$\=
M="))VQSP33P%L&)1X@R"E;+MT>'F@C<QC'1;6Z/,&MJ3A$X1.$3A%J5>O)\)
M*]EJ _5=_P!&,%Y2U.&Q]AULFD=6%E3V&!=HT"OK&(X @;7?7Z]40*$023II
M&4"*5/I$).1:H]-G]J.?*7OME:E?2^B_/=*ZN5QK1+3>@;KM3@99 XY7HA!!
M*&<_ HHL3&&$0/4QW$Z%CVA$@&GE*<[Z</(<>_Q7ICV#1U'9%,L%(>R,85EA
M!V$G(4M&J5B++I)&2(6*Q2G+6,,@ID Y'L@-AT(Q%D8GY!IIHMRJ\A.X_''M
MZIWVP(NI/$GLKMBD0B1Y27O/F=FDZL#6"2VRSZZ5NR=@:N0X43E]61--C,>I
MT=/D(T]8F6<2$6.).E_*#:8G>/\ #\[*TBD*FE'CSY^),YA&W:/R8A\Y_I#_
M &LQ+CD@7OSG.=ME.TF<^L^VVQ%N!XVV/R[HC2I=<M?")K1.L#7>V]GN+GR@
MH?9#5#JQTQJ:\V'*LKFP,QAMXA]\)UOKG,>F^!8=)I99-R<>GOW^>&__ &-.
M>)1[*6KAF)8B+)20QH'^E6D)('VTEC'_ #!(,9&JTGSI\4I4@L^FL6^^NVGI
MMZX(O*SIGM+L?K[L+RB*O/5?4.O693OJ[Z>%1V_#<K<_Q:9YE=@A8"M3CPGY
M<!+*:35-HDK)!,Y$RU?BP[1BP9* ]P'#J.[WULO3'JWMM'VG"YV25?L"LQU^
M0 >:.]TAQ3,EX-U+S#E1&VBB^X0P:A[ZD[#8SH-\HVN_I\\?J565^$3A$X1.
M$3A$X1.$4?%_>IO\/6?ZEMPBD.$3A$X1.$6L_<'DS3NJV;FK.*C?7K0:NS-\
M3 5 \BFDQ2 %$Z!,;9OIE*OTEU'V@,D.WU@%^37ZC.--LYX4OKD<OKW>[_1>
M1'>MAOEO_$1J;5E3O',-#2/%6M.JL\5^0;NM=GHK!82I)B5ZK98?I66,2R%\
MUE0SZU/<*=$>&]T<E2;A "D\<C_>O=^;\O<9E7[2QJ%965JTY2F!C)93&S/Z
MZP,&$80P^^="&,#)5,9(;+IG+(R;.^6&DDNV=(MI<YP55%_HU[<^#X?Z7=/_
M "'P?+E.YS-Z_2%"_-[_ ,T_^6QDK!/O]/WH8:7T_JO;L1<D_7/;D^L^O]+4
M,/SY.SZPI7,>T/UL=HCQB#/YJS\>!/S-K(%C]KX9*]6MOVOMGI,1?<W7?;<L
MVTO]+ T6-ILR_%$D=:1:XR6Q+^+&GYKSC$6,,<#8U_\ VH*^'.<_3>[<BO=(
MK5N1#M!K7;8K3H9]/]')H"<&0'\8WTQ&N92F[+WZ3XTCGQK'K#G4C,\F=M_E
MQKH1>(,#CM.J?B,]"619U]5+3&UZS[KKSZU=A^9%2LUU%!KJ5VY1"J:H$4%)
M! :=CZ3$<B-R,,(S:L&,*N6M898)[]?=^/KZL=->3?578;-%1ZTDL%>L;=81
M8)545.:0U48DT7:Q-=X+@O7_ )092%3%D%[' LIM69D\LFLDI,N_J1;3\(G"
M)PB<(G")PBCS?WE3_$)?Y4SX4.K>_P"Q4APJG")PB<(L"67M-^M+-%6AI\;J
MK ^@,C-A,(EG3(<5#3(\>(#A,!LFFUKBG%/FU)#''CA]R\G,^-\:U68S4POD
M9%'3W@J:ELC9&R/<^"F^ &PW9D9NYIC6AS97;<;&AMXG[=QA:C$IXW/;&V&\
M4\S7AX>XNAA^%&R-E[=B20U(+9'!S&M O&[:NM1^[G/8'8'=_4277H^M]@5"
M..XR;L\64JOM9-TUJ?JC(QSOS"$*(,O#1)6V\+!4RPS(*('7R0_)F./3L>EK
ML5Q[!(78!2XE2-.($2?&/IIG?#UM3 \-?\3&QC(HZ:"<MEAE$KGN;&6W(&MX
ML^JK\6PN)V$4]93M^+.\,[H9/\-3-&[9=OV-:UC889"V2.3;<7!E@;#>CJE=
M*OJ^=9DQM=DG8ER81EN(W>JV./XX(X!"X0%\>!ML19EUC^*;?&\F^=BIL9U]
MGH.#PF&DL89*;:E>13R3MJ!"UMF!L;VQQC8(;M6LXW))>1:VWX=&8Z<@Q/A)
MD>=T^43; %@ UP8P;.5[6)N22YW#I]H])=;=RQ*8>PD9;>--HU%&P#8K)7-B
ME+^(2&PUQQO6FZC=]5+%$ !'8*JZV/K[K0$/#)<3]-#[,C)%'* )&W OHYS;
M@VVFG9(VFNL-IINUULP5UL6P'"\<$(Q*G?.(!,UF[J:JE+X:@,;4TLYI9H34
MT=4V.-M31U&]I:@,8)8G[+;6"QV7K@60M5;;!2!Y4X0SPY;8VJ&&16NE+B #
M<%ALY]=@0I#YX AF$T<4&Y<T0T4V9I---OI:_"_A?WDLI)'%( V6..1H((;(
MUKP"-" X$ C@5CVP]X])0R/U5C9Z$#52)F8=,;3+(RK\DU=JHUY8BH7&$!*&
MP.0*F3#8-%%?-8-Y%VLQ(@<N@I.8:67R(!O;(D'C;,$Y9\]%)(X9&ADL<<C0
M00V2,/:'-S! <TBXX$9C*RZ3OLCQTL&*I9G^]1L.<VRK4^G/6=1W<RAV.]5Q
M/;Z[$H8$I2958S"O-U+(EQ%(*K7ZRZPM3@R1Y88H8@X@N8UQ:"X$AI(L;$@G
M,9CAGE?1?&:BH:F2&6HI*6HEIS>GDGIXI9("ZQO"^1CG1$V%RPMT%UY7=X4
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M]=ZZV@Z02&4D8]78DWRR3*]Y.-@7 N;?-]/YR/FIM],[#S_%LQ]UL?8KPM[
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M+_I]U"YS#*:VB$<DC(Q*^.G>:@-JI&1N:Y\=,97M+V,<T/D8UU.-4 EIX/\
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M'I##!#%KC2.***/772*./37&FD>FNNNFN,:ZXQC&,<]G:UK6M:UH:UH#6M:
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MO8-I,N]Y7.X898HK AMUN8&6.PUMYHQK[5L1N88LEE]N<<H\4Q"&^[JYF7$
M!#LV_#0MIZ=T9()BDA@:V**6/9D8P -> N$^!814[._P^FDV751.TS)XK:AU
M761R@$":&IJ7NGG@EVX))"7.C)5W%ZWH83R"S"55,-8!G+VPP.(1=8SXG-G6
M!)K"=J1KG&_R.5JU:*PCSG,).JX"22+,P0TD77-54.C,3IGF,QQQ%A/RED3G
M/B;;2T;GO+3J-IP!LX@]MM#1LE;.VGB;,V6:=L@;9XEJ(VQ3O!&=Y8V,:\:.
MV&$B[6D7;GP7;3A$X11[?+7"IGE#JOW>87FY3:M]R8U6S7 TOV[5G('I(9HO
MR9\.#=Q8Y"=1LRY@TWEQKKDB\]4?=7EA?.@:A:*,BJ+V^6(3RD0V!HDJIF!5
M5MZWLMXK'59J)<[M<:5< T8UH<)B/9&KN<DXL&084T>)I%GF0T'C:S2+]0";
MV'7A9<;NME;B#X7M:_=QNLK=W=P]E5Q[TOUM2B%B*S=DU#L2[V&ULNOG=L8@
MK.KD-88MD%,ZN7V8,]K=;&?:!=0$I%D9;)EB]MG>-V7'!)R  W.=A;*X&IYD
M?96^@XGH>'2^6O%8UK7G8DVEZTK,2:P]M-K$BJSJT7"GTIQ3( EMQ[)L76R9
MB-U\U+LKJ(M<;66[6WKBG<$"I2L,8K#64DL"B)LZY@6T!(SL+G/+P\E >E^=
MM-2.=^'595Z/\KQ>Y[O!3\];V.G#NJ==KM3WS5S7F8ME4===C#=86WW J2YS
MDT@UC/ V6:,8])&0$LQ.8A,P:QSBVVIS%KC/B+CS5!O;J+^61]_RL(W'R?[X
MAZ'UNW7R*FO^RRO*_L3I9'7V"]A$K>5VH]A]B(5"B/X&NDPUA=*JBO6:MMI]
MA=&1DAFP.D>V-(@ )-[V#;_0'[J;1L#Q)MZ]>-K:K$[+SV[#N@:QUU6:G$16
MGM[L"IU>37J*Z]IV3936/&WK?MA-6#*52W@;TBRD7JTMJM8BQLQ0HX=/<5"/
MHJ+*ENQ:]\K6OF!J2./074VB1?J>IM:XXYG@0.?"RV^L/;_:(^GAXH:)MZ3=
MNWS)GG:];7A"-R58U/Z7LG85MH"B-IJ5C0X^V"*4$16I&IXX,1^!SM"=M3(Y
M8?-QMD,^9UZY7T[[6!7(G3S.ITY9>^&:UYO7G78"^N];Y25<-3=#=:>3#\BB
MOX0;$4LM/4O7U+MR=7V#!B9!8*8^4SV7$3>I;!8((VVVWR?*IE4M3[L^HSZ$
MD9<#GQZ<[@0NL-,[<?#7ST5'G\T/)6*CZ-ZW7JG>G2WR.7]<ZAGT1_UY:K=4
MD_0-D[KOM<VZ\96YRYJ-TQ.AD0TEPSGU$L@I*QO#7?HC82"FR+ZD97U!&M@;
MV&1]GDN>ASMH<[ D\3RMWWR7-V)^(>Z#Z;Q?>OK#U7AM:NX>UPNN3;N1JBKS
MCJ;JVG;7?,$NY;L/:6ZV>0FLT=5'I/'G%BMH>T@&F YM.-D YWT%[9YGNX#,
M^''1+WTYV\@.!(XY>*W0ZR[L+O7>!J)<WT=];WKQSZH[WZYV^C!@G316%[:T
M;X.4H6#4@X=L)%56HV#R"9@3,-QX=]1LQ10PC*_(D'WYJWSMGF+C+0:=]^];
M4\XJIPB<(G")PB<(H^+^]3?X>L_U+;A%(<(G")PBQYVPX8U_KJUO5=UJG7)"
M=;AF1>;NFFL%8K"H(D<AXU9)AW]7W.V@2QL, 1[/ H=&6X<Q.I8\<H)(>?=[
M*ATUMUY+2RD=R>;5@ZLI=RUZMIS5RSH;MX0K*K+FO'65M/-VOBB3Z0'WT3\D
MX:+$'5CAVA:"-2(<W,P'+%)+'G"KD0T$BYU_'3O\N*ESED#IQ[[_ &\^*N+C
MMKNGK;H-"VL0R[/;/8G?>_6E;979(0HK=<7=E=SN4E(LK^L+K,S8AHU-+*5E
M+ZQM;I6F\N5:,]U$7*01HL"3R X=!G;+//SU2Y ZDY7ZGOY<."HD7FG/UXK.
MK]IF:]R]CQ]CV6EP)UO55@Z29+,5;KY)?FPSM0];W64TF5>Y6R5T]1!$*XUL
M*<8F $<-F^XV;]!S)!UORL."M]<B;7Z>]?'AP62$?F@O>=CHZ9IU1=UE>=7?
MK_KN2YN#$*^15;>S>D5G=]73LZ?*;^9!B8$QI"6Q_(/K"F:P#ZQS,/J"8E[9
MR.>8X6Y&Q2^G(FU^\7'GX+K=C>1%^J@GG=.L@KV^_CAUY7;1U]@M<5+K,S:]
M4,;F3BQ8C8PY9#:N!8L0Q"Y7;:!^Z#:3??/RX6'R]2;^=E"XC:Z6MXK6)[YW
M=O#5J]+I@JE6.R.K*SU(@[) WJCVSPH>RK-Y%J^J[.X4H5[B!J]K+V@-U5[H
MR8.>8\J!XLBU/83>^+>[(X7-R;:9BQ/G<6^RA=F1I;7+_P"JWHM@6G>_=P7B
M/<>Q7ZZ.J]C2W\?K:@60BC-J;EHFN';B'JVB=JD]9WJ=NUJ\Y85C'L^*O:-R
M],[B1[DB[+SHPL2PN.(M<^ O:^A\%RSMG8&]OK;KGY]5]V;S?/16RP5)-T1=
M+7A-:>UJ,M>PV^BJA']EZ<KHMQMN,CGL!S%JS\I32GBL)0]I26\/V899OI+J
M?I0S+4#3GH<AX]/JA-CI];6.N=^F>5^.62Q1%YJ=F6/R&IU6IL"7^CBZV7QY
M"3I[%0VHTTE6[AZLSV98#6/:FEN$JZ.[(U4195:IDBEJ=;9!9EBL<B6/<S1L
M@"^=\].AMI:]N:ES]1KEJ!QYWX9\--5TNA/.GL6X6OJBC]M!4ZL.;4WNUM;,
M@5YX2I[TA!UCV';*U:T6QK4G<(VOVZB.*K<L[_601?:89M-8,.AI-1;:]L_6
M]QEY% [0<\],B+$_0V]W K=+\^;G?NEO(R\"V*@ZVCJF*@=X5$*F[JW&)>DK
M$^$8E]=7,6<Q[@:^+TZ.P52XR094ME)E@2F"BJ#L#[[-D C6Q)!RMGP(Z<1]
MT!)!_L=W/36]CGW+V"YP7).$3A$X11YO[RI_B$O\J9\*'5O?]BI#A5.$3A$X
M1.$6@G;7G[5:&Q\B:_1NF^[.WVGC;5;"??K-3JPIQU<GO*?K//:@W7+FY,+"
M*R$<RU:=6:U9+JPW1I,M UA3':QDB(B=BH^SLU0S#)*BMH:)F*31MIHIY7FK
M?3OJOA#4L@;&6N8)@]K&.F9))L.<&B(&0:;B7;*GHWXY#287BN)R8%3SOK*B
MFIXAA\57%A_[DVAEJGSM>V4T[HW22,IY883(R-S]^YL+JQXV^<EM\@>Z>EZ,
M7U23UK6>U_!W/E3.NM><[W=/8\]J5RA#J125[0E*PI#92YEL-?:2KPW35;.G
M8F")922DHWVQ3 (<-H*ZI;6"JEH\?_: Z$6@?%\'+4E[@]@D;.Q[!%*P.<QC
MP]K72 !YZ^!=KJG&L5PNC=ASJ"GQ'LE_Y$65.=7'.<1@HVQM<R1T3Z22*4SP
MR%C99&.B>YL1<Z)NH?1'XM_8?91]0I-XZPI5-[)M_ECUYUS70("'\B:Y^-/8
M5V['ZXT[3JGU;+!LEHJM]ZQLE.M$,NY24%IJLG^E^)R-!#F,0['4],R:HIZN
M>:EAP>HJI7%L8?!BE-3TM4:.6S=G=2T]5'-$0 ]S-L7NPDZUA/ZDUM=)2T=7
MA])2U]5VDHJ"!@=,8JK :VKKJ$8C3;4FV:BGK,/GI:AI+HF2"-VSLRM N_A%
M^)?V?Y+]YT[J^R(^C7RV]IO(UPV7=..K*7V%X\:=&=J;]?5N/OQ.V8/5RZ#M
M\'$;:DD13U\PK,FDNBJ=?,.3+\,=[+4F%X?-5Q25\;Z>3#&,=6LB%-B7[A1_
M$R'#GL9&YQHG LG!$K1:VV' @=OLGV\Q#'L8IL/GBPB:.KBQR66/"Y9W5N"#
M",1-% ,8BDDF8P8FRTM(X&%[KW$180XYK3>?.J%[Y&/[RDLEKKJCS-A\,O''
MJGJZK N>S;U>:EUD@L5WETF:O$24C+"Q37@_ZY\YKJ*N5>G:Y*.R65KL;T7]
MG=Y'AD=/)%#*_ SCF)UE7*YE+3T\U7)%3BS(Y)!LQ"G;LQLEDEFG.RW9%FY6
M+MCN9L<FJXIZB"+M2.RV!X=A].R6OK*NFH(9ZL@R2PQ.VYS5O+YI8(8*>E^9
MY<X%]O(_$R\>0.Z:CT2X5=EH;G9'W45(<[O4-;5C==]F]Y5U?9NN^L+RG)N&
MEVBMIX;A*$Y)J]1M-1JKERL56:TJBR<::_ =EL2?0S8@Q]+)!%'6U#!')*]U
M324$KHJFK@>(/AS"US)'1B6:*:9D;WQ0O 79=V]P1F*TV$2QU\-5/-AE)*9H
M8(VT.(8O RHH</JXG50JQ4O9)$V5U/35%-3RRQQSU$;G6&N/0?X@_D=90/%C
ML_N;KSI?'1WEQWK>_'BHE]:GW=?V+US?D;SM9532+4HLL[M';$%ISU(\B8FI
M6*$BO[G!%[BG1Z;BR93$NS>&0OQ>DH:FN-?@V'T^)3"J; ZFJJ>2.C?.(7Q!
MDD,D/QC"ULC9!*&N <TYK!X-VUQRH9V=Q#%:+"OVGM+B]9@M*Z@DJV5U#60R
MXBRE-3%.9HJF&I&&S![XGP& O8XM>/E6//$;\6_L/O\ "\<*Q?>KZ50^W.U^
M_*C3[77 B'\R<OHGM#HGM[M_K;M;KR8UEN01.6XZR,HUAB,(<!*G*1^.1$(2
M<MA#[.,]C:;#G8G+3551445'AT\\,KA&'C$*3$**BJJ.I#6  !E6VHB+0QSX
MWQD%P:\GI=F_U)K<99@5/6X=2T>)8EC-+2U$#73&)V#XCA&)XG08E1%[RYQ=
M+0.I)PYTK8Y89VN#'/C#,X=!^>W:'DCVQY(=/J*Y3Z.&TZV[1O/@_P!C"8,<
M2=C(>K^R[QT/:;3;E;0S*\B4'L1/4;:B4KH X65"M2XHO$GR[3XQ^(]GJ7#*
M/#*U\D\[F55)3X]3.V6"FDJZ6#$(8H7M;M-#J9\T,CW[6S4PO#= #E\%[8XA
MCN)8YAD<%+2,DH<0J^R=<W;E-=#A]?5X/45%5&]^PXLK8J6IBCC# ^CJ8W.O
M<N&[_A_WE+Y+>+?07?10D"]GVGU94+8]7B:[ZA 68Y2/I: 0<2;;R9 #L,3,
M8':3;,FXD4.\GIOMMC&!QJ@&%XMB.'!Q<VDJYX8W'_<Z)KSNG._^IT987< 2
M;+:^S.+G'NSV#8PYK628CAU+4S,9?894/B;\0QER3L,G$C67-]D"^:V/YC%G
M4X1.$3A$X14R@_X>D_S+>/\ >UAY3KX-] H-/%WJ5<^15:W>27EWX[>(M?1V
M;R$[+5]?+;.RG55V&<!T\;NS!(8YSOMJ&MK6[HD5=%,/LR8: _0 ;%A1%DPS
M'!QSY3"L%Q/&I9(L,I7U+XFA\I#HXV1M<;-VY)7LC!<0=EI=M.V7$ AKB-8[
M3]L^S78VGIZKM)BD6'1U<KH:5KHYZB:=[&ATFZIZ6*>=S(@YN]E$>[C+XVO>
MUTC [6BE?B[?A]7FU350'R!35[?,&A*BQWU)9.OZ99H/K<+IMZ]:[@I3J#OI
M#_>(3K*0+MK+ 7M'B6(,J2'+5'8KM+3PB9V&R2BY#XJ>2*IGB(;MC>0PO>]N
MTW,6!O<:%S;ZK0?K/^G&(5CZ./M'#3$ .AJ<1IZK#J&J&\$3C35=;##"_8DN
MQVVYAVFOL'!CRWTA%*&.&'-"(@,#,@A*$+%FC(&*&(CUE@('GBVWBG@GBWTE
MAFBWVCDCVUWTVVUVQG.K$%I+7 M<TD.:0000;$$',$'(@Y@KT]CV2,;)&YKV
M/:U['L<',>QP#FN:YI(<UP(+7 D$$$&Q7/R+DG")PB<(G")PB<(G"*/;*P7B
MMDE:09)6.%YBMB-B6<?) + :00N#$XTD),.91YI(\2CS13Q^[WQ2:2:Z[8:(
MJ3UGU)UWTZD+KG6M9&JB,UD2X)6AELBA]V1F<;%EZX9&F[PR%28S.1B'>/28
MF24F338B:63>DDZHOWL?J7KCMQ:N5=C5-;:!4[##9-*5DD5DD9XAD&V/2N5I
M 3=.7(--*-/.M.%DG&ED'FVDAWVTR!(T*651!\:>C%9%,*4]=*$Y'7R\1359
MDY+93N$J =3V0-6=E<Q&^_+1K 68[A L&&@NC4TX_$7U)I4DS:.>>NOIX999
M*;(Y:9>_7OSU5MK'4?6]+8J&U6J*M*Q0H[+6DY8>",2@(KC9Q;G9ED/RSR:_
M3N+0$*Z*QOKOO]7#K\6\<6=H\B2=3?3Z"P^B6"J:CQKZ-0V$NU*.O%(3TZW?
MGTDV,IOOIM<<LSW.UAC"E8R #L=VC-@;O*.+%K),7+G?3;7;&N&T;6OPMPT[
M]4L.6F?CS4S7NB>H*FYAL%:Z_KR-P/=+=V) :M&D&VBNM\3PH+A8HXHYL#ZG
MOTX\(!^<1?#M#'KF.*.3UWRN;6OED/+1+#DNSV-U4D[':=<.6198#+K2YS6U
M.0'K!O\ 6Q,JM8Z58J\PUFTV]Z>P5NTLPC=8LQSQS:AEPR8D%UUV VOU2VG3
MW[_"JD7B]T'$L,49ZU3$AL1;B&RV/*<,CV8_8"1/6K?HR;,&1+5ALZKU?1HY
M93#9Y1E2E> #N*,+#'JN>?XRZ:)8'A[]^@Y*VZ=,]71VG6ZQTM1I:='B*RZN
M-,$Z$??ZS3W- 1-\QZD8'V/74RP-JY$1M#G?=83I#-F7(@>PZYM;A_-_4);W
MKZKI4OH;IWKII]YH_7E<K+'6"SC1S*Q=X=(![HY76"U0"B[2[B"1/&Z=48=&
M-!%KOE:#!IC086&'023J;I8*+ZXZ"HG5EO<VFHB[KAS*/3NN*]7(L:ZI:93J
M<TM3Z!.ATVS(3K$S?7%LR/R1/+KKB):&+I *!%ID3?ZGOO\ T@%N)Z9Z?GO\
M%F_D53A$X1.$3A$X11\7]ZF_P]9_J6W"*0X1.$3A%2^P>NZ5VK4V=%["KX5I
MJ3G=?(S1L-B-1#)%3(1NOWDV%G'GQL(R!#,BSI-IZ3#QYSZXQG&:"0;A%S4B
MB53KE!#5Z8JPF1#D$E0@X-8L,:3F2YF)D^I:%G%[?))G.WMV(VTT_LTUUU_3
M@DDW*+GN5+J?8=::TV\5Y3:JL\@T':HG8<1R\V.*:(F#:2"77.-9Q2H(# R8
MLZ$AF00%BRPDP12Z0&V818@&\4O'P-#I7!.M5@H$5FFN,94#2Q16&.SDIXZ\
M2YTMNCC6U:%DH88DI/M<XB(4Q1KYH]Q--8L6Y)N>[0>FBEA]^/ 6]%=8.E>K
M!CXFD-+4Z,8+97+S$7ZE[3:6VI4V'KZMO?=N3MC)JFF#PU\;.V,Q?1:8S+')
M/G,V5S]+>"6'OU[^J@;1XW=(72T6*Z6?KU4VLUM1EUJSLYBF\67J,VN%5$E>
MS$%8P EQ;ULTE3IO*+M-"/+G:&6.;3275M$"U\O#G?U2PSRUU4FXZ&Z=?OG]
MH;]>UTVPVJ*E0V-OL-)$:ZCZY=K['2/N$L$T62=ZXY4K# )=\9EQ]O#'FWE$
M&B@U7-K7R%[#OU]3YE+"][9G[*5[=ZT4=P]<6GKAV:<K#L@8^D+=9\'W)(W5
ML W2!ZOP3',-N:C>K5K86,B*2"2<...;3:/;;' -B#R0BX(73_H3ZMW,V934
MM-*RE=7"R$&^PG7>9_V"BUK5U:YUP3G74BQI-,+CM<>L?T_IB'6/?]O*YY\A
MY:)8>^HMZ9+H#^/W30@T08W7Z."" [K=F/K%@S209AU &$OZU-&GP5\XQ-0!
M7B"*YH)8]_IXLPDY(TEFUD7//G]=4L/0^(XKHL/&SHIH%6UY_65;G&J%7N%+
MK7]25$0GJM_7%J;BB$,A*C,U7OEQQHID6\^^=8RR<P;0[SR;;+GGK;Z:)89=
M-%U.T/''K;M%5JN/51))]T=>I135)!$.>3UNFNM9NI_7WIMC831 ^)JP:TSU
M&D*" )-^V2B3S[29 D>^-B+_ %0B_?I?I>]EGOD53A$X1.$4>;^\J?XA+_*F
M?"AU;W_8J0X53A$X1.$3A%I>;X.];D]I=R=C"7_N5(A\@0G.O<'3"2X*0NGK
ML_>]8[=0L+DP2[5B:TC6.6F:AQ;:+KB'7IG*E/82D)#E8*9'G&X_5"DH:9U-
M0R28:YGP5=)"]U;!''5_&M@:_?"$Q"?:-W0.E#'OB$@C<6K5G]DJ!V(8I7-K
M,4BAQIDHQ/"XJJ-N&5<TU!^VOJGPFG-0V<TH:+,JFP&6..=T+I8VO&.ZS^'#
M2Z<\Z2M-:\B_*51:^B^I!NB$5E$N'6,;2V=1@70>ZK*1>L?T0Y 9JULP"A"/
M,G"0,9:^F7Q&FEM?JVQ?:E[3SSQUT,N&82^&OK3B,D1AJ]B&M= 8'ST_^MVF
MN>'/D(D=(T22.+6M9LL;T:?L-24LV%5-/C?:&*IPC#&X/#.VJH-Y488RJ%7'
M258_;-B2-A9%"UT3(9##$P.>Z3;D?SQ_AD>,\9?BTUQK>\V#Q$[!N78?5UCP
M_4Q.6)-ZOS'LQW6;O-!78AK#4=+>?JQ5K815AJS(4&HK/7<IM(SX_P#E6*;.
M+,_T^ZQFF@IJN+=O+&"GIFTL<M.#*3%-N&EKWESVOVC=E@P-Y?\ @. [79Z3
M_6;[LU6U5=A\^^C$KW5=:^OEIZLB -FIA4O#XXPV-[-AMI+F0OV;\=O'R@>,
M76"[J?KC[O/7ESZ\V+#&Q3K3;"<PO]]L_8;?[DQ6*D\!<(;FV,0E&NP6LH::
M  .68J:"0J?%8EB51BM4ZKJM@2.CIXMF,.;&UM/3Q4S-AKWO+2Z.%CG_ #6<
M\N<  0!G\$P6CP"@9AU#O# R:KGVYRQ\SWUM945TNV]D<0<&RU,C8KMNV(,8
M2X@N.H&_X>8=AL'>H]COEBJ->LGEXJ\SN@+UU,]@3=N=5=I-^KT]'[&A)VL]
M0L5,+3M68EB)# /5V=:V37)D(V6B'+02Y,T.TKHHZ Q4\4TD6#/P/$:>LC,E
M'64C*M\],1NIHIVO8UT0<YKXGLD@:YCRUSFC6#V)9//BXGK)Z:"?M+'VIP:K
MPV80XEAV(2X=%1UP<9Z:>E?%(]L[F,?'41R154C98VOC8\Y KOX?G6=4[H%[
MS2]F=R:6PO;K0Z_AMF'6EF7=L6?JNKJ*?7[I=FEHZO<W9;:&:5"HTM177-NH
M(%C+!B..79)VFDEZ\O:2KFH#A\E+0[EHJFT[F-JHGT<57,^>2"!L56R!T39)
M'[D54-0Z)KBUK@+6[L'8R@IL5;B\5?BGQ+_@'UK)7T%1'B-1AU/%2P5=7)48
M?+51U$D4,0J'4-31,G<P/?'M7*A.E?PUND^EK+UN]AOG>79"CIBQW:X],]?=
MFWI0TZYZOMW8)MB-L5HK=5K-3J0[!_G:W6:%2SM\]G*11.C9%&X9>T9,?TK^
MU-?7Q549IZ"E?7Q00UU32T[V5-7#3-B;%#+---,61C<Q%[(!")"QNWM#)?+"
MNPF%85/02MK,7KH\*GJZG"Z.OJXI*+#ZFM=.Z>H@IZ>FIFOF/Q,XCDJ34.A$
MKS$6..T(6'\*_P : 9/%IDH9=HHK7XA4"S=;=5WE19D0ML,KEB0OD@WYQ,VJ
M4J]V?4I;,]?4\@18IB3O6A\^XY8)QJ\CF>UV*N_=FO9220XU415573OAD="V
M6*2.0[@;[:C;,(8XYPY[]N-C1<.:UP^0_3W 6N[/21R8A%4]F:*>APZKCJ(6
MU#H)H9HF_%.^&+)GTQJ)9J9S8XQ%-(]Q:YCWL=UTWX8/CMTH!UQ<O%FC(>J^
M\^B^M+W4NOKH!$DK..TW%EZN-H0.?)!^CIC%Y>UTS;*VV-&PP.KH&R#ROE<,
MF^\RLRR=K,3KW5,&+5$E7A]?54\U1 XR2_",BJVU#OVR.2=L<#@S:A8QSC&Z
M(B-Y&3V\8>P&!X2RAJNSU)#AV+X105E-15;!%!^X2SX>^C8<<FAI7RUC#)NZ
MF20,WK*AIFC!NZ-^V?BST@'XU^.'2'0@9T;77J;K.HTDQO#IO%"Z<)E T#UW
M##)C$D$3EU]P9Q0;X]T$96L.?UTYA\7KW8IB=?B+F['QE5-4!A-S&R1Y,<9/
M$L9LL)XD76R=GL);@6!X3@S7B3]MH*:D=*+@2RQ1-;-* <P)9=N0-/\ M#K<
M%GOF.683A$X1.$3A%3*#_AZ3_,MX_P![6'E.O@WT"@T\7>I4#WAV5KTSTSVO
MVYNC.LNO6/75ROV:\LQGZ]W^4J\P>?:QLXUDS'(;D'Z?YOCD^'7?:;XY/9[-
MNWA])\=74=%O&Q?%U4%-O7_[8]]*V/;=T;M7MQM;)8K'\4&!X'C&,FGDJAA6
M&5V(FFB_^2?X.FDJ-TP@&Q?N]G:L=D&]C:R_B+,[4Z/-6X\O_*=S?.X+[Y:
M=D+&GCM;ZZB85UBD6WLL97<ZYW*LM URZ;Z^JUJ3CHJMK5ZC/<]"J;94PR]C
M3S)]"_?&T>(-?^R80RFH:;!G4CV8G#)(V5DCZ<%\$M"^)T%=4S0R&6;?3" M
MGB>7MG:-G\&OQ; I(_\ S/M=-B&-XCVNBQ2.;LW5TT$E--!%B+FPUU+CD58V
MNP3#J2L@%/1MI*)U:'T%5 R.2AD<'[*CL.NV5S\4.@NK_'/QLOG7;SK*V+U/
M:5>[I%M=LH3OLSLAW5K\NZ9M?>=E756P6.GXLB:X(.K>P.N7]UAL%JV;HPJY
MEB,8%BBVI9#C.)5>*8K3U,=7"]]'+0.AAJ8Z2E9-3.KH</B?-'%/NGP2U=-5
M14YBAV)'2[):[9VRX9-6]D.SN%=F^R^(8;4876118K3XXVLK,/J,6Q2HI,1C
MP2KQ^KBHZBKH_B8*VEPC$L+J*]E35F>GCI=\R2/U&_!8[HU)=>2GB<M[GLW>
M%$\<(>IP.MK?8QMLPYUD0M:YV8#4C9XXV$76X5Y08CZW3LM=R *O)!O'+MI/
MO'#J/;R@V685C+J&+#ZG%#6NJX(G9Y2,EI'3@$L-4^GEO5/98.F!!&0)]:_0
MO''/J.U'9"/'*K'L.[--P=F%5M2TV-Z>6EQ6.BD<!(,*CKZ<#"H)1MQTA:02
M'%K?>KGG2_0Z^?=KG.=<;:YVU]/=CUQZZ^[_ *OKCU]<>[_L]?[?^SA2XN1<
M7&HXB^E^]?N=M<9UQG;7&=LYQKC.<8SMG&,[9QKC/ZYSC77.<XQZYQC&<_V8
MSPK]]%^\(G"*"0/H+"*65  V7Z",SU>T3@"1?/-(!+\,A(\4FVV90I\_M#$8
M]/DQC;7;2.33?36D6\@?-0&_IY+!]O[8NX<O=1E22U21%TDK-A=26(YOJV=6
M33K1?V3IA8&N'P- E7K;#6H-Y"2]IW9D[L&*5'A3$:P #*]\_P V]Z6US4).
M=K9?B_TR[_3K0^2*0-C]J:U^R,)]7<@#!DA7*M$]=7YL];I\;)SNVLX[ D?1
MY9U^DGV,%DPD#S.9$HQ$&1G4!>_3\$_8J@W //\ -OI?-22#R 4M@'9FM?>,
M!:JM9,;581I*A7JTDE&+>Z@J#"[?=U,L# T%-H1]9GY$ NIX,S5RITGDC%;.
MF8SM89WS[A[X)?7(Y7SR ROS/3\V6/-_*O5DQ%/J]=F;57<=%M,%%$$RMI!V
M'OD+7;8I4[I[&96&AL+;I4<*NS@-BU++<\DC1H4&6$0-=GK^/^/EKF@-]!P!
M^IZVX9&]LUF@7O"BFH\6L,@TJH[W>OT6"V10B_8"CK- BT5N!S-S=-I*]L^L
M(%0)/S#K,-9]2PY \!#2,.2Q\;7MQ]VS[DN/"]K\//EP[\EBY_Y5UJ,"2"O*
MCH["=00[^A'?DU?>*5>8'5&N@3M EMY=SKS'[1; 3-(7R%.+-\4^HYT^V(-"
M;LGZVX\STST4VAGW7^E^%[>*YY_)+$I"-6EK3)L7/=J]7K.]P(N"K-<7/^QK
M5218BOJ[1$ZW<E05%H0)( O:*X),@D-I%L3$87#9ZC0GCRO]U22+9<1W9FW/
MCPUMQ7R)Y95%E("2MK#XJO0N;FHN5AA>]?M *;'3.O:_V86TEGK-PL*^R+RJ
MS9 2M?RPR:&C;0'"SAX901+R(6D9<3IKGG;B!];)?WEE]5%6;RX2:=?6RQTJ
MG6EU9TU0['LP:8C6HE+PQ.OZM5+ PL+EHJO$B<^M!SWZG!LAJL];V?4@Y@#"
MFU-3MM +LY@'3+GQ\+\#J$)R.6G/AE?//3NN5N!SBJG")PB<(G")PB<(G")P
MB<(G"*/B_O4W^'K/]2VX12'"*"T?0;V26LX ;8(A3QN<LM@)-4F\,A>0\!QL
ML[?'NQUWQ\VPF-/7Z?W2:[[9TDUTMLKY:VMQ_I2^=K'OX*C7VZ615:*51*:O
M1D62Y!VMWAA9B3H$BI%3-$>C/?X%L,AK)J:QLZ(($#28*.(.5JXE)EPIU6L
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M!D?I(4'-@O; R[[D8W7*QK;^_ ?FWX3C;H/K?\?VHO?RY4@5,4DBIG/KSKU
ME[0)K]??4>$,[8I)1F[A8/$3<"[)7?H([R&6/O;D2O0]<&7(I);S9!U8-G/7
M*]N/7I8Z</&R$V'#2_+37G]U<9_*.A0.GM>^RVR=NB)'3[!":U,R8^VDV.HT
MZ*FP:"VV7=<[WMMU45X<ZQZHJJ<7"T+76,Q.OF9\FR;7]Z$]V@X%+_?Z$ ^J
MR1U+=V?8=-DLK=-)7CL7/LZM[I9\08+ 'I'9ENI(,3#(;%N#NTV!KPTK21<S
M-62L9"9%L^P.X_H(L? ?4709^9^A(62^15.$3A$X1.$3A$X11YO[RI_B$O\
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ML8@^4T@\"K2RU-FK<P(836R&#"5G,[-<H:$SJGVEV+9(5"7+,ZZP+CA66AD
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MM<PD PK]!9H6RU8M7,8I(MHS0%P(9&L@P8\4=N>9\TL.2^-NHNJ-XD$&_6=
MD@JDQ)-8BDIU>WCKQ)C*!P82DTW79U5D%N!AFQ,X6(92&8\+"7?<N+2;5<\S
MGKGJI899#+15*Z>._55S!U"WJZ6N[9LNUM**KU:I^NS5Y(KLB>4QVO=UMVD=
M3;B6VPR1D-%19@3!F0U7DALY-B]@<1URMJ>FEB+:);P[K?<'FK7-U%UB96P*
MDVH=5L-?7;0S0K[,D7V328Z%/A!EJ?(['.F8N24V-EIS@Z0AD>))-"83/I-+
MKNN=;^626%K<%R$]2]5F,'38OK6A$M;&)L#8&<]0K\K!V%M.K*V$;&[K]B6
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MG*/'5FB==HX)<PBD, H-=Y],$G;D[E<2+6Z_@'[\_)-KYK<[^8)^F2R!UWY
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M\1^?!75>1U"!*'654W6X4ZIC&H7U]?)6!I5K<@[%BB5AJ1MM-PV,[)+A[&%
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M[N(*X7F5K"&[SJ;ZQMRA550;VN59UD/[>(KTCZ,7L"P:$3CUX*DM=6]@&?\
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M'7EM0$25"M2 5C158(+3BSONH*/V*TV(:L#AM(@E+2U'5X9?K7!VWU .-CB
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(3A$X1.$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g108483g66t01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g66t01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1TB4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5Y@I0         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              #K   !"P         !
M      $              0L   #K                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     $GH    !    H
M (T   '@  $(8   $EX &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( (T H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M>QDM#7$[S^<7#]S^0CH+?Z59_4K_ "VILKL4:L_L7"J.EZ)DDDDY:__1WO\
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M'ZW8[\SZR.Q<:BO)R745[:C8QMA^G]&JSJW3;'M_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[==Q^8:\O27AA.^+-V](TVXNO1^$U(X;<1A@=[UIAABJ#L AL( '<!^;MO\
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M86566NNX6%O-%TAD[?9M 1:N9!-=SS."J"@13PRG/RE'Y_HMN;_?;=_A@_\
MROA^A:Y,?RI>&9^)*.60?L=QN"R1'@[<2(>V:='(!N/_ )AES?;<=M][5 >V
MW3:GZ+;FSMMN[(/<4_0M<F=Z7@:-\22.L-FKXZ>^'?Q1M.>0?PB6KEC1/*2A
M822@Q;2S+,7LGLLFHU464_D;6*?Q2F9I"4=^A1, AN8!KNK@T(N^X+P^'V6T
M6F;,\Q,D:LTP@:LV*"*/T1#4GS<+1/2H8Y7#HST<W=HO>?Y3LENM,V:;/,LY
M$^&#5U)AABB A!%7@A8O2M,UG26"XR ]KUT =_\ F.;^N_7I_-GMU#;W5>S@
MNPU0-[OF_?[ZNLB#BX.%&HPQJ><E@WJPX>/%&U<7%;%QWSEC11".[6A581FE
M LLQ @LV5?.7QU%O:;6.85O$<G*7E$"@4I>XC5QW)I-:[BE3I5FL\F<)T>O$
M9L408ZL,+ #Z(+OBKCN72.U7)*G2I$F3-AG1^<B,TQ!CJPPL-7="[]RQ*'@<
M<0T/_7GI(]1W999#MY!O:0=1Z=MQ[]-J[L=(=Z#_ &*R?XH_><3V+NCI_>7^
MZV7/'7P[>U8Z::N&1KGU-VU?ES6KE73';[:PLJWGB>0;3[7)(N'DO92C))[)
MLPC[==D"->&>D%H#@4G6Q#>*@3Y/-/Z0[U!K8K*/[\1;L3\_[R.%FLAX&(]=
M(BV3;>Y9'I<#SB((+HJ%SCI%,*9R*["TRT&YDS%.7?\ FG_1$X%W\]MP^:(N
MD*\XH8@;'9@2" 08B X(<@F&NSCQ"DZ?7@00;-9P30$".( ."7](5<#<SX*7
M^W;)XQ%NP$';[2^- BK:"AXR&;K+,LV^*LC%LD&*2JH%MGE!0Z:!1.!>G-N(
M;;[!8DR89LV;-B $4V9%,B +@11ESD&%7'%6--F&=-FS2SS9D<R)O[4<1BB;
M<Y+#)>>R3BGB_P"2['N*Q)>_]!#*-N5C[ [<LV&;!<II NBXW2\2V1(4PF1*
M F,!@ -PVW,&UNZ47!9M*;AO+1^V3IDBRWI(^#SXY(A\Z(!'!,> Q4$0BEPU
M((9PR[;1V_;1HS?EW7[994N;:+MGFT28)P)E&/4BEC7$+$C5CBHXJ078$' X
M.%CQ-1Z?AFT7B4I>@?!V7]Q#KN&X6P/-OUVV\OGK7_\ 5<T1AH;]OIW-#+D
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MT1%%L(&!+Y0 <P&J*_VCGE"]?[M>M0PV"FX>Y7FY0^H-O(?7U 1Z;U/6_9[
M$;93@P]B  !V^OUJ  '88J57;S]/XT(!_ >UT5-@';?KMZ^_W=OL^:I4'CCW
M-C@Q\<=BL[=."<?7CES&V;9MF_5OO%$3=<+:#I%\9%@W8WD1@2;*\9 F8':B
MA8UM[.<54_ $#CRF$W0I%,":TQ/O5X>0N^X;@/S]/J'<-P_7WJ"'#%0U7KVT
M50#;UZ]]Q$=_K[?1L'NJ>O)LNW#%2S>*J(;]Z(0_//8J   &P?/\X^8^FXCU
M';;<1$>XC1%6B)1$HB41*(E$72W#<<%:D4M-W'*L(:*078M#/9%TBT1.^E'[
M:*B8]$ZQR O(R\J]9142P2$[J2DWK2/9)+.W**)W/+*'RJ_CP]NQPH6LB\0W
M.DK?]IZE=*UDNM06A6S<2L%-2]FQ<;#Q>6K(OJ4N62&=^!8ET0EUDR=BBV0M
MR2OS&LTHG'A;TF=5F0D@*TO'.>?=GM"JU0'>A+-F"^9;'#'$*7O%.5[ S;CJ
MTLK8QN1C==AWO$-)NWIUCXA4G31V0# FX;KD2=1[YJKSM7\<^10>L'J2K-VB
MBX2.F!15VV8N/;AQ9^I7$HB41/FV^_W_ (]>U%!?)M[_ '*,W5'JMG[DOFSM
M*.E')4';^?;\NZSDI6\A8VC/JVQB@\[<C'+%XXO8WJY"QLBWOBUM:3XMUVDL
M$JYMTD@T<.H61=A\'450A>IP;A@?PR+'8ZZC0/K60R(>9TT9LRQ%Y&U38ZRI
MJ5Q^]D(.SS1+^\['P)E1U8C3)]YP=G1B]H8S5GTW#!BV9R+J$CIR58R"=O%>
MKI.$B$B &!HU"2_;AA1WK[)2:*$HB4161SQJ%Q;IPLEY?F4[A"&A691542:-
MEY25%HF8@/I0D/'D<2:D-#)'![/RJ+55I"QI%7[]1%LF8X$ZU$ KK%UZ8%6=
M:ILQ6]!YVTBW7#WG/R%O8LD\(PS+#5I1M]QT)8EUV1=S>ZY"Z,ON;FM [FX9
MR$DA05:.#&8LPC7:2C1%S[D9L:$/3CVUWNQ<[GGACG[>5CV$FT%06DBS:OVH
MK(JMU1;O$".$!5;K%(L@H*2A1.BL0BJ1MR*%*<H@!%]E$2B+XI*3C8:/>RTQ
M(,8F*C6RSV1DY)V@QCV#-N0RKAV]>NE$FS5L@F4RBRZZB:21"F.<Y2@(T11#
M9\UO9IONY+(<</N+B\Q.\1WGD$=4F([@0B("XGEG6K&("SB(\LVE\8X*X+B<
MBX?X\DT2,X6YQ231.Z73<H)B1J/MP?/;1LN(SQRD(TTZDL:ZJ<5Q&5L8OGAX
MUVNZB9Z F6BL9<]FW5%G]GG+3NF(<%(XC9J(=@9!PBH0"*%Y%T#'24*-$5_J
M(E$2B<^&_CSC@GK2U?Q6!;0?V78,U;#K47?+"5MK#,%<3UFVM=7*2Z-O_%NU
MKJF'3YE$0-P3S2YVTQ9\%<C^*0NOV%5 CM%N<%S%(QKA^-.):GM6+FG/6!>>
M%=0^3-)FLC4(AE6^CS&)C8AG5,905L7O,R.4+-3N61LD]GXBBG<8[BK.<)N$
MEKO,S*T;M#(+34HB50BHC]V'NQX]:IP!9R=Y<=6?:3U*8X!W ! 0'WAV^P1_
M6-%*K1$HB41*(E$2B)1$HBH(@'<0#<0 -^G4>@![Q$>@>O:BCLQX>^OBHW9F
MY[1XCN-=9VD6>;7+AFX\;Y+;X@OEL9.WIR[$[5%>W;SLW)UMI3<,]B8I&_XE
MG(+67+G9/).V9&.-.1CI&:B63E >6YYP*K!,)AB8%PX!KN+UR?;LSHL$>#_H
M[U2:;,HY15R^U^+5DL(E]CY[CYO+W.WM,]VM(+$KV+S#:K%.<?67?T[F&W6Z
M[K+%UKPD+*PM^6[(1\0@BVEIQ%4IC(+$8EGQIM#;'+@UIGBT_P#$P\3 1S6(
M@XQC#Q3%(J#*-C&J#%@S0+_11:M&Q$T$$P\B)$(4!Z[;T5&.-:O6M5V5$5-P
M >HAW  ]=Q\N_41\J(L7,OZGHC#&:]/F*KHM:1"W]04_,V;$Y+"023M^ OEI
M%/)&W+2>L0;+N7,E=RK-1G'*E6:-D%0$5U3FY$S/:H?.C;7R'=C^.2@=U6<+
M_45%:U&N2-/<W)I1F9[AG+T>9+9>UV:]L>^DK7OLCS$?PEB=[9\Q8&'<LP L
M8;(EV-VL[-2ES!%S#E166<*J+.><U6X,+;,^LOG[C0AZUV <):7<)8 N#+5Y
MXQL*-MF\<[W],Y-RI<)5G$E,7)=<\[7D'WC2KXRCHD.A(/)!Y'0[?V:+9NI*
M3>MF*#F3>G6<\LJ<AW<FJR%HB41>2ORXWUH67=MU1D"\NJ1MNVYF=96U'JD0
M?3KF*CW#U&*:+*$5*DX?G0!LB?P5A*=0!!)0=B&<\\\$4/.L/$K;BM:(,?9?
MPZ*R=WP$=-7O:V,),((4)Z\THYS"2^+;\EGD<$FPC47Y74?/Q[%U"*R::94'
M1VI52F3*0P-7P(;[CLVY+\>'IH$9N<)VL[UB6$SRA-6K>2]WX<:90"YY&7Q<
MR5;I1TI8*%CW/.7)!V[ 6E/1"Z5I_!3QZVGH$8B:>$(Z3;B4IBBUJ5 /:^XX
MY=RFX#L&P  ;!T#L'N#MT].@45(P'/A3L5:(OE?/F<8S>2,BZ;L8^/:+OG[U
MVJ1NU9LVJ2B[ETY75$J2+=N@DHLLJH<I$TR&.<2E 1HF?//#K6,-K9QTZZS,
M:7_:V&,T6'?K*XK=N:SY<UN/X>;E8,)1B^A7#J3M&;1%T5%$ZJATDIF']@?E
M)L +MU.825&(V%MNW%L:CEE"AH3X?&I/3#KEFR(+3,?ABRY27=C*NIR?B6V=
MK,FCJ-X.];UD[1E6EN7%D:SGO-',++E;0C8D+<.DX6545;IG$JXXP6  J*4K
MF35WI@Q?;O6R)&0\/#%>$AXR/BR/WR\D^+'LT&97DBY*F5P^<@@FF"[M<J21
M5G*G,JH"9 ,<0*&Q4+LZ(J"/E]/T (;^HCW\@]PB&X43GGE]BL%?.J?3IC+*
M=NX5R+F?']BY0NNWQNFWK2NNX&D"\E8,S]S%(/$'<F+:+*9Y(,WC5@S5?I/Y
M!=FY(Q;.006$I*UH:8]9;[_O! A?XL'#PRCEW+EGZG\(24O*W#,/+!L:YR0D
M3&+26*(6+GK:"W,T8^:0*EN7#=&2[<DE':H3LM<SA:*L]1W'-"?!C%H@W*86
M<DEG J'?VANI27:7]&-BXW>63G7(MH1<QJM_!!9&-KXR2[N.Y;W>N$[6B6\<
M=6*F;Q<O)5)>1*B09&05,:5?%(DC(/78()B!"7[2>WLV; L\-MO7Z?OO]=%"
M41*(E$2B)1$HB414YB^H?7[M_IZ>E$?W=[+75UAZ^<6WKD'-^F+6!IYRK:&*
ML2Y7L6'MW,V)+^4"\8:[;FB#/\;72UMF&D;>NR0&2=C(+,W%N&EV+7V%9E*Q
M[E5(Q5REGP(=N15G;$U"O!H+TS9?9:G8S6#9VL!KJ4TU9!PA+XQ<SEW6B[AL
MI72WMBZ0?V*C=\D+*("ZKBLZ96N)J%[3<<6>;Q1WMK*"X:*HG9.?'GPHH).&
MS:&XX-7W5R4Y0E*([B #V[^X=P^H1$0^<?6B*M$2B*.3B :S;PTCAAAK"8+=
M9C@,QW@_L*<%I=S&TEXQ1:,46;,FTA)H#&-WTFGXR;-:2=M6RBI/!*LDH('H
MI <D;*GAX%0HP.%\?:XK9GK.X?&J;*.)Y5M<+#)LSI:S]%S]VVY:=Q6Q=;=\
MM>6/+J?KS)[;7;W2B"99NU[I79ON52/%D#1T=&BDDBC;GP(&/?F,:UP6U?;;
M>::V[ M;E?-92XFT+%M[@DF386;*1FT6*"4J^:-#'4%JU=OBN'"#<5%!124(
MD)S\O,)4KNJ(@[^7?WT3GG!><O"7E("T[GG(.$5N6:AK>FI:(MU!P1JM/2<=
M&N7C&&2=*$4(W5E'2*3)-8Z9RI'7 YBF HA1%J_W3KGT_:MY['%V9_0SUH1U
M#HL9R,Q3G#%-Z2-U6LU81,^ZBY=C<T-;J[@S5DE/)&BYB,NNSGQ#*F52*^(D
M<#E*J(:K&'TJ=1.=<-K5>F2EGX:NEO/.E^%S/&Y7R]:F5[/R3?261L=N[8MI
M6TTFA)]HHYGI)2"(8L?$JW"X6:R+MDQ032]K*HXY$S*G)14DZQ=MF#C#VX."
MS[ZJ3O;M[MOL_5]&U%#<FO#'AXYU5:*4HB@?U'<9O!MFW3;D[BC*%AY!L"QI
M^ZK+U)81N"$G;1RDM'+.6<<G=5D.[KC(R,D'=HJ(NU9"SUEV[J:BY!X50A'B
M#$$BJU8AD=VVAW+#;1MP\\7:BL[Y.NJW[RN:%P%C[P+VTJ95PH"EB35P0V69
M)[=Q$)W)\(HRN2?G<7',-I?%&5<':VT9)9-9L*JQ2I$,3ABSXOGRS ]^[:5A
M(L(2'BX<'LC)!%L&C )"7>KR,H^]E1(C[7(/W1U'#MXXY/%<.%CG455.8QC"
M([T5*[,  -_>.X_?T]U$ ;!5\_X^5$6$.L76U@[2U'1UFY%R_#X=R)E.V;Q3
MQ+<MTVG<ER6HUN6)9)-V3Z8"%C7B#ALQE)&.6<1AE2K.6X'!3P43 J)/$=M7
M[J>&:US,_9=B.)(GB"1MQ#'LIJZQ;/1^E[4E"VC!0F4(&]M/.:YZ%BV^H+$[
M"214"2C\>W=[!>L*DJV93N.Y&XI"1EB1S>/ XE6*:P&3-LH=HP)%*-FZV6=(
MVD*SM'UFO[&L6^<IW3;3LT:K&PV0[YGKMC[6(TCF[9RUMEG+OG:,.WDGZ;N6
M>I-2DYG3U1$HE:-VJ")4/N;M\:^*RX -OO\ J_L[43GGV?@RB)1$HB41*(E$
M2B)1%"'Q:\X:F],]W:?\P8LS)(8YQ$X<W+9-Z1J%C-K\BWE]2;4CNQ1G8$PH
M.GT=+O&QX IT7:*S1V_240,!A-39W\\\<C,(%>LEFV/VX<U'DM.>G;4CJ3U@
M88UF:KM/%C8<N;&^*7L+<Z",JG<\9DM>>BG:M@2,5 N/$7M:[;%>/Y1>8</U
MGB:"$HK&,A$QRJH$=@1CWX;.+==%.\Q8,8QLFRC632/9H\XI-&+9%HV2%0YE
M%!300(FD3G4.=0_*0.8YC'-N8PB)0OKHB418VZP&&79'3-F=' US.+1RZWL>
M7DK&G6B*:[IO+Q2820H-$U2*%]K?-6KADU,!1,#EPEL(;B-$I1^>"US;!R%K
M@XDNG6Y<#75C:*SYBJ0=V[;:>H&5;)8MO7&&6(P>226D8@JCAC>+2P95-=.<
MDF*+)U( J")"B8QQ J@T-:ZU&%&PSJ=N52-E%LUX7Q3 XBQOC^RHZ%MIB_M"
MQ[=M1Z_M^&;1:#Q>*C6B$@JV*4@N4V;Z116?%;*K*<IU0$XF.'-14FI<XJ[-
M$2B)1%KE:G]3/$'T]\0>XL78ONY#*#7+A+(N3 6"+HLY)>TKEM-RF[C;S:EO
M"-4:N[#/8CR-<N9F974<_"J"K54[91PN '(&:M*EF&^F-.^M<7#9E\/S2%/V
M#?6HG/F6<.VCC.X<_78TGOP;K*L+P=V:[;(@%QI1$[X'LJ5J7!.>T3L5%IH)
MN&_M G>'5<&,:B/5@[;]M'Y[W4M!2%(4I"%*0A"@0A" !2D*4-BE*4  I2E
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8'GN[E[.BE*(E$2B)1$HB41*(E$2B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g108483g66z31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g66z31.jpg
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M 0$! ?_  !$( /<!2 ,!$0 "$0$#$0'_Q  >  $  @,! 0$! 0
M" D#!@<%! H! O_$ $$0  (" @,   ,&!@$" @8+  4&! <" P !" D4%1$2
M$Q886!<T<YBSUB$F,5%A&2(D)W'P(R4H,U)B=(>1H<'_Q  ; 0$!  ,! 0$
M             0($!@4#!__$ #P1  (! @,%!@4"!00" P$    ! @,1!"$Q
M!1)!46$&$W&!D? 4(J&QP0?1%2,RX?$6)#-")28T0V)2_]H # ,!  (1 Q$
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M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&A6=6*-<B.;KFR
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MVSQMDRI2GC^[Q];&_P"ZEO1JJ26&;<OY=/>;O%M-75HM15DLRW3GY2>R. .
M. . . . . 50?&Y4,FOX8_KG=C:;U672M2-I-.45)*JHO19/0ZO&C5_#5SQ9
MUECVDTQ@[E=2"PM:VKS+)VCHF0]A@Z]4G7($=LK^2Y_O;WG8M8B_RT?^AI_Q
MX\!:+P1GX*:56^R;N0$[<1*M)R=O7!.^47=UV HN!#=NAZMN<EG5Q8=>'KYS
M9WG]I(1$!B=,"5^)&Q'Q?P^]6+W[T(M.7OS-UX*. . . . . . :K,14D@VB
M'Z>GJ\UZ #IH@$YRP J2UAA)'OOL@,%,&Z+F6'CYO>67<N'$EZH\CO/+\77G
M][+[=F&-QM/"U<#3Q>)A@J]2%6O@X5ZL<+6JT\J=6KAXS5*I4IV^2<XN4>#5
ME;!P@YQFX0<XIJ,W%.:3U49-72?%)VYFU<UC,< < < < < < < A!\1QKNM)
M\9W.R^>OS-A:PZ L_0I*:,S,,\ =*=%V(T3P\#3%FR,Y,17WF-N<F+$W2AT?
M'<2C_A;8F._5VGZ>X78N-[8;&PW:#X9[*J5,2Z\<955'#5*D,'B)X6G6J.<(
MJ,\5&BE&4XQJ2M3DVI[LO.VM4Q5+9^)G@E)XE1CW>Y'?FKSBI2C"SWFHMM*S
MYVR-X\1,%L-7DVAV&\L3F-K%D(?*<<F89T&8=\SN1*PA2S0SY:'G%)3!. ^7
M+QW1(TC/=NRVR=&J1LVZ\=+MI0V5A>U6W,/L1T7LJECJD<'\-5[[#J&[%SC1
MJ*4E*G"JZD(;LI12BHQDXI,^NSYUYX+"SQ*DL1*C!U5**C+?:SWHI*SYJRZJ
MY*?G,&X. . . . . . . . . <OK>E*CI_<VR*LKA/0-[V<V,KCM5 4 -FQ'
M-G>WOLB4RAZ=64G;AW(D9:=>7?X$?*3)SCZM64G?WL]+:&V-K;66%6T]HXS'
MQP5!8;!QQ=>=:.&HJWR4M]MQ4K14G=N2A!-_*CY4J%&CO]S2ITN\FYSW(*._
M-ZRE9+>D^;SS9U#GFGU' ' ' ' ' ' ' *=OCP8TIW\,STIW<=:86+-QK:PN
MZADYTFQ7'_#ZW_X<./2O8.$Y?36[74&0.)]6T=6^>W*8%7^?^5FM8W,KHU2A
M'PSSOEG;CG]]"X&)_*QO_P!/I_QX\%/HX!SJHH^46KT'1GIQT=ZU4-U^%A9)
M^XL,<<H6K/#\.U&KK%CL#5EAECGJ;#6.)$UKRQFR<>L]O?73Q(M%X>],O3(Z
M+P4< < < < < < @Z_\ B_MZ]I5/Z_\ XT6 "ZJ]1E+'\*AN7V+1WO=K.Z_Q
M<Y_9#7\@,(='/Q&,/](F_6]PL7MZGP>]'?67:8#MB\#V/VKV2_@^SZ_\3Q<<
M5_%*J_W-#==#Y5#<;J58=S;#UN]AW"J5%W<]Y'GU,!&ICZ./=>O%T:4J:H1G
M:C*[E\TH\WO?,O\ M:.EG><7.+/0' ' ' ' ' ' ' ' ' ' ' 'V]=?]^_\
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MX1%0O.DSPNG'&#)V][=.770BT7A[]K+D='X*. . . . . . . . . . . .
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MS-K'%D[%J&=W;X>_:RKV49A']P,-<&3AKD2.LA'[\_/WP+38O\K&_H:?\>/
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M[%8G#/#+#X2>*[ZLJ=1QE;NHY?,\N.=KM1^6S:NB<'.+/0' ' ' ' ' ' '
M' ' ' ' ' *!?BA^DFZK_6-6UUK]#9TZD$?/)ASS#3/8U3^-!1-I[LCZ'B5U
M,[Q5%L%WTAT(CY1-H+Y97&K\?1J(#9#%++&=:]5;I>_'RMRUSO=VMUL82OPO
MPM:_&^O2R]67S ]OXP0/N_'ZD_BBA^WYGJ;K)=2/Q(FG/\?HCITQ]1#K;]OX
MGSNK1IUROO?CX:=>.SK#&&2T7A[T/4X*4U_'JV>?]?PSO1?\=B(Z!/S0'[72
M&! RQB,I]X95NY]I\"!@OS8>LM/W1.C.6@2>ZE@976O/*;$VYZM'>(CX<[JV
M?K]+EQL7^5C?T-/^/'@+1>",_!3FM-Y!NZHKKI>S1-@/6FK^D7E5\KN;77</
M0-CZ-723*R_]?>LX]:_NB-FSO+9W#ZU?B9Y[.LLNQ%IP\M/?V.E<%' ' *7_
M (VZO:C50-00ZI6KF9RT6]5Z83BT[L*Y3(T# *;PCR"T0) ($>]_9/9"U+9/
M+5A #FMFJ5*SRWYP]&[]A_1C%[*PNW]K/:N)V-AJ4]A8F-.6UU3W)3[^@Y*E
M.K.G34>[WWB:=W.K13C%*.\UX':&&(GA*'P\<3*<<91<EAI-2W/F3<DLVD[;
MKR49N+>63N-"8[L PC&1C.PWXC(&.[ GMU2"6&[&+JZV8D-^COO3NG8Y]9=2
M]NGOO5LW];,]??>&77/R*LTZM5Q=-Q=2;3I)QI-.3LZ<7G&G;^A/-1LGF>\M
M%X+5W?F^/B5B^[\]6/HKQ'AL\32/2_6RRMF/5I:M1[/"E_M.J?74_;V$U;1?
M?4;OOMQ[Z?<M*OU@JY=Q<L9O4J<-_2.Q";[/]M/_ './9O\ \:O_ !C[F^V%
MW.)_EKOI*I>7_P 1/ J6)OBDI+<W85/+V@E\3LY_P]XQ_$-*LG;X2Z7\QK=:
M:_[?-**_EY?-9JTWGYF>J. . . . . . . . . . . . . 8=TF/'[T]2-^G
M1W(W8Q]'6[;AJ[WR,^LLL-&G[^6/XF[/'#/+'5A][/+K'+OK'OK'O[*HRE?=
MC*6[%RENINT5K)V3LE=7;RS!FY . . . . . . . . . . . . 4?^ZY5X4^
MS7;Z)#TQZ* U-6:U*L!SN6K?:5<S8\I(3E:(8;#8'RCZ(4K J>'.##QQ'3D!
M'#UR6T[Q^R3K):R)?'=E<NO7+^_(P:=VTK9K.^MWT7K?7K96NK!3-)$('(1I
M.V9'G"A\R/+D:,(N^5IE1-._5)W1=>K1KC;=^&>.W9HPTZ<-.>66O'5KZQZP
MZADM%X+I].!ZO!2JOXU[>V*GPQO86E6JUILS4TT1:ZJS2EHVC!M5;K!*O&?8
M2LADP=6E:D%UL!G&CQYXA-TLCE*V$(^0I<G:M4O9'$?OC[OGGP+38OV_*QOM
M_P"_R^G[?_C^'CP%:RMI;+P,_!33J\D$):(GRBLQG($Y"V&W$9SH#&K3=*F[
M(&C.5O95X/"&B0IO9N[SR(C!L&+!A2N]FB+JQTX8?:(NOOTN;CP4< < A7[?
M\Y7/Z5K].5*5]$,?G0VOO@UG,,"[T8QW'P\6'-C=BM^X"9!D>NX4N3'+1(FV
M9L%SI437I(1N_LCR8O8]B^T.Q^SF/Q>*VSV?P_:&AB,!5PM+#XCNFJ%:<X25
M6,:]*M3^>,94924%5A&;=.6<HST-H86OBZ4(8?%SPDXU85'."NYQC>\'FLG=
M/BG:S5GE,N%HW1H<2-(E;)TB/&T:-\W=AKU[9F[5JPU[96W7IQPU8;)&>.6W
M/#5CCKQRS[QPQQQZZZZY"<E*<Y1@H1E*4HP3;4$VVH)R;DU%9)MMM*[;9O*Z
M23=W97>EWSLLE<^GF)1P!P!P!P!P!P!P!P!P!P!P!P!P!P"$GL/Q$I^Q"-(D
M6:Q'Y$SI-ZS=!^E+F1M&L[EOS%;=\>7\SKS[@$]&0>-@(88GWIHC3+*Z]&G9
MW/\ Q-/9]D>VF*[(T]M4\-L_ 8Y;:P*P=26,A*4J&ZJJC*#BUOTY*M+OL/*T
M*SC2<I+<M+0QVSZ>.>'=2K6IK#UE62I3W-]JV4O"V36:O)+^IDV^<8;XX X
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M$3J5)*JI;IH5\%*MC,-BEBJ])8=23H4Y6IU=Y-?.M-'9Y.Z2M9YDX><6;XX
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MU8?)_+W[7:3:26\W>#3BDDRROGYT>J. . . . .++EIIT X X X X X X X
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M-+7BI1>GCUC'A:JP$H1Q5H]TYJ+C_4MY?->-W&]KY7Y:G7:FU6-IJ^O-5OR
MLJU=26M86-)7,/N 9#MB(B=,NX3CUKTX=0=A?J7G'_"T:-/>'?7>C3JT]X:\
M?)VJ]G/:>T'LB-:&RWC<2]GQQ#O76#=63PZJN[;FJ6XI;S<KKYG*5V_O0[WN
M:7?N+K=W#O7'*/>;JW]W_P#.]>W0Z#S0/J. . . . . . . . . . . . .
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MM#&6@Q9Y3#KJ5)U8[-F7V^Z?FRTY?4Z!P4< < < < < < < < < < < < <
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MU8B1 $(@_)2E,^M>S%BG(WLW$-RHNE-L2:TZUQGU ^ILT%.B:PW5R671>_\
M*-=\G?#]IRC:=V(%AT_0#HRYV_Z2?<3L6L%4CIZ6[>]'6M;:0#^9-K&B?UM4
MTEX7E61%ZU]P($@+M@B-FX3'@[<PMSL[:>W?,^VUE#PZJ.J70[!3-&+CW>ZQ
M8<:N"DJETS!6W'5OL %[7B;3%6]L  T&9S9&_)X@ELBRFO>&8( #N88&?3]P
MMKIO+DW;G^,N/0^SROX-I.E/,?G2F[ IB@G)\J:BJEK1V;XM7*1&,U-J*A %
MAB8XY TM:#$[0;+BYA+5++:=1*1KDX[IVO"3GMQZ$MSL\WKGJR+_ +-ICS%>
MB!>GB*L:&K!3M.[JYL"ADV[,*CKF#7"#=SK0[?:2LM&S035G8XXSA7 >8_Z6
M!=22:O%B:(HG)JCM\V  WA:R;27.VE\^?CE_:Y8GUY=\R:-&.6_SQ0V/6G3C
MWMVYU+7W6&/6O#K[^>6>:]CUUCU]G??>67W>NNO^>_LX%D]4GY%9=JHGBKV
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M"T?86_N325STX^'4L4YUIZ?KK/6>F!&+;OB:DZ 0BZS3@!5)*;Z)Q4%ROKS
MU"]"VLN:=N&:Y?3D[/-<+ECDY4#>8$>XKK&#'FS&S-9%R2 :+KA'V3I)1)+
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MQYI1'OW^WW*EEP\[9\UTUZ-\-,Y<^-_-O=64]5^VR T3?84%=7&/!7,!TN;
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MO4XA-+E9\R=,DE#)T\;)[Y14^R,9J<1/LK"6ERRQ\^2(F2DN20G2=^P8&[<
*< < < < < __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g108483g73r83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g73r83.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $V*^26(X0DE-! 0      $T< 5H  QLE1QP!6@ #&R5'' (   (@>!P"
M4  536EC<F]S;V9T($]F9FEC92!5<V5R' (% !=0;W=E<E!O:6YT(%!R97-E
M;G1A=&EO;@ X0DE-!"4      !#%Y9V$,<94)9V>B5'TF+\R.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&0.G\         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE- _(       H  /_______P  .$))300-       $    >#A"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              48   ,,          $
M         0             ##    48                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   48     4F=H=&QO;F<   ,,    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   %&     %)G:'1L;VYG   ##     -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M          ,  0(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB )LZUNT+DW)TY7'.^EA;Q5QA;->[[,_,2= ?$7MWG0<P.XJC)2'=-US%43
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M>X-]P+W.YMKY?O#(HVR%P.C@!L=-+'2PMY^Q=1RD"2/'L82")=AYCL/ES#H
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MT]PMT8:*AK QP>YVOY ""+@:BQ TUOW*5RIB"#8V8UFF9G*,@/$*C,2@'$0
M  , B3D(CN'D/(>8;!O@8)C6*Q8H^GJ6-=2D@"5SM 3W6UL-!MK<$C>W7X#T
MRZ,XPS@4=7>K:T!^7O'KUYF_(#N*PD+ +K&44114$4U!*)"@.X<QWXN@;>0@
M'T!MUKU-M6UH <X#,-"38$GNYBWQ'-=345,-.Y@YN]]QOH;:G7?Y+E+&KHEV
M#9,VX!PB&XE$.6^W0-]Q#_P"J>,U[G<QKJ+"X-SW6[[6WONKSY6-8QS+#.TD
M[;@BQ]8.OE[.PDU<B<0,(F+N">P 'M;[\P]X#[QV\JH<Y@;< 7L7>&GP\M1?
M<64PU/XS,QN,[01I>V87OX6[KCXHK&NA5.*8 43@!A,("("/D&W0!V$=_P"S
MD%&2LRVU-B;6\02?81IM?Q4U,\/&.4@7MKR._?I8:]^FM]%TS-Q2,8VP"<1
MA>(HB)U! -A /<&_4.?OZ;!6+OL+D#4Z<FW(UUW.OL\E7Q80,^E[9=KZ^6][
M7OW[:W7&NFH9$Q3IF,3IPE >0[#U+MR^GJ _&JF=AP<#8Z[^K7E<]X]9YJT*
MQDCN$=0=QKIK^_AH;^2Y(J+XC%$NQ!(8!*0QN(.8@&XAS 1Y;#_9TI+4$DC7
M6X)&FMB=]?$#6_GRHKQ#3P"6]K6/?R!\/[:>:K52#>&2,=$@>R [F N_MFZB
M4O/V! 3<_P"W:M>*R#.UKW $[ D: "UB>9YV]HU)7*28NR)QM87)-^?.YTY^
MK54X,$_2,H<R0&2('$;?D81'B$>$.7D&P_'[*S7U,+\@#^U=S1K<>[?4Z7T/
MFL_#:^(\5Q (>6'7O[7J'ANJ5=D%-4Y> Y@.;D!Q#<@B/(NW3;H #OT'?;>L
MV,W:#<;:D:W'?K?:_KVULMLU]/(Z]A>X(N-N[S%R!<Z::!:'( AW9F_&<H !
M.+VB (EW\N@<A\]AY^ZJ0;:Y]#<GD;7M<7M?<:]J_@KV8Z]GN&_?\_:-=;;K
MG;[H%5*! *?;<2FV'?D(B!?<'NVWV'E5M_;++DD7-N6EP-=^?M-E?I9.$^>3
M0'A =KP!//ZYB]U^K/V81A_P?>C\HAL8,%6*!@]P^ATA_P"@/^GG7689_P!*
MSU__ -.7!5<G%J9G][S\5GG6P6.E$4>X^<([ZKW[M.H.[?/Y%%(5*)1%\<.L
M;-VHS&VIS4WCVW\HZ9/51[>6MN/0C+X[1'&F*9]-MJGPGB7'%F%N3&4V\._M
M][A24LB6NJ!BY(O?*+74Z&,&WU55GKPH'S/Q/G_;W+ZU<,LW4=A_%,>_>MI%
M\PQM8S-Y(,GZ<JS?NFMKQ:#AZTDTCJ)239TLF==!^DHHF\24(X(<Q5 ,)2KD
MT1*(E$6$W:3?S?NL[^K5F'\$3%$62V(OT3XP_5Y97X;C**&[#R'P5PZ*4HB@
M;HM> O2WY:UKHBVTS 3C-5A)QKLIA2<-U@V$2G3,19NX1.!5VCQLJB[9.DT7
M31=%RBDJ2_35,]'4155+*Z&H@>)(I66NUP\""US2+M>QP<Q["YCVN:X@T21L
ME8Z.1H<QX(<T[$'W@C<$6(-B"" 5YZY^P.M?<:RQ;D*945GNY>1^"LVRI4O_
M "A,N N0Q%EHR#15F:8,)$QM^X58\6]S-V7&HV>RYKFM^\/0, QT4$K\3P^&
MU/=DF.X)$3_#AI#3B^$YG!XA -JBG#\U,7V#F0BFJ*/45E(9FB"9P+[%M+5.
M'Y[C_IZBPMGYL?:TEOREW$9+&:=\T!E)"Y=)6I)J[C\CVZZ-'0+V17.SG9@;
M>.E,1BA)1!V]!ID"TE&;6?@I=K*.'<O',F5R,'<L#96?F+W2+!3A;J?I;T;<
MQ^&U#1)/'&W/!#U@&*0&)S8\]!5A[Z>>%T;6PR/?3/;%F$$,4=2)P_#ZRXF8
M<K2XV>[)9[>T";316#VO!)< )&N?8O=FQC2\)GTC)XOOY<5<@V@T;N4YHS5)
M@SR-:2I_#QM]0R*2AT/%"<"1M[138J/J_= * FT0@)FV74CQ6)4</#BQ.@;;
M#ZMY88<QD?AU8!FEH9G$!V6UY:*5U^L4I%WNJ(:EL>S@D?=T$Q_&C (=:PFC
M.C96C:_\LK1^232V1T9=>.M.LA*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$71<IDX1 NP;EZ!T  #V0^C<1';]W.J7W+'M'-KK#Q(LH8;%[B;Y
M@1?0Z6MOW<CY+\WG7IG):WNT)U$P@OA(QC,VY C'295]BD\)=4@V4 Y=]B&
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M03 AS"4W%Q\(E,4=S<0<@$!Y@._/?E6WP^O=4TKI'!K7 FY:"1JVX(-N?O\
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M\K/ &L;-O$ 1 O  +*%X/@ D.0PCO\>@[[@%:/$NCU)5G.8V@.N2,K7 G?\
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M+&,2X[R_@XM6\9W7*>&^2GC$47#99N9VZIH^)N/'[.P?E,RV7P<B61]=27D
M9 =<,DM(^!>7'Z-$%HX>^\ 9MX(F\:DBU[SV.\'&.%7H&4'I+%ADE$O716#K
M[[2F7AOJ.%VHC?AEF07B 9?2ZVC>F.7I'/TB^ZO0UW'I33>@G8(3T<AO2LI>
ML089UH<.J&3K(EXY JGOFR]K**G>V9XV^(:]_6R]&GH:*=Q?J@RG 0L>5\6#
MD/24S >$.+Z5;>)W:._&) B+=L/=&[KVLE]'GKH*WK=:S@Q/BZHR?+0S9\WX
MD\&0YY69NP_.W+9NALM5!CG P"NP'T/@4W7JR&K]-3X>9,?H^#POX6AQ'C-%
M/1R\+\:'@/S\27MC/I%H8Y[B.R!'>OF2%O7]W*._'+W."DC9/I1LHV\-C]SX
M H6XTCN\[^+1%-[X1R1-7B4 O"-H8=:/$(^OXD?2#Y7\0U0,E#Q6%F7#W</^
M&9'?-$VS\C['7994G2?B5/1NI^[W1AGW<AI(>KQX46TV/=4E;+Q>DD76#Z3F
MJLO#JWAU/QHG.99M[K1[C?QL58T5Z^Y):>H[^.?>DF5T A*WAZ.1[GP=]/!8
M']8&#_\ SLDW!-F+E;\X!T^E2_#L\5#%U_$6=1DCDXC*K++6<-I;DKG\,]8C
MDOFD;9F9P!N-E,'2C@5G2"K^[O1>;T_3U5/U6?"3)28)UJ3B<?H_#UAOHVHI
M_P E+)FF$,?9RNW4RWM#P]X3-W^M%X+^F89I#^JSB;!6SXKPABF]*PT+X4HL
M9ESP\+M]XI4%BF,'=%WWJZVDRUDU9UJL=QH60]5=->CBR&_%AARC),_9[\YS
M#D%A2XUQ<$H<%]$X)'U&NFKO2T5 68W6<8$=3KJ_C$5%#%>\-/P6<,@'.52/
MR1C\GSNP/E/R]_C<BI(^NWKH'R@MN\>D>^!:7'Z,V1CD^#PB;861N%D8Z'&.
M_&&)Z)_Y>_#_ $GB_;D=)U[K@](-S29\C*CA6;&W\C6\/2/LWOJMS]\__4D/
M2/[I]"_P:9E-Z!]!G[MRY*<T_6)L+ZWVZEU^,^7CB]0!)E%K*H\B6L\NS&5]
M63'.B%D+FL2Y[68O)%0YDRO)FWWT2U=/U4DSJ&("[DBKI1-(QQ*!S$3,;8H[
M8"P N38 7)N386N3S)W)YE<=(_.][\K&9WN?D8,K&9B3E8VYRL;>S1<V  NO
M!S+O9>ZP;EQ%V=6,K#R#BR(7T=8%P#9,W<3>[;OMF::90Q)-8K<7/-VR\+9%
MTDD[5NFU[(F+<CR1:&-[M2<2::TY<DG;1WMJ.Y5'U]67GQK0[-?5AAW"N*\=
MXIQW=>>\IW[AW5/:UYSUHRN5IF @,[9(RE9,OC3+;2Z&$JV/ WU$XS9KXVBI
M*^(^#L6%M4DPB-P-6J3F+G"+*S(78R:L;[F-2#^Z,NV;D5&_,IV?DJS6EYW_
M '*6%OM&V]6&,,X14!?\*SQF:3MA>S<56C=6)K;F"7;?Y&3>XSH04=;\"NY9
M)/KZV1>BV:.S.AM2&N&!U%9>GI;Y'K7PCANUVF*;/O:=@65UY+Q'F62RQ _*
M-&M8U!"[; A)(T+)1,:K*-%%YN-(J^9BW#@.1>9EZ]@]FN0P';]D6UF)-[D)
M;#.KC'MU,KUS!EJX,4P\WG#*4/>=C.,76=)-I*&QY&H0T<J2]CVK!0J[^;.1
MX+>34W<@17X_@ :[O_>[B_\ K ]HI_U:HB^AZB)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB411[CYPCOJO?NTZ@[M\_D44A4HE$2B)1$HB414
MO>E[V9C>UYF]\A79;EC69;K7QT_=EW34=;MN0C+O4T0=2LU+.6D='MQ6521!
M9TX23%55-,#"<Y0$BQ"[1:082W9WZP96*>M)*,DM+^6'\=(L'*+QB_8O+#E7
M#1XR=MSJ-W35T@HFLW<(*'262.11,YB& 1(LHL1?HGQA^KRROPW&44-V'D/@
MKAT4I1$HB41*(E$2B)1$HBQLU3:7L>ZKL8O,>WN5Q&231<DS8]\1'YJY;!NQ
MIL>.N*!=%.D<JB2A"IO61U ;2+,RC98"F%)9+H^B_2?$.BN)LQ"B+9(WM,-=
M12ZTU?2.N)*>=I!!!!)8\#-&^SA<9FNPJ^AAQ" PRW:X'-%*W22&0?E>P[Z'
M<;.&AY6^6O$V18S3WVF-_K:M"99NG+ML1T_:5X9%PO>+Q-*YEFUI0<? 3R%K
M0,#;ETE4FK?9QSV?54O@R 2CARLZB3$'PZ/T]BN'R](/LWH&]%#A5+A-4^GJ
MJ/#\9HV$TS75<TD\#JF>>HI;0SND93M%#FX;6!DH-G'@*:9E'C\_I'K$E2QC
MXI)Z:4Y9+1L:QXB9&R1I<P-<_P#&(#B;L T'K^TU]8:25(:VLVZPH%IWO>%B
M;LQ9CF[&)""(B"!Y"YK8=789$!$1W5N=1< ';O@*4A2^2OZ!8PZXJ<%Z'SOR
MVXM+BF)4CR?U".FJ64N8_P#XP&FPUOTXQ>E![%3B+1J<KX(9!OMFDC,GE>3S
MY*K#=I%8[!03HYEE%$>'<$;ETN7++J;\/(/$6;DZ!*7VNH^%4VWV IMMAQ?^
M'%<]H!P:/-?5U-THIH0!?FVLPN;Q_G&V_?5Z;A%[5+O*2@D)\NQ.S?D;>>BI
MTW:VV[%* BYC;:NI,%1 [UI:^>[*4% /]<L4?%&04@5,&P]WZ<.1,?9[Y0/;
MJ^/LGJ)1=LE52&PLQ]1@5:,QY<48KAYMX\ $[Y1LJ/O"QOYFL>!N0RKC)L>3
M>KS6/@7>L[*<2[9? K)023V/LH+)["(.+-MV6ET@V+Q>V6]8?&RP;C[.R:2H
M[\P 0V&K#OL=QY[;P8AA@.G8K)XX7;VT-'+B+?:X<]57]YJ-OYXIS_\ ;8]U
MO,2L@(\>Y2:?;5:+S0LM)N_ECA'\;%R4@C!3V*+B:.I!=@R7=IQR4E'^E8!L
MN^41*T0</)5!DFLL0[APD@!U2VC]C/3+C0QM]$31RRQQNG@Q6G>V-KWM:9#'
M)PIW!@)<YK(G/(!#6EU@I^\^&9'./6FEK7.#'TT@)R@FP<T.8+VM<NL+@D@:
MK*?1-K2L37%C2>R=8%KW3:<7;]W.K/=1]V>BQ?JO6L9&RAG* Q+U\W%L=&32
M(7C4*J"B:FY.'A$>7Z:=#:[H3B-/AM?54M7)44C:MDE+Q1&&.DDBRN$K&.S
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M+*)U3,:1A:XO:6TY?P@6O)<+,T<2X:ZJR*> 2F<0Q"8@@RB-@D(( (+[9C<
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L$B$2112(5--,I2$*4I0 "+GHB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g108483g75p65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g75p65.jpg
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M.RK$$\\Y;ZO7FBN)!V#E<,,8]PO-GD//DG%GAQGEP%:YNVZ*F_=N=HH1" (
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M:XLWT?=FI/L36'S8F@^*W+(^S7[!$@EC:YZ.Z57J9Y:$ 0! $ 0! $ 0! $
M0! $ 0! $!29U-^FZ\M_N6Z!?IS<D)K]AGO?\I=FA ( @" ( @" ( @" ("&
M)WYPFK_<]O+\Y=?51LAZRM(^2.(7QWAD7?'^KC5GG7A_\#XE$SJ\E(" ( @"
M ( @" ( @" ( @" ( @" I,ZF_3=>6_W+= OTYN2$U^PSWO^4NS0@$ 0! $
M0! $ 0! $!#$[\X35_N>WE^<NOJHV0]96D?)'$+X[PR+OC_5QJSSKP_^!\2B
M9U>2D! $ 0! $ 0! $ 0! $ 0! $ 0! 4F=3?INO+?[EN@7Z<W)":_89[W_*
M79H0" ( @" ( @" ( @" AB=^<)J_P!SV\OSEU]5&R'K*TCY(XA?'>&1=\?Z
MN-6>=>'_ ,#XE$SJ\E(" ( @" ( @" ( @" ( @" ^>7R5=T/(-T[WC5[56M
MA=:0]=WW<.I=6=6NGCE*GK?N#MX#,2=1B=TS4YLYR2@A=/2U$+MHY,/R( ?6
M&8EZ+=G) @_G@.<&1J-<BHJ+NB*JNWZ-\.G551=NOMW79/817W7\G/=ZC[?\
MB%\ZZS&G87K[XK7.L8FQM77B@'6&T]FI3=3@,A?16+^Q807]8"T>)+?#@G8F
M&DG9(\/$DWE]DWU (^M:U>5%WW?OLJ*FR;+LG3;KU3Q[OO+D=G^2#H]HQRB
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MZ\VZJOW;;+_E/RO*MW1_I]LH>E\;=ZQ: W/+4"B5W6M8LVW]-ZXV1:(ZEU;
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M RH[5NEFY!V*KX+)-FE3&NS*9#TEKY8XTQJUOI.25Z11TW2?5.F%ZL>5A $
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M_6^K_?\ $_NT ]N*7];ZO]_Q/[M /;BE_6^K_?\ $_NT ]N*7];ZO]_Q/[M
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- 0! $ 0! $ 0! ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g108483g79f61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g79f61.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2>^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )Z*^$!1CA"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%[P
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  >\    $  0![P
M   0 !.$))300F       .             #^    X0DE-! T       0
M >.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "
MT    &       !.$))30/X      !P  #___________________________
M__ ^@     _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@  #
MA"24T$"       $     $   )    "0      X0DE-!!X       0     .$
M))300:      ,U    !@             !2@   70          0
M                 !              %T   !2@
M !                         !     !        ;G5L;     (    &8F
M]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M  3&5F=&QO;F<          $)T;VUL;VYG   !2@    !29VAT;&]N9P   7
M0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M=S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F
M5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP96
M5N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M      4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M    !"=&]M;&]N9P   4H     4F=H=&QO;F<   %T     W5R;%1%6%0
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MEC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M  "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M  .$))3001       ! 0 X0DE-!!0       0    !.$))300,     !V+
M   0   *    ".   !X  !"D   !UO !@  ?_8_^T #$%D;V)E7T--  +_[@
M .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q
M,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1
M .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# S_P  1" ". * # 2(  A$! Q$!_]T !  *_\0!/P   0
M4! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !
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MLS(<*WN>PN?NL/J779F17;=;ZKGTY#K<=MS&^GO^R^MO\ 5NM6<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0Y)/#+5),4ZLE)%G#,XCB+%(GAH4IXV+CX4KW \JZZJ=$9\_ZTP^VWXQ[/C
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M3HJ?+*0L2@\7#<&'+&86YA:93ST=>6N O#AZ<>H[/KMK;6Q6A;<V]M&NE;L
MUT8U/4H=-#V9ZHRIY/:5B+1%&I!J./).IBA!%:+(:AML(^(*$AKCSBHL:0P^
M!ESJ_HU2[A?O4&TS'F,2INB&1,JD; )H)S9M5KM?V?$=N9ID &F1\6<VO7L
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M/]+\1V;M8_H??K'JJ7H(L'W'*MQ2KV:8BY7=L=L<17QZJR7/NK#&R=6>>$&
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M3JK"@Q&[#VF'9C #,NA4]B]#,OPW7E6. <V#&:G.2@RK0R^-=!BP)5^ . .
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M?WU2B]*;#]^AMM*#OGKY=MLUG8.WS%.3?B5"'T#9?;['=H=6IP <&+/%J_N
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M22R+@NNHE$,#XZT2)V8C3V(C*TNO^[;5A60,!], S8GU&^Y<TJ+)P(9[KGU
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M;$TM<(&T<7GML9CL7$-LVA4&R'"ZZ83K+\8ZJ$3C.B'1T9@DIMA+#0$K_ '
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M.C]2KMEB&X,":2(VKLVNTDU;WAKDR!#ER@@TO(?%-DY;8K!94%9)$J&EV'(
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ML9HA[FI[PY,^H68='/REO?WNMPT3V"BUWI>Z_7*</.3I<Y4.O(< TP/4M/\
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M8EKNEG?@#I$OLJ_(9GMW#<FTFP4E9-V<_@77J_J0/EEUN7FB/3I$JSG0)P^
M. . . . 68['_P!'C?/^!C:/^8YWFV6U]#6MX,G_ %6*9WHM[YNCGQ[NC]X+
M//G">?S_ /W?7S^7U^WT\X\?7Z?7\OKRF1ZEZ;/_ $X4VX9XT6N&.&W >,?G
MX\YS]?I^S[?7]V/U^OV_8%5V5HB88\<\.E=V&?'Z5.L/YM->?WC5+_( _EUI
M'YE)_59?[%AY3;V]U5YO&"V?:,R5SS5&/C@#@$0_K<240>D#Y)^Y!J+"#[LT
MB<(FS&]JSUK]N %O0\G*'B=RVB/)AT\].;B^Z$2H;?S%^5[,5CVFGGT+ YGH
MTWX%L7JW8SE?N4Z[PF=M6. HM/[:U_N4\T^R!K#BX>-I5R-%@CFVDO(<34EM
MYD#<NYGK5E)1&, 2V< < C&USZ>EAU'L[8FT-?;TR,+G4;2%Z]9GZ\@$_P '
MUK?O849V'W6/LCLNP/1;B0,GAC-<I9.(.JR:B"4XY,AV(FXF:R!0M8])^J!-
M:=@]>%MFJLN-I]<'NK6M2DZD#VUZMUO$.[UM5>-367BT_P#%6Q!QWL#;V9=F
M@N52'*!CPX^,$@R5$Y\\"P?J':;@T7=WI)$!.84DG6^R6A-<6@Y*LUT$SCP.
MG7C58^N? T\9N:ITPPMDE,GSI>+%JC<;HMF7F4-_!,YB/:F0)[^ . . . .
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M\(#;B$B*24EQYV6J1X#(E/X X X X!&=ZBP.#/-]+#$B%*?F .Y?7%8^8SK
MA;(\#)/?>HX,K,O8L9U$'4^)3&<L,R23;J;J[G\-1,(D*]O@$F/ ' ' ' '
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M:.TN@FO1.@+J+!]U*QM0P2V04*BDTV@V/5U O]L(48,\A:2UT-ND-?%&9<M
M@0,'!)@@@[(<G$L#8H%)T#M5U0J'??LW;6-K69R/>>N'5GX]P\O>5L'1[%7]
MG=MXI(=5P-CA&H%%#1ATL+(<!TT;7:M+(S9I9N#(-2S$QT,R/7UX-WZ][#Z4
MT>!TA)M>SC(#:)8N:'5/6NRB,H:,?J<V$U-E-IJ*/=L.2G$1TKSG/EQ>,>//
MUYSCH,O!8MW[9MN/;5I2MF09BS(,*#$FHG:VQ(C9ICU8U:+5R-17*FXPZ^4C
M-STI)LE)>+,/AS+GN;":KE:U8:HCG4V5ZZ&KNY3;^Q.B"7M8;9:*3XTV;"'.
M:IV*@A-A#'(31*5#AJK&),F,/=)#6YK[+:VHKD^$A]3:I;&'++_I*N%_BNQ_
MVE/@<=I=ZVZHJ69-ICEVM4QX[*=%,UR3*4KT>RS^DN]6O-A;:JNR*!21M5V1
M#GV:QZJV7!%1)12F%H(YAZ1FIJPAR9,>:CL8SC^6ZXE/WSSC+2[?6ZEM7(GY
M"R;>LZ?G8DW9SV2TO'1\5[(4Y#?$<UM$JC&(KG;D15,CNM9%IREL0(\S(QX$
M)L*.CHD1BHUJN@JUJ*J[56B89X9[-Q;^STZG_P"^M_Q&V3_U/Y40Y2']GIU/
M_P!];_B-LG_J?P"U6]N[G6.PZ0W( ";(D$S1S56PPX@;$H>R7)1 H3J)B% @
MQF_P?CWDB7+?:891YQ[3CB4^?KS;[6A1(UEVE!A,6)%BV?.0H;&I5SXD27B-
M8QJ;5<Y41$WJ9CH\GI2S-(%QK2M"8ARDA9]\;LST[-1G:L&6E)2VI*8F9B*[
M'5AP8,-\2([8UJKL-#TH&M8,:1,FM?;1$!1$"84+EBNJ]BCQ@L8/CN2YY$A.
ME5=F+"@PHK3LJ9,E.M1XT=IQYYQ#:%*Q57\S+U?W#:7[.NWR_NVGHC_6F[':
ME?TPW(KLI:S>M5;L3*ASLU*_YS_-=M_QX\9\Z@V;^W_ZJ?G_ %9\?GCC\S+U
M?W#:7[.XE.RG['5$[\%R*UJE+69_^-GE2NQ3?:U]WFZM#:%2!T_9SD2</J%:
MA38KU$V2EZ-+BAH3$F.ZG\'_ ,EQEYM;:T_DI.<?ERV4HUS)258]%:]DO!:Y
MJYM<V$U'(O%%144\XEY9B#-7BM^:EHC8TO,VU:LQ C,6K(L&-/1XD*(Q=K7L
M<US5VHJ*9K5\\)M($)9P,OX\'8Q T\&G>XDQ?C!)>$R0'2_AIC,>9'^(AR&7
MO<2X[$EGV_=OLM.I6A.H-E.WX X X X!;#=>T16D=/[/W$<@S"@?5]#M5\)#
M1ZFT32$.K!IAAZ%$6[Y;;?E(B98;<<PI#:G,+4E6$Y3D#!6N>HHXOK1V;W=<
M]5?*;AUBFA!ECHH&U8+"+%.NNO-<[(HZ15HE!A[L5B8*VA7AQUV0&=4+G0RC
MT9N>PF.A8%EHGJTD/Q$&K!+1\>//JEW(U#?4N+>52(%5;;['TCK8%)Z]PNNL
MRKC@F?NS=LEQ"K5<6,!!Y8_#LTE+BJP!U<WUA)L+3>_-HQ.LEQMY/76B0W8_
M6U1I%D&$I%LU99+GO2BP"E^*&8X$?KW( AH.TG[A(;=L#,*O$AC0=LR=RV+F
M!TE==XNP6B95%ZH6>_V^S5&\QMX=)]N#*J)-;;8KB %NWWJ:>:=M0*G99H>P
MFA0N&3<"PKN,L$D$2AX,5F ,.O1I3@%S^S/=7K3:^MW8*K5S8DHS8;+I#:X
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AO'*#[9NM^F0[J;%GY=;EGB@]N5,)@2;< < < < < __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g108483g79z77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g79z77.jpg
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M 0$! 0$! 0$!_\  $0@ J $G P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M       )!@<("P$""@0% __$ &@0   %!  " P00#PD*#@,   ,$!08'  $"
M"!$A"3%!$U%A<1(4%188&3-8@9&8H;'!UO *%S@Y5W)W>)>RMM'5X?$F-C=%
M57:XN=,B)"4G*$=6996U(RDR-$9T=8F3E):9HZ6FJ</_Q  < 0$  @(# 0
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MIQ9QM6*U0($,P;QR2SR@5!-YBYAYX9A[21"@% * 4 H!0"@% * 4 H!0"@%
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M!D30"@(Z-PK?Y7O1,^#;2>O:]+NW)_5[= 2+T H!0"@% * 4 H!0"@% * 4
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MN=>:]EY%945;%24%1PXI"(A$40"A-,M"'8ZB4?24>3)8U9CZ%-KW](^O>O\
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MURZ2</FC!00;,"^U * CHW"^J]Z)G[[2>OZN[<G]7/V.VU!SSZ21>@% * 4
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M!4E-<BDB98 %=/A EBI,HX@"I4L %AB$7+%@0@00L< @0\,,<<<=T^B7@JZ
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MII23)#31WM,AN1J ?/.=NDB1':_6PZ=.FUM-+E29,I-3',&C9HP,9P!+EBP
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M!Z7[H9ZR347W-L-?(R@'I?NAGK)-1?<VPU\C* >E^Z&>LDU%]S;#7R,H#&E
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,[9<RA H!0"@% ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g108483g90s31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g90s31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2+N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (M*^B10X0DE-! 0      &$< 5H  QLE1QP"   "_]P< E  "')R,CDT
M,38U' (% $!-:6-R;W-O9G0@4&]W97)0;VEN=" M($=E;D)I;U]3+3%?=7!D
M871E9"!F:6=U<F5S(&9I;F%L('1O('!R:6YT #A"24T$)0      $-[-P]OC
M64_!Z-3_TY/!WX0X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              -L   '"          !
M      $             !P@   -L                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     &%$    !    H
M $X   '@  "20   &#4 &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@               0  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!& )  P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
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M)#-45F)T=9;5\255E;+3U!A#1'.SPR9%1D=7@I?"8X64-F5F9W:$Q,7R_]H
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M>0QC6@[SGN.&M;I\8D@#M5+Y8XF/EDD8R.)CI)'N< UD;&ESWN)X-:T%Q/0
M2NL7V';B9G>+JR\>&MTDG)M(";X@:Y"Z<Q4HDL@K#:;5NCMXNHLBMU0V;KNF
M29YN721$41GY>67)OSPB.VVYMT=J9L_1,<Q\D=ND?4R,(/*54LY?,XD<=UQY
M-F=1&QC>#0N7\%MYGV@EVNNLK9&1SWBF9212 @PT4-((Z:/' .#!ORAOB\L^
M1PU<2>[;.!7K:HG?8/\ F?TCA%'<T<Z)B+@4QP1735,4! !,5,Y3[ (@(;B
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M5_OE:OZC+^D%5^ +[S7_ /M.G_10O4)GE*]]7 N7<N_7U=0_$/?PBQB0CP5
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M.VVP]X=_P]?7_;J[,(J8S(H[B) 'X 'P>#O]["+BZ 3O);!\';]>WXLC /$
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MI @?X0H?$;Z]_3A%',8^3#5F['YP Y6GFF.P\H.O:R:MAM__ (_[<H'\8_\
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MM,U,Z>&.5U/*6$L,D+GF-Y82TO:=TD:J[Y0LE,(F$3")A$PB81,(OP0 0$!
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M)/73A>]UYBV0:G64<2*C]@D!G46_20RO@ZN#(GE@:)3XF\^-IQFJRYS206M
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MWM4S@N^V_8(;;_$.X;][P]7?Z_!A%ATK'@N50IB[E,'P@(?%\O7\/X,D'H/
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MMMHJ]"K,Y<[K9(RJ5*LQKF8L-DL$HWBH6&BV:8J.7TC(.U$FS5ND4/=**G*
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MBGI9Z:E8Z O:PQQ,=$PQA^D;=UN0!GJ;AL5</WN[1LM;Q"+G0R;-5=4]U=-
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MTRI+BW.-(.(JOW=*!E(U*3"UZI7V!GH*-KUYZ"2::\U7RV",B[47F'E?2<%
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MD_FF]?&)/E?FM^NB;*^^3^:;U\8D^5^:WZZ)LK[Y/J 1$1*8   #<1$1/L
M "(CCQ_E<>'B Z^9Q4$@#)X!:_:D\4VA&E'2D;?J57"RK4I^77X14]CG^=+O
MLW5C(4SQ5DJ<0Y)!DC,DM^LZI2[F#H;;LIM'=0U]);I^1=J*FHC;2TQ;\ILT
M[V-D Z1%RCN&FH*\^VC\*NP.RQEBNFT="^LBR'VZWO-RKP\?]7)!1"<T[SG
MYTZ!H/QGM&2.O;4OV5(V[ACI%IT42B!R)6&]K\DX#OL"J5<AG:I1ZO=)&7GA
M#?856IB\I,>_MW@NP0^[W,.(.33T$9W2/DNJ9@UVIU=N4X.  '\0? -H_P!U
M YXDAV3V=<P$.#+A?IF.>TY(WFVVA?N9Q@L<^XG!'CQ8):NMW53B)U>UB5,.
MH5ZLDTQ.H*B<(@];1-=0'KY/-0,2Q918F3+[@JZK55T8-A574/RCCZ!;=G[9
M:&CX/H:.G?C!FY)\L[N!R9Y97S:D9+1((P=6L& !\];2;>;4[7/<=H+Y<Z^(
MNWA1B>.FM\9_!W+?2PPT8+1H'F%TIXN>3DF"%Q:[=:;G;DCOLNCV!N&P[M?@
M';;<=NKO!FT.^'')C)[&.'_F:G&!T+D3R/0V4?\ SQ\.H?:@/.L0?F8@)MDG
M0]1NUPE[X0'_ (*&W7N(=7QAFJJ1+OZEGQA^"[LQIO'LTR,>A9M":;E!XD^=
M[IEC(XGJB&->I19/&8<L_*0>]_L=MP#O?\Q$>W;P]_M'MQ/MF'#+ <Z^(XYU
MX_Q@QCAC7B-="NNA,.^,LE.#D_;&XSO'A]KZ"=>L=.@*C&7.P !Y2#P>L=@Z
M8WZAZNW^X! >_P#)\.V8KM_7!CZ<Y:[&-3\O)ZL'HSTZKO: QXT:\' X/:>D
MXU+!P/8?*HSEC1W(/N@^ZM_^&M]]NOL_W/[?CRR_E,C5F<8X.P>)T\;R\5U%
M 8MQWBR='%[<]'5'CACCU<>N/EE(H%5-VLD8>4;?9^U -]^]_N=O\N6QRF!J
MS@.AWUBMQF+Y,GTVG_RQV+T:>PUZI::Z>Z$:T0]Y?G80&H]WKU(G&#DQW:\A
M39U6/A;R[; VCP %*[!S!Y],HG36.XCVXMC&6 I0\UVUI*JIN%"^  R4L+ZF
M-P! 9,QKGP-<2[_K7MY/@1AQR-,KVCP9W&WT-JNL=8_<AKZFFHIF/>TF2FF?
M'%6/8!'O9@@EY<=.8V@:X7:8\UKT'BR4->,OSA.+X;T=8(;2XD5$@_L4H[&L
MZ:T:C7",B)$D3%N'<O8SVS5@B4C+QJ1'4<X!P=-15!J;DFT-Q>:G?IVE]S-$
M^KWGAL3&F6HGJ(7.C+W[K(N3H\L8[#7 ,!U*[UUULD0HC'6N$=@%TBMS8HQ)
M/(_F]!1TE5%'*V*-SI9N<7("25H#F.+G$@--Z0UVX=0?V)@%I9$I>NNL=*U+
ML:"T6NC*:>S"].8V-2>?,6K1ZDS/6]6XCHDTTB7\DF-<FY!)BJ]24*;*#;[E
MNQN,1YQ044])$X/:65+!,8N2#RYNLU')XA>UIY2-A.X0XJZ+O8M^H8*AHI+S
M=:2XU =&1+0R\U;4.F>QC7AG-[E%N3-B>_,,[PQT@(4%:O<1-;L&D^ID%#2+
M%_:YO6J]5",FT!<I3[KAXE+0^U-81J2ZK$J)8-Y>UR+$(MR9)-GO&&3!B8Y,
MSZ2W2QUE+)("V&.@AF<P_$;<FPBD+RT/WN6; ""?B9P\>/J=1<[W2S6ROACD
M9)53W:LI&2M)$[[&^IDN#8PYT6Z('5K@6G >&$1YW26C-(O6/2I/ANIU.D+H
MW;O6FF-9AW$.G-RSY^TN$'Q!R-U2CST\]</!,RK5IR:2D+V260D$&":4&T26
MZ0N@ZLNH:OX3FJ&P>*ZKE>).38UKJ>2W-AWN6$O*NQ*-UE-R9;O_ &PZ-!66
MRZ6T6*EIGU6'LMU/$Z+EY7O95P7E]6&&DYNZ%A,+C))6AX<U@$+,;SLYJXUX
MTJ4U+KEK@-5(VM4BKZ\ZYW+5BM_[O)*:KP%GNKZ6A)%M"LH!=E=6UDI2B-.9
MQDVX:FASE,9VDS9+G>CCBWU8IIHI*1\L\UOM\-)*1&.9R0T[62L,CI@Z Q3#
MER]@=OM)P26!IRG7BV&O@J8;BV"C@O%XJKE3_;A\(PU-4^6%[81 6UC:BEW:
M9L,SV-A.=]H:XN48Q6H>DZ-RT2O)+I7(=.'X<'VE\:J=>1=2NF.IKN$U")69
M^3C$(!RX(PK<C+Q)>[T8+]6.=N$)%LU5,R$Y<M]-6&&O@,#Y'27-M4[Q0&5=
M*)*=TK(WE[1O3MC?XCPP.:"TN&\L"*MMC:JT58J88FQV-]#&2Y[I+=<'1UX@
MG?&*=YW:=\L8Y=@D$9+9 PF,D72.UCT^;5.&ITGJ8TD-9F>D4W7 UH[JV+H[
M922U5CK2% +J&-<=6)L]=T-O+0*5P0B7#*&-,G@$I 6*CM5.EU#4&5\S:9S:
M)U8R0T1CC)=N4CH><FF,W)%HJ'-E=!R@WBPR[H+0#6RZ43::&EDKP^ZLM<T
MNW*S>*7W*.IYCS[FYD8YU(V6%M6V)S(C*8!+N^,,JA-7] *E-)-3ZD2-G9(:
MOU.PM;#:7LW>'L3)!PVV*J$M)I!]76DC-U^@:FRD<@P7"/.^!C$M'C%H[(@F
M"EF2BN,\9(IHHCS.:(Q1!E.U[?A2.7D=T2.:R6>E8\N!?C+G![VDY.3#<[)3
M3XY])4-;=*:=DU0^6N?$_P" :BF%07OIVR3045PD8&N#"]S8VNC8YK6A1A2]
M08EK2+_0M6]:XJRQ$RTE)D+?5=2-17&I;*;9U><8P-;:]*JB,/?:E/NI(T>^
MJ\RX-%183,E)F?Q3P%Q#+GIGFHIZBDH71NC+6&&6FIA2F-\L;I)-)S)3S1L9
MOMFC\=_)L9APP!KZ2MB925M%<;JR>*4/E%53W"M=<&2LII&PP-/-!'74T[WF
M-]/*71Q\K)(7Q.RU9%]S%BW'0;BGZ.19,OYN,%R@6636$3>TQ#K*9-!  +_D
MB4P]_<-^2%KPJ9^$+1O$$\PDU P/X\]I[_0LWP#;OP3M!N;V/A2G^,0=.:Z8
M(:WH[/1@#TYYY6O>E2.2[]7A+M\@X18),L>?(HF(=9@'DCX#=?7OOU#U^'JZ
MAZLD8P1UZCRC/'RYX]"AV<@\>.>W.,X\G'_-0A/5MZH<_NEQ'<VX<XH/?W 0
M]T/;VAMV@/>'MI(.>H@Z]V"!Y]=>GR84@CCQ!]_\_.-%@;BJ/S";<S@=P[QC
M_#V>Z[=_E[<:]GOYO3T=N-6!UD=)Z?6>&I[AYHZCZB_#4^R^[<B :?T,=A.H
M.X&LFI@=\1V#W'A^#P90,\H[\1FG1JZ0Z>37H&<Y6N8<W>K!)P+;;R//4W,=
M>GFZ=>@*4FE5?\H-S+CL(?X14 _$;X_A$1^$-JL'/5Y ,^0GNX#HQG0$[(8'
M6?+_ )Y/>/U*4:] NTS$YPZO(#;E 8ZFW>ZA 1Z^\.PAU[=_E94T'''AQ)]^
MX*DG'GX >_1VJ98ML*8%[0 .3MU> .H=MMNO\'4&#@D]WFX='DZ$ P!GR]^J
MRE$-B &PAUCM\(?!W\*5RX1,(F$3")A$PB81,(F$3")A$PB81,(F$6-6C]9(
M_OX?R384.X'R'U*/,*4PB81,(F$3")A$PB81,(F$3")A%+,7^QS/]X)]6$5?
MA$PB8113,?LH^_A!_KS?TGW/'Y%S%9]U3?CGU!6W,E8RAO6#]:0?\(??]VWS
M-H?CR>1G_F+47;A!Y9/4Q07FS6F3(R-1GAQ]_7U)D=:Q:TWFET=H+ZY6VMU5
MH <H%[#-1T04X?\ ) ^<(&6-V;$1*<XB( !1$0S,H[?<+C)R5OH:NND^32P2
MSD=KN38X-;T;Q( .AQHM+>-H[!L]#SB^WJU6>'!(?<J^EH@X#H9SB6,O)Z&L
M#CG3&HSJ1>O9">&ZFE53C9^9OCY/E!T:GPRZK<#AN <N4FS0T:9(1#K5:.7>
MQ=C%(<-@'M+?X,=K:XAT]-3VN(C._7SMW@, _P 33-J)@[LD8S&=2,+QR_\
M[I+P96?>CH:^OVBJ6G')6:@>8M[4 &KN#Z"F+2?PX99L<<$+2G4#V4V[O@<-
M=-M.X"N(J 9-"4M+QW8I(H"(E(LFQ9##QS9< ]WS;@THB4^Q#<X4!$_=4'@A
MMT6Z^ZW.IK'!N3%2,921$]+72/%1*YNA\9C87=0:5XU??W4^T-9RL6S>SULM
M,67-;57.:>Z5A:!D2,AAYA2PR8P0'BK8'<0X:+1K4'B7UWU4!9O==3+*_CW
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M.16B6C-_(IH\MJS?2*T6S74Y9 Y+A^WCI==JGR>4(JIQKP0$ #F1 1$(.<'
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MZ3^;%J_O'=?\,3\Y?IS^YQT^_P"WW5#^I./WK=B>'P!%_M.[^OG>5'V'4?\
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ME6[^]^T__!3]!HX/OW(E%_C/Z^_ZLQ\#T'\AB_+U/U4_>4V)_F5;O[W[3_\
M!3]!HX/OW(E%_C/Z^_ZLQ\#T'\AB_+U/U4_>4V)_F5;O[W[3_P#!3]!HX/OW
M(E%_C/Z^_P"K,? ]!_(8OR]3]5/WE-B?YE6[^]^T_P#P4_0:.#[]R)1?XS^O
MO^K,? ]!_(8OR]3]5/WE-B?YE6[^]^T__!3]!HX/OW(E%_C/Z^_ZLQ\#T'\A
MB_+U/U4_>4V)_F5;O[W[3_\ !5:3V'+@Y(0I1X.-/SB4  3FXH=?=S;=\?\
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M -&KP8#_ -WM#Y]OMLSZU^#[%OPSCV\)FG_\976[^KN4_OI[>_ZWA_V?:O\
M#5/_ $:_!A_\/:'^_NV7L7R/L6?#(/;PE:>C\?$KK</UUW(_?2V\SGX6A_\
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M8PAOOL(AA%781,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBXUE 1256,
MB5),ZA@#;<0(43" ;B ;B =6X@&_?PBXVC@KMJV=D*8I'*"+@A3;<HI%DRJ%
M VPB'* I@ =A$-]]A'"*HPB81,(F$3")A$PB81,(F$3")A$PB81?@]0"/@Z\
M(J.-?)R<>RD4B'33?-&[M,BG)Y9".42+%*?DB8O**4X ;DF$-P'81#KPBK<(
MF$3")A$PB81?!R<LNW9WP'X<(K6X;%/N4Q0WV[.]\&W>V'MWZA <(K0K$D/O
MN4!#KWY0<H/QAMU=?7N.3D^^J8!XZ=9'']7K]2H3P")O\$D;\  /P;[>#P[[
M[_$&,YZNX#U!1C!T)\Y/M*X_:\B ]:">_P .X_+N.WQ;_@R%*YTX-$HANDF&
MP[@!2E[?D\/>R<GL[A[%&!TD]Y/?DJXHQA2"'N0ZNK;8/JVV$0V#LWWP23Q)
M/E4C X >_#N5X0;[=0!L ;;[[AU=@@'P]0^#\&0BKP "@ !U ']OQ_7A$W#P
MA\N$3</"'RX1?NX;[;AOX._C(/ HK%8/ULP_Z=@?_%FF0>'G;ZPBUFXK6VK\
MJCI-7='7E@CYBP7:RL9-_"6)Q5&D>@WTHU!D(*2L4ZC6[6DA"1MN:5]\LP=P
MSMK-N6[:'5;N@>]%7E0<]'3T]7O^S.<*,K=KIQ(TRKNI%U U9V[+:=5H"&<(
MZ3:I3_=-731=Y$U:"=QM6G7$@69UID&QGM7LR#)G6H1BU50+&V)Y*12(D)/K
M\^.[&>O@,<."MAN*#7>5L>H<+6*57GBM<E9>O-(]2@ZCNC5.29ZAZ;52,=V>
MSMI-&M6]"3BK=;'R\945H]U&*4A^\6>K-4Y1"+*,G7LT_5QZ=<Z#7@-#HKG^
M;5Q#0^JK?3Y*EQCB'?:B+1+RZ3M?O7<6;9$>4%C+-:AT60D"UT&,;*V.S1J3
M]::C':34C'I"+2-LMA9$R<X(\_ =0U/6>@ \1C*P*D\3_$+%(:(U*?ILS>K+
M.U"74U0G5-';'5&D+9HN!U0<&24?A;!*5W'6:CPE>EVC"FJ0SL]CCG32P1BD
M[!L5" \,YSC73LZO8->C@<3Y2-8]:'6I.FFE]SK]54E;A0H_5F=G86NV>"B8
MBH$BIF/L]=1:RT_-+(VZ ODCIM'(FD'J9).!L,N]3B&[J+63;E.O CR_K&./
MOV:[B84IA$PB81,(NKWC?U&XB=.]6M V6A&MK4;=J1J)2ZO <,I-.ZK--+G5
M&DDX>ZM7RXV]]TFVP-8K5:%)5>8B%H1A$*(H-P.\D)$JB.NK'SLEIQ!*-Z25
MC>;\DQV^P.'+/<\@N:V-AW@1N@.#02=["\D\(%TVGM=ZV;BV<V@8:ZZW.@HZ
M;9+X+HIV5U'',Z2]7.OKI ^MIZ.EI-W>FIW4T<#F@!SY)<LUXD^,GB'A-2'&
MKZ]V:2>E2W&UK-PCDT")4J\DR:U;3.BVN3B[RE;4F/MU+=GM@J*LA*H.91S7
M@AY(&C>'1%%-?+/.IQ*V7?!B?634H@W6CQ8F2$/W\;YD+HSIG=#2!C.2>6GV
M[VGI;I)?'W!L]F.W]_V*&S(H:5L;*2TVVMFAN KA%\("O?4T1EF:^=U+R,NZ
MV%H (DK@DXB.(6Y:L:+0^KFI++4>!XEN#P_%&VB6]/K=:2THL@7.NQH5"M.X
M%FVD)*GC!6UJS(>V.IR=-+0YW?=8".5F^7*2HJ'2PME>)&U%)SD -:T1.WVC
M<:1@N9NR  OR[(SO')QMO!_M/M/7WFP0WN[1W6FVMV&.U[(!0TE(++5\_I8N
M8TCJ:-DDM%S:M9%FM?4U)G@<_EP'.:;Q"<?>KU:5XIWNINC\+*1^FG%% \..
MC473[>T;RUKN%U4H$;3:E.JR;(6;%-P:VDLLO=U56[-@R<J0R<$X>1G/O3:V
M9IJC)""V*I;3P[CQE[W\EN,=D8&>4#B[\%IQ@D#-^G\)%\I';827:QTTT5JV
MPIME;##0US(YZRON+[;!;Z"I=,PQL#S7-K)[B2R...0TXI'/AY23<OAOX@Y+
M7#\UJO6NA*:;ZC:):A&TWO\ 6$K$UM\*$FO6H*VQ,M7+.U81 RL/+05A8.$^
MF0\5(-'!5VSID02$44RX)S-RK7QF.2&3DWMW@\9+&R-+7 #>!:]IU (.01HN
MZV5VGEVA-ZI:RVFTW79^Z&U7.C;5,KH!*ZEIZV":EK&10<M#-354;AOPQ2,=
MO,>P$ F2)6)7F](W,<VDI^(=*U?GFDA5Y)U$SJ#MFB#QJ#!\R'I*1U5T$T54
MTM^DH**MC%,14Q1R%UIX']7'S+3Z&U;U]T]2TOID32YB^I+Z*5B_3CV^%N,A
M=;S<9B M<I9JO!V5(BD7 2]<DH>$1/#3D4N0I+(U9++P#8K-RL5.7::#AKG(
MZ->CKZ/<?M6U;U[E-0Z];&SJ/M=+D:YHI!VJ.:Z6:L4R),^NNL=JJ%@?U2*M
MDZLO 3E(B9-A*7"6E&LZC)0]?:HKMJ^W.+B.*<]G5Z3U=@U/OC-X_4K7UOK9
M>:.)HU]6OS;"(QRTKI?:S=P-(&VA=8N0=PIR,GHV)GWUBNS>QUN/E71W/<J?
M+*D=,WI31%=9E&3G Z^HZ#'M'7V>2)8;BMXF+11+59H+2A"/?U8^I<PU1MNF
M%TC'-O@*1I31M0H>&C:]$7R>-$V&RV*QSE"0=>V2?*WDX1QO J3,?(5XKKUZ
M!I[]?ZO*IR?3KQ.-,^?JTZQY%G-IU%UKN][852.:2,7#U+B&CVTB>K5N[13"
MS4%C3-69V.@']Y;W&"<#*+S=2K!+0FM$0U;8/9B!9+)W2J3B"LZ3CH?/CMST
M\>CL_4KGHMK=Q%ZDO=/4;#4Z=6&5@D9A[:USTS4%N[@(J%KE0DWM07:R\LQ1
MB+<G-SDM!DF'KQ^T4"/.HO6&<BQ>19R D]&/+GAW<<XZ^G!*P4.(7B*J[U[
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M74<YDRTVJQU38@ &1S5E-)+4%@P' /< <$D#  X%;.V#];,/^G8'_P 6:9Z
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g108483g98n32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108483g98n32.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'Y2^@(0X0DE-! 0      $4< 5H  QLE1QP"   "('@< E  %4UI8W)O
M<V]F="!/9F9I8V4@57-E<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX
M.$))300E       0]]%OU.<,5KE=:2M"S384G#A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              5X   ;\
M  $                          0             &_    5X
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   5X     4F=H
M=&QO;F<   ;\    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %>     %)G:'1L;VYG   &_     -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$$0       0$ .$))3004       $    !CA"24T$
M#      5)     $   "@    'P   >   #H@   5"  8  '_V/_B#%A)0T-?
M4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$
M &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !     -,M
M2% @(
M        $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K
M<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M%&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,
M  0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I
M9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M     !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y
M-C8M,BXQ
M              !865H@        \U$  0    $6S%A96B
M        6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8
MVEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W
M=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                         &1E
M<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P
M86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@                            !D
M97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0
M=FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M3 E6 %    !7'^=M96%S          $                        "CP
M  )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@
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M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUEKIRJHK_/WH"KK#[%1&C=+C>U>&Q[;08"*Z$9^RBQGZ?AX8R(^R(%/O_O\
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M8JBP,>U0@PTW4V74TTRE;9>*4XI3BE.*4XI3BE.*4XI4;KT_VMNVQ_\ U/\
M%_/UU0%']Y_MDY7[K]59-D&?U7^C92]BI/ZS^Y_;?VN*'">S_P!K_43RR1U(
M;&*?D!OQL^//CV\_3SH?OX\_*K$G@J\]J&<B/;:4D(&?1' =P*JDJ2Q[8#
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MIH;""YO+^S%A?PY"-K"80O(\(8!'+(_C3$HZ@/&PY(P\@_4_PK_%?+?A/?\
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M'J',$#(]-Y.26ZFFREBZV\LJS2SW27I-E/C;CUEE:,;HQ*8QLEYZ:OD=</\
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M;D0$OR8JM=NT\#TGRMY)U73O[U>K<[UOZ/\ -#):?6[=L?4FN"\[%Z^TKWG
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M<\]^F<9^HSU3JX_-#8^@UWSZ;M>W/L\=]SA\'\_:UM^UW29*^F?_ "QU7_\
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M[#J1^VJNA$L]BUX(Z"GMB9"=V'T,S8*,)>RAQ\\6*R7/K/#J2&!JJ(GPC@:
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MR[VIH878R-./96"UM8H%8$+YJF5$HE#)S&+%@S/5I#&S\M.N+-ZFG"6%/7)
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M3:[6G]CRUQIDFPFBMJ=2Q[E,SQV"1M80>%G=/QOL18Q]5WH2%>9C8Z^+PO\
M-XUR\#SX79/P^W\VV]O/O663CN;BL*CO?"(VF(5=R_##W'8M#_+\4Q>;0C^/
M9DY;K>5K#3BE>9GW>DT]0OEXT%]^NT@[9.^6'C!\ID?;DM,0 S37OH.ZK;&T
MV+J'O<R6/. ROR5GKSJ53]2VQ69N]([86[\ ?IPQ(??W]?[U))(4'7P@@:50
M2"Q;XB "QVQ^)B3QTN^*J!Z9N*BG%*I'5/\ Q(-\_P"Y'Y*_]]_:W%*NYQ2H
M@KZ_646[MELDIV4NV3*+K :^K^YCLL!*@$QV#GK\G&"6'%=%V8<5=<,I YY2
M9?QNNC,(L(A>\^3;IC1F<G) ^\J]GC%OX^3GA:H]]Z!N)';7FS7GE&+-P^,#
MBN_:9*XZJ?H/I6VOK<)T=!G^K)>G;GMVX,V:GMNFAU)&9$<W3B"WAP)"SHL4
M?>)@9F>;CC*'ROHNL>A;AZF24F$'=U[JXM1LULP9M\XCU(V"F'O/!)(=FD%8
MEBH$09K(8"(P@92-'W+UW,=D7[:?JC-W/3]ITQ->E\+8W3W=M:F*(&.5C*VC
M.$$S1H\\[I&TA17F<Z/&,)\^3'VD=[+D$BU=S1B*23D^F4<!_(6X!B(XP6"@
MD(//EMV%YY^MVG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KS
M#?"OKD:J>L-[ Q;"*LJG5M/LNOZ2G,N3JPC,4;"L>2$<]SJXQ_B[SQG-6P:Q
MJ/6FIISG>PGSB*R:Q=RP5=ETX:7=BI7IYXI54O:/^H\+_P!??(?_ #;:0XI5
MK>*4XI3BE.*4XI3BE.*4XI5##]O>B4GO^76IM*AP\I,]%51C+L)P>N5JD6R>
MWNP.XNDC$B,61O8;7E&!6VE+_)9&!+$">U"1JA"CNG'KH<1@)NDILFF6N'ZG
MCR/:7!QV[21G'J(^=RS+$64*':0W!E$0*BW,7<8..<]Q?)D8X3;1C'/"Q-V9
M5#B<:/#M\]@'8504V_Q,KD(RB9/0NU-E5CSW<-G>8:2DW[?PPUQ%(JJ]S 4G
MLN,U@ 6.21S59\/37%*KD:L_URYC"6PG6]KQI<29,<.]/ 8O'7/4%IC.IKV;
M V#O(M[=20LLUL1;R2PJR2H>UWI1%%W)(V2-91(RE1NKWMQ/'92SV$*WDP"F
M*,,"LFW56(*L.01"S\58%N/$'9J6-9NKA8]=4.P;"JT='OCRGUQM<Z9"PB:Q
M52T,% A;VNQLH,LX3L$[.4D#$J+//";J#K/'//KOZ^^5DH;2VR-];X^Z-]8P
M7ES%9WAC,1NK6.9T@N#&VC&9H@LA4@%>6B![5LP-*\$+S1B*9XHVEB#!A'(R
M@N@8>&",2NQ[ZW6;\TJRUPA&2X^0V$$\(V9:3V$QB$*@(D ,ZCCF[$-CADSR
M%)ZBEBE[@GZCEZCDCS[P^G/'ON[QR1A"\;H)%YQET91(FRO-"0 Z[!')=C8(
MWL&H#*=Z(/$Z.B#H_0Z]C^Q\US>4J:<4IQ2G%*<4IQ2G%*\S/RNZ=:W;Y M!
MR+K%>EJ.^T.HU6_85S67I*VU].BKS3:W0S"RN]6:0V!4(1;7!<VU#P@_M:YJ
MGS>=.+*,F0_@NLIU[>WGV\@?3WV? \^YT*LJ,VM%!S<JO)T31 4DL690B_$-
M.Y"GR%8E&"^F;D56G%*I]YC_ -;7O;_>W0_\G'DKBE7!XI3BE.*4XI3BE.*4
MXI3BE5B]F&ZC7>9-LF[WU]8MJ:G'3JL[AK^I@,&E@LHO=F28KA%P"MLC/(R'
M=9+3R,1FHF6 @A$F64L>&<$K9'D $CR ?8D>P.P1K?OL'^E7C($B%CI0ZECQ
M5] ,"3P?X'\?]+_"WLW@FHRJ5T]Z3>:=IV.Y:FU:)Z86/W,.K:.J<QYU)]7H
M2$N !K4K^WE#X&Y136&0"">RJ.S\ 56+'!/(7/EUX>TO.NVZ;REQ>8G%IU)%
M/.N+L8IP;2>W#0]MYG]4RA]-<<%-Q%W!'%W.UW#7W[,X+_AX3\4ND<9@^LNK
MIOPKN\=8OU;G[NQ=<SCLD\=\;B"TA_)896@#IC%N9(\5>"W:XO&M6O4AC%3P
MBVQC2-2Z_M/I^P:VTY=G-?5]6\)M<$B2L!7')7^:Z3)&CIQD,;^)W$5+T.*S
M9]QPPR]QF&P0_F2=V#*BQQ5A==37&.Q%Y+;Q>K6:[A@MDN^USFAAEGFXOPTQ
MXK))H Z=U'(_/<AT><]UEU)B/PGQO5'6^!L<E>?DL]GA+_(9:?""[[%C?7]I
M8V0E@[P>)3)+:6@9Y$#P02/V5DMM=J8AKD5P>6ZL)JE/$OG@M+9^J75R:%OG
M!&JFB=F%PK)(F>9(V"^3 K+ W,B#$;N7N6/K+I2WMG!;B[GN[:&T81LMU+/%
M';LLI41,)W<1$2EE$9#:<LO'>Q7EK/ YS(Y-\)C\-EK[,QO<QR8BSQUY<Y-)
M+(2->1O800O=*]HL4IN5:(- (Y#*$"-K)L<L<\<<\,NLL<NNLL<L>^LL<L<N
MOYZRQ[Z_GKOKOKOKOKOKOOKOKO\ GKFS[^U<H@@D$$$$@@C1!'@@@^00?!!]
MJ_O%13BE.*4XI3BE.*4XI6F7=C72^T?D)H.N-@?'QOJZ;?JN>M[Q5O0"?:FF
MZUK[/76HMCY3U:_/D*_TW6;;9Z7KC8^S3'65$M.M6]B8N>H'(-%??I$90D_M
MX/S\#SY V"2 ?&O;R!Y(]S5V.E5 R,/Y]JFF#.J[1G9%<\= <=M&&Y&,GD6;
M<UWWUUUWWWWUUUUU_/???^77777^GOOO_P NNN15*@^M^G/-ER+JZ^H>A-'V
MH^\62STZE!5O;%">%W"WT@2,^YU6KC+'Y4U@LE1!FB-LZ-3@6S0"2QDM11(<
M\<^U*K,SO%<UG[J]2;"N!DBZJTKP)Y>LUA/A$*/F$3IMV>VCCR(P@8IS"\XA
MH9,\1Q8)9Y>^OHCPRR[ZZYJ7][;8VRNLA>2&*TLX)+FXD",Y2&%2\C!$5G8A
M03Q4$G7@;KL].X#*=59[#]-X6!;G+YW(VF*QEN\T-ND]]?3);VT33W#QP0J\
MKJIDED2- >3L ":M)HG?NL/2-%ZV/J-X58*EVY8(?V!:=LCF_9J\!LS8/P7(
M81GTQXEP=XS?8^U)]??4>>7>.7\:6#SV,ZCL1D<3.UQ:&:2#N-#+ >[%QYKP
MF1'\<E\\='?@FN_^(/X==6?A?U!^F.L["+'9GT-MD?3PWUGD$])=M*L$GJ+&
M:>#;-!("G<YKQ^)0"-]@BL%5+W%L.M TPA=<$U,URTL-ZS2 #"VA,[/O,-<0
MP6"++MDVEJLZEZ3.N,PQ&48V.&4+O+-H5_&6"XM7RV0MH[-H[N"TQTEQ>F"-
M%NH9WO1;P+<#^),;4PS,T;_##ZA2GF5JU;_&Y>'HKIO*W&<BN<)?YSJ>TQO3
MZY"YEFQ-]86W3SY/(R8UQZ6R3+QWN/BCN8&,MZ<7(DX"VD52KSIUY&G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M;7@#PQLSQ!'?ZVQ]&
M ;@UQ>7$EQSKI>JFU7LPNQ"$M0KS2YEW%AMV\0L"K6'52']V#@K:SJQ7ZQ.[
M=T4O_*S59J5%?H[QW[9O.UWUKTOZ5;U.J._06J=DJPV^W=D)<Z95*W45*BTB
M+ZS6*_G7GR,-D"WZ TRWEPH=[QL,CZZM<7H7WB5222 /&AO6@ ?/OL@;/MXV
M3KSK6S6 ]></46H/'>HD>]?25L=V2H>C_-I%IIRVR";DKEK!;>Q=-3+!'FW=
MQT#O=3?,6261M#("YK.*SHR*M#QDJ% TDZHK=OQ2G%*<4IQ2G%*<4IQ2G%*H
M+ZF\8:=]J7<.H[LSW;-7:$JH%S3 (VHU=U<4QS:[,6L@5K3%88:;:FP$D$&P
M!89Q3UM?%UZ0D8*ICV,AGK.E.LLST;/>76&-H)KZU:TE-U;]\HH=)$EC'-.,
MD;C:!S)"VV[L,FEUIY+%VN4MK:.ZT5BN99%$3E)B1'""LQT=P.#J/B0_(3:9
M?.\.MNOMH>!/..KM7> M#Y;IB&VC %8D5VMTDC%=6K24U;6&SD,9F"./J>5M
MD"NZ,@QQ5H!RNF124L6 G/'MVE_C.O.HLGD^O,[^3%L87MY[*T CDN+58HK>
MV6,1SGB(NY)P8F6X9>VDZ,4%<^6&XP]E;V^'L_5 7 $B2R;94D+,\A8LFR6X
MKL?#&#R*%5-;*NOY_CK^>OX[_CK^>NN_YZZ[_P#/K^?XZ_G^/_O_ !U_/_VZ
MY\XKN5 ?I[T+5O*VD;KO6Z(K59:Y2(U&9Z>FKQV+XGMT]6U\7*",TQ>! - 6
MT@G/,..&'%#CFD[SSEZBAE[O36 NNJ,U98.SGM;:YO3*(YKR1HX%[,$EPP)1
M))&=DB98TCC9G<@: VPT[^\CQ]K+=RI(Z1!>2Q*&<\W5!H$@  L"S,0  3O>
M@8G\=>>=(:W$OWH33P.PUL_L(Q#O"T+MB,9LV*F>TC'VL-3 CD@BR19"D6UI
M*:*62X/P*(R%[<% " 1P]7J_J#-Y%[# 9=\?(.D4GPEM)CXU$<RVK1VKRM.&
M(G#+:1"-D6&/@H80J[N3KXVRM8!/>6RS*<FR7<JSD\E,G*0*%(!31E<L"6.S
MKD0%U=7GC:ZE.*4XI3BE.*4XI3BE:VMX_'P=M/VCK+VW3=\N-5;&UE4T-*7@
M@ZSI%OZ85M:+MY<[02V"P?PY$K-N!W Q*?5H>3]059ZC0;;)!*YJ2F4=4>?/
MGW_;V]O^W_NK,>IM&G>@]7 T958S:LV5;1TUL8!F.]LR4*;K66U*E>&:IU!6
M6 .=@6N$B1HMC0N\&%>F;$JV+!?)(M%G&??^/O5@S*=J2ITR[!(/%E*L-CY,
MI*L/8J2#X)K59H[XGO0&KO0M#VZX]52&HZQ;]J6&;%%"[[MR2&ZZAMNLR3:?
MU:\;%3NWNU[A8UN_-R8V>ON$$VT*NJR'46C^(W8BHJ]WB6K-:9;_ '%7'=_N
M6SV2_P!;K?R+O?XJ7!:W/Y/D7RD7%^SBU]3Z%4L>@89\%P?ZNJK.^PA1^S.R
MSNR32%*OEQ2G%*<4IQ2G%*<4IQ2G%*BG=\VYA]5W";ST'0S]R8!A]T839LK:
M&BS']M@,3^K#(BE@;8C8I>V68WX<N&?9^(F.??</<G7:E2MQ2JU^C/).C?58
MM/#W563K%!1CVIZ#H"P.D$D7;L485H*1,F,#EG$+_!73YX=YXRX3KQ\H9HX\
MB(I_-]1=)X3JI+2/-6TEPMC)+) ([B:W(,RJDJL870LK<(SK>PR+H@%@WU'\
M,_QDZ^_"&7-3="Y6WQDF?M[2VR/J,;89)7%A+++:2QI?03I'-#ZBYC#!2C1W
M,H=&81/'5;?"G5>U&)/QX?\ 9YNSE+1=-K-A:R=YFMT&M1W%*4RK:16YK8&=
MBW' SZSPK1[:<J?*68HY?)A^7C@PP\OG8L7E9'_#W]/WLT%EAX[_ !LY>6WQ
MJS6<1CLK8W:2"54/BWDE+$EF=#\?\0?7?P]O.K^D+6+_ (E?_DK!65]U!UO=
M=-]5V @LLEU3+8YR]CNL_E$P\]NUE)<*0<I;V<<*!$AM[A#V";9K<^62MTE:
M-I'6_P"D5C7>RPQ3%;&HU$SHQ,J4*SR%]:PCSP=62*&>5".!*0/$_:XQR9?S
MD1%+E((-ZWIA\R^$LOS^RML?DD1HY+6T<20QQ1L4MP")K@*QA5"RB>71]V!)
M5?C7XMP]"Q=?YX_ASGLKU-TM/+!=VV9S,!@OKN]N[>.YRA96L,6[QID);A(I
M'QUH64:$;H%FEL)SOU\VIQ2G%*<4IQ2G%*<4KS$;S\M76V_+[KG8!GF[RTVU
MA6-_Z[V!<MD^6M9Z!O/K9'A'7_S=>6_U0[V=^?N6EKRMGK:C@Q<ZAIPX0FK(
M&S&6^PFPQQQ23O7O[ >3OV^GMH?0?*KNQ<@DN=(J_&W,@*H4 '0T@UI5\\5T
MNSK=>G F/.48B*+N'J26"6./LF+N<?K/./+'#N>#J2+N:'ZN^ONQ=2Q]R8?5
MAU)AWE]7452M'.HOA[MU,V/K3:%^]#TBTV:N[6)V+LDJD:%/UU_B""HL^G;E
MKE*@$[W#9DNKIJ63I.EZY_\ I!-%5B])I45(6T]$\53W%HI6&[I\=6^/?7J[
M1WD)P[KK78/E#R&=;.]G[BVA?\&=89[@]N);6FCLFTWFRWBE<Q!A6Q8)4TP"
MV.3 @L:(4L@F>?QW7>*S><Z?N,;@IH8+J[E2.X,SB**6Q=)4N86/:DT) RCB
MJJ=#PPUH_</^'SK+H3H/\3<=U9^(>/N[_$XJVN+S'KCK-;JXM.H(I[:?%7T-
ML+NQC_Y62.5EY2&)25!A=? V._'KYJNWE/SH!JS8+"NLK/G:W]I-DK!1QJP?
M%[$M^V#V4>O6RSDA]B9PS21C=CY]8X9Q2Y]9=]]8?P^Z;O>E>G(L5?R6\EUZ
MJXN7-L[O&HGX:0O(D99T"\6(4J= ACNMW_B2_%+!?B_^)EQU;TW;9.UQ2X?'
M8B!<M#;P74IQ[W1:X$-O<W:1Q3]]71&E[BDL'12!NQ*:^N#MSWG7!XU:&1H:
M11K-6BA[$K(M;<UTQM0=KC85B-G*X7)T>"^K?A-25(@1Y#R> <PN0:2,?U\:
M94W-U)-CI(L,L=HECD]-VKJ]<W1O;7E_*'MDBMW \%A,Q'(*>/R*[M>G(^FL
M)>6>8DN.J;K)YV'-X-H66/&XFTAPS8._CF,*I*V3FNLM%*BSRM#Z",M'$)5,
MDL\V*\_3BE01L_T5KW4=_P!4:UML%LRLVZ7!"&@8I*JT=K&+4*03$\4UH#'F
M(IR &-A9&9L,X(HE>)!_UY0"%90]:QPUYD;/(7UNUN(,9$)KONW$<4B1L&X,
MD;D-)S92BA 29.*:VR[WK;'7%W;W5S"8NU9H'N.<J(RH0>+!&/)^1!4<026T
MNMD;G?G)K1IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*JE[1
M_P!1X7_K[Y#_ .;;2'%*M;Q2G%*<4IQ2G%*<4IQ2G%*C=?$3UMVV39!7_ /+
M75 CA8G-X9=6D$X639&1 =91=&YD WT..0::[M9%P\+.OFT 2(PO-5-"%._
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M.9,'>?0V$4\GCG;/?EL;)#B#F.0[L3W%X,<$[C F.86QN6;L\" T"CN%EV%
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M\@+E(SV&QXM@J\Q/R ![*M3[8D:7O&X+=?"IH6&6.LY:XXL1K-@K_D[Z);S
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MFV*'R"PR5K#V.( CO=F19V0(LI/08N/5<R[R()[B^S#CUCEWW)GCUUCW_/\
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M;:_JVNJ,TL*.0ZRA K%RX,<2*$H>2""0001[@^X^7GZ>?%2RLC,CJ4=6*LK
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M]-)?$&VM6T3?-JN'J"6E;;+UYN<=?5JW9V=R=V"S6VCJL![5G8*C7<<!CU5
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M6LDEAK).JM@*T$]R/LR]F_8*D.PYJ4U(75LN!LVG_@EGBS7!%B2Q]_?T_M4
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MJH%UV46,:J#[K-!CJ4K_ !'9L1@"GN<=UN%%1Y)JX.1(\?\ 7]@C9_IP3/U
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L0%/+B.0T&;P&V%.]LH#%5)*C<SQ44XI3BE.*4XI3BE.*4XI3BE.*4XI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530216408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001733294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GENERATION BIO CO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">301 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-7500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,427,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530320968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,889<span></span>
</td>
<td class="nump">$ 15,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">199,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Tenant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,408<span></span>
</td>
<td class="nump">2,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">267,735<span></span>
</td>
<td class="nump">18,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,781<span></span>
</td>
<td class="nump">21,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, noncurrent</a></td>
<td class="nump">2,051<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">294,155<span></span>
</td>
<td class="nump">42,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,953<span></span>
</td>
<td class="nump">6,907<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,220<span></span>
</td>
<td class="nump">9,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">14,922<span></span>
</td>
<td class="nump">15,981<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,142<span></span>
</td>
<td class="nump">25,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock (Series A, B and C), $0.0001 par value; no shares and 26,425,664 shares authorized at December 31, 2020 and 2019, respectively; no shares and 26,425,664 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 and no shares authorized at December 31, 2020 and 2019, respectively; no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 and 46,750,000 shares authorized at December 31, 2020 and 2019, respectively; 46,970,012 and 6,976,077 shares issued at December 31, 2020 and 2019, respectively; 46,291,877 and 5,270,889 shares outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">456,974<span></span>
</td>
<td class="nump">9,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(188,975)<span></span>
</td>
<td class="num">(108,452)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">268,013<span></span>
</td>
<td class="num">(98,592)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 294,155<span></span>
</td>
<td class="nump">$ 42,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530295720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,425,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,425,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,425,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">46,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">46,970,012<span></span>
</td>
<td class="nump">6,976,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">46,291,877<span></span>
</td>
<td class="nump">5,270,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530330328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 58,532<span></span>
</td>
<td class="nump">$ 50,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,582<span></span>
</td>
<td class="nump">12,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">81,114<span></span>
</td>
<td class="nump">62,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(81,114)<span></span>
</td>
<td class="num">(62,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss and net loss attributable to common stockholders</a></td>
<td class="num">$ (80,523)<span></span>
</td>
<td class="num">$ (61,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (2.95)<span></span>
</td>
<td class="num">$ (12.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">27,256,494<span></span>
</td>
<td class="nump">4,731,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,523)<span></span>
</td>
<td class="num">$ (61,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains on marketable securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (80,514)<span></span>
</td>
<td class="num">$ (61,308)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825525151960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series C Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series A, B and C Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance, convertible preferred stock at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, convertible preferred stock, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,425,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (41,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5,552<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (47,135)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,054,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for license,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,055,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on marketable securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(61,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,317)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance, convertible preferred stock at Dec. 31, 2019</a></td>
<td class="nump">$ 115,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, convertible preferred stock, shares at Dec. 31, 2019</a></td>
<td class="nump">26,425,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,425,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">$ (98,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,452)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,270,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C convertible preferred stock, net of issuance costs of $2,640, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,936,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C convertible preferred stock, net of issuance costs of $2,640</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock upon initial public offering, convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (224,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock into common stock upon initial public offering, convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,361,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering</a></td>
<td class="nump">224,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">224,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,094,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs of $3,185</a></td>
<td class="nump">210,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">210,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs of $3,185, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 3,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">792,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">792,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,022,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_VestingOfRestrictedCommonStockUnits', window );">Vesting of restricted common stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on marketable securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (80,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,523)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, convertible preferred stock, shares at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 268,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 456,974<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (188,975)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,291,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_VestingOfRestrictedCommonStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of restricted common stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_VestingOfRestrictedCommonStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825639354136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_StockIssuanceCosts', window );">Stock issuance of costs</a></td>
<td class="nump">$ 3,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gbio_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_StockIssuanceCosts', window );">Stock issuance of costs</a></td>
<td class="nump">$ 2,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gbio_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gbio_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530088584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (80,523)<span></span>
</td>
<td class="num">$ (61,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,412<span></span>
</td>
<td class="nump">4,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,432<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization (accretion) of premium (discount) on marketable securities, net</a></td>
<td class="nump">249<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable', window );">Tenant receivable</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,831)<span></span>
</td>
<td class="num">(1,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="num">(252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,444)<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">2,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred rent</a></td>
<td class="num">(1,059)<span></span>
</td>
<td class="nump">13,019<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(70,142)<span></span>
</td>
<td class="num">(40,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,518)<span></span>
</td>
<td class="num">(19,986)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(243,178)<span></span>
</td>
<td class="num">(20,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">43,500<span></span>
</td>
<td class="nump">88,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(205,196)<span></span>
</td>
<td class="nump">47,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs incurred and paid in current period</a></td>
<td class="nump">108,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering of common stock, net of underwriting discounts and commissions</a></td>
<td class="nump">213,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of deferred offering costs</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="num">(3,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">323,095<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">47,757<span></span>
</td>
<td class="nump">7,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">17,183<span></span>
</td>
<td class="nump">9,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">64,940<span></span>
</td>
<td class="nump">17,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">224,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses', window );">Issuance costs included in accrued expenses</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) during the reporting period in the amount due from the landlord for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_IncreaseDecreaseInTenantImprovementsAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock issuance costs included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_PreferredStockIssuanceCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531650408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Nature of the Business and Basis of Presentation </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company was incorporated on October&#160;21, 2016 as Torus Therapeutics, Inc. and subsequently changed its name to Generation Bio Co. (the &#8220;Company&#8221;). The Company is an innovative genetic medicines company creating a new class of gene therapy utilizing its proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-viral</div> gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases. The Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-viral</div> gene therapy platform incorporates its high-capacity DNA construct called closed-ended DNA (&#8220;ceDNA&#8221;), its cell-targeted lipid nanoparticle delivery system (&#8220;ctLNP&#8221;) and its established, scalable capsid-free manufacturing process. Using its approach, the Company is developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of diseases. The Company is also engineering its gene therapies to be redosable, which may enable individualized patient titration to reach the desired therapeutic expression and to maintain efficacy throughout a patient&#8217;s life. The Company is headquartered in Cambridge, Massachusetts. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In June 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold</div>&#160;12,105,263<div style="display:inline;">&#160;shares of its common stock, including&#160;</div> 1,578,947<div style="display:inline;">&#160;shares&#160;</div> pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $19.00<div style="display:inline;">&#160;per share, resulting&#160;</div>in net proceeds of $210.7&#160;million, after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, all of the Company&#8217;s outstanding convertible preferred stock automatically converted into shares of common stock. In January 2021, the Company issued and sold 9,200,000 shares of our common stock, including 1,200,000 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> public offering, resulting in net proceeds of $211.3&#160;million after deducting underwriting discounts and commissions and other offering expenses. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations with proceeds from the sales of instruments convertible into convertible preferred stock (which converted into convertible preferred stock in 2017), the sale of convertible preferred stock, and most recently, with proceeds from the sale of common stock in underwritten public offerings. The Company has incurred recurring losses, including net losses of $80.5&#160;million for the year ended December&#160;31, 2020. As of December&#160;31, 2020, the Company had an accumulated deficit of $189.0&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;18, 2021, the issuance date of these consolidated financial statements, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements reflect the operations of the Company and the Company&#8217;s wholly owned subsidiary, Generation Bio Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825608792392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of estimates </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of credit risk and of significant suppliers </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&#8217;s marketable securities as of December&#160;31, 2020 consisted of U.S government treasury securities, commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to significant credit risk. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash equivalents </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Restricted cash </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities. These amounts are classified as restricted cash (current and noncurrent) on the Company&#8217;s consolidated balance sheets. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable securities </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s marketable securities, which consisted of debt securities as of December&#160;31, 2020, are classified <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as&#160;available-for-sale&#160;and</div></div> are reported at fair value. Unrealized gains and losses <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on&#160;available-for-sale&#160;debt</div></div> securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity (deficit). Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair value measurements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and financial liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 1px; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the&#160;short-term&#160;nature of these liabilities. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Deferred rent </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Property and equipment </div></div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:51%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:2%;"></td><td style="font-family: &quot;times new roman&quot;;;width:47%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td><td style="border-bottom: 1pt solid rgb(0, 0, 0); line-height: 10pt; font-size: 10pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: 10pt;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Estimated Useful Life</div></div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Laboratory equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">5 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Computer equipment and software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">3 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Furniture and fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">5 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Leasehold improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">Shorter of remaining life of lease or useful life</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs for capital assets not yet placed into service are capitalized as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">construction-in-progress</div></div> and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. </div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of long-lived assets </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 or 2019. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Classification and accretion of convertible preferred stock </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s convertible preferred stock outstanding prior to the IPO was classified outside of stockholders&#8217; equity (deficit) on the consolidated balance sheets because the holders of such shares had redemption rights in the event of a deemed liquidation that, in certain situations, was not solely within the control of the Company and would have required the redemption of the then-outstanding convertible preferred stock. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Segment information </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that its chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Company has concluded that it operates as one segment. All long-lived assets are located in the United States. </div></div>  <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and development costs </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upfront payments and milestone payments made for the licensing of technology with no alternative future use are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. </div></div>   <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and manufacturing contract costs and accruals </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and costs for research and development and manufacturing activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred. The Company records accruals for costs incurred but not billed. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </div></div></div>   <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Patent costs </div></div></div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </div></div>   <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock-based compensation </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company measures stock options with service-based vesting or performance-based vesting granted to employees, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards and units using the difference between the purchase price per share of the award or unit, if any, and the fair value of the Company&#8217;s common stock at the date of grant. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation expense for awards with service-based vesting is generally recognized over the vesting period of the award using the straight-line method to record the expense. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&#160;accounts for forfeitures of share-based awards as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Comprehensive loss </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2020 and 2019, the Company&#8217;s only element of other comprehensive loss was unrealized gains (losses) on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities. </div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income taxes </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;two-step&#160;process</div> to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">deemed&#160;more-likely-than-not&#160;to</div> be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&#160;The Company&#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had accrued no amounts for interest and penalties on its consolidated balance sheets at December&#160;31, 2020 and 2019. </div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Net loss per share </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to closing of the IPO, the Company followed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method when computing net income (loss) per share as the Company had issued shares that met the definition of participating securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reported a net loss attributable to common stockholders for each of the years ended December&#160;31, 2020 and 2019. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recently adopted accounting pronouncements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13,</div> Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement. The new standard added, modified or removed disclosure requirements under Topic 820 for clarity and consistency. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2019. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-03</div> on January&#160;1, 2020 and the adoption did not have a material impact on its consolidated financial statements. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recently issued accounting pronouncements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. In July 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11,</div> which provides entities with an additional transition method to adopt Topic 842. Under the new transition method, an entity initially applies the new lease requirements at the adoption date, not the earliest period presented, and recognizes a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2018 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019. In November 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10,</div> which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2020, and interim periods within fiscal years beginning after December&#160;15, 2021. In June 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-05,</div> which grants a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> effective-date delay for nonpublic entities to annual reporting periods beginning after December&#160;15, 2021 and to interim periods within fiscal years beginning after December&#160;15, 2022. Early adoption is allowed. The Company plans to adopt ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> and related amendments, on January&#160;1, 2021 using the modified retrospective approach transition method as of the date of adoption. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. Upon adoption of the new standard, the Company expects to recognize a lease liability and related right <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of-use</div> asset on the consolidated balance sheet of approximately $49.7&#160;million and $33.4&#160;million, respectively. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> Financial Instruments &#8211; Credit Losses (Topic 326). The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale.</div></div> The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2020. Early adoption was permitted for all entities. In November 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10,</div> which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those fiscal years. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">, </div>Income Taxes &#8211; Simplifying the Accounting for Income Taxes (Topic 740). The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles as well as clarifying and amending existing guidance to improve consistent application. For public entities, the guidance is effective for annual reporting periods beginning after December&#160;15, 2020 and for interim periods within those fiscal years. For nonpublic entities, the guidance is effective for annual reporting periods beginning after December&#160;15, 2021 and to interim periods within fiscal years beginning after December&#160;15, 2022. Early adoption is permitted for all entities. Depending on the amendment, adoption may be applied on the retrospective, modified retrospective or prospective basis. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825608714984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities And Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Marketable securities and fair value measurements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3. Marketable securities and fair value measurements </div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, marketable securities by security type consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Gross</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Gross</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Estimated</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Amortized</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Unrealized</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Unrealized</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Cost</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Gains</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Losses</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Value</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">U.S. treasury securities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">129,446</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">129,451</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Corporate debt securities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,542</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,546</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Totals</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">199,429</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">13</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(4</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">199,438</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company did not have marketable securities as of December&#160;31, 2019. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the Company&#8217;s assets that are measured at fair value on a recurring basis and their level within the fair value hierarchy, which is described further within Note&#160;2,<div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div>Summary of Significant Accounting Policies: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:59%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2020&#160;Using:</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash equivalents:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">63,827</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">63,827</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Marketable securities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">129,451</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">129,451</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Commercial paper</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17,546</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17,546</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Totals</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">63,827</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">199,438</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">263,265</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:16;">&#160;</td><td colspan="16" style="font-family: &quot;times new roman&quot;;;height:16;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2019&#160;Using:</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash equivalents:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Totals</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds were valued by the Company based on quoted market prices, which represent a Level&#160;1 measurement within the fair value hierarchy. Marketable securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level&#160;2 measurement within the fair value hierarchy. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531868568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4. Property and equipment, net </div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:74%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Laboratory equipment</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,313</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,029</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">848</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">740</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and fixtures</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">826</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">826</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17,374</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">12,993</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Construction in progress</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,082</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,487</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">29,443</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">24,075</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less: Accumulated depreciation and amortization</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(5,662</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,230</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">23,781</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">21,845</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019 was $3.4&#160;million and $1.9&#160;million, respectively. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531639592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5. Accrued expenses </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued employee compensation and benefits</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6,150</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,255</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued external research and development expenses</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,772</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,344</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued professional fees</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">940</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">619</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,389</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,370</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">702</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">319</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">10,953</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6,907</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531753560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6. Convertible preferred stock </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, the Company had issued Series A convertible preferred stock (the &#8220;Series A&#8221;), Series B convertible preferred stock (the &#8220;Series B&#8221;) and Series C convertible preferred stock (the &#8220;Series C&#8221;). Collectively the Series A, Series B and Series C are referred to as the Preferred Stock. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;9, 2020, the Company issued and sold 19,936,296 shares of Series C at a price of $5.5914 per share for gross proceeds of $111.5&#160;million. The Company incurred issuance costs in connection with this transaction of $2.6&#160;million. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon issuance of each class of Preferred Stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of Preferred Stock. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the IPO in June 2020, the Company&#8217;s Preferred Stock automatically converted into 27,094,085 shares of common stock. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531639592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7. Equity </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company&#8217;s restated certificate of incorporation authorizes the Company to issue 150,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000&#160;shares of preferred stock, par value $0.0001 per share, all of which preferred stock is undesignated. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Holders of common stock are not entitled to receive dividends, unless declared by the board of directors. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531716872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8. Stock-based compensation </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s 2017 Stock Incentive Plan (the &#8220;2017 Plan&#8221;) provided for the Company to grant incentive or nonstatutory stock options, restricted stock, restricted stock units and other equity awards to employees, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> and directors of the Company. In January 2020, the number of shares of common stock authorized for issuance under the 2017 Plan was increased from 8,407,405&#160;shares to 10,275,717&#160;shares. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020 the Company&#8217;s board of directors adopted, and in June 2020 the Company&#8217;s stockholders approved, the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221; and, together with the 2017 Plan the &#8220;Plans&#8221;), which became effective on June&#160;11, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. Upon effectiveness of the 2020 Plan, the number of shares of common stock reserved for issuance under the 2020 Plan was the sum of (1) 2,547,698 shares; plus (2)&#160;the number of shares (up to a maximum of 7,173,014 shares) as was equal to the sum of (x)&#160;the number of shares of common stock reserved for issuance under the 2017 Plan that remained available for grant under the 2017 Plan on June&#160;11, 2020 and (y)&#160;the number of shares of common stock subject to outstanding awards granted under the 2017 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3)&#160;an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December&#160;31, 2021 and continuing until, and including, the fiscal year ending December&#160;31, 2030, equal to the lesser of (i) 4% of the number of shares of common stock outstanding on such date, and (ii)&#160;an amount determined by the board of directors. Upon the effectiveness of the 2020 Plan, the Company ceased granting additional awards under the 2017 Plan. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Plans are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions on any award under the Plans are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted under the Plans with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock as of the date of grant. Prior to the Company&#8217;s IPO, fair value of common stock was determined by the board of directors. Subsequent to the IPO, fair value of common stock is based on quoted market prices. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, 2,500,761 shares remained available for future issuance under the 2020 Plan. Shares subject to outstanding awards granted under the Plans that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be available for future awards under the 2020 Plan. The number of authorized shares reserved for issuance under the 2020 Plan was increased by 1,878,800 shares effective as of January&#160;1, 2021 in accordance with the provisions of the 2020 Plan described above. </div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Employee stock purchase plan </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020 the Company&#8217;s board of directors adopted, and in June 2020 the Company&#8217;s stockholders approved, the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;), which became effective June&#160;11, 2020. The 2020 ESPP will be administered by the Company&#8217;s board of directors or by a committee appointed by the board of directors. The 2020 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 481,231 shares of common stock. The number of shares of common stock reserved for issuance under the 2020 ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January&#160;1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January&#160;1, 2030, in an amount equal to the lowest of (1) 1,302,157 shares of common stock, (2) 1% of the number of shares of common stock outstanding on such date, and (3)&#160;an amount determined by the board of directors. As of December&#160;31, 2020, no offering periods had commenced under the 2020 ESPP and 481,231 shares were available for issuance. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 469,700 shares effective as of January&#160;1, 2021 in accordance with the provisions of the 2020 ESPP described above. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock option valuation </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company completed its IPO in 2020 and, accordingly, lacks company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&#8217;s stock options was determined utilizing the &#8220;simplified&#8221; method for awards that qualified as &#8220;plain-vanilla&#8221; options. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.60</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">77.30</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">75.7</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected dividend yield</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s stock option activity since December&#160;31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:61%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Average</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Average</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Aggregate</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Number</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Exercise</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Contractual</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Intrinsic</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">of Shares</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Price</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Term</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Value</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in years)</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,373,884</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.76</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.79</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,492</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,090,315</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">13.40</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(792,845</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.49</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(429,584</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4.73</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,241,770</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.89</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.69</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">99,467</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest as of December&#160;31, 2020</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,585,120</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">10.57</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">8.63</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">84,238</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Options exercisable as of December&#160;31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,108,099</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.54</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.68</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26,388</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had strike prices lower than the fair value of the Company&#8217;s common stock. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant-date fair value of awards granted during the years ended December&#160;31, 2020 and 2019 was $10.41 per share and $4.46 per share, respectively. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2020 and 2019 was $20.0&#160;million and $0.1&#160;million, respectively. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Restricted common stock units </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, the Company issued 26,242 restricted stock units with a fair value of $0.5&#160;million. The Company did not issue restricted stock units in the year ended December&#160;31, 2019. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Restricted common stock </div></div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s restricted common stock activity since December&#160;31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:66%;"></td><td style="vertical-align:bottom;;width:10%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Shares</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date&#160;Fair&#160;Value</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Unvested restricted common stock as of December&#160;31, 2019</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,705,188</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.22</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,022,234</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.17</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(4,819</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1.95</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Unvested restricted common stock as of December&#160;31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">678,135</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.28</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total fair value of restricted common stock vested during the years ended December&#160;31, 2020 and 2019 was approximately $15.8&#160;million and $7.0&#160;million, respectively. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records compensation cost for all share-based payment arrangements, including employee, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> and director stock options and restricted common stock. The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:82%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenses</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,301</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,753</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,111</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,454</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,412</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,207</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, total unrecognized compensation cost related to unvested stock-based awards was $27.1&#160;million, which is expected to be recognized over a weighted average period of 3.2&#160;years. Additionally, as of December&#160;31, 2020, the Company has unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable of $2.2&#160;million. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535880008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9. Income taxes </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to the uncertainty of realizing a benefit from those items. All of the Company&#8217;s operating losses since inception have been generated in the United States. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:75%;"></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:8%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal statutory income tax rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(21.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)%&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(21.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income taxes, net of federal benefit</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(7.0</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(5.9</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal and state research and development tax credits</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4.2</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(5.1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(2.6</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1.0</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.2</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in deferred tax asset valuation allowance</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">34.8</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">30.8</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Effective income tax rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets as of December&#160;31, 2020 and 2019 consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:72%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred tax assets:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">48,280</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">25,023</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development tax credit carryforwards</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,385</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,998</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,456</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,740</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,747</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,469</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">64,868</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">37,230</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred tax liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3,900</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(4,117</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total deferred tax liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(3,900</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,117</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(60,968</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(33,113</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net deferred tax assets</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company had federal net operating loss carryforwards of $177.3&#160;million, which may be available to offset future taxable income, of which $8.2&#160;million of the total net operating loss carryforwards expire at various dates beginning in 2036, while the remaining $169.1&#160;million do not expire but may be limited in their usage to an annual deduction equal to 80% of annual taxable income. As of December&#160;31, 2020, the Company had state net operating loss carryforwards of $174.7&#160;million, which may be available to offset future taxable income and expire at various dates beginning in 2036. In addition, as of December&#160;31, 2020, the Company also had federal and state research and development tax credit carryforwards of $6.3&#160;million and $3.9&#160;million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2036 and 2032, respectively. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 and Section&#160;383 of the Internal Revenue Code of 1986 as amended (the &#8220;Code&#8221;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">long-term&#160;tax-exempt&#160;rate,</div> and then could be subject to additional adjustments. Any limitation may result in expiration of a&#160;portion of the net operating loss carryforwards or research and development tax credit carryforwards before their utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets, which consist primarily of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of federal and state net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&#160;31, 2020 and 2019. The Company reevaluates the positive and negative evidence at each reporting period. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the valuation allowance for deferred tax assets during the year ended December&#160;31, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance for 2020 and 2019 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:74%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Valuation allowance as of beginning of year</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">33,113</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,246</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases recorded to income tax provision</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27,855</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">18,867</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Valuation allowance as of end of year</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60,968</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">33,113</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;more-likely-than-not&#160;threshold,</div> the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. No reserve for uncertain tax positions or related interest and penalties has been recorded at December&#160;31, 2020 and 2019. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2017 to the present. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law making several changes to the Code. The changes include, but are not limited to, increasing the limitation on the amount of deductible interest expense, allowing companies to carryback certain net operating losses, and increasing the amount of net operating loss carryforwards that corporations can use to offset taxable income. The tax law changes in the CARES Act did not have a material impact on the Company&#8217;s income tax provision. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531793960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LicenseAgreementsDisclosureAbstract', window );"><strong>License Agreements Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LicenseAgreementsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10. License agreements </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">NIH </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has an agreement with the U.S. Department of Health and Human Services, as represented by The National Heart, Lung, and Blood Institute, an Institute of the National Institutes of Health (&#8220;NIH&#8221;), entered into in 2017, pursuant to which NIH granted the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license, with the right to grant sublicenses,<br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;">under certain NIH intellectual property related to the Company&#8217;s ceDNA construct. In July 2019, the agreement was amended to include Association Institut de Myologie, Universite Pierre et Marie Curie, Centre National de la Recherche Scientifique, and Inserm Transfert SA, collectively referred to as the French Institutions, as a licensor. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is obligated to make future milestone payments of up to $0.4&#160;million per licensed product upon the achievement of specified milestones as well as royalties on a&#160;licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country&#160;basis</div></div> of a low single&#160;digit percentage of annual net sales of licensed products. The Company is obligated to pay a high single-digit royalty percentage of all sublicensing income. The royalties on net sales may be reduced by up to 25% in certain circumstances as defined in the agreement. The Company&#8217;s royalty obligation expires on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">licensed&#160;product-by-licensed&#160;product</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country&#160;basis</div></div> upon the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> licensed intellectual property rights in such country. Additionally, the Company is required to reimburse the French Institutions for a portion of certain past and ongoing patent related expenses related to the licensed technology. The agreement requires the Company to use reasonable commercial efforts to meet certain performance milestones and execute a commercial development plan within specified timeframes. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless terminated earlier, the agreement remains in effect until the last to expire of the licensed patent rights on a&#160;licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country&#160;basis.</div></div> NIH and the French Institutions may terminate the agreement if the Company fails to perform its material obligations, including but not limited to its failure to meet the applicable performance milestones despite using commercially reasonable efforts, and has not remediated such deficiency within a specified time period. NIH and the French Institutions can terminate the agreement in the event the Company becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, or determines to file a petition in bankruptcy. In addition, NIH and the French Institutions may terminate the agreement in the event of a material breach by the Company and failure to cure such breach within a certain period of time. The Company is currently in compliance with the terms of the agreement. The Company can voluntarily terminate the agreement with prior notice to NIH and the French Institutions. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During each of the years ended December&#160;31, 2020 and 2019, the Company recorded research and development expense of less than $0.1&#160;million under this agreement. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">UMass </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an agreement with the University of Massachusetts as represented by and solely on behalf of its Medical School (&#8220;UMass&#8221;), entered into in 2017, pursuant to which UMass granted the Company an exclusive license, with the right to grant sublicenses, under the UMass intellectual property related to the Company&#8217;s ceDNA construct. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is obligated to make future milestone payments of up to $0.8&#160;million per licensed product upon the achievement of specified milestones as well as royalties on a&#160;licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country&#160;basis</div></div> of a low single&#160;digit percentage of annual net sales of licensed products, subject to annual minimum royalties as defined in the agreement. Additionally, the Company has agreed to pay a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> single-digit royalty percentage of all sublicensing income, which will vary depending on when the sublicense agreement to a third party was executed. The milestone payments are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> and </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-creditable</div> against any other payments due to UMass under the agreement. The Company&#8217;s royalty obligation expires on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">licensed&#160;product-by-licensed&#160;product</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country&#160;basis</div></div> upon the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> licensed intellectual property rights in such country. The agreement requires the Company to use diligent efforts to meet certain performance milestones within specified timeframes. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As part of the arrangement, the Company agreed to issue 125,677 shares of its common stock to UMass. The Company recorded $0.1&#160;million as research and development expense and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">additional-paid-in</div> capital at the time of the agreement in 2017, representing the fair value of the common stock at that time. The shares were issued in August 2019. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless terminated earlier, the agreement will continue until the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> valid claim of the licensed patents. UMass may terminate the agreement if the Company fails to perform its material obligations, including but not limited to its failure to meet the applicable performance milestones despite using commercially reasonable efforts, and has not remediated such deficiency within a specified time period or negotiated a revised performance timeline. UMass can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event of a material breach by the Company and failure to cure such breach within a certain period of time. The Company is currently in compliance with the terms of the agreement. The Company can voluntarily terminate the agreement with prior notice to UMass. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During each of the years ended December&#160;31, 2020 and 2019, the Company recorded research and development expense of less than $0.1&#160;million under this agreement. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Other license agreements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has other license agreements under which it may become subject to future additional fees and milestone payments. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_LicenseAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_LicenseAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_LicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreements Disclosure [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_LicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535905336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11. Commitments and contingencies </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases its office and laboratory space under a noncancelable operating lease that was entered into in August 2018, as amended in July 2019, and expires in 2029. The Company has an option to extend for one additional term of five years at the greater of the then-current base rent, or the then-current fair market value. The lease agreement includes provisions for a free-rent period and annual rent increases, which are accrued or deferred as appropriate such that rent expense for the lease is recognized on a&#160;straight-line&#160;basis over the lease term (see Note&#160;2). The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The lease provides for a tenant improvement allowance, at the cost of the lessor, not to exceed $14.7&#160;million. Costs incurred by the Company for tenant improvements but not yet reimbursed by the landlord are presented on the accompanying consolidated balance sheets as tenant receivable. The Company posted a customary letter of credit in the amount of approximately $2.1&#160;million as a security deposit.&#160;The letter of credit is subject to increase if the Company were to sublease any portion of the leased premises. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Previously, the Company leased its office and laboratory space under noncancelable operating leases that expired during 2019. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rent expense for the years ended December&#160;31, 2020 and 2019 was $7.5&#160;million and $7.9&#160;million, respectively. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum lease payments as of December&#160;31, 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;; width: 88%;"></td><td style="font-family: &quot;times new roman&quot;; width: 3%;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 0.5%;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%;"></td><td style="font-family: &quot;times new roman&quot;; width: 0.5%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">7,053</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;">7,251</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2023</div></div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">7,441</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;">7,679</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2025</div></div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">7,881</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;">27,570</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 88%;;vertical-align:bottom;">&#160;</td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.5%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 8%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">64,875</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 88%;;vertical-align:bottom;">&#160;</td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.5%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 8%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">401(k) Plan </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has a defined-contribution plan under Section&#160;401(k) of the Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;pre-tax&#160;basis.</div> In September 2020, the Company adopted a match program<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">beginning on January 1, 2021,</div> for employee contributions to the 401(k) Plan up to a maximum of four percent of the employee&#8217;s salary, subject to the maximums established under the Code. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Indemnification agreements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Legal proceedings </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December&#160;31, 2020 and 2019. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535775880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12. Net loss per share </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Net loss per share </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:69%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,961,027</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">678,135</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,705,188</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Unvested restricted common stock units</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">19,681</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options to purchase common stock</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5,241,770</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,373,884</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,939,586</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">20,040,099</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531887496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information [Text Block]</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13. Selected Quarterly Financial Data (Unaudited) </div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following information has been derived from unaudited consolidated financial statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:30%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Dec. 31,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Sept. 30,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Dec. 31,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Sept. 30,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="30" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands, except per share)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating expenses</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">24,345</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">20,969</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,764</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">18,036</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,158</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,333</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,335</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,476</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(24,345</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(20,969</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(17,764</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(18,036</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(16,158</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(16,333</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(15,335</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(14,476</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(24,226</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(20,849</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,731</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,717</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(16,063</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(16,128</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(15,032</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(14,094</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, basic and diluted</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(0.53</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(0.46</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(1.50</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.22</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.09</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.31</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.30</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.29</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530109336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of estimates </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk and of significant suppliers</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of credit risk and of significant suppliers </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&#8217;s marketable securities as of December&#160;31, 2020 consisted of U.S government treasury securities, commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to significant credit risk. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash equivalents </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with a remaining maturity when purchased of three months or less to be cash equivalents. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_RestrictedcashpolicytextblockPolicyTextBlock', window );">Restricted cash</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Restricted cash </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities. These amounts are classified as restricted cash (current and noncurrent) on the Company&#8217;s consolidated balance sheets. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable securities </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s marketable securities, which consisted of debt securities as of December&#160;31, 2020, are classified <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as&#160;available-for-sale&#160;and</div></div> are reported at fair value. Unrealized gains and losses <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on&#160;available-for-sale&#160;debt</div></div> securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity (deficit). Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair value measurements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and financial liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 1px; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the&#160;short-term&#160;nature of these liabilities. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_DeferredrentpolicytextblockPolicyTextBlock', window );">Deferred rent</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Deferred rent </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Property and equipment </div></div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:51%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:2%;"></td><td style="font-family: &quot;times new roman&quot;;;width:47%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td><td style="border-bottom: 1pt solid rgb(0, 0, 0); line-height: 10pt; font-size: 10pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: 10pt;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Estimated Useful Life</div></div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Laboratory equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">5 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Computer equipment and software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">3 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Furniture and fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">5 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Leasehold improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">Shorter of remaining life of lease or useful life</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs for capital assets not yet placed into service are capitalized as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">construction-in-progress</div></div> and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of long-lived assets </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 or 2019. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock', window );">Classification and accretion of convertible preferred stock</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Classification and accretion of convertible preferred stock </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s convertible preferred stock outstanding prior to the IPO was classified outside of stockholders&#8217; equity (deficit) on the consolidated balance sheets because the holders of such shares had redemption rights in the event of a deemed liquidation that, in certain situations, was not solely within the control of the Company and would have required the redemption of the then-outstanding convertible preferred stock. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Segment information </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that its chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Company has concluded that it operates as one segment. All long-lived assets are located in the United States. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and development costs </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upfront payments and milestone payments made for the licensing of technology with no alternative future use are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock', window );">Research and manufacturing contract costs and accruals</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and manufacturing contract costs and accruals </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and costs for research and development and manufacturing activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred. The Company records accruals for costs incurred but not billed. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </div></div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_PatentcostpolicytextblockPolicyTextBlock', window );">Patent costs</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Patent costs </div></div></div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock-based compensation </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company measures stock options with service-based vesting or performance-based vesting granted to employees, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards and units using the difference between the purchase price per share of the award or unit, if any, and the fair value of the Company&#8217;s common stock at the date of grant. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation expense for awards with service-based vesting is generally recognized over the vesting period of the award using the straight-line method to record the expense. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&#160;accounts for forfeitures of share-based awards as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Comprehensive loss </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2020 and 2019, the Company&#8217;s only element of other comprehensive loss was unrealized gains (losses) on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income taxes </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;two-step&#160;process</div> to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">deemed&#160;more-likely-than-not&#160;to</div> be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&#160;The Company&#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had accrued no amounts for interest and penalties on its consolidated balance sheets at December&#160;31, 2020 and 2019. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Net loss per share </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to closing of the IPO, the Company followed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method when computing net income (loss) per share as the Company had issued shares that met the definition of participating securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reported a net loss attributable to common stockholders for each of the years ended December&#160;31, 2020 and 2019. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recently adopted accounting pronouncements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13,</div> Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement. The new standard added, modified or removed disclosure requirements under Topic 820 for clarity and consistency. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2019. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-03</div> on January&#160;1, 2020 and the adoption did not have a material impact on its consolidated financial statements. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recently issued accounting pronouncements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. In July 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11,</div> which provides entities with an additional transition method to adopt Topic 842. Under the new transition method, an entity initially applies the new lease requirements at the adoption date, not the earliest period presented, and recognizes a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2018 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019. In November 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10,</div> which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2020, and interim periods within fiscal years beginning after December&#160;15, 2021. In June 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-05,</div> which grants a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> effective-date delay for nonpublic entities to annual reporting periods beginning after December&#160;15, 2021 and to interim periods within fiscal years beginning after December&#160;15, 2022. Early adoption is allowed. The Company plans to adopt ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> and related amendments, on January&#160;1, 2021 using the modified retrospective approach transition method as of the date of adoption. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. Upon adoption of the new standard, the Company expects to recognize a lease liability and related right <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of-use</div> asset on the consolidated balance sheet of approximately $49.7&#160;million and $33.4&#160;million, respectively. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> Financial Instruments &#8211; Credit Losses (Topic 326). The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale.</div></div> The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2020. Early adoption was permitted for all entities. In November 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10,</div> which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those fiscal years. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">, </div>Income Taxes &#8211; Simplifying the Accounting for Income Taxes (Topic 740). The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles as well as clarifying and amending existing guidance to improve consistent application. For public entities, the guidance is effective for annual reporting periods beginning after December&#160;15, 2020 and for interim periods within those fiscal years. For nonpublic entities, the guidance is effective for annual reporting periods beginning after December&#160;15, 2021 and to interim periods within fiscal years beginning after December&#160;15, 2022. Early adoption is permitted for all entities. Depending on the amendment, adoption may be applied on the retrospective, modified retrospective or prospective basis. The Company is currently evaluating when to adopt the guidance and the impact the guidance will have on its consolidated financial statements. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ClassificationAndAccretionOfConvertiblePreferredStockPolicyTextBlock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_ClassificationandaccretionofconvertiblepreferredstockpolicytextblockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ComprehensiveLossPolicyPolicyTextBlock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_ComprehensivelosspolicypolicytextblockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_DeferredrentpolicytextblockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>DeferredRentPolicyTextBlock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_DeferredrentpolicytextblockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_PatentcostpolicytextblockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PatentCostPolicyTextBlock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_PatentcostpolicytextblockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_ResearchandmanufacturingcontractcostsandaccrualspolicytextblockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_RestrictedcashpolicytextblockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>RestrictedCashPolicyTextBlock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_RestrictedcashpolicytextblockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531666024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock', window );">Summary of Property and equipment</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:51%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:2%;"></td><td style="font-family: &quot;times new roman&quot;;;width:47%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-bottom: 1pt; line-height: 10pt; font-size: 10pt;;vertical-align:bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td><td style="border-bottom: 1pt solid rgb(0, 0, 0); line-height: 10pt; font-size: 10pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: 10pt;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Estimated Useful Life</div></div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Laboratory equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">5 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Computer equipment and software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">3 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Furniture and fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">5 years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Leasehold improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:top;">Shorter of remaining life of lease or useful life</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_PropertyplantandequipmentestimatedusefullifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530404520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities And Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of marketable securities</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, marketable securities by security type consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Gross</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Gross</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Estimated</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Amortized</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Unrealized</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Unrealized</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Cost</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Gains</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Losses</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Value</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">U.S. treasury securities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">129,446</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">129,451</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Corporate debt securities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,542</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,546</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Totals</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">199,429</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">13</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(4</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">199,438</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the Company&#8217;s assets that are measured at fair value on a recurring basis and their level within the fair value hierarchy, which is described further within Note&#160;2,<div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div>Summary of Significant Accounting Policies: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:59%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2020&#160;Using:</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash equivalents:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">63,827</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">63,827</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Marketable securities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">129,451</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">129,451</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Commercial paper</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">52,441</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17,546</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17,546</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Totals</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">63,827</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">199,438</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">263,265</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:16;">&#160;</td><td colspan="16" style="font-family: &quot;times new roman&quot;;;height:16;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2019&#160;Using:</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash equivalents:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Totals</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,076</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531639592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and equipment, net</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:74%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Laboratory equipment</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,313</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,029</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">848</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">740</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and fixtures</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">826</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">826</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17,374</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">12,993</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Construction in progress</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,082</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,487</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">29,443</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">24,075</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less: Accumulated depreciation and amortization</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(5,662</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,230</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">23,781</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">21,845</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535746888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued expenses and other current liabilities</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued employee compensation and benefits</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6,150</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,255</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued external research and development expenses</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,772</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,344</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued professional fees</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">940</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">619</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,389</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,370</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">702</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">319</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:top;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">10,953</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6,907</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535313976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Summary of Inputs Used in Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.60</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">77.30</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">75.7</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected dividend yield</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarizes the Company's stock option activity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s stock option activity since December&#160;31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:61%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Average</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Average</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Aggregate</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Number</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Exercise</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Contractual</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Intrinsic</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">of Shares</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Price</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Term</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Value</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in years)</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding as of December&#160;31, 2019</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,373,884</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.76</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.79</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,492</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,090,315</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">13.40</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(792,845</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.49</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(429,584</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4.73</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding as of December&#160;31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,241,770</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.89</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.69</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">99,467</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest as of December&#160;31, 2020</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,585,120</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">10.57</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">8.63</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">84,238</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Options exercisable as of December&#160;31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,108,099</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.54</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.68</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26,388</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">summarizes the Company's restricted common stock activity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s restricted common stock activity since December&#160;31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:66%;"></td><td style="vertical-align:bottom;;width:10%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Shares</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date&#160;Fair&#160;Value</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Unvested restricted common stock as of December&#160;31, 2019</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,705,188</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.22</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,022,234</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.17</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(4,819</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1.95</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Unvested restricted common stock as of December&#160;31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">678,135</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.28</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock-based compensation expense was classified in the statements of operations and comprehensive loss</a></td>
<td class="text">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:82%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenses</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,301</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,753</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,111</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,454</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,412</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,207</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531786520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of reconciliation of the U.S. federal statutory income tax rate</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:75%;"></td><td style="vertical-align:bottom;;width:9%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:8%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal statutory income tax rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(21.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)%&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(21.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income taxes, net of federal benefit</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(7.0</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(5.9</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal and state research and development tax credits</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4.2</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(5.1</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(2.6</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1.0</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.2</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in deferred tax asset valuation allowance</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">34.8</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">30.8</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Effective income tax rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Net deferred tax assets</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets as of December&#160;31, 2020 and 2019 consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:72%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred tax assets:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">48,280</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">25,023</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development tax credit carryforwards</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,385</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,998</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,456</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,740</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,747</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,469</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">64,868</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">37,230</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred tax liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3,900</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(4,117</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total deferred tax liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(3,900</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,117</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(60,968</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(33,113</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net deferred tax assets</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of changes in the valuation allowance for deferred tax assets</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the valuation allowance for deferred tax assets during the year ended December&#160;31, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance for 2020 and 2019 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:74%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Valuation allowance as of beginning of year</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">33,113</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,246</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases recorded to income tax provision</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27,855</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">18,867</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Valuation allowance as of end of year</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60,968</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">33,113</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535854264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of future minimum lease payments</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum lease payments as of December&#160;31, 2020 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;; width: 88%;"></td><td style="font-family: &quot;times new roman&quot;; width: 3%;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 0.5%;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%;"></td><td style="font-family: &quot;times new roman&quot;; width: 0.5%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">7,053</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;">7,251</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2023</div></div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">7,441</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;">7,679</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2025</div></div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">7,881</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 88%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; width: 8%;;text-align:right;;vertical-align:bottom;">27,570</td><td style="white-space: nowrap; width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 88%;;vertical-align:bottom;">&#160;</td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.5%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 8%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 88%;;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">64,875</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 88%;;vertical-align:bottom;">&#160;</td><td style="width: 3%;;vertical-align:bottom;">&#160;&#160;</td><td style="width: 0.5%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 8%;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="width: 0.5%;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535746888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of potential dilutive securities, presented based on amounts outstanding</a></td>
<td class="text">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:69%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:3%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160; </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,961,027</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">678,135</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,705,188</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Unvested restricted common stock units</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">19,681</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options to purchase common stock</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5,241,770</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,373,884</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,939,586</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">20,040,099</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825708298120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock', window );">Summary of information has been derived from unaudited consolidated financial statements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following information has been derived from unaudited consolidated financial statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:30%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Dec. 31,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Sept. 30,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Dec. 31,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Sept. 30,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2019</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="30" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(in thousands, except per share)</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating expenses</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">24,345</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">20,969</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,764</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">18,036</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,158</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,333</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,335</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,476</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(24,345</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(20,969</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(17,764</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(18,036</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(16,158</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(16,333</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(15,335</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(14,476</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(24,226</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(20,849</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,731</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,717</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(16,063</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(16,128</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(15,032</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(14,094</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, basic and diluted</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(0.53</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(0.46</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(1.50</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.22</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.09</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.31</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.30</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(3.29</td><td style="white-space: nowrap;;vertical-align:bottom;">)</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of information has been derived from unaudited consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_SummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825525153704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 21,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,226)<span></span>
</td>
<td class="num">$ (20,849)<span></span>
</td>
<td class="num">$ (17,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,717)<span></span>
</td>
<td class="num">$ (16,063)<span></span>
</td>
<td class="num">$ (16,128)<span></span>
</td>
<td class="num">$ (15,032)<span></span>
</td>
<td class="num">$ (14,094)<span></span>
</td>
<td class="num">$ (80,523)<span></span>
</td>
<td class="num">$ (61,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Used in BS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (188,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (108,452)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (188,975)<span></span>
</td>
<td class="num">$ (108,452)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 211,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,578,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Over-Allotment Option [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825527721464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary Of Property And Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment And Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, Useful life</a></td>
<td class="text">Shorter of remaining life of lease or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825531806024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Income Tax rate settlement</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 49.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 33.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Line Items] .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825525054856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities And Fair Value Measurements   - Summary of marketable securities (Detail) - Fair Value, Recurring [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 199,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">199,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">129,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">129,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">52,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">52,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">17,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 17,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825524793080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities And Fair Value Measurements  - Summary of assets measured at fair value on a recurring basis (Detail) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 199,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Totals</a></td>
<td class="nump">263,265<span></span>
</td>
<td class="nump">$ 15,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Totals</a></td>
<td class="nump">63,827<span></span>
</td>
<td class="nump">15,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Totals</a></td>
<td class="nump">199,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">63,827<span></span>
</td>
<td class="nump">15,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">63,827<span></span>
</td>
<td class="nump">$ 15,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">129,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">129,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">52,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">52,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">17,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 17,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825527740296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 29,443<span></span>
</td>
<td class="nump">$ 24,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(5,662)<span></span>
</td>
<td class="num">(2,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">23,781<span></span>
</td>
<td class="nump">21,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">9,313<span></span>
</td>
<td class="nump">5,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">17,374<span></span>
</td>
<td class="nump">12,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 1,082<span></span>
</td>
<td class="nump">$ 4,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gbio_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530267960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3,432<span></span>
</td>
<td class="nump">$ 1,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825617431048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_AccruedExpensesLineItems', window );"><strong>Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 6,150<span></span>
</td>
<td class="nump">$ 3,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent', window );">Accrued external research and development expenses</a></td>
<td class="nump">1,772<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 10,953<span></span>
</td>
<td class="nump">$ 6,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_AccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_AccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_AccruedExternalResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825527967944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,094,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gbio_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="nump">19,936,296<span></span>
</td>
<td class="nump">19,936,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price</a></td>
<td class="nump">$ 5.5914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="nump">$ 111,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_StockIssuanceCosts', window );">Stock issuance of costs</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from the issuance and sale of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock, before stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_GrossProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gbio_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gbio_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535544600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">46,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825524106072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based compenation by share based payment arrangement number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,090,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognised stock compensation on account of unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognised stock compensation on account of unvested options remaining period over which the compensation is to be recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">weighted average grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">weighted average grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.41<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">No of Instrinic stock option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember', window );">Unvested Stock Awards for Which Performance is not Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognised stock compensation on account of unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gbio_ServiceBasedOptionsMember', window );">Service Based Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share based compenation by share based payment arrangement number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,242<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">fair value of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gbio_TwoThousandAndTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock reserved for future issuance</a></td>
<td class="nump">2,547,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Stock based compensation vesting period service based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock based compensation period of expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gbio_TwoThousandAndTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan | Maximum | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,878,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gbio_TwoThousandAndTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan | Maximum | Additional From 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock reserved for future issuance</a></td>
<td class="nump">7,173,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gbio_TwoThousandAndTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan | Maximum | Annual Increase 2021 To 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage', window );">Percentage of common stock shares additionally reserved for issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember', window );">Employee Stock Purchase Plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based compensation by share based payment arrangement number of shares authorized for issuance</a></td>
<td class="nump">481,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember', window );">Employee Stock Purchase Plan 2020 | Maximum | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember', window );">Employee Stock Purchase Plan 2020 | Maximum | Annual Increase 2021 To 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage', window );">Percentage of common stock shares additionally reserved for issuance</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of share instruments newly issued under a share-based compensation plan</a></td>
<td class="nump">1,302,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | 2017 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based compensation by share based payment arrangement number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,407,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,275,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement, as a percentage of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gbio_UnvestedStockAwardsForWhichPerformanceIsNotProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gbio_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gbio_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gbio_TwoThousandAndTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gbio_TwoThousandAndTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_DateAxis=gbio_AdditionalFrom2017PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_DateAxis=gbio_AdditionalFrom2017PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_DateAxis=gbio_AnnualIncrease2021To2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_DateAxis=gbio_AnnualIncrease2021To2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gbio_EmployeeStockPurchasePlanTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gbio_TwoThousandAndSeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gbio_TwoThousandAndSeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535435144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Summary of Inputs Used in Black-Scholes Option Pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.30%<span></span>
</td>
<td class="nump">75.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825524755224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Summarizes the Company's Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares Outstanding , Beginning</a></td>
<td class="nump">3,373,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares | Granted</a></td>
<td class="nump">3,090,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares | Exercised</a></td>
<td class="num">(792,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares | Forfeited</a></td>
<td class="num">(429,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares Outstanding , Ending</a></td>
<td class="nump">5,241,770<span></span>
</td>
<td class="nump">3,373,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of shares | Vested and expected to vest</a></td>
<td class="nump">4,585,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares | Options exercisable</a></td>
<td class="nump">1,108,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Outstanding , Beginning</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price | Granted</a></td>
<td class="nump">13.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price | Exercised</a></td>
<td class="nump">4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price | Forfeited</a></td>
<td class="nump">4.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Outstanding , Ending</a></td>
<td class="nump">9.89<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price | Vested and expected to vest</a></td>
<td class="nump">10.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price | Options exercisable</a></td>
<td class="nump">$ 4.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term (in years) Outstanding</a></td>
<td class="text">8 years 8 months 8 days<span></span>
</td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term (in years) | Vested and expected to vest</a></td>
<td class="text">8 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term (in years) | Options exercisable</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value (in thousands) Outstanding</a></td>
<td class="nump">$ 99,467<span></span>
</td>
<td class="nump">$ 8,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value (in thousands) | Vested and expected to vest</a></td>
<td class="nump">84,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value (in thousands) | Options exercisable</a></td>
<td class="nump">$ 26,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825528866072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Summarizes the Company's Restricted Common Stock Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested restricted common stock, Beginning | Shares | shares</a></td>
<td class="nump">1,705,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested | Shares | shares</a></td>
<td class="num">(1,022,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited | Shares | shares</a></td>
<td class="num">(4,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested restricted common stock, Ending | Shares | shares</a></td>
<td class="nump">678,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of Unvested restricted common stock, Beginning | $ / shares | $ / shares</a></td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of Unvested restricted common stock, Vested | $ / shares | $ / shares</a></td>
<td class="nump">1.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of Unvested restricted common stock, Forfeited | $ / shares | $ / shares</a></td>
<td class="nump">1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of Unvested restricted common stock, Ending | $ / shares | $ / shares</a></td>
<td class="nump">$ 1.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825528834840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense was Classified in the Statements of Operations and Comprehensive Loss (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,412<span></span>
</td>
<td class="nump">$ 4,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">2,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,111<span></span>
</td>
<td class="nump">$ 1,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825525220280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_IncometaxLineItems', window );"><strong>IncomeTax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 169,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_PercentageOnAnnualTaxableIncome', window );">Percentage on annual taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_PercentageOfChangeInOwnership', window );">Percentage of change in ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate', window );">Unrecognized Tax Benefits of income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_TaxCreditCarryforwardExpirationYear', window );">Tax Credit Carry forward, Expiration Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_OperatingLossCarryforwardsExpirationYear', window );">Operating Loss Carry forwards, Expiration Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total net operations loss</a></td>
<td class="nump">24,345<span></span>
</td>
<td class="nump">$ 20,969<span></span>
</td>
<td class="nump">$ 17,764<span></span>
</td>
<td class="nump">$ 18,036<span></span>
</td>
<td class="nump">$ 16,158<span></span>
</td>
<td class="nump">$ 16,333<span></span>
</td>
<td class="nump">$ 15,335<span></span>
</td>
<td class="nump">$ 14,476<span></span>
</td>
<td class="nump">$ 81,114<span></span>
</td>
<td class="nump">$ 62,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=gbio_FederalIncomeTaxAuthorityMember', window );">Federal income tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_IncometaxLineItems', window );"><strong>IncomeTax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">177,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_IncometaxLineItems', window );"><strong>IncomeTax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">174,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember', window );">Federal and state research and development tax credit carry forwards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_IncometaxLineItems', window );"><strong>IncomeTax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_IncometaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_IncometaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_PercentageOfChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_PercentageOfChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_PercentageOnAnnualTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage on annual taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_PercentageOnAnnualTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits of income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_UnrecognizedTaxBenefitsOfIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=gbio_FederalIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=gbio_FederalIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=gbio_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530442808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of beginning of year</a></td>
<td class="nump">$ 33,113<span></span>
</td>
<td class="nump">$ 14,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Increases recorded to income tax provision</a></td>
<td class="nump">27,855<span></span>
</td>
<td class="nump">18,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of end of year</a></td>
<td class="nump">$ 60,968<span></span>
</td>
<td class="nump">$ 33,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121573983&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121573983&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825535509832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 48,280<span></span>
</td>
<td class="nump">$ 25,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">9,385<span></span>
</td>
<td class="nump">5,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred rent</a></td>
<td class="nump">4,456<span></span>
</td>
<td class="nump">4,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets</a></td>
<td class="nump">64,868<span></span>
</td>
<td class="nump">37,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(3,900)<span></span>
</td>
<td class="num">(4,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,900)<span></span>
</td>
<td class="num">(4,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (60,968)<span></span>
</td>
<td class="num">$ (33,113)<span></span>
</td>
<td class="num">$ (14,246)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825527577528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="num">(4.20%)<span></span>
</td>
<td class="num">(5.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="nump">34.80%<span></span>
</td>
<td class="nump">30.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530201960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LicenseAgreementsDisclosureLineItems', window );"><strong>License Agreements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 58,532<span></span>
</td>
<td class="nump">$ 50,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gbio_NihMember', window );">NIH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LicenseAgreementsDisclosureLineItems', window );"><strong>License Agreements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gbio_NihMember', window );">NIH [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LicenseAgreementsDisclosureLineItems', window );"><strong>License Agreements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_FutureMilestoneObligation', window );">Future milestone obligation</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_PercentageOfIncreaseDecreaseInNetSales', window );">Percentage of increase decrease in net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gbio_UmassMember', window );">UMass [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LicenseAgreementsDisclosureLineItems', window );"><strong>License Agreements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_FutureMilestoneObligation', window );">Future milestone obligation</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares Issued For Services</a></td>
<td class="nump">125,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Adjustments to Additional Paid in Capital, Other</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_FutureMilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future milestone obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_FutureMilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_LicenseAgreementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_LicenseAgreementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_PercentageOfIncreaseDecreaseInNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase decrease in net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_PercentageOfIncreaseDecreaseInNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gbio_NihMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gbio_NihMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gbio_UmassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gbio_UmassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825527771176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_DisclosureOfCommitementAndContingenciesLineItems', window );"><strong>Disclosure of Commitement and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LesseeOperatingLeaseYearOfExpiry', window );">Lessee operating lease year of expiry</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease agreement option to renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_TenantImprovementAllowanceMaximum', window );">Tenant improvement allowance maximum</a></td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gbio_LetterOfCreditForSecurityDeposit', window );">Letter of Credit for Security Deposit</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense operating lease</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_DisclosureOfCommitementAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of commitement and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_DisclosureOfCommitementAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_LesseeOperatingLeaseYearOfExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The year in which a lease is set to expire, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_LesseeOperatingLeaseYearOfExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_LetterOfCreditForSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit for security deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_LetterOfCreditForSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gbio_TenantImprovementAllowanceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gbio_TenantImprovementAllowanceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825616592856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 7,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">7,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">7,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">7,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">7,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">27,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future Minimum Lease Payments</a></td>
<td class="nump">$ 64,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825524990376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Potential Dilutive Securities, Presented Based on Amounts Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">5,939,586<span></span>
</td>
<td class="nump">20,040,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,961,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">678,135<span></span>
</td>
<td class="nump">1,705,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">19,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">5,241,770<span></span>
</td>
<td class="nump">3,373,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139825530201416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) - Summary of information has been derived from unaudited consolidated financial statements (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 24,345<span></span>
</td>
<td class="nump">$ 20,969<span></span>
</td>
<td class="nump">$ 17,764<span></span>
</td>
<td class="nump">$ 18,036<span></span>
</td>
<td class="nump">$ 16,158<span></span>
</td>
<td class="nump">$ 16,333<span></span>
</td>
<td class="nump">$ 15,335<span></span>
</td>
<td class="nump">$ 14,476<span></span>
</td>
<td class="nump">$ 81,114<span></span>
</td>
<td class="nump">$ 62,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(24,345)<span></span>
</td>
<td class="num">(20,969)<span></span>
</td>
<td class="num">(17,764)<span></span>
</td>
<td class="num">(18,036)<span></span>
</td>
<td class="num">(16,158)<span></span>
</td>
<td class="num">(16,333)<span></span>
</td>
<td class="num">(15,335)<span></span>
</td>
<td class="num">(14,476)<span></span>
</td>
<td class="num">(81,114)<span></span>
</td>
<td class="num">(62,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,226)<span></span>
</td>
<td class="num">$ (20,849)<span></span>
</td>
<td class="num">$ (17,731)<span></span>
</td>
<td class="num">$ (17,717)<span></span>
</td>
<td class="num">$ (16,063)<span></span>
</td>
<td class="num">$ (16,128)<span></span>
</td>
<td class="num">$ (15,032)<span></span>
</td>
<td class="num">$ (14,094)<span></span>
</td>
<td class="num">$ (80,523)<span></span>
</td>
<td class="num">$ (61,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share, basic and diluted</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (3.22)<span></span>
</td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (3.31)<span></span>
</td>
<td class="num">$ (3.30)<span></span>
</td>
<td class="num">$ (3.29)<span></span>
</td>
<td class="num">$ (2.95)<span></span>
</td>
<td class="num">$ (12.96)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG 5<F0?@_EI*?3PQ+RC^ 3#\#U!+ P04    "  '0G)2$%QGW-X%   I%P
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MYG@! F4%\/^5E.:PL!NT5ZK%_U!+ P04    "  '0G)2L7V@"'<&  "2'P
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MN.[5VG3VN=3&=FM.K H70:Y=@5*[UR_(1R$+K[O'HH2C+$LF6G72RQ()R]*
M7 U^8R7:-O>ER $^4+(N=5RKRC:_1^0:V*^K)QOK8+1OZ=OLL/; '1I_?_R,
M98Q@NHRFXKO7,1+6L6-"_)FK7&BW6@XZR)J9Q.39,B6+=!C0GCW3).Q>Q$AX
MTW3+7KJ/+,4^DCK_N]CQ0O9L=.)AT^HS(A,-(^G%D)P0PQ:QB_&)L)F&[9$Z
MBJ>* NV5CH:5SEO<?)7!!XJ.98X2&BV3@3L]=@?R<XR\ET,:ED.+'&J#XB")
MKB0 BW<M%ZO-CZ Z^\Q24*"5R.W'.?N[EXIG%Y:FR3"4/69I.K5-IKU$TK!$
MKGX9.V(&W?,'4=>[*C-= >E8#W&*L^'W*X_9,EY,M%#TX ->6#5?1XG;G4F0
MS%@4%_$R'O8 'K-CSL=L>NVD8>V\:[;;TGW4A:2U9;N4NE&N2-HMJ&5QT <
MF3Z%1-T>$T -#:DK[=65AM5UY334G0"$%=5^(CP4(:]?/7LW$L=DJK#T,DE/
MR.3ISM^F;]D4[>:)#7;3[9>[P0[6R\#S#7$YW&![C!;Q1"M >^6D8>7\-.I4
M#NF<1IZ./AV3<>T<&RV&BS,_.+FHN'IP!SH:.8>V1P#=T^[0Z,H=E0R>7^,/
MJ_;HIY^F/8GZS!04'8U*OH8IH_<IQ(UJ#W?:&R.W[GSD7AHC*W>YX0R:'6L
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MYP5XOW&(4KYA!>/9\,5_ 5!+ P04    "  '0G)2*-<+O><6  #I1@  &
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M7#T(\3M3+8H7SV?%U>75Y0/P7B3J7PB\%V?@G2"S^)_KI>\=M.5_'SC@BW3
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MJ-JA-K-B.8!2T-[9'F1"(MC16V5-655NP#Y@3!TI7;61TVMS!X>\$P$E4O@
M'J?Z,*>CJX'#ED]4%<*JA>C(6SPIN[TX1& ";$;BL';3 (P#U:UL<XWI*B#Z
MH;/WH,^9KM;#+%!TT [WP?1SOS,56558%QXX..\[<FX%<[0N*$K3%TO3-B#
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M]+$6R<5_6M;4@A#_LZ#!#$\;)!KED66EKH>EAU#M9"[1,GE*RI5!WB![8^^
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M7NC<4_S0VYW\,9.E[7N[E5\WIH2CY@(\7UG$S?"!!Z2_;O/Z_P!02P,$%
M  @ !T)R4NU<>)H;!   $0L  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&ULM599;]M&$/XK [8H$D 0Q=6M2 )D.4>!N##B.'TH^K B1^+"))?>74I1
M?WUGEX=9Q9+CASY(>\WQS<F9'Z1ZT#&B@>]IDNF%%QN3SWQ?AS&F7'=ECAF]
M;*5*N:&CVODZ5\@CQY0F/NOU1G[*1>8MY^[N5BWGLC")R/!6@2[2E*OC%2;R
ML/ "K[[X(G:QL1?^<I[S'=ZAN<]O%9W\1DHD4LRTD!DHW"Z\53"[&EAZ1_!-
MX$&W]F MV4CY8 ^_1PNO9P%A@J&Q$C@M>UQCDEA!!..QDNDU*BUC>U]+_^!L
M)ULV7.-:)G^*R,0+;^)!A%M>).:+/'S"RIZAE1?*1+M_.)2TPYX'8:&-3"MF
M0I"*K%SY]\H/+8;).096,3"'NU3D4%YSPY=S)0^@+#5)LQMGJN,F<"*S0;DS
MBEX%\9GE#5</:/@F0;C#L%#""-2PRB+XP(6";SPI$&Z0ZT(AQ<+HN6](K67V
MPTK%5:F"G5$1,+B1F8DUO,\BC/XKP">\#6A6@[YB%R5>8]B%?M !UF.]"_+Z
MC1/Z3E[_C+R6J=="AXFTUFKX:[711E'>_'U!QZ#1,7 Z!B\[6C\YFI.CMU;[
MWFE/7W#T116V?F<ZYR$N/"I0C6J/WK+?A5>KAI4&N05R,Z8;5(VK.Y1YSXG:
M'.O3$<PQ1P@E5:TV&%DQ)D;8RH3*7V2[&7Q44NOJ_[TV@BJ+Z%:I5$;\0[O[
MC)I+<KIU(5I+;> C=1H-GXF=-)=!>R,RTB(+33;IMW#?O>N"4<Z@8QOGKQ"P
M:6<P&-%N2K\W WA;7PX#$I^FJ$+!$\AY3G8/&1$'\-LO$Q:P=\U:7:^ERJ4B
M]-0%-J:M)QAWA@,&@X;#78S@JS0\<3"FI)%9"$&_A</>]B?PE1Q&6'*>'2$2
M$6320,SW>,;[_+E@!=.ND],X'AR?!I<9F7%1J90XE.-W5I)&BKZ)N0&NFIR(
M@,ZM5+'-E!HR 5!6,#5%4:83R22B!/=HVYB)75BPS1H+5%R%\;$#AUB$,1!G
MA#I48D-JMH4B>E7S_B')MZQSKA-95#^D*-QKEV6?'8B@6EFU]LL0G";,FNL8
M\+$0!-)*GMF&A<?*WP2+J"@^HWYGPL:TJ</:WE6/S];:['Q*-AE2Y>#I^8><
M/$G"G\[)DU0\EYF-C74RMFUD],I&PU<$))C^GP$)AIW>>'0F(-7C4\W]!/$S
M6@Y(A>"2-[)]KE4V;AJ(;#4\%M+VL(HO5R)$72>XPKKB>..#5J]]J4[.=>\+
ML KK\!I3"09$/?]4(#4U!AK-1"H2KEIRSZ-FKT/]W!?3;XTIE-0[-XQI^E@4
MF2DGEN:VF?=6Y9CS1%X.B^24G?T,)+@EUEYW//1 E0-8>3 R=T//1AH:H=PV
MIID5E26@]ZTD]U0'JZ"9@I?_ E!+ P04    "  '0G)29Y(_VA(#  "0!@
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MYLI2B_MC33,5M7.@]THI>[RX ,.47OT!4$L#!!0    (  ="<E*O7_$PMP,
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M71.40&Q7.EV)A4KE6@FU7*K4!Z!V(JIS9L10:!4WP71M,'T$L2K[(!X$[:&
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MY$ OGT(03<!3Q3!@[#$6LTP3@<'%&I9'X.CIE*F8\2<S&*==2; ;MA"8"FJ
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M1(?Z0.[*-H*;02Q(3)FE847=3 7'=\77):QZ@#"9CNW"JV5NRH*[D%T#!^H
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MAO;C0/-6FZ;JR0%7.@>QC.?+/Z<.=,5G6:")X46D*_-&FE?*[EM\";EH7*/
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MO<GY<JDDHIT6X/W<&%_?$(/F:^G-?P!02P,$%     @ !T)R4KS91>Q6!0
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M-PI-[TD ^RL'H.8',C#\Y^3J'U!+ P04    "  '0G)24Q?K*%\#  !\!P
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M5HL(S-#KAXG37>BO>^VH6X=A2\\C&F] ^XVF2SA.O(/IP=U] U!+ P04
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M0_YY48H2)_>R/I#<C235*R27%;RG(!W#V]!@\R- J1%/85?'L.^JLX@/6%_
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MW8:B++2C$@_+AGHJ&F] ][76[K#Q#OHNG?\%4$L#!!0    (  ="<E*.+4*
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M<"XRS%X#A#:K-K6D26V:="*>8;H/O7@/DBB).O!ZK50]C]??@7=%%E(1(ZT
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MY(!08$).@=G7&UZC$$[(8OS::@9U2.>X/]ZIW_G<;2X+9O!:B9\\I>4P^!)
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M;#FVWN"+*7&,0V'QC;.-:HV16<I<B%]F<K486XY!Q&(6:1."PN.>35D<FTB
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M &$*]/Z2<[6=F#;4?W62?U!+ P04    "  '0G)2%KTVJKX&  !>(@  &0
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M.MIU\B7G))]2Q102C%:@VFY(5N;GRR7A8_#I3]4EN),T$W][ (4;0*$!A'V
M0#E0; "5>!0&47DTMQA(!69>9"/* 9L -M<V DS50TG'=3%2HN@9%)IC%Q=A
M, A"V#WK+&K@XPU\[(7_F',:LVF>:)!"9Y"=A5U6PY@Q*Q1<A;/(%U0H@&O
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M4]DIS.Q4=HM]&*K0Z#;LM+%3%^PO]FWR;)^$J$ T=>)7[L"Q$Q!\).4]=A*
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M_%LH[94V,\']\4[[;]IYY<R4"IBP^&<4RL5]S^NA$&9T%<OO;/,%"H><3%_
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MUO"PO?/^S8E',7.FX4IF#SPVZ=#K>22&A*TR<RLWWZ$4U+;^(IEI]TLVY=S
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M&GP'N&:*+R]0=@)^3Z0TNXX-4+WE1O\ 4$L#!!0    (  ="<E)SF4I^# ,
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M#DE@3I=<WXOU-Z@2:AF^6'!E?\FZBO4<$B^5%ED%1@49R\M_^EP58@O@MP\
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M,JXHM1G>3G TPJ[*T^UNAO>&=10'K>+ JO@2> )4*B-%VNLH7:M=0)([<E.
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MQ00G$K*Q,_%O9Y'QMPXO##9JYTQ,)4LA7HUQEXX=SQ""$A)M$"@^UC"#LC1
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MA/2N!]A-V>AG8VA16PE:"HV"9H\%?G) &@=\GPFAMX9)T'W$XM]02P,$%
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MF&/C!])LP.^9$'HW,0::5G+T%U!+ P04    "  '0G)2"3*OY6D#  #3"P
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M&8& V%@(AG\;&(,0%@EY?*] O3JF==Q?WZ*_<<EC,@NF82S%)YZ8=.#U/)+
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MP6;GAAO\'@%E#^#^2DISG%@'U1?.Y"]02P,$%     @ !T)R4HH4M/!P @
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M\A9.PO'W/2\DS6,YLA7<!)V*O:D3OJL2]MY)>,8V/>*[M\1S/ >13]OE*W8
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M" N:/58"  !>#   #0   'AL+W-T>6QE<RYX;6S55UUOFS 4_2N64TVM-)5
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M<<#D$U!+ 0(4 Q0    (  ="<E('04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !T)R4@6KPX#N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ !T)R4IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  '0G)2Q @[';,%   ,&   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ !T)R4A!<9]S>!0  *1<  !@              ("!]@T  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  ="<E(UZ&\< @,  .4+
M   8              " @0H4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  '0G)2&M)2T <$  !>#0  &               @(%"%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ !T)R4K%]H AW
M!@  DA\  !@              ("!?QL  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    (  ="<E(CD'Q790(  )X%   8              "
M@2PB  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  '0G)2
M5*"CY=4&  !N&P  &               @('')   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ !T)R4@9JIBSQ"   )Q8  !@
M     ("!TBL  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M  ="<E(HUPN]YQ8  .E&   8              " @?DT  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  '0G)2[5QXFAL$   1"P  &0
M            @($63   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    (  ="<E)GDC_:$@,  ) &   9              " @6A0  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ !T)R4B%S<12L @
ML04  !D              ("!L5,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  '0G)2KU_Q,+<#  #'"   &0              @(&4
M5@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  ="<E+0
M: &*U0(  %,&   9              " @8):  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ !T)R4LJ$"6!]#   %2<  !D
M     ("!CET  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ="<E(#!$[%8P,  *L'   9              "
M@9"%  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ !T)R
M4FJ7@H-<&   +%(  !D              ("!*HD  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  '0G)2[OC;SLX"   <!@  &0
M        @(&]H0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   (  ="<E*9<9M-U0,   D*   9              " @<*D  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ !T)R4KOHK-;E @  _P4
M !D              ("!SJ@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  '0G)2'-8UXK0"  "Q!0  &0              @('JJP
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  ="<E*.+4*
M+@4  '(-   9              " @=6N  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ !T)R4A235?!Y!   -0P  !D
M ("!.K0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  '
M0G)2Z9?<5GD"  !:!0  &0              @('JN   >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  ="<E+-[/7K'0,  *8&   9
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M970S,RYX;6Q02P$"% ,4    "  '0G)2U(YMP$,#  !2#   &0
M    @('\S   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M  ="<E*![@X0V0,  +$1   9              " @7;0  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ !T)R4G0*1>%W P  R T  !D
M             ("!AM0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  '0G)241SIYET"  !3!0  &0              @($TV   >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  ="<E)2M.2ML@(
M +0'   9              " @<C:  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ !T)R4N>33>3K @  :P@  !D              ("!
ML=T  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  '0G)2
M6%#[<4\"  "!!@  &0              @('3X   >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    (  ="<E(6O3:JO@8  %XB   9
M      " @5GC  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ !T)R4G1MDX*8 @  ^@8  !D              ("!3NH  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  '0G)22\B!<HP$   L$@
M&0              @($=[0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    (  ="<E+\A=*$"P,  -<)   9              " @>#Q  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ !T)R4G.92GX,
M P  $0D  !D              ("!(O4  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    "  '0G)2:H)4=&,$  !1$@  &0
M@(%E^   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  ="
M<E*[F+'<LP(  - &   9              " @?_\  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ !T)R4BO+#<$D P  "PH  !D
M         ("!Z?\  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    "  '0G)2L" X1#8#  !6"@  &0              @(%$ P$ >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  ="<E(),J_E:0,  -,+
M   9              " @;$& 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
M4$L! A0#%     @ !T)R4JVU"WDU P  [0@  !D              ("!40H!
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  '0G)2BA2T
M\' "  "O!@  &0              @(&]#0$ >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;%!+ 0(4 Q0    (  ="<E*[C)TY7P,  ! ,   9
M  " @600 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M!T)R4D%8MX?S P  8 \  !D              ("!^A,! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    "  '0G)2" N:/58"  !>#   #0
M            @ $D& $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  ="<E*7
MBKL<P    !,"   +              "  :4: 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    (  ="<E+:!HB@7P0  "PD   /              "  8X; 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  '0G)2#Y142-H!  !9(   &@
M        @ $:( $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  '0G)2(5VG)LT!   D(   $P              @ $L(@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     /@ ^ .D0   J) $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>117</ContextCount>
  <ElementCount>343</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Marketable Securities And Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurements</Role>
      <ShortName>Marketable Securities And Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gbio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Marketable Securities And Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities And Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gbio.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Nature of the Business and Basis of Presentation - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Summary of Significant Accounting Policies - Summary Of Property And Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary Of Property And Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Marketable Securities And Fair Value Measurements   - Summary of marketable securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesDetail</Role>
      <ShortName>Marketable Securities And Fair Value Measurements   - Summary of marketable securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Marketable Securities And Fair Value Measurements  - Summary of assets measured at fair value on a recurring basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/MarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Marketable Securities And Fair Value Measurements  - Summary of assets measured at fair value on a recurring basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Accrued Expenses - Summary of Accrued expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Accrued expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Convertible Preferred Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/ConvertiblePreferredStockAdditionalInformationDetail</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/EquityAdditionalInformationDetail</Role>
      <ShortName>Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Stock-based compensation - Summary of Inputs Used in Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/StockBasedCompensationSummaryOfInputsUsedInBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-based compensation - Summary of Inputs Used in Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Stock-based compensation - Summarizes the Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysStockOptionActivityDetail</Role>
      <ShortName>Stock-based compensation - Summarizes the Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Stock-based compensation - Summarizes the Company's Restricted Common Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/StockBasedCompensationSummarizesTheCompanysRestrictedCommonStockActivityDetail</Role>
      <ShortName>Stock-based compensation - Summarizes the Company's Restricted Common Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense was Classified in the Statements of Operations and Comprehensive Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseWasClassifiedInTheStatementsOfOperationsAndComprehensiveLossDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense was Classified in the Statements of Operations and Comprehensive Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/IncomeTaxesSummaryOfChangesInTheValuationAllowanceForDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Summary of Net Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Income Taxes - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/IncomeTaxesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/LicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Net Loss per Share - Summary of Potential Dilutive Securities, Presented Based on Amounts Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesPresentedBasedOnAmountsOutstandingDetail</Role>
      <ShortName>Net Loss per Share - Summary of Potential Dilutive Securities, Presented Based on Amounts Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gbio-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Summary of information has been derived from unaudited consolidated financial statements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedSummaryOfInformationHasBeenDerivedFromUnauditedConsolidatedFinancialStatementsDetail</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) - Summary of information has been derived from unaudited consolidated financial statements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gbio.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gbio-20201231.xml</File>
    <File>gbio-20201231.xsd</File>
    <File>gbio-20201231_cal.xml</File>
    <File>gbio-20201231_def.xml</File>
    <File>gbio-20201231_lab.xml</File>
    <File>gbio-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0001193125-21-085043-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-085043-xbrl.zip
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M%%3>TL4$@K?L)MA0*9XLXY0+K ID*L&U/\'UP5F&@?\'NV>V7L)V\<=_!T[
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M<*2*I3!3+\!*61"G$"N'$#:#47^D3T>I\ZLURZK$ =^+E3BHEZMR("G3ZPU
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MCHGCPD,VEN%;5V\OJM\';YK,GWG6#4PS#SUXWHO>_>0&+-G3O4X18NGS*RL
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MWD%/8+;3+S)U[L'&F"+U8)'%EFH!_4#JF*#LT59#P]^ 1<+0CZLA.P0R*5Q
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ML#1DAQ0D2@.=)SU!8]Q+O=#Y!,@UB&)"!&9+RDJ72IX09F,]CGVS$^ Q<UI
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M,AI^K6:1\>TUS&_L*F' !Y*J$B2[C%C>^79KA9]3W"N*_7""3'3YQ4)'QB*
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M;"%?98$E>MN)!!"NF5A<<GMJIT?1A>&+ M1D:4I.KV]G6GBBMX.UBT[JH=)
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M;W5U/FO<7H>2FT))L86B.42Y!?2A\IS;;!P]L^]R=O.66SH)>S%X@WMSQ[$
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MP5VOU3U<[]<7A[OV)8=/'!EW%5UB"G<R[I2\VUW>'7+/EMK_N=+FDF%K.LR
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MQT$[;_WLS'%7:UAN=^MGT%ZQ?G9ENZLU?+</@'D;:&?>NUK#?/L N&(/[<J
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M).#LAX:#&#I09_C;H+OWZ[H+NO=#37I$0$C%= 4$9F JK#.T&=3X(1<R(/A
MPY,T@GXH=BS@)WNBKY&#3#\PJ/";=14&,$0#]4-MU]S"96 T\U@Z>,H_-JCP
MVW45AI D >V'(F'&+;C2 NORI@[2F4@2A+(.!N7FTK04CK#$F<+2#SU#U(>E
MW'OF/<ZI%[ZZ6G]HT&<NRP(X71@F$& 2#=H/)3XRAUF*V7_WJ:>8YZRNN* P
MB*AS217])*AO<X7[#O2R5+-SL=*/<CE4A(_$"$F,D2!*\BY&VI/26[WB09N"
M0T7AX2B7;=4O/)!WT:^=E5(:?\+J0",;A1 &"^4RN"86"E#WQ#Y-*CYI*[6
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M$TME;%FSK\'JI1_ [(+(G#GB67HQIV+&I)Z"6,@-(GK'<5_PZ* KU[L,\U<
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M,]BK"@  OHX  !4   !G8FEO+3(P,C Q,C,Q7V-A;"YX;6SM76UOXS82_G[
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M)*KL=UIM=C(M;+%4T'$B;6$V;V-T,>PT^/.JP)9E\%HE?Y;!6W67E_L(P?(
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M;$;5E/OV-A@+TAX >M04, &%KX>,QW"W3GFWW^?!8.5=,C'H^XQM 6]4-79
M$:O XK'AK=,\6XS.V6WG61L\8VS+\![O=Z(>"0,*5P46D?5.-B!I308W:?*4
M9G"4F6XV<[8L_.8ZL1VZ%MS:BWH@##OOF_ BH*EQG<9'DK,KRO7XA1UWP?#5
MS;+BC5OGV.F8I*^*I;U-=X TJMJ@M=2]X,>31=I>M^[%^".8>A+U2!?A(MB
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MI*I@@=>MC^Z=P?X318G5<&OT@!5-K/1'W4U^R[Q/GT=5;\C.HZ+JLD;.VG8
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MIE=?7&S$4OK>5!BQ*_]P.*-;[NL209O_G%+X89G%RPU4@?FO,7"8-$=!Q82
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M,UQ:FFF#0GT4A1[FZIF].-K0?O-VM]VFHF!!E-9OKEUD:Y9OQ%U+G7?TS'K
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M@ZDPW7))!)NDY9, HPMR+UB%B+]+R+O7#L(/2(EWK<0/G'C@IU'<VK&9D\"
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MR&R9FOPLL6>)N- XNUT]TGB7TJOU,BN3.$EW\-Q E<67T.+\>97N8AI_X/J
M1\1V,CWO:GT>Y1F7IKBFN7AF;*B\@E]"*-3Z8<4]N&L^(1VFRREI624UKP0,
MEG2X%3DT%;^05R.?$#0JZ#"]OC!O! 95FD=_XPDP+,38AO)>ECR_?^GO8"0!
M* !57&%C_WRY=W)#&)TBH2?$P!Z62@YE2U.!\5.T&2]KI]O4(2R..P]FVPL"
MQ"=*W=%6M9:A#@V1?VNK\X/%F\ RH7RT)MQH&Y1]C?;J8678>0YZ6ST''74+
M'%9W"!3UX3S+@WW=N7/[8<N_>X3]'E1?X;\JX.^!7W ;-9C#!]OT+,P_/$Y9
M]D1S\1CT=5X]W"B8&@6)9DL45#3[=@^8#F'24";2XE @<2@)[^>>&;]>VA%H
MVP@T 41TS86A]!>P;F^9)ZNR8N)SEI3%S>WG4;!HM</6V1WOV3U06K(5.@1A
M\BTG77R'@XHS21!SRF=N904(D[=R=:<3L@-N@E?XU;"9X\J]NH8V^VWWI:*"
MHB\24VRHCY@(MWLVCG!=&M9DG%)%"#\02$_SC4T< \)M(&( <+/W14M1Z,.?
M(]KO?PHOM,^!9Q=4M-"B>]!:[4.+UM#:<F@5P.:BJKD2TON8JP;I>DX:!<&C
M?"E<9VX$?U5NY,"<W?J0/JQ4#J12$O<ROXI_\/]"]./?_N'_!U!+ P04
M"  '0G)2T<1&:A1'   :J00 %0   &=B:6\M,C R,#$R,S%?<')E+GAM;.U]
M67/D.)+F^YKM?\BM><Y*A:1,26W3,Q:ZJK6C5*@E9=7TKJVE40R$@E,,,HJ'
MI.BU_>\+P.,.G"08#C+KH3M5$@#B^]QQ.1SN__KO[Y/XPRO)\BA-_OI3[^>#
MGSZ0)$R'4?+RUY_*8O3Q]*=__[?__M_^]7]\_/@+24@6%&3XX7GVX?+ZYN[#
M?YX_W'ZX2?(B2$+RX3(-RPE)B@\?/XR+8OJ73Y_>WMY^'HZB)$_CLJ ?R'\.
MT\DG^O=?X8,?'HY^/J#_27_JG7S\&F3A^./AP6'OP_\^./O+T=%?#@__SX?_
MV__Z_SY^9%V(H^3WYR G'VB7D_RO/ZU]Y/TYBW].LY=/AP<'1Y\6!7^"DG]Y
MSZ.-TF]'B[*]3__Y]?8Q')-)\#&:XUC68LV(ZO7.SLX^\;_2HGGTEYS7OTW#
MH. D:OOU05J"_=?'1;&/[%<?>X<?CWH_O^?#GQ@'61J3!S+ZP#__EV(V)7_]
M*8\FTYAUF_]NG)'17W]Z>8Y21N5![Q!J_\M%2J5\'[S0@JR1;P\WRYZRPEPR
M[ ^?U@I^JOM))OEHR'3F/(@9N8]C0HI<WP5IQ::Z=!]D5'7'I(C"(*[<OZU6
M'';VL:#_ST97/A@-IFP<LO'43X87Z62:D3%)\NB5W*:Y%;DVK38$AOZ>ZEL1
M/<?DGE8E6<;^GH:_TU[P?\=I/*33Q=4?953,+LDH"J.B*L:*'_,)>F5%=?WE
MID@)\O%UG+Y5UN.U!FIV\2XHRHP,1D]C<E[F44)R-C3.@SRBGZ&\Y?2#?,3H
MNFK14,TN/Y:329#-!J/'Z"6)J-B"I.B'85HF!5W1[RE?842TU)JV4K.S=,'_
MG10!5<)'$I995-!&*2_7093]&L0E^4J"G/+&Y:KKLEU;-3M^GZ5TLBQF] -L
MA$Q9JW=$.RM)J]7L#A5-5I+AU?N4SM=ZZ>X4KS^2Q9.)P0B65:S9)9BW=-]?
ME*H[YEB7Z6 F?-6DG!K-";):-3MS0S?O$_(4O.OU8*-HS<_>1B%3IOY+1LS&
MJZ!";36<3**"M\4W,'RNHF<9@_E.6;7N(D(*MG^Z)]GCF"Z@VJ5BNWA=Y20Q
M">D*^?<RR J2Q;/K**'[U2B(+X,B^)8$Y3"B?]9JJVDS>UF_W*YCSM8SL\\]
ML47*4=<7;>UQ(3;K?I46FUF4S?JKJ>QV@3;KDJ12(XN5H4XJZ[I;N,QZ(ZC0
MW IBUB6#!MRN)F;=DE3:S\IBJ%IVC>WK8-<?TL_2?X/X)AFEV83_\I).;)'V
MZ.WF&WM9D9:E1+.@&5J'']H+Y!J"=?"!/2[7R]Z**ID!=OXY#/C]/"=%/O_3
ML%\L2P^2_@-K)J/"XZ.S05+L.]',GD@Y#NG?S2BHV7@ST&H,["HMNMT8KA1E
M\_=F_;=LK"FK3PT)5&O3B:VH1J\-&FADTUYG#;-OL!$(2QV]2:9ED7^C?[Y)
MSN,@_/TQ'--OY8,I*W:?T34U>?F:#DE<!V"-SS4(/_HG/1Z,"?M#D,QR7A0Z
MT@^+Z)5?P-3%;/Z-_0%]('E!F2YXT0DMQ$=Z4Y"-OM:LDHO_/)^7?PORBSC(
M<[JC9%I)>VY^.>MD3#3>.W<&@AHSGVDK[CJ[)/AB'"0O).?LL5T?S+EQG+XQ
M!X+K-+N<+WFT&NP4K2$Y^%8#P/FFSQDT56L-=)[NR],DC.*(4\C/\]\>K\F0
M:GS,QD!9I-EL6?&!#HKJT*I_R_7U38T19M=6<R:[6OO0:JTV!V:I(M<E,RM]
MC9)H4DYNZ4F2W <S7J4V-(MON+5BKDZ,:4&_PHQ^$7,8?%T[6\\M9LS?BJY0
M]+P\80:7?$"W<460,'=%0[-<DY_>CT5U;1>[U,"_!?DY(501,]KUX7663I;%
MU_UDE@VN5F_#O0-FUSBMTS63Z2UE<8-?\DZE-V3WC_!;UF>M>R/W*4W#C89B
MYL699IN28NWDM"'NJYF3\.>7]/73D$2?F/38#UR,'P]Z<T_-?Z&_^LZ_TW^F
MF\X@+!;MQ<$SB?E7ON^4^7[2.S[[W)O#;:YC"S?=)]JNI%_K1:!;AP(I]+/-
M+@99N&B/_K@A@EU/UWF)3U/N5/8Q'$?Q4GHCJB,ZDN8?3C6=+G/:B70*,_9/
M']*,KJ5__8G6GR[L"[< 7=I1WDO.3^.2Z=/N#QF$ZSAXD8AFHPS //)?-N)>
MBX5SZ*=P%NIU'>5A$/^#!-DU_4VN&4%;I0'ZL?\"T_5?++JC-HB.+OU1.C07
MWEIY@/^Y;>(3(1 +\-A/ 5[1G5E!#SYTYQ$PBPUAFXZ+,F-T262HJ@(D?/%?
MC$8@Q)+\[+,D+VC_,W:"&I+W_R SI0BWR@+LD[;(3M9[L="^^"FTN<:MUH*K
M9$@U4;9[E!4'\*?^BTX+0"R]$S^EMU@+^DE2!O$#F::9;-(4%0709_Y+3=EY
ML<1._9;84Q8D.;<V&4EMNS@'_Z77'LE) 8BE=^:W]&#7I9XJA64!=HM.W.+>
M2X[>!WY*#9;K!_(2,=A)<1=,9$(3%074+3B)*SLO$9FGYA(Z73#CZ^-L\IS&
M$EEME.$X3UJP 1'W6B(=3^TEH&C744SNRLDSR92#:54,=+$%%A)IQR5B\M0V
MLCABAFE&EUSP"& &^ MVQY'-+M*A>AI4U@1.6G30-L$BD:_7II/YB0:V56QF
M89?),O.7J@JPT)[CMQJ$1)1>VT[8C)-=4-U\23.UY62C),5\>GK6@K5/U7>)
MO#PUFP"2QS&)X[D3FE)<ZP5!0UMPZ%9T72(L3ZTD<R"3((X7SW74TEHO"5NT
M@]:(2]AWB;P\M9$ DJL)R5[HO/Y+EKX58Y-1)JP!'+3 4F*"02)'3ZTE@*@_
M'&;L@1S\<TL5LZ>4HJ \X&^!U42/0'(O[K7E9 [D@OXXR)[2M\1$?JO2@+TU
M]A-Y_R6R\]2$LH&&GW@&V7V6OD80!T\KP*TJP$)K#N\:$!)1>FUOF4.Z3_,B
MB/]7--6>WT45@($6N#D80) (T5-K#)M0^AD)%&);+P(H6V!?$79:(AI/#2DL
MOF=\/TX3M3USNQB@;8'!1-IQB9@\-9+,W;9G5^\A?P*CN,<1%074+3AX*SLO
M$9FG=I(%E-[A\U-4Q#IQ+8IQM*<M.'1+.RX1D]<6DJOWU2T]W/NJC]L[Q2GZ
MS\='+1";%H!$?-8&DX)D.;G=BPQOPE'69V\OTJQ?%"0'XA7NYO(*WT^_'!X<
MM6"F-( @D:37)I-?T[BDA&=@*E<;*[?*4MQ'IU]:<Q<@Z[W$!]UK,\EO)([_
M(TG?DD<2Y'2O-;S)\U)S.2ZIPWEHSRE-AT(B3:\-)_?E<QR%UW$:J-W0U\IQ
MO*>M,5.*>BZ1E-=VD;68#_S=Y_KK3?4UN*(B;.1:<VU@!$4BW%KVDD_;;S?=
MON>4Y8JPTJN%6HV"_)E#*?./+T$P!=TB<9$O?K.M9/-??U^^6QV,EF]9[U/8
M.2K>@=I49U(ZZ1W;CAF'V'@ 1A,4O"#T%VF)JD3LYMC1H'+TN+3Z_M^A8'ET
MEWD0F/Y[)-I/:NL ,4CF2(VL-(*50G'T1A53QNO8+M-)$(GNYN2%@0HD"Z:Y
MH,0"5L!Q](35B]'+[H]OZ(]&PW99&*A .@?6&Z^[&!P]:,44)\0R,M@K;!8$
M"I L,0:2$8M2@L'1:U9\,<Y=3XVEN56>$W*(Y!"AD9%*H#(8CAZ\HJZC03YF
M,9/H/RSDYVL0$Q9%J;@(LFQ&SU \DJ]J:36ISPD[1CI3FHE2LM):H7/T@A93
M'401H.4Q"0QJ 3E(IJ$ZHC?!Y.@!+J; 'TA(J%ZS# 1WI-"+6EB>$G)RA+V;
MKB)D-1I'+W1?2?:<H@GX/B/3(%H$RJ:3V: 8DVR#+(6X#6K#:$#RCZLC?!ML
MKM[]X@[U9;!@NIZ9#'5!>6 $V?I5;:BKT+AZ).S-%MUT:PX,M'#J%J-P]9RX
M2(L@1INQ(67#?<R2L&RGU51,U?)JG)_/2/XIE0Y>1FA<O4KV9U:^2Y/0<F)>
M50%>O#AF&4I9B\35NV1,"2\">U^D>:&R96Z4 P;:9"H1=]_5:V1, :[M"XW&
MI[ \,.+%-ME0H&H8KIXMX^^8M%LEP.S%GM?*;+GLMZM7RYB[HMLH>([B14HR
M?O<U3F,*))^G*M+;I$V; -Y\N4(RO7NP1N?J;33F"%X#;7XW(:_$N<&*+E=9
MD%I]D*%T]:H:=0Z'+)7Y?3!C=CR#XZ^P G"";*<V$)EDOE=C<O7V&EG.+.'?
MYN#@6Y2U7ZG%KJ_/3+_'9RW6 @N(KAYUXYJW=\FRFOB!463OKLH"5^!Q]<X;
M<\NW.%$^,!<I^F]4&!V_5-6 'V2W$D<+O!%.5T_%/=GDF0UNCAXK\$9SV[@E
M+%>/S#$'MR)GE\K=1%X+V/'%4=?TU&8"R-5C=<PQ_$0F+ AE-@/E7SC00-JQ
M?E%DT7/)O2V>TOM ,\%;MP5,^N+M:ZH:U6&Z>BJ/N[6K9./1S+-8@9(K*X$!
M'E<O[C&GA_M%3SE>G=.AH#1G RMP@H6PI*XH4D"N7N0/R2A*^ .A7\IH&/!@
M6!B+_ORUGM:Q=*LH\(%\-*\L8"D:5Z_T<:?J50+9^R :WB07P30J E'\>DT-
MX 5YYUY9RCI0KA[W(]OARDD9LY>IW+2TD1D=TCBS7+1WI!B,GH)WM47.IB5@
M$?D"M;IJ5 3K*H( KHM+$=#MSO JR!*Z@<W7N+BDBU(8J9U==)6!*_0'N145
MPP*?JQ@%N*_[MGFRVLP#%^B'_(JR5N!Q%:+ YROZ&E?SP!/Z";ZBW(W12;2@
MOF$/)UH%F"7&I(A""J>;H2M.#T\P9M'*H2M.#WUY5&M"K&P>%:+Z,W3%;AB!
MTR-D;Q:)K#2"E4+Y,W0%4(%N"-$)2F('D</Y,W0%I^(8W?A19;SN8NA Z(JM
M"QBZFQED'/&0V_#N2<9#CIG?5,E:8-%7/Q^AGVJDLC2ZG]*"ZT 4C"W($'&N
M7Q;C-(O^N=HKZS5ANR:0A'Z^J:<!4E =B),AA,JC?5I+'6H!.5Y>1]I*? M0
M!\)@"&&JHVN:5@6:?#F#U9*["%4'0F)L7L966/7-&@#&T>\S+!7!$INC$!K^
MJ(/%DJ^N"!2U;<]GB*D+X3)$4+4+OKP2<-.V'9X!'E>A,V)_Q&RVTFMJ D%M
MV^"9@G(6: /3$+=RRJFPRAO4YFQAA]VP5@$;8%V(P+$30MYH=5?4 G9\L=!6
M$+L44!?"<>S@U"[JDAK BB_FVLIBW@+3A8 =EHDQ3*H!/VT[K1DA:BR2Q]Z<
M#I:\Y(/18$HRWCB\IUGSLF/^=?MV0@#/OF7_#/P.)#6XM'H'B'=:%5P->LAW
MSSHNC;T+>O)@"3C'G#PKUD1(_VM;?/17+(;:L P+NH,CV6L4$HD?@:PH(/=E
M&[,IC$W):1$X\AK8O^RXOQ@ RJ6^ LKRP '2+D4K&*D<%4 <.0H@V1M<^ CT
M?-F'J :E 09'/@)(DISO-)*7>01ADR07TCK B9_F8'D.*3V<#ESZ/U!94!Y9
M(H!+\DKBE,<AG2-6OEQ0U ."D*V#>O&)Q6Z&K .W_K^0A#(44YS]X21*(L9.
M08\2>N%K:H)?%;)EL*KX3;%UP!%@AR*;N1V(0-Y 5Q6R'(VK*W[$ERI+<*N7
M=R:"797F9'SQT_9GL%P+@'3@IOXN3=)-A(O<#OJ-F;8N(^KLS$^_';G$S6%U
MX<I>BK:*X)E+T\$!\A)M+C]+^2_1=2'SQ1TI5C-:_S6(8@B+LV;^GK^W.P_R
M*%1I@UU+8$-'?WIL.RE4!-F%Y!J+9]:+FVR.D)UCHK@LE+> FIK 4ML.\*:@
MNG#/_QN)7L845/^53H@OY*Z</)-L,.*XU^[%S#6B6H/ J9^.8')%J8FU(XX#
MVR$[%N$Z##:8!K6!+3\]QN2:80.L"\X%&ZNGZ58"&$ ^/=A(RF#GL,3DRH$
M-X:525@>NDQ&Z9#^/B-!3BX)_&MB]Z_=.!S4_?0E5%@<W.%VE<3$7RU;;L6O
MT^PQ6$\\VQ_^5YD7\_1GNKA:KCX!S".[<#A4('L-K<16%]*J*%:*:EL<8,<7
M7Q('6YLE(&<Y5-!"]JQ[S]'?T_FQB*C.;[X$$,8M6D1OPXOL4S%&L$%]$/"7
M_8^].@YW7WPY5AHQJ_$7V83EE?M==:'.8WG3B25-V) SC>TCJ@?<^')>W!27
M1K9*.%YYZ]E;&#>A:2/\",L#%[[<-BFE)3$L*E%AN?"Q19#+K7<XEQK[S?='
MNH&D>[ISYC&^N>Q])<S.)9">43W^*OX,>4Y62V)3>G:H'+GOX1[(UBX]I,*6
MEN4T8B>:L1&P'DD''/8D8;BUXE76 X*0K_JJB-H,50><]0Q";.M5P+0-(*Y%
M4WMUA!UPX]L.LJW5 W$%H 1YPUU%Z!HX'0C:XSIPZN?/WKSLM3I82:$X\N]#
M.E35CYE*6?#EU8Q41I*]FAR.*Z<]MP>I"ZD5T>0XI:L-X)$W8@J92$]4QL"Z
MX)+GXIG;B2^WG58S\"X&5WYS2',O=NK&S\='?GI8GD@O%:O#=.5H-^5WHK3C
M68$T S0<0_/8TWC)QDHA1^7*60Y?!^IG^Z%+JI^WQG(Y*W"X\G_S0+(6PUD<
M>N;4EXLK8[E*8;AR@/- K$QW(2+499E1C.!;LQXIBOG"S ,SZ :S<4/?3SZ?
M^1-JQ&J@VV-TY<A6;7LO.;EM+TXJ:'?DC?]))/_JC?'E[]B7;#4Z'7" TY6C
M&.[]F1D'/'JD2F_J- >,MFWVJ(74F=<9JI,A,X?D%,+"%L:/1W,K"1GV%&JB
MK0N;:5\<*$QUPAR6Q$?&W/)W!@J0D!=V%>2+"L!<64T%MNO"8/'%AE19!:2P
M)"I@;B;T0@54\]XZ%VO&TY4;MOT&U*Q=&&9MV8NXA2Q1JU9%]E;NQ!K0*L.&
M@>.V;50<89;H5:N>$-?=W9IN\HY/SSJB)1)H$F5HU7O@RF=DNP: ,U^<$9Q,
M&KO8)/K0*K=#U0C@?QMP?/G5.\G"*%>&%K!N"YALVSU9=9@2A6F5PZ)RC#C2
M&$5CP&7;;M%JX)3H3*L\&97P'TA>9%%8+-[LO079D#]8O$ZS$8F*,JN^'IFT
M_?WDR\&1-UX;3C3*"K9$P?;D2"FQ[/]*$5!0@]$*RIKW_[<D*J1V?(.JWT^_
M')VT9A*Q1B61J+6=%==&OWJMGC^EDO< 7-V?@YR3P4+$<2$^D#_**(\*,K_%
M@J'Q0,+T)>&M\*5:^::BV4_S^'<';;/4[(T5R4.[5D5UE#U3^)9D)(A9?JJ_
MI3&[C_\EB!(6MF&0K 5JR"A;R<OZQ%XCA$;=3X)<?/%#-M76QMF0:&FK'%[O
MLW04%9J84*M"@+UM]U."_DMDURISL0<>KKX$;JAX>VT!4Z(P%3U<KQ*LBZO&
M_5O;YA]GC$JB 17]6_$TP(EW:RL-NV(<$KE6]&Y%E&M=W]:S7NL,L5(8$J%6
M]&W=$FI[8ES!(C8F1112&CH:\.KS\3)C(P8ZZX!7M+^^7),:,2N;486P.A+P
MRM5[[&.L'(8:,6ED*H72[B!7#MYC'WN3Q5 J([%L%7"\C&O5_'/L8^S$A0J1
M""X +(&U.TME4Y$'3T\/?;GUL9J0E7 <!;]J>>1!RH4OYBBEM,225J-R%.<*
M:]FM&:R.<N!I]"*0CF3!E2+I0&BJQ_(YCX91D,U8A''#C;*LSO>3PX,OW@Q>
MHWE9"\51<"JLY7>%ZBZ8T!^?LB#)Z:&0PM%.T/K*P!*VI5@K0XGLS>&U.WK5
MS?U .UTORP!F[)M!<]&(9;L+IPL))NM'-:)S(?9HK;1MWL7@*DJ5L\/NPHTO
M2$)RD>9RM[;=DG"%X:/1'K@6'6+E()SE:=P>:3CF^B ?7\?I6XYH=5_VP<[8
MOE,-WFX>M\O&[LVX4!%J;%I7#)"6["9<+$+'_MENF&"L%J%CN7]N2R1Y1PJF
MT?=9^AK12?)\]BTGPYMDF::]3_=;K^!%9Y#!W+HQ8-&7T^*N<,7:4 .G(_-\
MN]P,*73D'6<-B8E50(#/D9$>-VW!FE,X\^A.PB@F&RDWGU)W\T43GP-Q8)]=
M;6>41IGH0#Z-16;PS9<(.J>HG0J<DL_(K\,:E;5D^Z)FHP.9-RX)[6L8<5ST
MYYAPH2;#_B3-BNB?.G4QJ0YT(;_S05 >*VXZ<!URD[P2H'B9;W,=ZF!T&>4A
M]S%/AO<9F43E1&54M6^-DGER=(CL5H:@:'6HJGM%XT4@JK7'2]SX3:FE9!:S
M^SB >^CI1/WRPZP!+@;LS'X(^F7)3MT+'R]4:CLE]1I_\T>>!OMT\T8X>=C/
M[U&F+FN&<"^C)#<8NSB>2$)'Q\UD2KD">W@_CM,W9O*GU)+H56+-K=,<S.K(
M.ZT*(A7<D=1EH/85EZ>S$%V_IT$TO)QCN'IGIQ)"%W;^TK>?YT1X>5:O01 4
MLA-W;;URQ$'M*SI/-8MCO:-S?IDQ<510)6$+P!NROWB#NJ,&73LGC*?*T@_Y
M@2*_#V::6TEM7> *^:*R0061P765*@;WR"] FY6TYU'P',6P$YQ/HTM"U_YF
MJS<63<-. 'E'W:Q:56'#51H;W*A(NW0LUNZ+<9"]6"K65EW.50_YF-^@YLC@
MUDZ%X\5:97YCZ>1"GK-_BKR]03BX5V#(6?*<E&J_7]H%%EA';A^*QH!+7YRZ
M:KI]F.!TE6@'U>\CF"W"Q85_E%%&-NRG=-4VL5";-P+<(3N)U1"YQ&_$'G_M
M1#M>K&<49TC(,+^F' O,[Z;J8]X*\(?L6N9>?RH04#M1CX^3S]<@^YWP\%Y&
M63.,Z@-C?KJJ.9QRE-"[D=)G>YC0<?$U*!C6V6!DJSJV;7$NSY"/[(W//.8T
M="&=CSF=3C;*P!WR#9AS%:J WUG*'O\.6]=1$M #KIO#EJ(QX-*7*%4U#ULF
M.+N0V6=]MET\L5/$C3-<O@Q: A:1[TAK"%^_>-F0X"HI$*Z9683^AL5J#^+[
M\CF.PL&(8E%'F31N [A#MB3N18'4\%VE!QJ2401Q]7\IHR'[+O)VVC(KD+8N
M,(9L#&Q48=2PNY 3:''&'(R6C,G>O^NJ?#_]<GCPN7,+D YM[<0]?IR[ES"-
M8B&85 -B_;0#N] '!>+:J7^\T ES[IP<>X ]/^V^U?6E GYGB7<0C\X,,_L?
M,VJ_!C$;,6LIL^@?^LEP\Q=K)2'5R[;CP-5[&)<LOCC]81PD+^2!CHTKNGM3
M'KOWVQ&08=L>L2)QY"QU3UOUO"FUY=%\#MIF.'(#V55.(<@Y0$%DQ9^JM<VS
M+^'4]ZA:\APEK<L^]%A.IS'G+X@749%NDE&:34"0!G&JS%H YGP)U6ZJ++;@
M7*4D\B0U<$\E][5B$$@76[B6LI)(7 3+548B3+'./77Y>Z(A)!R^@8<BP_.R
MN$N+?Y"")0Y5KA9F30#%V*'!G*B#-617>8Z<O@C=O!C9L%-0-'1SSHZA<R?^
M^8,S:=3+*FT!.]@1PFHI1'WL$LVP-A$+KJ$:#:AYQQQ$6.C>,3DO<[IPYNQU
MQWF01SES7%M]9-^!->>/F5@^V#2.0L-P5=)*3%"')PA!-1>L7I(\S*+I/#*+
M@. G*K7S6'U3;-\8X$9VF#,0BWB"KH'74?C._8:W?2PGDR";#4:/T4L2C:*0
M.8SND->!H7BTC$"QS[VOBE23X6?6 .##CD*EIU^R1;;#V,IA)O*%I//*=1!E
MOP9Q2;Z2(*>K(K_^V?=@6W:"A5**4]8/D^&FJL:%=72X_P$GZI3).%/6 S3(
MABDCNL4#S R<HW&U[^WDXJG#^BN'.U+L>Q!)7UP8C"1M7>X0<':*XN,C[ME*
MDTQ&ETTS@!7YFLM<(E)''WO K5S8MD_Y^_<M88LJ6TMY3X+89.E2U.+3X0'"
MRK452F/1M8TH"':CKF*+\&8>V=IF(B'QT*N+NJ7+H-P+?,]Z_$0FTS2C1\IY
MGO(EU0;C4EN7G[6_((S.34[-UCQA#4" O)<TYUFVO*FQM7(E R[V/5PV4[(K
M]&DW=_OA9PR+QDXZ^;NT('8+DW$;@!+9KB$A7G'=9P6ME6.%P]P-O;_O^.Y+
M6MFSG54_'DC,7%OY/0J/<O_,>KKPKC48:_4:IJ(]/EW>3OG(Q_EZMTU&;,V6
M@1'D*P%'0A6/>U<$M73W";&8GH+W_9\ EY^VVFDJ:K'S.,J]G:!/)F-350VP
MX,>?U'(M'E5&T%JY@-Y&(0_#^Y(16Z._Q"=CIT6C\6!:E;%]='KFP'=$\3&5
MMAO7Y3W%"K1A3:? *<0*9"N5GRZ0DPA"^O43NC;R"S^28%PT*[IBM9Y8M<-6
M^Y,#!'.^42]-UAR[A@ OLDF_FH3$ZU)%^*T<K'>$9S2\)QG?O^[=/A)D"25W
M^7T32XFD"I?#&8+-9+M#)B-,6@=08-M$=!2+QXT>5"N'R".)"7O<\?<RR.B7
MX]G\!6807P9%\"T)RF%$_[SOH;/;G37W5*O5S;(EMCLY/40P@"C[:3+JS!H
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M,/D=>>-_4@]MDP: ,^2K3&-=J(C-581:092"?6H$1P>H[[,H) OG*)42R.H
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M\V0G,4EQZ(^_^1,7= E.73I$[3:6+J][+N(@SPU?]LGJ "=(#H9&PI*YIN@
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MZ<< 6"-GR_UQ<6QA=_F-W'?9]0"$ANS2[;7ZVQ+I*)5I"\QUTF!90F-04^/
M72^X*][!#VW>:X!,1]E=/?#IKD/<@AOTX6#5$1!BI\V-.'RZRGOK]1Y)1YW
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M,=$!ZTU-/LYGX@8T+J(-?I4)YQ0[T6M#^B96[GV0B1E JRDEOPLF^O@@NJK
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M9@HW9Y]89Y^#G/S;_P=02P$"% ,4    "  '0G)2;?GG<B_D  "LT P $0
M            @ $     9V)I;RTR,#(P,3(S,2YX;6Q02P$"% ,4    "  '
M0G)2.^I(34 0  #)GP  $0              @ %>Y   9V)I;RTR,#(P,3(S
M,2YX<V102P$"% ,4    "  '0G)2DNLSV*L*  "^C@  %0
M@ '-]   9V)I;RTR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ !T)R4D!K
M=! B,0  0OD" !4              ( !J_\  &=B:6\M,C R,#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    (  ="<E(_38.BX64  -30!0 5              "
M 0 Q 0!G8FEO+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  '0G)2T<1&
M:A1'   :J00 %0              @ $4EP$ 9V)I;RTR,#(P,3(S,5]P<F4N
9>&UL4$L%!@     &  8 B@$  %O> 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
